data_2lln_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lln _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.869 0.366 . . . . 72.11 110.89 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.94 131.47 44.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 74.23 110.825 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.4 m -120.91 -177.18 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 73.42 111.124 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.417 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 25.1 p30 -143.42 156.7 60.43 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 74.04 110.874 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.417 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.9 Cg_endo -69.79 -3.08 11.3 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.655 2.237 . . . . 73.23 112.358 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.4 m -46.76 -68.3 0.2 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.205 -0.452 . . . . 63.11 111.124 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 24.4 p -150.02 26.07 0.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.451 . . . . 75.51 111.133 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.4 p -65.39 -29.1 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.26 -0.427 . . . . 75.23 111.102 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.9 ptt180 -102.53 -7.91 21.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 74.32 110.884 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.3 mt-30 -96.81 -37.67 10.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 65.22 110.914 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.84 133.68 41.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 73.0 110.877 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.11 -156.91 18.39 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.753 -0.737 . . . . 74.12 112.494 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -30.79 21.72 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.741 2.294 . . . . 62.34 112.333 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 13.5 m-90 -85.95 -12.53 50.24 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 72.23 110.922 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.62 -58.98 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 72.12 111.095 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.89 146.5 34.24 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.593 0.711 . . . . 75.12 110.867 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -14.17 35.62 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.664 2.243 . . . . 73.22 112.349 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.13 -24.43 59.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 75.41 111.056 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 mm-40 -86.34 5.01 36.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 71.51 110.87 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.39 -76.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.43 111.085 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 12.3 t -89.71 115.6 29.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 72.41 111.144 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.34 119.02 4.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 75.41 111.138 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.9 tp60 -68.06 123.37 20.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 70.54 110.876 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.4 p -120.18 -11.55 9.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 74.55 111.111 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.9 -169.33 12.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 75.4 112.517 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.65 18.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.682 2.255 . . . . 75.23 112.395 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 55.2 t30 -155.69 28.61 0.38 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 75.14 110.884 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -126.99 119.42 26.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.494 . . . . 73.31 110.9 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -96.32 140.23 31.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 74.21 110.961 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.467 ' HA ' HG21 ' A' ' 62' ' ' VAL . 85.9 m -93.76 115.02 27.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 70.33 111.173 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.3 t -102.24 139.06 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 72.11 111.124 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -120.49 140.85 50.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 74.12 110.924 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 99.1 t -138.3 136.06 44.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.486 . . . . 74.41 111.106 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -137.91 140.71 40.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 74.22 110.95 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.27 102.97 2.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 71.54 111.083 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 3.3 p90 -112.01 156.71 21.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 72.24 110.894 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.13 7.79 23.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.137 -0.483 . . . . 70.14 111.092 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -103.17 82.9 2.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 75.53 110.929 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 100.28 -135.04 11.93 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.739 . . . . 61.22 112.498 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -154.61 150.22 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.799 0.333 . . . . 73.41 110.954 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 2.9 pm0 -154.07 155.02 30.71 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.648 0.737 . . . . 75.43 110.874 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.81 4.2 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.676 2.25 . . . . 75.3 112.382 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -134.99 62.88 55.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.577 0.703 . . . . 73.34 110.873 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 76.58 1.14 Allowed 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.661 2.241 . . . . 73.23 112.351 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.9 mp -106.56 143.06 18.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 75.31 111.145 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -138.91 158.51 44.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 74.25 110.88 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.408 HG22 HG13 ' A' ' 61' ' ' ILE . 2.4 p -164.09 84.47 1.26 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.639 0.733 . . . . 72.22 111.143 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 121.93 8.62 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.675 2.25 . . . . 73.15 112.334 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -66.76 152.24 45.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.434 . . . . 72.0 110.9 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.0 -35.87 3.93 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.708 -0.758 . . . . 55.25 112.478 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.86 157.58 17.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.751 0.31 . . . . 74.12 111.114 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -66.8 144.78 56.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 71.35 110.859 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.408 HG13 HG22 ' A' ' 55' ' ' VAL . 5.7 mm -130.56 124.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 62.33 111.195 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.467 HG21 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -113.73 90.24 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 73.42 111.133 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -67.88 138.8 56.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 72.4 110.859 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.4 mttt -132.75 100.25 4.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 74.42 110.887 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 2.3 mp -106.87 141.63 21.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 72.21 111.151 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.2 t -154.67 138.02 15.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.183 -0.462 . . . . 73.13 111.14 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.8 159.58 56.36 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 74.03 110.854 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -51.68 0.38 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.678 2.252 . . . . 74.23 112.361 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -156.95 49.41 0.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 73.12 110.892 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -155.13 136.27 5.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 62.43 111.158 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 71.4 mt -86.21 142.53 12.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.186 -0.461 . . . . 72.53 111.115 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -118.3 -80.99 0.62 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.865 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 57.29 171.46 0.19 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.73 -0.748 . . . . 65.1 112.502 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -160.45 141.89 12.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.354 . . . . 63.32 110.927 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 7.1 t-80 -116.18 101.78 9.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 61.24 110.851 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 5.0 p -96.28 143.78 11.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 71.43 111.104 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -66.34 -172.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 72.11 110.938 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.89 -46.52 3.3 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.778 -0.725 . . . . 61.2 112.457 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.7 165.68 28.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.751 0.31 . . . . 74.42 111.149 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -79.48 58.36 2.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 75.12 110.947 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 12.9 tt -66.35 115.09 3.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 75.13 111.118 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.7 91.05 3.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.01 110.863 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.0 m -118.11 120.48 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 75.44 111.103 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -160.9 117.34 2.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.02 110.924 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 96.2 t -140.35 127.73 23.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 75.03 111.134 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.408 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -51.07 160.06 0.91 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.601 0.715 . . . . 63.42 110.921 179.972 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 54.0 Cg_endo -69.73 155.47 65.96 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.724 2.283 . . . . 73.31 112.353 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.65 10.7 46.33 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.797 -0.716 . . . . 74.13 112.513 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -164.69 119.2 1.37 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.871 0.367 . . . . 74.34 110.867 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 2.9 p -68.69 133.73 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 71.13 111.141 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -94.39 168.9 10.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 73.45 110.876 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 90.5 m -144.4 105.46 4.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 71.24 111.119 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.0 p -118.58 141.21 39.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 74.4 111.125 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -110.6 101.55 10.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 73.41 110.879 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -145.97 119.26 8.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.228 -0.442 . . . . 71.35 110.905 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.5 t -117.28 142.97 46.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.489 . . . . 71.34 111.181 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.0 -175.93 4.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 63.32 110.915 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 20.5 mtpt -126.21 -12.45 6.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.16 -0.473 . . . . 74.12 110.917 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -148.19 162.22 31.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.601 0.715 . . . . 75.5 110.908 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 156.9 62.23 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.69 2.26 . . . . 73.21 112.344 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.2 133.64 1.51 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.743 -0.742 . . . . 61.31 112.523 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -99.4 128.49 45.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 74.33 110.897 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -144.13 131.08 20.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 74.31 110.889 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 7.1 ptt180 -147.94 83.41 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 74.15 110.858 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.0 mt -151.01 145.03 16.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 75.2 111.155 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 75.12 111.131 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 43.1 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.814 0.34 . . . . 74.53 111.146 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.3 mp -144.92 141.55 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 75.34 111.123 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 85.1 t -131.29 133.95 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 73.25 111.135 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 97.4 t -103.9 134.93 43.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 71.11 111.093 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -117.87 130.66 56.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 71.22 110.846 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 73.41 110.856 179.973 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.851 0.358 . . . . 73.43 110.883 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -89.46 166.76 13.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 75.42 110.885 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 m -144.5 -179.31 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.459 . . . . 74.24 111.146 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -145.76 161.66 39.42 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.628 0.728 . . . . 65.0 110.904 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -4.47 14.09 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.687 2.258 . . . . 71.44 112.355 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 33.9 m -48.47 -70.78 0.08 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 64.32 111.178 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.5 p -150.92 35.26 0.6 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 72.03 111.17 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 14.0 p -69.56 -31.59 49.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 74.22 111.086 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.14 -5.09 51.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 75.52 110.889 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -104.53 -35.7 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 73.4 110.9 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -129.0 134.16 48.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 63.23 110.861 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.73 -160.3 13.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 72.4 112.5 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -26.27 27.71 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.746 2.297 . . . . 74.35 112.342 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 16.1 m-90 -87.17 -9.86 54.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.928 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.77 -59.46 2.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 54.15 111.134 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.62 144.38 28.5 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.605 0.717 . . . . 71.43 110.875 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -19.17 36.78 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.695 2.263 . . . . 72.3 112.39 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.75 -20.28 60.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 74.23 111.117 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mm-40 -87.28 6.82 31.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 73.32 110.868 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.43 -76.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 70.01 111.112 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.1 t -84.53 118.35 31.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 75.12 111.123 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.435 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 11.0 m -132.94 138.75 51.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 75.25 111.151 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.14 95.96 9.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 73.22 110.892 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.3 t -95.71 -35.82 11.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 71.02 111.163 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.79 -166.54 21.63 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.75 . . . . 72.13 112.507 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -44.93 1.77 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.677 2.251 . . . . 65.42 112.315 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -143.37 30.24 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 74.31 110.867 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -126.95 120.05 28.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 74.44 110.933 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -96.34 135.73 37.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 72.35 110.924 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.435 ' HB ' ' CG2' ' A' ' 30' ' ' VAL . 49.8 m -96.01 105.0 16.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.093 -0.503 . . . . 73.15 111.111 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -84.65 147.23 5.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 73.3 111.141 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -127.16 121.85 32.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 74.24 110.928 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 97.6 t -114.33 124.97 71.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 74.1 111.191 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -120.36 136.5 54.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 74.25 110.868 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.61 140.55 17.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 71.44 111.122 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -139.99 159.0 43.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 65.55 110.923 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.71 5.57 35.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 75.23 111.111 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -122.31 84.88 2.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 72.13 110.853 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.87 179.14 19.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.743 -0.742 . . . . 72.02 112.492 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -124.65 139.48 53.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.806 0.336 . . . . 63.2 110.922 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -142.17 162.09 47.24 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 73.2 110.875 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 179.9 3.37 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.675 2.25 . . . . 72.31 112.317 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -135.98 63.0 49.37 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.629 0.728 . . . . 65.33 110.909 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 73.77 1.32 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.643 2.229 . . . . 74.13 112.368 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.5 mp -110.57 113.91 45.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.246 -0.434 . . . . 73.34 111.179 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -110.07 135.43 50.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 74.41 110.908 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.4 p -138.9 81.76 21.58 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.665 0.745 . . . . 72.13 111.132 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 129.01 16.9 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.731 2.287 . . . . 73.33 112.356 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.44 152.2 40.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 74.51 110.897 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.61 -35.61 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.758 -0.734 . . . . 55.22 112.474 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.0 155.93 18.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 71.44 111.127 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -67.18 144.51 55.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 75.03 110.896 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 6.4 mm -128.83 119.61 50.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.455 . . . . 73.35 111.137 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 55.1 t -107.55 91.22 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 74.42 111.143 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -70.37 137.25 50.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 72.54 110.864 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -129.55 100.88 5.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 74.21 110.839 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.31 155.29 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 73.53 111.11 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.3 t -169.99 139.21 1.83 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.166 -0.47 . . . . 74.44 111.148 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -143.46 161.78 45.43 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.688 0.756 . . . . 73.4 110.857 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 -54.09 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.69 2.26 . . . . 75.25 112.392 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -159.16 38.3 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 71.3 110.878 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -138.73 135.16 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 74.21 111.114 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 28.7 mm -88.02 142.89 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 74.22 111.133 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 21.5 p-80 -174.85 136.9 0.42 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 73.01 110.859 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -143.76 -149.62 5.12 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 73.12 112.494 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 7.9 p90 -159.29 138.19 11.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.923 0.392 . . . . 75.02 110.925 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 41.6 t60 -128.34 98.83 5.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 72.14 110.858 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 6.6 p -80.58 144.61 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 74.21 111.111 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.3 pm0 -67.77 -175.44 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 64.13 110.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.54 -51.1 4.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.715 -0.755 . . . . 74.42 112.474 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.7 m -131.46 153.34 49.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.321 . . . . 64.15 111.174 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -76.0 66.08 2.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 71.14 110.89 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 12.5 tt -77.57 113.11 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 74.13 111.09 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.03 98.35 6.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 74.44 110.885 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.9 m -121.25 120.31 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.158 -0.474 . . . . 72.22 111.15 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -125.09 96.02 4.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 72.34 110.885 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.8 p -86.83 144.37 9.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 71.43 111.072 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 6.1 mp -111.05 156.62 40.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.6 0.714 . . . . 74.02 110.935 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 146.96 62.13 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.254 . . . . 74.42 112.365 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.22 8.96 86.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.734 -0.746 . . . . 61.32 112.467 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -146.69 173.61 12.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.918 0.39 . . . . 71.41 110.893 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 18.5 t -120.92 146.21 26.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 70.23 111.155 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.5 p -109.84 158.51 18.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 74.4 110.87 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 53.2 m -145.87 105.46 3.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.474 . . . . 72.04 111.128 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.11 136.23 60.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 74.41 111.143 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.2 mtm180 -105.86 92.47 4.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 74.14 110.827 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -134.66 115.17 13.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.452 . . . . 73.2 110.939 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 t -116.19 142.93 46.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 73.11 111.149 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.95 178.85 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 71.35 110.863 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.34 -21.94 7.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.118 -0.492 . . . . 73.41 110.912 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.97 158.3 74.15 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.592 0.71 . . . . 73.31 110.887 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 149.44 66.86 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.678 2.252 . . . . 74.2 112.363 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.87 156.67 9.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.752 . . . . 54.52 112.457 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -114.54 132.2 56.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.847 0.356 . . . . 65.41 110.868 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -143.62 146.41 33.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.158 -0.473 . . . . 72.03 110.923 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.551 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 13.9 ptt-85 -164.9 -164.58 0.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 74.32 110.863 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.551 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 7.3 tt 58.2 158.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 73.43 111.118 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 71.24 111.16 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 96.2 m . . . . . 0 C--O 1.232 0.165 0 CA-C-O 120.791 0.329 . . . . 75.13 111.166 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 2.5 mp -140.25 132.92 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 72.03 111.069 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.3 141.13 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 74.22 111.093 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 62.1 t -103.75 130.73 53.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 61.11 111.138 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -104.1 128.72 51.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 75.45 110.917 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 116.23 -0.441 . . . . 75.42 110.853 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.8 pm0 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.815 0.341 . . . . 75.33 110.892 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.43 142.67 28.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 74.23 110.848 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 16.4 m -118.46 -176.64 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.167 -0.469 . . . . 65.52 111.106 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.429 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 16.5 p30 -142.92 157.39 61.22 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.605 0.717 . . . . 72.52 110.887 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.429 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 54.0 Cg_endo -69.77 -3.06 11.25 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.646 2.23 . . . . 75.41 112.379 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 25.2 m -46.58 -69.98 0.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.452 . . . . 75.51 111.165 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.9 p -149.71 24.83 0.86 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 65.43 111.165 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.2 p -63.68 -30.97 51.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 74.31 111.133 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.28 -5.38 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 74.44 110.879 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 83.7 mm-40 -92.24 -37.42 12.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 72.25 110.942 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -141.89 133.42 26.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 74.13 110.898 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 126.97 -155.09 19.62 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.7 -0.762 . . . . 72.34 112.502 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.95 17.5 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.683 2.256 . . . . 72.45 112.351 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 12.2 m-90 -84.61 -13.98 50.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 74.22 110.916 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.78 -49.18 75.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.082 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -114.07 144.39 31.51 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.608 0.718 . . . . 75.14 110.862 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 -25.7 28.06 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.662 2.242 . . . . 73.32 112.318 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.22 -6.75 49.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 74.15 111.098 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 24.0 mm-40 -102.47 9.67 39.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 73.11 110.881 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.92 -79.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 63.43 111.146 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 39' ' ' VAL . 1.5 p -84.98 124.34 39.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 75.34 111.12 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.5 m -135.29 136.01 51.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 63.25 111.124 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -75.57 107.2 7.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 65.34 110.893 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 9.7 t -111.94 -32.95 6.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.218 -0.446 . . . . 61.14 111.141 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.76 -172.68 19.86 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.756 -0.735 . . . . 61.1 112.504 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -43.8 2.45 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.687 2.258 . . . . 73.23 112.357 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -140.96 35.27 1.75 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 64.31 110.876 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.35 119.09 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 73.0 110.889 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.404 ' HB3' HG21 ' A' ' 29' ' ' VAL . 15.2 m-85 -96.79 137.34 36.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 75.02 110.95 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.508 ' HA ' HG22 ' A' ' 62' ' ' VAL . 81.2 m -95.74 105.71 17.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 75.54 111.147 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 29' ' ' VAL . 9.9 t -92.66 138.52 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 72.43 111.12 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -120.75 114.82 22.2 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.191 -0.459 . . . . 72.32 110.951 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.4 t -104.14 130.79 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.14 -0.482 . . . . 73.15 111.102 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -125.07 121.52 34.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.47 . . . . 73.42 110.896 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -142.89 137.57 29.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.446 . . . . 75.14 111.088 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -145.52 159.94 42.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 75.33 110.858 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.82 5.55 32.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 62.52 111.108 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -110.26 70.59 0.73 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.45 110.831 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.07 -170.09 16.23 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.684 -0.77 . . . . 63.25 112.415 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.23 126.51 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.795 0.331 . . . . 75.45 110.929 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.436 ' HB3' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -136.42 161.0 64.62 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.567 0.699 . . . . 73.45 110.961 179.974 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.436 ' HD2' ' HB3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.76 178.68 4.32 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.707 2.271 . . . . 70.43 112.338 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -129.93 62.78 65.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.646 0.736 . . . . 75.1 110.905 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 75.56 1.23 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.657 2.238 . . . . 71.23 112.314 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.4 mp -106.89 98.18 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 71.23 111.133 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -82.14 129.6 34.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 64.32 110.889 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 30.7 t -137.01 81.31 33.35 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.633 0.73 . . . . 75.1 111.118 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 123.05 9.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.702 2.268 . . . . 72.34 112.355 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.29 155.18 40.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 71.45 110.933 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.36 -4.39 77.59 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.749 -0.739 . . . . 60.13 112.503 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.05 152.46 51.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.71 0.29 . . . . 75.1 111.129 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -66.66 139.37 57.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.265 -0.425 . . . . 73.44 110.887 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 7.2 mm -127.41 116.33 43.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.198 -0.456 . . . . 64.14 111.123 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.508 HG22 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -104.44 90.59 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 71.21 111.108 179.87 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -68.42 139.7 55.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 75.13 110.883 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -131.97 100.57 5.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 74.54 110.913 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 73.34 111.122 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.1 t -168.44 140.49 2.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.135 -0.484 . . . . 74.23 111.137 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.52 161.14 32.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.705 0.764 . . . . 75.45 110.861 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -55.46 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 65.11 112.322 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -156.96 61.97 0.51 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 63.25 110.85 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -155.84 135.44 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 75.25 111.163 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 36.4 mm -69.81 130.5 34.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 71.11 111.128 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 9.2 p-80 -119.98 -175.79 3.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.236 -0.438 . . . . 54.12 110.885 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 170.9 12.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 43.43 112.502 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -153.23 141.25 20.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.845 0.355 . . . . 75.15 110.918 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 76.2 t60 -122.1 104.38 9.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 75.42 110.878 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 3.5 p -94.3 137.86 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 74.45 111.143 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -59.96 -175.98 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 72.11 110.904 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.13 -50.97 4.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 75.2 112.45 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.26 171.71 12.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.773 0.321 . . . . 75.11 111.111 -179.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -93.17 47.61 1.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 73.44 110.852 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 12.5 tt -58.54 112.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 60.34 111.172 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.34 94.16 4.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 74.53 110.923 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.3 m -117.97 120.35 64.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 71.04 111.096 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -150.28 118.46 6.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 74.32 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.0 m -140.73 146.88 23.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.155 -0.475 . . . . 73.32 111.14 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.27 161.94 75.5 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.554 0.692 . . . . 75.42 110.969 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 159.65 52.61 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.25 . . . . 72.51 112.309 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 86.4 13.28 68.36 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.749 -0.739 . . . . 74.42 112.493 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -146.21 138.43 25.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.903 0.383 . . . . 75.21 110.892 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 99.5 t -90.93 105.89 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 53.03 111.153 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -89.31 137.67 32.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 75.23 110.855 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 92.9 m -110.01 105.51 14.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 74.23 111.172 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 44.7 t -98.19 147.95 6.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 71.55 111.104 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.61 110.93 15.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 73.34 110.882 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -156.68 122.64 4.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 72.05 110.887 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.8 t -123.39 135.55 54.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 64.43 111.152 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.79 -174.22 3.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 65.24 110.871 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -121.9 -26.4 4.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 73.2 110.915 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.1 mpp_? -134.51 161.41 63.89 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 74.22 110.88 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 154.22 67.89 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.652 2.235 . . . . 73.41 112.371 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.58 134.4 1.65 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.755 -0.736 . . . . 55.34 112.485 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -100.69 139.49 36.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 74.31 110.892 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -143.82 132.82 22.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 74.25 110.915 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.36 94.07 2.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 74.22 110.86 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.8 tt -177.63 131.55 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 75.43 111.17 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 74.45 111.093 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 6.7 m . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.826 0.346 . . . . 72.35 111.127 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 2.1 mp -149.14 139.12 16.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 74.42 111.177 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.5 p -127.5 135.92 61.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 64.42 111.182 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 41.3 t -104.48 127.65 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 74.53 111.103 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 12.4 mmmm -102.22 133.6 46.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 74.21 110.872 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 75.21 110.919 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.822 0.344 . . . . 73.53 110.891 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 166.56 10.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 75.35 110.884 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.8 m -144.41 -179.09 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 74.05 111.074 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.68 162.04 40.66 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.603 0.716 . . . . 62.23 110.902 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -3.67 12.49 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.676 2.251 . . . . 65.45 112.331 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 28.0 m -46.09 -70.44 0.1 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.239 -0.437 . . . . 64.43 111.17 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 28.3 p -150.05 27.59 0.77 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 70.14 111.157 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.2 p -65.22 -30.77 51.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 73.22 111.13 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -100.74 -15.74 17.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.148 -0.478 . . . . 74.42 110.863 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -88.45 -33.04 17.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 74.35 110.898 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -141.35 135.12 30.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 73.22 110.913 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.44 -160.69 19.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.753 -0.737 . . . . 72.1 112.492 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -25.8 28.21 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.265 . . . . 75.53 112.343 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 14.5 m-90 -87.07 -12.6 46.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 75.32 110.95 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.86 -59.43 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.451 . . . . 73.43 111.093 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.42 144.55 28.45 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.556 0.693 . . . . 71.44 110.879 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -27.75 26.37 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.689 2.26 . . . . 75.41 112.359 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.41 -18.38 60.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 72.32 111.094 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 -87.82 7.64 29.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 70.24 110.939 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.14 -78.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 64.35 111.112 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.433 ' HA ' ' HA ' ' A' ' 39' ' ' VAL . 1.8 p -93.1 124.93 45.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 74.31 111.113 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.2 m -119.67 149.86 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 64.43 111.108 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.65 121.99 27.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 73.12 110.963 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.91 -42.6 2.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 74.43 111.122 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.47 170.65 13.81 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 61.5 112.488 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.695 2.264 . . . . 74.23 112.31 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -156.29 34.34 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 64.52 110.908 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -154.0 155.64 35.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.128 -0.487 . . . . 74.33 110.898 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -143.05 147.99 35.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 72.34 110.913 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 52.0 m -101.37 104.22 15.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 72.53 111.127 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.433 ' HA ' ' HA ' ' A' ' 29' ' ' VAL . 6.7 t -85.18 135.13 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 74.02 111.137 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -117.12 121.66 41.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.18 -0.464 . . . . 72.41 110.933 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.0 m -122.73 143.9 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 63.34 111.131 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -138.69 143.85 39.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.479 . . . . 62.23 110.889 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -149.54 123.52 9.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 73.14 111.129 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -121.41 154.47 36.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 71.12 110.814 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.84 6.87 33.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 62.23 111.074 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -122.37 86.07 2.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 75.43 110.906 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.91 -165.92 12.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.755 -0.736 . . . . 62.34 112.54 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -136.3 143.43 44.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.842 0.353 . . . . 74.03 110.893 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.413 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.7 pm0 -145.37 155.59 53.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 72.13 110.901 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.413 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.9 Cg_endo -69.75 174.45 9.48 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.253 . . . . 74.55 112.35 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.1 m-20 -127.99 62.37 56.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.631 0.729 . . . . 72.23 110.869 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 74.43 1.26 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.655 2.237 . . . . 74.31 112.343 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.9 mp -110.58 113.89 45.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 74.12 111.154 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -108.59 119.47 39.61 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.491 . . . . 72.13 110.908 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.1 p -124.77 85.71 56.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.61 0.719 . . . . 74.14 111.125 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 122.57 9.25 Favored 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 122.673 2.249 . . . . 72.31 112.347 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.57 150.45 48.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 73.34 110.881 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.81 -30.46 5.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 62.41 112.507 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.83 152.12 23.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.736 0.303 . . . . 63.41 111.119 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.82 142.36 54.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.456 . . . . 75.11 110.861 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 4.7 mm -126.87 124.16 64.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 75.05 111.106 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 55.0 t -107.92 91.25 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 71.11 111.173 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -69.48 135.02 49.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 71.25 110.887 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -131.43 100.44 5.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 74.45 110.865 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.5 mp -97.17 156.07 3.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.264 -0.426 . . . . 73.12 111.098 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 7.2 t -166.01 137.9 3.86 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 75.02 111.141 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.472 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -152.21 159.76 32.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.646 0.736 . . . . 71.14 110.912 -179.876 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.472 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.76 -53.98 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.665 2.243 . . . . 73.33 112.403 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -154.88 65.84 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 73.24 110.864 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.433 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.4 135.55 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 74.32 111.126 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.2 mm -66.9 145.54 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 75.31 111.107 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -108.75 -167.05 1.17 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 74.45 110.834 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.84 120.73 3.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 41.12 112.513 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -121.16 142.84 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.904 0.383 . . . . 74.54 110.9 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -89.14 137.19 32.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 73.11 110.872 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 94.8 t -130.03 141.47 46.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 73.14 111.161 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.6 mt-10 -75.26 175.67 8.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 65.34 110.878 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.06 -51.65 4.14 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.676 -0.773 . . . . 64.34 112.514 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.25 147.24 51.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 74.11 111.156 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -76.71 64.57 2.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 71.31 110.881 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 8.0 tt -58.23 125.94 15.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 73.2 111.176 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.7 89.67 3.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.853 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.7 m -115.87 120.65 65.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 75.5 111.158 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -155.79 114.51 3.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 72.12 110.838 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 61.6 t -140.46 146.71 24.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 74.15 111.138 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.422 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.6 OUTLIER -69.69 155.68 93.06 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.585 0.707 . . . . 71.4 110.902 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.422 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 54.1 Cg_endo -69.74 159.8 52.09 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.234 . . . . 75.02 112.379 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.21 17.25 51.31 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.761 -0.733 . . . . 72.11 112.493 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -156.26 155.77 32.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.88 0.371 . . . . 74.13 110.886 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 98.2 t -104.85 109.78 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 71.15 111.123 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -83.83 169.46 15.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 74.35 110.879 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 98.3 m -137.99 122.22 18.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.144 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 21.3 t -124.57 130.6 73.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 73.13 111.155 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.7 mmm180 -102.57 70.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 73.14 110.9 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -110.13 130.73 55.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.153 -0.476 . . . . 72.25 110.931 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.1 t -139.64 142.25 37.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.475 . . . . 71.44 111.133 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -97.0 -175.49 3.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 75.52 110.861 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.1 mttt -125.34 -12.52 6.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 64.21 110.899 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -145.81 162.14 37.24 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.557 0.694 . . . . 72.44 110.865 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 154.0 68.21 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.679 2.253 . . . . 62.41 112.347 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.45 141.17 3.05 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.727 -0.749 . . . . 23.23 112.483 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -106.59 130.14 54.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.808 0.337 . . . . 60.42 110.905 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.3 p90 -144.04 146.32 32.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 73.01 110.922 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.17 -175.76 5.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 74.21 110.848 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mp 65.62 150.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 73.11 111.195 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 72.23 111.167 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 67.9 m . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.74 0.305 . . . . 73.54 111.164 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 2.8 mp -147.36 140.72 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 74.33 111.123 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 50.2 t -128.41 129.28 68.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 53.11 111.116 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 87.9 t -103.59 136.86 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 75.35 111.082 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.3 mmmt -113.83 131.78 56.12 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 72.25 110.902 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 73.34 110.874 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.874 0.369 . . . . 62.32 110.859 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.64 166.78 13.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 63.14 110.85 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 35.9 m -150.02 140.6 16.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.178 -0.465 . . . . 71.13 111.104 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.1 162.84 19.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.578 0.704 . . . . 72.03 110.855 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.96 9.33 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.651 2.234 . . . . 71.2 112.384 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 3.2 m -46.24 -67.43 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.207 -0.451 . . . . 74.13 111.168 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 26.8 p -146.67 13.86 1.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 74.11 111.138 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 p -50.64 -31.93 9.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 111.136 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.14 -17.41 14.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 74.32 110.883 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 22.1 mm100 -79.62 -31.21 41.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 74.44 110.94 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -149.24 140.48 23.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.231 -0.441 . . . . 74.43 110.884 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.19 -157.16 17.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.691 -0.766 . . . . 73.21 112.46 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 -30.6 22.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 50.31 112.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 14.9 m-90 -87.21 -7.48 57.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.226 -0.443 . . . . 73.42 110.921 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.29 -60.08 2.51 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 74.53 111.054 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.56 142.59 29.57 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.577 0.703 . . . . 75.32 110.916 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -28.38 25.07 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.666 2.244 . . . . 65.01 112.347 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.18 -11.69 60.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 73.03 111.115 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.5 mm-40 -95.35 24.71 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 74.31 110.935 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.58 -79.58 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 74.51 111.067 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.86 141.01 23.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 74.24 111.153 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 m -128.1 150.16 33.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 74.23 111.164 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.1 118.79 29.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 73.14 110.925 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.9 t -121.06 -21.06 6.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 72.32 111.148 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.29 168.38 20.19 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 62.11 112.5 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.25 20.57 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.652 2.235 . . . . 65.22 112.33 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.0 t30 -159.33 23.25 0.19 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.445 . . . . 60.35 110.874 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -138.87 153.97 48.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 72.51 110.865 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -141.97 142.15 32.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 72.23 110.966 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.2 m -95.74 104.55 16.48 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.115 -0.493 . . . . 75.41 111.144 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 t -84.5 140.06 16.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 74.5 111.156 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.29 122.76 39.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 72.14 110.918 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.6 m -118.73 123.26 71.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.11 -0.495 . . . . 74.53 111.113 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -115.88 132.88 56.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 71.15 110.894 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.44 114.47 3.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 65.44 111.087 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -129.36 152.09 49.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 75.22 110.878 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.14 1.77 46.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.09 -0.504 . . . . 53.44 111.145 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -95.83 72.0 3.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 75.24 110.868 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.21 -150.88 17.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.754 -0.736 . . . . 73.43 112.471 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 p90 -136.37 150.93 49.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.36 . . . . 74.21 110.907 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -162.09 162.06 20.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.591 0.71 . . . . 73.51 110.904 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 157.36 60.63 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.281 . . . . 74.44 112.35 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -133.09 66.69 76.32 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.644 0.735 . . . . 62.34 110.877 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.83 114.03 3.58 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.676 2.251 . . . . 73.33 112.367 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.5 mm -117.21 151.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 71.3 111.136 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.2 tt0 -155.25 120.62 4.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 71.3 110.929 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.419 HG21 HG13 ' A' ' 61' ' ' ILE . 2.4 p -139.7 82.03 18.75 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.651 0.739 . . . . 74.31 111.131 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 123.67 10.31 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.698 2.266 . . . . 74.32 112.349 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.23 155.11 40.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 72.32 110.96 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.41 -8.73 73.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 72.01 112.469 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.02 155.77 48.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 71.51 111.115 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -66.75 141.37 57.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 71.25 110.857 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.419 HG13 HG21 ' A' ' 55' ' ' VAL . 5.7 mm -130.14 119.18 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 62.43 111.106 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 54.8 t -102.28 98.42 6.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 74.12 111.129 179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -76.97 126.34 30.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 75.42 110.851 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.9 mttt -120.32 100.09 6.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 64.33 110.911 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mt -98.22 153.21 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 75.35 111.111 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 13.4 t -171.35 145.97 2.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 75.34 111.185 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.409 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -153.29 159.62 31.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.678 0.751 . . . . 74.03 110.854 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.409 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.76 -54.83 0.2 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.73 2.287 . . . . 63.1 112.325 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -156.53 60.55 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.238 -0.437 . . . . 72.43 110.884 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.29 136.35 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.459 . . . . 70.5 111.136 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 41.4 mm -67.08 144.2 14.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 73.45 111.09 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -136.98 158.11 45.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 74.02 110.827 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.71 129.83 1.11 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.779 -0.724 . . . . 71.14 112.515 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.0 p90 -117.47 141.93 47.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 74.23 110.862 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -112.1 90.74 3.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 75.42 110.846 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 27.6 t -73.36 145.53 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 74.22 111.115 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -75.66 -175.56 2.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 73.4 110.858 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.91 -51.38 4.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 55.24 112.437 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.41 179.28 6.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.777 0.322 . . . . 72.31 111.161 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 11.2 m-80 -90.19 48.01 1.51 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 63.22 110.868 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 3.3 tp -63.14 111.0 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 72.03 111.139 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.87 122.73 46.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 64.43 110.852 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.2 m -143.51 120.1 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 75.33 111.126 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.25 112.59 2.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 65.43 110.888 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 23.5 t -140.5 144.28 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 73.05 111.142 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 1.4 mp -61.53 161.11 21.16 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.591 0.71 . . . . 54.53 110.919 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 159.53 53.11 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.667 2.245 . . . . 70.53 112.347 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.23 10.88 60.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.718 -0.753 . . . . 75.44 112.492 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -152.6 159.39 43.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.862 0.363 . . . . 74.35 110.869 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 95.7 t -98.43 143.34 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 73.33 111.138 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 7.3 p -121.3 97.24 5.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 71.22 110.899 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.2 t -85.63 141.33 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.116 -0.493 . . . . 72.21 111.167 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.6 p -154.24 150.3 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 74.33 111.136 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -109.6 116.4 31.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 74.12 110.894 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -151.45 114.96 4.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 74.3 110.945 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.6 t -116.55 136.24 53.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.14 -0.482 . . . . 71.25 111.123 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -87.06 -172.47 3.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 74.33 110.922 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.1 tttt -123.19 -26.14 4.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 73.2 110.909 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -140.71 162.06 50.97 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.708 . . . . 74.42 110.871 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 150.72 68.57 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 74.4 112.345 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.09 143.85 3.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.733 -0.746 . . . . 73.23 112.506 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -108.82 134.53 51.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.84 0.352 . . . . 73.52 110.906 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -143.54 131.53 21.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 73.15 110.933 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.39 111.27 5.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.08 -0.509 . . . . 74.51 110.867 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.0 tp -178.61 142.95 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 74.23 111.098 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 17.7 tt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 62.42 111.11 179.841 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 15.1 t . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.714 0.293 . . . . 74.11 111.21 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 3.3 mp -153.1 134.27 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.243 -0.435 . . . . 75.05 111.11 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.6 p -126.23 137.61 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 74.32 111.139 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.14 141.97 22.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 74.31 111.134 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.8 mmtt -116.33 132.42 56.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 75.43 110.937 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 71.41 110.875 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.839 0.352 . . . . 72.34 110.892 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -93.1 135.38 34.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 71.04 110.85 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 7.8 m -115.01 -179.22 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 62.32 111.133 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -147.04 162.63 32.22 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 71.34 110.867 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -4.33 13.79 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.677 2.251 . . . . 71.41 112.367 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 5.4 m -48.75 -66.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.24 -0.436 . . . . 75.5 111.112 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 3.2 p -155.59 37.35 0.37 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 71.42 111.149 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.4 p -77.19 -27.52 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.214 -0.448 . . . . 73.34 111.137 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 20.4 ptt85 -104.28 -10.76 17.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 75.24 110.853 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -94.35 -36.96 11.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.453 . . . . 72.32 110.927 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.87 133.88 40.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 72.55 110.883 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.02 -157.18 19.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 45.25 112.507 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -30.06 22.79 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 72.53 112.36 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 14.0 m-90 -86.82 -10.89 52.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 74.32 110.926 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.66 -59.32 3.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 75.23 111.112 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.63 144.85 29.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.612 0.72 . . . . 72.35 110.868 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -17.24 37.75 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.665 2.243 . . . . 73.41 112.322 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -24.09 59.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 72.02 111.132 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.7 mm-40 -90.05 10.54 23.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 72.23 110.931 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -78.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 74.12 111.15 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.1 p -108.2 128.71 63.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 72.53 111.149 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.01 144.04 28.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 71.12 111.139 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.0 tp60 -75.48 121.45 22.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 74.21 110.905 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 t -119.95 -12.88 9.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 62.21 111.166 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.61 -167.66 12.15 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.751 -0.737 . . . . 72.32 112.496 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 -36.12 11.4 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 73.01 112.337 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -153.58 34.45 0.45 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 73.23 110.884 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.14 118.09 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 74.14 110.889 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -97.66 138.47 35.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.94 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 55.9 m -95.66 102.59 14.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 72.34 111.13 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.9 t -84.24 146.33 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 75.04 111.156 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -126.8 124.06 38.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.143 -0.48 . . . . 74.43 110.962 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 92.1 t -125.37 138.67 53.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.491 . . . . 70.21 111.121 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -138.61 141.84 39.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.166 -0.47 . . . . 74.02 110.94 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.68 109.11 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 71.33 111.065 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -122.77 153.43 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 74.25 110.852 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.26 4.3 35.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 75.21 111.13 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -95.24 78.11 3.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.937 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.59 -139.92 14.75 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 74.4 112.489 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -148.42 150.06 32.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.845 0.355 . . . . 71.13 110.943 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -158.19 162.55 26.69 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.571 0.701 . . . . 73.44 110.963 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 157.03 61.78 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.722 2.281 . . . . 73.54 112.317 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.49 66.08 76.11 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.598 0.713 . . . . 72.43 110.847 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 118.36 5.64 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.693 2.262 . . . . 71.0 112.302 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.4 mm -124.55 151.51 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 75.14 111.123 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -155.22 115.66 3.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 75.4 110.836 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 21.2 t -131.34 82.02 63.61 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.647 0.737 . . . . 75.43 111.145 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 121.87 8.56 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.692 2.261 . . . . 75.14 112.368 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -68.3 152.85 44.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.253 -0.43 . . . . 65.12 110.933 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.95 -36.33 3.7 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 73.11 112.495 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.77 158.06 17.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.8 0.333 . . . . 74.13 111.066 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -67.87 144.53 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.45 . . . . 74.55 110.922 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.7 mm -128.21 120.01 52.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 73.3 111.114 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 55.2 t -103.9 91.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 75.32 111.128 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -69.61 134.95 49.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 74.55 110.906 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 15.6 mttt -131.53 100.16 5.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.153 -0.476 . . . . 74.44 110.877 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -107.11 143.32 17.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 74.13 111.156 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.5 t -156.38 136.18 12.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 74.23 111.166 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.95 161.51 48.3 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.699 0.761 . . . . 73.4 110.853 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -50.81 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.671 2.247 . . . . 71.32 112.385 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -155.78 49.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 71.21 110.842 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.21 135.94 3.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.146 -0.479 . . . . 71.51 111.117 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 95.0 mt -86.45 105.64 14.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.14 111.147 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -99.46 69.65 1.67 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 64.42 110.901 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.15 155.5 21.07 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.73 -0.748 . . . . 63.11 112.466 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 3.3 p90 -128.61 142.82 50.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.883 0.373 . . . . 75.34 110.886 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -118.56 94.1 4.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 74.15 110.854 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.1 t -74.11 140.9 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 75.53 111.147 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 pm0 -75.3 -176.05 2.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 74.05 110.869 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.7 -51.86 4.61 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.723 -0.751 . . . . 63.13 112.491 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 10.7 m -124.02 157.16 35.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.813 0.34 . . . . 75.53 111.174 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -77.15 60.06 1.84 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 61.04 110.874 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 11.5 tt -78.51 116.53 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 73.32 111.137 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -123.19 96.69 5.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 75.41 110.85 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.6 m -114.39 119.89 62.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 70.14 111.105 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.64 117.36 7.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.14 -0.482 . . . . 70.53 110.886 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.6 p -140.62 128.29 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 63.21 111.117 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -57.52 157.91 12.5 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.59 0.71 . . . . 72.03 110.959 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 159.16 54.46 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.685 2.256 . . . . 63.55 112.339 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.1 11.73 59.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 74.24 112.511 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -163.86 118.19 1.53 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.897 0.379 . . . . 71.4 110.897 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 3.5 p -68.8 143.28 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 74.45 111.129 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.09 169.29 8.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 70.42 110.814 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 87.8 m -145.45 111.28 5.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.121 -0.491 . . . . 73.14 111.112 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 8.0 p -124.45 150.7 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 74.31 111.131 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -114.93 97.49 6.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.831 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 40.5 t80 -139.9 110.08 6.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 74.42 110.947 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.1 t -110.68 143.5 41.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 74.24 111.177 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.6 -178.89 5.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.258 -0.428 . . . . 74.32 110.853 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.7 mttt -119.85 -12.9 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 75.43 110.927 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.16 161.66 31.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.62 0.724 . . . . 75.01 110.831 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.67 152.43 69.75 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 2.26 . . . . 64.42 112.384 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 159.4 130.43 1.14 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.785 -0.722 . . . . 63.14 112.494 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -99.22 130.46 45.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 72.35 110.866 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -135.42 146.39 48.23 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.197 -0.456 . . . . 74.2 110.93 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.542 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 0.7 OUTLIER -148.22 -163.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 72.42 110.907 179.99 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.542 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 1.2 tt 58.94 158.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 73.34 111.129 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 72.14 111.157 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 68.7 m . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.771 0.32 . . . . 74.21 111.118 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.3 mp -150.01 143.66 17.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 75.33 111.136 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 m -134.47 140.74 45.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 73.33 111.133 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.68 126.03 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 73.5 111.17 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 11.3 mmmm -108.92 141.51 40.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 65.33 110.909 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.209 -0.451 . . . . 73.42 110.928 179.963 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.803 0.335 . . . . 75.12 110.867 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -104.52 143.98 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 75.44 110.904 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.0 m -110.64 -177.55 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 73.44 111.138 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.404 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 4.9 p30 -143.79 156.18 59.31 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.626 0.727 . . . . 70.34 110.87 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.81 -3.58 12.34 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.652 2.235 . . . . 75.11 112.338 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 3.7 m -47.56 -63.74 0.97 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.237 -0.438 . . . . 71.32 111.14 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -155.67 29.04 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.244 -0.435 . . . . 74.02 111.133 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.4 p -64.57 -30.23 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.435 . . . . 65.25 111.12 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.0 ptt-85 -101.17 -6.63 24.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.35 110.874 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 11.3 mm-40 -97.43 -37.46 9.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 75.5 110.924 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -135.11 133.93 39.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 71.1 110.852 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.05 -158.76 18.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.717 -0.754 . . . . 72.23 112.466 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -29.02 24.71 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.657 2.238 . . . . 72.32 112.364 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 15.0 m-90 -87.12 -11.42 50.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.26 -0.427 . . . . 75.54 110.893 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.36 -59.16 5.07 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.267 -0.424 . . . . 74.13 111.074 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.91 143.63 26.99 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.598 0.713 . . . . 75.12 110.885 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -22.69 31.51 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.735 2.29 . . . . 74.24 112.288 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.8 -7.27 51.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.271 -0.422 . . . . 35.4 111.104 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 31.7 mm-40 -104.73 5.27 33.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 71.44 110.887 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -77.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 74.15 111.1 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.3 p -103.39 108.4 24.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 74.43 111.109 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -114.91 149.86 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 75.1 111.138 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -67.96 122.32 17.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 75.23 110.895 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.7 t -119.73 -33.55 3.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 51.44 111.132 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.06 175.85 17.94 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 71.35 112.493 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.67 24.21 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.721 2.281 . . . . 74.12 112.336 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -161.03 34.79 0.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 74.14 110.895 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -150.91 160.29 44.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 74.51 110.94 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -143.12 144.32 32.18 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.244 -0.435 . . . . 74.54 110.906 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.2 m -97.62 103.14 15.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 73.22 111.142 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.9 t -85.05 137.67 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 72.32 111.18 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -120.26 113.12 19.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 73.51 110.966 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 59.1 t -110.42 133.82 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 74.13 111.122 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -139.31 139.36 37.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 73.23 110.868 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.16 122.66 5.63 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 74.51 111.107 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -121.56 145.57 47.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 75.31 110.874 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.32 48.12 1.57 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.474 . . . . 72.51 111.117 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -120.9 -50.7 2.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 64.22 110.879 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -133.71 -119.01 1.95 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.773 -0.727 . . . . 75.32 112.54 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -150.17 136.68 19.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 74.34 110.894 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -130.39 159.41 70.76 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.578 0.704 . . . . 71.42 110.939 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -176.97 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.672 2.248 . . . . 71.51 112.367 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -137.57 62.5 36.23 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.672 0.748 . . . . 74.34 110.926 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 6.45 1.3 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.67 2.247 . . . . 74.54 112.313 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.437 ' H ' ' CD1' ' A' ' 53' ' ' ILE . 4.7 mp -48.39 131.28 5.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 75.13 111.136 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -140.18 149.6 43.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 64.14 110.883 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.9 t -151.0 81.96 6.09 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.618 0.723 . . . . 73.53 111.132 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 123.08 9.74 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.647 2.232 . . . . 71.33 112.332 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.1 155.3 40.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 65.24 110.923 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.54 -9.67 70.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.729 -0.748 . . . . 70.23 112.469 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.36 154.35 50.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.759 0.314 . . . . 71.02 111.125 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -64.88 144.55 57.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 75.44 110.944 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 7.6 mm -129.44 115.16 33.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 65.13 111.127 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 77.2 t -99.06 97.72 6.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 72.0 111.122 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -75.85 132.06 40.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 75.41 110.872 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -130.82 100.06 5.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.931 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.38 153.24 4.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 75.51 111.11 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.5 t -167.1 128.66 1.62 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 72.23 111.134 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.425 ' HB2' HG23 ' A' ' 70' ' ' VAL . 0.1 OUTLIER -140.25 166.16 25.39 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.637 0.732 . . . . 74.33 110.84 -179.875 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.406 ' HD2' ' CB ' ' A' ' 67' ' ' SER . 54.4 Cg_endo -69.72 -54.8 0.2 Allowed 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.668 2.245 . . . . 72.1 112.389 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -158.7 57.22 0.44 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 74.32 110.917 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.425 HG23 ' HB2' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.62 140.23 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.142 -0.481 . . . . 75.34 111.108 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.0 mm -85.3 150.82 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 74.1 111.101 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -115.69 -84.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.472 . . . . 74.43 110.903 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.88 98.85 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.743 -0.741 . . . . 73.05 112.492 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -106.31 142.47 35.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 75.0 110.89 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -110.8 142.39 42.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 75.55 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.4 t -135.89 136.19 50.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 73.21 111.142 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -64.21 -177.2 0.26 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.181 -0.463 . . . . 74.34 110.925 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 84.32 -51.22 4.53 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.747 -0.74 . . . . 65.33 112.479 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.1 m -135.12 160.94 36.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.774 0.321 . . . . 75.53 111.202 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -86.01 76.58 9.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 73.3 110.893 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 4.8 tt -85.01 121.81 37.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 73.52 111.11 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -116.5 95.42 5.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 74.14 110.878 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.8 m -115.63 120.37 64.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 74.51 111.147 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -156.59 110.02 2.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.2 -0.454 . . . . 71.31 110.874 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.8 p -140.74 147.11 23.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 62.54 111.12 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.28 161.1 80.26 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.567 0.699 . . . . 72.41 110.905 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 159.64 52.67 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.654 2.236 . . . . 74.14 112.333 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.39 85.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.722 -0.751 . . . . 75.11 112.469 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -139.37 145.25 38.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.932 0.396 . . . . 74.53 110.889 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 21.2 t -99.3 110.66 27.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.165 -0.47 . . . . 72.25 111.157 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -91.37 165.97 13.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 62.34 110.846 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.4 t -144.19 140.15 29.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 71.41 111.168 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.9 p -153.79 127.55 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 73.11 111.126 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.0 mtm180 -93.95 111.11 22.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 73.14 110.885 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -145.75 118.45 8.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.429 . . . . 73.12 110.872 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.3 t -114.39 132.03 56.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 71.44 111.161 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -177.59 6.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 73.42 110.854 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.3 ttpt -121.52 -24.28 5.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 74.51 110.901 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.49 160.21 57.69 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.613 0.721 . . . . 73.23 110.899 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 127.85 15.16 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.689 2.26 . . . . 72.21 112.313 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.12 146.33 14.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 70.01 112.521 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -105.57 135.71 46.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.84 0.352 . . . . 74.34 110.881 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -143.97 148.87 35.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.169 -0.469 . . . . 75.54 110.947 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 30.6 ttp85 -168.78 157.9 8.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 75.31 110.882 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mp 66.79 147.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.176 -0.466 . . . . 75.41 111.096 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 74.13 111.11 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' THR . . . . . 0.413 HG22 ' CD1' ' A' ' 53' ' ' ILE . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.73 0.3 . . . . 65.1 111.197 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.4 mp -149.06 120.53 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 74.21 111.13 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.0 p -114.83 127.14 72.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 75.02 111.089 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 42.7 t -97.88 131.2 45.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 74.32 111.149 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 15.2 mmmt -104.97 128.53 53.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 75.45 110.86 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 60.22 110.884 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.87 0.367 . . . . 71.54 110.869 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -86.02 137.97 32.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 72.13 110.867 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.1 m -120.72 -177.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.131 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.436 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 33.8 p30 -144.16 156.75 57.88 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.596 0.712 . . . . 72.03 110.882 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.6 Cg_endo -69.76 -2.28 9.9 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.674 2.249 . . . . 73.31 112.356 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.6 m -45.24 -65.24 0.56 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.223 -0.444 . . . . 74.34 111.124 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.2 p -150.26 17.84 0.84 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 71.12 111.121 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.4 p -57.17 -25.8 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 74.34 111.145 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.426 HH12 ' NE2' ' A' ' 18' ' ' GLN . 3.5 ptt85 -106.71 -8.05 17.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 75.03 110.851 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.426 ' NE2' HH12 ' A' ' 17' ' ' ARG . 0.8 OUTLIER -94.03 -32.22 13.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.4 110.92 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -142.56 144.19 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 74.35 110.902 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.96 -156.56 15.58 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.765 -0.731 . . . . 74.02 112.482 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 -35.94 11.69 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.661 2.24 . . . . 65.34 112.328 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 13.5 m-90 -84.66 -7.25 59.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.213 -0.449 . . . . 70.34 110.92 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.02 -54.19 45.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.24 -0.437 . . . . 52.13 111.105 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.68 141.99 30.89 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.653 0.74 . . . . 75.04 110.855 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.673 2.248 . . . . 74.12 112.372 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.59 -36.99 65.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 64.21 111.06 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.466 ' N ' HE21 ' A' ' 27' ' ' GLN . 0.0 OUTLIER -95.31 33.06 1.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 75.52 110.929 -179.962 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.73 -76.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 73.22 111.101 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 38' ' ' THR . 2.3 p -101.88 129.79 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 72.21 111.103 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -142.33 139.99 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 73.32 111.151 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.0 tp60 -72.4 123.34 22.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 75.33 110.903 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -120.28 -10.45 9.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 75.24 111.165 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.98 -168.83 12.46 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 74.24 112.479 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -33.8 16.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.654 2.236 . . . . 72.21 112.368 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -154.31 28.7 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 73.04 110.896 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -126.83 119.43 26.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 75.11 110.912 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 63.0 m-85 -96.37 134.7 39.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 74.25 110.906 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.467 ' HA ' HG23 ' A' ' 62' ' ' VAL . 92.5 m -93.84 104.23 16.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 74.43 111.119 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.1 t -86.85 132.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 71.31 111.096 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -118.07 115.66 25.3 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.19 -0.459 . . . . 75.1 110.917 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.8 m -114.05 119.71 61.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 73.32 111.131 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -114.97 132.86 56.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 73.13 110.927 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -154.59 131.28 10.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 75.3 111.066 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -127.1 163.03 24.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 75.13 110.868 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.03 2.9 48.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.098 -0.501 . . . . 71.21 111.124 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 3.5 p90 -122.3 84.43 2.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 73.12 110.865 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.01 158.72 12.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 75.31 112.464 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -111.77 120.8 43.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.798 0.332 . . . . 73.4 110.976 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -127.08 162.36 48.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 60.24 110.883 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 162.49 41.87 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.659 2.239 . . . . 75.45 112.34 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 -137.95 67.19 48.8 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.614 0.721 . . . . 74.43 110.851 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 98.99 0.72 Allowed 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.643 2.228 . . . . 73.22 112.35 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.5 mm -100.57 157.44 4.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 75.34 111.131 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -155.42 122.08 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.909 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.422 HG22 ' HA ' ' A' ' 124' ' ' VAL . 6.0 m -142.68 86.6 9.53 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.612 0.72 . . . . 73.1 111.137 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 122.74 9.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.689 2.259 . . . . 73.31 112.344 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.06 155.75 23.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 72.32 110.904 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.98 -0.97 76.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.694 -0.765 . . . . 72.44 112.484 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.95 150.4 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.787 0.327 . . . . 74.23 111.086 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -68.14 138.23 55.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 74.12 110.883 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.0 mm -128.28 117.78 46.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 70.2 111.139 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.467 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -104.23 94.2 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 75.32 111.145 179.841 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -64.52 142.86 58.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 74.44 110.899 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -133.36 98.36 4.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.42 110.917 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.3 mp -106.8 137.01 39.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.26 -0.427 . . . . 73.31 111.15 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.5 t -154.96 134.62 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 74.33 111.121 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.2 161.38 39.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.688 0.756 . . . . 64.31 110.852 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 -52.98 0.3 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.699 2.266 . . . . 73.4 112.308 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -158.31 53.61 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 62.51 110.856 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -155.12 140.95 11.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 74.42 111.121 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.5 mm -85.83 151.23 3.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 75.33 111.132 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 78.2 t60 -125.47 -83.93 0.63 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.17 -0.468 . . . . 73.52 110.872 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 61.13 158.57 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.724 -0.751 . . . . 71.34 112.504 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -145.76 141.9 28.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.928 0.394 . . . . 75.33 110.859 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 31.0 t-80 -104.35 140.29 38.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 70.51 110.844 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 94.1 t -126.31 134.66 65.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 73.11 111.154 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -75.14 169.69 17.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 75.42 110.887 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.33 -51.28 4.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 51.33 112.504 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.3 m -116.29 151.47 35.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 74.3 111.109 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -86.04 58.79 5.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.909 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 7.7 tt -62.87 126.11 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 71.02 111.121 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -116.53 90.9 3.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 74.44 110.896 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.6 m -115.74 120.06 63.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 74.3 111.1 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -155.71 114.66 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 74.14 110.834 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 94.3 t -140.2 145.04 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 73.23 111.104 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.1 mp -79.79 159.91 70.35 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.644 0.735 . . . . 75.54 110.904 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 159.7 52.43 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.687 2.258 . . . . 73.4 112.354 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.58 10.02 48.49 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.75 -0.738 . . . . 74.51 112.519 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -169.36 126.24 0.91 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.891 0.376 . . . . 71.24 110.888 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 2.4 p -65.17 118.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 70.33 111.158 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -81.57 166.7 20.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 64.23 110.894 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 97.8 m -136.27 134.86 38.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.43 111.174 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.2 t -144.48 131.5 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 72.33 111.116 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -109.58 95.1 5.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 75.02 110.904 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -136.13 127.25 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.196 -0.456 . . . . 71.23 110.874 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.8 t -128.2 143.27 51.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 74.25 111.145 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -100.75 -173.26 2.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 72.02 110.907 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.03 -24.43 4.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.141 -0.482 . . . . 73.42 110.855 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -132.39 162.16 58.72 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.613 0.72 . . . . 74.43 110.895 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 155.45 65.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.711 2.274 . . . . 74.01 112.358 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.46 133.15 2.34 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.74 -0.743 . . . . 74.43 112.433 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -97.24 144.09 27.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.863 0.363 . . . . 75.35 110.866 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -137.74 132.63 33.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 74.14 110.949 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.82 120.98 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 74.44 110.853 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 5.6 tt -178.22 137.32 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 75.25 111.136 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 74.13 111.106 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 13.4 t . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.794 0.331 . . . . 74.1 111.107 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 5.9 mm -141.52 148.24 21.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.51 111.121 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 71.3 t -135.07 115.46 18.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.143 -0.481 . . . . 74.3 111.146 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . 0.422 ' HA ' HG22 ' A' ' 55' ' ' VAL . 95.9 t -102.25 121.69 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 74.42 111.112 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.1 mmmt -106.22 138.73 41.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 73.05 110.878 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.222 -0.445 . . . . 73.22 110.868 179.996 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 15.8 mp0 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.856 0.36 . . . . 74.24 110.921 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.71 149.46 23.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 75.32 110.866 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.8 m -147.39 -178.29 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 70.44 111.125 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -144.3 162.31 40.47 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.618 0.723 . . . . 73.31 110.858 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -4.59 14.34 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.633 2.222 . . . . 74.13 112.317 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.6 m -48.83 -67.14 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.431 . . . . 75.54 111.105 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 3.1 p -155.46 38.27 0.38 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 73.33 111.179 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.8 p -76.22 -31.97 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 75.44 111.139 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.4 ptt-85 -97.25 -11.61 23.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 74.41 110.894 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.6 mm-40 -95.53 -37.32 10.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.893 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -132.65 134.17 44.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 75.2 110.869 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.57 -158.95 18.23 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.764 -0.731 . . . . 74.33 112.506 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -26.86 26.93 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.623 2.215 . . . . 75.04 112.373 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 13.3 m-90 -87.39 -13.34 43.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 71.11 110.91 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.18 -59.67 2.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.267 -0.424 . . . . 73.33 111.054 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.18 144.07 29.34 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.623 0.725 . . . . 75.52 110.833 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -28.97 24.7 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.62 2.213 . . . . 73.54 112.369 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.4 -16.98 60.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 72.41 111.089 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.2 mm-40 -88.36 8.3 28.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 75.21 110.947 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.39 -78.4 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 74.0 111.08 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.1 p -103.02 126.51 57.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 64.43 111.114 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -134.97 150.13 29.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 65.01 111.083 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -71.02 121.03 17.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 71.13 110.892 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.7 t -120.13 -33.05 4.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 75.34 111.153 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.79 178.49 16.49 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.706 -0.759 . . . . 74.22 112.476 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -18.14 37.33 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.727 2.284 . . . . 74.42 112.368 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 -153.3 30.08 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.196 -0.456 . . . . 75.42 110.872 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -140.96 157.46 45.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 72.24 110.919 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -140.56 138.39 34.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 75.34 110.95 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.501 ' HA ' HG21 ' A' ' 62' ' ' VAL . 75.4 m -92.98 103.86 16.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 75.51 111.143 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 t -90.25 140.39 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 74.51 111.158 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -124.14 120.44 32.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.12 110.893 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 4.5 m -121.61 146.52 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 74.43 111.129 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -139.1 143.94 38.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.166 -0.47 . . . . 72.41 110.935 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.84 106.2 3.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.441 . . . . 72.23 111.102 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.6 p90 -129.07 144.99 51.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 72.42 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.62 0.36 52.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 65.11 111.132 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.55 33.97 1.37 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 74.53 110.848 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.75 -141.73 8.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.743 -0.741 . . . . 75.13 112.494 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -155.48 155.17 33.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 73.32 110.899 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.406 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -156.66 156.2 29.62 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.607 0.718 . . . . 75.3 110.883 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.4 Cg_endo -69.82 -179.78 3.18 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 73.4 112.334 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.414 ' HB3' ' HB ' ' A' ' 121' ' ' THR . 0.4 OUTLIER -131.94 61.36 57.59 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.609 0.719 . . . . 73.44 110.881 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 7.16 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.659 2.24 . . . . 75.32 112.359 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.407 ' H ' ' C ' ' A' ' 51' ' ' ASN . 3.7 mp -46.86 143.34 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 72.43 111.121 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -144.18 164.69 29.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 64.53 110.891 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.412 HG23 HG13 ' A' ' 61' ' ' ILE . 2.4 p -165.4 82.87 1.11 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 72.22 111.15 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 122.49 9.18 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 75.13 112.354 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.25 154.9 40.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 73.24 110.89 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.59 -7.87 77.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.771 -0.728 . . . . 62.21 112.451 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.03 159.03 41.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.768 0.318 . . . . 65.12 111.064 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -71.76 140.71 49.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 73.31 110.917 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.412 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -129.56 115.48 34.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 73.22 111.169 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.501 HG21 ' HA ' ' A' ' 38' ' ' THR . 1.1 m -103.76 90.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 73.12 111.107 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -66.45 140.87 58.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.913 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -132.42 98.61 4.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 71.13 110.931 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.4 mp -97.72 158.41 3.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 74.31 111.157 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.2 t -168.73 135.59 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 74.34 111.144 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.417 ' CB ' HG22 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -139.72 159.93 63.11 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.669 0.747 . . . . 75.43 110.858 -179.847 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -52.77 0.31 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.697 2.265 . . . . 70.11 112.398 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -153.02 41.11 0.56 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 61.5 110.847 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.417 HG22 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -142.3 135.07 27.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.229 -0.441 . . . . 73.15 111.125 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.9 mt -72.95 146.39 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 74.23 111.134 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 30.6 p80 -113.65 -168.16 1.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 71.32 110.848 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.87 118.16 2.06 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.743 -0.742 . . . . 44.44 112.51 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -117.63 144.38 45.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 72.24 110.842 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 32.9 t-80 -106.03 130.19 53.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 75.21 110.839 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 2.4 p -131.71 128.82 60.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.472 . . . . 73.34 111.089 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -58.08 -177.53 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 63.21 110.874 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.3 -47.6 1.95 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.738 -0.744 . . . . 74.11 112.444 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.28 179.49 7.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.857 0.36 . . . . 73.12 111.086 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -92.31 78.88 5.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 74.13 110.896 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 6.8 tt -88.56 123.43 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 72.22 111.102 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -122.67 92.56 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 74.05 110.919 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.6 m -116.48 119.92 63.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 71.23 111.174 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -165.44 111.15 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 73.11 110.906 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 86.2 t -140.63 140.81 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 71.14 111.133 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.0 mp -56.88 160.77 5.46 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.567 0.699 . . . . 72.34 110.928 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 160.68 48.83 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.672 2.248 . . . . 70.31 112.375 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.2 17.24 56.14 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.742 -0.742 . . . . 72.23 112.504 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -159.79 157.47 29.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.881 0.372 . . . . 74.31 110.886 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 86.1 t -102.92 133.5 46.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 72.14 111.107 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -109.53 115.29 29.64 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.845 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.5 m -94.46 124.43 38.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.062 -0.517 . . . . 74.21 111.158 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.7 p -134.67 137.66 50.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 75.43 111.197 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -103.24 108.56 19.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.154 -0.476 . . . . 73.45 110.902 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -141.35 112.26 7.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 74.11 110.909 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -112.86 137.31 51.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.47 . . . . 71.11 111.109 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.32 -175.28 3.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 73.14 110.919 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.5 mtmm -123.63 -12.78 7.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.871 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.6 mpp_? -150.87 161.79 28.94 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.603 0.716 . . . . 75.32 110.904 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.83 64.95 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.763 2.309 . . . . 71.44 112.331 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.92 141.58 3.18 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.733 -0.746 . . . . 62.53 112.493 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -106.18 128.84 54.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 72.22 110.898 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 5.9 p90 -143.98 146.19 32.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.155 -0.475 . . . . 75.14 110.947 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.92 -176.52 5.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 73.11 110.846 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 18.9 mm 66.37 155.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 73.41 111.103 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 74.43 111.096 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' THR . . . . . 0.414 ' HB ' ' HB3' ' A' ' 51' ' ' ASN . 4.2 m . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.777 0.322 . . . . 75.03 111.152 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.6 mp -146.77 120.4 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 75.25 111.174 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.6 p -116.41 142.2 31.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 73.32 111.103 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 60.5 t -106.05 122.17 59.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.162 -0.472 . . . . 74.2 111.161 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -90.39 134.94 34.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 75.44 110.936 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 71.53 110.897 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 25.2 mp0 . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.859 0.361 . . . . 74.55 110.888 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -92.59 137.71 32.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 74.12 110.863 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 12.5 m -136.32 -177.94 2.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 73.43 111.127 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -143.93 162.52 40.47 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.589 0.709 . . . . 70.14 110.897 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -4.12 13.38 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.697 2.265 . . . . 73.45 112.355 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 23.3 m -47.64 -70.04 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 70.43 111.126 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 3.7 p -155.96 38.74 0.36 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 73.42 111.147 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.4 p -75.52 -42.25 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.253 -0.431 . . . . 73.5 111.13 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.97 11.25 26.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 74.32 110.868 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 16.7 mm-40 -105.55 -33.26 8.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 71.34 110.879 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . 0.47 ' O ' ' CG ' ' A' ' 19' ' ' GLU . 28.5 tt0 -142.55 13.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 74.31 110.859 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -103.35 -154.85 24.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.741 -0.742 . . . . 75.23 112.487 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.449 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.2 Cg_endo -69.75 -23.06 31.26 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.684 2.256 . . . . 64.43 112.351 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.449 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 18.2 m-90 -91.03 -7.27 52.35 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 73.44 110.939 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.18 -44.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 75.54 111.132 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.43 137.71 20.74 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.61 0.719 . . . . 73.4 110.892 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -17.83 37.14 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.692 2.261 . . . . 61.23 112.314 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.19 -37.8 69.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 55.15 111.134 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 57.3 mm-40 -84.79 4.9 30.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 72.32 110.911 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.65 -73.29 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 64.41 111.107 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 38' ' ' THR . 2.0 p -105.93 123.01 60.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.235 -0.439 . . . . 60.35 111.105 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.6 t -137.76 150.35 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.457 . . . . 73.32 111.126 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -75.67 121.29 22.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 72.14 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.4 p -121.31 -41.6 2.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.433 . . . . 75.53 111.163 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.73 -166.74 34.8 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.734 -0.746 . . . . 61.24 112.515 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -36.76 10.21 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.673 2.248 . . . . 72.12 112.378 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -152.7 28.95 0.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.249 -0.432 . . . . 73.2 110.861 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 127.53 44.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 74.23 110.893 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 18.0 m-85 -96.66 135.62 38.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 75.31 110.899 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.481 ' HA ' HG22 ' A' ' 62' ' ' VAL . 51.7 m -92.01 102.36 14.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.114 -0.493 . . . . 52.01 111.162 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.5 t -85.75 139.01 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 74.11 111.099 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -120.2 100.61 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 75.03 110.927 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.4 m -96.33 142.43 13.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.104 -0.498 . . . . 73.21 111.108 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.1 tp -130.31 144.21 51.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.925 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -154.52 98.57 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 75.13 111.132 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -113.88 155.96 24.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 75.32 110.854 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.76 31.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 72.12 111.103 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -105.73 75.36 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 75.41 110.866 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.43 -162.37 17.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.713 -0.756 . . . . 53.11 112.491 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 34.1 p90 -126.67 151.88 47.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.834 0.349 . . . . 73.21 110.926 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.08 159.97 68.95 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.64 0.733 . . . . 73.05 110.889 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -176.38 1.48 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.701 2.267 . . . . 75.32 112.316 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -138.11 62.16 30.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.615 0.721 . . . . 72.44 110.856 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 6.27 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.719 2.28 . . . . 65.12 112.334 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.6 mp -48.4 107.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 74.23 111.094 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -110.75 140.19 45.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.14 110.9 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.0 m -140.59 86.36 12.32 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.655 0.74 . . . . 73.52 111.152 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 121.92 8.61 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.686 2.258 . . . . 75.52 112.374 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.95 153.33 42.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 74.2 110.906 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.8 -9.59 75.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 73.41 112.52 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.58 154.72 50.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.741 0.305 . . . . 74.03 111.12 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -67.09 144.4 56.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 70.03 110.899 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 6.7 mm -129.12 101.03 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 64.4 111.142 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.481 HG22 ' HA ' ' A' ' 38' ' ' THR . 0.4 OUTLIER -89.19 100.1 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 72.44 111.104 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -72.89 141.6 47.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 70.13 110.911 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -132.62 99.21 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 75.03 110.901 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.4 mp -98.37 153.92 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 74.34 111.081 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -169.18 136.62 1.83 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 75.3 111.127 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.403 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -148.22 159.44 39.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.67 0.748 . . . . 72.13 110.857 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -55.14 0.19 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.659 2.239 . . . . 74.22 112.352 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -156.3 62.89 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 74.21 110.866 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.403 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.28 136.15 4.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 63.21 111.162 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.2 mm -71.12 143.7 14.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 73.3 111.124 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 9.5 p-80 -125.55 -168.89 1.91 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 74.24 110.852 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.18 132.89 3.49 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 65.2 112.439 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -126.35 142.04 51.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 74.44 110.903 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -103.93 89.28 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 75.35 110.902 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 15.6 t -74.63 131.81 34.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 72.41 111.138 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -68.14 178.36 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 75.24 110.908 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.96 -51.05 1.71 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.729 -0.748 . . . . 71.45 112.495 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.0 179.51 6.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.822 0.344 . . . . 70.45 111.142 -179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 22.5 m120 -87.94 67.42 9.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 70.11 110.871 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 13.2 tt -76.86 119.71 25.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 75.41 111.134 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -116.35 103.32 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 74.31 110.933 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.8 m -125.59 120.52 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.44 111.195 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -155.33 113.45 3.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 73.32 110.878 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 60.9 t -140.85 147.31 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 72.11 111.099 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.468 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -73.48 158.68 86.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.632 0.73 . . . . 73.21 110.954 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.468 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.6 Cg_endo -69.82 159.79 52.05 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.686 2.258 . . . . 63.34 112.333 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.41 17.35 50.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.767 -0.73 . . . . 63.21 112.479 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -165.24 138.48 4.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.947 0.403 . . . . 72.24 110.858 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.38 137.69 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.137 -0.483 . . . . 75.55 111.081 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.5 t -119.98 131.7 55.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.113 -0.494 . . . . 62.43 110.847 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.4 t -96.92 145.76 25.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 72.04 111.119 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 40.1 t -145.99 125.6 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 73.23 111.139 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -102.99 115.43 30.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 75.42 110.89 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -162.27 109.62 1.33 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 63.31 110.908 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -107.72 143.04 36.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.487 . . . . 74.43 111.115 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.41 174.91 6.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 64.34 110.858 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -119.72 -20.36 7.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.489 . . . . 73.31 110.858 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -139.35 158.48 68.79 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.653 0.74 . . . . 75.51 110.814 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 158.07 58.22 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.656 2.237 . . . . 74.35 112.355 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 156.27 136.53 2.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 70.45 112.497 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -101.67 134.75 44.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 74.51 110.892 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -143.9 127.24 16.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 75.42 110.951 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.8 105.96 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 75.13 110.901 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 6.3 tt 179.8 142.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 74.43 111.103 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 72.44 111.125 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 46.3 m . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.779 0.323 . . . . 63.24 111.201 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.6 mp -141.73 119.46 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 73.03 111.158 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.0 p -116.44 136.88 52.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 71.11 111.125 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 35.5 t -100.67 128.1 53.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 61.13 111.169 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.6 mmtt -111.99 132.55 54.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 71.23 110.896 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.207 -0.451 . . . . 71.44 110.926 179.961 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.821 0.343 . . . . 72.31 110.908 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -93.77 127.91 39.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 75.01 110.892 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 7.1 m -110.8 -178.79 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 75.4 111.153 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -144.41 162.17 40.81 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.593 0.711 . . . . 74.04 110.909 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -3.32 11.81 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.705 2.27 . . . . 74.2 112.306 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.9 m -44.92 -70.14 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 74.11 111.09 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.6 p -149.62 22.97 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 74.42 111.148 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.6 p -61.42 -23.75 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 74.35 111.106 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -105.91 -19.88 13.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 72.53 110.844 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -85.29 -28.29 25.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 72.35 110.912 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -145.06 146.66 31.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.467 . . . . 74.11 110.864 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.64 -158.91 14.02 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.794 -0.717 . . . . 72.13 112.453 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.447 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.0 Cg_endo -69.73 -30.26 22.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.665 2.243 . . . . 73.4 112.373 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.447 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 17.2 m-90 -85.86 -8.36 58.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.196 -0.457 . . . . 75.0 110.887 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.63 -59.63 2.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 75.11 111.103 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.54 145.8 34.09 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.588 0.709 . . . . 74.44 110.891 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.644 2.229 . . . . 64.33 112.36 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.0 -22.62 60.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 74.12 111.089 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -116.42 30.86 7.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 74.3 110.916 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.35 -57.01 3.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 74.43 111.097 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -113.18 101.89 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 74.02 111.124 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.9 t -117.14 148.87 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 75.32 111.119 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.435 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -80.39 117.4 21.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 74.3 110.915 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.9 p -105.79 -43.6 4.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 65.03 111.131 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.13 -173.24 22.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.79 -0.719 . . . . 73.31 112.501 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -5.61 16.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.7 2.267 . . . . 74.23 112.307 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -175.41 30.15 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 74.31 110.845 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.6 mp0 -126.62 118.42 24.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 74.33 110.91 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.435 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 54.2 m-85 -98.93 130.4 45.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 74.31 110.94 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 24.7 m -95.62 105.65 17.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.11 -0.496 . . . . 71.01 111.157 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 18.3 t -88.02 146.3 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 75.04 111.128 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -127.27 106.65 9.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 74.54 110.947 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.2 m -107.08 142.76 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 62.22 111.096 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -139.41 143.27 37.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 74.45 110.858 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.35 114.76 3.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 71.3 111.083 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -127.67 155.06 44.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 75.42 110.905 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.9 4.21 38.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.465 . . . . 53.14 111.103 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -104.25 74.76 1.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 72.41 110.861 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 109.37 -160.11 13.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.726 -0.749 . . . . 75.55 112.544 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 11.4 p90 -135.25 144.94 47.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.793 0.33 . . . . 73.14 110.948 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -143.69 162.3 42.21 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.609 0.718 . . . . 75.52 110.883 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -176.09 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.63 2.22 . . . . 72.12 112.338 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 62.9 m-20 -130.79 59.93 49.46 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.622 0.725 . . . . 73.13 110.884 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 73.84 1.31 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.7 2.267 . . . . 64.11 112.353 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.1 mp -117.14 122.71 70.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 75.15 111.086 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -125.75 129.3 49.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.879 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.404 HG21 HG13 ' A' ' 61' ' ' ILE . 2.6 p -136.51 80.47 38.69 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.635 0.731 . . . . 74.45 111.098 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 122.92 9.59 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.701 2.268 . . . . 75.35 112.321 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.49 154.71 40.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.237 -0.438 . . . . 74.23 110.932 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.33 -10.34 71.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 54.51 112.49 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.28 143.11 48.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 73.04 111.087 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -61.15 135.19 57.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 71.21 110.867 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.404 HG13 HG21 ' A' ' 55' ' ' VAL . 12.4 mm -122.62 123.5 68.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.118 -0.492 . . . . 73.43 111.135 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 41.9 t -101.9 92.23 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.42 111.134 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.79 138.33 54.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 73.43 110.873 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -131.15 102.01 5.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 74.55 110.91 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.6 mp -102.92 139.84 22.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 75.34 111.146 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 10.1 t -158.62 137.74 11.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 65.03 111.163 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.425 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -141.59 160.93 54.78 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.674 0.75 . . . . 71.42 110.865 -179.875 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.425 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.86 -54.39 0.22 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.655 2.237 . . . . 52.14 112.349 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -157.32 59.03 0.51 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 72.4 110.882 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -155.93 135.97 4.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 75.41 111.17 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 mm -67.4 144.97 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 73.21 111.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 9.1 p80 -132.96 -176.58 4.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 73.01 110.848 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.62 132.66 3.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.741 -0.742 . . . . 60.2 112.455 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -121.03 144.3 48.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.845 0.355 . . . . 71.14 110.891 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.42 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 9.7 p80 -103.82 88.17 2.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 72.45 110.881 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.9 t -74.94 115.67 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 65.12 111.125 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.89 177.45 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 74.11 110.91 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.41 -49.07 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.788 -0.72 . . . . 75.52 112.489 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.46 179.38 6.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.751 0.31 . . . . 73.42 111.163 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 24.4 m120 -88.35 50.36 1.96 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 70.41 110.882 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 6.2 tp -60.94 116.04 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 75.05 111.1 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -116.9 100.82 8.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.876 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.4 m -121.86 124.13 70.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 73.04 111.13 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -164.61 108.62 0.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 71.03 110.856 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 45.1 t -140.4 146.49 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 74.34 111.189 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.74 161.23 62.68 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.58 0.705 . . . . 74.12 110.948 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.94 51.54 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.73 2.287 . . . . 71.43 112.305 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.37 5.48 75.67 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.75 -0.738 . . . . 62.31 112.515 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -147.9 117.95 7.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.899 0.38 . . . . 73.24 110.872 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 3.8 p -77.94 118.98 25.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 70.42 111.104 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.85 134.05 37.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.11 -0.495 . . . . 74.14 110.835 -179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 74.2 m -98.84 109.39 22.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 70.42 111.15 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 39.7 t -106.86 148.33 11.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 72.32 111.138 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -121.05 107.52 12.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.476 . . . . 74.54 110.831 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -153.18 130.39 11.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 74.11 110.949 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 29.7 m -139.95 141.57 36.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 75.34 111.143 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -96.57 -176.42 3.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 74.2 110.907 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -123.15 -12.55 7.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 75.35 110.905 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.95 162.85 51.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.647 0.737 . . . . 74.35 110.863 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 149.54 66.92 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.686 2.257 . . . . 64.34 112.328 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.4 136.92 2.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 61.52 112.459 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.41 132.82 53.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.847 0.356 . . . . 73.44 110.875 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -143.27 137.17 28.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.181 -0.463 . . . . 74.2 110.895 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.551 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.17 -164.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 73.23 110.877 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.551 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 7.7 tt 57.55 158.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 75.43 111.097 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 74.35 111.118 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 55.1 m . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.775 0.321 . . . . 73.43 111.169 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 5.1 mp -146.48 129.66 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 71.35 111.115 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.27 137.06 55.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 75.2 111.119 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 15.7 t -99.73 125.18 53.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 75.13 111.115 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.6 mmmt -99.26 130.68 45.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 73.23 110.879 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 74.53 110.863 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.847 0.356 . . . . 75.41 110.919 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.12 136.74 38.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 73.41 110.85 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.2 m -128.46 -178.66 2.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 74.24 111.103 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 161.94 41.54 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.647 0.737 . . . . 64.14 110.854 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -4.71 14.58 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.735 2.29 . . . . 62.51 112.359 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.2 m -48.44 -66.92 0.32 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.185 -0.461 . . . . 74.35 111.138 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 2.8 p -155.62 37.59 0.37 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.446 . . . . 73.21 111.163 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 14.7 p -74.29 -34.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 75.11 111.119 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 11.5 ptt85 -95.17 -10.73 29.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 75.44 110.865 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 -97.69 -35.08 10.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 75.45 110.892 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -131.86 136.95 47.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 74.35 110.906 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 118.21 -159.5 14.25 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 62.42 112.495 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -26.89 26.94 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.63 2.22 . . . . 71.21 112.325 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 15.7 m-90 -86.37 -10.94 53.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.235 -0.439 . . . . 72.33 110.929 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.9 -59.0 3.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 71.05 111.079 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.85 144.61 29.7 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.573 0.702 . . . . 73.31 110.898 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -15.32 37.02 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.686 2.257 . . . . 74.43 112.349 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.29 -6.46 48.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 34.31 111.117 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.8 mm-40 -106.39 6.49 30.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 72.54 110.883 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -51.95 -76.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 70.54 111.07 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.2 t -83.13 130.75 35.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 74.34 111.131 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 32.3 t -144.67 114.35 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 73.43 111.109 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -60.03 116.51 4.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 74.34 110.904 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.4 t -119.9 -38.74 2.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 73.0 111.136 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.91 173.61 18.82 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.732 . . . . 75.32 112.539 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.04 3.57 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.726 2.284 . . . . 75.1 112.339 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 53.2 t30 67.78 34.96 4.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 74.5 110.898 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -145.48 156.96 44.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 72.31 110.901 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 43.1 m-85 -143.16 141.27 31.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 75.32 110.955 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 54.4 m -94.86 104.87 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.117 -0.492 . . . . 74.21 111.152 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 15.7 t -87.35 152.62 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 74.43 111.097 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -127.2 140.25 52.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 73.02 110.913 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.0 t -139.1 137.98 41.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 63.54 111.106 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -138.42 141.49 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 73.3 110.873 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.58 101.18 2.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 73.1 111.104 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -116.57 147.35 41.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 74.44 110.857 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.23 0.26 52.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 75.11 111.115 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -94.19 39.28 1.08 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 75.44 110.908 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.63 -137.93 8.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 64.51 112.526 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 31.1 t80 -155.24 160.6 40.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.802 0.334 . . . . 74.23 110.959 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -165.23 162.18 14.07 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.581 0.705 . . . . 75.25 110.912 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 176.74 6.37 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.703 2.269 . . . . 73.2 112.348 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -133.89 63.25 62.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.616 0.722 . . . . 64.01 110.85 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 72.1 1.48 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.268 . . . . 74.4 112.372 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.9 mp -106.41 121.55 59.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 74.31 111.152 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -120.0 115.4 23.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 75.31 110.893 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.6 p -123.35 78.47 53.56 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.621 0.724 . . . . 72.45 111.15 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 123.02 9.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.704 2.27 . . . . 72.42 112.342 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -68.61 154.72 41.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.267 -0.424 . . . . 75.31 110.875 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.1 -6.28 76.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 73.41 112.517 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.31 156.44 47.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.76 0.314 . . . . 75.35 111.072 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -67.42 138.53 56.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.915 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 4.4 mm -130.87 114.8 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 64.43 111.118 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 39.5 t -101.23 94.29 3.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 75.35 111.123 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -70.47 132.61 45.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 74.44 110.884 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 36.2 mttt -128.74 99.74 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 75.23 110.914 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -104.22 158.63 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 75.52 111.159 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 7.9 t -167.01 141.91 4.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 63.2 111.144 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.425 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -148.48 158.46 40.5 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.686 0.755 . . . . 75.42 110.852 -179.88 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.425 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.6 Cg_endo -69.8 -55.48 0.17 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.725 2.283 . . . . 75.53 112.31 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -154.91 68.39 0.7 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.852 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.417 HG21 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.2 -171.15 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.215 -0.448 . . . . 74.22 111.143 -179.992 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.9 mm -138.11 140.49 40.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 75.22 111.126 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -115.23 -85.46 0.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 73.3 110.848 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 53.85 94.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.71 -0.757 . . . . 34.11 112.48 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -100.14 143.09 30.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 70.13 110.868 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -120.22 142.84 48.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 73.04 110.846 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.9 p -127.78 122.83 59.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 71.34 111.112 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -52.16 160.85 0.7 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 74.04 110.897 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.15 -51.93 4.55 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.786 -0.721 . . . . 44.52 112.467 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.85 160.91 14.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.827 0.346 . . . . 73.24 111.132 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -101.03 35.49 2.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.466 . . . . 74.43 110.924 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 20.0 tt -54.73 124.91 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 75.31 111.117 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -123.76 82.75 2.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 74.24 110.897 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 5.1 m -110.33 119.33 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 62.51 111.106 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -165.39 103.32 0.73 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 64.13 110.896 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 18.1 m -140.36 139.37 35.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.148 -0.478 . . . . 75.1 111.13 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.7 mp -59.88 163.39 7.63 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.583 0.706 . . . . 72.45 110.936 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 70' ' ' VAL . 54.3 Cg_endo -69.74 159.93 51.6 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.669 2.246 . . . . 65.41 112.343 179.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.5 17.38 57.1 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 72.41 112.469 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -158.42 143.45 16.35 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 74.34 110.881 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 52.3 t -81.42 146.12 7.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.136 -0.484 . . . . 74.13 111.115 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -103.82 158.08 16.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.44 110.891 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 26.6 m -147.28 123.23 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 75.33 111.164 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.4 p -153.15 136.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 74.12 111.126 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.0 mtm180 -96.33 81.46 3.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 75.43 110.84 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -106.11 121.89 45.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.209 -0.451 . . . . 72.5 110.935 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 t -133.74 138.46 45.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 72.31 111.135 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.43 -168.9 1.68 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.899 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.5 mtpt -123.12 -27.12 4.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 74.02 110.917 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . 0.43 ' HB3' ' HD2' ' A' ' 100' ' ' PRO . 13.3 mmt180 -129.18 156.07 78.87 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 73.43 110.916 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . 0.43 ' HD2' ' HB3' ' A' ' 99' ' ' ARG . 54.0 Cg_endo -69.72 152.08 69.43 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.672 2.248 . . . . 75.04 112.329 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.7 150.49 6.84 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.758 -0.734 . . . . 70.34 112.485 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -112.63 127.74 56.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.885 0.374 . . . . 63.31 110.867 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -143.93 136.46 26.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 72.51 110.911 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.538 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 0.1 OUTLIER -144.38 -167.29 2.59 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.119 -0.492 . . . . 74.43 110.885 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.538 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 0.6 OUTLIER 56.93 159.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 70.42 111.074 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 7.0 tt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 75.22 111.121 179.861 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 28.6 m . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.775 0.321 . . . . 73.34 111.161 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.8 mp -147.88 109.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 73.44 111.112 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.6 p -114.97 140.65 35.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 75.24 111.091 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 68.9 t -104.16 118.49 51.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 75.42 111.125 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 5.1 mmmt -89.98 131.21 35.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 70.54 110.912 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 75.43 110.906 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.822 0.344 . . . . 74.31 110.9 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.95 124.14 34.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 74.34 110.92 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.9 m -111.4 -178.99 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.456 . . . . 74.4 111.146 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -145.59 162.27 37.21 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.594 0.711 . . . . 72.02 110.887 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 -4.03 13.19 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.688 2.258 . . . . 74.13 112.339 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.9 m -46.93 -65.2 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 72.52 111.166 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 2.0 p -155.63 32.54 0.36 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.237 -0.438 . . . . 72.44 111.127 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.9 p -70.96 -29.14 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.232 -0.44 . . . . 64.2 111.125 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.8 ptt-85 -97.55 -9.03 27.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.879 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -101.41 -31.9 10.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 73.33 110.918 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -132.8 134.82 45.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 74.12 110.908 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.98 -158.56 14.62 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.782 -0.723 . . . . 73.2 112.542 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.433 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 53.8 Cg_endo -69.78 -28.81 24.68 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.693 2.262 . . . . 64.34 112.377 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.433 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 18.5 m-90 -87.01 -5.67 59.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 75.31 110.921 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.5 -59.34 2.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.246 -0.434 . . . . 64.51 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -113.93 144.68 32.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.554 0.692 . . . . 65.2 110.891 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -5.02 15.23 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.683 2.256 . . . . 75.22 112.384 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.77 -19.0 61.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.128 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.24 31.16 6.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 74.21 110.929 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.2 -73.1 0.13 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.05 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.404 ' HA ' ' O ' ' A' ' 38' ' ' THR . 2.0 p -111.63 106.54 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.441 . . . . 74.22 111.157 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -117.45 149.92 19.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 72.23 111.157 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -79.64 124.21 28.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 73.24 110.94 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.7 t -119.19 -14.83 9.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 61.32 111.136 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.42 -170.93 12.81 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 74.34 112.484 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -36.02 11.42 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.252 . . . . 72.14 112.33 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 20.2 t30 -149.76 34.61 0.69 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.225 -0.443 . . . . 73.51 110.861 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -137.33 117.44 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 75.33 110.91 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -98.24 143.13 29.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 75.14 110.918 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.404 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 51.9 m -99.05 102.21 13.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 73.33 111.158 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 t -83.53 143.15 12.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 75.52 111.117 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -125.0 112.7 16.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.196 -0.456 . . . . 74.52 110.937 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 85.4 t -109.53 125.9 66.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.12 -0.491 . . . . 63.14 111.107 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -115.64 137.18 52.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 74.21 110.928 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.05 117.56 4.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 72.11 111.082 179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -145.38 140.54 27.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 65.43 110.885 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.4 27.03 1.31 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 74.31 111.124 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -120.92 25.26 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 73.43 110.886 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 169.32 -146.9 10.53 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.816 -0.707 . . . . 52.22 112.523 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -155.57 116.4 3.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.798 0.332 . . . . 74.32 110.914 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.437 ' HG3' ' HD2' ' A' ' 50' ' ' PRO . 2.1 mp0 -134.65 163.32 52.02 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.591 0.71 . . . . 75.14 110.919 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.437 ' HD2' ' HG3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.79 162.15 43.19 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.64 2.226 . . . . 74.34 112.362 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 -124.29 64.34 36.81 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.586 0.708 . . . . 73.32 110.917 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 113.18 3.28 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.669 2.246 . . . . 74.54 112.375 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.5 mm -126.13 144.99 34.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 74.22 111.161 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -155.23 115.6 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 74.14 110.918 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.7 m -130.75 84.29 59.08 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.63 0.729 . . . . 73.34 111.127 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 122.62 9.3 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 73.42 112.369 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.7 154.56 38.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 65.41 110.9 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.62 -8.39 72.34 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 72.43 112.476 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.16 157.32 45.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.714 0.292 . . . . 71.42 111.142 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -70.19 144.7 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 71.4 110.915 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.4 mm -128.79 105.35 12.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 70.51 111.112 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 25.4 t -84.74 100.68 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 74.15 111.074 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -76.89 135.15 38.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.1 110.876 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 8.7 mttt -132.28 100.19 4.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 72.41 110.93 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.6 mp -109.08 141.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 71.52 111.115 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 7.8 t -155.92 135.3 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 72.13 111.135 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -141.96 161.1 53.02 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.7 0.762 . . . . 73.24 110.826 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -53.34 0.28 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.674 2.249 . . . . 52.11 112.365 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -156.67 57.82 0.55 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 71.14 110.823 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.49 141.43 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.254 -0.43 . . . . 75.13 111.126 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 25.1 mm -85.35 155.18 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 74.23 111.093 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -123.75 -86.28 0.64 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.121 -0.49 . . . . 75.2 110.857 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.04 101.6 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.721 -0.752 . . . . 62.14 112.469 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 2.5 p90 -103.5 144.94 30.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.917 0.389 . . . . 74.34 110.854 -179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -106.0 142.25 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 71.33 110.884 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 44.3 t -137.53 143.6 33.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 62.24 111.131 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -73.2 -175.7 1.94 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.478 . . . . 65.22 110.912 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.09 -51.09 3.98 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.75 -0.738 . . . . 60.55 112.493 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.14 179.5 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.828 0.347 . . . . 70.25 111.127 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 -88.17 61.05 6.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 65.21 110.891 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 4.8 tp -71.16 99.72 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 74.3 111.13 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -110.4 112.11 23.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 75.15 110.919 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 1.5 m -130.82 122.93 53.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.457 . . . . 75.21 111.161 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -152.64 112.79 4.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 71.44 110.874 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 57.3 t -140.55 144.28 27.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 73.33 111.119 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.27 160.06 80.54 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.631 0.729 . . . . 74.32 110.899 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 159.82 51.97 Favored 'Trans proline' 0 C--N 1.34 0.126 0 C-N-CA 122.708 2.272 . . . . 73.23 112.28 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.61 -1.27 56.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 74.34 112.465 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -147.0 156.75 43.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.884 0.374 . . . . 74.45 110.891 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 2.1 p -105.55 113.9 43.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 71.03 111.119 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.54 168.2 19.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 64.45 110.876 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 96.5 m -134.5 139.35 45.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 65.34 111.129 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.9 t -143.45 137.63 25.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.236 -0.438 . . . . 75.11 111.128 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.04 72.63 0.79 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.469 . . . . 74.33 110.886 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -108.41 141.17 40.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 74.51 110.924 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.1 t -140.06 143.19 36.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.137 -0.483 . . . . 71.41 111.162 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -101.1 177.18 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 72.02 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.34 -12.79 8.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.462 . . . . 75.14 110.877 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -144.57 162.03 41.01 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.653 0.74 . . . . 75.13 110.914 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 155.58 65.62 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.73 2.287 . . . . 62.25 112.314 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 162.27 135.37 1.8 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.773 -0.727 . . . . 74.32 112.53 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -108.92 124.89 51.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.866 0.365 . . . . 74.14 110.901 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -136.04 135.27 39.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.198 -0.456 . . . . 72.23 110.954 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.561 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 0.5 OUTLIER -144.24 -177.56 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 75.22 110.858 -179.95 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.561 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 6.6 tt 59.79 158.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 73.13 111.122 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 72.22 111.164 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 99.4 m . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.741 0.305 . . . . 71.13 111.138 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 3.1 mp -153.41 138.08 9.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 73.12 111.131 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.5 p -134.22 134.69 55.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 71.12 111.151 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 48.1 t -103.61 129.13 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 73.41 111.152 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt -107.19 129.1 54.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.134 -0.484 . . . . 73.35 110.885 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 73.14 110.878 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.828 0.347 . . . . 73.1 110.877 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.67 139.26 40.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 75.44 110.874 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.8 m -130.1 -177.55 2.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 75.54 111.124 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.402 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 55.9 p-10 -144.07 155.47 58.6 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.563 0.697 . . . . 74.44 110.893 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.402 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.4 Cg_endo -69.84 -3.94 13.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.656 2.237 . . . . 73.53 112.351 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 23.2 m -49.07 -64.7 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 53.32 111.092 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 2.7 p -156.04 34.91 0.34 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 62.51 111.15 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 p -70.59 -29.19 37.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 71.12 111.069 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 ptt-85 -98.74 -7.91 26.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 74.21 110.879 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -101.62 -34.79 9.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 73.15 110.927 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.51 133.2 46.07 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 73.53 110.891 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 120.25 -158.15 15.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.747 -0.74 . . . . 62.11 112.507 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -30.11 22.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.73 2.287 . . . . 75.43 112.321 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 13.5 m-90 -84.89 -10.21 57.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.279 -0.418 . . . . 74.1 110.921 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.85 -59.46 2.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 74.41 111.072 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.76 144.64 28.21 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.64 0.733 . . . . 72.53 110.815 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -26.35 27.8 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.686 2.257 . . . . 75.32 112.335 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.02 -18.31 60.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.262 -0.426 . . . . 74.13 111.093 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 19.0 mm-40 -87.35 6.85 31.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 75.22 110.887 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.87 -77.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.266 -0.424 . . . . 72.43 111.084 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.54 116.95 23.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 71.34 111.131 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.0 t -145.77 131.06 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 71.5 111.167 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.59 125.47 26.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 73.31 110.877 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.2 t -117.46 -41.39 2.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 74.02 111.148 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.73 -164.11 18.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 73.35 112.482 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -43.99 2.37 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.7 2.266 . . . . 73.15 112.372 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -141.27 34.45 1.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 73.31 110.908 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -131.4 119.71 22.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 72.15 110.847 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -97.0 140.93 30.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 71.12 110.919 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.461 ' HA ' HG23 ' A' ' 62' ' ' VAL . 96.7 m -93.79 122.45 36.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 61.22 111.137 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 18.5 t -109.05 108.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 74.1 111.107 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -94.18 105.45 17.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 73.21 110.924 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 59.8 t -98.73 132.65 43.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.082 -0.508 . . . . 71.44 111.167 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -123.85 133.82 53.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.226 -0.443 . . . . 75.22 110.91 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.06 132.01 10.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 74.41 111.083 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -145.26 147.54 32.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 72.41 110.912 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.74 50.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.179 -0.464 . . . . 72.04 111.133 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -95.72 34.05 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 73.31 110.86 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.49 -138.56 6.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.75 -0.738 . . . . 65.05 112.505 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -155.17 157.02 36.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.801 0.334 . . . . 73.41 110.957 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -165.33 162.05 13.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.582 0.706 . . . . 73.31 110.938 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 178.64 4.34 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.677 2.251 . . . . 75.11 112.37 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -138.41 63.46 34.78 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.602 0.715 . . . . 73.34 110.869 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 73.1 1.36 Allowed 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.719 2.279 . . . . 71.2 112.361 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.8 mp -106.73 136.44 41.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 73.11 111.13 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -133.13 118.05 18.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.169 -0.469 . . . . 71.52 110.891 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 19.6 t -119.9 82.8 28.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 73.11 111.146 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 122.06 8.75 Favored 'Trans proline' 0 N--CA 1.465 -0.173 0 C-N-CA 122.718 2.279 . . . . 72.42 112.358 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -69.79 153.03 43.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 74.2 110.914 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.27 -4.62 83.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 64.51 112.484 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.42 156.24 48.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 71.13 111.112 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -66.71 140.6 57.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 74.24 110.897 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.6 mm -130.23 115.01 30.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.134 -0.485 . . . . 72.43 111.116 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.461 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -103.0 90.95 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.17 -0.468 . . . . 71.43 111.161 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 72.2 m-85 -68.13 138.81 56.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 74.13 110.864 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 5.4 mttt -131.83 99.36 4.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 72.44 110.943 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.5 mp -106.76 142.55 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 64.34 111.152 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 14.2 t -153.81 128.29 9.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 72.22 111.155 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.507 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 1.0 OUTLIER -131.33 160.23 68.08 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.677 0.751 . . . . 65.11 110.854 -179.847 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.507 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.72 -53.2 0.28 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.708 2.272 . . . . 71.13 112.343 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . 0.4 ' HA ' ' HG3' ' A' ' 87' ' ' PRO . 3.7 m-20 -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 73.23 110.888 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.432 HG23 ' HB2' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.9 133.41 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 72.23 111.16 179.984 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . 0.459 ' CG2' ' H ' ' A' ' 72' ' ' HIS . 10.1 mm -91.73 172.53 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 62.32 111.105 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . 0.459 ' H ' ' CG2' ' A' ' 71' ' ' ILE . 0.1 OUTLIER 76.28 148.86 0.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.124 -0.489 . . . . 73.32 110.896 179.915 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -121.12 -94.68 1.37 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.731 -0.747 . . . . 62.23 112.489 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -152.02 149.33 28.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.897 0.38 . . . . 74.24 110.871 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -114.73 143.1 45.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 75.33 110.836 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 5.9 p -119.67 145.07 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 75.0 111.141 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.3 172.55 12.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 73.04 110.886 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.51 -52.05 4.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.731 -0.747 . . . . 72.44 112.479 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 16.8 m -123.1 154.13 39.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.333 . . . . 64.31 111.139 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -88.41 65.87 8.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 60.52 110.903 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -57.03 134.12 21.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.195 -0.457 . . . . 70.44 111.169 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.37 81.62 1.61 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 75.3 110.87 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 19.6 m -116.63 117.73 56.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 72.22 111.141 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -166.88 117.8 0.92 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 72.43 110.893 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.0 m -140.18 137.4 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 75.12 111.089 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.08 156.44 1.79 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.576 0.703 . . . . 74.43 110.961 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.4 ' HG3' ' HA ' ' A' ' 69' ' ' ASP . 53.1 Cg_endo -69.83 159.21 54.21 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.671 2.247 . . . . 72.22 112.316 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 87.39 3.36 81.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.71 -0.757 . . . . 74.42 112.523 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -148.59 117.56 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 72.01 110.876 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 1.7 p -60.33 137.19 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 75.44 111.138 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.58 163.91 17.17 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 75.53 110.899 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.6 m -146.69 104.83 3.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 74.13 111.135 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 4.4 p -130.07 154.36 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 75.54 111.14 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -122.67 100.4 6.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 75.35 110.912 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 49.9 t80 -134.81 108.31 7.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.19 -0.459 . . . . 70.04 110.885 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.8 t -103.94 135.54 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 75.53 111.184 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.44 -177.57 4.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 65.55 110.828 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.7 mtmt -125.72 -22.03 4.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 72.33 110.897 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.14 158.92 72.75 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.587 0.708 . . . . 74.44 110.868 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 152.89 69.3 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.696 2.264 . . . . 74.23 112.343 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 168.64 143.43 3.83 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 64.15 112.475 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -110.27 133.09 53.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.832 0.348 . . . . 75.24 110.92 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -143.78 136.63 27.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.148 -0.478 . . . . 75.43 110.921 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.534 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.49 -167.82 2.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 73.31 110.894 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.534 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 8.5 tt 56.64 159.32 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 74.35 111.118 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 74.41 111.112 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 52.3 m . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.792 0.33 . . . . 72.35 111.2 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.8 mp -146.82 139.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 75.43 111.098 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.81 135.08 53.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 73.3 111.174 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 57.4 t -102.65 123.94 56.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 70.53 111.147 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.1 mmtt -98.29 134.25 41.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 75.22 110.918 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 72.12 110.892 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.882 0.372 . . . . 71.52 110.87 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? -99.02 121.42 40.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 64.52 110.87 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.7 m -118.61 -179.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 73.5 111.16 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.99 162.16 39.22 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.688 0.756 . . . . 74.34 110.799 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.85 -2.96 11.12 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.662 2.241 . . . . 73.55 112.349 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -44.86 -62.78 1.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 74.54 111.15 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.8 23.87 0.39 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 74.41 111.166 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.0 p -65.89 -30.98 51.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 72.52 111.098 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -106.3 -6.93 18.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 73.33 110.886 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -95.24 -36.44 11.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 72.3 110.894 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -140.94 132.28 26.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 75.01 110.85 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.91 -156.95 21.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 73.42 112.487 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.4 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.8 Cg_endo -69.76 -32.91 17.65 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 74.41 112.356 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.448 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 10.5 m-90 -84.92 -17.87 36.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.445 . . . . 75.44 110.951 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.45 -61.33 2.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 75.51 111.092 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.69 144.36 29.41 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.612 0.72 . . . . 73.42 110.828 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -11.37 30.69 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.692 2.262 . . . . 74.03 112.32 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.69 -27.52 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 63.01 111.119 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.502 ' N ' HE21 ' A' ' 27' ' ' GLN . 0.0 OUTLIER -111.04 31.84 5.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 74.34 110.862 -179.9 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.77 -41.82 29.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 75.24 111.1 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.64 130.33 69.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 74.41 111.113 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -146.87 137.87 18.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.096 -0.502 . . . . 73.33 111.064 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -79.68 115.87 19.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 75.54 110.937 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -113.79 -21.06 10.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 75.44 111.142 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.27 -167.48 14.05 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 62.33 112.511 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.94 3.88 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.715 2.277 . . . . 75.32 112.363 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -148.42 29.73 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 72.25 110.876 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -126.95 116.32 20.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 75.32 110.891 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -95.75 140.33 30.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 71.44 110.966 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.462 ' HA ' HG23 ' A' ' 62' ' ' VAL . 88.0 m -92.38 109.9 21.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 72.43 111.176 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 t -89.93 130.07 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 75.34 111.108 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -113.98 105.13 12.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 74.23 110.956 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.0 m -100.15 147.01 8.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.145 -0.48 . . . . 74.42 111.158 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.448 ' HG ' ' HB3' ' A' ' 22' ' ' TRP . 0.3 OUTLIER -133.67 133.16 41.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.245 -0.434 . . . . 74.15 110.948 179.961 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.78 98.72 1.94 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 73.12 111.083 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -123.85 143.03 50.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.855 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.86 0.17 53.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 74.41 111.114 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -97.2 66.33 2.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 73.1 110.871 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.28 -137.07 10.47 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.455 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -155.17 150.27 26.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.861 0.363 . . . . 72.2 110.924 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -165.32 163.29 13.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.583 0.706 . . . . 72.44 110.925 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 176.08 7.28 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.618 2.212 . . . . 70.33 112.335 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . 0.442 ' O ' HG12 ' A' ' 53' ' ' ILE . 4.1 m120 -129.86 62.72 65.3 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.623 0.725 . . . . 75.04 110.914 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 111.15 2.72 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 72.14 112.342 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . 0.442 HG12 ' O ' ' A' ' 51' ' ' ASN . 1.1 mm -130.66 151.58 36.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 73.32 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -156.06 115.77 3.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 74.41 110.866 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.3 t -135.37 76.44 56.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.699 . . . . 75.01 111.139 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 121.55 8.23 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.695 2.263 . . . . 73.11 112.329 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.5 155.29 38.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.239 -0.437 . . . . 75.33 110.949 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.56 -13.32 65.85 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 61.12 112.49 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.43 154.48 50.74 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 63.35 111.077 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -64.69 136.08 56.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 75.25 110.906 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 8.1 mm -127.25 96.21 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 75.12 111.11 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.462 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.2 OUTLIER -84.46 102.18 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 71.4 111.143 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -73.49 139.62 45.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 71.41 110.922 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 15.8 mttt -131.83 98.78 4.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.472 . . . . 75.33 110.928 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.511 ' O ' ' HA ' ' A' ' 90' ' ' VAL . 1.3 mp -97.56 157.29 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 73.02 111.147 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.3 t -170.24 126.21 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 73.13 111.164 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.433 ' HB3' HG22 ' A' ' 70' ' ' VAL . 3.6 m -127.44 161.99 51.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.656 0.741 . . . . 64.13 110.879 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.419 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.9 Cg_endo -69.82 -51.8 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.645 2.23 . . . . 74.11 112.334 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -155.52 29.52 0.38 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 75.32 110.809 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.433 HG22 ' HB3' ' A' ' 67' ' ' SER . 25.9 m -128.37 144.35 38.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 74.52 111.109 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 24.1 mm -69.73 157.2 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.479 . . . . 72.41 111.13 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -114.7 -164.4 0.94 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.18 -0.464 . . . . 73.5 110.865 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.71 130.48 3.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.815 -0.707 . . . . 45.33 112.479 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -136.76 144.39 43.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.884 0.373 . . . . 74.32 110.91 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 36.8 t-80 -93.66 133.6 36.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.119 -0.492 . . . . 72.41 110.822 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 87.0 t -126.72 143.27 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 73.2 111.117 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -75.52 177.01 7.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 74.43 110.856 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.74 -51.59 4.57 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 61.21 112.489 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.1 m -140.64 154.12 46.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.797 0.332 . . . . 72.35 111.106 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -76.6 64.58 2.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 73.3 110.88 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 11.3 tt -54.9 128.29 14.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.469 . . . . 75.52 111.124 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -115.58 97.06 5.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 74.22 110.869 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.5 m -125.48 120.44 57.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 74.4 111.075 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -154.33 115.72 4.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 74.53 110.832 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 94.1 t -139.28 146.53 25.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.485 . . . . 74.25 111.16 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.404 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -75.65 157.99 83.54 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.586 0.708 . . . . 73.44 110.923 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 53.3 Cg_endo -69.78 153.8 68.43 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.719 2.28 . . . . 74.31 112.321 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.69 7.06 59.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.752 -0.737 . . . . 74.03 112.496 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -156.75 141.94 17.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.873 0.368 . . . . 74.53 110.878 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 3.6 p -95.69 126.3 48.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 74.4 111.122 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -87.5 177.36 7.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 71.23 110.798 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 98.8 m -144.82 105.48 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 74.32 111.139 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.8 p -134.82 137.8 50.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 74.42 111.109 179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -113.27 139.9 48.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 75.25 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -166.06 94.8 0.57 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.245 -0.434 . . . . 75.13 110.955 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -84.33 143.76 29.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 74.43 111.113 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.12 -169.41 2.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.43 110.889 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mttt -124.93 -28.26 3.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 74.33 110.897 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.17 158.87 70.21 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.605 0.717 . . . . 75.43 110.841 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 147.74 63.44 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.722 2.281 . . . . 74.44 112.342 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.27 153.58 8.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 43.35 112.484 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -116.74 132.2 56.75 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.826 0.346 . . . . 75.43 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -143.83 141.18 30.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 73.43 110.9 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.85 177.43 8.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.491 . . . . 74.33 110.91 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.3 mm 67.48 146.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.213 -0.449 . . . . 74.13 111.184 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 75.42 111.133 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 12.5 t . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.793 0.33 . . . . 72.24 111.114 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 2.9 mp -153.79 137.33 8.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.205 -0.452 . . . . 74.33 111.126 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.5 p -127.55 139.03 53.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 61.34 111.094 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 49.1 t -109.27 117.17 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 73.52 111.162 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -86.98 138.76 31.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 74.14 110.888 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.447 . . . . 75.14 110.911 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.821 0.343 . . . . 73.44 110.91 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -96.04 145.18 25.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.494 . . . . 74.43 110.853 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.1 m -136.64 -178.58 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 64.11 111.14 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.13 161.98 42.51 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.641 0.734 . . . . 75.41 110.876 179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 -3.5 12.14 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.692 2.261 . . . . 73.41 112.362 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 25.8 m -44.96 -70.21 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 51.1 111.165 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.6 p -149.59 24.1 0.88 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 64.31 111.152 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.6 p -62.85 -26.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 74.15 111.118 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -106.07 -17.21 14.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 73.53 110.865 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -83.91 -35.9 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 72.32 110.923 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 -142.38 140.82 32.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 73.43 110.895 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.24 -158.53 17.86 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.732 -0.747 . . . . 64.24 112.476 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.72 -30.97 21.63 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 72.33 112.398 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 12.2 m-90 -84.6 -13.91 50.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.942 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.88 -59.42 3.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 63.34 111.105 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.01 147.63 34.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.565 0.698 . . . . 64.34 110.876 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -26.67 27.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.667 2.244 . . . . 72.25 112.361 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -80.14 -1.12 38.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 72.41 111.069 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.8 mm-40 -105.27 5.07 31.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 71.13 110.953 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.3 -74.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 73.45 111.099 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.0 t -71.91 126.78 33.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.436 . . . . 74.01 111.127 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.0 m -150.34 127.01 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 73.34 111.13 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -76.28 114.44 14.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.459 . . . . 63.12 110.926 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.2 t -120.05 -13.17 9.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.263 -0.426 . . . . 71.32 111.116 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.36 -173.25 13.78 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.753 -0.737 . . . . 62.11 112.514 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -36.72 10.34 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 75.21 112.336 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -150.86 34.35 0.6 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 72.1 110.863 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -134.55 117.8 16.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 71.54 110.945 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -98.58 134.33 41.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 75.02 110.947 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.494 ' HA ' HG22 ' A' ' 62' ' ' VAL . 56.7 m -95.07 115.04 26.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.482 . . . . 74.34 111.136 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.33 126.62 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 75.13 111.131 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 84.8 m-85 -103.13 113.78 27.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.198 -0.455 . . . . 75.12 110.859 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.8 m -97.5 131.4 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.11 -0.496 . . . . 71.4 111.126 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -120.19 135.66 54.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 74.53 110.89 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -156.44 113.98 3.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 74.33 111.065 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 7.0 p90 -128.5 151.08 49.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 73.11 110.889 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.47 1.44 48.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 75.23 111.074 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -92.15 75.65 5.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.261 -0.427 . . . . 73.41 110.852 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.46 -127.75 9.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 73.12 112.499 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -141.67 162.34 35.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.824 0.345 . . . . 74.4 110.909 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.8 pm0 -161.07 155.93 20.24 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 74.4 110.93 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -176.23 1.41 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.675 2.25 . . . . 73.23 112.337 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -130.28 60.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.605 0.717 . . . . 72.42 110.881 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 73.94 1.32 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.675 2.25 . . . . 61.24 112.35 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.9 mp -125.84 132.39 70.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 73.23 111.146 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -131.62 156.69 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 70.51 110.906 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.417 ' O ' HG12 ' A' ' 55' ' ' VAL . 2.9 p -157.47 77.88 3.72 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.619 0.723 . . . . 74.32 111.148 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 121.46 8.15 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.696 2.264 . . . . 73.23 112.356 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -68.26 154.24 42.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 65.24 110.924 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.94 -10.16 69.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.76 -0.733 . . . . 73.11 112.493 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.5 159.9 39.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.773 0.32 . . . . 63.03 111.106 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -72.57 141.34 48.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.43 110.895 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 3.8 mm -125.96 119.48 54.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.169 -0.469 . . . . 74.32 111.124 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.494 HG22 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -110.19 90.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 55.13 111.087 179.905 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -74.81 144.18 43.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 74.34 110.872 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.41 100.81 6.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 73.15 110.908 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.9 mt -94.23 147.3 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 74.32 111.125 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -166.12 136.93 3.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 71.12 111.146 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.34 160.61 41.73 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.698 0.761 . . . . 74.05 110.835 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -54.87 0.2 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.674 2.249 . . . . 74.34 112.353 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -156.88 61.43 0.52 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 73.21 110.854 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.16 135.9 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 74.15 111.112 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.0 mm -73.61 145.17 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 75.21 111.142 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -126.56 -168.57 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 74.22 110.876 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 133.31 115.21 1.59 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 73.24 112.475 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -111.03 142.71 42.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.842 0.354 . . . . 73.14 110.879 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -115.17 142.63 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 74.55 110.816 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 16.6 t -133.68 147.66 30.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 74.41 111.126 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -70.01 -178.65 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 64.01 110.907 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.53 -51.17 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.721 -0.752 . . . . 71.43 112.5 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.1 m -136.89 153.86 50.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.789 0.328 . . . . 75.02 111.16 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -77.39 60.44 2.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 75.11 110.9 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 7.2 tt -69.58 115.26 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 74.05 111.123 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -115.78 104.25 11.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.48 . . . . 74.31 110.883 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.79 120.14 56.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 73.32 111.139 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.5 pp20? -157.23 117.23 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 72.45 110.867 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -140.35 146.54 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 74.25 111.113 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -64.21 158.49 64.06 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.619 0.723 . . . . 75.02 110.922 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 152.86 69.37 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.235 . . . . 71.52 112.332 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.62 11.46 63.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.757 -0.735 . . . . 64.02 112.463 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -145.83 118.17 8.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 74.44 110.952 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 39.2 t -63.43 105.59 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 64.02 111.173 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 66.0 p -91.98 114.33 26.84 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 64.22 110.867 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.3 t -81.83 145.99 30.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 74.51 111.17 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.2 t -139.94 117.85 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 74.23 111.107 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.0 mmm180 -102.8 107.91 18.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 75.34 110.894 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -155.95 141.38 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 65.4 110.938 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.5 t -135.14 143.63 46.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 74.43 111.102 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -95.56 -175.5 3.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 70.13 110.88 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -123.06 -12.27 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.116 -0.493 . . . . 73.15 110.876 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.83 161.93 28.09 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.646 0.736 . . . . 75.52 110.835 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 156.7 62.68 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 64.55 112.316 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.0 132.51 1.37 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 64.32 112.51 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -101.79 132.84 47.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.889 0.376 . . . . 63.02 110.918 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -143.8 129.61 19.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.49 . . . . 73.42 110.913 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.0 95.3 2.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.501 . . . . 75.2 110.843 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.5 tt -178.19 143.77 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 73.11 111.118 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 65.24 111.106 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 53.4 m . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.768 0.318 . . . . 74.35 111.161 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 3.7 mp -147.55 140.17 18.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 75.42 111.12 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.46 138.33 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 74.14 111.099 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 44.0 t -104.05 125.15 58.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 72.22 111.116 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 31.2 mmtt -107.19 133.83 51.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 71.34 110.91 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 72.43 110.865 179.952 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.871 0.367 . . . . 63.33 110.856 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -84.3 144.33 28.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.492 . . . . 74.21 110.892 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.3 m -134.24 -177.37 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 72.1 111.111 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . 0.449 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 21.4 p30 -143.77 157.72 57.75 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.586 0.708 . . . . 74.42 110.855 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.449 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.75 -2.8 10.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.243 . . . . 75.14 112.313 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 9.7 m -48.26 -67.72 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 74.4 111.147 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.4 p -151.0 30.24 0.64 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.45 . . . . 73.14 111.131 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.9 p -78.83 -24.96 13.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.24 -0.436 . . . . 75.21 111.113 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.427 ' CZ ' ' HD3' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -98.65 -18.23 18.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 75.42 110.892 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.9 mm-40 -100.92 -31.42 11.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 63.33 110.896 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -129.28 138.68 51.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 73.41 110.874 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 116.68 -161.78 12.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 41.24 112.494 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -27.77 25.87 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 2.239 . . . . 70.03 112.375 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 13.5 m-90 -84.45 -17.48 39.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 75.54 110.916 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.64 -59.8 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 74.04 111.124 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.45 143.0 25.91 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.605 0.717 . . . . 73.22 110.86 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -14.99 37.04 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 64.53 112.353 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -6.58 48.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 75.2 111.131 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 34.1 mm-40 -108.26 5.8 26.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 64.03 110.965 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.76 -78.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.213 -0.449 . . . . 71.12 111.123 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -81.92 125.88 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 72.12 111.113 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.441 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 25.1 m -141.66 142.62 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 55.25 111.154 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -82.31 110.52 17.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 73.24 110.928 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.7 t -108.89 -41.3 4.78 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 74.3 111.138 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.9 175.61 19.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.47 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 116.53 4.6 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.727 2.285 . . . . 74.11 112.34 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 66.97 35.31 4.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 73.44 110.866 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -147.87 152.6 37.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.218 -0.446 . . . . 74.35 110.941 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -141.72 140.96 33.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.222 -0.445 . . . . 72.23 110.957 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.542 ' HA ' HG23 ' A' ' 62' ' ' VAL . 28.8 m -90.95 117.55 29.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 74.04 111.18 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 t -100.35 107.4 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 71.01 111.14 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -88.45 127.38 35.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.189 -0.46 . . . . 73.52 110.913 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 77.0 t -119.82 108.04 22.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.109 -0.496 . . . . 75.05 111.119 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -101.5 126.57 48.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 75.13 110.904 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -152.87 128.44 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 64.25 111.145 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -145.78 147.01 31.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.44 . . . . 74.31 110.9 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.77 31.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 74.44 111.088 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -104.63 54.84 0.72 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 72.42 110.876 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 131.67 -139.16 10.71 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 53.02 112.445 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -154.98 151.46 28.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.854 0.359 . . . . 75.4 110.926 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -165.68 162.98 12.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.576 0.703 . . . . 71.11 110.901 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 154.04 68.2 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.697 2.264 . . . . 73.01 112.332 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -128.22 66.4 72.67 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.574 0.702 . . . . 73.44 110.921 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 115.21 3.98 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.707 2.271 . . . . 64.12 112.374 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.6 mm -125.82 146.47 31.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 74.31 111.1 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -155.1 118.03 4.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 71.22 110.885 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . 0.406 HG22 HG13 ' A' ' 61' ' ' ILE . 2.1 p -132.72 85.32 47.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.669 0.747 . . . . 75.1 111.123 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.84 123.13 9.78 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.625 2.217 . . . . 73.21 112.363 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.35 145.98 55.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 75.34 110.865 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.41 -28.31 9.22 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 74.2 112.51 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.6 156.86 17.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.74 0.305 . . . . 72.32 111.103 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -66.4 142.13 57.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 65.22 110.916 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . 0.406 HG13 HG22 ' A' ' 55' ' ' VAL . 4.7 mm -131.89 119.95 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 73.31 111.145 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.542 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.3 OUTLIER -114.01 89.44 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 75.21 111.142 179.847 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -66.61 137.18 56.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 73.41 110.92 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 8.6 mttm -133.77 100.65 4.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 64.1 110.898 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 2.6 mp -102.17 157.86 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.444 . . . . 74.53 111.119 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.7 t -165.48 142.19 5.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 72.32 111.163 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.417 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -151.27 162.18 27.54 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 74.12 110.862 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.427 ' HD3' ' CZ ' ' A' ' 17' ' ' ARG . 53.8 Cg_endo -69.76 -55.68 0.17 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.729 2.286 . . . . 72.54 112.348 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -155.93 60.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.458 . . . . 74.13 110.832 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.05 134.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 73.44 111.132 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.8 mm -64.8 145.06 14.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.142 -0.481 . . . . 73.11 111.118 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -140.79 115.49 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.474 . . . . 71.43 110.848 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.26 132.58 3.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 60.43 112.496 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -117.15 142.64 46.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.829 0.347 . . . . 74.13 110.866 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.6 t-80 -126.05 105.17 8.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 74.32 110.882 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.9 p -97.06 144.95 9.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 73.31 111.102 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -61.16 -175.44 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 73.24 110.92 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 90.36 -51.08 3.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.702 -0.761 . . . . 71.21 112.514 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.4 m -140.18 158.85 43.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.791 0.329 . . . . 73.51 111.182 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -76.17 60.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 74.54 110.892 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 13.4 tt -72.4 110.08 5.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 73.22 111.104 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.12 97.88 6.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 72.05 110.88 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.6 m -118.23 119.9 62.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 74.04 111.11 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -150.71 115.52 5.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 74.51 110.894 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.3 p -140.67 146.52 24.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 72.01 111.094 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.2 mp -69.71 160.04 81.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.647 0.737 . . . . 71.4 110.915 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 160.29 50.27 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.657 2.238 . . . . 74.42 112.372 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.31 17.71 54.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.775 -0.726 . . . . 63.54 112.474 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -163.38 135.58 5.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.875 0.369 . . . . 75.45 110.909 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 61.9 t -76.37 138.06 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 70.44 111.13 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.2 107.74 15.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 74.15 110.862 -179.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.2 m -81.73 120.02 24.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 74.24 111.131 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 46.7 t -120.61 122.79 68.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.269 -0.423 . . . . 74.14 111.148 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.4 mmm180 -100.85 102.45 13.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 75.33 110.88 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 52.9 t80 -151.93 120.41 6.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 74.11 110.921 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.3 t -114.93 139.91 49.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.105 -0.498 . . . . 73.23 111.156 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -90.96 -170.1 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 72.44 110.863 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 25.5 mttt -129.44 -25.52 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 74.54 110.896 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.1 mtp180 -135.98 154.64 77.78 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 74.41 110.832 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 156.84 62.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.651 2.234 . . . . 71.04 112.318 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.19 133.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 71.34 112.48 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.57 128.73 38.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.832 0.349 . . . . 72.1 110.871 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.3 p90 -143.87 132.04 21.85 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 72.22 110.911 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 43.5 mtm180 -144.88 -176.59 5.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 73.34 110.892 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.0 mt 66.35 144.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 70.13 111.157 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 74.24 111.15 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 9.9 t . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.746 0.307 . . . . 73.52 111.135 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 3.7 mp -150.33 142.01 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.234 -0.439 . . . . 75.2 111.157 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 28.0 t -132.97 130.19 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 75.05 111.121 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 42.5 t -103.07 130.38 53.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 72.43 111.135 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -108.18 134.15 51.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 75.51 110.901 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.34 110.894 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.867 0.365 . . . . 71.33 110.911 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.07 154.09 20.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 74.4 110.895 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 10.6 m -126.74 -178.05 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 74.53 111.165 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.81 161.74 44.6 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.591 0.71 . . . . 62.43 110.867 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -4.24 13.64 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.695 2.264 . . . . 74.23 112.379 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 42.2 m -48.46 -71.0 0.07 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.198 -0.455 . . . . 75.53 111.157 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 44.8 p -151.59 36.68 0.57 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 65.01 111.159 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.0 p -78.93 -25.58 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 64.41 111.129 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -97.52 -18.2 19.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 74.2 110.834 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -101.43 -28.4 12.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.445 . . . . 72.45 110.923 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.33 133.17 42.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 73.23 110.914 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.88 -158.67 17.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 74.32 112.473 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . 0.42 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 53.4 Cg_endo -69.75 -34.65 14.17 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.72 2.28 . . . . 65.53 112.342 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . 0.42 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 14.9 m-90 -84.98 -6.95 59.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 72.14 110.912 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -59.12 4.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 70.42 111.106 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.99 141.7 25.37 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.592 0.71 . . . . 73.3 110.896 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -7.17 20.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 71.43 112.311 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.06 -25.5 60.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 73.1 111.094 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . 0.509 ' N ' HE21 ' A' ' 27' ' ' GLN . 0.0 OUTLIER -110.99 34.21 4.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 75.01 110.919 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.59 -69.03 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 73.41 111.115 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 38' ' ' THR . 1.6 p -111.33 125.18 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.448 . . . . 75.25 111.097 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.97 151.46 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 72.12 111.179 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . 0.414 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -72.69 119.29 16.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 74.32 110.879 -179.974 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.2 p -120.94 -42.58 2.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.157 -0.474 . . . . 75.55 111.137 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.39 -168.22 16.83 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.749 -0.739 . . . . 74.2 112.504 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 109.8 2.4 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 73.33 112.354 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.9 t30 49.92 30.58 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 71.43 110.878 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.43 120.98 26.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.177 -0.465 . . . . 72.44 110.891 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . 0.414 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 39.7 m-85 -94.43 141.97 27.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 72.15 110.924 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.41 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 21.9 m -99.66 99.78 10.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 73.15 111.16 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.34 131.57 33.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 71.41 111.087 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -113.63 100.69 8.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.176 -0.465 . . . . 73.22 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 34.8 m -97.45 129.94 46.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 74.03 111.141 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 18.5 tp -124.24 138.54 54.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 75.51 110.928 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.68 123.41 5.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.467 . . . . 74.34 111.094 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -143.09 144.1 32.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 72.45 110.876 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.13 4.89 32.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 52.24 111.114 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -103.34 72.9 1.18 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 61.33 110.846 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 115.08 -141.69 17.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 70.13 112.522 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -152.89 148.4 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.807 0.337 . . . . 72.24 110.938 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -165.15 162.97 13.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 73.04 110.913 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 158.58 56.53 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.686 2.257 . . . . 74.44 112.374 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -131.88 67.02 79.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.704 0.764 . . . . 64.51 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 119.56 6.49 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 73.34 112.336 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.5 mm -131.27 124.13 54.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 74.13 111.106 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -131.24 116.38 17.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 74.55 110.891 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 t -130.1 80.6 70.59 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.63 0.729 . . . . 71.25 111.12 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 121.12 7.82 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.746 2.298 . . . . 74.5 112.331 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.12 155.57 39.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 75.35 110.929 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.52 -6.53 76.81 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.754 -0.736 . . . . 74.0 112.481 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.82 155.34 49.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 73.3 111.094 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -64.84 143.42 57.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 75.4 110.897 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 8.6 mm -131.65 124.53 54.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 71.11 111.124 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 46.8 t -111.22 93.48 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 75.32 111.146 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -71.82 137.06 47.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 74.14 110.858 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -132.28 99.52 4.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 75.21 110.907 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.6 mp -98.03 153.53 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 72.54 111.147 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.2 t -171.77 137.77 1.03 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 73.2 111.165 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.44 162.21 45.97 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.708 0.766 . . . . 73.14 110.843 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -52.01 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 65.41 112.322 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -155.91 36.67 0.35 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 73.51 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -140.17 -179.24 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 72.12 111.139 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.1 mt -144.91 156.68 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.201 -0.454 . . . . 74.21 111.183 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -168.52 98.17 0.41 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 73.33 110.835 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -95.02 135.72 12.56 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 73.13 112.504 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -99.05 142.1 30.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.876 0.369 . . . . 73.14 110.872 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.9 p80 -125.24 142.69 51.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 74.33 110.897 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.2 t -131.83 147.56 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 75.42 111.134 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -71.49 -175.44 1.3 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 74.43 110.867 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.12 -51.45 4.58 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 75.22 112.49 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.6 m -135.52 151.35 50.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.782 0.325 . . . . 73.23 111.153 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.5 m-80 -74.13 70.13 1.56 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 71.34 110.871 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 14.1 tt -87.77 104.37 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 72.44 111.099 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -115.83 103.85 11.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 73.11 110.893 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -114.32 120.62 64.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 70.12 111.113 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.32 121.09 17.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 70.34 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.7 p -139.36 147.64 24.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 75.33 111.142 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.473 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -90.58 163.92 28.63 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.594 0.712 . . . . 73.05 110.911 179.927 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.473 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.5 Cg_endo -69.77 147.77 63.56 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.682 2.254 . . . . 72.03 112.317 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.01 9.18 58.51 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.754 -0.736 . . . . 73.23 112.492 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -146.34 173.68 12.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.869 0.366 . . . . 73.33 110.876 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 17.5 t -129.37 119.49 48.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 72.31 111.117 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -103.75 133.66 48.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 63.03 110.822 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 60.7 m -103.13 131.87 49.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 71.52 111.12 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 19.0 t -125.26 127.6 72.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 74.01 111.114 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -107.78 92.6 4.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 73.41 110.858 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -140.77 133.43 28.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.157 -0.474 . . . . 75.04 110.902 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.7 t -123.16 140.19 53.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 71.23 111.159 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -96.3 -174.82 3.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 75.04 110.861 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -125.89 -29.02 3.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 73.34 110.928 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.35 155.59 81.28 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.597 0.713 . . . . 73.45 110.897 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 170.56 16.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.647 2.231 . . . . 70.45 112.351 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 154.99 133.32 1.71 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 70.0 112.479 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.13 125.54 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 65.51 110.903 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.75 146.61 33.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 75.35 110.94 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.23 97.89 1.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.15 110.838 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.4 tt -175.51 151.96 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.151 -0.477 . . . . 74.53 111.118 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 74.43 111.189 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 4.8 t . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.763 0.316 . . . . 72.21 111.168 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 2.1 mp -153.9 137.63 8.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 74.21 111.121 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 26.9 t -126.14 122.58 61.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 74.23 111.149 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 44.3 t -101.52 112.1 33.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 75.24 111.119 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 17.8 mmmt -84.45 135.26 34.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 72.24 110.897 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 74.43 110.945 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.808 0.337 . . . . 72.14 110.885 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.54 168.46 10.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 75.34 110.851 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 1.4 t -141.54 166.71 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 74.13 111.098 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 55.9 p-10 -161.12 153.45 16.97 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.594 0.711 . . . . 74.35 110.843 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -4.34 13.85 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.684 2.256 . . . . 71.1 112.326 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 40.6 m -44.44 -72.23 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 72.12 111.094 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 6.7 p -156.62 33.08 0.31 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 72.22 111.144 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.9 p -78.58 -19.92 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 74.04 111.105 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -100.68 -9.38 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 70.12 110.896 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -103.53 -32.87 9.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 63.14 110.881 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -140.16 125.98 19.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 73.54 110.861 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 132.26 -155.99 21.78 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.741 . . . . 74.01 112.515 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -37.83 8.65 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.723 2.282 . . . . 71.52 112.349 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -84.51 -12.57 53.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.211 -0.449 . . . . 72.11 110.917 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.79 -59.54 4.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 75.31 111.087 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.21 142.84 25.37 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 51.3 110.88 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 -22.83 31.81 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.644 2.229 . . . . 64.52 112.376 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.51 -17.56 61.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 75.25 111.097 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 3.5 mm100 -89.35 10.13 23.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 75.24 110.929 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.26 -77.53 0.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 55.52 111.083 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.1 t -84.38 122.06 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 73.02 111.165 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.8 131.62 53.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.451 . . . . 64.2 111.106 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -71.31 118.28 13.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 74.31 110.899 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.0 t -119.38 -41.49 2.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 74.44 111.175 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.34 171.2 13.72 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.765 -0.731 . . . . 70.11 112.487 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -10.21 28.02 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.685 2.257 . . . . 73.04 112.358 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -157.69 34.81 0.26 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.283 -0.417 . . . . 73.54 110.883 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -151.29 160.04 44.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 74.5 110.896 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.7 m-85 -143.31 146.64 33.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.252 -0.431 . . . . 75.43 110.941 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 99.5 m -97.23 121.99 39.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.119 -0.491 . . . . 74.11 111.165 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 17.9 t -100.37 134.58 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 74.03 111.137 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -120.65 100.51 7.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 73.3 110.932 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 32.8 m -98.78 128.53 50.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 74.1 111.129 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -120.74 138.23 54.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 71.24 110.928 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.22 137.04 14.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 73.12 111.049 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -145.29 150.06 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 73.31 110.918 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.41 18.69 4.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 72.43 111.118 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -84.34 -61.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 74.33 110.868 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -127.44 -122.43 2.52 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.786 -0.721 . . . . 75.23 112.488 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -143.91 145.02 31.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.869 0.366 . . . . 74.33 110.904 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . 0.422 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.0 pm0 -154.37 156.09 31.4 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.56 0.695 . . . . 74.53 110.892 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.2 Cg_endo -69.79 177.38 5.65 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.632 2.222 . . . . 75.23 112.343 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -131.23 62.3 64.39 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.592 0.71 . . . . 65.03 110.905 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 70.77 1.56 Allowed 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.661 2.241 . . . . 75.13 112.377 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.3 mp -105.88 128.29 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 75.11 111.151 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -126.3 135.11 51.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.468 . . . . 74.31 110.878 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.5 p -140.12 81.95 17.79 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.657 0.741 . . . . 74.4 111.08 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 123.55 10.22 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.715 2.277 . . . . 72.14 112.328 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -66.87 152.37 45.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 71.44 110.951 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.42 -36.51 3.7 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 75.31 112.49 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -106.22 150.12 26.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.749 0.309 . . . . 61.14 111.129 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -66.42 142.07 57.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 74.33 110.901 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.8 mm -126.25 119.43 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 74.23 111.116 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 64.3 t -98.33 92.08 2.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 74.1 111.118 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -70.9 136.59 48.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.906 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 8.7 mttt -132.09 98.64 4.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 75.14 110.908 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.6 mp -103.17 137.5 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 71.23 111.11 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 4.2 t -155.73 135.89 12.99 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 75.43 111.123 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.418 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -135.87 161.19 64.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.633 0.73 . . . . 75.31 110.859 -179.863 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.8 Cg_endo -69.68 -53.95 0.25 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.675 2.25 . . . . 72.11 112.361 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -156.83 56.15 0.54 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 74.54 110.866 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.01 136.23 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 72.33 111.152 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.4 mm -64.33 149.14 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.164 -0.471 . . . . 75.11 111.115 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -133.11 -178.5 4.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 65.54 110.886 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 135.37 139.69 4.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 42.15 112.485 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -130.57 144.68 51.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.894 0.378 . . . . 73.2 110.837 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 8.0 t-80 -101.06 142.13 32.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.106 -0.497 . . . . 72.3 110.863 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 58.2 t -131.84 138.13 53.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 74.54 111.118 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -75.51 179.45 5.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 73.24 110.862 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.14 -52.03 4.57 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.781 -0.723 . . . . 74.13 112.48 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.62 179.7 4.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.82 0.343 . . . . 75.03 111.123 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -105.77 65.5 0.71 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 73.53 110.893 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 7.5 tt -72.47 121.68 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 73.51 111.159 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.07 90.47 3.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 110.827 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 5.1 m -115.05 118.41 58.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 72.51 111.126 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -166.72 104.73 0.59 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.145 -0.48 . . . . 71.15 110.878 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 2.4 m -140.64 146.61 23.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 72.54 111.109 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.408 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -57.8 159.78 9.36 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.559 0.695 . . . . 74.51 110.915 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 53.9 Cg_endo -69.74 159.67 52.55 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.71 2.274 . . . . 73.32 112.343 179.864 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 90.82 4.51 69.53 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.695 -0.764 . . . . 42.12 112.463 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -147.19 117.81 7.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.872 0.368 . . . . 73.53 110.928 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 1.8 p -74.49 130.04 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 73.51 111.134 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.17 112.26 24.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 75.25 110.816 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.7 m -90.12 115.72 27.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 74.12 111.117 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 8.6 p -128.75 152.22 36.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 72.2 111.117 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.82 103.02 11.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 70.52 110.901 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.0 t80 -134.28 114.95 13.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 75.14 110.92 -179.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.0 t -129.09 134.85 48.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.117 -0.492 . . . . 65.44 111.109 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -90.85 -176.73 4.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 73.35 110.849 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -121.25 -13.04 8.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 75.02 110.947 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.73 162.74 49.28 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.634 0.731 . . . . 74.53 110.87 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 150.05 67.45 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.686 2.257 . . . . 75.32 112.318 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.73 157.47 10.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.727 -0.749 . . . . 54.44 112.49 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.8 pm0 -120.26 125.17 47.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.872 0.368 . . . . 73.24 110.855 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -133.01 146.64 51.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.483 . . . . 72.24 110.885 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . 0.413 ' O ' ' HB ' ' A' ' 105' ' ' ILE . 0.4 OUTLIER -174.3 -162.11 0.13 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 74.32 110.83 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.413 ' HB ' ' O ' ' A' ' 104' ' ' ARG . 21.2 mm 75.28 117.79 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 74.53 111.161 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 71.53 111.144 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 53.6 m . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.751 0.31 . . . . 74.53 111.166 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 5.3 mp -145.35 117.24 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 64.25 111.144 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.6 p -121.65 141.49 41.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 75.03 111.094 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 87.0 t -101.5 136.59 32.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 74.0 111.163 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -114.49 125.72 54.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 74.33 110.869 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 74.41 110.871 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.832 0.348 . . . . 74.52 110.896 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.7 mpt_? -105.01 121.36 43.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 73.41 110.863 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 5.6 m -113.49 -179.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 75.42 111.17 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 162.63 38.29 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.571 0.7 . . . . 71.22 110.891 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -2.78 10.78 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.656 2.237 . . . . 72.34 112.36 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 29.1 m -44.75 -67.34 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.231 -0.441 . . . . 62.32 111.109 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 43.4 p -150.67 21.29 0.81 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 54.21 111.142 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.3 p -77.65 -16.88 14.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 71.33 111.157 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ARG . . . . . 0.434 ' NE ' ' HD3' ' A' ' 68' ' ' PRO . 0.0 OUTLIER -106.66 -25.0 11.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 72.31 110.876 -179.951 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -92.6 -24.24 18.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 74.11 110.92 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -143.58 147.32 34.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 71.23 110.928 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.01 -158.74 14.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.73 -0.748 . . . . 75.32 112.489 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -33.9 15.48 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.678 2.252 . . . . 71.53 112.332 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 11.8 m-90 -83.2 -12.87 56.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.256 -0.429 . . . . 74.54 110.898 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.44 -57.13 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.256 -0.429 . . . . 51.53 111.134 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.34 142.22 25.19 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.564 0.697 . . . . 75.24 110.927 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -6.73 19.3 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.708 2.272 . . . . 72.54 112.359 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.79 -12.87 61.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 64.25 111.109 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 17.6 mm-40 -99.0 14.4 29.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.443 . . . . 74.51 110.93 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.0 -14.84 61.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.463 . . . . 71.13 111.089 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.0 t -145.21 119.31 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 74.24 111.092 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . 0.418 ' CG1' ' HB ' ' A' ' 38' ' ' THR . 1.6 p -144.21 140.92 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 63.11 111.153 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.33 100.88 13.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 74.04 110.87 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.4 t -98.07 -34.46 10.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.232 -0.44 . . . . 75.32 111.147 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.71 -168.44 17.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 74.43 112.472 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -37.83 8.56 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.654 2.236 . . . . 54.2 112.334 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -148.27 34.68 0.8 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 73.45 110.864 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -135.41 119.87 18.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 65.32 110.893 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -95.87 140.89 29.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 73.5 110.983 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.525 ' HA ' HG22 ' A' ' 62' ' ' VAL . 22.3 m -94.81 107.82 19.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 70.42 111.141 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.1 t -89.25 130.0 39.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.224 -0.444 . . . . 75.41 111.137 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -116.03 113.15 22.81 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.909 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 31.2 m -111.35 125.1 68.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 71.24 111.117 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -121.92 126.28 48.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.122 -0.49 . . . . 74.32 110.907 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -144.54 144.96 31.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 70.03 111.115 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 12.2 p90 -136.65 152.74 50.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 73.15 110.908 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.77 12.2 13.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 72.4 111.063 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -120.48 66.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 74.11 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 123.31 -147.88 16.71 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.747 -0.739 . . . . 62.44 112.507 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -150.71 155.88 40.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 64.32 110.929 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -164.48 162.54 15.31 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.624 0.726 . . . . 70.12 110.916 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 140.09 41.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.696 2.264 . . . . 70.2 112.354 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -131.61 68.19 80.67 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.624 0.726 . . . . 75.54 110.879 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 72.75 1.42 Allowed 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.707 2.271 . . . . 71.3 112.363 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.6 mp -77.37 91.34 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 74.0 111.1 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -83.48 138.54 33.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.882 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.5 t -143.93 85.79 8.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.593 0.711 . . . . 70.2 111.101 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 122.95 9.62 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.669 2.246 . . . . 74.43 112.335 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.55 153.09 43.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 72.42 110.901 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.84 -35.83 3.85 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.72 -0.752 . . . . 60.33 112.51 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.86 155.09 19.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.747 0.308 . . . . 73.44 111.112 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -65.52 143.8 57.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 75.43 110.886 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 6.6 mm -128.73 118.69 47.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 70.4 111.142 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' VAL . . . . . 0.525 HG22 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -107.77 90.06 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 64.11 111.156 179.882 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -65.08 142.03 58.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 73.53 110.884 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -132.63 99.77 4.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 74.14 110.92 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 90' ' ' VAL . 1.3 mp -102.77 145.65 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 65.24 111.128 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.9 t -161.24 132.57 5.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 75.22 111.154 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' SER . . . . . 0.581 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -145.13 163.97 29.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.674 0.749 . . . . 74.13 110.905 -179.868 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' PRO . . . . . 0.581 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.1 Cg_endo -69.73 -56.36 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.701 2.268 . . . . 64.21 112.385 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -152.87 67.91 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 74.01 110.905 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.448 HG21 ' HB2' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.3 134.86 2.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 74.05 111.138 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.02 143.75 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 70.11 111.072 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -108.75 -166.32 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.128 -0.487 . . . . 75.15 110.864 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.64 122.45 3.51 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.771 -0.728 . . . . 71.24 112.497 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -119.87 142.38 48.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.916 0.389 . . . . 64.44 110.898 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -93.41 135.63 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.123 -0.489 . . . . 74.12 110.876 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 59.1 t -137.19 142.88 36.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 65.54 111.172 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -75.5 -176.31 3.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 64.14 110.871 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 87.47 -50.91 4.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.777 -0.725 . . . . 61.21 112.474 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.82 173.44 11.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 71.22 111.099 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 28.6 m120 -85.41 59.43 5.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 75.54 110.884 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 6.4 tp -56.69 116.87 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 54.53 111.101 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.23 100.42 8.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 74.52 110.907 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 5.7 m -127.29 122.87 60.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 74.15 111.154 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -160.6 114.68 2.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 74.52 110.895 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 96.7 t -140.36 145.09 26.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 74.33 111.158 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.22 156.65 89.56 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.609 0.719 . . . . 74.31 110.907 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 160.71 48.7 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.728 2.285 . . . . 74.2 112.347 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 97.84 -0.13 59.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 71.23 112.469 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -146.15 156.7 43.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.889 0.376 . . . . 73.34 110.862 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.422 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 1.6 p -105.7 108.75 25.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 75.45 111.128 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.22 164.77 22.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.882 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 77.7 m -129.24 105.21 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 74.22 111.134 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 24.6 t -101.79 130.81 50.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.239 -0.437 . . . . 63.31 111.14 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -110.44 92.45 4.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 73.41 110.851 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.2 t80 -143.01 114.08 7.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 74.43 110.927 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.7 t -113.87 142.9 45.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 73.51 111.143 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.08 179.98 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 74.42 110.842 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -121.08 -12.77 8.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.922 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.9 mpp_? -149.05 162.03 30.45 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.564 0.697 . . . . 73.31 110.913 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 153.63 68.67 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.731 2.287 . . . . 75.14 112.313 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 157.18 131.12 1.3 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.725 -0.75 . . . . 71.12 112.435 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -101.75 138.76 38.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.865 0.364 . . . . 72.44 110.865 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -143.87 140.6 29.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.135 -0.484 . . . . 74.42 110.921 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 46.3 mtm180 -144.89 72.79 1.34 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 73.22 110.895 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 55.8 mt -151.05 144.27 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.226 -0.443 . . . . 74.32 111.124 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 73.51 111.145 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 86.5 m . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.784 0.326 . . . . 71.11 111.155 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 1.4 mp -153.34 136.51 7.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 72.43 111.102 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 1.9 p -117.78 126.56 74.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 73.15 111.133 179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 61.9 t -101.14 117.68 46.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 74.04 111.109 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.0 mmmt -93.59 137.54 32.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 72.54 110.907 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 72.11 110.924 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.6 ttt . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.812 0.339 . . . . 61.55 110.884 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 90.0 t -72.78 82.65 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 71.13 111.147 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -143.96 78.14 14.18 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 72.14 111.133 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -179.34 2.86 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.644 2.229 . . . . 73.31 112.362 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -178.58 -75.29 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 73.12 111.159 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -55.55 -84.27 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.797 -0.716 . . . . 73.1 112.481 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.89 168.37 13.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.822 0.344 . . . . 73.55 110.887 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 6.6 tp 66.29 122.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 72.23 110.889 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -100.14 132.38 45.53 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.126 -0.488 . . . . 72.11 110.89 179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.94 131.47 44.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 74.23 110.825 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.4 m -120.91 -177.18 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 73.42 111.124 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.417 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 25.1 p30 -143.42 156.7 60.43 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 74.04 110.874 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.417 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.9 Cg_endo -69.79 -3.08 11.3 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.655 2.237 . . . . 73.23 112.358 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.4 m -46.76 -68.3 0.2 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.205 -0.452 . . . . 63.11 111.124 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 24.4 p -150.02 26.07 0.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.451 . . . . 75.51 111.133 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.4 p -65.39 -29.1 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.26 -0.427 . . . . 75.23 111.102 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.9 ptt180 -102.53 -7.91 21.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 74.32 110.884 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.3 mt-30 -96.81 -37.67 10.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 65.22 110.914 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.84 133.68 41.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 73.0 110.877 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.11 -156.91 18.39 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.753 -0.737 . . . . 74.12 112.494 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -30.79 21.72 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.741 2.294 . . . . 62.34 112.333 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 13.5 m-90 -85.95 -12.53 50.24 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 72.23 110.922 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.62 -58.98 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 72.12 111.095 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.89 146.5 34.24 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.593 0.711 . . . . 75.12 110.867 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -14.17 35.62 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.664 2.243 . . . . 73.22 112.349 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.13 -24.43 59.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 75.41 111.056 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 mm-40 -86.34 5.01 36.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 71.51 110.87 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.39 -76.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.43 111.085 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 12.3 t -89.71 115.6 29.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 72.41 111.144 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.34 119.02 4.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 75.41 111.138 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 11.9 tp60 -68.06 123.37 20.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 70.54 110.876 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.4 p -120.18 -11.55 9.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 74.55 111.111 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.9 -169.33 12.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 75.4 112.517 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.65 18.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.682 2.255 . . . . 75.23 112.395 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 55.2 t30 -155.69 28.61 0.38 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 75.14 110.884 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -126.99 119.42 26.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.494 . . . . 73.31 110.9 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -96.32 140.23 31.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 74.21 110.961 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.467 ' HA ' HG21 ' A' ' 62' ' ' VAL . 85.9 m -93.76 115.02 27.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 70.33 111.173 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.3 t -102.24 139.06 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 72.11 111.124 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -120.49 140.85 50.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 74.12 110.924 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 99.1 t -138.3 136.06 44.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.486 . . . . 74.41 111.106 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -137.91 140.71 40.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 74.22 110.95 179.92 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.27 102.97 2.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 71.54 111.083 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 3.3 p90 -112.01 156.71 21.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 72.24 110.894 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.13 7.79 23.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.137 -0.483 . . . . 70.14 111.092 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -103.17 82.9 2.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 75.53 110.929 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 100.28 -135.04 11.93 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.739 . . . . 61.22 112.498 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -154.61 150.22 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.799 0.333 . . . . 73.41 110.954 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 2.9 pm0 -154.07 155.02 30.71 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.648 0.737 . . . . 75.43 110.874 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.81 4.2 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.676 2.25 . . . . 75.3 112.382 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -134.99 62.88 55.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.577 0.703 . . . . 73.34 110.873 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 76.58 1.14 Allowed 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.661 2.241 . . . . 73.23 112.351 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.9 mp -106.56 143.06 18.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 75.31 111.145 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -138.91 158.51 44.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 74.25 110.88 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.408 HG22 HG13 ' A' ' 61' ' ' ILE . 2.4 p -164.09 84.47 1.26 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.639 0.733 . . . . 72.22 111.143 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 121.93 8.62 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.675 2.25 . . . . 73.15 112.334 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -66.76 152.24 45.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.434 . . . . 72.0 110.9 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.0 -35.87 3.93 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.708 -0.758 . . . . 55.25 112.478 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.86 157.58 17.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.751 0.31 . . . . 74.12 111.114 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.3 mp0 -66.8 144.78 56.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 71.35 110.859 -179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.408 HG13 HG22 ' A' ' 55' ' ' VAL . 5.7 mm -130.56 124.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 62.33 111.195 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.467 HG21 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -113.73 90.24 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 73.42 111.133 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.1 m-85 -67.88 138.8 56.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 72.4 110.859 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.4 mttt -132.75 100.25 4.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 74.42 110.887 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 2.3 mp -106.87 141.63 21.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 72.21 111.151 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.2 t -154.67 138.02 15.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.183 -0.462 . . . . 73.13 111.14 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -142.8 159.58 56.36 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 74.03 110.854 -179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -51.68 0.38 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.678 2.252 . . . . 74.23 112.361 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -156.95 49.41 0.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 73.12 110.892 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -155.13 136.27 5.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 62.43 111.158 -179.948 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 71.4 mt -86.21 142.53 12.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.186 -0.461 . . . . 72.53 111.115 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -118.3 -80.99 0.62 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.865 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 57.29 171.46 0.19 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.73 -0.748 . . . . 65.1 112.502 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -160.45 141.89 12.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.354 . . . . 63.32 110.927 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 7.1 t-80 -116.18 101.78 9.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 61.24 110.851 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 5.0 p -96.28 143.78 11.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 71.43 111.104 -179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -66.34 -172.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 72.11 110.938 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.89 -46.52 3.3 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.778 -0.725 . . . . 61.2 112.457 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -146.7 165.68 28.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.751 0.31 . . . . 74.42 111.149 -179.82 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -79.48 58.36 2.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 75.12 110.947 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 12.9 tt -66.35 115.09 3.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 75.13 111.118 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.7 91.05 3.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.01 110.863 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.0 m -118.11 120.48 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 75.44 111.103 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -160.9 117.34 2.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.02 110.924 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 96.2 t -140.35 127.73 23.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 75.03 111.134 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.408 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -51.07 160.06 0.91 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.601 0.715 . . . . 63.42 110.921 179.972 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 54.0 Cg_endo -69.73 155.47 65.96 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.724 2.283 . . . . 73.31 112.353 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.65 10.7 46.33 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.797 -0.716 . . . . 74.13 112.513 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -164.69 119.2 1.37 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.871 0.367 . . . . 74.34 110.867 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 2.9 p -68.69 133.73 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 71.13 111.141 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -94.39 168.9 10.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 73.45 110.876 -179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 90.5 m -144.4 105.46 4.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 71.24 111.119 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.0 p -118.58 141.21 39.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 74.4 111.125 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -110.6 101.55 10.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 73.41 110.879 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -145.97 119.26 8.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.228 -0.442 . . . . 71.35 110.905 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.5 t -117.28 142.97 46.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.489 . . . . 71.34 111.181 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.0 -175.93 4.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 63.32 110.915 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 20.5 mtpt -126.21 -12.45 6.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.16 -0.473 . . . . 74.12 110.917 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -148.19 162.22 31.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.601 0.715 . . . . 75.5 110.908 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 156.9 62.23 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.69 2.26 . . . . 73.21 112.344 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.2 133.64 1.51 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.743 -0.742 . . . . 61.31 112.523 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -99.4 128.49 45.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 74.33 110.897 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -144.13 131.08 20.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 74.31 110.889 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 7.1 ptt180 -147.94 83.41 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 74.15 110.858 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.0 mt -151.01 145.03 16.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 75.2 111.155 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.67 140.0 36.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 75.12 111.131 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 179.57 153.44 0.46 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 73.34 110.867 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 54.2 m-20 51.45 53.29 13.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 74.22 110.902 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 39.9 mm-40 -98.6 62.5 1.41 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.225 -0.443 . . . . 73.52 110.96 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 69.43 -75.4 0.07 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.248 -0.433 . . . . 74.01 110.907 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 56.1 m -75.31 -24.81 57.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.13 -0.487 . . . . 74.23 110.853 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.02 43.29 9.93 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 71.02 112.529 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -52.82 171.25 0.06 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.911 0.386 . . . . 72.31 110.875 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 173.88 34.7 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.75 . . . . 71.21 112.444 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -179.33 37.93 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.754 0.311 . . . . 75.31 110.829 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -162.25 -67.8 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.244 -0.435 . . . . 71.15 110.905 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 27.9 p30 -58.19 -175.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 61.42 110.876 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 20.9 mmt -115.28 176.78 4.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 75.44 110.898 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -89.27 122.74 32.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.277 -0.42 . . . . 70.24 110.885 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.93 167.95 0.3 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.753 -0.736 . . . . 65.01 112.475 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 43.1 m -154.03 118.66 4.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.814 0.34 . . . . 74.53 111.146 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.3 mp -144.92 141.55 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 75.34 111.123 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 85.1 t -131.29 133.95 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 73.25 111.135 179.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 97.4 t -103.9 134.93 43.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 71.11 111.093 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -117.87 130.66 56.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 71.22 110.846 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 73.41 110.856 179.973 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.83 0.348 . . . . 73.44 110.876 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 3.2 m 38.06 80.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 72.43 111.116 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.1 pt -111.81 78.2 2.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.602 0.715 . . . . 74.54 111.09 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 -170.76 0.41 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.639 2.226 . . . . 73.42 112.349 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.23 35.41 1.21 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 62.44 111.067 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 171.76 164.77 27.91 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.698 -0.763 . . . . 73.44 112.466 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.46 -166.39 0.23 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.832 0.349 . . . . 72.32 110.9 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.1 pp -54.82 178.18 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 63.42 110.916 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 -103.13 136.27 43.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 73.43 110.883 179.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -89.46 166.76 13.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 75.42 110.885 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 m -144.5 -179.31 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.459 . . . . 74.24 111.146 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -145.76 161.66 39.42 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.628 0.728 . . . . 65.0 110.904 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -4.47 14.09 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.687 2.258 . . . . 71.44 112.355 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 33.9 m -48.47 -70.78 0.08 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 64.32 111.178 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 30.5 p -150.92 35.26 0.6 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 72.03 111.17 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 14.0 p -69.56 -31.59 49.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 74.22 111.086 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -93.14 -5.09 51.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 75.52 110.889 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -104.53 -35.7 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 73.4 110.9 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -129.0 134.16 48.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 63.23 110.861 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.73 -160.3 13.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 72.4 112.5 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -26.27 27.71 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.746 2.297 . . . . 74.35 112.342 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 16.1 m-90 -87.17 -9.86 54.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.928 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.77 -59.46 2.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 54.15 111.134 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.62 144.38 28.5 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.605 0.717 . . . . 71.43 110.875 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -19.17 36.78 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.695 2.263 . . . . 72.3 112.39 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.75 -20.28 60.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 74.23 111.117 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mm-40 -87.28 6.82 31.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 73.32 110.868 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.43 -76.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 70.01 111.112 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 20.1 t -84.53 118.35 31.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 75.12 111.123 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.435 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 11.0 m -132.94 138.75 51.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 75.25 111.151 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.14 95.96 9.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 73.22 110.892 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.3 t -95.71 -35.82 11.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 71.02 111.163 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.79 -166.54 21.63 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.75 . . . . 72.13 112.507 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -44.93 1.77 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.677 2.251 . . . . 65.42 112.315 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -143.37 30.24 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 74.31 110.867 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -126.95 120.05 28.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 74.44 110.933 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -96.34 135.73 37.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 72.35 110.924 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.435 ' HB ' ' CG2' ' A' ' 30' ' ' VAL . 49.8 m -96.01 105.0 16.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.093 -0.503 . . . . 73.15 111.111 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -84.65 147.23 5.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 73.3 111.141 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -127.16 121.85 32.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 74.24 110.928 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 97.6 t -114.33 124.97 71.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 74.1 111.191 179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tm? -120.36 136.5 54.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 74.25 110.868 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.61 140.55 17.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 71.44 111.122 179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -139.99 159.0 43.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 65.55 110.923 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.71 5.57 35.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 75.23 111.111 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -122.31 84.88 2.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 72.13 110.853 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.87 179.14 19.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.743 -0.742 . . . . 72.02 112.492 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -124.65 139.48 53.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.806 0.336 . . . . 63.2 110.922 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 5.4 mt-30 -142.17 162.09 47.24 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 73.2 110.875 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 179.9 3.37 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.675 2.25 . . . . 72.31 112.317 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.6 m-80 -135.98 63.0 49.37 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.629 0.728 . . . . 65.33 110.909 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 73.77 1.32 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.643 2.229 . . . . 74.13 112.368 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.5 mp -110.57 113.91 45.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.246 -0.434 . . . . 73.34 111.179 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -110.07 135.43 50.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 74.41 110.908 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.4 p -138.9 81.76 21.58 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.665 0.745 . . . . 72.13 111.132 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 129.01 16.9 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.731 2.287 . . . . 73.33 112.356 179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.44 152.2 40.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 74.51 110.897 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.61 -35.61 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.758 -0.734 . . . . 55.22 112.474 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.0 155.93 18.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 71.44 111.127 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -67.18 144.51 55.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 75.03 110.896 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 6.4 mm -128.83 119.61 50.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.455 . . . . 73.35 111.137 179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 55.1 t -107.55 91.22 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 74.42 111.143 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 65.3 m-85 -70.37 137.25 50.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 72.54 110.864 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -129.55 100.88 5.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 74.21 110.839 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.31 155.29 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 73.53 111.11 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.3 t -169.99 139.21 1.83 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.166 -0.47 . . . . 74.44 111.148 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -143.46 161.78 45.43 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.688 0.756 . . . . 73.4 110.857 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.72 -54.09 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.69 2.26 . . . . 75.25 112.392 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -159.16 38.3 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 71.3 110.878 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -138.73 135.16 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 74.21 111.114 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 28.7 mm -88.02 142.89 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 74.22 111.133 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 21.5 p-80 -174.85 136.9 0.42 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 73.01 110.859 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -143.76 -149.62 5.12 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 73.12 112.494 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 7.9 p90 -159.29 138.19 11.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.923 0.392 . . . . 75.02 110.925 -179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 41.6 t60 -128.34 98.83 5.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 72.14 110.858 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 6.6 p -80.58 144.61 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 74.21 111.111 179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.3 pm0 -67.77 -175.44 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 64.13 110.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.54 -51.1 4.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.715 -0.755 . . . . 74.42 112.474 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.7 m -131.46 153.34 49.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.321 . . . . 64.15 111.174 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 2.5 p30 -76.0 66.08 2.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 71.14 110.89 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 12.5 tt -77.57 113.11 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 74.13 111.09 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.03 98.35 6.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 74.44 110.885 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.9 m -121.25 120.31 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.158 -0.474 . . . . 72.22 111.15 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -125.09 96.02 4.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 72.34 110.885 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.8 p -86.83 144.37 9.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 71.43 111.072 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 6.1 mp -111.05 156.62 40.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.6 0.714 . . . . 74.02 110.935 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 146.96 62.13 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.254 . . . . 74.42 112.365 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.22 8.96 86.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.734 -0.746 . . . . 61.32 112.467 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -146.69 173.61 12.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.918 0.39 . . . . 71.41 110.893 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 18.5 t -120.92 146.21 26.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 70.23 111.155 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.5 p -109.84 158.51 18.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 74.4 110.87 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 53.2 m -145.87 105.46 3.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.474 . . . . 72.04 111.128 -179.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 7.6 p -123.11 136.23 60.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 74.41 111.143 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.2 mtm180 -105.86 92.47 4.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 74.14 110.827 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -134.66 115.17 13.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.452 . . . . 73.2 110.939 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 t -116.19 142.93 46.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 73.11 111.149 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.95 178.85 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 71.35 110.863 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.34 -21.94 7.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.118 -0.492 . . . . 73.41 110.912 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.97 158.3 74.15 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.592 0.71 . . . . 73.31 110.887 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 149.44 66.86 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.678 2.252 . . . . 74.2 112.363 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.87 156.67 9.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.752 . . . . 54.52 112.457 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -114.54 132.2 56.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.847 0.356 . . . . 65.41 110.868 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -143.62 146.41 33.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.158 -0.473 . . . . 72.03 110.923 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.551 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 13.9 ptt-85 -164.9 -164.58 0.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 74.32 110.863 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.551 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 7.3 tt 58.2 158.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 73.43 111.118 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -119.28 140.05 44.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 71.24 111.16 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 56.7 m -141.67 -42.51 0.36 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.167 -0.47 . . . . 73.43 110.87 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 61.2 m-20 -125.43 76.03 1.52 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.183 -0.462 . . . . 73.55 110.886 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -122.62 -5.13 8.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 71.42 110.886 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 70.6 t80 63.41 155.39 0.05 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 75.32 110.889 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 7.2 t 65.76 15.34 10.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.112 -0.495 . . . . 64.41 110.854 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -159.89 -129.12 1.02 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.799 -0.715 . . . . 71.23 112.542 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 3.1 tm? 62.54 104.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.843 0.354 . . . . 75.25 110.888 -179.968 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.06 -20.56 50.08 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.763 -0.732 . . . . 52.23 112.514 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -152.25 128.93 10.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.723 0.297 . . . . 74.4 110.876 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 14.0 mt-30 63.6 -169.35 0.19 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 75.32 110.909 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 63.76 97.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 74.14 110.915 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.27 175.32 5.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 74.23 110.853 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 -91.29 161.94 14.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 70.21 110.879 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -130.68 103.88 0.58 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.71 -0.757 . . . . 40.0 112.465 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 96.2 m -74.98 116.23 15.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.791 0.329 . . . . 75.13 111.166 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 2.5 mp -140.25 132.92 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 72.03 111.069 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.3 141.13 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 74.22 111.093 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 62.1 t -103.75 130.73 53.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 61.11 111.138 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -104.1 128.72 51.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 75.45 110.917 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 116.23 -0.441 . . . . 75.42 110.853 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.2 mtp . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.799 0.333 . . . . 71.43 110.85 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 98.2 t -108.03 113.15 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 75.55 111.163 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 28.5 pt -151.16 153.75 33.14 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.622 0.725 . . . . 74.43 111.142 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.77 -176.96 1.66 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.651 2.234 . . . . 73.35 112.34 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.94 -24.96 16.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 72.52 111.085 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -173.62 129.22 1.62 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.749 -0.739 . . . . 74.32 112.526 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.07 163.75 0.11 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.79 0.328 . . . . 72.31 110.894 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.31 164.38 0.08 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.259 -0.428 . . . . 73.11 110.905 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.8 pm0 -132.46 130.36 40.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 75.33 110.892 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.43 142.67 28.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 74.23 110.848 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 16.4 m -118.46 -176.64 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.167 -0.469 . . . . 65.52 111.106 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.429 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 16.5 p30 -142.92 157.39 61.22 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.605 0.717 . . . . 72.52 110.887 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.429 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 54.0 Cg_endo -69.77 -3.06 11.25 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.646 2.23 . . . . 75.41 112.379 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 25.2 m -46.58 -69.98 0.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.452 . . . . 75.51 111.165 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.9 p -149.71 24.83 0.86 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 65.43 111.165 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.2 p -63.68 -30.97 51.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 74.31 111.133 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -103.28 -5.38 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 74.44 110.879 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 83.7 mm-40 -92.24 -37.42 12.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 72.25 110.942 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -141.89 133.42 26.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 74.13 110.898 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 126.97 -155.09 19.62 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.7 -0.762 . . . . 72.34 112.502 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.95 17.5 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.683 2.256 . . . . 72.45 112.351 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 12.2 m-90 -84.61 -13.98 50.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 74.22 110.916 -179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.78 -49.18 75.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.082 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -114.07 144.39 31.51 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.608 0.718 . . . . 75.14 110.862 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 -25.7 28.06 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.662 2.242 . . . . 73.32 112.318 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.22 -6.75 49.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 74.15 111.098 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 24.0 mm-40 -102.47 9.67 39.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 73.11 110.881 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.92 -79.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 63.43 111.146 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 39' ' ' VAL . 1.5 p -84.98 124.34 39.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 75.34 111.12 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.5 m -135.29 136.01 51.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 63.25 111.124 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -75.57 107.2 7.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 65.34 110.893 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 9.7 t -111.94 -32.95 6.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.218 -0.446 . . . . 61.14 111.141 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.76 -172.68 19.86 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.756 -0.735 . . . . 61.1 112.504 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -43.8 2.45 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.687 2.258 . . . . 73.23 112.357 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -140.96 35.27 1.75 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 64.31 110.876 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.35 119.09 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 73.0 110.889 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.404 ' HB3' HG21 ' A' ' 29' ' ' VAL . 15.2 m-85 -96.79 137.34 36.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 75.02 110.95 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.508 ' HA ' HG22 ' A' ' 62' ' ' VAL . 81.2 m -95.74 105.71 17.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 75.54 111.147 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 29' ' ' VAL . 9.9 t -92.66 138.52 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 72.43 111.12 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -120.75 114.82 22.2 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.191 -0.459 . . . . 72.32 110.951 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 64.4 t -104.14 130.79 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.14 -0.482 . . . . 73.15 111.102 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -125.07 121.52 34.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.47 . . . . 73.42 110.896 179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -142.89 137.57 29.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.446 . . . . 75.14 111.088 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -145.52 159.94 42.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 75.33 110.858 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.82 5.55 32.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 62.52 111.108 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -110.26 70.59 0.73 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.45 110.831 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.07 -170.09 16.23 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.684 -0.77 . . . . 63.25 112.415 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.23 126.51 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.795 0.331 . . . . 75.45 110.929 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.436 ' HB3' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -136.42 161.0 64.62 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.567 0.699 . . . . 73.45 110.961 179.974 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.436 ' HD2' ' HB3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.76 178.68 4.32 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.707 2.271 . . . . 70.43 112.338 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -129.93 62.78 65.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.646 0.736 . . . . 75.1 110.905 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 75.56 1.23 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.657 2.238 . . . . 71.23 112.314 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.4 mp -106.89 98.18 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 71.23 111.133 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -82.14 129.6 34.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 64.32 110.889 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 30.7 t -137.01 81.31 33.35 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.633 0.73 . . . . 75.1 111.118 179.964 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.8 123.05 9.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.702 2.268 . . . . 72.34 112.355 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.29 155.18 40.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 71.45 110.933 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.36 -4.39 77.59 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.749 -0.739 . . . . 60.13 112.503 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.05 152.46 51.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.71 0.29 . . . . 75.1 111.129 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -66.66 139.37 57.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.265 -0.425 . . . . 73.44 110.887 -179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 7.2 mm -127.41 116.33 43.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.198 -0.456 . . . . 64.14 111.123 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.508 HG22 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -104.44 90.59 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 71.21 111.108 179.87 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -68.42 139.7 55.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 75.13 110.883 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -131.97 100.57 5.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 74.54 110.913 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 73.34 111.122 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.1 t -168.44 140.49 2.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.135 -0.484 . . . . 74.23 111.137 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -149.52 161.14 32.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.705 0.764 . . . . 75.45 110.861 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -55.46 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 65.11 112.322 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -156.96 61.97 0.51 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 63.25 110.85 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -155.84 135.44 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 75.25 111.163 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 36.4 mm -69.81 130.5 34.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 71.11 111.128 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 9.2 p-80 -119.98 -175.79 3.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.236 -0.438 . . . . 54.12 110.885 179.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 170.9 12.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 43.43 112.502 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -153.23 141.25 20.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.845 0.355 . . . . 75.15 110.918 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 76.2 t60 -122.1 104.38 9.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 75.42 110.878 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 3.5 p -94.3 137.86 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 74.45 111.143 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -59.96 -175.98 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 72.11 110.904 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.13 -50.97 4.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 75.2 112.45 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -129.26 171.71 12.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.773 0.321 . . . . 75.11 111.111 -179.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.2 m-80 -93.17 47.61 1.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 73.44 110.852 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 12.5 tt -58.54 112.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 60.34 111.172 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.34 94.16 4.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 74.53 110.923 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.3 m -117.97 120.35 64.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 71.04 111.096 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -150.28 118.46 6.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 74.32 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 5.0 m -140.73 146.88 23.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.155 -0.475 . . . . 73.32 111.14 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.27 161.94 75.5 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.554 0.692 . . . . 75.42 110.969 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 159.65 52.61 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.25 . . . . 72.51 112.309 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 86.4 13.28 68.36 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.749 -0.739 . . . . 74.42 112.493 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -146.21 138.43 25.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.903 0.383 . . . . 75.21 110.892 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 99.5 t -90.93 105.89 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 53.03 111.153 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -89.31 137.67 32.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 75.23 110.855 -179.839 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 92.9 m -110.01 105.51 14.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 74.23 111.172 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 44.7 t -98.19 147.95 6.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 71.55 111.104 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.61 110.93 15.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 73.34 110.882 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -156.68 122.64 4.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 72.05 110.887 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.8 t -123.39 135.55 54.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 64.43 111.152 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.79 -174.22 3.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 65.24 110.871 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -121.9 -26.4 4.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 73.2 110.915 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.1 mpp_? -134.51 161.41 63.89 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 74.22 110.88 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 154.22 67.89 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.652 2.235 . . . . 73.41 112.371 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.58 134.4 1.65 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.755 -0.736 . . . . 55.34 112.485 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -100.69 139.49 36.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 74.31 110.892 -179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -143.82 132.82 22.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 74.25 110.915 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.36 94.07 2.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 74.22 110.86 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.8 tt -177.63 131.55 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 75.43 111.17 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -106.2 145.77 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 74.45 111.093 179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -163.98 -74.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 73.12 110.874 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 6.4 m120 -81.09 106.67 13.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.466 . . . . 75.4 110.905 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -167.8 -77.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 74.32 110.914 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER 175.91 -168.49 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.427 . . . . 72.41 110.915 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 68.66 -76.4 0.06 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.148 -0.478 . . . . 75.31 110.9 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 153.61 95.31 0.11 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.748 -0.739 . . . . 70.2 112.5 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -51.77 131.87 30.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.919 0.39 . . . . 73.5 110.88 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 146.79 -101.77 0.24 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.73 -0.747 . . . . 70.53 112.499 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 19.0 m170 -94.09 40.3 1.08 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.744 0.307 . . . . 74.12 110.849 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -172.73 172.54 4.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.231 -0.44 . . . . 64.23 110.878 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 37.9 t-20 66.08 119.46 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 75.43 110.894 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -71.18 174.88 5.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 75.23 110.901 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -91.28 129.7 37.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 71.13 110.886 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.8 82.49 0.4 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.713 -0.756 . . . . 64.12 112.476 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 6.7 m -80.7 115.02 19.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.826 0.346 . . . . 72.35 111.127 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 2.1 mp -149.14 139.12 16.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 74.42 111.177 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.5 p -127.5 135.92 61.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 64.42 111.182 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 41.3 t -104.48 127.65 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 74.53 111.103 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 12.4 mmmm -102.22 133.6 46.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 74.21 110.872 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 75.21 110.919 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.7 mtt . . . . . 0 C--O 1.23 0.079 0 CA-C-O 120.774 0.321 . . . . 74.5 110.875 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.3 p 41.43 37.14 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 72.34 111.074 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.4 pt -122.52 77.97 46.28 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.592 0.71 . . . . 73.11 111.099 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -177.65 1.98 Allowed 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.689 2.259 . . . . 74.11 112.369 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -156.26 159.8 39.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.257 -0.429 . . . . 71.04 111.101 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 56.95 32.2 62.16 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.742 -0.742 . . . . 71.34 112.515 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -171.48 -168.97 0.66 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.745 0.307 . . . . 74.5 110.931 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -57.69 -172.98 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.231 -0.44 . . . . 74.11 110.913 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -115.8 134.34 55.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 73.53 110.891 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 166.56 10.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 75.35 110.884 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.8 m -144.41 -179.09 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 74.05 111.074 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.68 162.04 40.66 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.603 0.716 . . . . 62.23 110.902 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -3.67 12.49 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.676 2.251 . . . . 65.45 112.331 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 28.0 m -46.09 -70.44 0.1 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.239 -0.437 . . . . 64.43 111.17 179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 28.3 p -150.05 27.59 0.77 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 70.14 111.157 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.2 p -65.22 -30.77 51.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 73.22 111.13 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -100.74 -15.74 17.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.148 -0.478 . . . . 74.42 110.863 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -88.45 -33.04 17.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 74.35 110.898 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -141.35 135.12 30.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 73.22 110.913 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.44 -160.69 19.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.753 -0.737 . . . . 72.1 112.492 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -25.8 28.21 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.265 . . . . 75.53 112.343 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 14.5 m-90 -87.07 -12.6 46.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 75.32 110.95 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.86 -59.43 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.451 . . . . 73.43 111.093 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.42 144.55 28.45 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.556 0.693 . . . . 71.44 110.879 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -27.75 26.37 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.689 2.26 . . . . 75.41 112.359 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.41 -18.38 60.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 72.32 111.094 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 -87.82 7.64 29.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 70.24 110.939 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.14 -78.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 64.35 111.112 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.433 ' HA ' ' HA ' ' A' ' 39' ' ' VAL . 1.8 p -93.1 124.93 45.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 74.31 111.113 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.2 m -119.67 149.86 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 64.43 111.108 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.65 121.99 27.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 73.12 110.963 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -121.91 -42.6 2.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 74.43 111.122 -179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.47 170.65 13.81 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 61.5 112.488 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.695 2.264 . . . . 74.23 112.31 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -156.29 34.34 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 64.52 110.908 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -154.0 155.64 35.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.128 -0.487 . . . . 74.33 110.898 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -143.05 147.99 35.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 72.34 110.913 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 52.0 m -101.37 104.22 15.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 72.53 111.127 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.433 ' HA ' ' HA ' ' A' ' 29' ' ' VAL . 6.7 t -85.18 135.13 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 74.02 111.137 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -117.12 121.66 41.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.18 -0.464 . . . . 72.41 110.933 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.0 m -122.73 143.9 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 63.34 111.131 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -138.69 143.85 39.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.479 . . . . 62.23 110.889 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -149.54 123.52 9.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 73.14 111.129 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -121.41 154.47 36.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 71.12 110.814 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.84 6.87 33.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 62.23 111.074 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -122.37 86.07 2.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 75.43 110.906 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.91 -165.92 12.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.755 -0.736 . . . . 62.34 112.54 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -136.3 143.43 44.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.842 0.353 . . . . 74.03 110.893 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.413 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.7 pm0 -145.37 155.59 53.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 72.13 110.901 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.413 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.9 Cg_endo -69.75 174.45 9.48 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.253 . . . . 74.55 112.35 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.1 m-20 -127.99 62.37 56.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.631 0.729 . . . . 72.23 110.869 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 74.43 1.26 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.655 2.237 . . . . 74.31 112.343 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.9 mp -110.58 113.89 45.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 74.12 111.154 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -108.59 119.47 39.61 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.491 . . . . 72.13 110.908 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.1 p -124.77 85.71 56.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.61 0.719 . . . . 74.14 111.125 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 122.57 9.25 Favored 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 122.673 2.249 . . . . 72.31 112.347 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.57 150.45 48.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 73.34 110.881 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.81 -30.46 5.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 62.41 112.507 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.83 152.12 23.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.736 0.303 . . . . 63.41 111.119 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -68.82 142.36 54.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.456 . . . . 75.11 110.861 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 4.7 mm -126.87 124.16 64.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 75.05 111.106 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 55.0 t -107.92 91.25 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 71.11 111.173 179.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -69.48 135.02 49.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 71.25 110.887 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -131.43 100.44 5.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 74.45 110.865 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.5 mp -97.17 156.07 3.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.264 -0.426 . . . . 73.12 111.098 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 7.2 t -166.01 137.9 3.86 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 75.02 111.141 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.472 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -152.21 159.76 32.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.646 0.736 . . . . 71.14 110.912 -179.876 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.472 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.76 -53.98 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.665 2.243 . . . . 73.33 112.403 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -154.88 65.84 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 73.24 110.864 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.433 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.4 135.55 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 74.32 111.126 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.2 mm -66.9 145.54 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 75.31 111.107 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -108.75 -167.05 1.17 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 74.45 110.834 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.84 120.73 3.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 41.12 112.513 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -121.16 142.84 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.904 0.383 . . . . 74.54 110.9 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -89.14 137.19 32.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 73.11 110.872 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 94.8 t -130.03 141.47 46.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 73.14 111.161 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.6 mt-10 -75.26 175.67 8.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 65.34 110.878 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.06 -51.65 4.14 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.676 -0.773 . . . . 64.34 112.514 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.25 147.24 51.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 74.11 111.156 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -76.71 64.57 2.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 71.31 110.881 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 8.0 tt -58.23 125.94 15.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 73.2 111.176 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.7 89.67 3.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.853 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.7 m -115.87 120.65 65.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 75.5 111.158 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -155.79 114.51 3.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 72.12 110.838 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 61.6 t -140.46 146.71 24.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 74.15 111.138 179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.422 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.6 OUTLIER -69.69 155.68 93.06 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.585 0.707 . . . . 71.4 110.902 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.422 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 54.1 Cg_endo -69.74 159.8 52.09 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.234 . . . . 75.02 112.379 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.21 17.25 51.31 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.761 -0.733 . . . . 72.11 112.493 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -156.26 155.77 32.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.88 0.371 . . . . 74.13 110.886 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 98.2 t -104.85 109.78 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 71.15 111.123 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -83.83 169.46 15.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 74.35 110.879 -179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 98.3 m -137.99 122.22 18.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.144 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 21.3 t -124.57 130.6 73.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 73.13 111.155 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.7 mmm180 -102.57 70.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 73.14 110.9 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 14.8 t80 -110.13 130.73 55.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.153 -0.476 . . . . 72.25 110.931 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.1 t -139.64 142.25 37.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.475 . . . . 71.44 111.133 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -97.0 -175.49 3.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 75.52 110.861 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.1 mttt -125.34 -12.52 6.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 64.21 110.899 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -145.81 162.14 37.24 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.557 0.694 . . . . 72.44 110.865 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 154.0 68.21 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.679 2.253 . . . . 62.41 112.347 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.45 141.17 3.05 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.727 -0.749 . . . . 23.23 112.483 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -106.59 130.14 54.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.808 0.337 . . . . 60.42 110.905 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.3 p90 -144.04 146.32 32.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 73.01 110.922 -179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.17 -175.76 5.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 74.21 110.848 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 mp 65.62 150.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 73.11 111.195 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -109.68 145.75 15.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 72.23 111.167 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -175.07 33.44 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.166 -0.47 . . . . 73.31 110.904 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 22.8 t-20 -174.84 60.43 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.138 -0.483 . . . . 73.4 110.866 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -107.46 -175.39 2.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 74.23 110.899 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -121.33 69.76 0.92 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.205 -0.452 . . . . 73.01 110.942 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 35.9 t -176.95 -36.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.13 -0.487 . . . . 74.22 110.899 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 156.56 145.77 4.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.718 -0.753 . . . . 71.22 112.476 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.1 pt? -127.83 133.49 49.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.879 0.371 . . . . 75.25 110.924 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 136.43 -107.49 0.61 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.719 -0.753 . . . . 64.25 112.454 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -51.91 -73.89 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.743 0.306 . . . . 72.33 110.861 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -71.1 -169.74 0.4 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 72.1 110.899 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.55 95.97 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.208 -0.451 . . . . 73.51 110.904 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.45 174.84 6.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 75.13 110.875 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -91.33 120.09 31.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 75.13 110.921 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -87.58 -179.78 47.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.747 -0.739 . . . . 72.24 112.531 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 67.9 m -154.71 137.02 14.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.74 0.305 . . . . 73.54 111.164 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 2.8 mp -147.36 140.72 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 74.33 111.123 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 50.2 t -128.41 129.28 68.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 53.11 111.116 179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 87.9 t -103.59 136.86 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 75.35 111.082 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.3 mmmt -113.83 131.78 56.12 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 72.25 110.902 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 73.34 110.874 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.1 ptp . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.807 0.337 . . . . 71.42 110.843 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 63.0 t -116.28 86.07 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.237 -0.438 . . . . 74.22 111.123 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -138.08 77.79 36.12 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.635 0.731 . . . . 73.13 111.143 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -177.59 1.95 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.673 2.249 . . . . 70.04 112.356 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -167.56 161.58 13.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 73.42 111.111 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 109.31 -34.74 5.33 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.734 -0.746 . . . . 71.33 112.507 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -168.4 120.11 0.81 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.813 0.339 . . . . 65.43 110.898 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 62.07 162.51 0.08 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 53.42 110.885 179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.98 132.93 53.77 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.183 -0.462 . . . . 62.32 110.859 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.64 166.78 13.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 63.14 110.85 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 35.9 m -150.02 140.6 16.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.178 -0.465 . . . . 71.13 111.104 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.1 162.84 19.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.578 0.704 . . . . 72.03 110.855 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.96 9.33 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.651 2.234 . . . . 71.2 112.384 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 3.2 m -46.24 -67.43 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.207 -0.451 . . . . 74.13 111.168 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 26.8 p -146.67 13.86 1.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 74.11 111.138 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 p -50.64 -31.93 9.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 111.136 179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.14 -17.41 14.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 74.32 110.883 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 22.1 mm100 -79.62 -31.21 41.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 74.44 110.94 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -149.24 140.48 23.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.231 -0.441 . . . . 74.43 110.884 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.19 -157.16 17.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.691 -0.766 . . . . 73.21 112.46 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 -30.6 22.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 50.31 112.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 14.9 m-90 -87.21 -7.48 57.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.226 -0.443 . . . . 73.42 110.921 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.29 -60.08 2.51 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 74.53 111.054 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.56 142.59 29.57 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.577 0.703 . . . . 75.32 110.916 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -28.38 25.07 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.666 2.244 . . . . 65.01 112.347 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.18 -11.69 60.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 73.03 111.115 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.5 mm-40 -95.35 24.71 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 74.31 110.935 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.58 -79.58 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 74.51 111.067 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 1.8 p -106.86 141.01 23.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 74.24 111.153 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 m -128.1 150.16 33.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 74.23 111.164 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.1 118.79 29.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 73.14 110.925 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.9 t -121.06 -21.06 6.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 72.32 111.148 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.29 168.38 20.19 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 62.11 112.5 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.25 20.57 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.652 2.235 . . . . 65.22 112.33 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 18.0 t30 -159.33 23.25 0.19 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.445 . . . . 60.35 110.874 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -138.87 153.97 48.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 72.51 110.865 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -141.97 142.15 32.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 72.23 110.966 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.2 m -95.74 104.55 16.48 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.115 -0.493 . . . . 75.41 111.144 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 t -84.5 140.06 16.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 74.5 111.156 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.29 122.76 39.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 72.14 110.918 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.6 m -118.73 123.26 71.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.11 -0.495 . . . . 74.53 111.113 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -115.88 132.88 56.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 71.15 110.894 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.44 114.47 3.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 65.44 111.087 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 5.9 p90 -129.36 152.09 49.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 75.22 110.878 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.14 1.77 46.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.09 -0.504 . . . . 53.44 111.145 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -95.83 72.0 3.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 75.24 110.868 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.21 -150.88 17.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.754 -0.736 . . . . 73.43 112.471 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 p90 -136.37 150.93 49.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.36 . . . . 74.21 110.907 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -162.09 162.06 20.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.591 0.71 . . . . 73.51 110.904 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 157.36 60.63 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.281 . . . . 74.44 112.35 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -133.09 66.69 76.32 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.644 0.735 . . . . 62.34 110.877 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.83 114.03 3.58 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.676 2.251 . . . . 73.33 112.367 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.5 mm -117.21 151.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 71.3 111.136 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.2 tt0 -155.25 120.62 4.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 71.3 110.929 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.419 HG21 HG13 ' A' ' 61' ' ' ILE . 2.4 p -139.7 82.03 18.75 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.651 0.739 . . . . 74.31 111.131 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.81 123.67 10.31 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.698 2.266 . . . . 74.32 112.349 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.23 155.11 40.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 72.32 110.96 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.41 -8.73 73.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 72.01 112.469 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.02 155.77 48.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 71.51 111.115 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -66.75 141.37 57.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 71.25 110.857 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.419 HG13 HG21 ' A' ' 55' ' ' VAL . 5.7 mm -130.14 119.18 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 62.43 111.106 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 54.8 t -102.28 98.42 6.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 74.12 111.129 179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 72.0 m-85 -76.97 126.34 30.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 75.42 110.851 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.9 mttt -120.32 100.09 6.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 64.33 110.911 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mt -98.22 153.21 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 75.35 111.111 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 13.4 t -171.35 145.97 2.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 75.34 111.185 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.409 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -153.29 159.62 31.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.678 0.751 . . . . 74.03 110.854 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.409 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.76 -54.83 0.2 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.73 2.287 . . . . 63.1 112.325 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -156.53 60.55 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.238 -0.437 . . . . 72.43 110.884 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.29 136.35 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.459 . . . . 70.5 111.136 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 41.4 mm -67.08 144.2 14.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 73.45 111.09 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -136.98 158.11 45.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 74.02 110.827 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.71 129.83 1.11 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.779 -0.724 . . . . 71.14 112.515 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.0 p90 -117.47 141.93 47.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 74.23 110.862 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -112.1 90.74 3.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 75.42 110.846 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 27.6 t -73.36 145.53 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 74.22 111.115 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -75.66 -175.56 2.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 73.4 110.858 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.91 -51.38 4.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 55.24 112.437 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -132.41 179.28 6.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.777 0.322 . . . . 72.31 111.161 -179.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 11.2 m-80 -90.19 48.01 1.51 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 63.22 110.868 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 3.3 tp -63.14 111.0 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 72.03 111.139 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.87 122.73 46.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 64.43 110.852 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.2 m -143.51 120.1 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 75.33 111.126 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.25 112.59 2.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 65.43 110.888 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 23.5 t -140.5 144.28 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 73.05 111.142 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 1.4 mp -61.53 161.11 21.16 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.591 0.71 . . . . 54.53 110.919 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 159.53 53.11 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.667 2.245 . . . . 70.53 112.347 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.23 10.88 60.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.718 -0.753 . . . . 75.44 112.492 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -152.6 159.39 43.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.862 0.363 . . . . 74.35 110.869 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 95.7 t -98.43 143.34 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 73.33 111.138 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 7.3 p -121.3 97.24 5.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 71.22 110.899 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.2 t -85.63 141.33 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.116 -0.493 . . . . 72.21 111.167 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 12.6 p -154.24 150.3 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 74.33 111.136 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -109.6 116.4 31.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 74.12 110.894 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -151.45 114.96 4.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 74.3 110.945 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.6 t -116.55 136.24 53.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.14 -0.482 . . . . 71.25 111.123 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -87.06 -172.47 3.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 74.33 110.922 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.1 tttt -123.19 -26.14 4.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 73.2 110.909 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -140.71 162.06 50.97 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.708 . . . . 74.42 110.871 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 150.72 68.57 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 74.4 112.345 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.09 143.85 3.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.733 -0.746 . . . . 73.23 112.506 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -108.82 134.53 51.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.84 0.352 . . . . 73.52 110.906 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.1 p90 -143.54 131.53 21.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 73.15 110.933 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.39 111.27 5.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.08 -0.509 . . . . 74.51 110.867 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.0 tp -178.61 142.95 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 74.23 111.098 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 17.7 tt -130.38 126.39 61.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 62.42 111.11 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 178.98 170.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 73.21 110.913 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 51.63 30.41 6.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 74.51 110.925 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 5.0 mm-40 -100.58 -25.19 14.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.476 . . . . 64.05 110.893 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 63.14 -173.42 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 72.21 110.937 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER 57.07 25.77 11.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.48 . . . . 73.52 110.882 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 61.88 36.53 92.94 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.727 . . . . 75.33 112.501 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -70.82 -74.77 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.882 0.372 . . . . 71.44 110.95 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -87.0 90.16 1.66 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 63.24 112.482 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 1.8 m80 -128.11 -74.85 0.57 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.696 0.284 . . . . 74.13 110.884 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -117.03 -23.81 7.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 64.42 110.932 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -59.48 -179.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 74.3 110.927 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.53 174.47 6.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.481 . . . . 65.52 110.879 179.923 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -97.8 149.83 21.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.228 -0.442 . . . . 74.0 110.856 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -72.42 79.41 0.67 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.727 -0.749 . . . . 72.3 112.446 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 15.1 t -85.47 134.28 34.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.714 0.293 . . . . 74.11 111.21 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 3.3 mp -153.1 134.27 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.243 -0.435 . . . . 75.05 111.11 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.6 p -126.23 137.61 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 74.32 111.139 179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 47.3 t -108.14 141.97 22.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 74.31 111.134 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.8 mmtt -116.33 132.42 56.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 75.43 110.937 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 71.41 110.875 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.1 tpt . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.813 0.34 . . . . 72.01 110.862 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.5 m -116.99 68.85 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 73.12 111.143 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -124.12 77.97 59.6 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.633 0.73 . . . . 75.0 111.174 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 -177.34 1.82 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.66 2.24 . . . . 74.33 112.354 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -152.4 80.55 1.24 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.454 . . . . 62.12 111.132 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -179.81 -57.25 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.707 -0.759 . . . . 71.01 112.449 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.5 tptt -172.32 152.13 2.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 74.42 110.878 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 62.08 162.35 0.08 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 74.25 110.915 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.1 pt-20 -118.96 141.79 48.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 72.34 110.892 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -93.1 135.38 34.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 71.04 110.85 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 7.8 m -115.01 -179.22 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 62.32 111.133 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -147.04 162.63 32.22 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 71.34 110.867 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -4.33 13.79 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.677 2.251 . . . . 71.41 112.367 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 5.4 m -48.75 -66.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.24 -0.436 . . . . 75.5 111.112 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 3.2 p -155.59 37.35 0.37 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 71.42 111.149 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.4 p -77.19 -27.52 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.214 -0.448 . . . . 73.34 111.137 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 20.4 ptt85 -104.28 -10.76 17.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 75.24 110.853 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -94.35 -36.96 11.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.453 . . . . 72.32 110.927 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.87 133.88 40.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 72.55 110.883 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.02 -157.18 19.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 45.25 112.507 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -30.06 22.79 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 72.53 112.36 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 14.0 m-90 -86.82 -10.89 52.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 74.32 110.926 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.66 -59.32 3.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 75.23 111.112 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.63 144.85 29.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.612 0.72 . . . . 72.35 110.868 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -17.24 37.75 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.665 2.243 . . . . 73.41 112.322 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -24.09 59.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 72.02 111.132 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.7 mm-40 -90.05 10.54 23.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 72.23 110.931 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -78.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 74.12 111.15 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.1 p -108.2 128.71 63.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 72.53 111.149 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.01 144.04 28.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 71.12 111.139 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.0 tp60 -75.48 121.45 22.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 74.21 110.905 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 t -119.95 -12.88 9.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 62.21 111.166 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.61 -167.66 12.15 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.751 -0.737 . . . . 72.32 112.496 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 -36.12 11.4 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 73.01 112.337 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -153.58 34.45 0.45 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 73.23 110.884 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.14 118.09 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 74.14 110.889 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -97.66 138.47 35.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.94 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 55.9 m -95.66 102.59 14.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 72.34 111.13 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.9 t -84.24 146.33 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 75.04 111.156 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -126.8 124.06 38.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.143 -0.48 . . . . 74.43 110.962 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 92.1 t -125.37 138.67 53.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.491 . . . . 70.21 111.121 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -138.61 141.84 39.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.166 -0.47 . . . . 74.02 110.94 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.68 109.11 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 71.33 111.065 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -122.77 153.43 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 74.25 110.852 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.26 4.3 35.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 75.21 111.13 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -95.24 78.11 3.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.937 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.59 -139.92 14.75 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 74.4 112.489 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -148.42 150.06 32.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.845 0.355 . . . . 71.13 110.943 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -158.19 162.55 26.69 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.571 0.701 . . . . 73.44 110.963 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 157.03 61.78 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.722 2.281 . . . . 73.54 112.317 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.49 66.08 76.11 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.598 0.713 . . . . 72.43 110.847 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.85 118.36 5.64 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.693 2.262 . . . . 71.0 112.302 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.4 mm -124.55 151.51 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 75.14 111.123 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.3 tt0 -155.22 115.66 3.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 75.4 110.836 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 21.2 t -131.34 82.02 63.61 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.647 0.737 . . . . 75.43 111.145 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 121.87 8.56 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.692 2.261 . . . . 75.14 112.368 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -68.3 152.85 44.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.253 -0.43 . . . . 65.12 110.933 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.95 -36.33 3.7 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 73.11 112.495 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.77 158.06 17.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.8 0.333 . . . . 74.13 111.066 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -67.87 144.53 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.45 . . . . 74.55 110.922 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.7 mm -128.21 120.01 52.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 73.3 111.114 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 55.2 t -103.9 91.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 75.32 111.128 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -69.61 134.95 49.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 74.55 110.906 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 15.6 mttt -131.53 100.16 5.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.153 -0.476 . . . . 74.44 110.877 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -107.11 143.32 17.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 74.13 111.156 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.5 t -156.38 136.18 12.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 74.23 111.166 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.95 161.51 48.3 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.699 0.761 . . . . 73.4 110.853 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -50.81 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.671 2.247 . . . . 71.32 112.385 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -155.78 49.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 71.21 110.842 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.21 135.94 3.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.146 -0.479 . . . . 71.51 111.117 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 95.0 mt -86.45 105.64 14.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.14 111.147 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 44.8 t-80 -99.46 69.65 1.67 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 64.42 110.901 179.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.15 155.5 21.07 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.73 -0.748 . . . . 63.11 112.466 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 3.3 p90 -128.61 142.82 50.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.883 0.373 . . . . 75.34 110.886 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -118.56 94.1 4.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 74.15 110.854 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.1 t -74.11 140.9 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 75.53 111.147 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 pm0 -75.3 -176.05 2.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 74.05 110.869 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.7 -51.86 4.61 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.723 -0.751 . . . . 63.13 112.491 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 10.7 m -124.02 157.16 35.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.813 0.34 . . . . 75.53 111.174 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 1.1 m120 -77.15 60.06 1.84 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 61.04 110.874 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 11.5 tt -78.51 116.53 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 73.32 111.137 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -123.19 96.69 5.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 75.41 110.85 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.6 m -114.39 119.89 62.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 70.14 111.105 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.64 117.36 7.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.14 -0.482 . . . . 70.53 110.886 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.6 p -140.62 128.29 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 63.21 111.117 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -57.52 157.91 12.5 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.59 0.71 . . . . 72.03 110.959 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 159.16 54.46 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.685 2.256 . . . . 63.55 112.339 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.1 11.73 59.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 74.24 112.511 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -163.86 118.19 1.53 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.897 0.379 . . . . 71.4 110.897 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 3.5 p -68.8 143.28 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 74.45 111.129 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.09 169.29 8.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 70.42 110.814 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 87.8 m -145.45 111.28 5.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.121 -0.491 . . . . 73.14 111.112 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 8.0 p -124.45 150.7 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 74.31 111.131 179.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -114.93 97.49 6.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.831 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 40.5 t80 -139.9 110.08 6.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 74.42 110.947 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.1 t -110.68 143.5 41.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 74.24 111.177 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.6 -178.89 5.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.258 -0.428 . . . . 74.32 110.853 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.7 mttt -119.85 -12.9 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 75.43 110.927 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.16 161.66 31.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.62 0.724 . . . . 75.01 110.831 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.67 152.43 69.75 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 2.26 . . . . 64.42 112.384 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 159.4 130.43 1.14 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.785 -0.722 . . . . 63.14 112.494 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -99.22 130.46 45.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 72.35 110.866 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -135.42 146.39 48.23 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.197 -0.456 . . . . 74.2 110.93 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.542 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 0.7 OUTLIER -148.22 -163.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 72.42 110.907 179.99 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.542 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 1.2 tt 58.94 158.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 73.34 111.129 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.56 138.41 43.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 72.14 111.157 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 6.9 t -171.61 71.44 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.225 -0.443 . . . . 73.53 110.864 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -179.68 -37.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 75.0 110.886 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -57.25 179.73 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 73.32 110.92 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 1.6 p90 -104.56 -20.06 13.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 73.31 110.94 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -52.1 -63.41 1.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.142 -0.481 . . . . 72.24 110.88 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -178.04 -156.73 17.26 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.735 -0.745 . . . . 75.11 112.47 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 3.4 pp -162.7 26.49 0.1 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.853 0.359 . . . . 73.44 110.935 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -168.42 -89.46 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.774 -0.727 . . . . 41.15 112.505 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 15.8 p80 -64.64 -14.74 59.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.739 0.304 . . . . 75.11 110.869 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 -61.9 -164.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 75.21 110.871 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -56.33 -175.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 74.5 110.92 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 1.2 mtt -69.47 175.29 4.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.43 110.876 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -91.19 167.62 12.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 72.43 110.878 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -101.48 166.1 18.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.695 -0.764 . . . . 74.34 112.49 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 68.7 m -154.93 127.6 8.02 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.771 0.32 . . . . 74.21 111.118 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.3 mp -150.01 143.66 17.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 75.33 111.136 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 m -134.47 140.74 45.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 73.33 111.133 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.68 126.03 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 73.5 111.17 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 11.3 mmmm -108.92 141.51 40.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 65.33 110.909 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.209 -0.451 . . . . 73.42 110.928 179.963 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.8 mmt . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.866 0.365 . . . . 62.35 110.914 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.3 p -154.07 128.02 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.217 -0.447 . . . . 74.54 111.121 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.9 pt -129.43 153.71 80.63 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.642 0.734 . . . . 74.34 111.155 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -177.3 1.81 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.699 2.266 . . . . 71.5 112.328 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -162.09 74.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 73.43 111.062 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.26 -17.74 54.58 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.791 -0.719 . . . . 73.32 112.463 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -104.04 -172.22 2.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.758 0.313 . . . . 75.31 110.905 -179.933 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.3 pp -58.74 -174.78 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.266 -0.425 . . . . 75.34 110.922 179.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -86.39 131.02 34.3 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.227 -0.442 . . . . 75.12 110.867 179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -104.52 143.98 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 75.44 110.904 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.0 m -110.64 -177.55 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 73.44 111.138 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.404 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 4.9 p30 -143.79 156.18 59.31 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.626 0.727 . . . . 70.34 110.87 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.81 -3.58 12.34 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.652 2.235 . . . . 75.11 112.338 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 3.7 m -47.56 -63.74 0.97 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.237 -0.438 . . . . 71.32 111.14 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -155.67 29.04 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.244 -0.435 . . . . 74.02 111.133 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.4 p -64.57 -30.23 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.435 . . . . 65.25 111.12 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 4.0 ptt-85 -101.17 -6.63 24.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.35 110.874 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 11.3 mm-40 -97.43 -37.46 9.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 75.5 110.924 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -135.11 133.93 39.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 71.1 110.852 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.05 -158.76 18.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.717 -0.754 . . . . 72.23 112.466 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -29.02 24.71 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.657 2.238 . . . . 72.32 112.364 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 15.0 m-90 -87.12 -11.42 50.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.26 -0.427 . . . . 75.54 110.893 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.36 -59.16 5.07 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.267 -0.424 . . . . 74.13 111.074 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.91 143.63 26.99 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.598 0.713 . . . . 75.12 110.885 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -22.69 31.51 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.735 2.29 . . . . 74.24 112.288 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.8 -7.27 51.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.271 -0.422 . . . . 35.4 111.104 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 31.7 mm-40 -104.73 5.27 33.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 71.44 110.887 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -77.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 74.15 111.1 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.3 p -103.39 108.4 24.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 74.43 111.109 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -114.91 149.86 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 75.1 111.138 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -67.96 122.32 17.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 75.23 110.895 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.7 t -119.73 -33.55 3.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 51.44 111.132 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.06 175.85 17.94 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 71.35 112.493 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.67 24.21 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.721 2.281 . . . . 74.12 112.336 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -161.03 34.79 0.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 74.14 110.895 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -150.91 160.29 44.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 74.51 110.94 -179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -143.12 144.32 32.18 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.244 -0.435 . . . . 74.54 110.906 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.2 m -97.62 103.14 15.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 73.22 111.142 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.9 t -85.05 137.67 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 72.32 111.18 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -120.26 113.12 19.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 73.51 110.966 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 59.1 t -110.42 133.82 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 74.13 111.122 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -139.31 139.36 37.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 73.23 110.868 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.16 122.66 5.63 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 74.51 111.107 179.785 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -121.56 145.57 47.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 75.31 110.874 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.32 48.12 1.57 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.474 . . . . 72.51 111.117 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -120.9 -50.7 2.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 64.22 110.879 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -133.71 -119.01 1.95 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.773 -0.727 . . . . 75.32 112.54 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -150.17 136.68 19.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 74.34 110.894 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -130.39 159.41 70.76 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.578 0.704 . . . . 71.42 110.939 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -176.97 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.672 2.248 . . . . 71.51 112.367 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -137.57 62.5 36.23 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.672 0.748 . . . . 74.34 110.926 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 6.45 1.3 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.67 2.247 . . . . 74.54 112.313 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.437 ' H ' ' CD1' ' A' ' 53' ' ' ILE . 4.7 mp -48.39 131.28 5.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 75.13 111.136 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -140.18 149.6 43.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 64.14 110.883 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.9 t -151.0 81.96 6.09 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.618 0.723 . . . . 73.53 111.132 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 123.08 9.74 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.647 2.232 . . . . 71.33 112.332 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.1 155.3 40.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 65.24 110.923 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.54 -9.67 70.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.729 -0.748 . . . . 70.23 112.469 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.36 154.35 50.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.759 0.314 . . . . 71.02 111.125 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -64.88 144.55 57.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 75.44 110.944 -179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 7.6 mm -129.44 115.16 33.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 65.13 111.127 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 77.2 t -99.06 97.72 6.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 72.0 111.122 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 87.9 m-85 -75.85 132.06 40.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 75.41 110.872 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -130.82 100.06 5.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.931 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.38 153.24 4.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 75.51 111.11 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.5 t -167.1 128.66 1.62 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 72.23 111.134 179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.425 ' HB2' HG23 ' A' ' 70' ' ' VAL . 0.1 OUTLIER -140.25 166.16 25.39 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.637 0.732 . . . . 74.33 110.84 -179.875 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.406 ' HD2' ' CB ' ' A' ' 67' ' ' SER . 54.4 Cg_endo -69.72 -54.8 0.2 Allowed 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.668 2.245 . . . . 72.1 112.389 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -158.7 57.22 0.44 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 74.32 110.917 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.425 HG23 ' HB2' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.62 140.23 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.142 -0.481 . . . . 75.34 111.108 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.0 mm -85.3 150.82 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 74.1 111.101 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 11.9 m170 -115.69 -84.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.472 . . . . 74.43 110.903 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.88 98.85 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.743 -0.741 . . . . 73.05 112.492 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -106.31 142.47 35.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 75.0 110.89 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -110.8 142.39 42.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 75.55 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.4 t -135.89 136.19 50.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 73.21 111.142 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -64.21 -177.2 0.26 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.181 -0.463 . . . . 74.34 110.925 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 84.32 -51.22 4.53 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.747 -0.74 . . . . 65.33 112.479 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.1 m -135.12 160.94 36.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.774 0.321 . . . . 75.53 111.202 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -86.01 76.58 9.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 73.3 110.893 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 4.8 tt -85.01 121.81 37.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 73.52 111.11 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -116.5 95.42 5.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 74.14 110.878 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.8 m -115.63 120.37 64.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 74.51 111.147 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -156.59 110.02 2.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.2 -0.454 . . . . 71.31 110.874 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.8 p -140.74 147.11 23.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 62.54 111.12 179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.28 161.1 80.26 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.567 0.699 . . . . 72.41 110.905 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 159.64 52.67 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.654 2.236 . . . . 74.14 112.333 179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.39 85.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.722 -0.751 . . . . 75.11 112.469 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -139.37 145.25 38.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.932 0.396 . . . . 74.53 110.889 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 21.2 t -99.3 110.66 27.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.165 -0.47 . . . . 72.25 111.157 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -91.37 165.97 13.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 62.34 110.846 -179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.4 t -144.19 140.15 29.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 71.41 111.168 -179.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.9 p -153.79 127.55 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 73.11 111.126 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.0 mtm180 -93.95 111.11 22.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 73.14 110.885 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -145.75 118.45 8.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.429 . . . . 73.12 110.872 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.3 t -114.39 132.03 56.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 71.44 111.161 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -177.59 6.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 73.42 110.854 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.3 ttpt -121.52 -24.28 5.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 74.51 110.901 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.49 160.21 57.69 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.613 0.721 . . . . 73.23 110.899 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 127.85 15.16 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.689 2.26 . . . . 72.21 112.313 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.12 146.33 14.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 70.01 112.521 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -105.57 135.71 46.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.84 0.352 . . . . 74.34 110.881 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -143.97 148.87 35.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.169 -0.469 . . . . 75.54 110.947 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 30.6 ttp85 -168.78 157.9 8.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 75.31 110.882 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.0 mp 66.79 147.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.176 -0.466 . . . . 75.41 111.096 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.86 136.85 31.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 74.13 111.11 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -179.89 36.75 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.171 -0.468 . . . . 74.34 110.9 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -175.72 63.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.185 -0.461 . . . . 75.32 110.902 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -174.03 -170.14 0.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 62.33 110.924 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 5.3 t80 -67.2 89.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 64.03 110.971 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -179.24 -60.15 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.127 -0.488 . . . . 61.41 110.847 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.73 19.08 58.77 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.81 -0.71 . . . . 74.0 112.485 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 1.6 tt 52.14 86.56 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.81 0.338 . . . . 74.43 110.899 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -110.25 -135.91 7.18 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.756 -0.735 . . . . 73.45 112.541 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 36.0 p-80 -126.68 26.46 6.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.686 0.279 . . . . 74.12 110.827 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -145.83 46.19 1.27 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 72.43 110.924 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -145.62 173.55 11.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 73.4 110.904 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 10.1 mmt -134.22 174.44 10.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 74.14 110.91 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -100.62 159.85 14.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 74.33 110.904 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -151.69 110.65 0.47 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 61.0 112.465 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' THR . . . . . 0.413 HG22 ' CD1' ' A' ' 53' ' ' ILE . 0.8 OUTLIER -86.77 152.92 22.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.73 0.3 . . . . 65.1 111.197 -179.907 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.4 mp -149.06 120.53 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 74.21 111.13 179.921 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.0 p -114.83 127.14 72.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 75.02 111.089 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 42.7 t -97.88 131.2 45.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 74.32 111.149 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 15.2 mmmt -104.97 128.53 53.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 75.45 110.86 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 60.22 110.884 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.5 ptm . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.761 0.315 . . . . 75.25 110.877 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 25.0 m -114.12 139.37 40.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.261 -0.427 . . . . 75.22 111.111 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.4 pt -150.96 77.88 7.51 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.594 0.712 . . . . 75.1 111.133 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -178.14 2.2 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.73 2.287 . . . . 73.11 112.346 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -152.74 91.82 1.6 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 65.32 111.098 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 169.86 -119.69 0.83 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 72.23 112.521 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.07 157.03 17.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.814 0.34 . . . . 75.24 110.879 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.49 163.75 0.08 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.23 -0.441 . . . . 73.12 110.909 179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.22 141.38 48.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 71.54 110.869 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -86.02 137.97 32.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 72.13 110.867 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.1 m -120.72 -177.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.131 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.436 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 33.8 p30 -144.16 156.75 57.88 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.596 0.712 . . . . 72.03 110.882 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.6 Cg_endo -69.76 -2.28 9.9 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.674 2.249 . . . . 73.31 112.356 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.6 m -45.24 -65.24 0.56 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.223 -0.444 . . . . 74.34 111.124 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.2 p -150.26 17.84 0.84 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 71.12 111.121 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.4 p -57.17 -25.8 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 74.34 111.145 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.426 HH12 ' NE2' ' A' ' 18' ' ' GLN . 3.5 ptt85 -106.71 -8.05 17.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 75.03 110.851 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.426 ' NE2' HH12 ' A' ' 17' ' ' ARG . 0.8 OUTLIER -94.03 -32.22 13.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.4 110.92 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -142.56 144.19 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 74.35 110.902 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.96 -156.56 15.58 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.765 -0.731 . . . . 74.02 112.482 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 -35.94 11.69 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.661 2.24 . . . . 65.34 112.328 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 13.5 m-90 -84.66 -7.25 59.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.213 -0.449 . . . . 70.34 110.92 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.02 -54.19 45.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.24 -0.437 . . . . 52.13 111.105 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.68 141.99 30.89 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.653 0.74 . . . . 75.04 110.855 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.673 2.248 . . . . 74.12 112.372 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.59 -36.99 65.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 64.21 111.06 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.466 ' N ' HE21 ' A' ' 27' ' ' GLN . 0.0 OUTLIER -95.31 33.06 1.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 75.52 110.929 -179.962 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.73 -76.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 73.22 111.101 179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 38' ' ' THR . 2.3 p -101.88 129.79 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 72.21 111.103 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -142.33 139.99 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 73.32 111.151 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 13.0 tp60 -72.4 123.34 22.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 75.33 110.903 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -120.28 -10.45 9.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 75.24 111.165 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.98 -168.83 12.46 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 74.24 112.479 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -33.8 16.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.654 2.236 . . . . 72.21 112.368 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -154.31 28.7 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 73.04 110.896 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -126.83 119.43 26.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 75.11 110.912 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 63.0 m-85 -96.37 134.7 39.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 74.25 110.906 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.467 ' HA ' HG23 ' A' ' 62' ' ' VAL . 92.5 m -93.84 104.23 16.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 74.43 111.119 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.1 t -86.85 132.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 71.31 111.096 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -118.07 115.66 25.3 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.19 -0.459 . . . . 75.1 110.917 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.8 m -114.05 119.71 61.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 73.32 111.131 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -114.97 132.86 56.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 73.13 110.927 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -154.59 131.28 10.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 75.3 111.066 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -127.1 163.03 24.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 75.13 110.868 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.03 2.9 48.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.098 -0.501 . . . . 71.21 111.124 179.923 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 3.5 p90 -122.3 84.43 2.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 73.12 110.865 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.01 158.72 12.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 75.31 112.464 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -111.77 120.8 43.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.798 0.332 . . . . 73.4 110.976 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -127.08 162.36 48.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 60.24 110.883 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 162.49 41.87 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.659 2.239 . . . . 75.45 112.34 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 -137.95 67.19 48.8 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.614 0.721 . . . . 74.43 110.851 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 98.99 0.72 Allowed 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.643 2.228 . . . . 73.22 112.35 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.5 mm -100.57 157.44 4.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 75.34 111.131 179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 16.4 tt0 -155.42 122.08 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.909 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.422 HG22 ' HA ' ' A' ' 124' ' ' VAL . 6.0 m -142.68 86.6 9.53 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.612 0.72 . . . . 73.1 111.137 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 122.74 9.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.689 2.259 . . . . 73.31 112.344 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.06 155.75 23.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 72.32 110.904 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.98 -0.97 76.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.694 -0.765 . . . . 72.44 112.484 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.95 150.4 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.787 0.327 . . . . 74.23 111.086 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -68.14 138.23 55.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 74.12 110.883 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.0 mm -128.28 117.78 46.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 70.2 111.139 179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.467 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -104.23 94.2 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 75.32 111.145 179.841 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -64.52 142.86 58.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 74.44 110.899 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -133.36 98.36 4.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.42 110.917 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.3 mp -106.8 137.01 39.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.26 -0.427 . . . . 73.31 111.15 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.5 t -154.96 134.62 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 74.33 111.121 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -146.2 161.38 39.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.688 0.756 . . . . 64.31 110.852 -179.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.72 -52.98 0.3 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.699 2.266 . . . . 73.4 112.308 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -158.31 53.61 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 62.51 110.856 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -155.12 140.95 11.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 74.42 111.121 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.5 mm -85.83 151.23 3.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 75.33 111.132 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 78.2 t60 -125.47 -83.93 0.63 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.17 -0.468 . . . . 73.52 110.872 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 61.13 158.57 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.724 -0.751 . . . . 71.34 112.504 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -145.76 141.9 28.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.928 0.394 . . . . 75.33 110.859 -179.864 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 31.0 t-80 -104.35 140.29 38.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 70.51 110.844 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 94.1 t -126.31 134.66 65.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 73.11 111.154 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -75.14 169.69 17.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 75.42 110.887 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.33 -51.28 4.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 51.33 112.504 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.3 m -116.29 151.47 35.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 74.3 111.109 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -86.04 58.79 5.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.909 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 7.7 tt -62.87 126.11 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 71.02 111.121 179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -116.53 90.9 3.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 74.44 110.896 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.6 m -115.74 120.06 63.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 74.3 111.1 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -155.71 114.66 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 74.14 110.834 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 94.3 t -140.2 145.04 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 73.23 111.104 179.958 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.1 mp -79.79 159.91 70.35 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.644 0.735 . . . . 75.54 110.904 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 159.7 52.43 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.687 2.258 . . . . 73.4 112.354 179.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.58 10.02 48.49 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.75 -0.738 . . . . 74.51 112.519 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -169.36 126.24 0.91 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.891 0.376 . . . . 71.24 110.888 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 2.4 p -65.17 118.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 70.33 111.158 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -81.57 166.7 20.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 64.23 110.894 -179.852 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 97.8 m -136.27 134.86 38.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.43 111.174 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 16.2 t -144.48 131.5 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 72.33 111.116 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -109.58 95.1 5.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 75.02 110.904 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 41.5 t80 -136.13 127.25 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.196 -0.456 . . . . 71.23 110.874 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.8 t -128.2 143.27 51.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 74.25 111.145 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -100.75 -173.26 2.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 72.02 110.907 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.03 -24.43 4.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.141 -0.482 . . . . 73.42 110.855 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -132.39 162.16 58.72 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.613 0.72 . . . . 74.43 110.895 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 155.45 65.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.711 2.274 . . . . 74.01 112.358 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.46 133.15 2.34 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.74 -0.743 . . . . 74.43 112.433 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -97.24 144.09 27.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.863 0.363 . . . . 75.35 110.866 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -137.74 132.63 33.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 74.14 110.949 -179.885 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.82 120.98 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 74.44 110.853 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 5.6 tt -178.22 137.32 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 75.25 111.136 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.08 142.93 28.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 74.13 111.106 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 6.3 p -179.96 -42.32 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.456 . . . . 64.54 110.848 179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -153.7 127.52 8.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.446 . . . . 73.55 110.853 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -131.39 -40.14 1.13 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 64.42 110.912 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -175.48 -40.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.144 -0.48 . . . . 75.11 110.874 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.8 t -94.46 -39.86 10.2 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.143 -0.48 . . . . 75.42 110.896 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 139.49 -129.42 4.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.712 -0.756 . . . . 52.44 112.482 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -173.12 -169.88 0.59 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.861 0.362 . . . . 75.31 110.886 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 162.76 -171.22 38.52 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.761 -0.733 . . . . 62.23 112.464 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 40.6 p-80 -57.16 -24.25 53.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.773 0.32 . . . . 75.31 110.867 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 21.7 mt-30 -103.69 70.1 1.0 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.44 . . . . 74.45 110.892 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -155.67 100.96 2.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 72.55 110.922 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -71.57 173.88 7.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 72.41 110.873 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -92.17 120.1 32.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 65.02 110.888 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -81.87 92.26 1.53 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.742 -0.742 . . . . 72.23 112.485 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 13.4 t -86.48 154.14 21.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.794 0.331 . . . . 74.1 111.107 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 5.9 mm -141.52 148.24 21.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.51 111.121 179.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 71.3 t -135.07 115.46 18.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.143 -0.481 . . . . 74.3 111.146 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . 0.422 ' HA ' HG22 ' A' ' 55' ' ' VAL . 95.9 t -102.25 121.69 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 74.42 111.112 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.1 mmmt -106.22 138.73 41.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 73.05 110.878 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.222 -0.445 . . . . 73.22 110.868 179.996 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 ptt? . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.797 0.332 . . . . 70.34 110.819 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.0 t -79.33 78.29 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 72.34 111.14 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.9 pt -145.23 78.58 12.2 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 72.44 111.144 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -177.59 1.93 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.726 2.284 . . . . 70.4 112.356 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -170.49 -37.72 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.218 -0.446 . . . . 74.32 111.148 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -52.53 -50.96 46.14 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 71.33 112.464 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 41.5 tptt -171.13 154.23 3.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.792 0.33 . . . . 75.22 110.901 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.81 163.29 0.08 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.441 . . . . 75.43 110.939 179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 15.8 mp0 -119.41 136.54 54.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.474 . . . . 74.24 110.921 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.71 149.46 23.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 75.32 110.866 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.8 m -147.39 -178.29 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 70.44 111.125 179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -144.3 162.31 40.47 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.618 0.723 . . . . 73.31 110.858 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -4.59 14.34 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.633 2.222 . . . . 74.13 112.317 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.6 m -48.83 -67.14 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.431 . . . . 75.54 111.105 -179.96 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 3.1 p -155.46 38.27 0.38 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 73.33 111.179 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.8 p -76.22 -31.97 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 75.44 111.139 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.4 ptt-85 -97.25 -11.61 23.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 74.41 110.894 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.6 mm-40 -95.53 -37.32 10.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.893 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -132.65 134.17 44.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 75.2 110.869 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.57 -158.95 18.23 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.764 -0.731 . . . . 74.33 112.506 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -26.86 26.93 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.623 2.215 . . . . 75.04 112.373 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 13.3 m-90 -87.39 -13.34 43.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 71.11 110.91 179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.18 -59.67 2.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.267 -0.424 . . . . 73.33 111.054 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.18 144.07 29.34 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.623 0.725 . . . . 75.52 110.833 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -28.97 24.7 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.62 2.213 . . . . 73.54 112.369 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.4 -16.98 60.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 72.41 111.089 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.2 mm-40 -88.36 8.3 28.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 75.21 110.947 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.39 -78.4 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 74.0 111.08 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.1 p -103.02 126.51 57.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 64.43 111.114 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -134.97 150.13 29.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 65.01 111.083 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -71.02 121.03 17.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 71.13 110.892 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.7 t -120.13 -33.05 4.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 75.34 111.153 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.79 178.49 16.49 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.706 -0.759 . . . . 74.22 112.476 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -18.14 37.33 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.727 2.284 . . . . 74.42 112.368 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 -153.3 30.08 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.196 -0.456 . . . . 75.42 110.872 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -140.96 157.46 45.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 72.24 110.919 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -140.56 138.39 34.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 75.34 110.95 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.501 ' HA ' HG21 ' A' ' 62' ' ' VAL . 75.4 m -92.98 103.86 16.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 75.51 111.143 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 t -90.25 140.39 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 74.51 111.158 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -124.14 120.44 32.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.12 110.893 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 4.5 m -121.61 146.52 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 74.43 111.129 179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -139.1 143.94 38.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.166 -0.47 . . . . 72.41 110.935 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.84 106.2 3.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.441 . . . . 72.23 111.102 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.6 p90 -129.07 144.99 51.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 72.42 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.62 0.36 52.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 65.11 111.132 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.55 33.97 1.37 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 74.53 110.848 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.75 -141.73 8.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.743 -0.741 . . . . 75.13 112.494 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -155.48 155.17 33.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 73.32 110.899 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.406 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -156.66 156.2 29.62 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.607 0.718 . . . . 75.3 110.883 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.406 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.4 Cg_endo -69.82 -179.78 3.18 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 73.4 112.334 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.414 ' HB3' ' HB ' ' A' ' 121' ' ' THR . 0.4 OUTLIER -131.94 61.36 57.59 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.609 0.719 . . . . 73.44 110.881 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 7.16 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.659 2.24 . . . . 75.32 112.359 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.407 ' H ' ' C ' ' A' ' 51' ' ' ASN . 3.7 mp -46.86 143.34 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 72.43 111.121 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -144.18 164.69 29.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 64.53 110.891 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.412 HG23 HG13 ' A' ' 61' ' ' ILE . 2.4 p -165.4 82.87 1.11 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 72.22 111.15 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.72 122.49 9.18 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 75.13 112.354 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.25 154.9 40.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 73.24 110.89 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.59 -7.87 77.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.771 -0.728 . . . . 62.21 112.451 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.03 159.03 41.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.768 0.318 . . . . 65.12 111.064 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -71.76 140.71 49.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 73.31 110.917 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.412 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -129.56 115.48 34.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 73.22 111.169 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.501 HG21 ' HA ' ' A' ' 38' ' ' THR . 1.1 m -103.76 90.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 73.12 111.107 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -66.45 140.87 58.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.913 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -132.42 98.61 4.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 71.13 110.931 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.4 mp -97.72 158.41 3.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 74.31 111.157 179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.2 t -168.73 135.59 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 74.34 111.144 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.417 ' CB ' HG22 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -139.72 159.93 63.11 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.669 0.747 . . . . 75.43 110.858 -179.847 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -52.77 0.31 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.697 2.265 . . . . 70.11 112.398 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -153.02 41.11 0.56 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 61.5 110.847 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.417 HG22 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -142.3 135.07 27.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.229 -0.441 . . . . 73.15 111.125 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.9 mt -72.95 146.39 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 74.23 111.134 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 30.6 p80 -113.65 -168.16 1.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 71.32 110.848 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.87 118.16 2.06 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.743 -0.742 . . . . 44.44 112.51 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -117.63 144.38 45.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 72.24 110.842 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 32.9 t-80 -106.03 130.19 53.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 75.21 110.839 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 2.4 p -131.71 128.82 60.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.472 . . . . 73.34 111.089 -179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -58.08 -177.53 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 63.21 110.874 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.3 -47.6 1.95 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.738 -0.744 . . . . 74.11 112.444 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -147.28 179.49 7.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.857 0.36 . . . . 73.12 111.086 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -92.31 78.88 5.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 74.13 110.896 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 6.8 tt -88.56 123.43 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 72.22 111.102 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -122.67 92.56 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 74.05 110.919 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.6 m -116.48 119.92 63.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 71.23 111.174 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -165.44 111.15 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 73.11 110.906 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 86.2 t -140.63 140.81 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 71.14 111.133 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.0 mp -56.88 160.77 5.46 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.567 0.699 . . . . 72.34 110.928 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 160.68 48.83 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.672 2.248 . . . . 70.31 112.375 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.2 17.24 56.14 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.742 -0.742 . . . . 72.23 112.504 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -159.79 157.47 29.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.881 0.372 . . . . 74.31 110.886 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 86.1 t -102.92 133.5 46.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 72.14 111.107 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -109.53 115.29 29.64 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.845 -179.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.5 m -94.46 124.43 38.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.062 -0.517 . . . . 74.21 111.158 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 10.7 p -134.67 137.66 50.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 75.43 111.197 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -103.24 108.56 19.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.154 -0.476 . . . . 73.45 110.902 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -141.35 112.26 7.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 74.11 110.909 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -112.86 137.31 51.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.47 . . . . 71.11 111.109 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.32 -175.28 3.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 73.14 110.919 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.5 mtmm -123.63 -12.78 7.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.871 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.6 mpp_? -150.87 161.79 28.94 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.603 0.716 . . . . 75.32 110.904 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.83 64.95 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.763 2.309 . . . . 71.44 112.331 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.92 141.58 3.18 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.733 -0.746 . . . . 62.53 112.493 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -106.18 128.84 54.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 72.22 110.898 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 5.9 p90 -143.98 146.19 32.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.155 -0.475 . . . . 75.14 110.947 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.92 -176.52 5.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 73.11 110.846 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 18.9 mm 66.37 155.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 73.41 111.103 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -110.81 145.73 16.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 74.43 111.096 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 1.8 t -170.95 137.31 1.19 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.169 -0.469 . . . . 74.13 110.861 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 69.53 -75.27 0.07 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 63.35 110.921 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 59.22 172.03 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 71.42 110.922 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 8.1 t80 -77.06 64.31 2.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.237 -0.438 . . . . 75.22 110.91 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 75.38 46.28 0.12 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 62.14 110.852 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -132.09 -133.16 3.41 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.774 -0.727 . . . . 63.35 112.484 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 52.2 tp 61.99 -85.31 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.899 0.38 . . . . 71.31 110.887 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 47.48 53.19 12.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 61.21 112.458 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 20.0 m170 50.92 32.67 7.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.786 0.327 . . . . 73.22 110.889 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -154.02 -165.02 2.0 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.201 -0.454 . . . . 72.21 110.912 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.6 t30 67.45 120.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 73.52 110.91 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 5.8 mmm -71.52 174.55 6.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 71.21 110.817 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -130.64 167.7 18.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 75.45 110.885 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -150.14 156.07 26.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 63.42 112.5 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' THR . . . . . 0.414 ' HB ' ' HB3' ' A' ' 51' ' ' ASN . 4.2 m -85.16 145.23 27.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.777 0.322 . . . . 75.03 111.152 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.6 mp -146.77 120.4 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 75.25 111.174 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 2.6 p -116.41 142.2 31.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 73.32 111.103 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 60.5 t -106.05 122.17 59.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.162 -0.472 . . . . 74.2 111.161 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -90.39 134.94 34.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 75.44 110.936 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 71.53 110.897 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.817 0.342 . . . . 75.24 110.849 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 2.5 p -162.2 95.05 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.266 -0.425 . . . . 75.35 111.134 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -153.15 78.08 5.97 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.551 0.691 . . . . 74.01 111.121 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 -177.4 1.84 Allowed 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.721 2.28 . . . . 75.41 112.319 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -168.21 126.48 1.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 62.34 111.101 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 132.81 -57.47 0.71 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.772 -0.728 . . . . 72.13 112.507 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -152.53 133.03 13.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.82 0.343 . . . . 72.44 110.898 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.23 164.37 0.08 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 73.34 110.913 179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 25.2 mp0 -129.64 135.99 49.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 74.55 110.888 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -92.59 137.71 32.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 74.12 110.863 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 12.5 m -136.32 -177.94 2.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 73.43 111.127 179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -143.93 162.52 40.47 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.589 0.709 . . . . 70.14 110.897 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -4.12 13.38 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.697 2.265 . . . . 73.45 112.355 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 23.3 m -47.64 -70.04 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 70.43 111.126 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 3.7 p -155.96 38.74 0.36 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 73.42 111.147 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.4 p -75.52 -42.25 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.253 -0.431 . . . . 73.5 111.13 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -108.97 11.25 26.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 74.32 110.868 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 16.7 mm-40 -105.55 -33.26 8.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 71.34 110.879 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.47 ' O ' ' CG ' ' A' ' 19' ' ' GLU . 28.5 tt0 -142.55 13.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 74.31 110.859 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -103.35 -154.85 24.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.741 -0.742 . . . . 75.23 112.487 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.449 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.2 Cg_endo -69.75 -23.06 31.26 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.684 2.256 . . . . 64.43 112.351 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.449 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 18.2 m-90 -91.03 -7.27 52.35 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 73.44 110.939 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.18 -44.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 75.54 111.132 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.43 137.71 20.74 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.61 0.719 . . . . 73.4 110.892 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -17.83 37.14 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.692 2.261 . . . . 61.23 112.314 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.19 -37.8 69.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 55.15 111.134 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 57.3 mm-40 -84.79 4.9 30.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 72.32 110.911 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.65 -73.29 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 64.41 111.107 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.42 ' HA ' ' O ' ' A' ' 38' ' ' THR . 2.0 p -105.93 123.01 60.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.235 -0.439 . . . . 60.35 111.105 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.6 t -137.76 150.35 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.457 . . . . 73.32 111.126 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -75.67 121.29 22.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 72.14 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.4 p -121.31 -41.6 2.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.433 . . . . 75.53 111.163 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.73 -166.74 34.8 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.734 -0.746 . . . . 61.24 112.515 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -36.76 10.21 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.673 2.248 . . . . 72.12 112.378 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -152.7 28.95 0.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.249 -0.432 . . . . 73.2 110.861 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 127.53 44.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 74.23 110.893 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 18.0 m-85 -96.66 135.62 38.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 75.31 110.899 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.481 ' HA ' HG22 ' A' ' 62' ' ' VAL . 51.7 m -92.01 102.36 14.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.114 -0.493 . . . . 52.01 111.162 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.5 t -85.75 139.01 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 74.11 111.099 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -120.2 100.61 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 75.03 110.927 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.4 m -96.33 142.43 13.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.104 -0.498 . . . . 73.21 111.108 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.1 tp -130.31 144.21 51.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.925 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -154.52 98.57 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 75.13 111.132 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 3.1 p90 -113.88 155.96 24.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 75.32 110.854 -179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.76 31.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 72.12 111.103 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -105.73 75.36 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 75.41 110.866 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.43 -162.37 17.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.713 -0.756 . . . . 53.11 112.491 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 34.1 p90 -126.67 151.88 47.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.834 0.349 . . . . 73.21 110.926 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.08 159.97 68.95 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.64 0.733 . . . . 73.05 110.889 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -176.38 1.48 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.701 2.267 . . . . 75.32 112.316 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -138.11 62.16 30.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.615 0.721 . . . . 72.44 110.856 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 6.27 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.719 2.28 . . . . 65.12 112.334 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 3.6 mp -48.4 107.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 74.23 111.094 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 39.7 tt0 -110.75 140.19 45.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.14 110.9 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.0 m -140.59 86.36 12.32 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.655 0.74 . . . . 73.52 111.152 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 121.92 8.61 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.686 2.258 . . . . 75.52 112.374 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.95 153.33 42.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 74.2 110.906 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.8 -9.59 75.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 73.41 112.52 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.58 154.72 50.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.741 0.305 . . . . 74.03 111.12 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -67.09 144.4 56.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 70.03 110.899 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 6.7 mm -129.12 101.03 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 64.4 111.142 179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.481 HG22 ' HA ' ' A' ' 38' ' ' THR . 0.4 OUTLIER -89.19 100.1 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 72.44 111.104 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.0 m-85 -72.89 141.6 47.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 70.13 110.911 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -132.62 99.21 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 75.03 110.901 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.4 mp -98.37 153.92 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 74.34 111.081 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -169.18 136.62 1.83 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 75.3 111.127 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.403 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -148.22 159.44 39.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.67 0.748 . . . . 72.13 110.857 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -55.14 0.19 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.659 2.239 . . . . 74.22 112.352 179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -156.3 62.89 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 74.21 110.866 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.403 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.28 136.15 4.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 63.21 111.162 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.2 mm -71.12 143.7 14.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 73.3 111.124 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 9.5 p-80 -125.55 -168.89 1.91 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 74.24 110.852 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.18 132.89 3.49 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 65.2 112.439 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -126.35 142.04 51.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 74.44 110.903 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -103.93 89.28 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 75.35 110.902 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 15.6 t -74.63 131.81 34.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 72.41 111.138 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -68.14 178.36 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 75.24 110.908 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.96 -51.05 1.71 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.729 -0.748 . . . . 71.45 112.495 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -140.0 179.51 6.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.822 0.344 . . . . 70.45 111.142 -179.831 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 22.5 m120 -87.94 67.42 9.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 70.11 110.871 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 13.2 tt -76.86 119.71 25.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 75.41 111.134 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -116.35 103.32 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 74.31 110.933 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.8 m -125.59 120.52 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.44 111.195 179.895 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -155.33 113.45 3.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 73.32 110.878 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 60.9 t -140.85 147.31 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 72.11 111.099 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.468 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -73.48 158.68 86.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.632 0.73 . . . . 73.21 110.954 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.468 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.6 Cg_endo -69.82 159.79 52.05 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.686 2.258 . . . . 63.34 112.333 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.41 17.35 50.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.767 -0.73 . . . . 63.21 112.479 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -165.24 138.48 4.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.947 0.403 . . . . 72.24 110.858 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.38 137.69 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.137 -0.483 . . . . 75.55 111.081 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.5 t -119.98 131.7 55.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.113 -0.494 . . . . 62.43 110.847 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.4 t -96.92 145.76 25.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 72.04 111.119 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 40.1 t -145.99 125.6 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 73.23 111.139 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -102.99 115.43 30.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 75.42 110.89 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -162.27 109.62 1.33 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 63.31 110.908 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -107.72 143.04 36.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.487 . . . . 74.43 111.115 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.41 174.91 6.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 64.34 110.858 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -119.72 -20.36 7.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.489 . . . . 73.31 110.858 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -139.35 158.48 68.79 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.653 0.74 . . . . 75.51 110.814 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 158.07 58.22 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.656 2.237 . . . . 74.35 112.355 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 156.27 136.53 2.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 70.45 112.497 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -101.67 134.75 44.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 74.51 110.892 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER -143.9 127.24 16.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 75.42 110.951 -179.82 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.8 105.96 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 75.13 110.901 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 6.3 tt 179.8 142.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 74.43 111.103 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -122.84 141.51 42.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 72.44 111.125 179.839 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 5.4 p 179.4 -42.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 71.55 110.848 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -89.57 62.37 5.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 74.0 110.881 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -178.69 136.82 0.15 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 73.14 110.909 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -72.06 121.1 18.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 74.42 110.91 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 6.3 p -179.85 34.47 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.122 -0.49 . . . . 75.02 110.906 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 53.98 66.12 2.99 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.733 -0.746 . . . . 71.11 112.471 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 1.2 tt -51.8 108.97 0.31 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.839 0.352 . . . . 63.43 110.897 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 149.99 -89.73 0.14 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.794 -0.717 . . . . 74.53 112.5 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -113.58 -28.6 7.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.719 0.295 . . . . 74.52 110.859 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -54.5 -27.02 35.07 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 63.32 110.925 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -144.75 -169.41 3.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 73.52 110.856 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -134.99 177.99 7.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 64.14 110.907 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 -88.07 119.3 28.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.228 -0.442 . . . . 75.2 110.928 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.9 173.15 23.36 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.728 -0.749 . . . . 51.11 112.53 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 46.3 m -154.41 119.98 5.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.779 0.323 . . . . 63.24 111.201 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.6 mp -141.73 119.46 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 73.03 111.158 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.0 p -116.44 136.88 52.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 71.11 111.125 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 35.5 t -100.67 128.1 53.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 61.13 111.169 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.6 mmtt -111.99 132.55 54.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 71.23 110.896 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.207 -0.451 . . . . 71.44 110.926 179.961 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.839 0.352 . . . . 71.42 110.88 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 20.6 t -127.31 66.41 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 75.31 111.106 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.6 pt -112.18 78.38 2.43 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.603 0.715 . . . . 75.54 111.109 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -176.47 1.5 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.695 2.263 . . . . 75.33 112.31 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -86.72 -169.46 2.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.229 -0.441 . . . . 62.21 111.068 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.61 26.8 74.09 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 72.55 112.471 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.43 170.04 0.15 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.851 0.358 . . . . 73.34 110.877 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.56 163.79 0.08 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 74.14 110.922 179.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -120.28 138.17 53.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 72.31 110.908 179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -93.77 127.91 39.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 75.01 110.892 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 7.1 m -110.8 -178.79 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 75.4 111.153 -179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -144.41 162.17 40.81 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.593 0.711 . . . . 74.04 110.909 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -3.32 11.81 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.705 2.27 . . . . 74.2 112.306 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 26.9 m -44.92 -70.14 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 74.11 111.09 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 27.6 p -149.62 22.97 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 74.42 111.148 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.6 p -61.42 -23.75 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 74.35 111.106 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -105.91 -19.88 13.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 72.53 110.844 -179.939 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -85.29 -28.29 25.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 72.35 110.912 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 4.9 pt-20 -145.06 146.66 31.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.467 . . . . 74.11 110.864 -179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.64 -158.91 14.02 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.794 -0.717 . . . . 72.13 112.453 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.447 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.0 Cg_endo -69.73 -30.26 22.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.665 2.243 . . . . 73.4 112.373 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.447 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 17.2 m-90 -85.86 -8.36 58.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.196 -0.457 . . . . 75.0 110.887 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -72.63 -59.63 2.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 75.11 111.103 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.54 145.8 34.09 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.588 0.709 . . . . 74.44 110.891 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.644 2.229 . . . . 64.33 112.36 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.0 -22.62 60.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 74.12 111.089 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -116.42 30.86 7.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 74.3 110.916 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.35 -57.01 3.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 74.43 111.097 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.9 t -113.18 101.89 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 74.02 111.124 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.9 t -117.14 148.87 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 75.32 111.119 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.435 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -80.39 117.4 21.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 74.3 110.915 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 15.9 p -105.79 -43.6 4.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 65.03 111.131 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.13 -173.24 22.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.79 -0.719 . . . . 73.31 112.501 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -5.61 16.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.7 2.267 . . . . 74.23 112.307 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -175.41 30.15 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 74.31 110.845 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.6 mp0 -126.62 118.42 24.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 74.33 110.91 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.435 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 54.2 m-85 -98.93 130.4 45.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 74.31 110.94 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 24.7 m -95.62 105.65 17.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.11 -0.496 . . . . 71.01 111.157 -179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 18.3 t -88.02 146.3 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 75.04 111.128 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -127.27 106.65 9.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 74.54 110.947 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.2 m -107.08 142.76 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 62.22 111.096 179.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -139.41 143.27 37.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 74.45 110.858 179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.35 114.76 3.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 71.3 111.083 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 4.1 p90 -127.67 155.06 44.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 75.42 110.905 -179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.9 4.21 38.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.465 . . . . 53.14 111.103 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -104.25 74.76 1.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 72.41 110.861 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 109.37 -160.11 13.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.726 -0.749 . . . . 75.55 112.544 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 11.4 p90 -135.25 144.94 47.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.793 0.33 . . . . 73.14 110.948 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -143.69 162.3 42.21 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.609 0.718 . . . . 75.52 110.883 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -176.09 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.63 2.22 . . . . 72.12 112.338 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 62.9 m-20 -130.79 59.93 49.46 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.622 0.725 . . . . 73.13 110.884 -179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 73.84 1.31 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.7 2.267 . . . . 64.11 112.353 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.1 mp -117.14 122.71 70.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 75.15 111.086 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 10.5 tt0 -125.75 129.3 49.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.879 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.404 HG21 HG13 ' A' ' 61' ' ' ILE . 2.6 p -136.51 80.47 38.69 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.635 0.731 . . . . 74.45 111.098 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 122.92 9.59 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.701 2.268 . . . . 75.35 112.321 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.49 154.71 40.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.237 -0.438 . . . . 74.23 110.932 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.33 -10.34 71.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 54.51 112.49 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.28 143.11 48.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 73.04 111.087 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -61.15 135.19 57.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 71.21 110.867 -179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.404 HG13 HG21 ' A' ' 55' ' ' VAL . 12.4 mm -122.62 123.5 68.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.118 -0.492 . . . . 73.43 111.135 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 41.9 t -101.9 92.23 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.42 111.134 179.841 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.79 138.33 54.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 73.43 110.873 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -131.15 102.01 5.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 74.55 110.91 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.6 mp -102.92 139.84 22.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 75.34 111.146 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 10.1 t -158.62 137.74 11.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 65.03 111.163 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.425 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -141.59 160.93 54.78 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.674 0.75 . . . . 71.42 110.865 -179.875 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.425 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.86 -54.39 0.22 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.655 2.237 . . . . 52.14 112.349 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -157.32 59.03 0.51 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 72.4 110.882 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -155.93 135.97 4.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 75.41 111.17 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 mm -67.4 144.97 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 73.21 111.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 9.1 p80 -132.96 -176.58 4.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 73.01 110.848 179.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.62 132.66 3.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.741 -0.742 . . . . 60.2 112.455 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -121.03 144.3 48.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.845 0.355 . . . . 71.14 110.891 -179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.42 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 9.7 p80 -103.82 88.17 2.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 72.45 110.881 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.9 t -74.94 115.67 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 65.12 111.125 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.89 177.45 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 74.11 110.91 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.41 -49.07 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.788 -0.72 . . . . 75.52 112.489 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -134.46 179.38 6.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.751 0.31 . . . . 73.42 111.163 -179.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 24.4 m120 -88.35 50.36 1.96 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 70.41 110.882 179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 6.2 tp -60.94 116.04 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 75.05 111.1 179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -116.9 100.82 8.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.876 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.4 m -121.86 124.13 70.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 73.04 111.13 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -164.61 108.62 0.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 71.03 110.856 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 45.1 t -140.4 146.49 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 74.34 111.189 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.74 161.23 62.68 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.58 0.705 . . . . 74.12 110.948 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.94 51.54 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.73 2.287 . . . . 71.43 112.305 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.37 5.48 75.67 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.75 -0.738 . . . . 62.31 112.515 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -147.9 117.95 7.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.899 0.38 . . . . 73.24 110.872 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 3.8 p -77.94 118.98 25.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 70.42 111.104 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -94.85 134.05 37.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.11 -0.495 . . . . 74.14 110.835 -179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 74.2 m -98.84 109.39 22.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 70.42 111.15 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 39.7 t -106.86 148.33 11.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 72.32 111.138 179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -121.05 107.52 12.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.476 . . . . 74.54 110.831 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -153.18 130.39 11.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 74.11 110.949 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 29.7 m -139.95 141.57 36.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 75.34 111.143 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -96.57 -176.42 3.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 74.2 110.907 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -123.15 -12.55 7.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 75.35 110.905 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.95 162.85 51.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.647 0.737 . . . . 74.35 110.863 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 149.54 66.92 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.686 2.257 . . . . 64.34 112.328 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.4 136.92 2.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 61.52 112.459 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -109.41 132.82 53.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.847 0.356 . . . . 73.44 110.875 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -143.27 137.17 28.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.181 -0.463 . . . . 74.2 110.895 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.551 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.17 -164.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 73.23 110.877 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.551 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 7.7 tt 57.55 158.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 75.43 111.097 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -119.91 145.32 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 74.35 111.118 179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -179.29 35.19 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.172 -0.467 . . . . 73.12 110.923 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -159.95 80.75 0.71 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 73.21 110.858 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 4.1 mp0 -160.37 -44.05 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 73.42 110.901 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER 63.35 94.38 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 75.32 110.932 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -179.58 34.53 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.087 -0.506 . . . . 74.55 110.894 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 103.02 26.06 7.22 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.746 -0.74 . . . . 70.33 112.495 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.9 pp -60.71 -170.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.878 0.37 . . . . 71.01 110.861 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 80.52 -85.64 1.34 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.752 -0.737 . . . . 62.1 112.475 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -75.14 -25.02 58.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.776 0.322 . . . . 74.13 110.851 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -117.32 -169.68 1.71 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 74.2 110.975 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 5.6 t-20 63.61 106.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.448 . . . . 74.12 110.899 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 1.1 ptp -71.49 173.12 8.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.158 -0.474 . . . . 72.42 110.913 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -92.16 125.9 37.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 70.53 110.886 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -81.8 179.5 53.33 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.727 -0.749 . . . . 74.43 112.437 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 55.1 m -155.24 117.24 4.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.775 0.321 . . . . 73.43 111.169 -179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 5.1 mp -146.48 129.66 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 71.35 111.115 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 9.9 p -132.27 137.06 55.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 75.2 111.119 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 15.7 t -99.73 125.18 53.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 75.13 111.115 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.6 mmmt -99.26 130.68 45.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 73.23 110.879 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 74.53 110.863 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.087 0 CA-C-O 120.833 0.349 . . . . 73.04 110.912 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.3 t 60.89 84.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 75.41 111.148 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.8 pt -120.32 153.47 55.9 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.619 0.723 . . . . 72.31 111.12 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 -176.73 1.56 Allowed 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.664 2.243 . . . . 54.32 112.374 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.1 -62.97 1.22 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 74.4 111.107 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -154.44 19.32 0.61 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.752 -0.737 . . . . 61.0 112.512 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.16 146.04 2.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.786 0.327 . . . . 74.14 110.932 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.16 164.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.247 -0.433 . . . . 64.45 110.925 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -120.45 143.56 48.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 75.41 110.919 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.12 136.74 38.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 73.41 110.85 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.2 m -128.46 -178.66 2.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 74.24 111.103 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 161.94 41.54 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.647 0.737 . . . . 64.14 110.854 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -4.71 14.58 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.735 2.29 . . . . 62.51 112.359 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 4.2 m -48.44 -66.92 0.32 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.185 -0.461 . . . . 74.35 111.138 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 2.8 p -155.62 37.59 0.37 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.446 . . . . 73.21 111.163 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 14.7 p -74.29 -34.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 75.11 111.119 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 11.5 ptt85 -95.17 -10.73 29.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 75.44 110.865 -179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 -97.69 -35.08 10.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 75.45 110.892 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -131.86 136.95 47.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 74.35 110.906 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 118.21 -159.5 14.25 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 62.42 112.495 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -26.89 26.94 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.63 2.22 . . . . 71.21 112.325 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 15.7 m-90 -86.37 -10.94 53.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.235 -0.439 . . . . 72.33 110.929 179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.9 -59.0 3.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 71.05 111.079 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.85 144.61 29.7 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.573 0.702 . . . . 73.31 110.898 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -15.32 37.02 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.686 2.257 . . . . 74.43 112.349 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.29 -6.46 48.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 34.31 111.117 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.8 mm-40 -106.39 6.49 30.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 72.54 110.883 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -51.95 -76.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 70.54 111.07 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 14.2 t -83.13 130.75 35.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 74.34 111.131 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 32.3 t -144.67 114.35 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 73.43 111.109 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -60.03 116.51 4.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 74.34 110.904 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.4 t -119.9 -38.74 2.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 73.0 111.136 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.91 173.61 18.82 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.732 . . . . 75.32 112.539 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.04 3.57 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.726 2.284 . . . . 75.1 112.339 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 53.2 t30 67.78 34.96 4.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 74.5 110.898 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -145.48 156.96 44.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 72.31 110.901 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 43.1 m-85 -143.16 141.27 31.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 75.32 110.955 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 54.4 m -94.86 104.87 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.117 -0.492 . . . . 74.21 111.152 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 15.7 t -87.35 152.62 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 74.43 111.097 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -127.2 140.25 52.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 73.02 110.913 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 60.0 t -139.1 137.98 41.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 63.54 111.106 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -138.42 141.49 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 73.3 110.873 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.58 101.18 2.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 73.1 111.104 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -116.57 147.35 41.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 74.44 110.857 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.23 0.26 52.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 75.11 111.115 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -94.19 39.28 1.08 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 75.44 110.908 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.63 -137.93 8.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 64.51 112.526 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 31.1 t80 -155.24 160.6 40.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.802 0.334 . . . . 74.23 110.959 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -165.23 162.18 14.07 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.581 0.705 . . . . 75.25 110.912 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 176.74 6.37 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.703 2.269 . . . . 73.2 112.348 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 6.6 m120 -133.89 63.25 62.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.616 0.722 . . . . 64.01 110.85 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 72.1 1.48 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.268 . . . . 74.4 112.372 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.9 mp -106.41 121.55 59.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 74.31 111.152 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -120.0 115.4 23.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 75.31 110.893 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.6 p -123.35 78.47 53.56 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.621 0.724 . . . . 72.45 111.15 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 123.02 9.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.704 2.27 . . . . 72.42 112.342 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -68.61 154.72 41.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.267 -0.424 . . . . 75.31 110.875 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.1 -6.28 76.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 73.41 112.517 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.31 156.44 47.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.76 0.314 . . . . 75.35 111.072 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -67.42 138.53 56.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.915 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 4.4 mm -130.87 114.8 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 64.43 111.118 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 39.5 t -101.23 94.29 3.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 75.35 111.123 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -70.47 132.61 45.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 74.44 110.884 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 36.2 mttt -128.74 99.74 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 75.23 110.914 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -104.22 158.63 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 75.52 111.159 179.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 7.9 t -167.01 141.91 4.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 63.2 111.144 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.425 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -148.48 158.46 40.5 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.686 0.755 . . . . 75.42 110.852 -179.88 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.425 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.6 Cg_endo -69.8 -55.48 0.17 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.725 2.283 . . . . 75.53 112.31 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -154.91 68.39 0.7 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.852 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.417 HG21 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.2 -171.15 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.215 -0.448 . . . . 74.22 111.143 -179.992 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.9 mm -138.11 140.49 40.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 75.22 111.126 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -115.23 -85.46 0.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 73.3 110.848 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 53.85 94.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.71 -0.757 . . . . 34.11 112.48 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -100.14 143.09 30.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 70.13 110.868 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -120.22 142.84 48.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 73.04 110.846 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.9 p -127.78 122.83 59.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 71.34 111.112 179.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -52.16 160.85 0.7 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 74.04 110.897 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.15 -51.93 4.55 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.786 -0.721 . . . . 44.52 112.467 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.85 160.91 14.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.827 0.346 . . . . 73.24 111.132 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -101.03 35.49 2.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.466 . . . . 74.43 110.924 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 20.0 tt -54.73 124.91 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 75.31 111.117 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -123.76 82.75 2.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 74.24 110.897 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 5.1 m -110.33 119.33 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 62.51 111.106 179.945 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -165.39 103.32 0.73 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 64.13 110.896 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 18.1 m -140.36 139.37 35.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.148 -0.478 . . . . 75.1 111.13 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.7 mp -59.88 163.39 7.63 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.583 0.706 . . . . 72.45 110.936 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 70' ' ' VAL . 54.3 Cg_endo -69.74 159.93 51.6 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.669 2.246 . . . . 65.41 112.343 179.829 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.5 17.38 57.1 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 72.41 112.469 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -158.42 143.45 16.35 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 74.34 110.881 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 52.3 t -81.42 146.12 7.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.136 -0.484 . . . . 74.13 111.115 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -103.82 158.08 16.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.44 110.891 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 26.6 m -147.28 123.23 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 75.33 111.164 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.4 p -153.15 136.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 74.12 111.126 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.0 mtm180 -96.33 81.46 3.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 75.43 110.84 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 2.9 t80 -106.11 121.89 45.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.209 -0.451 . . . . 72.5 110.935 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 t -133.74 138.46 45.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 72.31 111.135 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.43 -168.9 1.68 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.899 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.5 mtpt -123.12 -27.12 4.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 74.02 110.917 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . 0.43 ' HB3' ' HD2' ' A' ' 100' ' ' PRO . 13.3 mmt180 -129.18 156.07 78.87 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 73.43 110.916 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . 0.43 ' HD2' ' HB3' ' A' ' 99' ' ' ARG . 54.0 Cg_endo -69.72 152.08 69.43 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.672 2.248 . . . . 75.04 112.329 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.7 150.49 6.84 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.758 -0.734 . . . . 70.34 112.485 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -112.63 127.74 56.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.885 0.374 . . . . 63.31 110.867 -179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -143.93 136.46 26.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 72.51 110.911 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.538 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 0.1 OUTLIER -144.38 -167.29 2.59 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.119 -0.492 . . . . 74.43 110.885 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.538 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 0.6 OUTLIER 56.93 159.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 70.42 111.074 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 7.0 tt -104.66 134.81 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 75.22 111.121 179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 26.4 m -141.45 -42.3 0.37 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 64.34 110.858 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -106.64 126.03 51.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 63.14 110.914 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -175.46 -51.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 73.52 110.916 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 2.4 t80 63.33 83.83 0.16 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 75.14 110.93 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -179.49 -34.97 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 71.51 110.869 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 178.2 33.01 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.728 -0.748 . . . . 55.02 112.49 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -70.27 -179.5 2.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.849 0.357 . . . . 73.43 110.935 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.7 -114.85 4.62 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.748 -0.739 . . . . 71.11 112.481 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 59.1 t-80 -68.11 -29.3 68.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.767 0.317 . . . . 73.33 110.881 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -106.7 -175.62 2.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 75.33 110.877 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 63.88 104.63 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.167 -0.469 . . . . 71.53 110.883 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -70.96 174.59 5.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 74.44 110.865 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 1.2 p90 -141.63 167.66 21.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 73.53 110.907 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -143.6 162.21 27.69 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 74.23 112.513 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 28.6 m -85.81 141.19 29.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.775 0.321 . . . . 73.34 111.161 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.8 mp -147.88 109.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 73.44 111.112 179.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 8.6 p -114.97 140.65 35.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 75.24 111.091 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 68.9 t -104.16 118.49 51.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 75.42 111.125 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 5.1 mmmt -89.98 131.21 35.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 70.54 110.912 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 75.43 110.906 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.2 mtt . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.848 0.356 . . . . 75.52 110.91 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 40.0 t -85.85 73.16 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 75.1 111.119 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.3 pt -140.62 78.0 21.9 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.588 0.708 . . . . 72.43 111.082 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.76 -178.14 2.21 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.679 2.253 . . . . 71.55 112.357 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.99 175.06 10.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 65.01 111.137 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.13 -61.18 2.23 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.757 -0.735 . . . . 53.21 112.491 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -174.41 156.16 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.789 0.328 . . . . 72.21 110.922 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.65 163.68 0.08 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.249 -0.432 . . . . 71.23 110.871 179.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -127.58 143.7 51.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 74.31 110.9 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.95 124.14 34.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 74.34 110.92 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.9 m -111.4 -178.99 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.456 . . . . 74.4 111.146 180.0 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -145.59 162.27 37.21 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.594 0.711 . . . . 72.02 110.887 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 -4.03 13.19 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.688 2.258 . . . . 74.13 112.339 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.9 m -46.93 -65.2 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 72.52 111.166 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 2.0 p -155.63 32.54 0.36 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.237 -0.438 . . . . 72.44 111.127 179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.9 p -70.96 -29.14 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.232 -0.44 . . . . 64.2 111.125 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.8 ptt-85 -97.55 -9.03 27.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.879 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -101.41 -31.9 10.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 73.33 110.918 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -132.8 134.82 45.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 74.12 110.908 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.98 -158.56 14.62 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.782 -0.723 . . . . 73.2 112.542 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.433 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 53.8 Cg_endo -69.78 -28.81 24.68 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.693 2.262 . . . . 64.34 112.377 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.433 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 18.5 m-90 -87.01 -5.67 59.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 75.31 110.921 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.5 -59.34 2.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.246 -0.434 . . . . 64.51 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -113.93 144.68 32.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.554 0.692 . . . . 65.2 110.891 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -5.02 15.23 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.683 2.256 . . . . 75.22 112.384 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.77 -19.0 61.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.128 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.24 31.16 6.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 74.21 110.929 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.2 -73.1 0.13 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.05 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.404 ' HA ' ' O ' ' A' ' 38' ' ' THR . 2.0 p -111.63 106.54 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.441 . . . . 74.22 111.157 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -117.45 149.92 19.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 72.23 111.157 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -79.64 124.21 28.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 73.24 110.94 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.7 t -119.19 -14.83 9.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 61.32 111.136 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.42 -170.93 12.81 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 74.34 112.484 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -36.02 11.42 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.252 . . . . 72.14 112.33 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 20.2 t30 -149.76 34.61 0.69 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.225 -0.443 . . . . 73.51 110.861 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -137.33 117.44 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 75.33 110.91 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -98.24 143.13 29.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 75.14 110.918 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.404 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 51.9 m -99.05 102.21 13.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 73.33 111.158 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 t -83.53 143.15 12.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 75.52 111.117 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -125.0 112.7 16.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.196 -0.456 . . . . 74.52 110.937 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 85.4 t -109.53 125.9 66.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.12 -0.491 . . . . 63.14 111.107 179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -115.64 137.18 52.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 74.21 110.928 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.05 117.56 4.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 72.11 111.082 179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -145.38 140.54 27.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 65.43 110.885 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.4 27.03 1.31 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 74.31 111.124 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -120.92 25.26 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 73.43 110.886 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 169.32 -146.9 10.53 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.816 -0.707 . . . . 52.22 112.523 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -155.57 116.4 3.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.798 0.332 . . . . 74.32 110.914 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.437 ' HG3' ' HD2' ' A' ' 50' ' ' PRO . 2.1 mp0 -134.65 163.32 52.02 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.591 0.71 . . . . 75.14 110.919 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.437 ' HD2' ' HG3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.79 162.15 43.19 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.64 2.226 . . . . 74.34 112.362 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 -124.29 64.34 36.81 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.586 0.708 . . . . 73.32 110.917 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 113.18 3.28 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.669 2.246 . . . . 74.54 112.375 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.5 mm -126.13 144.99 34.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 74.22 111.161 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -155.23 115.6 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 74.14 110.918 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.7 m -130.75 84.29 59.08 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.63 0.729 . . . . 73.34 111.127 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 122.62 9.3 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 73.42 112.369 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.7 154.56 38.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 65.41 110.9 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.62 -8.39 72.34 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 72.43 112.476 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.16 157.32 45.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.714 0.292 . . . . 71.42 111.142 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 3.0 mt-10 -70.19 144.7 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 71.4 110.915 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.4 mm -128.79 105.35 12.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 70.51 111.112 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 25.4 t -84.74 100.68 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 74.15 111.074 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -76.89 135.15 38.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.1 110.876 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 8.7 mttt -132.28 100.19 4.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 72.41 110.93 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.6 mp -109.08 141.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 71.52 111.115 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 7.8 t -155.92 135.3 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 72.13 111.135 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -141.96 161.1 53.02 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.7 0.762 . . . . 73.24 110.826 -179.867 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -53.34 0.28 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.674 2.249 . . . . 52.11 112.365 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -156.67 57.82 0.55 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 71.14 110.823 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.49 141.43 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.254 -0.43 . . . . 75.13 111.126 179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 25.1 mm -85.35 155.18 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 74.23 111.093 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -123.75 -86.28 0.64 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.121 -0.49 . . . . 75.2 110.857 179.872 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.04 101.6 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.721 -0.752 . . . . 62.14 112.469 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 2.5 p90 -103.5 144.94 30.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.917 0.389 . . . . 74.34 110.854 -179.88 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -106.0 142.25 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 71.33 110.884 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 44.3 t -137.53 143.6 33.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 62.24 111.131 179.953 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -73.2 -175.7 1.94 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.478 . . . . 65.22 110.912 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.09 -51.09 3.98 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.75 -0.738 . . . . 60.55 112.493 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.14 179.5 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.828 0.347 . . . . 70.25 111.127 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 -88.17 61.05 6.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 65.21 110.891 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 4.8 tp -71.16 99.72 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 74.3 111.13 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -110.4 112.11 23.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 75.15 110.919 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 1.5 m -130.82 122.93 53.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.457 . . . . 75.21 111.161 179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -152.64 112.79 4.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 71.44 110.874 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 57.3 t -140.55 144.28 27.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 73.33 111.119 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.27 160.06 80.54 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.631 0.729 . . . . 74.32 110.899 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 159.82 51.97 Favored 'Trans proline' 0 C--N 1.34 0.126 0 C-N-CA 122.708 2.272 . . . . 73.23 112.28 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.61 -1.27 56.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 74.34 112.465 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -147.0 156.75 43.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.884 0.374 . . . . 74.45 110.891 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 2.1 p -105.55 113.9 43.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 71.03 111.119 179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.54 168.2 19.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 64.45 110.876 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 96.5 m -134.5 139.35 45.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 65.34 111.129 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.9 t -143.45 137.63 25.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.236 -0.438 . . . . 75.11 111.128 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.04 72.63 0.79 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.469 . . . . 74.33 110.886 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -108.41 141.17 40.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 74.51 110.924 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.1 t -140.06 143.19 36.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.137 -0.483 . . . . 71.41 111.162 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -101.1 177.18 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 72.02 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.34 -12.79 8.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.462 . . . . 75.14 110.877 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -144.57 162.03 41.01 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.653 0.74 . . . . 75.13 110.914 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 155.58 65.62 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.73 2.287 . . . . 62.25 112.314 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 162.27 135.37 1.8 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.773 -0.727 . . . . 74.32 112.53 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -108.92 124.89 51.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.866 0.365 . . . . 74.14 110.901 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -136.04 135.27 39.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.198 -0.456 . . . . 72.23 110.954 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.561 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 0.5 OUTLIER -144.24 -177.56 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 75.22 110.858 -179.95 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.561 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 6.6 tt 59.79 158.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 73.13 111.122 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.33 140.26 34.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 72.22 111.164 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -177.96 47.55 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.195 -0.457 . . . . 72.51 110.894 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -177.36 50.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.162 -0.472 . . . . 74.53 110.904 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -174.12 177.57 2.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.458 . . . . 71.44 110.882 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -114.43 121.18 42.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 74.42 110.901 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -169.37 -40.99 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.117 -0.492 . . . . 74.52 110.88 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 166.39 -43.13 0.27 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.731 -0.747 . . . . 74.25 112.53 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER 62.56 164.38 0.1 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.849 0.357 . . . . 65.3 110.905 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 52.59 -112.54 2.16 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.748 -0.739 . . . . 70.03 112.498 179.915 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 52.8 p-80 -79.96 175.84 10.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.738 0.304 . . . . 75.54 110.893 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 69.14 -75.57 0.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.25 -0.432 . . . . 74.53 110.953 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 35.5 t30 -71.83 124.59 25.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 64.23 110.896 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 21.8 mmt -71.35 174.75 6.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 71.11 110.847 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -90.89 152.77 20.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.237 -0.438 . . . . 73.34 110.899 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -101.08 73.42 0.38 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.698 -0.763 . . . . 75.11 112.484 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 99.4 m -74.38 124.84 27.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.741 0.305 . . . . 71.13 111.138 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 3.1 mp -153.41 138.08 9.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 73.12 111.131 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 11.5 p -134.22 134.69 55.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 71.12 111.151 179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 48.1 t -103.61 129.13 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 73.41 111.152 179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt -107.19 129.1 54.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.134 -0.484 . . . . 73.35 110.885 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 73.14 110.878 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.863 0.363 . . . . 74.45 110.85 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 90.4 t -81.15 99.91 4.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 75.24 111.136 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 31.3 pt -95.78 153.81 39.24 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.665 0.745 . . . . 74.51 111.081 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -178.73 2.48 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.624 2.216 . . . . 73.1 112.395 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -173.35 76.54 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 60.21 111.103 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.78 -18.7 56.93 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.693 -0.765 . . . . 63.25 112.477 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.15 -177.51 3.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.809 0.338 . . . . 74.1 110.913 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.2 pp -60.76 -175.44 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.21 -0.45 . . . . 73.12 110.927 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 4.0 mm-40 -64.89 123.16 18.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 73.1 110.877 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.67 139.26 40.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 75.44 110.874 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.8 m -130.1 -177.55 2.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 75.54 111.124 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.402 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 55.9 p-10 -144.07 155.47 58.6 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.563 0.697 . . . . 74.44 110.893 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.402 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.4 Cg_endo -69.84 -3.94 13.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.656 2.237 . . . . 73.53 112.351 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 23.2 m -49.07 -64.7 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 53.32 111.092 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 2.7 p -156.04 34.91 0.34 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 62.51 111.15 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 p -70.59 -29.19 37.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 71.12 111.069 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 7.2 ptt-85 -98.74 -7.91 26.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 74.21 110.879 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -101.62 -34.79 9.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 73.15 110.927 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.51 133.2 46.07 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 73.53 110.891 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 120.25 -158.15 15.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.747 -0.74 . . . . 62.11 112.507 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -30.11 22.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.73 2.287 . . . . 75.43 112.321 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 13.5 m-90 -84.89 -10.21 57.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.279 -0.418 . . . . 74.1 110.921 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.85 -59.46 2.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 74.41 111.072 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.76 144.64 28.21 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.64 0.733 . . . . 72.53 110.815 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -26.35 27.8 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.686 2.257 . . . . 75.32 112.335 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.02 -18.31 60.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.262 -0.426 . . . . 74.13 111.093 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 19.0 mm-40 -87.35 6.85 31.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 75.22 110.887 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.87 -77.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.266 -0.424 . . . . 72.43 111.084 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.54 116.95 23.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 71.34 111.131 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.0 t -145.77 131.06 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 71.5 111.167 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.59 125.47 26.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 73.31 110.877 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.2 t -117.46 -41.39 2.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 74.02 111.148 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.73 -164.11 18.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 73.35 112.482 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -43.99 2.37 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.7 2.266 . . . . 73.15 112.372 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -141.27 34.45 1.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 73.31 110.908 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -131.4 119.71 22.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 72.15 110.847 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -97.0 140.93 30.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 71.12 110.919 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.461 ' HA ' HG23 ' A' ' 62' ' ' VAL . 96.7 m -93.79 122.45 36.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 61.22 111.137 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 18.5 t -109.05 108.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 74.1 111.107 179.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 66.6 m-85 -94.18 105.45 17.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 73.21 110.924 -179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 59.8 t -98.73 132.65 43.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.082 -0.508 . . . . 71.44 111.167 179.885 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -123.85 133.82 53.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.226 -0.443 . . . . 75.22 110.91 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.06 132.01 10.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 74.41 111.083 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -145.26 147.54 32.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 72.41 110.912 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.74 50.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.179 -0.464 . . . . 72.04 111.133 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -95.72 34.05 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 73.31 110.86 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.49 -138.56 6.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.75 -0.738 . . . . 65.05 112.505 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -155.17 157.02 36.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.801 0.334 . . . . 73.41 110.957 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -165.33 162.05 13.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.582 0.706 . . . . 73.31 110.938 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 178.64 4.34 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.677 2.251 . . . . 75.11 112.37 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -138.41 63.46 34.78 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.602 0.715 . . . . 73.34 110.869 -179.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 73.1 1.36 Allowed 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.719 2.279 . . . . 71.2 112.361 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.8 mp -106.73 136.44 41.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 73.11 111.13 179.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -133.13 118.05 18.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.169 -0.469 . . . . 71.52 110.891 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 19.6 t -119.9 82.8 28.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 73.11 111.146 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.73 122.06 8.75 Favored 'Trans proline' 0 N--CA 1.465 -0.173 0 C-N-CA 122.718 2.279 . . . . 72.42 112.358 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -69.79 153.03 43.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 74.2 110.914 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.27 -4.62 83.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 64.51 112.484 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.42 156.24 48.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 71.13 111.112 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -66.71 140.6 57.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 74.24 110.897 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.6 mm -130.23 115.01 30.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.134 -0.485 . . . . 72.43 111.116 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.461 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -103.0 90.95 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.17 -0.468 . . . . 71.43 111.161 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 72.2 m-85 -68.13 138.81 56.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 74.13 110.864 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 5.4 mttt -131.83 99.36 4.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 72.44 110.943 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.5 mp -106.76 142.55 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 64.34 111.152 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 14.2 t -153.81 128.29 9.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 72.22 111.155 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.507 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 1.0 OUTLIER -131.33 160.23 68.08 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.677 0.751 . . . . 65.11 110.854 -179.847 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.507 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.72 -53.2 0.28 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.708 2.272 . . . . 71.13 112.343 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . 0.4 ' HA ' ' HG3' ' A' ' 87' ' ' PRO . 3.7 m-20 -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 73.23 110.888 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.432 HG23 ' HB2' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.9 133.41 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 72.23 111.16 179.984 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . 0.459 ' CG2' ' H ' ' A' ' 72' ' ' HIS . 10.1 mm -91.73 172.53 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 62.32 111.105 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . 0.459 ' H ' ' CG2' ' A' ' 71' ' ' ILE . 0.1 OUTLIER 76.28 148.86 0.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.124 -0.489 . . . . 73.32 110.896 179.915 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -121.12 -94.68 1.37 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.731 -0.747 . . . . 62.23 112.489 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 3.6 p90 -152.02 149.33 28.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.897 0.38 . . . . 74.24 110.871 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -114.73 143.1 45.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 75.33 110.836 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 5.9 p -119.67 145.07 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 75.0 111.141 179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.3 172.55 12.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 73.04 110.886 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.51 -52.05 4.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.731 -0.747 . . . . 72.44 112.479 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 16.8 m -123.1 154.13 39.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.333 . . . . 64.31 111.139 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -88.41 65.87 8.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 60.52 110.903 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -57.03 134.12 21.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.195 -0.457 . . . . 70.44 111.169 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.37 81.62 1.61 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 75.3 110.87 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 19.6 m -116.63 117.73 56.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 72.22 111.141 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -166.88 117.8 0.92 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 72.43 110.893 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.0 m -140.18 137.4 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 75.12 111.089 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.08 156.44 1.79 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.576 0.703 . . . . 74.43 110.961 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.4 ' HG3' ' HA ' ' A' ' 69' ' ' ASP . 53.1 Cg_endo -69.83 159.21 54.21 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.671 2.247 . . . . 72.22 112.316 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 87.39 3.36 81.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.71 -0.757 . . . . 74.42 112.523 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -148.59 117.56 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 72.01 110.876 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 1.7 p -60.33 137.19 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 75.44 111.138 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.58 163.91 17.17 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 75.53 110.899 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.6 m -146.69 104.83 3.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 74.13 111.135 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 4.4 p -130.07 154.36 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 75.54 111.14 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -122.67 100.4 6.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 75.35 110.912 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 49.9 t80 -134.81 108.31 7.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.19 -0.459 . . . . 70.04 110.885 -179.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.8 t -103.94 135.54 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 75.53 111.184 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.44 -177.57 4.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 65.55 110.828 -179.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.7 mtmt -125.72 -22.03 4.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 72.33 110.897 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.14 158.92 72.75 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.587 0.708 . . . . 74.44 110.868 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 152.89 69.3 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.696 2.264 . . . . 74.23 112.343 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 168.64 143.43 3.83 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 64.15 112.475 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -110.27 133.09 53.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.832 0.348 . . . . 75.24 110.92 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.2 p90 -143.78 136.63 27.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.148 -0.478 . . . . 75.43 110.921 -179.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.534 ' O ' ' CG2' ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.49 -167.82 2.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 73.31 110.894 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.534 ' CG2' ' O ' ' A' ' 104' ' ' ARG . 8.5 tt 56.64 159.32 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 74.35 111.118 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.47 142.64 29.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 74.41 111.112 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 5.8 p 179.53 -42.64 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 74.53 110.937 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -100.82 81.25 2.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 73.33 110.854 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 9.1 mm-40 -129.42 -76.11 0.55 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.213 -0.449 . . . . 74.54 110.927 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 9.4 t80 179.69 -47.34 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 74.3 110.893 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -92.58 97.71 10.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.136 -0.484 . . . . 75.14 110.881 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -45.98 105.22 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.728 -0.749 . . . . 72.32 112.514 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 13.6 tp -142.77 137.82 30.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.891 0.376 . . . . 74.52 110.917 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -122.59 -11.5 5.48 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.769 -0.729 . . . . 61.3 112.461 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -130.82 -169.4 2.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.705 0.288 . . . . 72.13 110.883 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 67.85 -77.88 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 71.43 110.892 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 28.1 p30 -57.32 -176.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 63.43 110.904 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.25 175.57 6.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 74.04 110.879 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -90.89 120.26 31.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 74.43 110.868 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -77.18 170.35 55.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.731 -0.747 . . . . 74.43 112.537 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 52.3 m -154.7 121.36 5.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.792 0.33 . . . . 72.35 111.2 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 4.8 mp -146.82 139.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 75.43 111.098 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.6 p -134.81 135.08 53.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 73.3 111.174 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 57.4 t -102.65 123.94 56.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 70.53 111.147 179.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.1 mmtt -98.29 134.25 41.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 75.22 110.918 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 72.12 110.892 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.0 mmt . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.788 0.328 . . . . 72.53 110.902 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 12.1 p 41.51 37.01 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 73.03 111.15 179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.9 pt -112.53 78.6 2.75 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.622 0.725 . . . . 75.3 111.133 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 -178.81 2.5 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.71 2.273 . . . . 71.35 112.361 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -150.48 92.03 1.81 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.459 . . . . 64.44 111.086 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 166.56 62.0 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.719 -0.753 . . . . 71.41 112.5 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 66.0 146.73 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.814 0.34 . . . . 73.1 110.877 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.1 164.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 73.13 110.895 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -126.97 148.23 50.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 71.52 110.87 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? -99.02 121.42 40.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 64.52 110.87 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 15.7 m -118.61 -179.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 73.5 111.16 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.99 162.16 39.22 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.688 0.756 . . . . 74.34 110.799 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.85 -2.96 11.12 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.662 2.241 . . . . 73.55 112.349 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -44.86 -62.78 1.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 74.54 111.15 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.8 23.87 0.39 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 74.41 111.166 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.0 p -65.89 -30.98 51.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 72.52 111.098 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -106.3 -6.93 18.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 73.33 110.886 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -95.24 -36.44 11.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 72.3 110.894 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -140.94 132.28 26.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 75.01 110.85 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.91 -156.95 21.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 73.42 112.487 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.4 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.8 Cg_endo -69.76 -32.91 17.65 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 74.41 112.356 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.448 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 10.5 m-90 -84.92 -17.87 36.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.445 . . . . 75.44 110.951 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.45 -61.33 2.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 75.51 111.092 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.69 144.36 29.41 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.612 0.72 . . . . 73.42 110.828 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -11.37 30.69 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.692 2.262 . . . . 74.03 112.32 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.69 -27.52 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 63.01 111.119 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.502 ' N ' HE21 ' A' ' 27' ' ' GLN . 0.0 OUTLIER -111.04 31.84 5.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 74.34 110.862 -179.9 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.77 -41.82 29.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 75.24 111.1 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.64 130.33 69.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 74.41 111.113 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -146.87 137.87 18.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.096 -0.502 . . . . 73.33 111.064 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -79.68 115.87 19.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 75.54 110.937 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -113.79 -21.06 10.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 75.44 111.142 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.27 -167.48 14.05 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 62.33 112.511 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.94 3.88 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.715 2.277 . . . . 75.32 112.363 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -148.42 29.73 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 72.25 110.876 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -126.95 116.32 20.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 75.32 110.891 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -95.75 140.33 30.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 71.44 110.966 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.462 ' HA ' HG23 ' A' ' 62' ' ' VAL . 88.0 m -92.38 109.9 21.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 72.43 111.176 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 t -89.93 130.07 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 75.34 111.108 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -113.98 105.13 12.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 74.23 110.956 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 25.0 m -100.15 147.01 8.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.145 -0.48 . . . . 74.42 111.158 179.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.448 ' HG ' ' HB3' ' A' ' 22' ' ' TRP . 0.3 OUTLIER -133.67 133.16 41.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.245 -0.434 . . . . 74.15 110.948 179.961 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.78 98.72 1.94 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 73.12 111.083 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -123.85 143.03 50.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.855 -179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.86 0.17 53.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 74.41 111.114 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -97.2 66.33 2.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 73.1 110.871 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.28 -137.07 10.47 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.455 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -155.17 150.27 26.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.861 0.363 . . . . 72.2 110.924 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -165.32 163.29 13.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.583 0.706 . . . . 72.44 110.925 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 176.08 7.28 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.618 2.212 . . . . 70.33 112.335 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . 0.442 ' O ' HG12 ' A' ' 53' ' ' ILE . 4.1 m120 -129.86 62.72 65.3 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.623 0.725 . . . . 75.04 110.914 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 111.15 2.72 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 72.14 112.342 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . 0.442 HG12 ' O ' ' A' ' 51' ' ' ASN . 1.1 mm -130.66 151.58 36.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 73.32 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.3 tt0 -156.06 115.77 3.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 74.41 110.866 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.3 t -135.37 76.44 56.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.699 . . . . 75.01 111.139 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 121.55 8.23 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.695 2.263 . . . . 73.11 112.329 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.5 155.29 38.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.239 -0.437 . . . . 75.33 110.949 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.56 -13.32 65.85 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 61.12 112.49 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.43 154.48 50.74 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 63.35 111.077 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -64.69 136.08 56.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 75.25 110.906 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 8.1 mm -127.25 96.21 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 75.12 111.11 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.462 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.2 OUTLIER -84.46 102.18 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 71.4 111.143 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -73.49 139.62 45.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 71.41 110.922 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 15.8 mttt -131.83 98.78 4.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.472 . . . . 75.33 110.928 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.511 ' O ' ' HA ' ' A' ' 90' ' ' VAL . 1.3 mp -97.56 157.29 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 73.02 111.147 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.3 t -170.24 126.21 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 73.13 111.164 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.433 ' HB3' HG22 ' A' ' 70' ' ' VAL . 3.6 m -127.44 161.99 51.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.656 0.741 . . . . 64.13 110.879 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.419 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.9 Cg_endo -69.82 -51.8 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.645 2.23 . . . . 74.11 112.334 179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -155.52 29.52 0.38 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 75.32 110.809 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.433 HG22 ' HB3' ' A' ' 67' ' ' SER . 25.9 m -128.37 144.35 38.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 74.52 111.109 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 24.1 mm -69.73 157.2 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.479 . . . . 72.41 111.13 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -114.7 -164.4 0.94 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.18 -0.464 . . . . 73.5 110.865 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.71 130.48 3.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.815 -0.707 . . . . 45.33 112.479 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -136.76 144.39 43.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.884 0.373 . . . . 74.32 110.91 -179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 36.8 t-80 -93.66 133.6 36.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.119 -0.492 . . . . 72.41 110.822 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 87.0 t -126.72 143.27 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 73.2 111.117 -179.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -75.52 177.01 7.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 74.43 110.856 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.74 -51.59 4.57 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 61.21 112.489 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.1 m -140.64 154.12 46.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.797 0.332 . . . . 72.35 111.106 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -76.6 64.58 2.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 73.3 110.88 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 11.3 tt -54.9 128.29 14.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.469 . . . . 75.52 111.124 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -115.58 97.06 5.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 74.22 110.869 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.5 m -125.48 120.44 57.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 74.4 111.075 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -154.33 115.72 4.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 74.53 110.832 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 94.1 t -139.28 146.53 25.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.485 . . . . 74.25 111.16 179.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.404 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -75.65 157.99 83.54 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.586 0.708 . . . . 73.44 110.923 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.404 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 53.3 Cg_endo -69.78 153.8 68.43 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.719 2.28 . . . . 74.31 112.321 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.69 7.06 59.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.752 -0.737 . . . . 74.03 112.496 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -156.75 141.94 17.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.873 0.368 . . . . 74.53 110.878 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 3.6 p -95.69 126.3 48.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 74.4 111.122 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -87.5 177.36 7.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 71.23 110.798 -179.829 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 98.8 m -144.82 105.48 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 74.32 111.139 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 9.8 p -134.82 137.8 50.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 74.42 111.109 179.869 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -113.27 139.9 48.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 75.25 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -166.06 94.8 0.57 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.245 -0.434 . . . . 75.13 110.955 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -84.33 143.76 29.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 74.43 111.113 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.12 -169.41 2.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.43 110.889 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mttt -124.93 -28.26 3.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 74.33 110.897 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.17 158.87 70.21 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.605 0.717 . . . . 75.43 110.841 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 147.74 63.44 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.722 2.281 . . . . 74.44 112.342 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.27 153.58 8.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 43.35 112.484 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -116.74 132.2 56.75 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.826 0.346 . . . . 75.43 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.4 p90 -143.83 141.18 30.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 73.43 110.9 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.85 177.43 8.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.491 . . . . 74.33 110.91 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.3 mm 67.48 146.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.213 -0.449 . . . . 74.13 111.184 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -108.17 143.56 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 75.42 111.133 179.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 4.9 p -127.08 84.19 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.156 -0.475 . . . . 74.03 110.865 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.4 m120 72.3 -69.31 0.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 74.52 110.892 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 59.91 20.33 9.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 72.41 110.909 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 1.2 m-30 62.67 82.3 0.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.17 -0.468 . . . . 75.35 110.91 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 179.63 -70.16 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.095 -0.502 . . . . 74.22 110.901 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 161.96 74.33 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.741 -0.742 . . . . 61.23 112.507 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 3.1 tm? -51.75 120.62 5.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.81 0.338 . . . . 75.03 110.97 -179.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 152.12 -117.33 0.81 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.71 -0.757 . . . . 62.4 112.495 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 19.4 p80 -91.16 48.43 1.5 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.762 0.315 . . . . 73.23 110.878 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -151.17 19.74 0.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 72.35 110.916 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -179.9 -176.36 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 71.45 110.935 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -142.8 175.06 10.11 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.197 -0.456 . . . . 75.42 110.876 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 11.4 m-85 -91.06 123.37 34.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 74.44 110.873 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -123.22 124.11 5.52 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.716 -0.754 . . . . 32.24 112.494 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 12.5 t -86.47 154.24 21.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.793 0.33 . . . . 72.24 111.114 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 2.9 mp -153.79 137.33 8.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.205 -0.452 . . . . 74.33 111.126 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.5 p -127.55 139.03 53.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 61.34 111.094 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 49.1 t -109.27 117.17 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 73.52 111.162 179.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -86.98 138.76 31.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 74.14 110.888 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.447 . . . . 75.14 110.911 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 ptm . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.851 0.358 . . . . 73.04 110.899 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 32.8 m -88.93 137.21 21.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 70.14 111.136 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.9 pt -153.03 78.45 5.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.615 0.721 . . . . 74.51 111.131 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -177.49 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.688 2.259 . . . . 70.2 112.396 179.851 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -147.94 60.11 1.12 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 73.52 111.085 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -146.47 -78.83 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.756 -0.735 . . . . 74.1 112.465 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.06 127.92 55.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.86 0.362 . . . . 75.22 110.887 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 48.29 -168.76 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 75.42 110.894 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -123.02 131.91 53.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 73.44 110.91 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -96.04 145.18 25.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.494 . . . . 74.43 110.853 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.1 m -136.64 -178.58 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 64.11 111.14 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.13 161.98 42.51 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.641 0.734 . . . . 75.41 110.876 179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 -3.5 12.14 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.692 2.261 . . . . 73.41 112.362 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 25.8 m -44.96 -70.21 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 51.1 111.165 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 25.6 p -149.59 24.1 0.88 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 64.31 111.152 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.6 p -62.85 -26.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 74.15 111.118 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -106.07 -17.21 14.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 73.53 110.865 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -83.91 -35.9 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 72.32 110.923 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 -142.38 140.82 32.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 73.43 110.895 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.24 -158.53 17.86 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.732 -0.747 . . . . 64.24 112.476 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.72 -30.97 21.63 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 72.33 112.398 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 12.2 m-90 -84.6 -13.91 50.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.942 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.88 -59.42 3.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 63.34 111.105 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.01 147.63 34.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.565 0.698 . . . . 64.34 110.876 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -26.67 27.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.667 2.244 . . . . 72.25 112.361 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -80.14 -1.12 38.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 72.41 111.069 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.8 mm-40 -105.27 5.07 31.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 71.13 110.953 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.3 -74.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 73.45 111.099 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.0 t -71.91 126.78 33.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.436 . . . . 74.01 111.127 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 19.0 m -150.34 127.01 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 73.34 111.13 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -76.28 114.44 14.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.459 . . . . 63.12 110.926 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.2 t -120.05 -13.17 9.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.263 -0.426 . . . . 71.32 111.116 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.36 -173.25 13.78 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.753 -0.737 . . . . 62.11 112.514 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -36.72 10.34 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 75.21 112.336 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -150.86 34.35 0.6 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 72.1 110.863 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -134.55 117.8 16.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 71.54 110.945 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -98.58 134.33 41.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 75.02 110.947 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.494 ' HA ' HG22 ' A' ' 62' ' ' VAL . 56.7 m -95.07 115.04 26.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.482 . . . . 74.34 111.136 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -110.33 126.62 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 75.13 111.131 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 84.8 m-85 -103.13 113.78 27.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.198 -0.455 . . . . 75.12 110.859 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 15.8 m -97.5 131.4 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.11 -0.496 . . . . 71.4 111.126 179.886 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -120.19 135.66 54.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 74.53 110.89 179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -156.44 113.98 3.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 74.33 111.065 179.799 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 7.0 p90 -128.5 151.08 49.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 73.11 110.889 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.47 1.44 48.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 75.23 111.074 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -92.15 75.65 5.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.261 -0.427 . . . . 73.41 110.852 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.46 -127.75 9.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 73.12 112.499 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -141.67 162.34 35.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.824 0.345 . . . . 74.4 110.909 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 1.8 pm0 -161.07 155.93 20.24 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 74.4 110.93 179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -176.23 1.41 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.675 2.25 . . . . 73.23 112.337 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -130.28 60.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.605 0.717 . . . . 72.42 110.881 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 73.94 1.32 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.675 2.25 . . . . 61.24 112.35 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.9 mp -125.84 132.39 70.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 73.23 111.146 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -131.62 156.69 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 70.51 110.906 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.417 ' O ' HG12 ' A' ' 55' ' ' VAL . 2.9 p -157.47 77.88 3.72 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.619 0.723 . . . . 74.32 111.148 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 121.46 8.15 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.696 2.264 . . . . 73.23 112.356 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -68.26 154.24 42.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 65.24 110.924 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.94 -10.16 69.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.76 -0.733 . . . . 73.11 112.493 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.5 159.9 39.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.773 0.32 . . . . 63.03 111.106 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.8 mp0 -72.57 141.34 48.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.43 110.895 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 3.8 mm -125.96 119.48 54.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.169 -0.469 . . . . 74.32 111.124 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.494 HG22 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -110.19 90.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 55.13 111.087 179.905 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 38.7 m-85 -74.81 144.18 43.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 74.34 110.872 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.41 100.81 6.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 73.15 110.908 179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.9 mt -94.23 147.3 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 74.32 111.125 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -166.12 136.93 3.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 71.12 111.146 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -146.34 160.61 41.73 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.698 0.761 . . . . 74.05 110.835 -179.883 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 -54.87 0.2 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.674 2.249 . . . . 74.34 112.353 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -156.88 61.43 0.52 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 73.21 110.854 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.16 135.9 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 74.15 111.112 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.0 mm -73.61 145.17 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 75.21 111.142 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -126.56 -168.57 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 74.22 110.876 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 133.31 115.21 1.59 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 73.24 112.475 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -111.03 142.71 42.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.842 0.354 . . . . 73.14 110.879 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.554 ' N ' HE22 ' A' ' 109' ' ' GLN . 6.9 p80 -115.17 142.63 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 74.55 110.816 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 16.6 t -133.68 147.66 30.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 74.41 111.126 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -70.01 -178.65 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 64.01 110.907 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.53 -51.17 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.721 -0.752 . . . . 71.43 112.5 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.1 m -136.89 153.86 50.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.789 0.328 . . . . 75.02 111.16 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -77.39 60.44 2.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 75.11 110.9 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 7.2 tt -69.58 115.26 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 74.05 111.123 179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -115.78 104.25 11.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.48 . . . . 74.31 110.883 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.79 120.14 56.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 73.32 111.139 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.5 pp20? -157.23 117.23 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 72.45 110.867 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -140.35 146.54 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 74.25 111.113 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -64.21 158.49 64.06 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.619 0.723 . . . . 75.02 110.922 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 152.86 69.37 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.235 . . . . 71.52 112.332 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.62 11.46 63.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.757 -0.735 . . . . 64.02 112.463 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -145.83 118.17 8.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 74.44 110.952 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 39.2 t -63.43 105.59 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 64.02 111.173 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 66.0 p -91.98 114.33 26.84 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 64.22 110.867 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.3 t -81.83 145.99 30.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 74.51 111.17 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 87.2 t -139.94 117.85 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 74.23 111.107 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.0 mmm180 -102.8 107.91 18.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 75.34 110.894 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -155.95 141.38 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 65.4 110.938 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.5 t -135.14 143.63 46.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 74.43 111.102 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -95.56 -175.5 3.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 70.13 110.88 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -123.06 -12.27 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.116 -0.493 . . . . 73.15 110.876 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.83 161.93 28.09 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.646 0.736 . . . . 75.52 110.835 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 156.7 62.68 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 64.55 112.316 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.0 132.51 1.37 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 64.32 112.51 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -101.79 132.84 47.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.889 0.376 . . . . 63.02 110.918 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -143.8 129.61 19.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.49 . . . . 73.42 110.913 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.0 95.3 2.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.501 . . . . 75.2 110.843 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.5 tt -178.19 143.77 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 73.11 111.118 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -118.1 144.59 25.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 65.24 111.106 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 55.3 m -114.42 -75.81 0.59 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.468 . . . . 62.43 110.889 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -134.38 -39.46 0.82 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 74.43 110.929 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . 0.554 HE22 ' N ' ' A' ' 75' ' ' HIS . 5.8 mm100 71.32 -70.02 0.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 73.44 110.923 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 73.6 t80 -152.68 -74.38 0.14 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.177 -0.465 . . . . 75.15 110.958 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.8 t -52.51 -35.35 52.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.056 -0.52 . . . . 55.21 110.879 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 109.91 59.63 0.51 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.763 -0.732 . . . . 71.34 112.487 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 11.2 tp 57.5 95.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.889 0.376 . . . . 73.22 110.917 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -60.15 -169.61 0.44 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.714 -0.755 . . . . 73.44 112.479 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 73.6 t60 -55.95 -25.65 44.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.725 0.298 . . . . 73.12 110.858 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -133.4 -68.9 0.56 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 75.42 110.938 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 61.99 102.54 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 74.55 110.86 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.44 174.33 6.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 74.42 110.868 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -91.78 121.97 33.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 73.32 110.9 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.3 84.86 0.24 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.725 -0.75 . . . . 73.22 112.495 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 53.4 m -75.21 117.73 17.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.768 0.318 . . . . 74.35 111.161 -179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 3.7 mp -147.55 140.17 18.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 75.42 111.12 179.936 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 5.6 m -134.46 138.33 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 74.14 111.099 179.831 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 44.0 t -104.05 125.15 58.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 72.22 111.116 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 31.2 mmtt -107.19 133.83 51.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 71.34 110.91 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 72.43 110.865 179.952 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 4.2 mmt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.832 0.349 . . . . 75.44 110.876 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 35.5 m 40.14 44.51 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 63.42 111.115 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.0 pt -109.92 81.33 2.02 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.596 0.713 . . . . 75.42 111.108 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -173.22 0.68 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.645 2.23 . . . . 74.05 112.391 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.56 144.47 31.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 71.31 111.093 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 63.53 95.83 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.702 -0.761 . . . . 72.12 112.521 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.29 164.29 0.11 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.838 0.352 . . . . 73.35 110.915 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.3 tp 65.86 121.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 75.25 110.938 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -121.16 117.1 26.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.201 -0.454 . . . . 63.33 110.856 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -84.3 144.33 28.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.492 . . . . 74.21 110.892 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.3 m -134.24 -177.37 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 72.1 111.111 179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . 0.449 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 21.4 p30 -143.77 157.72 57.75 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.586 0.708 . . . . 74.42 110.855 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.449 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.75 -2.8 10.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.243 . . . . 75.14 112.313 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 9.7 m -48.26 -67.72 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 74.4 111.147 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 38.4 p -151.0 30.24 0.64 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.45 . . . . 73.14 111.131 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.9 p -78.83 -24.96 13.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.24 -0.436 . . . . 75.21 111.113 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.427 ' CZ ' ' HD3' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -98.65 -18.23 18.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 75.42 110.892 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.9 mm-40 -100.92 -31.42 11.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 63.33 110.896 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -129.28 138.68 51.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 73.41 110.874 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 116.68 -161.78 12.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 41.24 112.494 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -27.77 25.87 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 2.239 . . . . 70.03 112.375 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 13.5 m-90 -84.45 -17.48 39.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 75.54 110.916 179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.64 -59.8 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 74.04 111.124 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.45 143.0 25.91 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.605 0.717 . . . . 73.22 110.86 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -14.99 37.04 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 64.53 112.353 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -6.58 48.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 75.2 111.131 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 34.1 mm-40 -108.26 5.8 26.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 64.03 110.965 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.76 -78.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.213 -0.449 . . . . 71.12 111.123 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -81.92 125.88 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 72.12 111.113 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.441 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 25.1 m -141.66 142.62 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 55.25 111.154 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -82.31 110.52 17.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 73.24 110.928 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.7 t -108.89 -41.3 4.78 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 74.3 111.138 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.9 175.61 19.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.47 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 116.53 4.6 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.727 2.285 . . . . 74.11 112.34 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 66.97 35.31 4.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 73.44 110.866 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -147.87 152.6 37.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.218 -0.446 . . . . 74.35 110.941 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -141.72 140.96 33.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.222 -0.445 . . . . 72.23 110.957 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.542 ' HA ' HG23 ' A' ' 62' ' ' VAL . 28.8 m -90.95 117.55 29.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 74.04 111.18 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 t -100.35 107.4 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 71.01 111.14 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 70.7 m-85 -88.45 127.38 35.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.189 -0.46 . . . . 73.52 110.913 -179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 77.0 t -119.82 108.04 22.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.109 -0.496 . . . . 75.05 111.119 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -101.5 126.57 48.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 75.13 110.904 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -152.87 128.44 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 64.25 111.145 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -145.78 147.01 31.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.44 . . . . 74.31 110.9 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.77 31.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 74.44 111.088 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -104.63 54.84 0.72 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 72.42 110.876 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 131.67 -139.16 10.71 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 53.02 112.445 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -154.98 151.46 28.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.854 0.359 . . . . 75.4 110.926 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -165.68 162.98 12.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.576 0.703 . . . . 71.11 110.901 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 154.04 68.2 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.697 2.264 . . . . 73.01 112.332 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -128.22 66.4 72.67 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.574 0.702 . . . . 73.44 110.921 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.72 115.21 3.98 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.707 2.271 . . . . 64.12 112.374 179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.6 mm -125.82 146.47 31.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 74.31 111.1 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -155.1 118.03 4.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 71.22 110.885 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . 0.406 HG22 HG13 ' A' ' 61' ' ' ILE . 2.1 p -132.72 85.32 47.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.669 0.747 . . . . 75.1 111.123 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.84 123.13 9.78 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.625 2.217 . . . . 73.21 112.363 179.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.35 145.98 55.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 75.34 110.865 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.41 -28.31 9.22 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 74.2 112.51 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.6 156.86 17.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.74 0.305 . . . . 72.32 111.103 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -66.4 142.13 57.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 65.22 110.916 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . 0.406 HG13 HG22 ' A' ' 55' ' ' VAL . 4.7 mm -131.89 119.95 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 73.31 111.145 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.542 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.3 OUTLIER -114.01 89.44 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 75.21 111.142 179.847 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -66.61 137.18 56.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 73.41 110.92 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 8.6 mttm -133.77 100.65 4.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 64.1 110.898 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 2.6 mp -102.17 157.86 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.444 . . . . 74.53 111.119 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.7 t -165.48 142.19 5.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 72.32 111.163 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.417 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -151.27 162.18 27.54 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 74.12 110.862 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.427 ' HD3' ' CZ ' ' A' ' 17' ' ' ARG . 53.8 Cg_endo -69.76 -55.68 0.17 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.729 2.286 . . . . 72.54 112.348 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -155.93 60.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.458 . . . . 74.13 110.832 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.05 134.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 73.44 111.132 179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.8 mm -64.8 145.06 14.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.142 -0.481 . . . . 73.11 111.118 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 6.8 p80 -140.79 115.49 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.474 . . . . 71.43 110.848 179.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.26 132.58 3.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 60.43 112.496 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -117.15 142.64 46.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.829 0.347 . . . . 74.13 110.866 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.6 t-80 -126.05 105.17 8.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 74.32 110.882 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 4.9 p -97.06 144.95 9.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 73.31 111.102 -179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -61.16 -175.44 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 73.24 110.92 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 90.36 -51.08 3.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.702 -0.761 . . . . 71.21 112.514 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 7.4 m -140.18 158.85 43.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.791 0.329 . . . . 73.51 111.182 -179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -76.17 60.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 74.54 110.892 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 13.4 tt -72.4 110.08 5.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 73.22 111.104 179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.12 97.88 6.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 72.05 110.88 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.6 m -118.23 119.9 62.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 74.04 111.11 179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -150.71 115.52 5.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 74.51 110.894 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 7.3 p -140.67 146.52 24.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 72.01 111.094 179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.2 mp -69.71 160.04 81.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.647 0.737 . . . . 71.4 110.915 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 160.29 50.27 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.657 2.238 . . . . 74.42 112.372 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.31 17.71 54.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.775 -0.726 . . . . 63.54 112.474 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -163.38 135.58 5.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.875 0.369 . . . . 75.45 110.909 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 61.9 t -76.37 138.06 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 70.44 111.13 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -115.2 107.74 15.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 74.15 110.862 -179.836 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.2 m -81.73 120.02 24.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 74.24 111.131 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 46.7 t -120.61 122.79 68.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.269 -0.423 . . . . 74.14 111.148 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.4 mmm180 -100.85 102.45 13.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 75.33 110.88 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 52.9 t80 -151.93 120.41 6.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 74.11 110.921 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.3 t -114.93 139.91 49.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.105 -0.498 . . . . 73.23 111.156 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -90.96 -170.1 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 72.44 110.863 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 25.5 mttt -129.44 -25.52 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 74.54 110.896 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.1 mtp180 -135.98 154.64 77.78 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 74.41 110.832 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 156.84 62.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.651 2.234 . . . . 71.04 112.318 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.19 133.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 71.34 112.48 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.57 128.73 38.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.832 0.349 . . . . 72.1 110.871 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.3 p90 -143.87 132.04 21.85 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 72.22 110.911 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 43.5 mtm180 -144.88 -176.59 5.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 73.34 110.892 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.0 mt 66.35 144.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 70.13 111.157 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -103.68 145.05 13.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 74.24 111.15 179.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 9.0 t -104.46 -67.24 0.91 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 71.13 110.894 179.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -146.81 102.29 3.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 63.15 110.866 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -97.72 25.83 5.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 75.44 110.864 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 59.11 175.67 0.07 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.236 -0.438 . . . . 72.42 110.903 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER 63.18 25.64 14.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.12 -0.491 . . . . 70.22 110.89 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.6 95.92 0.39 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.721 -0.752 . . . . 72.13 112.499 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -66.06 -178.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.889 0.376 . . . . 71.32 110.899 -179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 88.53 -117.31 4.81 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.772 -0.727 . . . . 65.33 112.481 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 31.3 m170 -52.51 148.17 7.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.748 0.308 . . . . 63.4 110.88 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 61.83 55.35 2.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 75.12 110.902 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -179.25 93.98 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 74.23 110.869 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -71.66 174.45 6.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 72.44 110.904 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -91.84 121.1 33.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.228 -0.442 . . . . 72.53 110.909 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -83.8 176.57 52.21 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.752 -0.737 . . . . 71.35 112.503 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 9.9 t -154.56 136.8 14.84 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.746 0.307 . . . . 73.52 111.135 -179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 3.7 mp -150.33 142.01 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.234 -0.439 . . . . 75.2 111.157 179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 28.0 t -132.97 130.19 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 75.05 111.121 179.83 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 42.5 t -103.07 130.38 53.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 72.43 111.135 179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -108.18 134.15 51.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 75.51 110.901 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.34 110.894 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.815 0.341 . . . . 75.11 110.844 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 2.4 p 38.15 82.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.234 -0.439 . . . . 64.32 111.098 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -117.31 153.29 49.99 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.642 0.734 . . . . 64.21 111.125 179.889 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -176.94 1.64 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.663 2.242 . . . . 74.21 112.392 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.99 68.3 1.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.453 . . . . 63.24 111.089 179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 127.62 -93.21 0.37 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.787 -0.72 . . . . 74.24 112.514 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.96 161.65 14.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.818 0.342 . . . . 72.11 110.914 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.41 164.29 0.08 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 71.43 110.891 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.35 131.53 48.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 71.33 110.911 179.933 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.07 154.09 20.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 74.4 110.895 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 10.6 m -126.74 -178.05 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 74.53 111.165 179.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.81 161.74 44.6 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.591 0.71 . . . . 62.43 110.867 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -4.24 13.64 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.695 2.264 . . . . 74.23 112.379 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 42.2 m -48.46 -71.0 0.07 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.198 -0.455 . . . . 75.53 111.157 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 44.8 p -151.59 36.68 0.57 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 65.01 111.159 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.0 p -78.93 -25.58 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 64.41 111.129 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -97.52 -18.2 19.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 74.2 110.834 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -101.43 -28.4 12.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.445 . . . . 72.45 110.923 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.33 133.17 42.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 73.23 110.914 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.88 -158.67 17.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 74.32 112.473 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.42 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 53.4 Cg_endo -69.75 -34.65 14.17 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.72 2.28 . . . . 65.53 112.342 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . 0.42 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 14.9 m-90 -84.98 -6.95 59.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 72.14 110.912 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -59.12 4.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 70.42 111.106 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.99 141.7 25.37 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.592 0.71 . . . . 73.3 110.896 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -7.17 20.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 71.43 112.311 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.06 -25.5 60.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 73.1 111.094 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . 0.509 ' N ' HE21 ' A' ' 27' ' ' GLN . 0.0 OUTLIER -110.99 34.21 4.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 75.01 110.919 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.59 -69.03 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 73.41 111.115 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.41 ' HA ' ' O ' ' A' ' 38' ' ' THR . 1.6 p -111.33 125.18 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.448 . . . . 75.25 111.097 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.97 151.46 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 72.12 111.179 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . 0.414 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -72.69 119.29 16.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 74.32 110.879 -179.974 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.2 p -120.94 -42.58 2.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.157 -0.474 . . . . 75.55 111.137 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.39 -168.22 16.83 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.749 -0.739 . . . . 74.2 112.504 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 109.8 2.4 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 73.33 112.354 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.9 t30 49.92 30.58 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 71.43 110.878 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.43 120.98 26.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.177 -0.465 . . . . 72.44 110.891 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . 0.414 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 39.7 m-85 -94.43 141.97 27.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 72.15 110.924 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.41 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 21.9 m -99.66 99.78 10.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 73.15 111.16 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.34 131.57 33.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 71.41 111.087 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -113.63 100.69 8.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.176 -0.465 . . . . 73.22 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 34.8 m -97.45 129.94 46.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 74.03 111.141 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 18.5 tp -124.24 138.54 54.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 75.51 110.928 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.68 123.41 5.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.467 . . . . 74.34 111.094 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -143.09 144.1 32.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 72.45 110.876 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.13 4.89 32.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 52.24 111.114 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -103.34 72.9 1.18 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 61.33 110.846 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 115.08 -141.69 17.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 70.13 112.522 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -152.89 148.4 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.807 0.337 . . . . 72.24 110.938 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -165.15 162.97 13.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 73.04 110.913 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 158.58 56.53 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.686 2.257 . . . . 74.44 112.374 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -131.88 67.02 79.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.704 0.764 . . . . 64.51 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 119.56 6.49 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 73.34 112.336 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 1.5 mm -131.27 124.13 54.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 74.13 111.106 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.6 tt0 -131.24 116.38 17.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 74.55 110.891 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 5.7 t -130.1 80.6 70.59 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.63 0.729 . . . . 71.25 111.12 179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 121.12 7.82 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.746 2.298 . . . . 74.5 112.331 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.12 155.57 39.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 75.35 110.929 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.52 -6.53 76.81 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.754 -0.736 . . . . 74.0 112.481 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.82 155.34 49.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 73.3 111.094 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -64.84 143.42 57.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 75.4 110.897 -179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 8.6 mm -131.65 124.53 54.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 71.11 111.124 179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 46.8 t -111.22 93.48 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 75.32 111.146 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -71.82 137.06 47.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 74.14 110.858 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -132.28 99.52 4.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 75.21 110.907 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.6 mp -98.03 153.53 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 72.54 111.147 179.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.2 t -171.77 137.77 1.03 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 73.2 111.165 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -142.44 162.21 45.97 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.708 0.766 . . . . 73.14 110.843 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -52.01 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 65.41 112.322 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -155.91 36.67 0.35 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 73.51 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -140.17 -179.24 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 72.12 111.139 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.1 mt -144.91 156.68 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.201 -0.454 . . . . 74.21 111.183 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 35.6 p-80 -168.52 98.17 0.41 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 73.33 110.835 179.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -95.02 135.72 12.56 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 73.13 112.504 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -99.05 142.1 30.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.876 0.369 . . . . 73.14 110.872 -179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.9 p80 -125.24 142.69 51.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 74.33 110.897 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.2 t -131.83 147.56 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 75.42 111.134 179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -71.49 -175.44 1.3 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 74.43 110.867 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.12 -51.45 4.58 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 75.22 112.49 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.6 m -135.52 151.35 50.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.782 0.325 . . . . 73.23 111.153 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.5 m-80 -74.13 70.13 1.56 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 71.34 110.871 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 14.1 tt -87.77 104.37 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 72.44 111.099 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -115.83 103.85 11.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 73.11 110.893 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -114.32 120.62 64.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 70.12 111.113 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.32 121.09 17.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 70.34 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.7 p -139.36 147.64 24.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 75.33 111.142 179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.473 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -90.58 163.92 28.63 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.594 0.712 . . . . 73.05 110.911 179.927 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.473 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.5 Cg_endo -69.77 147.77 63.56 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.682 2.254 . . . . 72.03 112.317 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.01 9.18 58.51 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.754 -0.736 . . . . 73.23 112.492 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -146.34 173.68 12.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.869 0.366 . . . . 73.33 110.876 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 17.5 t -129.37 119.49 48.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 72.31 111.117 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -103.75 133.66 48.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 63.03 110.822 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 60.7 m -103.13 131.87 49.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 71.52 111.12 -179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 19.0 t -125.26 127.6 72.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 74.01 111.114 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -107.78 92.6 4.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 73.41 110.858 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -140.77 133.43 28.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.157 -0.474 . . . . 75.04 110.902 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.7 t -123.16 140.19 53.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 71.23 111.159 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -96.3 -174.82 3.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 75.04 110.861 -179.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -125.89 -29.02 3.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 73.34 110.928 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.35 155.59 81.28 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.597 0.713 . . . . 73.45 110.897 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 170.56 16.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.647 2.231 . . . . 70.45 112.351 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 154.99 133.32 1.71 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 70.0 112.479 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.13 125.54 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 65.51 110.903 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.75 146.61 33.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 75.35 110.94 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.23 97.89 1.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.15 110.838 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.4 tt -175.51 151.96 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.151 -0.477 . . . . 74.53 111.118 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -114.43 141.47 30.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 74.43 111.189 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 24.9 t -179.07 -74.36 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 74.31 110.907 179.937 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 45.2 m-20 -62.52 94.7 0.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.461 . . . . 75.53 110.886 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -170.2 -173.58 1.53 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 74.52 110.914 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 6.2 t80 -119.56 68.88 0.82 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.454 . . . . 72.32 110.918 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -151.98 -49.19 0.11 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 74.33 110.897 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 127.57 104.03 1.25 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.746 -0.74 . . . . 71.33 112.467 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 21.1 tp -51.36 149.09 4.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.835 0.35 . . . . 74.23 110.885 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 90.5 -157.8 25.9 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.696 -0.764 . . . . 73.14 112.489 179.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 58.36 -165.71 0.17 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.773 0.321 . . . . 75.13 110.859 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -51.44 -26.95 8.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 74.23 110.943 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -53.63 101.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.47 . . . . 61.43 110.883 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -76.16 177.03 7.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 75.32 110.884 179.903 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -89.71 120.21 30.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.245 -0.434 . . . . 75.24 110.872 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -72.28 -175.93 26.98 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 64.23 112.472 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 4.8 t -154.88 146.82 23.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.763 0.316 . . . . 72.21 111.168 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 2.1 mp -153.9 137.63 8.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 74.21 111.121 179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 26.9 t -126.14 122.58 61.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 74.23 111.149 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 44.3 t -101.52 112.1 33.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 75.24 111.119 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 17.8 mmmt -84.45 135.26 34.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 72.24 110.897 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 74.43 110.945 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.804 0.335 . . . . 74.43 110.859 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.1 m -111.28 139.01 37.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 55.53 111.163 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -150.46 77.93 7.89 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.639 0.733 . . . . 71.53 111.124 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -177.51 1.91 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.692 2.262 . . . . 62.43 112.33 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -145.0 -70.77 0.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.475 . . . . 73.25 111.108 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -101.14 17.55 55.78 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.766 -0.731 . . . . 60.34 112.446 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 13.1 mmmt -115.08 178.93 4.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.831 0.348 . . . . 74.43 110.88 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -63.77 -174.06 0.09 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.22 -0.446 . . . . 63.54 110.948 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -78.53 129.37 34.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.438 . . . . 72.14 110.885 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.54 168.46 10.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 75.34 110.851 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 1.4 t -141.54 166.71 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 74.13 111.098 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 55.9 p-10 -161.12 153.45 16.97 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.594 0.711 . . . . 74.35 110.843 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -4.34 13.85 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.684 2.256 . . . . 71.1 112.326 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 40.6 m -44.44 -72.23 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 72.12 111.094 -179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 6.7 p -156.62 33.08 0.31 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 72.22 111.144 -179.947 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.9 p -78.58 -19.92 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 74.04 111.105 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -100.68 -9.38 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 70.12 110.896 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -103.53 -32.87 9.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 63.14 110.881 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -140.16 125.98 19.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 73.54 110.861 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 132.26 -155.99 21.78 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.741 . . . . 74.01 112.515 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -37.83 8.65 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.723 2.282 . . . . 71.52 112.349 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 7.8 m-90 -84.51 -12.57 53.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.211 -0.449 . . . . 72.11 110.917 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.79 -59.54 4.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 75.31 111.087 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.21 142.84 25.37 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 51.3 110.88 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 -22.83 31.81 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.644 2.229 . . . . 64.52 112.376 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.51 -17.56 61.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 75.25 111.097 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 3.5 mm100 -89.35 10.13 23.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 75.24 110.929 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.26 -77.53 0.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 55.52 111.083 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.1 t -84.38 122.06 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 73.02 111.165 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.8 131.62 53.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.451 . . . . 64.2 111.106 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -71.31 118.28 13.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 74.31 110.899 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.0 t -119.38 -41.49 2.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 74.44 111.175 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.34 171.2 13.72 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.765 -0.731 . . . . 70.11 112.487 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -10.21 28.02 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.685 2.257 . . . . 73.04 112.358 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -157.69 34.81 0.26 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.283 -0.417 . . . . 73.54 110.883 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -151.29 160.04 44.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 74.5 110.896 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.7 m-85 -143.31 146.64 33.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.252 -0.431 . . . . 75.43 110.941 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 99.5 m -97.23 121.99 39.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.119 -0.491 . . . . 74.11 111.165 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 17.9 t -100.37 134.58 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 74.03 111.137 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -120.65 100.51 7.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 73.3 110.932 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 32.8 m -98.78 128.53 50.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 74.1 111.129 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -120.74 138.23 54.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 71.24 110.928 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.22 137.04 14.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 73.12 111.049 179.831 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 2.9 p90 -145.29 150.06 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 73.31 110.918 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.41 18.69 4.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 72.43 111.118 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -84.34 -61.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 74.33 110.868 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -127.44 -122.43 2.52 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.786 -0.721 . . . . 75.23 112.488 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -143.91 145.02 31.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.869 0.366 . . . . 74.33 110.904 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . 0.422 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.0 pm0 -154.37 156.09 31.4 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.56 0.695 . . . . 74.53 110.892 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.2 Cg_endo -69.79 177.38 5.65 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.632 2.222 . . . . 75.23 112.343 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 8.5 m-20 -131.23 62.3 64.39 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.592 0.71 . . . . 65.03 110.905 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 70.77 1.56 Allowed 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.661 2.241 . . . . 75.13 112.377 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 4.3 mp -105.88 128.29 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 75.11 111.151 179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -126.3 135.11 51.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.468 . . . . 74.31 110.878 179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 2.5 p -140.12 81.95 17.79 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.657 0.741 . . . . 74.4 111.08 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 123.55 10.22 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.715 2.277 . . . . 72.14 112.328 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -66.87 152.37 45.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 71.44 110.951 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.42 -36.51 3.7 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 75.31 112.49 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -106.22 150.12 26.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.749 0.309 . . . . 61.14 111.129 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -66.42 142.07 57.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 74.33 110.901 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 5.8 mm -126.25 119.43 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 74.23 111.116 -179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 64.3 t -98.33 92.08 2.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 74.1 111.118 179.834 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -70.9 136.59 48.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.906 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 8.7 mttt -132.09 98.64 4.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 75.14 110.908 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.6 mp -103.17 137.5 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 71.23 111.11 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 4.2 t -155.73 135.89 12.99 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 75.43 111.123 179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.418 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -135.87 161.19 64.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.633 0.73 . . . . 75.31 110.859 -179.863 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.8 Cg_endo -69.68 -53.95 0.25 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.675 2.25 . . . . 72.11 112.361 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -156.83 56.15 0.54 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 74.54 110.866 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.01 136.23 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 72.33 111.152 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.4 mm -64.33 149.14 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.164 -0.471 . . . . 75.11 111.115 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -133.11 -178.5 4.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 65.54 110.886 179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 135.37 139.69 4.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 42.15 112.485 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -130.57 144.68 51.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.894 0.378 . . . . 73.2 110.837 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 8.0 t-80 -101.06 142.13 32.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.106 -0.497 . . . . 72.3 110.863 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 58.2 t -131.84 138.13 53.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 74.54 111.118 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -75.51 179.45 5.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 73.24 110.862 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.14 -52.03 4.57 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.781 -0.723 . . . . 74.13 112.48 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.62 179.7 4.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.82 0.343 . . . . 75.03 111.123 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -105.77 65.5 0.71 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 73.53 110.893 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 7.5 tt -72.47 121.68 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 73.51 111.159 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.07 90.47 3.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 110.827 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 5.1 m -115.05 118.41 58.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 72.51 111.126 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -166.72 104.73 0.59 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.145 -0.48 . . . . 71.15 110.878 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 2.4 m -140.64 146.61 23.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 72.54 111.109 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.408 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -57.8 159.78 9.36 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.559 0.695 . . . . 74.51 110.915 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . 0.408 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 53.9 Cg_endo -69.74 159.67 52.55 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.71 2.274 . . . . 73.32 112.343 179.864 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 90.82 4.51 69.53 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.695 -0.764 . . . . 42.12 112.463 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -147.19 117.81 7.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.872 0.368 . . . . 73.53 110.928 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 1.8 p -74.49 130.04 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 73.51 111.134 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -102.17 112.26 24.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 75.25 110.816 -179.812 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.7 m -90.12 115.72 27.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 74.12 111.117 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 8.6 p -128.75 152.22 36.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 72.2 111.117 179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.82 103.02 11.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 70.52 110.901 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.0 t80 -134.28 114.95 13.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 75.14 110.92 -179.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.0 t -129.09 134.85 48.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.117 -0.492 . . . . 65.44 111.109 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -90.85 -176.73 4.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 73.35 110.849 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -121.25 -13.04 8.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 75.02 110.947 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.73 162.74 49.28 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.634 0.731 . . . . 74.53 110.87 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 150.05 67.45 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.686 2.257 . . . . 75.32 112.318 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.73 157.47 10.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.727 -0.749 . . . . 54.44 112.49 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.8 pm0 -120.26 125.17 47.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.872 0.368 . . . . 73.24 110.855 -179.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -133.01 146.64 51.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.483 . . . . 72.24 110.885 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . 0.413 ' O ' ' HB ' ' A' ' 105' ' ' ILE . 0.4 OUTLIER -174.3 -162.11 0.13 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 74.32 110.83 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.413 ' HB ' ' O ' ' A' ' 104' ' ' ARG . 21.2 mm 75.28 117.79 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 74.53 111.161 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.447 ' O ' ' CB ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -85.2 -175.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 71.53 111.144 179.849 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . 0.447 ' CB ' ' O ' ' A' ' 106' ' ' ILE . 2.9 t 79.8 42.97 0.06 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.185 -0.462 . . . . 71.12 110.871 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . 0.48 ' O ' ' N ' ' A' ' 110' ' ' TYR . 8.2 m-20 -154.16 -81.38 0.09 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 70.13 110.928 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 17.9 mp0 50.49 -87.76 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 72.31 110.912 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . 0.48 ' N ' ' O ' ' A' ' 108' ' ' ASN . 87.2 t80 -134.96 -39.1 0.78 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 74.53 110.938 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.2 m -114.83 -33.8 5.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.105 -0.498 . . . . 64.1 110.843 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 103.88 122.8 5.15 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.746 -0.74 . . . . 52.1 112.519 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -131.54 -78.76 0.52 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.852 0.358 . . . . 71.5 110.932 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 44.88 -153.17 0.55 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.722 -0.751 . . . . 65.44 112.47 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 15.1 t-160 53.66 67.57 0.98 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.745 0.307 . . . . 74.43 110.9 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -179.47 -79.04 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.456 . . . . 75.13 110.887 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 10.4 p-10 -95.78 179.77 4.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 74.25 110.912 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.88 175.41 7.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 73.33 110.86 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -90.56 133.48 35.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.245 -0.434 . . . . 74.42 110.868 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -73.15 -173.78 26.09 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 61.12 112.457 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 53.6 m -156.41 126.04 6.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.751 0.31 . . . . 74.53 111.166 -179.819 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 5.3 mp -145.35 117.24 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 64.25 111.144 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 10.6 p -121.65 141.49 41.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 75.03 111.094 179.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 87.0 t -101.5 136.59 32.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 74.0 111.163 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -114.49 125.72 54.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 74.33 110.869 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 74.41 110.871 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.5 mmm . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.857 0.361 . . . . 72.51 110.884 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 17.3 m -68.62 136.63 26.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.21 -0.45 . . . . 73.31 111.095 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.8 pt -108.14 153.59 41.74 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.603 0.716 . . . . 74.25 111.149 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -176.26 1.43 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.731 2.288 . . . . 71.44 112.323 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -150.49 84.75 1.37 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 73.32 111.097 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.21 -101.31 1.84 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.695 -0.764 . . . . 73.32 112.51 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.35 158.41 19.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.787 0.327 . . . . 73.32 110.886 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 61.33 164.34 0.08 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.222 -0.445 . . . . 75.33 110.956 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 1.6 mm-40 -123.44 148.26 46.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 74.52 110.896 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.7 mpt_? -105.01 121.36 43.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 73.41 110.863 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 5.6 m -113.49 -179.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 75.42 111.17 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 162.63 38.29 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.571 0.7 . . . . 71.22 110.891 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -2.78 10.78 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.656 2.237 . . . . 72.34 112.36 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 29.1 m -44.75 -67.34 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.231 -0.441 . . . . 62.32 111.109 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 43.4 p -150.67 21.29 0.81 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 54.21 111.142 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.3 p -77.65 -16.88 14.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 71.33 111.157 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ARG . . . . . 0.434 ' NE ' ' HD3' ' A' ' 68' ' ' PRO . 0.0 OUTLIER -106.66 -25.0 11.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 72.31 110.876 -179.951 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -92.6 -24.24 18.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 74.11 110.92 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -143.58 147.32 34.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 71.23 110.928 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.01 -158.74 14.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.73 -0.748 . . . . 75.32 112.489 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -33.9 15.48 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.678 2.252 . . . . 71.53 112.332 -179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 11.8 m-90 -83.2 -12.87 56.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.256 -0.429 . . . . 74.54 110.898 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.44 -57.13 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.256 -0.429 . . . . 51.53 111.134 179.886 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.34 142.22 25.19 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.564 0.697 . . . . 75.24 110.927 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -6.73 19.3 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.708 2.272 . . . . 72.54 112.359 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.79 -12.87 61.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 64.25 111.109 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 17.6 mm-40 -99.0 14.4 29.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.443 . . . . 74.51 110.93 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.0 -14.84 61.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.463 . . . . 71.13 111.089 179.884 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 7.0 t -145.21 119.31 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 74.24 111.092 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . 0.418 ' CG1' ' HB ' ' A' ' 38' ' ' THR . 1.6 p -144.21 140.92 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 63.11 111.153 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.33 100.88 13.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 74.04 110.87 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.4 t -98.07 -34.46 10.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.232 -0.44 . . . . 75.32 111.147 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.71 -168.44 17.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 74.43 112.472 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -37.83 8.56 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.654 2.236 . . . . 54.2 112.334 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -148.27 34.68 0.8 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 73.45 110.864 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -135.41 119.87 18.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 65.32 110.893 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -95.87 140.89 29.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 73.5 110.983 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.525 ' HA ' HG22 ' A' ' 62' ' ' VAL . 22.3 m -94.81 107.82 19.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 70.42 111.141 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.1 t -89.25 130.0 39.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.224 -0.444 . . . . 75.41 111.137 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -116.03 113.15 22.81 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.909 -179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 31.2 m -111.35 125.1 68.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 71.24 111.117 179.906 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -121.92 126.28 48.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.122 -0.49 . . . . 74.32 110.907 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -144.54 144.96 31.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 70.03 111.115 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 12.2 p90 -136.65 152.74 50.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 73.15 110.908 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.77 12.2 13.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 72.4 111.063 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -120.48 66.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 74.11 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 123.31 -147.88 16.71 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.747 -0.739 . . . . 62.44 112.507 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -150.71 155.88 40.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 64.32 110.929 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -164.48 162.54 15.31 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.624 0.726 . . . . 70.12 110.916 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 140.09 41.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.696 2.264 . . . . 70.2 112.354 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -131.61 68.19 80.67 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.624 0.726 . . . . 75.54 110.879 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 72.75 1.42 Allowed 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.707 2.271 . . . . 71.3 112.363 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ILE . . . . . . . . . . . . . 2.6 mp -77.37 91.34 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 74.0 111.1 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -83.48 138.54 33.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.882 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 6.5 t -143.93 85.79 8.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.593 0.711 . . . . 70.2 111.101 -179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 122.95 9.62 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.669 2.246 . . . . 74.43 112.335 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.55 153.09 43.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 72.42 110.901 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.84 -35.83 3.85 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.72 -0.752 . . . . 60.33 112.51 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.86 155.09 19.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.747 0.308 . . . . 73.44 111.112 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -65.52 143.8 57.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 75.43 110.886 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ILE . . . . . . . . . . . . . 6.6 mm -128.73 118.69 47.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 70.4 111.142 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . 0.525 HG22 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -107.77 90.06 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 64.11 111.156 179.882 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -65.08 142.03 58.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 73.53 110.884 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -132.63 99.77 4.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 74.14 110.92 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ILE . . . . . 0.422 ' O ' ' HA ' ' A' ' 90' ' ' VAL . 1.3 mp -102.77 145.65 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 65.24 111.128 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.9 t -161.24 132.57 5.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 75.22 111.154 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' SER . . . . . 0.581 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -145.13 163.97 29.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.674 0.749 . . . . 74.13 110.905 -179.868 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' PRO . . . . . 0.581 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.1 Cg_endo -69.73 -56.36 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.701 2.268 . . . . 64.21 112.385 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -152.87 67.91 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 74.01 110.905 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.448 HG21 ' HB2' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.3 134.86 2.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 74.05 111.138 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.02 143.75 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 70.11 111.072 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.9 OUTLIER -108.75 -166.32 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.128 -0.487 . . . . 75.15 110.864 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.64 122.45 3.51 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.771 -0.728 . . . . 71.24 112.497 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -119.87 142.38 48.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.916 0.389 . . . . 64.44 110.898 -179.911 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -93.41 135.63 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.123 -0.489 . . . . 74.12 110.876 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 59.1 t -137.19 142.88 36.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 65.54 111.172 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -75.5 -176.31 3.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 64.14 110.871 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 87.47 -50.91 4.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.777 -0.725 . . . . 61.21 112.474 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -142.82 173.44 11.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 71.22 111.099 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 28.6 m120 -85.41 59.43 5.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 75.54 110.884 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 6.4 tp -56.69 116.87 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 54.53 111.101 179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.23 100.42 8.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 74.52 110.907 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 5.7 m -127.29 122.87 60.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 74.15 111.154 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -160.6 114.68 2.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 74.52 110.895 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 96.7 t -140.36 145.09 26.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 74.33 111.158 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.22 156.65 89.56 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.609 0.719 . . . . 74.31 110.907 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 160.71 48.7 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.728 2.285 . . . . 74.2 112.347 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 97.84 -0.13 59.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 71.23 112.469 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -146.15 156.7 43.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.889 0.376 . . . . 73.34 110.862 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.422 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 1.6 p -105.7 108.75 25.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 75.45 111.128 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.22 164.77 22.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.882 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 77.7 m -129.24 105.21 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 74.22 111.134 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . . . . . . . . . 24.6 t -101.79 130.81 50.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.239 -0.437 . . . . 63.31 111.14 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -110.44 92.45 4.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 73.41 110.851 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.2 t80 -143.01 114.08 7.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 74.43 110.927 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.7 t -113.87 142.9 45.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 73.51 111.143 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.08 179.98 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 74.42 110.842 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -121.08 -12.77 8.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.922 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.9 mpp_? -149.05 162.03 30.45 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.564 0.697 . . . . 73.31 110.913 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 153.63 68.67 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.731 2.287 . . . . 75.14 112.313 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 157.18 131.12 1.3 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.725 -0.75 . . . . 71.12 112.435 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -101.75 138.76 38.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.865 0.364 . . . . 72.44 110.865 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -143.87 140.6 29.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.135 -0.484 . . . . 74.42 110.921 -179.898 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 46.3 mtm180 -144.89 72.79 1.34 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 73.22 110.895 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 55.8 mt -151.05 144.27 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.226 -0.443 . . . . 74.32 111.124 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -133.87 142.17 42.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 73.51 111.145 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 34.7 t -177.78 113.89 0.08 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 74.14 110.89 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 56.96 94.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 74.23 110.922 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -92.81 42.92 1.11 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 73.32 110.945 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 41.3 t80 70.05 -71.83 0.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 71.22 110.918 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 8.5 p -52.92 -39.49 62.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 75.4 110.889 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 138.73 103.11 0.58 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.724 -0.75 . . . . 74.4 112.474 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 1.4 tt -51.7 140.69 18.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.872 0.368 . . . . 73.34 110.962 -179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -131.72 -162.55 10.51 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.753 . . . . 61.54 112.447 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 62.0 m170 -96.25 164.59 12.6 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.735 0.303 . . . . 74.35 110.883 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 60.5 mm-40 63.67 16.24 9.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 74.21 110.936 -179.895 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -94.9 130.99 41.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 72.51 110.891 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -71.32 175.4 5.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 74.14 110.911 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 30.9 m-85 -90.5 167.39 12.62 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.432 . . . . 74.31 110.886 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -79.45 53.6 4.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.768 -0.73 . . . . 74.12 112.494 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 86.5 m -75.0 112.45 11.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.784 0.326 . . . . 71.11 111.155 -179.851 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ILE . . . . . . . . . . . . . 1.4 mp -153.34 136.51 7.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 72.43 111.102 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 1.9 p -117.78 126.56 74.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 73.15 111.133 179.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 61.9 t -101.14 117.68 46.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 74.04 111.109 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.0 mmmt -93.59 137.54 32.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 72.54 110.907 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 72.11 110.924 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.428 ' O ' HG12 ' A' ' 90' ' ' VAL . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.869 0.366 . . . . 63.33 110.89 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.94 131.47 44.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 74.23 110.825 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.4 m -120.91 -177.18 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 73.42 111.124 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.43 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 25.1 p30 -143.42 156.7 60.43 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 74.04 110.874 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.43 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.9 Cg_endo -69.79 -3.08 11.3 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.655 2.237 . . . . 73.23 112.358 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.696 HG22 HG23 ' A' ' 15' ' ' THR . 12.4 m -46.76 -68.3 0.2 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.205 -0.452 . . . . 61.41 111.124 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.696 HG23 HG22 ' A' ' 14' ' ' THR . 24.4 p -150.02 26.07 0.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.451 . . . . 75.51 111.133 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.4 p -65.39 -29.1 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.26 -0.427 . . . . 75.23 111.102 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.9 ptt180 -102.53 -7.91 21.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 74.11 110.884 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.3 mt-30 -96.81 -37.67 10.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 63.55 110.914 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.84 133.68 41.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 71.32 110.877 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.11 -156.91 18.39 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.753 -0.737 . . . . 74.12 112.494 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -30.79 21.72 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.741 2.294 . . . . 62.34 112.333 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.788 ' HB3' HD13 ' A' ' 42' ' ' LEU . 13.5 m-90 -85.95 -12.53 50.24 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 61.22 110.922 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.62 -58.98 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 64.41 111.095 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.89 146.5 34.24 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.593 0.711 . . . . 75.12 110.867 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -14.17 35.62 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.664 2.243 . . . . 71.55 112.349 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.13 -24.43 59.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 73.02 111.056 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 mm-40 -86.34 5.01 36.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 64.44 110.87 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.39 -76.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.43 111.085 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 12.3 t -89.71 115.6 29.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 71.21 111.144 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.34 119.02 4.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 75.41 111.138 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -68.06 123.37 20.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 70.54 110.876 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.4 p -120.18 -11.55 9.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 74.55 111.111 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.9 -169.33 12.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 75.4 112.517 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.65 18.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.682 2.255 . . . . 75.23 112.395 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.5 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 55.2 t30 -155.69 28.61 0.38 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 74.23 110.884 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -126.99 119.42 26.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.494 . . . . 73.31 110.9 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -96.32 140.23 31.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 74.21 110.961 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.683 ' HA ' HG23 ' A' ' 62' ' ' VAL . 85.9 m -93.76 115.02 27.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 70.33 111.173 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.3 t -102.24 139.06 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 63.02 111.124 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -120.49 140.85 50.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 61.54 110.924 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.509 HG22 ' CG1' ' A' ' 53' ' ' ILE . 99.1 t -138.3 136.06 44.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.486 . . . . 73.54 111.106 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.788 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -137.91 140.71 40.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 74.22 110.95 179.92 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.27 102.97 2.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 71.54 111.083 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 3.3 p90 -112.01 156.71 21.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 72.24 110.894 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.13 7.79 23.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.137 -0.483 . . . . 55.25 111.092 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -103.17 82.9 2.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 74.12 110.929 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 100.28 -135.04 11.93 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.739 . . . . 52.23 112.498 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -154.61 150.22 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.799 0.333 . . . . 73.41 110.954 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 2.9 pm0 -154.07 155.02 30.71 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.648 0.737 . . . . 53.32 110.874 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.81 4.2 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.676 2.25 . . . . 75.3 112.382 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.742 ' O ' HD12 ' A' ' 53' ' ' ILE . 2.1 m120 -134.99 62.88 55.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.577 0.703 . . . . 73.34 110.873 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 76.58 1.14 Allowed 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.661 2.241 . . . . 64.34 112.351 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.742 HD12 ' O ' ' A' ' 51' ' ' ASN . 3.9 mp -106.56 143.06 18.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 75.31 111.145 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -138.91 158.51 44.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 72.23 110.88 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.8 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -164.09 84.47 1.26 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.639 0.733 . . . . 52.21 111.143 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.676 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.72 121.93 8.62 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.675 2.25 . . . . 60.02 112.334 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -66.76 152.24 45.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.434 . . . . 72.0 110.9 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.0 -35.87 3.93 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.708 -0.758 . . . . 52.31 112.478 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.5 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -105.86 157.58 17.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.751 0.31 . . . . 74.12 111.114 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.715 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.3 mp0 -66.8 144.78 56.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 71.35 110.859 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.763 HG13 HG23 ' A' ' 55' ' ' VAL . 5.7 mm -130.56 124.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 62.33 111.195 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.683 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -113.73 90.24 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 73.31 111.133 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.59 ' HB2' HG12 ' A' ' 93' ' ' VAL . 64.1 m-85 -67.88 138.8 56.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 65.13 110.859 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.4 mttt -132.75 100.25 4.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 74.42 110.887 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.57 HD11 ' CE2' ' A' ' 74' ' ' PHE . 2.3 mp -106.87 141.63 21.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 71.25 111.151 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.2 t -154.67 138.02 15.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.183 -0.462 . . . . 73.13 111.14 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.411 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -142.8 159.58 56.36 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 74.03 110.854 -179.84 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.411 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.7 -51.68 0.38 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.678 2.252 . . . . 74.13 112.361 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -156.95 49.41 0.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 50.54 110.892 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.41 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.13 136.27 5.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 62.43 111.158 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 71.4 mt -86.21 142.53 12.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.186 -0.461 . . . . 71.11 111.115 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 43.3 t-80 -118.3 -80.99 0.62 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.865 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 57.29 171.46 0.19 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.73 -0.748 . . . . 65.1 112.502 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.57 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.8 p90 -160.45 141.89 12.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.354 . . . . 63.0 110.927 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 7.1 t-80 -116.18 101.78 9.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 61.24 110.851 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.727 HG12 HG21 ' A' ' 81' ' ' ILE . 5.0 p -96.28 143.78 11.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 61.24 111.104 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -66.34 -172.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 72.11 110.938 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.89 -46.52 3.3 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.778 -0.725 . . . . 61.2 112.457 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.419 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.8 OUTLIER -146.7 165.68 28.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.751 0.31 . . . . 74.42 111.149 -179.82 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.419 ' H ' HG22 ' A' ' 79' ' ' THR . 3.8 m120 -79.48 58.36 2.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 75.12 110.947 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.727 HG21 HG12 ' A' ' 76' ' ' VAL . 12.9 tt -66.35 115.09 3.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 63.41 111.118 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.7 91.05 3.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.01 110.863 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.43 ' CG1' HG21 ' A' ' 93' ' ' VAL . 7.0 m -118.11 120.48 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 75.44 111.103 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -160.9 117.34 2.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.02 110.924 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.498 HG21 ' OG ' ' A' ' 91' ' ' SER . 96.2 t -140.35 127.73 23.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 75.03 111.134 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.419 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -51.07 160.06 0.91 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.601 0.715 . . . . 63.42 110.921 179.972 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.419 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 54.0 Cg_endo -69.73 155.47 65.96 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.724 2.283 . . . . 71.41 112.353 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.65 10.7 46.33 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.797 -0.716 . . . . 64.35 112.513 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -164.69 119.2 1.37 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.871 0.367 . . . . 74.34 110.867 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.428 HG12 ' O ' ' A' ' 9' ' ' GLU . 2.9 p -68.69 133.73 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 63.25 111.141 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.498 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -94.39 168.9 10.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 54.25 110.876 -179.87 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 90.5 m -144.4 105.46 4.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 71.24 111.119 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.59 HG12 ' HB2' ' A' ' 63' ' ' PHE . 9.0 p -118.58 141.21 39.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 62.51 111.125 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -110.6 101.55 10.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 71.31 110.879 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -145.97 119.26 8.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.228 -0.442 . . . . 64.42 110.905 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.5 t -117.28 142.97 46.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.489 . . . . 71.13 111.181 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.0 -175.93 4.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 63.11 110.915 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 20.5 mtpt -126.21 -12.45 6.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.16 -0.473 . . . . 74.12 110.917 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -148.19 162.22 31.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.601 0.715 . . . . 75.5 110.908 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 156.9 62.23 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.69 2.26 . . . . 73.21 112.344 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.2 133.64 1.51 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.743 -0.742 . . . . 60.44 112.523 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -99.4 128.49 45.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 74.33 110.897 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -144.13 131.08 20.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 74.31 110.889 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 7.1 ptt180 -147.94 83.41 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 74.15 110.858 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.0 mt -151.01 145.03 16.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 73.14 111.155 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 71.41 111.131 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.568 ' HB ' HD13 ' A' ' 53' ' ' ILE . 43.1 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.814 0.34 . . . . 74.32 111.146 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.596 HG13 HG21 ' A' ' 53' ' ' ILE . 4.3 mp -144.92 141.55 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 75.34 111.123 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.493 ' O ' HG12 ' A' ' 55' ' ' VAL . 85.1 t -131.29 133.95 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 72.4 111.135 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.8 HG22 HG13 ' A' ' 55' ' ' VAL . 97.4 t -103.9 134.93 43.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 54.41 111.093 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -117.87 130.66 56.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 65.33 110.846 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 73.41 110.856 179.973 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.851 0.358 . . . . 73.43 110.883 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -89.46 166.76 13.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 70.53 110.885 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 m -144.5 -179.31 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.459 . . . . 71.3 111.146 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -145.76 161.66 39.42 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.628 0.728 . . . . 65.0 110.904 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -4.47 14.09 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.687 2.258 . . . . 70.51 112.355 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.796 HG22 HG23 ' A' ' 15' ' ' THR . 33.9 m -48.47 -70.78 0.08 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 62.33 111.178 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.796 HG23 HG22 ' A' ' 14' ' ' THR . 30.5 p -150.92 35.26 0.6 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 72.03 111.17 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 14.0 p -69.56 -31.59 49.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 61.53 111.086 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.407 ' HB3' HD21 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -93.14 -5.09 51.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 75.52 110.889 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -104.53 -35.7 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 73.4 110.9 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -129.0 134.16 48.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 63.23 110.861 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.73 -160.3 13.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 64.21 112.5 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -26.27 27.71 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.746 2.297 . . . . 73.1 112.342 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 16.1 m-90 -87.17 -9.86 54.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.192 -0.458 . . . . 61.24 110.928 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.77 -59.46 2.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 54.15 111.134 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.62 144.38 28.5 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.605 0.717 . . . . 71.43 110.875 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -19.17 36.78 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.695 2.263 . . . . 72.3 112.39 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.75 -20.28 60.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 74.23 111.117 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mm-40 -87.28 6.82 31.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 73.32 110.868 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.43 -76.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 70.01 111.112 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.404 HG21 ' HB3' ' A' ' 54' ' ' GLU . 20.1 t -84.53 118.35 31.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 72.02 111.123 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.445 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 11.0 m -132.94 138.75 51.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 75.25 111.151 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.14 95.96 9.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 73.22 110.892 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.3 t -95.71 -35.82 11.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 65.31 111.163 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.79 -166.54 21.63 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.75 . . . . 62.13 112.507 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -44.93 1.77 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.677 2.251 . . . . 65.42 112.315 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -143.37 30.24 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 74.31 110.867 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -126.95 120.05 28.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 74.42 110.933 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -96.34 135.73 37.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 72.35 110.924 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.445 ' HB ' ' CG2' ' A' ' 30' ' ' VAL . 49.8 m -96.01 105.0 16.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.093 -0.503 . . . . 54.12 111.111 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -84.65 147.23 5.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 73.1 111.141 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -127.16 121.85 32.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 73.54 110.928 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.499 HG22 ' CG1' ' A' ' 53' ' ' ILE . 97.6 t -114.33 124.97 71.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 73.23 111.191 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.667 HD12 ' OE1' ' A' ' 49' ' ' GLN . 3.3 tm? -120.36 136.5 54.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 64.53 110.868 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.507 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -155.61 140.55 17.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 52.44 111.122 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -139.99 159.0 43.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 64.55 110.923 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.71 5.57 35.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 53.55 111.111 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -122.31 84.88 2.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 72.13 110.853 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.87 179.14 19.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.743 -0.742 . . . . 72.02 112.492 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -124.65 139.48 53.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.806 0.336 . . . . 63.2 110.922 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.667 ' OE1' HD12 ' A' ' 42' ' ' LEU . 5.4 mt-30 -142.17 162.09 47.24 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 73.2 110.875 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 179.9 3.37 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.675 2.25 . . . . 64.43 112.317 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.659 ' O ' HD12 ' A' ' 53' ' ' ILE . 4.6 m-80 -135.98 63.0 49.37 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.629 0.728 . . . . 63.33 110.909 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 73.77 1.32 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.643 2.229 . . . . 72.13 112.368 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.659 HD12 ' O ' ' A' ' 51' ' ' ASN . 4.5 mp -110.57 113.91 45.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.246 -0.434 . . . . 72.44 111.179 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.404 ' HB3' HG21 ' A' ' 29' ' ' VAL . 12.3 tt0 -110.07 135.43 50.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 74.41 110.908 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.857 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -138.9 81.76 21.58 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.665 0.745 . . . . 72.13 111.132 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.626 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.2 Cg_endo -69.71 129.01 16.9 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.731 2.287 . . . . 73.33 112.356 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.449 HE22 ' HA ' ' A' ' 126' ' ' GLU . 1.7 pm0 -73.44 152.2 40.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 71.12 110.897 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.61 -35.61 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.758 -0.734 . . . . 52.51 112.474 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.0 155.93 18.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 71.44 111.127 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.696 ' O ' HD13 ' A' ' 61' ' ' ILE . 40.4 mt-10 -67.18 144.51 55.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 75.03 110.896 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.696 HD13 ' O ' ' A' ' 60' ' ' GLU . 6.4 mm -128.83 119.61 50.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.455 . . . . 73.35 111.137 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.822 HG13 HG23 ' A' ' 92' ' ' THR . 55.1 t -107.55 91.22 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 74.42 111.143 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.571 ' HB2' HG12 ' A' ' 93' ' ' VAL . 65.3 m-85 -70.37 137.25 50.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 61.12 110.864 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -129.55 100.88 5.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 74.21 110.839 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.732 ' CG2' HG11 ' A' ' 85' ' ' VAL . 1.8 mp -100.31 155.29 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 73.53 111.11 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.4 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.3 t -169.99 139.21 1.83 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.166 -0.47 . . . . 72.02 111.148 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.4 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -143.46 161.78 45.43 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.688 0.756 . . . . 73.4 110.857 -179.86 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.4 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.72 -54.09 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.69 2.26 . . . . 70.22 112.392 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -159.16 38.3 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 71.3 110.878 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -138.73 135.16 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 72.42 111.114 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.514 HD13 ' HD3' ' A' ' 87' ' ' PRO . 28.7 mm -88.02 142.89 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 73.33 111.133 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 6.0 p80 -174.85 136.9 0.42 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 73.01 110.859 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -143.76 -149.62 5.12 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 62.34 112.494 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.468 ' CE2' HD11 ' A' ' 65' ' ' ILE . 7.9 p90 -159.29 138.19 11.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.923 0.392 . . . . 51.12 110.925 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 41.6 t60 -128.34 98.83 5.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 71.34 110.858 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.704 HG12 HG21 ' A' ' 81' ' ' ILE . 6.6 p -80.58 144.61 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 63.14 111.111 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.3 pm0 -67.77 -175.44 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 62.12 110.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.54 -51.1 4.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.715 -0.755 . . . . 74.13 112.474 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.7 m -131.46 153.34 49.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.321 . . . . 62.41 111.174 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -76.0 66.08 2.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 71.14 110.89 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.704 HG21 HG12 ' A' ' 76' ' ' VAL . 12.5 tt -77.57 113.11 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 70.32 111.09 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.03 98.35 6.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 52.01 110.885 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.9 m -121.25 120.31 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.158 -0.474 . . . . 72.22 111.15 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -125.09 96.02 4.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 62.54 110.885 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.732 HG11 ' CG2' ' A' ' 65' ' ' ILE . 5.8 p -86.83 144.37 9.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 63.01 111.072 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 6.1 mp -111.05 156.62 40.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.6 0.714 . . . . 72.31 110.935 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.514 ' HD3' HD13 ' A' ' 71' ' ' ILE . 54.1 Cg_endo -69.71 146.96 62.13 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.254 . . . . 74.42 112.365 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.22 8.96 86.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.734 -0.746 . . . . 20.31 112.467 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -146.69 173.61 12.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.918 0.39 . . . . 71.41 110.893 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 18.5 t -120.92 146.21 26.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 70.23 111.155 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.416 ' OG ' HD12 ' A' ' 65' ' ' ILE . 1.5 p -109.84 158.51 18.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 72.34 110.87 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.822 HG23 HG13 ' A' ' 62' ' ' VAL . 53.2 m -145.87 105.46 3.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.474 . . . . 63.33 111.128 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.571 HG12 ' HB2' ' A' ' 63' ' ' PHE . 7.6 p -123.11 136.23 60.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 71.14 111.143 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.2 mtm180 -105.86 92.47 4.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 74.12 110.827 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -134.66 115.17 13.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.452 . . . . 73.2 110.939 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 t -116.19 142.93 46.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 73.11 111.149 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.95 178.85 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 71.35 110.863 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.34 -21.94 7.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.118 -0.492 . . . . 72.55 110.912 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.97 158.3 74.15 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.592 0.71 . . . . 73.12 110.887 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 149.44 66.86 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.678 2.252 . . . . 74.2 112.363 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.87 156.67 9.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.752 . . . . 54.52 112.457 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.616 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -114.54 132.2 56.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.847 0.356 . . . . 63.24 110.868 -179.874 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -143.62 146.41 33.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.158 -0.473 . . . . 55.41 110.923 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.949 ' O ' HG22 ' A' ' 105' ' ' ILE . 13.9 ptt-85 -164.9 -164.58 0.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 74.32 110.863 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.949 HG22 ' O ' ' A' ' 104' ' ' ARG . 7.3 tt 58.2 158.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 61.32 111.118 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 61.14 111.16 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.644 ' O ' HD13 ' A' ' 53' ' ' ILE . 96.2 m . . . . . 0 C--O 1.232 0.165 0 CA-C-O 120.791 0.329 . . . . 75.13 111.166 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.511 HG13 HG21 ' A' ' 53' ' ' ILE . 2.5 mp -140.25 132.92 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 65.14 111.069 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.616 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -134.3 141.13 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 73.0 111.093 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.857 HG22 HG13 ' A' ' 55' ' ' VAL . 62.1 t -103.75 130.73 53.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 61.11 111.138 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -104.1 128.72 51.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 70.24 110.917 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.449 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 116.23 -0.441 . . . . 75.42 110.853 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.8 pm0 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.815 0.341 . . . . 75.33 110.892 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.43 142.67 28.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 62.45 110.848 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.568 HG13 HG23 ' A' ' 90' ' ' VAL . 16.4 m -118.46 -176.64 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.167 -0.469 . . . . 65.52 111.106 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.444 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 16.5 p30 -142.92 157.39 61.22 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.605 0.717 . . . . 54.52 110.887 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 54.0 Cg_endo -69.77 -3.06 11.25 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.646 2.23 . . . . 75.41 112.379 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.82 HG22 HG23 ' A' ' 15' ' ' THR . 25.2 m -46.58 -69.98 0.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.452 . . . . 75.51 111.165 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.82 HG23 HG22 ' A' ' 14' ' ' THR . 25.9 p -149.71 24.83 0.86 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 65.43 111.165 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.2 p -63.68 -30.97 51.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 74.31 111.133 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.487 ' NH1' HD21 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -103.28 -5.38 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 74.44 110.879 -179.973 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 83.7 mm-40 -92.24 -37.42 12.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 71.11 110.942 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -141.89 133.42 26.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 72.3 110.898 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 126.97 -155.09 19.62 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.7 -0.762 . . . . 72.34 112.502 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.95 17.5 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.683 2.256 . . . . 72.45 112.351 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.442 ' HB3' HD23 ' A' ' 42' ' ' LEU . 12.2 m-90 -84.61 -13.98 50.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 73.32 110.916 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.78 -49.18 75.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.082 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -114.07 144.39 31.51 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.608 0.718 . . . . 75.14 110.862 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 -25.7 28.06 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.662 2.242 . . . . 61.43 112.318 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.22 -6.75 49.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 74.15 111.098 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 7.0 mm100 -102.47 9.67 39.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 72.44 110.881 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.92 -79.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 62.22 111.146 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.572 HG23 ' HB3' ' A' ' 37' ' ' TYR . 1.5 p -84.98 124.34 39.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 53.21 111.12 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.5 m -135.29 136.01 51.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 63.25 111.124 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.57 107.2 7.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 52.05 110.893 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 9.7 t -111.94 -32.95 6.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.218 -0.446 . . . . 55.02 111.141 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.76 -172.68 19.86 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.756 -0.735 . . . . 34.11 112.504 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -43.8 2.45 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.687 2.258 . . . . 73.23 112.357 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -140.96 35.27 1.75 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 64.31 110.876 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -138.35 119.09 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 60.03 110.889 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.572 ' HB3' HG23 ' A' ' 29' ' ' VAL . 15.2 m-85 -96.79 137.34 36.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 71.42 110.95 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.741 ' HA ' HG23 ' A' ' 62' ' ' VAL . 81.2 m -95.74 105.71 17.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 73.45 111.147 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.463 ' HA ' ' HA ' ' A' ' 29' ' ' VAL . 9.9 t -92.66 138.52 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 64.13 111.12 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -120.75 114.82 22.2 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.191 -0.459 . . . . 72.32 110.951 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.485 HG22 HG13 ' A' ' 53' ' ' ILE . 64.4 t -104.14 130.79 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.14 -0.482 . . . . 73.15 111.102 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.487 HD21 ' NH1' ' A' ' 17' ' ' ARG . 1.7 tm? -125.07 121.52 34.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.47 . . . . 71.12 110.896 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -142.89 137.57 29.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.446 . . . . 62.43 111.088 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -145.52 159.94 42.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 74.04 110.858 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.82 5.55 32.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 54.33 111.108 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -110.26 70.59 0.73 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.45 110.831 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.07 -170.09 16.23 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.684 -0.77 . . . . 55.55 112.415 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.23 126.51 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.795 0.331 . . . . 72.41 110.929 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.46 ' HB3' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -136.42 161.0 64.62 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.567 0.699 . . . . 73.45 110.961 179.974 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.46 ' HD2' ' HB3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.76 178.68 4.32 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.707 2.271 . . . . 70.43 112.338 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.708 ' O ' HD12 ' A' ' 53' ' ' ILE . 1.1 m-80 -129.93 62.78 65.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.646 0.736 . . . . 64.5 110.905 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 75.56 1.23 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.657 2.238 . . . . 71.23 112.314 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.753 HD13 ' O ' ' A' ' 121' ' ' THR . 4.4 mp -106.89 98.18 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 64.11 111.133 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -82.14 129.6 34.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 61.41 110.889 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.69 ' O ' HG13 ' A' ' 124' ' ' VAL . 30.7 t -137.01 81.31 33.35 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.633 0.73 . . . . 75.1 111.118 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.596 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.8 123.05 9.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.702 2.268 . . . . 72.34 112.355 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.506 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.1 pm0 -69.29 155.18 40.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 71.45 110.933 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.36 -4.39 77.59 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.749 -0.739 . . . . 60.13 112.503 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.05 152.46 51.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.71 0.29 . . . . 75.1 111.129 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.68 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.0 mp0 -66.66 139.37 57.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.265 -0.425 . . . . 64.43 110.887 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.68 HD13 ' O ' ' A' ' 60' ' ' GLU . 7.2 mm -127.41 116.33 43.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.198 -0.456 . . . . 64.14 111.123 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -104.44 90.59 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 71.21 111.108 179.87 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -68.42 139.7 55.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 75.13 110.883 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -131.97 100.57 5.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 64.11 110.913 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.8 mp -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 73.32 111.122 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.1 t -168.44 140.49 2.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.135 -0.484 . . . . 72.4 111.137 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.451 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -149.52 161.14 32.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.705 0.764 . . . . 75.45 110.861 -179.883 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.424 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.78 -55.46 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 42.12 112.322 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -156.96 61.97 0.51 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 63.25 110.85 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.451 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.84 135.44 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 61.32 111.163 179.955 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 36.4 mm -69.81 130.5 34.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 64.11 111.128 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.66 ' HE2' HG23 ' A' ' 85' ' ' VAL . 9.2 p-80 -119.98 -175.79 3.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.236 -0.438 . . . . 51.22 110.885 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 170.9 12.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 33.22 112.502 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.5 p90 -153.23 141.25 20.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.845 0.355 . . . . 75.15 110.918 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 76.2 t60 -122.1 104.38 9.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 73.11 110.878 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.686 HG12 HG21 ' A' ' 81' ' ' ILE . 3.5 p -94.3 137.86 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 74.44 111.143 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -59.96 -175.98 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 61.41 110.904 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.13 -50.97 4.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 44.41 112.45 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.464 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -129.26 171.71 12.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.773 0.321 . . . . 73.22 111.111 -179.816 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.464 ' H ' HG22 ' A' ' 79' ' ' THR . 3.2 m-80 -93.17 47.61 1.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 73.44 110.852 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.686 HG21 HG12 ' A' ' 76' ' ' VAL . 12.5 tt -58.54 112.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 60.34 111.172 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.34 94.16 4.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 74.53 110.923 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.421 HG11 ' CG1' ' A' ' 93' ' ' VAL . 3.3 m -117.97 120.35 64.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 54.11 111.096 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -150.28 118.46 6.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 74.32 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.851 HG21 ' HB2' ' A' ' 91' ' ' SER . 5.0 m -140.73 146.88 23.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.155 -0.475 . . . . 73.32 111.14 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.27 161.94 75.5 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.554 0.692 . . . . 75.42 110.969 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 159.65 52.61 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.25 . . . . 72.11 112.309 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 86.4 13.28 68.36 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.749 -0.739 . . . . 74.42 112.493 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -146.21 138.43 25.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.903 0.383 . . . . 71.23 110.892 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.568 HG23 HG13 ' A' ' 11' ' ' VAL . 99.5 t -90.93 105.89 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 53.03 111.153 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.851 ' HB2' HG21 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -89.31 137.67 32.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 73.3 110.855 -179.839 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 92.9 m -110.01 105.51 14.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 74.23 111.172 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.421 ' CG1' HG11 ' A' ' 83' ' ' VAL . 44.7 t -98.19 147.95 6.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 71.54 111.104 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.61 110.93 15.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 70.21 110.882 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -156.68 122.64 4.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 72.05 110.887 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.8 t -123.39 135.55 54.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 64.43 111.152 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.79 -174.22 3.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 65.24 110.871 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -121.9 -26.4 4.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 72.11 110.915 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.1 mpp_? -134.51 161.41 63.89 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 70.04 110.88 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 154.22 67.89 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.652 2.235 . . . . 63.32 112.371 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.58 134.4 1.65 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.755 -0.736 . . . . 32.23 112.485 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.743 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -100.69 139.49 36.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 74.31 110.892 -179.883 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -143.82 132.82 22.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 74.24 110.915 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.36 94.07 2.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 61.13 110.86 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.8 tt -177.63 131.55 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 75.34 111.17 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 64.33 111.093 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.753 ' O ' HD13 ' A' ' 53' ' ' ILE . 6.7 m . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.826 0.346 . . . . 64.42 111.127 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.444 ' CG2' HG21 ' A' ' 55' ' ' VAL . 2.1 mp -149.14 139.12 16.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 74.34 111.177 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.743 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.5 p -127.5 135.92 61.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 64.32 111.182 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 55' ' ' VAL . 41.3 t -104.48 127.65 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 74.21 111.103 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 12.4 mmmm -102.22 133.6 46.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 70.21 110.872 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.506 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 75.21 110.919 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.822 0.344 . . . . 64.21 110.891 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 166.56 10.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 75.35 110.884 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.8 m -144.41 -179.09 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 71.35 111.074 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.68 162.04 40.66 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.603 0.716 . . . . 62.23 110.902 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -3.67 12.49 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.676 2.251 . . . . 65.45 112.331 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 28.0 m -46.09 -70.44 0.1 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.239 -0.437 . . . . 63.21 111.17 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 28.3 p -150.05 27.59 0.77 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 64.4 111.157 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.2 p -65.22 -30.77 51.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 73.22 111.13 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.428 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.7 OUTLIER -100.74 -15.74 17.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.148 -0.478 . . . . 63.33 110.863 -179.95 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -88.45 -33.04 17.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 61.04 110.898 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -141.35 135.12 30.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 73.03 110.913 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.44 -160.69 19.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.753 -0.737 . . . . 72.1 112.492 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -25.8 28.21 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.265 . . . . 53.24 112.343 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.733 ' HB3' HD13 ' A' ' 42' ' ' LEU . 14.5 m-90 -87.07 -12.6 46.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 75.32 110.95 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.86 -59.43 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.451 . . . . 73.43 111.093 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.42 144.55 28.45 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.556 0.693 . . . . 71.44 110.879 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -27.75 26.37 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.689 2.26 . . . . 75.41 112.359 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.41 -18.38 60.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 72.32 111.094 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 -87.82 7.64 29.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 70.14 110.939 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.14 -78.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 64.35 111.112 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 39' ' ' VAL . 1.8 p -93.1 124.93 45.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 74.23 111.113 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.2 m -119.67 149.86 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 64.43 111.108 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.65 121.99 27.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 72.21 110.963 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.462 HG21 ' OG1' ' A' ' 38' ' ' THR . 0.6 OUTLIER -121.91 -42.6 2.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 73.1 111.122 -179.881 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.47 170.65 13.81 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 61.5 112.488 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.695 2.264 . . . . 72.43 112.31 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -156.29 34.34 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 64.52 110.908 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -154.0 155.64 35.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.128 -0.487 . . . . 74.33 110.898 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -143.05 147.99 35.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 72.34 110.913 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.462 ' OG1' HG21 ' A' ' 32' ' ' THR . 52.0 m -101.37 104.22 15.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 72.53 111.127 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.573 HG11 HG23 ' A' ' 53' ' ' ILE . 6.7 t -85.18 135.13 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 72.44 111.137 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -117.12 121.66 41.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.18 -0.464 . . . . 72.41 110.933 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.0 m -122.73 143.9 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 55.44 111.131 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.733 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -138.69 143.85 39.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.479 . . . . 62.23 110.889 179.993 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -149.54 123.52 9.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 73.14 111.129 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -121.41 154.47 36.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 62.45 110.814 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.84 6.87 33.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 54.42 111.074 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -122.37 86.07 2.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 75.43 110.906 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.91 -165.92 12.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.755 -0.736 . . . . 62.34 112.54 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -136.3 143.43 44.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.842 0.353 . . . . 74.03 110.893 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.417 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.7 pm0 -145.37 155.59 53.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 72.13 110.901 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.417 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.9 Cg_endo -69.75 174.45 9.48 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.253 . . . . 63.31 112.35 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.73 ' O ' HD12 ' A' ' 53' ' ' ILE . 2.1 m-20 -127.99 62.37 56.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.631 0.729 . . . . 72.23 110.869 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 74.43 1.26 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.655 2.237 . . . . 73.1 112.343 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.73 HD12 ' O ' ' A' ' 51' ' ' ASN . 3.9 mp -110.58 113.89 45.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 54.43 111.154 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -108.59 119.47 39.61 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.491 . . . . 72.13 110.908 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.848 HG23 HG13 ' A' ' 61' ' ' ILE . 2.1 p -124.77 85.71 56.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.61 0.719 . . . . 74.14 111.125 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.619 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.4 Cg_endo -69.76 122.57 9.25 Favored 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 122.673 2.249 . . . . 72.31 112.347 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.57 150.45 48.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 64.01 110.881 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.81 -30.46 5.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 52.23 112.507 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.83 152.12 23.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.736 0.303 . . . . 54.21 111.119 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.63 ' O ' HD13 ' A' ' 61' ' ' ILE . 0.4 OUTLIER -68.82 142.36 54.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.456 . . . . 75.11 110.861 -179.897 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.848 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -126.87 124.16 64.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 62.11 111.106 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 1.042 HG13 HG23 ' A' ' 92' ' ' THR . 55.0 t -107.92 91.25 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 71.11 111.173 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -69.48 135.02 49.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 65.31 110.887 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -131.43 100.44 5.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 62.13 110.865 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.775 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.5 mp -97.17 156.07 3.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.264 -0.426 . . . . 73.12 111.098 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.607 HG23 HD12 ' A' ' 42' ' ' LEU . 7.2 t -166.01 137.9 3.86 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 43.44 111.141 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.639 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -152.21 159.76 32.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.646 0.736 . . . . 71.14 110.912 -179.876 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.76 -53.98 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.665 2.243 . . . . 71.21 112.403 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -154.88 65.84 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 73.24 110.864 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.639 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.4 135.55 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 74.32 111.126 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.2 mm -66.9 145.54 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 75.31 111.107 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.775 ' HB3' HG21 ' A' ' 65' ' ' ILE . 1.3 m-70 -108.75 -167.05 1.17 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 74.45 110.834 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.84 120.73 3.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 41.12 112.513 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -121.16 142.84 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.904 0.383 . . . . 74.54 110.9 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -89.14 137.19 32.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 73.11 110.872 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.741 HG13 ' CE2' ' A' ' 103' ' ' TYR . 94.8 t -130.03 141.47 46.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 62.42 111.161 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.6 mt-10 -75.26 175.67 8.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 64.11 110.878 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.06 -51.65 4.14 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.676 -0.773 . . . . 64.34 112.514 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.25 147.24 51.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 74.11 111.156 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -76.71 64.57 2.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 65.55 110.881 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.767 HD12 ' CD2' ' A' ' 95' ' ' TYR . 8.0 tt -58.23 125.94 15.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 73.2 111.176 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.7 89.67 3.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.853 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.575 HG11 HG21 ' A' ' 93' ' ' VAL . 3.7 m -115.87 120.65 65.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 73.42 111.158 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -155.79 114.51 3.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 72.12 110.838 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.652 HG21 ' OG ' ' A' ' 91' ' ' SER . 61.6 t -140.46 146.71 24.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 74.15 111.138 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.433 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.6 OUTLIER -69.69 155.68 93.06 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.585 0.707 . . . . 63.03 110.902 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.433 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 54.1 Cg_endo -69.74 159.8 52.09 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.234 . . . . 71.1 112.379 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.21 17.25 51.31 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.761 -0.733 . . . . 64.11 112.493 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -156.26 155.77 32.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.88 0.371 . . . . 73.13 110.886 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.4 HG21 ' HH2' ' A' ' 22' ' ' TRP . 98.2 t -104.85 109.78 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 55.31 111.123 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.652 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.4 OUTLIER -83.83 169.46 15.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 73.11 110.879 -179.856 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 92' ' ' THR . . . . . 1.042 HG23 HG13 ' A' ' 62' ' ' VAL . 98.3 m -137.99 122.22 18.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.144 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.575 HG21 HG11 ' A' ' 83' ' ' VAL . 21.3 t -124.57 130.6 73.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 71.02 111.155 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.7 mmm180 -102.57 70.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 70.24 110.9 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.767 ' CD2' HD12 ' A' ' 81' ' ' ILE . 14.8 t80 -110.13 130.73 55.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.153 -0.476 . . . . 72.25 110.931 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.1 t -139.64 142.25 37.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.475 . . . . 63.02 111.133 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -97.0 -175.49 3.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 73.25 110.861 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.1 mttt -125.34 -12.52 6.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 35.13 110.899 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -145.81 162.14 37.24 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.557 0.694 . . . . 70.22 110.865 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 154.0 68.21 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.679 2.253 . . . . 61.03 112.347 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.45 141.17 3.05 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.727 -0.749 . . . . 23.23 112.483 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -106.59 130.14 54.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.808 0.337 . . . . 60.42 110.905 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' TYR . . . . . 0.741 ' CE2' HG13 ' A' ' 76' ' ' VAL . 4.3 p90 -144.04 146.32 32.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 73.01 110.922 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.494 ' HG2' HD12 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -155.17 -175.76 5.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 74.21 110.848 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.494 HD12 ' HG2' ' A' ' 104' ' ' ARG . 1.9 mp 65.62 150.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 72.41 111.195 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 55.31 111.167 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.722 ' O ' HD13 ' A' ' 53' ' ' ILE . 67.9 m . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.74 0.305 . . . . 73.54 111.164 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.446 ' CG2' HG11 ' A' ' 55' ' ' VAL . 2.8 mp -147.36 140.72 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 72.25 111.123 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 55' ' ' VAL . 50.2 t -128.41 129.28 68.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 35.51 111.116 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.776 HG22 HG13 ' A' ' 55' ' ' VAL . 87.9 t -103.59 136.86 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 75.35 111.082 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.3 mmmt -113.83 131.78 56.12 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 72.25 110.902 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 73.34 110.874 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.874 0.369 . . . . 62.12 110.859 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.64 166.78 13.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 61.11 110.85 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 16' ' ' VAL . 35.9 m -150.02 140.6 16.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.178 -0.465 . . . . 62.11 111.104 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.1 162.84 19.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.578 0.704 . . . . 72.03 110.855 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.96 9.33 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.651 2.234 . . . . 60.1 112.384 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.464 HG22 HG23 ' A' ' 15' ' ' THR . 3.2 m -46.24 -67.43 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.207 -0.451 . . . . 74.13 111.168 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.464 HG23 HG22 ' A' ' 14' ' ' THR . 26.8 p -146.67 13.86 1.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 71.32 111.138 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 11' ' ' VAL . 12.6 p -50.64 -31.93 9.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 111.136 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.14 -17.41 14.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 74.32 110.883 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 22.1 mm100 -79.62 -31.21 41.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 74.44 110.94 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -149.24 140.48 23.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.231 -0.441 . . . . 72.31 110.884 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.19 -157.16 17.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.691 -0.766 . . . . 73.21 112.46 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 -30.6 22.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 50.21 112.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 14.9 m-90 -87.21 -7.48 57.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.226 -0.443 . . . . 62.15 110.921 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.29 -60.08 2.51 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 74.53 111.054 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.56 142.59 29.57 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.577 0.703 . . . . 75.32 110.916 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -28.38 25.07 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.666 2.244 . . . . 65.01 112.347 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.18 -11.69 60.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 73.03 111.115 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.5 mm-40 -95.35 24.71 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 74.31 110.935 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.503 ' HB2' ' HB2' ' A' ' 52' ' ' PRO . . . -56.58 -79.58 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 74.51 111.067 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.507 HG11 ' HB3' ' A' ' 54' ' ' GLU . 1.8 p -106.86 141.01 23.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 72.02 111.153 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 m -128.1 150.16 33.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 74.13 111.164 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -89.1 118.79 29.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 72.33 110.925 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.9 t -121.06 -21.06 6.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 63.33 111.148 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.29 168.38 20.19 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 54.21 112.5 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.25 20.57 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.652 2.235 . . . . 65.22 112.33 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.507 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 18.0 t30 -159.33 23.25 0.19 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.445 . . . . 60.35 110.874 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -138.87 153.97 48.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 71.43 110.865 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -141.97 142.15 32.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 72.23 110.966 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.2 m -95.74 104.55 16.48 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.115 -0.493 . . . . 75.41 111.144 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 t -84.5 140.06 16.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 74.5 111.156 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.29 122.76 39.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 72.14 110.918 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.618 HG12 HD12 ' A' ' 53' ' ' ILE . 16.6 m -118.73 123.26 71.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.11 -0.495 . . . . 71.03 111.113 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.685 HD11 ' CD2' ' A' ' 44' ' ' PHE . 3.0 tm? -115.88 132.88 56.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 71.15 110.894 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.507 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -155.44 114.47 3.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 52.33 111.087 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.685 ' CD2' HD11 ' A' ' 42' ' ' LEU . 5.9 p90 -129.36 152.09 49.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 42.02 110.878 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.421 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -85.14 1.77 46.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.09 -0.504 . . . . 53.44 111.145 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -95.83 72.0 3.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 73.24 110.868 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.21 -150.88 17.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.754 -0.736 . . . . 73.43 112.471 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 p90 -136.37 150.93 49.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.36 . . . . 65.15 110.907 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -162.09 162.06 20.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.591 0.71 . . . . 73.51 110.904 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 157.36 60.63 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.281 . . . . 74.44 112.35 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -133.09 66.69 76.32 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.644 0.735 . . . . 62.34 110.877 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.503 ' HB2' ' HB2' ' A' ' 28' ' ' ALA . 53.8 Cg_endo -69.83 114.03 3.58 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.676 2.251 . . . . 73.33 112.367 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.618 HD12 HG12 ' A' ' 41' ' ' VAL . 1.5 mm -117.21 151.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 61.53 111.136 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.507 ' HB3' HG11 ' A' ' 29' ' ' VAL . 13.2 tt0 -155.25 120.62 4.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 71.3 110.929 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.923 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -139.7 82.03 18.75 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.651 0.739 . . . . 74.31 111.131 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.8 Cg_endo -69.81 123.67 10.31 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.698 2.266 . . . . 74.32 112.349 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.489 HE22 ' HA ' ' A' ' 126' ' ' GLU . 1.8 pm0 -69.23 155.11 40.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 72.32 110.96 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.41 -8.73 73.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 72.01 112.469 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.507 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -133.02 155.77 48.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 61.21 111.115 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.717 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.2 mt-10 -66.75 141.37 57.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 70.51 110.857 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.748 HG13 HG23 ' A' ' 55' ' ' VAL . 5.7 mm -130.14 119.18 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 54.12 111.106 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.553 HG13 ' OG1' ' A' ' 92' ' ' THR . 54.8 t -102.28 98.42 6.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 71.51 111.129 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.5 ' HB2' HG12 ' A' ' 93' ' ' VAL . 72.0 m-85 -76.97 126.34 30.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 75.42 110.851 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.9 mttt -120.32 100.09 6.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 63.32 110.911 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.474 ' HA ' HG23 ' A' ' 41' ' ' VAL . 1.8 mt -98.22 153.21 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 72.33 111.111 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 13.4 t -171.35 145.97 2.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 74.03 111.185 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.448 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -153.29 159.62 31.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.678 0.751 . . . . 74.03 110.854 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.438 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.76 -54.83 0.2 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.73 2.287 . . . . 63.1 112.325 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -156.53 60.55 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.238 -0.437 . . . . 72.43 110.884 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.448 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.29 136.35 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.459 . . . . 64.11 111.136 179.995 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 41.4 mm -67.08 144.2 14.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 65.53 111.09 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -136.98 158.11 45.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 74.02 110.827 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.71 129.83 1.11 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.779 -0.724 . . . . 71.14 112.515 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.0 p90 -117.47 141.93 47.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 74.23 110.862 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -112.1 90.74 3.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 75.42 110.846 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.722 ' HB ' HG21 ' A' ' 81' ' ' ILE . 27.6 t -73.36 145.53 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 74.22 111.115 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -75.66 -175.56 2.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 71.41 110.858 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.91 -51.38 4.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 55.24 112.437 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.45 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -132.41 179.28 6.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.777 0.322 . . . . 71.25 111.161 -179.846 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.45 ' H ' HG22 ' A' ' 79' ' ' THR . 11.2 m-80 -90.19 48.01 1.51 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 63.22 110.868 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.722 HG21 ' HB ' ' A' ' 76' ' ' VAL . 3.3 tp -63.14 111.0 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 64.43 111.139 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.87 122.73 46.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 64.43 110.852 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.2 m -143.51 120.1 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 34.3 111.126 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.25 112.59 2.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 43.21 110.888 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 23.5 t -140.5 144.28 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 73.05 111.142 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 1.4 mp -61.53 161.11 21.16 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.591 0.71 . . . . 54.53 110.919 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 159.53 53.11 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.667 2.245 . . . . 45.33 112.347 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.23 10.88 60.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.718 -0.753 . . . . 75.44 112.492 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -152.6 159.39 43.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.862 0.363 . . . . 74.35 110.869 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 95.7 t -98.43 143.34 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 62.44 111.138 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 7.3 p -121.3 97.24 5.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 61.22 110.899 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.553 ' OG1' HG13 ' A' ' 62' ' ' VAL . 1.2 t -85.63 141.33 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.116 -0.493 . . . . 54.51 111.167 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.5 HG12 ' HB2' ' A' ' 63' ' ' PHE . 12.6 p -154.24 150.3 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 72.44 111.136 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -109.6 116.4 31.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 62.33 110.894 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -151.45 114.96 4.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 74.3 110.945 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.6 t -116.55 136.24 53.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.14 -0.482 . . . . 62.02 111.123 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -87.06 -172.47 3.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 74.33 110.922 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.1 tttt -123.19 -26.14 4.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 61.34 110.909 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -140.71 162.06 50.97 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.708 . . . . 74.42 110.871 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 150.72 68.57 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 72.12 112.345 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.09 143.85 3.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.733 -0.746 . . . . 73.23 112.506 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.743 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -108.82 134.53 51.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.84 0.352 . . . . 73.52 110.906 -179.883 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 103' ' ' TYR . . . . . 0.604 ' CE2' HG13 ' A' ' 76' ' ' VAL . 2.1 p90 -143.54 131.53 21.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 73.15 110.933 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.39 111.27 5.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.08 -0.509 . . . . 74.51 110.867 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.0 tp -178.61 142.95 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 74.23 111.098 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.437 HG23 ' O ' ' A' ' 106' ' ' ILE . 17.7 tt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 42.05 111.11 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.609 HG23 HG13 ' A' ' 53' ' ' ILE . 15.1 t . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.714 0.293 . . . . 53.13 111.21 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.582 HD12 ' C ' ' A' ' 121' ' ' THR . 3.3 mp -153.1 134.27 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.243 -0.435 . . . . 72.2 111.11 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.743 HG23 ' HB3' ' A' ' 102' ' ' GLU . 8.6 p -126.23 137.61 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 73.14 111.139 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.923 HG22 HG13 ' A' ' 55' ' ' VAL . 47.3 t -108.14 141.97 22.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 34.44 111.134 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.8 mmtt -116.33 132.42 56.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 75.43 110.937 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.489 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 71.41 110.875 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.477 ' O ' HG12 ' A' ' 90' ' ' VAL . 2.1 pt-20 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.839 0.352 . . . . 72.34 110.892 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -93.1 135.38 34.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 64.22 110.85 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.447 HG21 HG21 ' A' ' 16' ' ' VAL . 7.8 m -115.01 -179.22 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 60.52 111.133 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -147.04 162.63 32.22 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 71.34 110.867 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -4.33 13.79 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.677 2.251 . . . . 71.41 112.367 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.411 ' O ' HG23 ' A' ' 15' ' ' THR . 5.4 m -48.75 -66.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.24 -0.436 . . . . 75.5 111.112 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 14' ' ' THR . 3.2 p -155.59 37.35 0.37 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 71.42 111.149 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.447 HG21 HG21 ' A' ' 11' ' ' VAL . 8.4 p -77.19 -27.52 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.214 -0.448 . . . . 73.32 111.137 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 20.4 ptt85 -104.28 -10.76 17.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 75.24 110.853 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -94.35 -36.96 11.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.453 . . . . 72.32 110.927 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.87 133.88 40.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 55.43 110.883 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.02 -157.18 19.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 45.25 112.507 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -30.06 22.79 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 72.53 112.36 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.777 ' HB3' HD13 ' A' ' 42' ' ' LEU . 14.0 m-90 -86.82 -10.89 52.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 74.32 110.926 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.66 -59.32 3.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 75.23 111.112 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.63 144.85 29.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.612 0.72 . . . . 71.44 110.868 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -17.24 37.75 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.665 2.243 . . . . 71.03 112.322 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -24.09 59.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 72.02 111.132 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.7 mm-40 -90.05 10.54 23.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 72.23 110.931 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -78.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 74.12 111.15 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.614 HG11 ' CB ' ' A' ' 54' ' ' GLU . 2.1 p -108.2 128.71 63.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 71.13 111.149 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.01 144.04 28.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 64.01 111.139 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 -75.48 121.45 22.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 73.31 110.905 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 t -119.95 -12.88 9.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 62.12 111.166 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.61 -167.66 12.15 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.751 -0.737 . . . . 72.32 112.496 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 -36.12 11.4 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 65.3 112.337 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -153.58 34.45 0.45 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 73.23 110.884 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -134.14 118.09 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 72.21 110.889 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -97.66 138.47 35.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.94 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 55.9 m -95.66 102.59 14.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 72.34 111.13 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.9 t -84.24 146.33 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 75.04 111.156 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -126.8 124.06 38.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.143 -0.48 . . . . 64.4 110.962 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.457 HG22 HD12 ' A' ' 53' ' ' ILE . 92.1 t -125.37 138.67 53.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.491 . . . . 70.21 111.121 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.777 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -138.61 141.84 39.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.166 -0.47 . . . . 74.02 110.94 179.951 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.68 109.11 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 45.54 111.065 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -122.77 153.43 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 74.25 110.852 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.26 4.3 35.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 75.21 111.13 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -95.24 78.11 3.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.937 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.59 -139.92 14.75 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 71.23 112.489 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -148.42 150.06 32.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.845 0.355 . . . . 53.03 110.943 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -158.19 162.55 26.69 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.571 0.701 . . . . 73.44 110.963 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 157.03 61.78 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.722 2.281 . . . . 73.54 112.317 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.49 66.08 76.11 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.598 0.713 . . . . 45.04 110.847 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.526 ' C ' HD13 ' A' ' 53' ' ' ILE . 53.1 Cg_endo -69.85 118.36 5.64 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.693 2.262 . . . . 63.5 112.302 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.618 HG21 ' HA ' ' A' ' 122' ' ' ILE . 2.4 mm -124.55 151.51 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 73.42 111.123 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.614 ' CB ' HG11 ' A' ' 29' ' ' VAL . 8.3 tt0 -155.22 115.66 3.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 75.4 110.836 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.686 ' O ' HG13 ' A' ' 124' ' ' VAL . 21.2 t -131.34 82.02 63.61 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.647 0.737 . . . . 71.23 111.145 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.729 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.75 121.87 8.56 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.692 2.261 . . . . 71.14 112.368 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -68.3 152.85 44.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.253 -0.43 . . . . 65.12 110.933 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.95 -36.33 3.7 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 73.11 112.495 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.77 158.06 17.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.8 0.333 . . . . 62.12 111.066 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.672 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.5 mt-10 -67.87 144.53 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.45 . . . . 63.24 110.922 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.729 HD12 ' HD2' ' A' ' 56' ' ' PRO . 5.7 mm -128.21 120.01 52.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 72.11 111.114 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.985 HG13 HG23 ' A' ' 92' ' ' THR . 55.2 t -103.9 91.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 71.34 111.128 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.618 ' HB2' HG12 ' A' ' 93' ' ' VAL . 90.5 m-85 -69.61 134.95 49.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 71.31 110.906 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.421 ' HD3' HG21 ' A' ' 90' ' ' VAL . 15.6 mttt -131.53 100.16 5.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.153 -0.476 . . . . 64.14 110.877 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.584 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.8 mp -107.11 143.32 17.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 54.02 111.156 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.5 t -156.38 136.18 12.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 74.23 111.166 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.404 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -142.95 161.51 48.3 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.699 0.761 . . . . 73.4 110.853 -179.86 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.404 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.0 Cg_endo -69.77 -50.81 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.671 2.247 . . . . 50.34 112.385 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -155.78 49.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 62.2 110.842 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.21 135.94 3.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.146 -0.479 . . . . 71.51 111.117 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 95.0 mt -86.45 105.64 14.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.14 111.147 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.408 ' O ' HG21 ' A' ' 65' ' ' ILE . 76.0 t60 -99.46 69.65 1.67 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 53.41 110.901 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.15 155.5 21.07 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.73 -0.748 . . . . 41.14 112.466 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.584 ' CE2' HD11 ' A' ' 65' ' ' ILE . 3.3 p90 -128.61 142.82 50.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.883 0.373 . . . . 72.3 110.886 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -118.56 94.1 4.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 74.15 110.854 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.529 HG13 ' CE2' ' A' ' 103' ' ' TYR . 10.1 t -74.11 140.9 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 75.53 111.147 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 pm0 -75.3 -176.05 2.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 72.43 110.869 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.7 -51.86 4.61 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.723 -0.751 . . . . 61.11 112.491 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.406 HG22 ' N ' ' A' ' 80' ' ' ASN . 10.7 m -124.02 157.16 35.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.813 0.34 . . . . 75.53 111.174 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.406 ' N ' HG22 ' A' ' 79' ' ' THR . 1.1 m120 -77.15 60.06 1.84 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 61.04 110.874 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.552 ' O ' HG23 ' A' ' 81' ' ' ILE . 11.5 tt -78.51 116.53 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 53.33 111.137 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -123.19 96.69 5.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 75.41 110.85 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.6 m -114.39 119.89 62.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 70.14 111.105 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.64 117.36 7.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.14 -0.482 . . . . 62.22 110.886 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.81 HG11 ' HB2' ' A' ' 91' ' ' SER . 7.6 p -140.62 128.29 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 63.2 111.117 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -57.52 157.91 12.5 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.59 0.71 . . . . 63.55 110.959 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 159.16 54.46 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.685 2.256 . . . . 62.22 112.339 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.1 11.73 59.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 72.01 112.511 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -163.86 118.19 1.53 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.897 0.379 . . . . 71.4 110.897 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.477 HG12 ' O ' ' A' ' 9' ' ' GLU . 3.5 p -68.8 143.28 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 74.45 111.129 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.81 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.3 OUTLIER -107.09 169.29 8.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 70.42 110.814 -179.854 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.985 HG23 HG13 ' A' ' 62' ' ' VAL . 87.8 m -145.45 111.28 5.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.121 -0.491 . . . . 73.14 111.112 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.618 HG12 ' HB2' ' A' ' 63' ' ' PHE . 8.0 p -124.45 150.7 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 71.13 111.131 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -114.93 97.49 6.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.831 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.544 ' CD2' HD12 ' A' ' 81' ' ' ILE . 40.5 t80 -139.9 110.08 6.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 73.33 110.947 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.1 t -110.68 143.5 41.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 71.4 111.177 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.6 -178.89 5.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.258 -0.428 . . . . 74.21 110.853 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.7 mttt -119.85 -12.9 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 73.13 110.927 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.16 161.66 31.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.62 0.724 . . . . 75.01 110.831 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.67 152.43 69.75 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 2.26 . . . . 64.42 112.384 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 159.4 130.43 1.14 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.785 -0.722 . . . . 52.22 112.494 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -99.22 130.46 45.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 72.35 110.866 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' TYR . . . . . 0.529 ' CE2' HG13 ' A' ' 76' ' ' VAL . 1.0 OUTLIER -135.42 146.39 48.23 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.197 -0.456 . . . . 74.2 110.93 -179.872 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.942 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.7 OUTLIER -148.22 -163.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 71.32 110.907 179.99 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.942 HG22 ' O ' ' A' ' 104' ' ' ARG . 1.2 tt 58.94 158.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 73.34 111.129 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 72.14 111.157 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.586 ' C ' HD12 ' A' ' 122' ' ' ILE . 68.7 m . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.771 0.32 . . . . 65.32 111.118 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.618 ' HA ' HG21 ' A' ' 53' ' ' ILE . 4.3 mp -150.01 143.66 17.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 72.34 111.136 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 m -134.47 140.74 45.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 73.33 111.133 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.686 HG13 ' O ' ' A' ' 55' ' ' VAL . 58.5 t -113.68 126.03 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 73.5 111.17 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 11.3 mmmm -108.92 141.51 40.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 61.24 110.909 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.209 -0.451 . . . . 72.55 110.928 179.963 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.803 0.335 . . . . 75.12 110.867 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -104.52 143.98 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 72.01 110.904 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.514 HG21 ' OG1' ' A' ' 66' ' ' THR . 17.0 m -110.64 -177.55 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 73.44 111.138 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.416 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 4.9 p30 -143.79 156.18 59.31 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.626 0.727 . . . . 70.15 110.87 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.81 -3.58 12.34 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.652 2.235 . . . . 41.12 112.338 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 3.7 m -47.56 -63.74 0.97 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.237 -0.438 . . . . 63.51 111.14 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -155.67 29.04 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.244 -0.435 . . . . 61.44 111.133 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.4 p -64.57 -30.23 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.435 . . . . 65.25 111.12 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.453 ' HB3' HD21 ' A' ' 42' ' ' LEU . 4.0 ptt-85 -101.17 -6.63 24.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.35 110.874 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 11.3 mm-40 -97.43 -37.46 9.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 75.5 110.924 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -135.11 133.93 39.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 71.1 110.852 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.05 -158.76 18.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.717 -0.754 . . . . 72.23 112.466 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -29.02 24.71 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.657 2.238 . . . . 72.32 112.364 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.783 ' HB3' HD13 ' A' ' 42' ' ' LEU . 15.0 m-90 -87.12 -11.42 50.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.26 -0.427 . . . . 64.43 110.893 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.36 -59.16 5.07 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.267 -0.424 . . . . 74.13 111.074 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.91 143.63 26.99 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.598 0.713 . . . . 75.12 110.885 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -22.69 31.51 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.735 2.29 . . . . 72.43 112.288 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.8 -7.27 51.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.271 -0.422 . . . . 23.02 111.104 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 8.9 mm100 -104.73 5.27 33.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 71.44 110.887 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -77.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 62.23 111.1 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.3 p -103.39 108.4 24.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 74.43 111.109 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -114.91 149.86 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 74.14 111.138 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -67.96 122.32 17.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 60.23 110.895 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.572 HG23 ' HG3' ' A' ' 36' ' ' GLN . 1.7 t -119.73 -33.55 3.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 51.32 111.132 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.06 175.85 17.94 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 60.52 112.493 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.67 24.21 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.721 2.281 . . . . 74.12 112.336 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -161.03 34.79 0.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 74.14 110.895 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.572 ' HG3' HG23 ' A' ' 32' ' ' THR . 0.2 OUTLIER -150.91 160.29 44.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 64.31 110.94 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -143.12 144.32 32.18 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.244 -0.435 . . . . 73.4 110.906 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.2 m -97.62 103.14 15.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 64.3 111.142 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.9 t -85.05 137.67 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 62.35 111.18 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -120.26 113.12 19.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 73.35 110.966 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.494 HG22 HG13 ' A' ' 53' ' ' ILE . 59.1 t -110.42 133.82 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 74.13 111.122 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.783 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.6 OUTLIER -139.31 139.36 37.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 53.51 110.868 -179.982 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.648 ' HB3' ' CE1' ' A' ' 72' ' ' HIS . . . -155.16 122.66 5.63 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 74.22 111.107 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -121.56 145.57 47.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 75.31 110.874 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.32 48.12 1.57 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.474 . . . . 72.51 111.117 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -120.9 -50.7 2.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 64.02 110.879 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -133.71 -119.01 1.95 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.773 -0.727 . . . . 75.32 112.54 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -150.17 136.68 19.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 74.34 110.894 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -130.39 159.41 70.76 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.578 0.704 . . . . 61.23 110.939 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -176.97 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.672 2.248 . . . . 62.3 112.367 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.514 ' C ' HD12 ' A' ' 53' ' ' ILE . 1.0 OUTLIER -137.57 62.5 36.23 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.672 0.748 . . . . 52.42 110.926 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 6.45 1.3 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.67 2.247 . . . . 74.54 112.313 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.935 HD13 HG22 ' A' ' 121' ' ' THR . 4.7 mp -48.39 131.28 5.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 75.13 111.136 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.445 ' HB3' HG11 ' A' ' 29' ' ' VAL . 10.6 tt0 -140.18 149.6 43.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 52.34 110.883 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 61' ' ' ILE . 86.9 t -151.0 81.96 6.09 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.618 0.723 . . . . 60.23 111.132 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.69 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.5 Cg_endo -69.79 123.08 9.74 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.647 2.232 . . . . 71.33 112.332 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.479 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.0 pm0 -70.1 155.3 40.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 65.24 110.923 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.54 -9.67 70.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.729 -0.748 . . . . 70.23 112.469 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.36 154.35 50.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.759 0.314 . . . . 71.02 111.125 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.681 ' O ' HD13 ' A' ' 61' ' ' ILE . 20.9 mt-10 -64.88 144.55 57.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 75.44 110.944 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.737 HG13 HG13 ' A' ' 55' ' ' VAL . 7.6 mm -129.44 115.16 33.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 65.13 111.127 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.593 HG13 ' OG1' ' A' ' 92' ' ' THR . 77.2 t -99.06 97.72 6.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 44.33 111.122 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.514 ' HB2' HG12 ' A' ' 93' ' ' VAL . 87.9 m-85 -75.85 132.06 40.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 70.41 110.872 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -130.82 100.06 5.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.931 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.38 153.24 4.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 75.51 111.11 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.771 HG23 HD12 ' A' ' 42' ' ' LEU . 9.5 t -167.1 128.66 1.62 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 72.23 111.134 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.473 ' HB2' HG23 ' A' ' 70' ' ' VAL . 0.1 OUTLIER -140.25 166.16 25.39 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.637 0.732 . . . . 74.33 110.84 -179.875 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' CB ' ' A' ' 67' ' ' SER . 54.4 Cg_endo -69.72 -54.8 0.2 Allowed 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.668 2.245 . . . . 72.1 112.389 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -158.7 57.22 0.44 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 74.32 110.917 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.473 HG23 ' HB2' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.62 140.23 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.142 -0.481 . . . . 71.44 111.108 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.463 HD13 ' HD3' ' A' ' 87' ' ' PRO . 35.0 mm -85.3 150.82 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 74.1 111.101 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.648 ' CE1' ' HB3' ' A' ' 43' ' ' ALA . 11.9 m170 -115.69 -84.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.472 . . . . 74.43 110.903 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.88 98.85 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.743 -0.741 . . . . 73.05 112.492 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -106.31 142.47 35.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 74.35 110.89 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -110.8 142.39 42.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 75.55 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.4 t -135.89 136.19 50.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 62.02 111.142 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -64.21 -177.2 0.26 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.181 -0.463 . . . . 74.34 110.925 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 84.32 -51.22 4.53 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.747 -0.74 . . . . 60.14 112.479 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.1 m -135.12 160.94 36.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.774 0.321 . . . . 74.02 111.202 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -86.01 76.58 9.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 64.03 110.893 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.451 ' O ' HG23 ' A' ' 81' ' ' ILE . 4.8 tt -85.01 121.81 37.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 72.45 111.11 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -116.5 95.42 5.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 73.42 110.878 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.8 m -115.63 120.37 64.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 63.03 111.147 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -156.59 110.02 2.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.2 -0.454 . . . . 71.31 110.874 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.759 HG11 ' HB2' ' A' ' 91' ' ' SER . 13.8 p -140.74 147.11 23.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 62.54 111.12 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.28 161.1 80.26 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.567 0.699 . . . . 62.32 110.905 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.463 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.6 Cg_endo -69.75 159.64 52.67 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.654 2.236 . . . . 74.14 112.333 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.39 85.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.722 -0.751 . . . . 75.11 112.469 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -139.37 145.25 38.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.932 0.396 . . . . 74.53 110.889 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.504 HG23 HG13 ' A' ' 11' ' ' VAL . 21.2 t -99.3 110.66 27.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.165 -0.47 . . . . 72.25 111.157 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.759 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -91.37 165.97 13.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 51.33 110.846 -179.851 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.593 ' OG1' HG13 ' A' ' 62' ' ' VAL . 1.4 t -144.19 140.15 29.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 43.21 111.168 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.514 HG12 ' HB2' ' A' ' 63' ' ' PHE . 9.9 p -153.79 127.55 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 73.11 111.126 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.0 mtm180 -93.95 111.11 22.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 73.14 110.885 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -145.75 118.45 8.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.429 . . . . 73.12 110.872 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.3 t -114.39 132.03 56.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 71.44 111.161 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -177.59 6.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 73.42 110.854 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.3 ttpt -121.52 -24.28 5.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 61.42 110.901 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.49 160.21 57.69 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.613 0.721 . . . . 65.35 110.899 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 127.85 15.16 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.689 2.26 . . . . 72.21 112.313 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.12 146.33 14.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 63.44 112.521 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -105.57 135.71 46.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.84 0.352 . . . . 74.34 110.881 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -143.97 148.87 35.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.169 -0.469 . . . . 73.13 110.947 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.421 ' C ' HD12 ' A' ' 105' ' ' ILE . 30.6 ttp85 -168.78 157.9 8.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 65.52 110.882 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.421 HD12 ' C ' ' A' ' 104' ' ' ARG . 2.0 mp 66.79 147.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.176 -0.466 . . . . 74.44 111.096 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 74.12 111.11 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.935 HG22 HD13 ' A' ' 53' ' ' ILE . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.73 0.3 . . . . 64.41 111.197 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.658 HG13 HG21 ' A' ' 53' ' ' ILE . 4.4 mp -149.06 120.53 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 55.21 111.13 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.494 HG12 ' O ' ' A' ' 53' ' ' ILE . 3.0 p -114.83 127.14 72.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 74.41 111.089 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.711 HG13 ' O ' ' A' ' 55' ' ' VAL . 42.7 t -97.88 131.2 45.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 74.32 111.149 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 15.2 mmmt -104.97 128.53 53.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 64.1 110.86 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.479 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 60.22 110.884 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.43 ' O ' HG12 ' A' ' 90' ' ' VAL . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.87 0.367 . . . . 71.54 110.869 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -86.02 137.97 32.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 71.21 110.867 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.453 HG21 ' OG1' ' A' ' 66' ' ' THR . 17.1 m -120.72 -177.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.131 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.447 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 33.8 p30 -144.16 156.75 57.88 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.596 0.712 . . . . 72.03 110.882 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.6 Cg_endo -69.76 -2.28 9.9 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.674 2.249 . . . . 73.31 112.356 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.75 HG22 HG23 ' A' ' 15' ' ' THR . 26.6 m -45.24 -65.24 0.56 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.223 -0.444 . . . . 72.44 111.124 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.75 HG23 HG22 ' A' ' 14' ' ' THR . 38.2 p -150.26 17.84 0.84 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 71.12 111.121 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.4 p -57.17 -25.8 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 64.3 111.145 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.5 ptt85 -106.71 -8.05 17.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 73.12 110.851 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 6.6 mm-40 -94.03 -32.22 13.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.4 110.92 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.471 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 7.8 pt-20 -142.56 144.19 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 74.35 110.902 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.96 -156.56 15.58 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.765 -0.731 . . . . 33.41 112.482 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.454 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.3 Cg_endo -69.77 -35.94 11.69 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.661 2.24 . . . . 65.34 112.328 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.403 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 13.5 m-90 -84.66 -7.25 59.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.213 -0.449 . . . . 70.34 110.92 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.471 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -62.02 -54.19 45.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.24 -0.437 . . . . 52.13 111.105 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.68 141.99 30.89 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.653 0.74 . . . . 75.04 110.855 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.673 2.248 . . . . 72.31 112.372 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.59 -36.99 65.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 64.21 111.06 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.454 ' HG3' ' HA ' ' A' ' 21' ' ' PRO . 5.0 pm0 -95.31 33.06 1.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.4 110.929 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.478 ' HB2' ' HG2' ' A' ' 52' ' ' PRO . . . -55.73 -76.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 73.22 111.101 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.734 HG11 ' CB ' ' A' ' 54' ' ' GLU . 2.3 p -101.88 129.79 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 62.34 111.103 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -142.33 139.99 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 73.32 111.151 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -72.4 123.34 22.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 75.33 110.903 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -120.28 -10.45 9.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 75.24 111.165 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.98 -168.83 12.46 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 51.5 112.479 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -33.8 16.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.654 2.236 . . . . 50.34 112.368 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -154.31 28.7 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 73.04 110.896 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -126.83 119.43 26.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 42.02 110.912 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 63.0 m-85 -96.37 134.7 39.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 74.25 110.906 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.689 ' HA ' HG23 ' A' ' 62' ' ' VAL . 92.5 m -93.84 104.23 16.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 64.13 111.119 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.1 t -86.85 132.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 71.31 111.096 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -118.07 115.66 25.3 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.19 -0.459 . . . . 75.1 110.917 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.473 HG12 HD12 ' A' ' 53' ' ' ILE . 15.8 m -114.05 119.71 61.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 72.04 111.131 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.49 ' C ' HD13 ' A' ' 42' ' ' LEU . 3.2 tm? -114.97 132.86 56.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 73.13 110.927 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.46 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -154.59 131.28 10.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 75.3 111.066 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.404 ' CD2' HD11 ' A' ' 42' ' ' LEU . 2.9 p90 -127.1 163.03 24.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 75.13 110.868 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.799 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -87.03 2.9 48.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.098 -0.501 . . . . 71.21 111.124 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 3.5 p90 -122.3 84.43 2.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 73.12 110.865 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.01 158.72 12.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 75.31 112.464 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -111.77 120.8 43.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.798 0.332 . . . . 73.4 110.976 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -127.08 162.36 48.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 60.24 110.883 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 162.49 41.87 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.659 2.239 . . . . 62.43 112.34 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 -137.95 67.19 48.8 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.614 0.721 . . . . 72.45 110.851 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.478 ' HG2' ' HB2' ' A' ' 28' ' ' ALA . 53.9 Cg_endo -69.81 98.99 0.72 Allowed 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.643 2.228 . . . . 73.22 112.35 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.545 HG13 HG23 ' A' ' 121' ' ' THR . 1.5 mm -100.57 157.44 4.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 75.34 111.131 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.734 ' CB ' HG11 ' A' ' 29' ' ' VAL . 16.4 tt0 -155.42 122.08 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.909 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.957 HG12 HG21 ' A' ' 61' ' ' ILE . 6.0 m -142.68 86.6 9.53 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.612 0.72 . . . . 72.15 111.137 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.549 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.8 Cg_endo -69.76 122.74 9.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.689 2.259 . . . . 73.31 112.344 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.06 155.75 23.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 64.51 110.904 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.98 -0.97 76.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.694 -0.765 . . . . 72.44 112.484 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.95 150.4 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.787 0.327 . . . . 74.23 111.086 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.676 ' O ' HD13 ' A' ' 61' ' ' ILE . 2.6 mp0 -68.14 138.23 55.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 65.24 110.883 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.957 HG21 HG12 ' A' ' 55' ' ' VAL . 5.0 mm -128.28 117.78 46.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 53.14 111.139 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.689 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -104.23 94.2 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 71.52 111.145 179.841 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.663 ' CZ ' HG11 ' A' ' 55' ' ' VAL . 40.2 m-85 -64.52 142.86 58.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 74.23 110.899 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -133.36 98.36 4.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.917 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.676 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.3 mp -106.8 137.01 39.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.26 -0.427 . . . . 73.31 111.15 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.453 ' OG1' HG21 ' A' ' 11' ' ' VAL . 6.5 t -154.96 134.62 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 70.04 111.121 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.415 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -146.2 161.38 39.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.688 0.756 . . . . 64.31 110.852 -179.893 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.5 Cg_endo -69.72 -52.98 0.3 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.699 2.266 . . . . 73.4 112.308 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -158.31 53.61 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 62.51 110.856 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.799 HG11 ' HB2' ' A' ' 45' ' ' ALA . 0.0 OUTLIER -155.12 140.95 11.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 71.41 111.121 179.977 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.572 HD13 ' HD3' ' A' ' 87' ' ' PRO . 30.5 mm -85.83 151.23 3.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 52.02 111.132 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.564 ' HB3' HG21 ' A' ' 65' ' ' ILE . 78.2 t60 -125.47 -83.93 0.63 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.17 -0.468 . . . . 61.35 110.872 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 61.13 158.57 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.724 -0.751 . . . . 71.34 112.504 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.676 ' CE2' HD11 ' A' ' 65' ' ' ILE . 0.8 OUTLIER -145.76 141.9 28.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.928 0.394 . . . . 65.32 110.859 -179.864 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 75' ' ' HIS . . . . . 0.651 ' HB3' HG23 ' A' ' 105' ' ' ILE . 31.0 t-80 -104.35 140.29 38.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 70.51 110.844 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.62 HG22 ' CE2' ' A' ' 103' ' ' TYR . 94.1 t -126.31 134.66 65.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 71.02 111.154 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -75.14 169.69 17.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 75.42 110.887 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.33 -51.28 4.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 51.33 112.504 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.3 m -116.29 151.47 35.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 74.3 111.109 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -86.04 58.79 5.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.909 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.504 HD12 ' CD2' ' A' ' 95' ' ' TYR . 7.7 tt -62.87 126.11 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 70.11 111.121 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -116.53 90.9 3.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 74.44 110.896 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.581 HG11 HG11 ' A' ' 93' ' ' VAL . 3.6 m -115.74 120.06 63.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 74.3 111.1 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -155.71 114.66 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 74.14 110.834 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.581 HG21 ' HB3' ' A' ' 91' ' ' SER . 94.3 t -140.2 145.04 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 65.42 111.104 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.1 mp -79.79 159.91 70.35 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.644 0.735 . . . . 60.33 110.904 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.572 ' HD3' HD13 ' A' ' 71' ' ' ILE . 54.0 Cg_endo -69.74 159.7 52.43 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.687 2.258 . . . . 73.4 112.354 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.58 10.02 48.49 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.75 -0.738 . . . . 74.24 112.519 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -169.36 126.24 0.91 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.891 0.376 . . . . 71.24 110.888 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.43 HG12 ' O ' ' A' ' 9' ' ' GLU . 2.4 p -65.17 118.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 70.33 111.158 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.581 ' HB3' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -81.57 166.7 20.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 64.14 110.894 -179.852 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 97.8 m -136.27 134.86 38.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.43 111.174 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.581 HG11 HG11 ' A' ' 83' ' ' VAL . 16.2 t -144.48 131.5 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 72.33 111.116 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -109.58 95.1 5.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 75.02 110.904 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.504 ' CD2' HD12 ' A' ' 81' ' ' ILE . 41.5 t80 -136.13 127.25 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.196 -0.456 . . . . 71.23 110.874 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.8 t -128.2 143.27 51.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 70.3 111.145 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -100.75 -173.26 2.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 72.02 110.907 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.03 -24.43 4.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.141 -0.482 . . . . 70.34 110.855 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -132.39 162.16 58.72 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.613 0.72 . . . . 74.43 110.895 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 155.45 65.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.711 2.274 . . . . 64.03 112.358 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.46 133.15 2.34 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.74 -0.743 . . . . 74.43 112.433 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -97.24 144.09 27.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.863 0.363 . . . . 75.35 110.866 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' TYR . . . . . 0.62 ' CE2' HG22 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -137.74 132.63 33.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 72.31 110.949 -179.885 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.82 120.98 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 73.24 110.853 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.651 HG23 ' HB3' ' A' ' 75' ' ' HIS . 5.6 tt -178.22 137.32 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 75.25 111.136 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 44.01 111.106 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.602 ' O ' HD13 ' A' ' 122' ' ' ILE . 13.4 t . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.794 0.331 . . . . 74.1 111.107 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 121' ' ' THR . 5.9 mm -141.52 148.24 21.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.51 111.121 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.405 ' O ' HG22 ' A' ' 55' ' ' VAL . 71.3 t -135.07 115.46 18.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.143 -0.481 . . . . 55.33 111.146 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.847 HG22 HG23 ' A' ' 55' ' ' VAL . 95.9 t -102.25 121.69 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 74.42 111.112 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.1 mmmt -106.22 138.73 41.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 64.04 110.878 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.222 -0.445 . . . . 73.22 110.868 179.996 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 15.8 mp0 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.856 0.36 . . . . 74.24 110.921 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.71 149.46 23.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 75.32 110.866 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.601 HG21 HG21 ' A' ' 16' ' ' VAL . 13.8 m -147.39 -178.29 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 51.44 111.125 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -144.3 162.31 40.47 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.618 0.723 . . . . 73.31 110.858 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -4.59 14.34 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.633 2.222 . . . . 74.13 112.317 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.408 ' O ' HG23 ' A' ' 15' ' ' THR . 4.6 m -48.83 -67.14 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.431 . . . . 72.31 111.105 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.408 HG23 ' O ' ' A' ' 14' ' ' THR . 3.1 p -155.46 38.27 0.38 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 61.21 111.179 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.601 HG21 HG21 ' A' ' 11' ' ' VAL . 11.8 p -76.22 -31.97 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 75.44 111.139 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.476 ' HB3' HD11 ' A' ' 42' ' ' LEU . 7.4 ptt-85 -97.25 -11.61 23.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 74.41 110.894 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.6 mm-40 -95.53 -37.32 10.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.893 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -132.65 134.17 44.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 73.22 110.869 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.57 -158.95 18.23 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.764 -0.731 . . . . 74.33 112.506 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -26.86 26.93 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.623 2.215 . . . . 62.54 112.373 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.732 ' HB3' HD13 ' A' ' 42' ' ' LEU . 13.3 m-90 -87.39 -13.34 43.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 64.43 110.91 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.18 -59.67 2.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.267 -0.424 . . . . 73.33 111.054 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.18 144.07 29.34 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.623 0.725 . . . . 75.52 110.833 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -28.97 24.7 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.62 2.213 . . . . 60.2 112.369 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.4 -16.98 60.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 70.15 111.089 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.2 mm-40 -88.36 8.3 28.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 74.4 110.947 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.39 -78.4 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 71.21 111.08 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.1 p -103.02 126.51 57.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 64.43 111.114 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -134.97 150.13 29.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 44.53 111.083 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -71.02 121.03 17.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 63.21 110.892 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.552 HG23 ' HG3' ' A' ' 36' ' ' GLN . 1.7 t -120.13 -33.05 4.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 75.34 111.153 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.79 178.49 16.49 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.706 -0.759 . . . . 74.22 112.476 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -18.14 37.33 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.727 2.284 . . . . 71.52 112.368 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 -153.3 30.08 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.196 -0.456 . . . . 71.21 110.872 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.552 ' HG3' HG23 ' A' ' 32' ' ' THR . 3.0 pt20 -140.96 157.46 45.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 62.44 110.919 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -140.56 138.39 34.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 75.34 110.95 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.753 ' HA ' HG23 ' A' ' 62' ' ' VAL . 75.4 m -92.98 103.86 16.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 75.51 111.143 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 t -90.25 140.39 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 64.45 111.158 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -124.14 120.44 32.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.01 110.893 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.658 HG23 HG23 ' A' ' 65' ' ' ILE . 4.5 m -121.61 146.52 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 74.43 111.129 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.732 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -139.1 143.94 38.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.166 -0.47 . . . . 72.41 110.935 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.84 106.2 3.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.441 . . . . 72.23 111.102 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.6 p90 -129.07 144.99 51.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 65.22 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.62 0.36 52.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 52.42 111.132 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.55 33.97 1.37 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 74.21 110.848 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.75 -141.73 8.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.743 -0.741 . . . . 51.25 112.494 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -155.48 155.17 33.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 71.21 110.899 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.412 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -156.66 156.2 29.62 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.607 0.718 . . . . 75.3 110.883 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.412 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.4 Cg_endo -69.82 -179.78 3.18 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 65.14 112.334 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.438 ' HB3' ' HB ' ' A' ' 121' ' ' THR . 0.4 OUTLIER -131.94 61.36 57.59 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.609 0.719 . . . . 73.44 110.881 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 7.16 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.659 2.24 . . . . 75.32 112.359 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.646 HG21 HG13 ' A' ' 122' ' ' ILE . 3.7 mp -46.86 143.34 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 61.13 111.121 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -144.18 164.69 29.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 64.53 110.891 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.879 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -165.4 82.87 1.11 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 72.22 111.15 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.589 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.72 122.49 9.18 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 75.13 112.354 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.506 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.7 pm0 -68.25 154.9 40.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 72.43 110.89 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.59 -7.87 77.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.771 -0.728 . . . . 62.21 112.451 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.03 159.03 41.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.768 0.318 . . . . 65.12 111.064 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.754 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.4 mp0 -71.76 140.71 49.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 73.31 110.917 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.778 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -129.56 115.48 34.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 53.31 111.169 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.753 HG23 ' HA ' ' A' ' 38' ' ' THR . 1.1 m -103.76 90.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 73.12 111.107 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.522 ' HB2' HG12 ' A' ' 93' ' ' VAL . 71.4 m-85 -66.45 140.87 58.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.913 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -132.42 98.61 4.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 71.13 110.931 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.658 HG23 HG23 ' A' ' 41' ' ' VAL . 1.4 mp -97.72 158.41 3.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 71.24 111.157 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.2 t -168.73 135.59 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 72.35 111.144 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.63 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -139.72 159.93 63.11 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.669 0.747 . . . . 50.41 110.858 -179.847 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.416 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.1 Cg_endo -69.71 -52.77 0.31 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.697 2.265 . . . . 70.11 112.398 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -153.02 41.11 0.56 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 53.54 110.847 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.63 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -142.3 135.07 27.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.229 -0.441 . . . . 73.15 111.125 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.9 mt -72.95 146.39 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 72.01 111.134 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.588 ' CB ' HG21 ' A' ' 65' ' ' ILE . 30.6 p80 -113.65 -168.16 1.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 71.32 110.848 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.87 118.16 2.06 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.743 -0.742 . . . . 35.4 112.51 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -117.63 144.38 45.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 63.22 110.842 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 32.9 t-80 -106.03 130.19 53.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 75.21 110.839 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.676 HG12 HG21 ' A' ' 81' ' ' ILE . 2.4 p -131.71 128.82 60.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.472 . . . . 63.51 111.089 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -58.08 -177.53 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 63.21 110.874 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.3 -47.6 1.95 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.738 -0.744 . . . . 74.11 112.444 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.409 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -147.28 179.49 7.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.857 0.36 . . . . 73.12 111.086 -179.803 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.409 ' H ' HG22 ' A' ' 79' ' ' THR . 4.2 m120 -92.31 78.88 5.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 74.13 110.896 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.676 HG21 HG12 ' A' ' 76' ' ' VAL . 6.8 tt -88.56 123.43 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 71.21 111.102 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -122.67 92.56 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 72.2 110.919 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.6 m -116.48 119.92 63.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 51.0 111.174 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -165.44 111.15 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 61.32 110.906 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.414 HG21 ' OG ' ' A' ' 91' ' ' SER . 86.2 t -140.63 140.81 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 70.44 111.133 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.0 mp -56.88 160.77 5.46 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.567 0.699 . . . . 72.34 110.928 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 160.68 48.83 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.672 2.248 . . . . 60.1 112.375 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.2 17.24 56.14 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.742 -0.742 . . . . 43.41 112.504 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -159.79 157.47 29.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.881 0.372 . . . . 74.31 110.886 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 86.1 t -102.92 133.5 46.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 54.11 111.107 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.414 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.6 OUTLIER -109.53 115.29 29.64 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.845 -179.871 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.5 m -94.46 124.43 38.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.062 -0.517 . . . . 74.21 111.158 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.522 HG12 ' HB2' ' A' ' 63' ' ' PHE . 10.7 p -134.67 137.66 50.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 74.32 111.197 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -103.24 108.56 19.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.154 -0.476 . . . . 70.42 110.902 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -141.35 112.26 7.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 74.11 110.909 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -112.86 137.31 51.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.47 . . . . 61.42 111.109 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.32 -175.28 3.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 71.24 110.919 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.5 mtmm -123.63 -12.78 7.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.871 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.6 mpp_? -150.87 161.79 28.94 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.603 0.716 . . . . 75.3 110.904 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.83 64.95 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.763 2.309 . . . . 71.44 112.331 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.92 141.58 3.18 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.733 -0.746 . . . . 62.53 112.493 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -106.18 128.84 54.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 62.22 110.898 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 5.9 p90 -143.98 146.19 32.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.155 -0.475 . . . . 72.01 110.947 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.92 -176.52 5.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 73.11 110.846 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.406 HG22 ' N ' ' A' ' 106' ' ' ILE . 18.9 mm 66.37 155.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 73.11 111.103 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.418 ' C ' HD13 ' A' ' 106' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 74.43 111.096 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.535 ' O ' HD13 ' A' ' 53' ' ' ILE . 4.2 m . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.777 0.322 . . . . 73.31 111.152 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.646 HG13 HG21 ' A' ' 53' ' ' ILE . 4.6 mp -146.77 120.4 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 75.25 111.174 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 55' ' ' VAL . 2.6 p -116.41 142.2 31.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 73.32 111.103 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.879 HG22 HG13 ' A' ' 55' ' ' VAL . 60.5 t -106.05 122.17 59.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.162 -0.472 . . . . 74.2 111.161 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -90.39 134.94 34.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 75.31 110.936 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.506 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 71.53 110.897 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 25.2 mp0 . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.859 0.361 . . . . 73.51 110.888 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -92.59 137.71 32.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 73.24 110.863 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.47 HG21 HG21 ' A' ' 16' ' ' VAL . 12.5 m -136.32 -177.94 2.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 65.32 111.127 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -143.93 162.52 40.47 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.589 0.709 . . . . 70.14 110.897 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -4.12 13.38 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.697 2.265 . . . . 73.45 112.355 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.425 ' O ' HG23 ' A' ' 15' ' ' THR . 23.3 m -47.64 -70.04 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 70.43 111.126 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.425 HG23 ' O ' ' A' ' 14' ' ' THR . 3.7 p -155.96 38.74 0.36 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 73.42 111.147 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.581 HG22 ' CE3' ' A' ' 22' ' ' TRP . 13.4 p -75.52 -42.25 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.253 -0.431 . . . . 73.5 111.13 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.548 ' HB2' HD22 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -108.97 11.25 26.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 74.32 110.868 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 11.6 mm100 -105.55 -33.26 8.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 71.34 110.879 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.47 ' CG ' ' O ' ' A' ' 19' ' ' GLU . 28.5 tt0 -142.55 13.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 74.31 110.859 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -103.35 -154.85 24.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.741 -0.742 . . . . 75.23 112.487 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.462 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.2 Cg_endo -69.75 -23.06 31.26 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.684 2.256 . . . . 62.21 112.351 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.581 ' CE3' HG22 ' A' ' 16' ' ' VAL . 18.2 m-90 -91.03 -7.27 52.35 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 73.44 110.939 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.18 -44.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 51.41 111.132 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.43 137.71 20.74 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.61 0.719 . . . . 73.4 110.892 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -17.83 37.14 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.692 2.261 . . . . 61.23 112.314 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.19 -37.8 69.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 31.43 111.134 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -84.79 4.9 30.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 72.32 110.911 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.65 -73.29 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 50.03 111.107 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.475 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.0 p -105.93 123.01 60.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.235 -0.439 . . . . 60.35 111.105 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.6 t -137.76 150.35 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.457 . . . . 72.24 111.126 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.423 ' NE2' ' CD2' ' A' ' 37' ' ' TYR . 1.3 mm-40 -75.67 121.29 22.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 70.41 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.4 p -121.31 -41.6 2.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.433 . . . . 75.53 111.163 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.73 -166.74 34.8 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.734 -0.746 . . . . 60.52 112.515 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -36.76 10.21 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.673 2.248 . . . . 64.23 112.378 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ASN . . . . . 0.502 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 63.8 t30 -152.7 28.95 0.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.249 -0.432 . . . . 73.03 110.861 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 127.53 44.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 74.23 110.893 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.423 ' CD2' ' NE2' ' A' ' 31' ' ' GLN . 18.0 m-85 -96.66 135.62 38.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 73.32 110.899 -179.837 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.78 ' HA ' HG23 ' A' ' 62' ' ' VAL . 51.7 m -92.01 102.36 14.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.114 -0.493 . . . . 52.01 111.162 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.424 HG11 HG23 ' A' ' 53' ' ' ILE . 12.5 t -85.75 139.01 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 64.23 111.099 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -120.2 100.61 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 75.03 110.927 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.497 HG12 HG12 ' A' ' 53' ' ' ILE . 15.4 m -96.33 142.43 13.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.104 -0.498 . . . . 70.42 111.108 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.568 HD21 ' CE2' ' A' ' 44' ' ' PHE . 15.1 tp -130.31 144.21 51.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.925 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.42 ' H ' HD12 ' A' ' 42' ' ' LEU . . . -154.52 98.57 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 63.33 111.132 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.568 ' CE2' HD21 ' A' ' 42' ' ' LEU . 3.1 p90 -113.88 155.96 24.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 71.24 110.854 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.76 31.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 62.21 111.103 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -105.73 75.36 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 54.33 110.866 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.43 -162.37 17.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.713 -0.756 . . . . 53.11 112.491 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 34.1 p90 -126.67 151.88 47.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.834 0.349 . . . . 73.21 110.926 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.08 159.97 68.95 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.64 0.733 . . . . 63.25 110.889 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -176.38 1.48 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.701 2.267 . . . . 74.3 112.316 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.478 ' CB ' HG21 ' A' ' 121' ' ' THR . 1.6 m120 -138.11 62.16 30.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.615 0.721 . . . . 72.25 110.856 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 6.27 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.719 2.28 . . . . 65.12 112.334 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.645 HG21 HG13 ' A' ' 122' ' ' ILE . 3.6 mp -48.4 107.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 74.23 111.094 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.475 ' HB3' HG11 ' A' ' 29' ' ' VAL . 39.7 tt0 -110.75 140.19 45.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.14 110.9 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 1.0 HG12 HG21 ' A' ' 61' ' ' ILE . 3.0 m -140.59 86.36 12.32 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.655 0.74 . . . . 73.52 111.152 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.658 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.0 Cg_endo -69.74 121.92 8.61 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.686 2.258 . . . . 64.11 112.374 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.95 153.33 42.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 71.02 110.906 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.8 -9.59 75.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 71.14 112.52 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.502 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -133.58 154.72 50.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.741 0.305 . . . . 74.03 111.12 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.713 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.6 mm-40 -67.09 144.4 56.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 70.03 110.899 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 1.0 HG21 HG12 ' A' ' 55' ' ' VAL . 6.7 mm -129.12 101.03 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 64.4 111.142 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.78 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.4 OUTLIER -89.19 100.1 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 63.52 111.104 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.476 ' HZ ' HG11 ' A' ' 55' ' ' VAL . 70.0 m-85 -72.89 141.6 47.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 62.51 110.911 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -132.62 99.21 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 75.03 110.901 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.598 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.4 mp -98.37 153.92 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 72.52 111.081 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -169.18 136.62 1.83 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 62.43 111.127 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.491 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -148.22 159.44 39.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.67 0.748 . . . . 63.53 110.857 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.403 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.4 Cg_endo -69.81 -55.14 0.19 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.659 2.239 . . . . 73.35 112.352 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -156.3 62.89 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 72.32 110.866 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.491 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.28 136.15 4.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 63.21 111.162 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.2 mm -71.12 143.7 14.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 73.3 111.124 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.598 ' CG ' HG21 ' A' ' 65' ' ' ILE . 24.8 p80 -125.55 -168.89 1.91 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 74.24 110.852 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.18 132.89 3.49 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 65.2 112.439 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -126.35 142.04 51.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 65.23 110.903 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -103.93 89.28 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 75.24 110.902 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.787 HG13 ' CE2' ' A' ' 103' ' ' TYR . 15.6 t -74.63 131.81 34.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 63.43 111.138 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -68.14 178.36 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 71.31 110.908 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.96 -51.05 1.71 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.729 -0.748 . . . . 65.32 112.495 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.435 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -140.0 179.51 6.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.822 0.344 . . . . 52.23 111.142 -179.831 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.435 ' H ' HG22 ' A' ' 79' ' ' THR . 22.5 m120 -87.94 67.42 9.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 70.11 110.871 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.467 ' O ' HG23 ' A' ' 81' ' ' ILE . 13.2 tt -76.86 119.71 25.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 74.24 111.134 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -116.35 103.32 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 74.31 110.933 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.519 HG11 HG21 ' A' ' 93' ' ' VAL . 2.8 m -125.59 120.52 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.44 111.195 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -155.33 113.45 3.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 73.32 110.878 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.668 HG21 ' OG ' ' A' ' 91' ' ' SER . 60.9 t -140.85 147.31 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 71.13 111.099 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.492 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -73.48 158.68 86.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.632 0.73 . . . . 73.21 110.954 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.6 Cg_endo -69.82 159.79 52.05 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.686 2.258 . . . . 63.34 112.333 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.41 17.35 50.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.767 -0.73 . . . . 32.4 112.479 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -165.24 138.48 4.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.947 0.403 . . . . 71.52 110.858 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.38 137.69 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.137 -0.483 . . . . 70.22 111.081 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.668 ' OG ' HG21 ' A' ' 85' ' ' VAL . 3.5 t -119.98 131.7 55.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.113 -0.494 . . . . 62.43 110.847 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.4 t -96.92 145.76 25.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 54.41 111.119 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.519 HG21 HG11 ' A' ' 83' ' ' VAL . 40.1 t -145.99 125.6 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 73.23 111.139 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -102.99 115.43 30.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 71.21 110.89 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -162.27 109.62 1.33 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 62.55 110.908 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -107.72 143.04 36.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.487 . . . . 74.43 111.115 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.41 174.91 6.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 64.34 110.858 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -119.72 -20.36 7.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.489 . . . . 65.54 110.858 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -139.35 158.48 68.79 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.653 0.74 . . . . 75.51 110.814 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.424 ' HA ' ' HB ' ' A' ' 124' ' ' VAL . 53.7 Cg_endo -69.76 158.07 58.22 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.656 2.237 . . . . 74.35 112.355 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 156.27 136.53 2.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 54.24 112.497 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.507 ' HB3' HG23 ' A' ' 123' ' ' VAL . 1.5 pm0 -101.67 134.75 44.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 74.42 110.892 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' TYR . . . . . 0.787 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.7 OUTLIER -143.9 127.24 16.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 73.44 110.951 -179.82 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.8 105.96 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 75.13 110.901 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 6.3 tt 179.8 142.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 62.41 111.103 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 72.44 111.125 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.557 ' O ' HD13 ' A' ' 53' ' ' ILE . 46.3 m . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.779 0.323 . . . . 62.02 111.201 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.645 HG13 HG21 ' A' ' 53' ' ' ILE . 4.6 mp -141.73 119.46 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 64.34 111.158 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.507 HG23 ' HB3' ' A' ' 102' ' ' GLU . 9.0 p -116.44 136.88 52.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 71.11 111.125 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 55' ' ' VAL . 35.5 t -100.67 128.1 53.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 30.31 111.169 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.6 mmtt -111.99 132.55 54.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 71.23 110.896 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.207 -0.451 . . . . 64.0 110.926 179.961 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.497 ' O ' HG12 ' A' ' 90' ' ' VAL . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.821 0.343 . . . . 72.31 110.908 . . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -93.77 127.91 39.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 73.22 110.892 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.437 HG21 HG21 ' A' ' 16' ' ' VAL . 7.1 m -110.8 -178.79 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 63.22 111.153 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -144.41 162.17 40.81 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.593 0.711 . . . . 74.04 110.909 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -3.32 11.81 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.705 2.27 . . . . 43.31 112.306 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 26.9 m -44.92 -70.14 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 63.35 111.09 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 27.6 p -149.62 22.97 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 74.42 111.148 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.437 HG21 HG21 ' A' ' 11' ' ' VAL . 10.6 p -61.42 -23.75 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 74.35 111.106 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.518 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.6 OUTLIER -105.91 -19.88 13.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 72.31 110.844 -179.939 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -85.29 -28.29 25.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 61.1 110.912 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.402 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 4.9 pt-20 -145.06 146.66 31.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.467 . . . . 74.11 110.864 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.64 -158.91 14.02 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.794 -0.717 . . . . 31.34 112.453 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.46 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.0 Cg_endo -69.73 -30.26 22.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.665 2.243 . . . . 72.3 112.373 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.729 ' HB3' HD13 ' A' ' 42' ' ' LEU . 17.2 m-90 -85.86 -8.36 58.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.196 -0.457 . . . . 74.12 110.887 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.402 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -72.63 -59.63 2.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 33.22 111.103 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.54 145.8 34.09 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.588 0.709 . . . . 74.44 110.891 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.644 2.229 . . . . 64.33 112.36 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.0 -22.62 60.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 74.12 111.089 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -116.42 30.86 7.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 54.13 110.916 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.35 -57.01 3.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 74.43 111.097 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.78 HG21 ' HB3' ' A' ' 54' ' ' GLU . 21.9 t -113.18 101.89 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 74.02 111.124 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.9 t -117.14 148.87 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 75.32 111.119 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.452 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -80.39 117.4 21.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 64.24 110.915 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 32' ' ' THR . . . . . 0.449 HG21 ' OG1' ' A' ' 38' ' ' THR . 15.9 p -105.79 -43.6 4.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 65.03 111.131 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.13 -173.24 22.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.79 -0.719 . . . . 73.31 112.501 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -5.61 16.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.7 2.267 . . . . 74.23 112.307 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -175.41 30.15 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 74.31 110.845 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLN . . . . . 0.412 ' HG3' ' HB2' ' A' ' 60' ' ' GLU . 4.6 mp0 -126.62 118.42 24.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 74.33 110.91 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.452 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 54.2 m-85 -98.93 130.4 45.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 74.31 110.94 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.449 ' OG1' HG21 ' A' ' 32' ' ' THR . 24.7 m -95.62 105.65 17.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.11 -0.496 . . . . 71.01 111.157 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.437 HG13 HG22 ' A' ' 29' ' ' VAL . 18.3 t -88.02 146.3 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 75.04 111.128 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -127.27 106.65 9.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 74.54 110.947 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.532 HG12 ' CG1' ' A' ' 53' ' ' ILE . 16.2 m -107.08 142.76 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 60.43 111.096 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.729 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.6 OUTLIER -139.41 143.27 37.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 74.45 110.858 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.35 114.76 3.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 71.3 111.083 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.507 ' CD2' HD21 ' A' ' 42' ' ' LEU . 4.1 p90 -127.67 155.06 44.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 75.42 110.905 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.9 4.21 38.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.465 . . . . 53.14 111.103 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -104.25 74.76 1.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 72.41 110.861 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 109.37 -160.11 13.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.726 -0.749 . . . . 75.55 112.544 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 11.4 p90 -135.25 144.94 47.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.793 0.33 . . . . 73.14 110.948 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -143.69 162.3 42.21 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.609 0.718 . . . . 45.23 110.883 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -176.09 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.63 2.22 . . . . 72.12 112.338 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.678 ' O ' HD12 ' A' ' 53' ' ' ILE . 62.9 m-20 -130.79 59.93 49.46 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.622 0.725 . . . . 73.13 110.884 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 73.84 1.31 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.7 2.267 . . . . 64.11 112.353 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.7 HG21 HG13 ' A' ' 122' ' ' ILE . 4.1 mp -117.14 122.71 70.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 75.15 111.086 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.78 ' HB3' HG21 ' A' ' 29' ' ' VAL . 10.5 tt0 -125.75 129.3 49.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.879 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 124' ' ' VAL . 2.6 p -136.51 80.47 38.69 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.635 0.731 . . . . 54.41 111.098 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.446 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.74 122.92 9.59 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.701 2.268 . . . . 75.35 112.321 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.473 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.4 pm0 -67.49 154.71 40.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.237 -0.438 . . . . 74.23 110.932 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.33 -10.34 71.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 54.51 112.49 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.28 143.11 48.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 73.04 111.087 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.559 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.9 mp0 -61.15 135.19 57.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 71.21 110.867 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.651 HG13 HG23 ' A' ' 55' ' ' VAL . 12.4 mm -122.62 123.5 68.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.118 -0.492 . . . . 73.43 111.135 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.963 HG13 HG23 ' A' ' 92' ' ' THR . 41.9 t -101.9 92.23 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.42 111.134 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.79 138.33 54.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 73.43 110.873 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -131.15 102.01 5.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 74.55 110.91 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 74' ' ' PHE . 1.6 mp -102.92 139.84 22.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 71.52 111.146 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 10.1 t -158.62 137.74 11.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 53.54 111.163 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.457 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -141.59 160.93 54.78 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.674 0.75 . . . . 64.31 110.865 -179.875 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.457 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.86 -54.39 0.22 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.655 2.237 . . . . 52.14 112.349 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -157.32 59.03 0.51 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 44.44 110.882 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.407 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.93 135.97 4.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 73.42 111.17 179.983 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 mm -67.4 144.97 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 73.11 111.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.4 ' HB2' HG21 ' A' ' 65' ' ' ILE . 9.1 p80 -132.96 -176.58 4.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 72.43 110.848 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.62 132.66 3.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.741 -0.742 . . . . 60.2 112.455 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.504 ' CZ ' HD11 ' A' ' 65' ' ' ILE . 1.8 p90 -121.03 144.3 48.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.845 0.355 . . . . 64.32 110.891 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' HIS . . . . . 0.42 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 9.7 p80 -103.82 88.17 2.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 72.45 110.881 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.784 HG13 ' CE2' ' A' ' 103' ' ' TYR . 10.9 t -74.94 115.67 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 62.01 111.125 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.89 177.45 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 74.11 110.91 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.41 -49.07 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.788 -0.72 . . . . 62.22 112.489 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.437 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -134.46 179.38 6.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.751 0.31 . . . . 70.02 111.163 -179.905 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.437 ' H ' HG22 ' A' ' 79' ' ' THR . 24.4 m120 -88.35 50.36 1.96 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 70.41 110.882 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.494 ' O ' HG23 ' A' ' 81' ' ' ILE . 6.2 tp -60.94 116.04 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 71.34 111.1 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -116.9 100.82 8.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 42.54 110.876 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.605 HG11 HG21 ' A' ' 93' ' ' VAL . 3.4 m -121.86 124.13 70.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 73.04 111.13 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -164.61 108.62 0.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 71.03 110.856 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.591 HG21 ' OG ' ' A' ' 91' ' ' SER . 45.1 t -140.4 146.49 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 44.13 111.189 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.74 161.23 62.68 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.58 0.705 . . . . 72.01 110.948 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.94 51.54 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.73 2.287 . . . . 71.43 112.305 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.37 5.48 75.67 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.75 -0.738 . . . . 50.01 112.515 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -147.9 117.95 7.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.899 0.38 . . . . 73.24 110.872 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.497 HG12 ' O ' ' A' ' 9' ' ' GLU . 3.8 p -77.94 118.98 25.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 70.42 111.104 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.591 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -94.85 134.05 37.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.11 -0.495 . . . . 74.02 110.835 -179.835 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.963 HG23 HG13 ' A' ' 62' ' ' VAL . 74.2 m -98.84 109.39 22.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 70.42 111.15 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.605 HG21 HG11 ' A' ' 83' ' ' VAL . 39.7 t -106.86 148.33 11.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 61.3 111.138 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -121.05 107.52 12.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.476 . . . . 74.54 110.831 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -153.18 130.39 11.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 52.34 110.949 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 29.7 m -139.95 141.57 36.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 75.34 111.143 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -96.57 -176.42 3.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 74.2 110.907 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -123.15 -12.55 7.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 61.11 110.905 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.95 162.85 51.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.647 0.737 . . . . 74.35 110.863 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 149.54 66.92 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.686 2.257 . . . . 64.34 112.328 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.4 136.92 2.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 61.52 112.459 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.711 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.5 OUTLIER -109.41 132.82 53.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.847 0.356 . . . . 70.23 110.875 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 103' ' ' TYR . . . . . 0.784 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.9 OUTLIER -143.27 137.17 28.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.181 -0.463 . . . . 52.21 110.895 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.93 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.17 -164.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 73.23 110.877 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.93 HG22 ' O ' ' A' ' 104' ' ' ARG . 7.7 tt 57.55 158.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 75.43 111.097 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 60.31 111.118 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.567 ' O ' HD13 ' A' ' 53' ' ' ILE . 55.1 m . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.775 0.321 . . . . 73.43 111.169 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.7 HG13 HG21 ' A' ' 53' ' ' ILE . 5.1 mp -146.48 129.66 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 64.42 111.115 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.711 HG23 ' HB3' ' A' ' 102' ' ' GLU . 9.9 p -132.27 137.06 55.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 71.42 111.119 179.816 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.679 HG13 ' O ' ' A' ' 55' ' ' VAL . 15.7 t -99.73 125.18 53.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 72.03 111.115 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.6 mmmt -99.26 130.68 45.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 71.34 110.879 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.473 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 61.5 110.863 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.847 0.356 . . . . 75.41 110.919 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.12 136.74 38.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 73.41 110.85 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.518 HG21 HG21 ' A' ' 16' ' ' VAL . 15.2 m -128.46 -178.66 2.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 64.34 111.103 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 161.94 41.54 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.647 0.737 . . . . 64.14 110.854 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -4.71 14.58 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.735 2.29 . . . . 62.01 112.359 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.407 ' O ' HG23 ' A' ' 15' ' ' THR . 4.2 m -48.44 -66.92 0.32 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.185 -0.461 . . . . 74.35 111.138 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 14' ' ' THR . 2.8 p -155.62 37.59 0.37 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.446 . . . . 63.15 111.163 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.518 HG21 HG21 ' A' ' 11' ' ' VAL . 14.7 p -74.29 -34.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 75.11 111.119 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.427 ' HB3' HD11 ' A' ' 42' ' ' LEU . 11.5 ptt85 -95.17 -10.73 29.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 73.45 110.865 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 -97.69 -35.08 10.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 62.41 110.892 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -131.86 136.95 47.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 63.24 110.906 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 118.21 -159.5 14.25 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 11.21 112.495 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -26.89 26.94 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.63 2.22 . . . . 62.15 112.325 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.748 ' HB3' HD13 ' A' ' 42' ' ' LEU . 15.7 m-90 -86.37 -10.94 53.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.235 -0.439 . . . . 71.54 110.929 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.9 -59.0 3.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 61.14 111.079 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.85 144.61 29.7 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.573 0.702 . . . . 73.31 110.898 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -15.32 37.02 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.686 2.257 . . . . 62.21 112.349 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.29 -6.46 48.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 31.04 111.117 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 8.3 mm100 -106.39 6.49 30.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 72.54 110.883 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -51.95 -76.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 70.54 111.07 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.451 HG13 ' HB3' ' A' ' 37' ' ' TYR . 14.2 t -83.13 130.75 35.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 74.34 111.131 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 32.3 t -144.67 114.35 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 73.43 111.109 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -60.03 116.51 4.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 74.34 110.904 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.4 t -119.9 -38.74 2.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 63.43 111.136 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.91 173.61 18.82 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.732 . . . . 24.35 112.539 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.04 3.57 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.726 2.284 . . . . 64.21 112.339 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 53.2 t30 67.78 34.96 4.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 74.33 110.898 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -145.48 156.96 44.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 62.14 110.901 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.451 ' HB3' HG13 ' A' ' 29' ' ' VAL . 43.1 m-85 -143.16 141.27 31.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 74.55 110.955 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.528 HG23 ' HE3' ' A' ' 64' ' ' LYS . 54.4 m -94.86 104.87 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.117 -0.492 . . . . 74.21 111.152 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.466 HG11 HG23 ' A' ' 53' ' ' ILE . 15.7 t -87.35 152.62 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 51.24 111.097 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -127.2 140.25 52.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 64.11 110.913 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.593 HG22 ' CG1' ' A' ' 53' ' ' ILE . 60.0 t -139.1 137.98 41.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 63.54 111.106 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.748 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.4 OUTLIER -138.42 141.49 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 73.3 110.873 179.92 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.58 101.18 2.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 73.1 111.104 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -116.57 147.35 41.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 74.44 110.857 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.23 0.26 52.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 73.44 111.115 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -94.19 39.28 1.08 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 75.44 110.908 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.63 -137.93 8.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 64.51 112.526 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 31.1 t80 -155.24 160.6 40.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.802 0.334 . . . . 74.23 110.959 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -165.23 162.18 14.07 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.581 0.705 . . . . 73.04 110.912 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 176.74 6.37 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.703 2.269 . . . . 72.14 112.348 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.639 ' C ' HD12 ' A' ' 53' ' ' ILE . 6.6 m120 -133.89 63.25 62.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.616 0.722 . . . . 53.51 110.85 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 72.1 1.48 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.268 . . . . 74.4 112.372 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.722 HG21 HG13 ' A' ' 122' ' ' ILE . 4.9 mp -106.41 121.55 59.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 70.14 111.152 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -120.0 115.4 23.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 75.31 110.893 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.862 HG13 HG22 ' A' ' 124' ' ' VAL . 2.6 p -123.35 78.47 53.56 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.621 0.724 . . . . 54.42 111.15 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.721 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.73 123.02 9.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.704 2.27 . . . . 64.14 112.342 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.507 HE22 ' HA ' ' A' ' 126' ' ' GLU . 1.1 pm0 -68.61 154.72 41.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.267 -0.424 . . . . 61.14 110.875 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.1 -6.28 76.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 73.41 112.517 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.31 156.44 47.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.76 0.314 . . . . 72.03 111.072 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.742 ' O ' HD13 ' A' ' 61' ' ' ILE . 6.3 mt-10 -67.42 138.53 56.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.915 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.742 HD13 ' O ' ' A' ' 60' ' ' GLU . 4.4 mm -130.87 114.8 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 41.31 111.118 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 92' ' ' THR . 39.5 t -101.23 94.29 3.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 75.35 111.123 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -70.47 132.61 45.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 74.44 110.884 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.528 ' HE3' HG23 ' A' ' 38' ' ' THR . 36.2 mttt -128.74 99.74 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 75.23 110.914 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.502 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.8 mp -104.22 158.63 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 72.22 111.159 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.414 ' N ' HG22 ' A' ' 65' ' ' ILE . 7.9 t -167.01 141.91 4.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 62.13 111.144 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.586 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -148.48 158.46 40.5 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.686 0.755 . . . . 62.51 110.852 -179.88 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.45 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.6 Cg_endo -69.8 -55.48 0.17 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.725 2.283 . . . . 74.12 112.31 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -154.91 68.39 0.7 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.852 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.586 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.2 -171.15 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.215 -0.448 . . . . 74.22 111.143 -179.992 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.509 HD13 ' O ' ' A' ' 70' ' ' VAL . 30.9 mm -138.11 140.49 40.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 71.14 111.126 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.502 ' CG ' HG21 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -115.23 -85.46 0.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 73.3 110.848 179.917 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 53.85 94.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.71 -0.757 . . . . 31.34 112.48 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -100.14 143.09 30.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 70.13 110.868 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -120.22 142.84 48.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 73.04 110.846 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.806 HG11 ' CZ ' ' A' ' 95' ' ' TYR . 4.9 p -127.78 122.83 59.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 71.34 111.112 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -52.16 160.85 0.7 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 74.04 110.897 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.15 -51.93 4.55 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.786 -0.721 . . . . 41.14 112.467 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.85 160.91 14.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.827 0.346 . . . . 73.24 111.132 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -101.03 35.49 2.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.466 . . . . 71.24 110.924 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.635 HG21 HG12 ' A' ' 76' ' ' VAL . 20.0 tt -54.73 124.91 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 75.03 111.117 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -123.76 82.75 2.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 74.24 110.897 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.447 HG11 HG11 ' A' ' 93' ' ' VAL . 5.1 m -110.33 119.33 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 62.51 111.106 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -165.39 103.32 0.73 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 62.42 110.896 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 18.1 m -140.36 139.37 35.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.148 -0.478 . . . . 75.1 111.13 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.7 mp -59.88 163.39 7.63 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.583 0.706 . . . . 72.45 110.936 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 159.93 51.6 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.669 2.246 . . . . 50.43 112.343 179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.5 17.38 57.1 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 71.31 112.469 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -158.42 143.45 16.35 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 74.34 110.881 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 52.3 t -81.42 146.12 7.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.136 -0.484 . . . . 74.13 111.115 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -103.82 158.08 16.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.44 110.891 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 62' ' ' VAL . 26.6 m -147.28 123.23 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 75.33 111.164 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.447 HG11 HG11 ' A' ' 83' ' ' VAL . 9.4 p -153.15 136.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 51.33 111.126 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.0 mtm180 -96.33 81.46 3.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 75.02 110.84 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.806 ' CZ ' HG11 ' A' ' 76' ' ' VAL . 2.9 t80 -106.11 121.89 45.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.209 -0.451 . . . . 72.5 110.935 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 t -133.74 138.46 45.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 70.13 111.135 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.43 -168.9 1.68 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.899 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.5 mtpt -123.12 -27.12 4.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 70.42 110.917 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ARG . . . . . 0.437 ' HB3' ' HD2' ' A' ' 100' ' ' PRO . 13.3 mmt180 -129.18 156.07 78.87 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 73.04 110.916 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' PRO . . . . . 0.437 ' HD2' ' HB3' ' A' ' 99' ' ' ARG . 54.0 Cg_endo -69.72 152.08 69.43 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.672 2.248 . . . . 52.33 112.329 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.7 150.49 6.84 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.758 -0.734 . . . . 70.34 112.485 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.691 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -112.63 127.74 56.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.885 0.374 . . . . 63.31 110.867 -179.879 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -143.93 136.46 26.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 72.51 110.911 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.914 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.1 OUTLIER -144.38 -167.29 2.59 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.119 -0.492 . . . . 74.23 110.885 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.914 HG22 ' O ' ' A' ' 104' ' ' ARG . 0.6 OUTLIER 56.93 159.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 55.12 111.074 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 7.0 tt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 75.22 111.121 179.861 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.568 ' O ' HD13 ' A' ' 53' ' ' ILE . 28.6 m . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.775 0.321 . . . . 73.34 111.161 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.722 HG13 HG21 ' A' ' 53' ' ' ILE . 4.8 mp -147.88 109.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 73.35 111.112 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.691 HG23 ' HB3' ' A' ' 102' ' ' GLU . 8.6 p -114.97 140.65 35.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 75.24 111.091 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.862 HG22 HG13 ' A' ' 55' ' ' VAL . 68.9 t -104.16 118.49 51.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 74.51 111.125 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 5.1 mmmt -89.98 131.21 35.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 70.24 110.912 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.507 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 72.23 110.906 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.546 ' O ' HG12 ' A' ' 90' ' ' VAL . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.822 0.344 . . . . 62.15 110.9 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.95 124.14 34.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 74.34 110.92 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 16' ' ' VAL . 13.9 m -111.4 -178.99 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.456 . . . . 74.4 111.146 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -145.59 162.27 37.21 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.594 0.711 . . . . 72.02 110.887 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 -4.03 13.19 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.688 2.258 . . . . 71.53 112.339 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.411 ' O ' HG23 ' A' ' 15' ' ' THR . 1.9 m -46.93 -65.2 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 71.43 111.166 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 14' ' ' THR . 2.0 p -155.63 32.54 0.36 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.237 -0.438 . . . . 72.44 111.127 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 11' ' ' VAL . 13.9 p -70.96 -29.14 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.232 -0.44 . . . . 63.13 111.125 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.8 ptt-85 -97.55 -9.03 27.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.879 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -101.41 -31.9 10.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 73.33 110.918 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -132.8 134.82 45.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 74.12 110.908 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.98 -158.56 14.62 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.782 -0.723 . . . . 73.2 112.542 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.446 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 53.8 Cg_endo -69.78 -28.81 24.68 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.693 2.262 . . . . 64.34 112.377 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.446 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 18.5 m-90 -87.01 -5.67 59.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 75.31 110.921 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.5 -59.34 2.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.246 -0.434 . . . . 55.44 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -113.93 144.68 32.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.554 0.692 . . . . 65.2 110.891 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -5.02 15.23 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.683 2.256 . . . . 70.12 112.384 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.77 -19.0 61.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.128 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.24 31.16 6.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 74.21 110.929 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.2 -73.1 0.13 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.05 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.655 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.0 p -111.63 106.54 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.441 . . . . 65.02 111.157 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -117.45 149.92 19.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 64.35 111.157 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -79.64 124.21 28.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 73.24 110.94 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.7 t -119.19 -14.83 9.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 52.11 111.136 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.42 -170.93 12.81 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 73.22 112.484 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -36.02 11.42 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.252 . . . . 72.14 112.33 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 20.2 t30 -149.76 34.61 0.69 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.225 -0.443 . . . . 61.24 110.861 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -137.33 117.44 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 73.4 110.91 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -98.24 143.13 29.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 74.23 110.918 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 51.9 m -99.05 102.21 13.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 73.33 111.158 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 t -83.53 143.15 12.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 75.52 111.117 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -125.0 112.7 16.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.196 -0.456 . . . . 73.01 110.937 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.5 HG22 HD12 ' A' ' 53' ' ' ILE . 85.4 t -109.53 125.9 66.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.12 -0.491 . . . . 63.01 111.107 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.692 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.5 tm? -115.64 137.18 52.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 74.21 110.928 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.692 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.05 117.56 4.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 72.11 111.082 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -145.38 140.54 27.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 53.33 110.885 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.4 27.03 1.31 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 74.31 111.124 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -120.92 25.26 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 73.43 110.886 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 169.32 -146.9 10.53 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.816 -0.707 . . . . 52.22 112.523 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -155.57 116.4 3.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.798 0.332 . . . . 74.32 110.914 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.457 ' HG3' ' HD2' ' A' ' 50' ' ' PRO . 2.1 mp0 -134.65 163.32 52.02 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.591 0.71 . . . . 75.14 110.919 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.457 ' HD2' ' HG3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.79 162.15 43.19 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.64 2.226 . . . . 74.34 112.362 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 -124.29 64.34 36.81 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.586 0.708 . . . . 73.32 110.917 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.601 ' C ' HD13 ' A' ' 53' ' ' ILE . 54.3 Cg_endo -69.72 113.18 3.28 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.669 2.246 . . . . 74.54 112.375 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.601 HD13 ' C ' ' A' ' 52' ' ' PRO . 1.5 mm -126.13 144.99 34.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 71.22 111.161 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.655 ' HB3' HG11 ' A' ' 29' ' ' VAL . 24.0 tt0 -155.23 115.6 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 74.14 110.918 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 1.002 HG12 HG21 ' A' ' 61' ' ' ILE . 2.7 m -130.75 84.29 59.08 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.63 0.729 . . . . 73.34 111.127 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.703 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.77 122.62 9.3 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 73.02 112.369 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.7 154.56 38.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 53.45 110.9 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.62 -8.39 72.34 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 72.43 112.476 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.16 157.32 45.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.714 0.292 . . . . 51.1 111.142 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.728 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.0 mt-10 -70.19 144.7 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 71.4 110.915 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 1.002 HG21 HG12 ' A' ' 55' ' ' VAL . 5.4 mm -128.79 105.35 12.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 52.54 111.112 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.622 HG13 HG23 ' A' ' 92' ' ' THR . 25.4 t -84.74 100.68 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 73.24 111.074 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.478 ' CZ ' HG11 ' A' ' 55' ' ' VAL . 96.0 m-85 -76.89 135.15 38.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.1 110.876 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.47 ' HD3' HG21 ' A' ' 90' ' ' VAL . 8.7 mttt -132.28 100.19 4.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 62.32 110.93 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.508 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.6 mp -109.08 141.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 55.42 111.115 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 7.8 t -155.92 135.3 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 72.13 111.135 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.44 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -141.96 161.1 53.02 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.7 0.762 . . . . 54.03 110.826 -179.867 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.419 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.0 Cg_endo -69.74 -53.34 0.28 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.674 2.249 . . . . 51.4 112.365 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -156.67 57.82 0.55 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 71.14 110.823 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.44 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.49 141.43 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.254 -0.43 . . . . 75.13 111.126 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 72' ' ' HIS . 25.1 mm -85.35 155.18 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 71.53 111.093 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.508 ' CG ' HG21 ' A' ' 65' ' ' ILE . 0.2 OUTLIER -123.75 -86.28 0.64 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.121 -0.49 . . . . 71.12 110.857 179.872 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.04 101.6 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.721 -0.752 . . . . 62.14 112.469 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.479 ' CE2' HD11 ' A' ' 65' ' ' ILE . 2.5 p90 -103.5 144.94 30.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.917 0.389 . . . . 74.34 110.854 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -106.0 142.25 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 71.33 110.884 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.747 ' HB ' HG21 ' A' ' 81' ' ' ILE . 44.3 t -137.53 143.6 33.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 52.23 111.131 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -73.2 -175.7 1.94 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.478 . . . . 64.11 110.912 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.09 -51.09 3.98 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.75 -0.738 . . . . 52.12 112.493 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.442 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -142.14 179.5 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.828 0.347 . . . . 62.0 111.127 -179.862 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.442 ' H ' HG22 ' A' ' 79' ' ' THR . 6.8 t-20 -88.17 61.05 6.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 65.21 110.891 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.747 HG21 ' HB ' ' A' ' 76' ' ' VAL . 4.8 tp -71.16 99.72 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 73.11 111.13 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -110.4 112.11 23.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 72.24 110.919 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.808 HG11 HG21 ' A' ' 93' ' ' VAL . 1.5 m -130.82 122.93 53.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.457 . . . . 72.52 111.161 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -152.64 112.79 4.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 71.44 110.874 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.631 HG21 ' OG ' ' A' ' 91' ' ' SER . 57.3 t -140.55 144.28 27.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 60.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.27 160.06 80.54 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.631 0.729 . . . . 71.33 110.899 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.424 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.4 Cg_endo -69.76 159.82 51.97 Favored 'Trans proline' 0 C--N 1.34 0.126 0 C-N-CA 122.708 2.272 . . . . 53.31 112.28 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.61 -1.27 56.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 74.34 112.465 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -147.0 156.75 43.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.884 0.374 . . . . 74.45 110.891 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.546 HG12 ' O ' ' A' ' 9' ' ' GLU . 2.1 p -105.55 113.9 43.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 71.03 111.119 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.631 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -80.54 168.2 19.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 34.43 110.876 -179.87 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 92' ' ' THR . . . . . 0.622 HG23 HG13 ' A' ' 62' ' ' VAL . 96.5 m -134.5 139.35 45.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 65.34 111.129 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.808 HG21 HG11 ' A' ' 83' ' ' VAL . 9.9 t -143.45 137.63 25.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.236 -0.438 . . . . 71.01 111.128 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.04 72.63 0.79 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.469 . . . . 71.51 110.886 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -108.41 141.17 40.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 74.51 110.924 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.1 t -140.06 143.19 36.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.137 -0.483 . . . . 63.21 111.162 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -101.1 177.18 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 70.35 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.34 -12.79 8.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.462 . . . . 71.54 110.877 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -144.57 162.03 41.01 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.653 0.74 . . . . 74.3 110.914 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 155.58 65.62 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.73 2.287 . . . . 62.25 112.314 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 162.27 135.37 1.8 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.773 -0.727 . . . . 74.32 112.53 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.841 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -108.92 124.89 51.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.866 0.365 . . . . 74.14 110.901 -179.896 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -136.04 135.27 39.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.198 -0.456 . . . . 71.21 110.954 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.95 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.5 OUTLIER -144.24 -177.56 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 60.11 110.858 -179.95 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.95 HG22 ' O ' ' A' ' 104' ' ' ARG . 6.6 tt 59.79 158.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 73.13 111.122 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 72.04 111.164 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.557 ' C ' HD12 ' A' ' 122' ' ' ILE . 99.4 m . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.741 0.305 . . . . 63.42 111.138 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.576 HG13 HG21 ' A' ' 53' ' ' ILE . 3.1 mp -153.41 138.08 9.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 73.12 111.131 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.841 HG23 ' HB3' ' A' ' 102' ' ' GLU . 11.5 p -134.22 134.69 55.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 71.12 111.151 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.742 HG22 HG23 ' A' ' 55' ' ' VAL . 48.1 t -103.61 129.13 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 73.41 111.152 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt -107.19 129.1 54.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.134 -0.484 . . . . 63.31 110.885 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 64.51 110.878 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.45 ' O ' HG12 ' A' ' 90' ' ' VAL . 4.0 mm-40 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.828 0.347 . . . . 73.1 110.877 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.67 139.26 40.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 74.04 110.874 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.8 m -130.1 -177.55 2.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 73.35 111.124 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.411 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 55.9 p-10 -144.07 155.47 58.6 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.563 0.697 . . . . 73.01 110.893 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.4 Cg_endo -69.84 -3.94 13.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.656 2.237 . . . . 73.53 112.351 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.43 ' O ' HG23 ' A' ' 15' ' ' THR . 23.2 m -49.07 -64.7 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 44.23 111.092 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.43 HG23 ' O ' ' A' ' 14' ' ' THR . 2.7 p -156.04 34.91 0.34 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 62.21 111.15 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 p -70.59 -29.19 37.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 61.33 111.069 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.552 ' HB3' HD21 ' A' ' 42' ' ' LEU . 7.2 ptt-85 -98.74 -7.91 26.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 71.43 110.879 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -101.62 -34.79 9.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 73.15 110.927 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.51 133.2 46.07 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 73.53 110.891 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 120.25 -158.15 15.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.747 -0.74 . . . . 62.11 112.507 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -30.11 22.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.73 2.287 . . . . 74.0 112.321 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.416 ' HB3' HD23 ' A' ' 42' ' ' LEU . 13.5 m-90 -84.89 -10.21 57.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.279 -0.418 . . . . 74.1 110.921 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.85 -59.46 2.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 74.41 111.072 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.76 144.64 28.21 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.64 0.733 . . . . 72.33 110.815 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -26.35 27.8 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.686 2.257 . . . . 75.32 112.335 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.02 -18.31 60.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.262 -0.426 . . . . 52.32 111.093 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 19.0 mm-40 -87.35 6.85 31.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 75.22 110.887 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.87 -77.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.266 -0.424 . . . . 62.55 111.084 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.54 116.95 23.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 71.34 111.131 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.0 t -145.77 131.06 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 71.5 111.167 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.59 125.47 26.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 72.23 110.877 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.2 t -117.46 -41.39 2.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 72.24 111.148 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.73 -164.11 18.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 73.35 112.482 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -43.99 2.37 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.7 2.266 . . . . 41.51 112.372 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -141.27 34.45 1.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 73.31 110.908 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -131.4 119.71 22.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 71.31 110.847 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -97.0 140.93 30.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 62.4 110.919 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.694 ' HA ' HG23 ' A' ' 62' ' ' VAL . 96.7 m -93.79 122.45 36.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 61.22 111.137 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.907 HG11 HG23 ' A' ' 53' ' ' ILE . 18.5 t -109.05 108.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 60.44 111.107 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.408 ' CZ ' HG21 ' A' ' 38' ' ' THR . 66.6 m-85 -94.18 105.45 17.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 73.21 110.924 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.602 HG22 ' CG1' ' A' ' 53' ' ' ILE . 59.8 t -98.73 132.65 43.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.082 -0.508 . . . . 71.44 111.167 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.643 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.6 tm? -123.85 133.82 53.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.226 -0.443 . . . . 74.13 110.91 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.643 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.06 132.01 10.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 74.41 111.083 179.83 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -145.26 147.54 32.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 72.41 110.912 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.74 50.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.179 -0.464 . . . . 71.51 111.133 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -95.72 34.05 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 73.31 110.86 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.49 -138.56 6.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.75 -0.738 . . . . 65.05 112.505 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -155.17 157.02 36.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.801 0.334 . . . . 65.41 110.957 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -165.33 162.05 13.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.582 0.706 . . . . 73.31 110.938 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 178.64 4.34 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.677 2.251 . . . . 75.11 112.37 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.63 ' C ' HD12 ' A' ' 53' ' ' ILE . 8.0 m-80 -138.41 63.46 34.78 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.602 0.715 . . . . 73.34 110.869 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 73.1 1.36 Allowed 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.719 2.279 . . . . 65.4 112.361 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.907 HG23 HG11 ' A' ' 39' ' ' VAL . 4.8 mp -106.73 136.44 41.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 71.13 111.13 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -133.13 118.05 18.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.169 -0.469 . . . . 63.21 110.891 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.719 ' O ' HG13 ' A' ' 124' ' ' VAL . 19.6 t -119.9 82.8 28.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 73.11 111.146 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.688 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.73 122.06 8.75 Favored 'Trans proline' 0 N--CA 1.465 -0.173 0 C-N-CA 122.718 2.279 . . . . 72.34 112.358 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.514 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.2 pm0 -69.79 153.03 43.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 43.24 110.914 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.27 -4.62 83.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 64.51 112.484 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.42 156.24 48.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 62.01 111.112 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.726 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.8 mp0 -66.71 140.6 57.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 74.24 110.897 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.726 HD13 ' O ' ' A' ' 60' ' ' GLU . 5.6 mm -130.23 115.01 30.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.134 -0.485 . . . . 72.43 111.116 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.694 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -103.0 90.95 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.17 -0.468 . . . . 71.1 111.161 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.663 ' HB2' HG12 ' A' ' 93' ' ' VAL . 72.2 m-85 -68.13 138.81 56.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 74.13 110.864 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.442 ' HD3' HG21 ' A' ' 90' ' ' VAL . 5.4 mttt -131.83 99.36 4.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 72.44 110.943 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.5 mp -106.76 142.55 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 63.24 111.152 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.429 ' O ' HG23 ' A' ' 66' ' ' THR . 14.2 t -153.81 128.29 9.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 72.22 111.155 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.687 ' CB ' HG23 ' A' ' 70' ' ' VAL . 1.0 OUTLIER -131.33 160.23 68.08 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.677 0.751 . . . . 65.11 110.854 -179.847 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.533 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.72 -53.2 0.28 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.708 2.272 . . . . 62.11 112.343 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ASP . . . . . 0.422 ' HA ' ' HG3' ' A' ' 87' ' ' PRO . 3.7 m-20 -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 73.23 110.888 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.687 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.9 133.41 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 65.41 111.16 179.984 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.706 HG22 ' H ' ' A' ' 72' ' ' HIS . 10.1 mm -91.73 172.53 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 62.32 111.105 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.706 ' H ' HG22 ' A' ' 71' ' ' ILE . 0.1 OUTLIER 76.28 148.86 0.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.124 -0.489 . . . . 73.32 110.896 179.915 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -121.12 -94.68 1.37 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.731 -0.747 . . . . 62.23 112.489 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.519 ' CG ' HD11 ' A' ' 122' ' ' ILE . 3.6 p90 -152.02 149.33 28.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.897 0.38 . . . . 73.11 110.871 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -114.73 143.1 45.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 75.33 110.836 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.728 HG12 ' CG2' ' A' ' 81' ' ' ILE . 5.9 p -119.67 145.07 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 65.12 111.141 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.3 172.55 12.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 73.04 110.886 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.51 -52.05 4.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.731 -0.747 . . . . 71.33 112.479 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 16.8 m -123.1 154.13 39.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.333 . . . . 64.31 111.139 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -88.41 65.87 8.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 60.52 110.903 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.728 ' CG2' HG12 ' A' ' 76' ' ' VAL . 0.7 OUTLIER -57.03 134.12 21.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.195 -0.457 . . . . 64.3 111.169 179.922 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.37 81.62 1.61 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 75.3 110.87 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.454 ' O ' HG23 ' A' ' 83' ' ' VAL . 19.6 m -116.63 117.73 56.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 72.22 111.141 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -166.88 117.8 0.92 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 72.43 110.893 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.0 m -140.18 137.4 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 65.33 111.089 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.08 156.44 1.79 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.576 0.703 . . . . 73.34 110.961 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.487 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.1 Cg_endo -69.83 159.21 54.21 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.671 2.247 . . . . 72.22 112.316 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 87.39 3.36 81.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.71 -0.757 . . . . 74.42 112.523 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -148.59 117.56 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 72.01 110.876 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.45 HG12 ' O ' ' A' ' 9' ' ' GLU . 1.7 p -60.33 137.19 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 74.45 111.138 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.58 163.91 17.17 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 73.52 110.899 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.6 m -146.69 104.83 3.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 54.02 111.135 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.663 HG12 ' HB2' ' A' ' 63' ' ' PHE . 4.4 p -130.07 154.36 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 74.32 111.14 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -122.67 100.4 6.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 73.32 110.912 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.412 ' CD2' HD12 ' A' ' 81' ' ' ILE . 49.9 t80 -134.81 108.31 7.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.19 -0.459 . . . . 70.04 110.885 -179.789 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.8 t -103.94 135.54 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 75.53 111.184 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.474 ' HD2' HG21 ' A' ' 124' ' ' VAL . 0.1 OUTLIER -93.44 -177.57 4.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 62.54 110.828 -179.942 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.7 mtmt -125.72 -22.03 4.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 62.04 110.897 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.14 158.92 72.75 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.587 0.708 . . . . 71.21 110.868 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 152.89 69.3 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.696 2.264 . . . . 73.24 112.343 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 168.64 143.43 3.83 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 63.1 112.475 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.693 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -110.27 133.09 53.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.832 0.348 . . . . 44.32 110.92 -179.918 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 103' ' ' TYR . . . . . 0.477 ' CZ ' HG23 ' A' ' 76' ' ' VAL . 1.2 p90 -143.78 136.63 27.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.148 -0.478 . . . . 75.43 110.921 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.912 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.49 -167.82 2.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 63.3 110.894 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.912 HG22 ' O ' ' A' ' 104' ' ' ARG . 8.5 tt 56.64 159.32 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 52.11 111.118 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 63.22 111.112 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.658 ' O ' HD13 ' A' ' 53' ' ' ILE . 52.3 m . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.792 0.33 . . . . 65.11 111.2 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.539 HD12 ' C ' ' A' ' 121' ' ' THR . 4.8 mp -146.82 139.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 61.0 111.098 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.693 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -134.81 135.08 53.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 71.32 111.174 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.719 HG13 ' O ' ' A' ' 55' ' ' VAL . 57.4 t -102.65 123.94 56.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 43.14 111.147 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.1 mmtt -98.29 134.25 41.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 72.34 110.918 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.514 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 71.53 110.892 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.882 0.372 . . . . 71.52 110.87 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? -99.02 121.42 40.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 63.11 110.87 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.436 HG21 ' OG1' ' A' ' 66' ' ' THR . 15.7 m -118.61 -179.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 63.33 111.16 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.99 162.16 39.22 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.688 0.756 . . . . 74.34 110.799 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.85 -2.96 11.12 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.662 2.241 . . . . 73.55 112.349 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -44.86 -62.78 1.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 74.54 111.15 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.8 23.87 0.39 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 72.4 111.166 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.411 HG21 HG21 ' A' ' 11' ' ' VAL . 10.0 p -65.89 -30.98 51.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 72.52 111.098 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.676 ' CB ' HD11 ' A' ' 42' ' ' LEU . 0.2 OUTLIER -106.3 -6.93 18.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 73.33 110.886 -179.978 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -95.24 -36.44 11.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 72.11 110.894 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -140.94 132.28 26.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 75.01 110.85 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.91 -156.95 21.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 73.42 112.487 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.463 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.8 Cg_endo -69.76 -32.91 17.65 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 70.21 112.356 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.786 ' O ' HD12 ' A' ' 42' ' ' LEU . 10.5 m-90 -84.92 -17.87 36.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.445 . . . . 75.44 110.951 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.45 -61.33 2.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 75.51 111.092 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.69 144.36 29.41 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.612 0.72 . . . . 73.42 110.828 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -11.37 30.69 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.692 2.262 . . . . 61.45 112.32 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.69 -27.52 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 63.01 111.119 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.463 ' HG3' ' HA ' ' A' ' 21' ' ' PRO . 3.5 pm0 -111.04 31.84 5.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 74.34 110.862 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.77 -41.82 29.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 43.11 111.1 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.701 HG21 ' CB ' ' A' ' 54' ' ' GLU . 60.3 t -114.64 130.33 69.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 65.42 111.113 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -146.87 137.87 18.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.096 -0.502 . . . . 61.13 111.064 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -79.68 115.87 19.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 75.33 110.937 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -113.79 -21.06 10.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 73.12 111.142 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.27 -167.48 14.05 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 61.12 112.511 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.94 3.88 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.715 2.277 . . . . 75.32 112.363 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -148.42 29.73 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 71.44 110.876 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -126.95 116.32 20.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 75.32 110.891 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -95.75 140.33 30.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 71.44 110.966 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.716 ' HA ' HG23 ' A' ' 62' ' ' VAL . 88.0 m -92.38 109.9 21.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 72.43 111.176 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 t -89.93 130.07 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 75.34 111.108 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -113.98 105.13 12.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 74.23 110.956 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.554 HG12 HD12 ' A' ' 53' ' ' ILE . 25.0 m -100.15 147.01 8.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.145 -0.48 . . . . 74.42 111.158 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.786 HD12 ' O ' ' A' ' 22' ' ' TRP . 0.3 OUTLIER -133.67 133.16 41.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.245 -0.434 . . . . 65.31 110.948 179.961 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.78 98.72 1.94 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 63.44 111.083 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.507 ' HD1' HD22 ' A' ' 42' ' ' LEU . 52.5 p90 -123.85 143.03 50.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.855 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.86 0.17 53.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 74.41 111.114 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -97.2 66.33 2.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 73.1 110.871 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.28 -137.07 10.47 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.455 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -155.17 150.27 26.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.861 0.363 . . . . 72.2 110.924 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -165.32 163.29 13.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.583 0.706 . . . . 72.44 110.925 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 176.08 7.28 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.618 2.212 . . . . 70.33 112.335 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.441 ' O ' HG12 ' A' ' 53' ' ' ILE . 4.1 m120 -129.86 62.72 65.3 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.623 0.725 . . . . 71.31 110.914 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.662 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.7 Cg_endo -69.73 111.15 2.72 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 53.44 112.342 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.669 HG21 HG13 ' A' ' 122' ' ' ILE . 1.1 mm -130.66 151.58 36.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 71.53 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.701 ' CB ' HG21 ' A' ' 29' ' ' VAL . 6.3 tt0 -156.06 115.77 3.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 60.32 110.866 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.678 ' O ' HG13 ' A' ' 124' ' ' VAL . 6.3 t -135.37 76.44 56.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.699 . . . . 61.33 111.139 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.638 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.2 Cg_endo -69.8 121.55 8.23 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.695 2.263 . . . . 65.42 112.329 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.507 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.5 pm0 -66.5 155.29 38.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.239 -0.437 . . . . 74.54 110.949 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.56 -13.32 65.85 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 24.23 112.49 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.43 154.48 50.74 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 63.35 111.077 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.693 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.1 mt-10 -64.69 136.08 56.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 75.25 110.906 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.693 HD13 ' O ' ' A' ' 60' ' ' GLU . 8.1 mm -127.25 96.21 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 75.12 111.11 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.716 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.2 OUTLIER -84.46 102.18 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 71.4 111.143 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -73.49 139.62 45.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 71.41 110.922 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 15.8 mttt -131.83 98.78 4.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.472 . . . . 75.33 110.928 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.747 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.3 mp -97.56 157.29 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 73.02 111.147 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.436 ' OG1' HG21 ' A' ' 11' ' ' VAL . 12.3 t -170.24 126.21 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 42.25 111.164 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.661 ' HB3' HG22 ' A' ' 70' ' ' VAL . 3.6 m -127.44 161.99 51.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.656 0.741 . . . . 63.24 110.879 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -51.8 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.645 2.23 . . . . 74.1 112.334 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -155.52 29.52 0.38 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 63.44 110.809 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.661 HG22 ' HB3' ' A' ' 67' ' ' SER . 25.9 m -128.37 144.35 38.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 71.12 111.109 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.535 HD13 ' HD3' ' A' ' 87' ' ' PRO . 24.1 mm -69.73 157.2 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.479 . . . . 71.23 111.13 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.747 ' HB3' HG21 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -114.7 -164.4 0.94 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.18 -0.464 . . . . 73.5 110.865 179.888 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.71 130.48 3.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.815 -0.707 . . . . 42.31 112.479 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.572 ' CE1' HG21 ' A' ' 83' ' ' VAL . 1.5 p90 -136.76 144.39 43.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.884 0.373 . . . . 74.14 110.91 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 36.8 t-80 -93.66 133.6 36.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.119 -0.492 . . . . 65.2 110.822 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.721 HG13 ' CE2' ' A' ' 103' ' ' TYR . 87.0 t -126.72 143.27 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 73.2 111.117 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -75.52 177.01 7.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 74.43 110.856 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.74 -51.59 4.57 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 61.21 112.489 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.1 m -140.64 154.12 46.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.797 0.332 . . . . 62.51 111.106 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -76.6 64.58 2.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 73.3 110.88 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 11.3 tt -54.9 128.29 14.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.469 . . . . 73.24 111.124 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -115.58 97.06 5.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 64.41 110.869 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.572 HG21 ' CE1' ' A' ' 74' ' ' PHE . 3.5 m -125.48 120.44 57.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 42.4 111.075 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -154.33 115.72 4.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 74.53 110.832 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.661 HG21 ' CB ' ' A' ' 91' ' ' SER . 94.1 t -139.28 146.53 25.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.485 . . . . 73.42 111.16 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.416 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -75.65 157.99 83.54 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.586 0.708 . . . . 73.44 110.923 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.535 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.3 Cg_endo -69.78 153.8 68.43 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.719 2.28 . . . . 74.31 112.321 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.69 7.06 59.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.752 -0.737 . . . . 74.03 112.496 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -156.75 141.94 17.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.873 0.368 . . . . 72.23 110.878 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 3.6 p -95.69 126.3 48.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 71.52 111.122 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.661 ' CB ' HG21 ' A' ' 85' ' ' VAL . 0.8 OUTLIER -87.5 177.36 7.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 71.23 110.798 -179.829 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 98.8 m -144.82 105.48 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 63.44 111.139 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.509 HG11 HG11 ' A' ' 83' ' ' VAL . 9.8 p -134.82 137.8 50.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 74.42 111.109 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -113.27 139.9 48.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 75.25 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -166.06 94.8 0.57 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.245 -0.434 . . . . 75.13 110.955 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -84.33 143.76 29.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 74.43 111.113 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.12 -169.41 2.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.43 110.889 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mttt -124.93 -28.26 3.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 62.53 110.897 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.17 158.87 70.21 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.605 0.717 . . . . 75.43 110.841 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 147.74 63.44 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.722 2.281 . . . . 74.44 112.342 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.27 153.58 8.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 43.35 112.484 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -116.74 132.2 56.75 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.826 0.346 . . . . 75.43 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' TYR . . . . . 0.721 ' CE2' HG13 ' A' ' 76' ' ' VAL . 2.4 p90 -143.83 141.18 30.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 65.01 110.9 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.85 177.43 8.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.491 . . . . 74.33 110.91 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.3 mm 67.48 146.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.213 -0.449 . . . . 74.13 111.184 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 75.42 111.133 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.665 HG23 HG13 ' A' ' 53' ' ' ILE . 12.5 t . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.793 0.33 . . . . 70.54 111.114 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.669 HG13 HG21 ' A' ' 53' ' ' ILE . 2.9 mp -153.79 137.33 8.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.205 -0.452 . . . . 73.32 111.126 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.5 p -127.55 139.03 53.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 52.34 111.094 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.678 HG13 ' O ' ' A' ' 55' ' ' VAL . 49.1 t -109.27 117.17 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 73.52 111.162 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -86.98 138.76 31.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 74.14 110.888 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.507 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.447 . . . . 65.34 110.911 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.821 0.343 . . . . 73.44 110.91 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -96.04 145.18 25.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.494 . . . . 70.13 110.853 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.1 m -136.64 -178.58 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 62.43 111.14 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.13 161.98 42.51 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.641 0.734 . . . . 75.41 110.876 179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 -3.5 12.14 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.692 2.261 . . . . 63.31 112.362 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 25.8 m -44.96 -70.21 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 42.42 111.165 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 25.6 p -149.59 24.1 0.88 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 64.31 111.152 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.6 p -62.85 -26.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 55.12 111.118 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -106.07 -17.21 14.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 70.05 110.865 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -83.91 -35.9 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 64.4 110.923 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 -142.38 140.82 32.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 73.43 110.895 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.24 -158.53 17.86 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.732 -0.747 . . . . 64.24 112.476 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.72 -30.97 21.63 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 72.33 112.398 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 12.2 m-90 -84.6 -13.91 50.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.942 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.88 -59.42 3.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 63.34 111.105 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.01 147.63 34.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.565 0.698 . . . . 64.34 110.876 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -26.67 27.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.667 2.244 . . . . 72.25 112.361 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -80.14 -1.12 38.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 72.41 111.069 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.8 mm-40 -105.27 5.07 31.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 52.34 110.953 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.3 -74.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 73.45 111.099 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 1.066 HG22 HG12 ' A' ' 39' ' ' VAL . 48.0 t -71.91 126.78 33.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.436 . . . . 71.0 111.127 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.45 ' O ' HG23 ' A' ' 30' ' ' VAL . 19.0 m -150.34 127.01 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 73.03 111.13 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 -76.28 114.44 14.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.459 . . . . 52.43 110.926 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.2 t -120.05 -13.17 9.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.263 -0.426 . . . . 71.32 111.116 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.36 -173.25 13.78 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.753 -0.737 . . . . 62.11 112.514 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -36.72 10.34 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 73.35 112.336 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -150.86 34.35 0.6 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 72.1 110.863 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -134.55 117.8 16.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 71.54 110.945 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -98.58 134.33 41.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 75.02 110.947 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.783 ' HA ' HG23 ' A' ' 62' ' ' VAL . 56.7 m -95.07 115.04 26.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.482 . . . . 74.34 111.136 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 1.066 HG12 HG22 ' A' ' 29' ' ' VAL . 34.6 m -110.33 126.62 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 75.13 111.131 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 84.8 m-85 -103.13 113.78 27.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.198 -0.455 . . . . 75.12 110.859 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.517 HG12 ' CG1' ' A' ' 53' ' ' ILE . 15.8 m -97.5 131.4 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.11 -0.496 . . . . 71.4 111.126 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.736 HD11 ' CD2' ' A' ' 44' ' ' PHE . 3.2 tm? -120.19 135.66 54.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 71.11 110.89 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.527 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -156.44 113.98 3.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 73.12 111.065 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.736 ' CD2' HD11 ' A' ' 42' ' ' LEU . 7.0 p90 -128.5 151.08 49.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 73.11 110.889 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.47 1.44 48.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 75.23 111.074 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -92.15 75.65 5.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.261 -0.427 . . . . 73.41 110.852 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.46 -127.75 9.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 73.12 112.499 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -141.67 162.34 35.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.824 0.345 . . . . 74.4 110.909 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.405 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 1.8 pm0 -161.07 155.93 20.24 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 73.34 110.93 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.74 -176.23 1.41 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.675 2.25 . . . . 63.23 112.337 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.656 ' O ' HD12 ' A' ' 53' ' ' ILE . 4.1 m120 -130.28 60.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.605 0.717 . . . . 64.24 110.881 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 73.94 1.32 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.675 2.25 . . . . 61.24 112.35 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.656 HD12 ' O ' ' A' ' 51' ' ' ASN . 2.9 mp -125.84 132.39 70.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 73.23 111.146 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -131.62 156.69 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 61.13 110.906 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.836 HG13 HG22 ' A' ' 124' ' ' VAL . 2.9 p -157.47 77.88 3.72 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.619 0.723 . . . . 70.21 111.148 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.769 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.76 121.46 8.15 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.696 2.264 . . . . 73.23 112.356 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.453 HE22 ' HA ' ' A' ' 126' ' ' GLU . 1.1 pm0 -68.26 154.24 42.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 65.24 110.924 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.94 -10.16 69.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.76 -0.733 . . . . 73.11 112.493 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.5 159.9 39.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.773 0.32 . . . . 60.43 111.106 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.63 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.8 mp0 -72.57 141.34 48.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.43 110.895 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.769 HD12 ' HD2' ' A' ' 56' ' ' PRO . 3.8 mm -125.96 119.48 54.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.169 -0.469 . . . . 71.32 111.124 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.783 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -110.19 90.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 55.13 111.087 179.905 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.505 ' CD2' HG21 ' A' ' 39' ' ' VAL . 38.7 m-85 -74.81 144.18 43.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 72.31 110.872 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.402 ' HD3' HG11 ' A' ' 90' ' ' VAL . 0.1 OUTLIER -127.41 100.81 6.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 73.15 110.908 179.956 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.9 mt -94.23 147.3 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 74.32 111.125 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -166.12 136.93 3.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 71.12 111.146 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.457 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -146.34 160.61 41.73 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.698 0.761 . . . . 74.05 110.835 -179.883 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.403 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.6 Cg_endo -69.79 -54.87 0.2 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.674 2.249 . . . . 72.45 112.353 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -156.88 61.43 0.52 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 73.21 110.854 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.457 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.16 135.9 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 53.15 111.112 179.98 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.0 mm -73.61 145.17 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 75.21 111.142 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -126.56 -168.57 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 64.35 110.876 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 133.31 115.21 1.59 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 63.44 112.475 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -111.03 142.71 42.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.842 0.354 . . . . 72.12 110.879 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -115.17 142.63 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 74.55 110.816 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 16.6 t -133.68 147.66 30.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 72.1 111.126 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -70.01 -178.65 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 64.01 110.907 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.53 -51.17 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.721 -0.752 . . . . 71.43 112.5 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.1 m -136.89 153.86 50.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.789 0.328 . . . . 75.02 111.16 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -77.39 60.44 2.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 70.53 110.9 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.467 ' O ' HG23 ' A' ' 81' ' ' ILE . 7.2 tt -69.58 115.26 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 71.34 111.123 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.78 104.25 11.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.48 . . . . 74.03 110.883 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.452 HG11 ' CG2' ' A' ' 93' ' ' VAL . 3.6 m -125.79 120.14 56.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 60.44 111.139 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.5 pp20? -157.23 117.23 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 72.24 110.867 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -140.35 146.54 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 62.1 111.113 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.402 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -64.21 158.49 64.06 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.619 0.723 . . . . 73.3 110.922 179.966 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.402 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 54.0 Cg_endo -69.77 152.86 69.37 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.235 . . . . 71.52 112.332 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.62 11.46 63.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.757 -0.735 . . . . 64.02 112.463 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -145.83 118.17 8.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 74.44 110.952 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.402 HG11 ' HD3' ' A' ' 64' ' ' LYS . 39.2 t -63.43 105.59 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 63.25 111.173 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 66.0 p -91.98 114.33 26.84 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 51.11 110.867 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.3 t -81.83 145.99 30.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 61.43 111.17 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.452 ' CG2' HG11 ' A' ' 83' ' ' VAL . 87.2 t -139.94 117.85 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 71.34 111.107 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.0 mmm180 -102.8 107.91 18.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 73.34 110.894 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -155.95 141.38 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 61.25 110.938 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.5 t -135.14 143.63 46.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 74.43 111.102 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -95.56 -175.5 3.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 62.01 110.88 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -123.06 -12.27 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.116 -0.493 . . . . 73.15 110.876 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.83 161.93 28.09 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.646 0.736 . . . . 70.4 110.835 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 156.7 62.68 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 64.55 112.316 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.0 132.51 1.37 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 64.32 112.51 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -101.79 132.84 47.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.889 0.376 . . . . 62.44 110.918 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -143.8 129.61 19.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.49 . . . . 63.3 110.913 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.0 95.3 2.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.501 . . . . 71.52 110.843 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.5 tt -178.19 143.77 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 73.11 111.118 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 64.02 111.106 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.633 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.4 m . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.768 0.318 . . . . 55.04 111.161 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.579 HG13 HG21 ' A' ' 53' ' ' ILE . 3.7 mp -147.55 140.17 18.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 75.42 111.12 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.478 ' O ' HG12 ' A' ' 55' ' ' VAL . 5.6 m -134.46 138.33 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 71.41 111.099 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.836 HG22 HG13 ' A' ' 55' ' ' VAL . 44.0 t -104.05 125.15 58.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 72.22 111.116 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 31.2 mmtt -107.19 133.83 51.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 65.54 110.91 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.453 ' HA ' HE22 ' A' ' 57' ' ' GLN . 22.3 mt-10 . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 72.43 110.865 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.871 0.367 . . . . 52.41 110.856 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -84.3 144.33 28.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.492 . . . . 74.21 110.892 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.435 ' HB ' HG21 ' A' ' 16' ' ' VAL . 13.3 m -134.24 -177.37 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 72.1 111.111 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.463 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 21.4 p30 -143.77 157.72 57.75 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.586 0.708 . . . . 74.42 110.855 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.463 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.75 -2.8 10.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.243 . . . . 75.14 112.313 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.606 HG22 HG23 ' A' ' 15' ' ' THR . 9.7 m -48.26 -67.72 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 74.33 111.147 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.606 HG23 HG22 ' A' ' 14' ' ' THR . 38.4 p -151.0 30.24 0.64 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.45 . . . . 72.42 111.131 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.435 HG21 ' HB ' ' A' ' 11' ' ' VAL . 4.9 p -78.83 -24.96 13.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.24 -0.436 . . . . 72.53 111.113 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.505 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.9 OUTLIER -98.65 -18.23 18.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 75.42 110.892 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.9 mm-40 -100.92 -31.42 11.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 63.33 110.896 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -129.28 138.68 51.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 73.41 110.874 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 116.68 -161.78 12.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 41.24 112.494 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -27.77 25.87 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 2.239 . . . . 70.03 112.375 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.449 ' HB3' HD23 ' A' ' 42' ' ' LEU . 13.5 m-90 -84.45 -17.48 39.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 75.54 110.916 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.64 -59.8 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 53.45 111.124 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.45 143.0 25.91 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.605 0.717 . . . . 60.32 110.86 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -14.99 37.04 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 62.51 112.353 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -6.58 48.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 75.2 111.131 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -108.26 5.8 26.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 64.03 110.965 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.76 -78.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.213 -0.449 . . . . 71.12 111.123 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -81.92 125.88 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 61.04 111.113 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.45 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 25.1 m -141.66 142.62 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 55.25 111.154 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -82.31 110.52 17.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 70.43 110.928 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.7 t -108.89 -41.3 4.78 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 74.3 111.138 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.9 175.61 19.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.47 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 116.53 4.6 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.727 2.285 . . . . 74.11 112.34 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 66.97 35.31 4.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 73.44 110.866 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -147.87 152.6 37.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.218 -0.446 . . . . 74.35 110.941 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -141.72 140.96 33.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.222 -0.445 . . . . 65.3 110.957 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.79 ' HA ' HG23 ' A' ' 62' ' ' VAL . 28.8 m -90.95 117.55 29.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 74.04 111.18 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 t -100.35 107.4 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 71.01 111.14 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.465 ' CZ ' HG21 ' A' ' 38' ' ' THR . 70.7 m-85 -88.45 127.38 35.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.189 -0.46 . . . . 73.52 110.913 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.836 HG22 HD12 ' A' ' 53' ' ' ILE . 77.0 t -119.82 108.04 22.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.109 -0.496 . . . . 75.05 111.119 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.505 HD11 ' HB3' ' A' ' 17' ' ' ARG . 0.7 OUTLIER -101.5 126.57 48.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 65.11 110.904 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -152.87 128.44 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 53.02 111.145 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -145.78 147.01 31.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.44 . . . . 74.31 110.9 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.77 31.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 74.44 111.088 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -104.63 54.84 0.72 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 61.03 110.876 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 131.67 -139.16 10.71 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 53.02 112.445 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -154.98 151.46 28.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.854 0.359 . . . . 73.41 110.926 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -165.68 162.98 12.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.576 0.703 . . . . 60.03 110.901 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 154.04 68.2 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.697 2.264 . . . . 72.42 112.332 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -128.22 66.4 72.67 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.574 0.702 . . . . 73.44 110.921 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.626 ' O ' HD13 ' A' ' 53' ' ' ILE . 54.3 Cg_endo -69.72 115.21 3.98 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.707 2.271 . . . . 52.35 112.374 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.836 HD12 HG22 ' A' ' 41' ' ' VAL . 2.6 mm -125.82 146.47 31.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 73.42 111.1 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -155.1 118.03 4.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 71.22 110.885 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.83 HG23 HG13 ' A' ' 61' ' ' ILE . 2.1 p -132.72 85.32 47.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.669 0.747 . . . . 44.12 111.123 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.4 Cg_endo -69.84 123.13 9.78 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.625 2.217 . . . . 73.21 112.363 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.35 145.98 55.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 74.53 110.865 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.41 -28.31 9.22 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 74.2 112.51 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.6 156.86 17.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.74 0.305 . . . . 72.32 111.103 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.729 ' O ' HD13 ' A' ' 61' ' ' ILE . 2.2 mt-10 -66.4 142.13 57.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 64.25 110.916 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.83 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -131.89 119.95 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 73.31 111.145 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.79 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.3 OUTLIER -114.01 89.44 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 54.43 111.142 179.847 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -66.61 137.18 56.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 65.44 110.92 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' LYS . . . . . 0.566 ' HD3' HG11 ' A' ' 90' ' ' VAL . 8.6 mttm -133.77 100.65 4.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 64.1 110.898 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.582 HD11 ' CE2' ' A' ' 74' ' ' PHE . 2.6 mp -102.17 157.86 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.444 . . . . 74.53 111.119 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.415 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.7 t -165.48 142.19 5.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 64.41 111.163 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.457 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -151.27 162.18 27.54 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 74.12 110.862 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HD3' ' CZ ' ' A' ' 17' ' ' ARG . 53.8 Cg_endo -69.76 -55.68 0.17 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.729 2.286 . . . . 72.54 112.348 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -155.93 60.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.458 . . . . 74.13 110.832 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.457 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.05 134.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 70.42 111.132 179.986 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.8 mm -64.8 145.06 14.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.142 -0.481 . . . . 70.15 111.118 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.574 ' HB2' HG21 ' A' ' 65' ' ' ILE . 9.5 p-80 -140.79 115.49 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.474 . . . . 71.43 110.848 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.26 132.58 3.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 60.43 112.496 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.582 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.9 p90 -117.15 142.64 46.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.829 0.347 . . . . 74.13 110.866 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.6 t-80 -126.05 105.17 8.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 74.32 110.882 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.458 HG12 HG21 ' A' ' 81' ' ' ILE . 4.9 p -97.06 144.95 9.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 43.13 111.102 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -61.16 -175.44 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 71.0 110.92 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 90.36 -51.08 3.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.702 -0.761 . . . . 71.21 112.514 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.425 HG22 ' N ' ' A' ' 80' ' ' ASN . 7.4 m -140.18 158.85 43.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.791 0.329 . . . . 71.12 111.182 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.425 ' N ' HG22 ' A' ' 79' ' ' THR . 3.5 m120 -76.17 60.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 73.03 110.892 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.518 ' O ' HG23 ' A' ' 81' ' ' ILE . 13.4 tt -72.4 110.08 5.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 73.22 111.104 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.12 97.88 6.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 51.4 110.88 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.48 HG11 HG21 ' A' ' 93' ' ' VAL . 2.6 m -118.23 119.9 62.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 74.03 111.11 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -150.71 115.52 5.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 74.51 110.894 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.714 HG11 ' HB2' ' A' ' 91' ' ' SER . 7.3 p -140.67 146.52 24.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 72.01 111.094 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.2 mp -69.71 160.04 81.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.647 0.737 . . . . 51.54 110.915 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 160.29 50.27 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.657 2.238 . . . . 73.31 112.372 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.31 17.71 54.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.775 -0.726 . . . . 54.35 112.474 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -163.38 135.58 5.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.875 0.369 . . . . 73.24 110.909 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.566 HG11 ' HD3' ' A' ' 64' ' ' LYS . 61.9 t -76.37 138.06 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 70.44 111.13 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.714 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -115.2 107.74 15.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 72.34 110.862 -179.836 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.2 m -81.73 120.02 24.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 73.31 111.131 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.48 HG21 HG11 ' A' ' 83' ' ' VAL . 46.7 t -120.61 122.79 68.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.269 -0.423 . . . . 74.14 111.148 179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.4 mmm180 -100.85 102.45 13.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 55.34 110.88 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 52.9 t80 -151.93 120.41 6.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 62.34 110.921 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.3 t -114.93 139.91 49.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.105 -0.498 . . . . 64.41 111.156 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -90.96 -170.1 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 72.44 110.863 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 25.5 mttt -129.44 -25.52 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 70.43 110.896 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.1 mtp180 -135.98 154.64 77.78 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 74.41 110.832 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 156.84 62.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.651 2.234 . . . . 71.04 112.318 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.19 133.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 44.43 112.48 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.57 128.73 38.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.832 0.349 . . . . 72.1 110.871 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.3 p90 -143.87 132.04 21.85 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 72.22 110.911 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 43.5 mtm180 -144.88 -176.59 5.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 64.22 110.892 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.0 mt 66.35 144.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 70.13 111.157 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 74.24 111.15 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.764 HG23 HG13 ' A' ' 53' ' ' ILE . 9.9 t . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.746 0.307 . . . . 73.11 111.135 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.55 HD12 ' C ' ' A' ' 121' ' ' THR . 3.7 mp -150.33 142.01 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.234 -0.439 . . . . 75.2 111.157 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.48 ' O ' HG12 ' A' ' 55' ' ' VAL . 28.0 t -132.97 130.19 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 75.05 111.121 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.824 HG22 HG13 ' A' ' 55' ' ' VAL . 42.5 t -103.07 130.38 53.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 64.44 111.135 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -108.18 134.15 51.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 75.51 110.901 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.34 110.894 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.867 0.365 . . . . 71.33 110.911 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.07 154.09 20.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 70.13 110.895 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 16' ' ' VAL . 10.6 m -126.74 -178.05 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 73.13 111.165 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.81 161.74 44.6 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.591 0.71 . . . . 62.43 110.867 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -4.24 13.64 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.695 2.264 . . . . 74.23 112.379 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.721 HG22 HG23 ' A' ' 15' ' ' THR . 42.2 m -48.46 -71.0 0.07 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.198 -0.455 . . . . 75.53 111.157 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.721 HG23 HG22 ' A' ' 14' ' ' THR . 44.8 p -151.59 36.68 0.57 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 62.35 111.159 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 11' ' ' VAL . 10.0 p -78.93 -25.58 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 64.41 111.129 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -97.52 -18.2 19.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 71.51 110.834 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -101.43 -28.4 12.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.445 . . . . 72.45 110.923 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.33 133.17 42.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 73.23 110.914 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.88 -158.67 17.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 74.32 112.473 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.474 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.4 Cg_endo -69.75 -34.65 14.17 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.72 2.28 . . . . 65.53 112.342 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.437 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 14.9 m-90 -84.98 -6.95 59.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 64.52 110.912 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -59.12 4.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 51.21 111.106 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.99 141.7 25.37 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.592 0.71 . . . . 73.3 110.896 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -7.17 20.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 62.31 112.311 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.06 -25.5 60.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 72.22 111.094 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.474 ' HG3' ' HA ' ' A' ' 21' ' ' PRO . 3.7 pm0 -110.99 34.21 4.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 72.03 110.919 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.59 -69.03 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 63.04 111.115 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.561 HG11 ' CB ' ' A' ' 54' ' ' GLU . 1.6 p -111.33 125.18 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.448 . . . . 63.53 111.097 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.97 151.46 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 65.35 111.179 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLN . . . . . 0.433 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -72.69 119.29 16.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 74.32 110.879 -179.974 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.2 p -120.94 -42.58 2.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.157 -0.474 . . . . 55.34 111.137 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.39 -168.22 16.83 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.749 -0.739 . . . . 74.2 112.504 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 109.8 2.4 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 73.33 112.354 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.9 t30 49.92 30.58 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 71.43 110.878 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.43 120.98 26.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.177 -0.465 . . . . 72.44 110.891 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' TYR . . . . . 0.433 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 39.7 m-85 -94.43 141.97 27.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 61.2 110.924 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.419 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 21.9 m -99.66 99.78 10.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 72.21 111.16 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.34 131.57 33.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 61.03 111.087 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -113.63 100.69 8.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.176 -0.465 . . . . 73.22 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.753 HG12 HD12 ' A' ' 53' ' ' ILE . 34.8 m -97.45 129.94 46.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 74.01 111.141 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 18.5 tp -124.24 138.54 54.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 70.34 110.928 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.741 ' HB3' ' CE1' ' A' ' 72' ' ' HIS . . . -155.68 123.41 5.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.467 . . . . 74.34 111.094 179.833 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -143.09 144.1 32.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 72.45 110.876 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.13 4.89 32.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 51.14 111.114 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -103.34 72.9 1.18 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 61.33 110.846 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 115.08 -141.69 17.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 70.13 112.522 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -152.89 148.4 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.807 0.337 . . . . 72.24 110.938 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -165.15 162.97 13.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 73.04 110.913 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 158.58 56.53 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.686 2.257 . . . . 64.12 112.374 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -131.88 67.02 79.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.704 0.764 . . . . 64.51 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.724 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.9 Cg_endo -69.76 119.56 6.49 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 55.31 112.336 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.806 HG13 HG23 ' A' ' 121' ' ' THR . 1.5 mm -131.27 124.13 54.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 74.13 111.106 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.561 ' CB ' HG11 ' A' ' 29' ' ' VAL . 8.6 tt0 -131.24 116.38 17.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 73.01 110.891 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.731 HG13 HG21 ' A' ' 61' ' ' ILE . 5.7 t -130.1 80.6 70.59 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.63 0.729 . . . . 71.25 111.12 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.551 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.7 121.12 7.82 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.746 2.298 . . . . 74.5 112.331 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.508 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.5 pm0 -68.12 155.57 39.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 72.22 110.929 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.52 -6.53 76.81 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.754 -0.736 . . . . 74.0 112.481 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.82 155.34 49.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 73.3 111.094 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.763 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.5 mt-10 -64.84 143.42 57.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 71.01 110.897 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.763 HD13 ' O ' ' A' ' 60' ' ' GLU . 8.6 mm -131.65 124.53 54.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 44.21 111.124 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 1.018 HG13 HG23 ' A' ' 92' ' ' THR . 46.8 t -111.22 93.48 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 75.32 111.146 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -71.82 137.06 47.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 65.31 110.858 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -132.28 99.52 4.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 65.44 110.907 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.411 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.6 mp -98.03 153.53 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 70.35 111.147 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.2 t -171.77 137.77 1.03 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 60.15 111.165 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.447 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -142.44 162.21 45.97 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.708 0.766 . . . . 52.43 110.843 -179.836 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.426 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.8 Cg_endo -69.71 -52.01 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 65.13 112.322 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -155.91 36.67 0.35 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 64.5 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.447 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -140.17 -179.24 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 72.12 111.139 -179.961 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ILE . . . . . 0.634 HG23 ' O ' ' A' ' 85' ' ' VAL . 33.1 mt -144.91 156.68 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.201 -0.454 . . . . 74.21 111.183 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.741 ' CE1' ' HB3' ' A' ' 43' ' ' ALA . 35.6 p-80 -168.52 98.17 0.41 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 73.33 110.835 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -95.02 135.72 12.56 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 73.13 112.504 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.608 ' CE1' HG21 ' A' ' 83' ' ' VAL . 9.3 p90 -99.05 142.1 30.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.876 0.369 . . . . 72.51 110.872 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.9 p80 -125.24 142.69 51.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 73.32 110.897 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.697 HG11 ' CE1' ' A' ' 97' ' ' PHE . 21.2 t -131.83 147.56 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 75.42 111.134 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -71.49 -175.44 1.3 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 74.43 110.867 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.12 -51.45 4.58 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 73.23 112.49 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.6 m -135.52 151.35 50.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.782 0.325 . . . . 72.55 111.153 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.5 m-80 -74.13 70.13 1.56 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 71.24 110.871 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.547 ' O ' HG23 ' A' ' 81' ' ' ILE . 14.1 tt -87.77 104.37 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 72.44 111.099 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -115.83 103.85 11.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 64.43 110.893 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.765 HG11 HG21 ' A' ' 93' ' ' VAL . 0.9 OUTLIER -114.32 120.62 64.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 62.44 111.113 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.32 121.09 17.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 70.34 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.634 ' O ' HG23 ' A' ' 71' ' ' ILE . 13.7 p -139.36 147.64 24.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 63.42 111.142 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.504 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -90.58 163.92 28.63 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.594 0.712 . . . . 73.05 110.911 179.927 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.504 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.5 Cg_endo -69.77 147.77 63.56 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.682 2.254 . . . . 72.03 112.317 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.01 9.18 58.51 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.754 -0.736 . . . . 73.23 112.492 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -146.34 173.68 12.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.869 0.366 . . . . 72.3 110.876 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 17.5 t -129.37 119.49 48.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 71.31 111.117 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -103.75 133.66 48.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 54.21 110.822 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' THR . . . . . 1.018 HG23 HG13 ' A' ' 62' ' ' VAL . 60.7 m -103.13 131.87 49.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 71.52 111.12 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.765 HG21 HG11 ' A' ' 83' ' ' VAL . 19.0 t -125.26 127.6 72.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 72.45 111.114 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -107.78 92.6 4.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 52.35 110.858 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -140.77 133.43 28.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.157 -0.474 . . . . 75.04 110.902 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.7 t -123.16 140.19 53.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 71.23 111.159 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' PHE . . . . . 0.697 ' CE1' HG11 ' A' ' 76' ' ' VAL . 75.2 m-85 -96.3 -174.82 3.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 74.33 110.861 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -125.89 -29.02 3.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 72.2 110.928 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.35 155.59 81.28 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.597 0.713 . . . . 71.11 110.897 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 170.56 16.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.647 2.231 . . . . 64.12 112.351 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 154.99 133.32 1.71 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 70.0 112.479 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.13 125.54 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 65.51 110.903 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.75 146.61 33.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 73.45 110.94 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.23 97.89 1.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.15 110.838 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.4 tt -175.51 151.96 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.151 -0.477 . . . . 74.31 111.118 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 73.34 111.189 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.806 HG23 HG13 ' A' ' 53' ' ' ILE . 4.8 t . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.763 0.316 . . . . 53.14 111.168 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.603 HG13 HG21 ' A' ' 53' ' ' ILE . 2.1 mp -153.9 137.63 8.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 71.53 111.121 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 26.9 t -126.14 122.58 61.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 74.23 111.149 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.652 HG13 ' O ' ' A' ' 55' ' ' VAL . 44.3 t -101.52 112.1 33.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 75.24 111.119 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 17.8 mmmt -84.45 135.26 34.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 54.53 110.897 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.508 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 74.43 110.945 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.808 0.337 . . . . 71.21 110.885 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.54 168.46 10.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 75.34 110.851 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.87 ' CG1' HG21 ' A' ' 16' ' ' VAL . 1.4 t -141.54 166.71 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 60.44 111.098 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ASP . . . . . 0.427 ' H ' HG12 ' A' ' 11' ' ' VAL . 55.9 p-10 -161.12 153.45 16.97 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.594 0.711 . . . . 73.44 110.843 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -4.34 13.85 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.684 2.256 . . . . 71.1 112.326 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.459 ' O ' HG23 ' A' ' 15' ' ' THR . 40.6 m -44.44 -72.23 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 65.24 111.094 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 14' ' ' THR . 6.7 p -156.62 33.08 0.31 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 52.34 111.144 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.87 HG21 ' CG1' ' A' ' 11' ' ' VAL . 4.9 p -78.58 -19.92 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 74.04 111.105 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -100.68 -9.38 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 60.02 110.896 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -103.53 -32.87 9.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 63.14 110.881 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -140.16 125.98 19.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 73.54 110.861 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 132.26 -155.99 21.78 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.741 . . . . 24.22 112.515 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -37.83 8.65 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.723 2.282 . . . . 71.52 112.349 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' TRP . . . . . 0.483 ' HE3' HG22 ' A' ' 16' ' ' VAL . 7.8 m-90 -84.51 -12.57 53.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.211 -0.449 . . . . 72.11 110.917 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.79 -59.54 4.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 75.31 111.087 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.21 142.84 25.37 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 51.3 110.88 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 -22.83 31.81 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.644 2.229 . . . . 61.52 112.376 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.51 -17.56 61.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 75.25 111.097 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 3.5 mm100 -89.35 10.13 23.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 75.24 110.929 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.26 -77.53 0.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 50.42 111.083 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.435 HG21 ' HB3' ' A' ' 54' ' ' GLU . 21.1 t -84.38 122.06 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 72.4 111.165 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.8 131.62 53.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.451 . . . . 62.15 111.106 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -71.31 118.28 13.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 72.31 110.899 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.0 t -119.38 -41.49 2.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 71.2 111.175 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.34 171.2 13.72 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.765 -0.731 . . . . 32.34 112.487 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -10.21 28.02 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.685 2.257 . . . . 72.03 112.358 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -157.69 34.81 0.26 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.283 -0.417 . . . . 63.4 110.883 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -151.29 160.04 44.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 63.51 110.896 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.7 m-85 -143.31 146.64 33.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.252 -0.431 . . . . 75.43 110.941 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 99.5 m -97.23 121.99 39.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.119 -0.491 . . . . 74.11 111.165 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 17.9 t -100.37 134.58 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 72.24 111.137 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -120.65 100.51 7.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 73.3 110.932 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.495 HG12 HG13 ' A' ' 53' ' ' ILE . 32.8 m -98.78 128.53 50.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 74.1 111.129 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.706 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.8 tm? -120.74 138.23 54.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 71.24 110.928 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.706 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.22 137.04 14.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 73.12 111.049 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PHE . . . . . 0.427 ' HD2' HD11 ' A' ' 42' ' ' LEU . 2.9 p90 -145.29 150.06 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 73.31 110.918 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.41 18.69 4.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 54.42 111.118 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -84.34 -61.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 60.42 110.868 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -127.44 -122.43 2.52 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.786 -0.721 . . . . 75.23 112.488 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -143.91 145.02 31.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.869 0.366 . . . . 74.33 110.904 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLN . . . . . 0.427 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.0 pm0 -154.37 156.09 31.4 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.56 0.695 . . . . 74.53 110.892 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.2 Cg_endo -69.79 177.38 5.65 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.632 2.222 . . . . 75.23 112.343 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.712 ' O ' HD12 ' A' ' 53' ' ' ILE . 8.5 m-20 -131.23 62.3 64.39 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.592 0.71 . . . . 61.15 110.905 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 70.77 1.56 Allowed 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.661 2.241 . . . . 74.25 112.377 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.712 HD12 ' O ' ' A' ' 51' ' ' ASN . 4.3 mp -105.88 128.29 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 75.11 111.151 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.435 ' HB3' HG21 ' A' ' 29' ' ' VAL . 11.2 tt0 -126.3 135.11 51.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.468 . . . . 73.43 110.878 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.741 HG13 HG22 ' A' ' 124' ' ' VAL . 2.5 p -140.12 81.95 17.79 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.657 0.741 . . . . 74.4 111.08 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.59 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.74 123.55 10.22 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.715 2.277 . . . . 61.25 112.328 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.452 HE22 ' HA ' ' A' ' 126' ' ' GLU . 1.3 pm0 -66.87 152.37 45.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 71.44 110.951 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.42 -36.51 3.7 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 61.23 112.49 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -106.22 150.12 26.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.749 0.309 . . . . 61.14 111.129 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.619 ' O ' HD13 ' A' ' 61' ' ' ILE . 18.1 mt-10 -66.42 142.07 57.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 55.32 110.901 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.717 HG13 HG23 ' A' ' 55' ' ' VAL . 5.8 mm -126.25 119.43 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 45.35 111.116 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 1.091 HG13 HG23 ' A' ' 92' ' ' THR . 64.3 t -98.33 92.08 2.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 73.52 111.118 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.506 ' HB2' HG12 ' A' ' 93' ' ' VAL . 66.9 m-85 -70.9 136.59 48.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.906 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 8.7 mttt -132.09 98.64 4.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 64.54 110.908 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.715 HD11 ' CZ ' ' A' ' 74' ' ' PHE . 1.6 mp -103.17 137.5 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 71.23 111.11 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' THR . . . . . 0.419 ' OG1' HG11 ' A' ' 11' ' ' VAL . 4.2 t -155.73 135.89 12.99 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 75.43 111.123 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.449 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -135.87 161.19 64.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.633 0.73 . . . . 75.31 110.859 -179.863 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.8 Cg_endo -69.68 -53.95 0.25 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.675 2.25 . . . . 72.11 112.361 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -156.83 56.15 0.54 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 74.54 110.866 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.01 136.23 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 63.2 111.152 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.4 mm -64.33 149.14 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.164 -0.471 . . . . 74.45 111.115 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.582 ' HB2' HG21 ' A' ' 65' ' ' ILE . 2.4 p-80 -133.11 -178.5 4.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 65.54 110.886 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 135.37 139.69 4.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 35.45 112.485 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.715 ' CZ ' HD11 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -130.57 144.68 51.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.894 0.378 . . . . 73.2 110.837 -179.845 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 8.0 t-80 -101.06 142.13 32.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.106 -0.497 . . . . 72.3 110.863 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.612 HG22 ' CD2' ' A' ' 103' ' ' TYR . 58.2 t -131.84 138.13 53.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 62.02 111.118 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -75.51 179.45 5.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 73.24 110.862 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.14 -52.03 4.57 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.781 -0.723 . . . . 74.13 112.48 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.62 179.7 4.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.82 0.343 . . . . 75.03 111.123 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -105.77 65.5 0.71 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 61.13 110.893 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.58 HD12 ' CD2' ' A' ' 95' ' ' TYR . 7.5 tt -72.47 121.68 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 73.51 111.159 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -117.07 90.47 3.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 110.827 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 5.1 m -115.05 118.41 58.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 62.02 111.126 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -166.72 104.73 0.59 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.145 -0.48 . . . . 71.15 110.878 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.545 HG23 ' HE2' ' A' ' 72' ' ' HIS . 2.4 m -140.64 146.61 23.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 72.54 111.109 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.422 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -57.8 159.78 9.36 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.559 0.695 . . . . 72.24 110.915 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 87' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 53.9 Cg_endo -69.74 159.67 52.55 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.71 2.274 . . . . 73.32 112.343 179.864 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 90.82 4.51 69.53 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.695 -0.764 . . . . 21.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -147.19 117.81 7.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.872 0.368 . . . . 73.53 110.928 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 1.8 p -74.49 130.04 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 62.04 111.134 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.54 ' HB2' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -102.17 112.26 24.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 75.25 110.816 -179.812 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 92' ' ' THR . . . . . 1.091 HG23 HG13 ' A' ' 62' ' ' VAL . 52.7 m -90.12 115.72 27.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 65.31 111.117 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 63' ' ' PHE . 8.6 p -128.75 152.22 36.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 55.14 111.117 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.82 103.02 11.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 70.52 110.901 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.58 ' CD2' HD12 ' A' ' 81' ' ' ILE . 9.0 t80 -134.28 114.95 13.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 75.14 110.92 -179.876 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.0 t -129.09 134.85 48.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.117 -0.492 . . . . 65.44 111.109 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -90.85 -176.73 4.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 54.44 110.849 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -121.25 -13.04 8.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 73.21 110.947 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.73 162.74 49.28 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.634 0.731 . . . . 52.23 110.87 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 150.05 67.45 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.686 2.257 . . . . 75.32 112.318 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.73 157.47 10.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.727 -0.749 . . . . 54.44 112.49 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.765 ' HB3' HG23 ' A' ' 123' ' ' VAL . 3.8 pm0 -120.26 125.17 47.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.872 0.368 . . . . 65.23 110.855 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' TYR . . . . . 0.612 ' CD2' HG22 ' A' ' 76' ' ' VAL . 1.0 OUTLIER -133.01 146.64 51.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.483 . . . . 72.15 110.885 -179.838 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ARG . . . . . 0.417 ' O ' ' HB ' ' A' ' 105' ' ' ILE . 0.4 OUTLIER -174.3 -162.11 0.13 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 74.32 110.83 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.417 ' HB ' ' O ' ' A' ' 104' ' ' ARG . 21.2 mm 75.28 117.79 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 71.34 111.161 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 64.24 111.144 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.607 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.6 m . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.751 0.31 . . . . 63.5 111.166 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.637 HG13 HG21 ' A' ' 53' ' ' ILE . 5.3 mp -145.35 117.24 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 61.2 111.144 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.765 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -121.65 141.49 41.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 72.14 111.094 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' VAL . . . . . 0.741 HG22 HG13 ' A' ' 55' ' ' VAL . 87.0 t -101.5 136.59 32.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 74.0 111.163 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -114.49 125.72 54.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 62.21 110.869 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.452 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 74.0 110.871 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLU . . . . . 0.427 ' O ' HG12 ' A' ' 90' ' ' VAL . 1.6 mm-40 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.832 0.348 . . . . 74.52 110.896 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.7 mpt_? -105.01 121.36 43.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 61.55 110.863 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.462 ' HB ' HG21 ' A' ' 16' ' ' VAL . 5.6 m -113.49 -179.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 75.42 111.17 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 162.63 38.29 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.571 0.7 . . . . 71.22 110.891 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -2.78 10.78 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.656 2.237 . . . . 65.31 112.36 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.751 HG22 HG23 ' A' ' 15' ' ' THR . 29.1 m -44.75 -67.34 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.231 -0.441 . . . . 62.32 111.109 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' THR . . . . . 0.751 HG23 HG22 ' A' ' 14' ' ' THR . 43.4 p -150.67 21.29 0.81 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 54.21 111.142 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' VAL . . . . . 0.462 HG21 ' HB ' ' A' ' 11' ' ' VAL . 1.3 p -77.65 -16.88 14.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 71.11 111.157 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ARG . . . . . 0.431 ' NE ' ' HD3' ' A' ' 68' ' ' PRO . 0.0 OUTLIER -106.66 -25.0 11.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 72.31 110.876 -179.951 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -92.6 -24.24 18.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 74.11 110.92 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLU . . . . . 0.458 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 11.3 tt0 -143.58 147.32 34.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 61.35 110.928 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.01 -158.74 14.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.73 -0.748 . . . . 75.32 112.489 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.42 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.9 Cg_endo -69.81 -33.9 15.48 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.678 2.252 . . . . 71.53 112.332 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 11.8 m-90 -83.2 -12.87 56.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.256 -0.429 . . . . 74.54 110.898 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ALA . . . . . 0.458 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -62.44 -57.13 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.256 -0.429 . . . . 51.01 111.134 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.34 142.22 25.19 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.564 0.697 . . . . 64.23 110.927 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -6.73 19.3 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.708 2.272 . . . . 72.54 112.359 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.79 -12.87 61.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 64.1 111.109 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLN . . . . . 0.42 ' HG3' ' HA ' ' A' ' 21' ' ' PRO . 17.6 mm-40 -99.0 14.4 29.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.443 . . . . 74.51 110.93 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ALA . . . . . 0.458 ' HB2' ' HG2' ' A' ' 52' ' ' PRO . . . -65.0 -14.84 61.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.463 . . . . 71.13 111.089 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.522 HG22 ' HB3' ' A' ' 54' ' ' GLU . 7.0 t -145.21 119.31 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 74.24 111.092 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.766 HG13 ' HB ' ' A' ' 38' ' ' THR . 1.6 p -144.21 140.92 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 60.25 111.153 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.33 100.88 13.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 74.04 110.87 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.4 t -98.07 -34.46 10.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.232 -0.44 . . . . 61.13 111.147 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.71 -168.44 17.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 74.43 112.472 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -37.83 8.56 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.654 2.236 . . . . 54.2 112.334 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -148.27 34.68 0.8 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 73.45 110.864 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -135.41 119.87 18.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 65.32 110.893 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -95.87 140.89 29.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 73.5 110.983 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.766 ' HB ' HG13 ' A' ' 30' ' ' VAL . 22.3 m -94.81 107.82 19.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 70.42 111.141 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.1 t -89.25 130.0 39.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.224 -0.444 . . . . 61.22 111.137 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' TYR . . . . . 0.409 ' CD2' ' HB2' ' A' ' 21' ' ' PRO . 49.0 m-85 -116.03 113.15 22.81 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 74.3 110.909 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 41' ' ' VAL . 31.2 m -111.35 125.1 68.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 71.24 111.117 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.416 HD11 ' CZ ' ' A' ' 17' ' ' ARG . 2.9 tm? -121.92 126.28 48.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.122 -0.49 . . . . 60.23 110.907 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -144.54 144.96 31.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 53.21 111.115 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 12.2 p90 -136.65 152.74 50.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 73.15 110.908 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ALA . . . . . 0.553 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -87.77 12.2 13.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 72.4 111.063 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -120.48 66.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 72.5 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 123.31 -147.88 16.71 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.747 -0.739 . . . . 62.44 112.507 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -150.71 155.88 40.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 64.32 110.929 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -164.48 162.54 15.31 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.624 0.726 . . . . 62.22 110.916 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 140.09 41.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.696 2.264 . . . . 70.2 112.354 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ASN . . . . . 0.621 ' O ' HD12 ' A' ' 53' ' ' ILE . 14.3 m-20 -131.61 68.19 80.67 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.624 0.726 . . . . 73.51 110.879 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PRO . . . . . 0.458 ' HG2' ' HB2' ' A' ' 28' ' ' ALA . 53.5 Cg_endo -69.75 72.75 1.42 Allowed 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.707 2.271 . . . . 71.3 112.363 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ILE . . . . . 0.731 HD13 ' O ' ' A' ' 121' ' ' THR . 2.6 mp -77.37 91.34 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 73.4 111.1 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLU . . . . . 0.522 ' HB3' HG22 ' A' ' 29' ' ' VAL . 9.1 tt0 -83.48 138.54 33.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.882 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' VAL . . . . . 0.586 HG13 HG21 ' A' ' 61' ' ' ILE . 6.5 t -143.93 85.79 8.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.593 0.711 . . . . 70.2 111.101 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' PRO . . . . . 0.675 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.78 122.95 9.62 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.669 2.246 . . . . 74.2 112.335 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLN . . . . . 0.508 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.6 pm0 -70.55 153.09 43.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 72.42 110.901 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.84 -35.83 3.85 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.72 -0.752 . . . . 54.31 112.51 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.86 155.09 19.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.747 0.308 . . . . 73.44 111.112 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.678 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.9 mp0 -65.52 143.8 57.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 73.52 110.886 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ILE . . . . . 0.678 HD13 ' O ' ' A' ' 60' ' ' GLU . 6.6 mm -128.73 118.69 47.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 70.4 111.142 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' VAL . . . . . 0.756 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -107.77 90.06 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 53.53 111.156 179.882 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -65.08 142.03 58.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 70.3 110.884 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -132.63 99.77 4.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 64.52 110.92 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ILE . . . . . 0.697 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.3 mp -102.77 145.65 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 65.24 111.128 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.9 t -161.24 132.57 5.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 75.22 111.154 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' SER . . . . . 0.647 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -145.13 163.97 29.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.674 0.749 . . . . 72.41 110.905 -179.868 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 68' ' ' PRO . . . . . 0.605 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.1 Cg_endo -69.73 -56.36 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.701 2.268 . . . . 62.41 112.385 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -152.87 67.91 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 74.01 110.905 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.647 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.3 134.86 2.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 65.34 111.138 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.02 143.75 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 52.41 111.072 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' HIS . . . . . 0.697 ' HB3' HG21 ' A' ' 65' ' ' ILE . 0.9 OUTLIER -108.75 -166.32 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.128 -0.487 . . . . 75.15 110.864 179.864 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.64 122.45 3.51 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.771 -0.728 . . . . 71.02 112.497 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' PHE . . . . . 0.452 ' CE2' HD11 ' A' ' 65' ' ' ILE . 0.3 OUTLIER -119.87 142.38 48.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.916 0.389 . . . . 62.42 110.898 -179.911 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -93.41 135.63 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.123 -0.489 . . . . 71.53 110.876 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.691 HG13 ' CE2' ' A' ' 103' ' ' TYR . 59.1 t -137.19 142.88 36.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 65.54 111.172 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -75.5 -176.31 3.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 62.03 110.871 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 87.47 -50.91 4.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.777 -0.725 . . . . 61.21 112.474 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.455 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -142.82 173.44 11.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 43.21 111.099 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ASN . . . . . 0.455 ' H ' HG22 ' A' ' 79' ' ' THR . 28.6 m120 -85.41 59.43 5.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 75.54 110.884 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ILE . . . . . 0.471 ' O ' HG23 ' A' ' 81' ' ' ILE . 6.4 tp -56.69 116.87 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 51.34 111.101 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.23 100.42 8.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 74.52 110.907 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.486 HG11 HG21 ' A' ' 93' ' ' VAL . 5.7 m -127.29 122.87 60.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 74.15 111.154 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -160.6 114.68 2.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 71.11 110.895 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.721 HG21 ' OG ' ' A' ' 91' ' ' SER . 96.7 t -140.36 145.09 26.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 64.31 111.158 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.22 156.65 89.56 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.609 0.719 . . . . 74.31 110.907 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 160.71 48.7 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.728 2.285 . . . . 64.24 112.347 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 97.84 -0.13 59.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 71.23 112.469 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -146.15 156.7 43.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.889 0.376 . . . . 73.34 110.862 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.43 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 1.6 p -105.7 108.75 25.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 54.52 111.128 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 91' ' ' SER . . . . . 0.721 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -80.22 164.77 22.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.882 -179.865 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 77.7 m -129.24 105.21 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 62.44 111.134 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.486 HG21 HG11 ' A' ' 83' ' ' VAL . 24.6 t -101.79 130.81 50.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.239 -0.437 . . . . 63.31 111.14 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -110.44 92.45 4.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 72.1 110.851 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.2 t80 -143.01 114.08 7.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 74.02 110.927 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.7 t -113.87 142.9 45.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 65.34 111.143 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.08 179.98 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 74.42 110.842 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -121.08 -12.77 8.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.922 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.9 mpp_? -149.05 162.03 30.45 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.564 0.697 . . . . 73.31 110.913 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 153.63 68.67 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.731 2.287 . . . . 75.14 112.313 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 157.18 131.12 1.3 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.725 -0.75 . . . . 71.12 112.435 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.432 ' CG ' HG23 ' A' ' 123' ' ' VAL . 23.0 mt-10 -101.75 138.76 38.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.865 0.364 . . . . 71.21 110.865 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' TYR . . . . . 0.691 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.3 OUTLIER -143.87 140.6 29.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.135 -0.484 . . . . 74.42 110.921 -179.898 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 46.3 mtm180 -144.89 72.79 1.34 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 73.22 110.895 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 55.8 mt -151.05 144.27 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.226 -0.443 . . . . 73.34 111.124 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 73.51 111.145 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' THR . . . . . 0.731 ' O ' HD13 ' A' ' 53' ' ' ILE . 86.5 m . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.784 0.326 . . . . 71.11 111.155 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' ILE . . . . . 0.535 HG23 ' CG2' ' A' ' 55' ' ' VAL . 1.4 mp -153.34 136.51 7.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 43.54 111.102 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' VAL . . . . . 0.432 HG23 ' CG ' ' A' ' 102' ' ' GLU . 1.9 p -117.78 126.56 74.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 71.21 111.133 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 61.9 t -101.14 117.68 46.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 74.04 111.109 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.0 mmmt -93.59 137.54 32.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 72.21 110.907 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLU . . . . . 0.508 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 64.15 110.924 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.6 ttt . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.812 0.339 . . . . 61.55 110.884 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.571 HG13 ' HB3' ' A' ' 10' ' ' ARG . 90.0 t -72.78 82.65 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 71.05 111.147 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -143.96 78.14 14.18 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 65.32 111.133 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -179.34 2.86 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.644 2.229 . . . . 73.31 112.362 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -178.58 -75.29 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 73.12 111.159 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -55.55 -84.27 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.797 -0.716 . . . . 73.1 112.481 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.89 168.37 13.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.822 0.344 . . . . 64.2 110.887 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.428 HD12 ' HA ' ' A' ' 8' ' ' LEU . 6.6 tp 66.29 122.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 64.32 110.889 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.428 ' O ' HG12 ' A' ' 90' ' ' VAL . 0.9 OUTLIER -100.14 132.38 45.53 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.126 -0.488 . . . . 63.33 110.89 179.932 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.571 ' HB3' HG13 ' A' ' 2' ' ' VAL . 0.0 OUTLIER -97.94 131.47 44.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 74.23 110.825 -179.882 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.4 m -120.91 -177.18 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 73.42 111.124 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.43 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 25.1 p30 -143.42 156.7 60.43 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 74.04 110.874 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.43 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.9 Cg_endo -69.79 -3.08 11.3 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.655 2.237 . . . . 73.23 112.358 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.696 HG22 HG23 ' A' ' 15' ' ' THR . 12.4 m -46.76 -68.3 0.2 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.205 -0.452 . . . . 61.41 111.124 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.696 HG23 HG22 ' A' ' 14' ' ' THR . 24.4 p -150.02 26.07 0.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.451 . . . . 75.51 111.133 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.4 p -65.39 -29.1 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.26 -0.427 . . . . 75.23 111.102 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.9 ptt180 -102.53 -7.91 21.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 74.11 110.884 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.3 mt-30 -96.81 -37.67 10.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 63.55 110.914 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.84 133.68 41.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 71.32 110.877 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.11 -156.91 18.39 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.753 -0.737 . . . . 74.12 112.494 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -30.79 21.72 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.741 2.294 . . . . 62.34 112.333 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.788 ' HB3' HD13 ' A' ' 42' ' ' LEU . 13.5 m-90 -85.95 -12.53 50.24 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 61.22 110.922 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.62 -58.98 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 64.41 111.095 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.89 146.5 34.24 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.593 0.711 . . . . 75.12 110.867 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -14.17 35.62 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.664 2.243 . . . . 71.55 112.349 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.13 -24.43 59.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 73.02 111.056 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 mm-40 -86.34 5.01 36.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 64.44 110.87 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.39 -76.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.43 111.085 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 12.3 t -89.71 115.6 29.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 71.21 111.144 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.34 119.02 4.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 75.41 111.138 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -68.06 123.37 20.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 70.54 110.876 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.4 p -120.18 -11.55 9.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 74.55 111.111 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.9 -169.33 12.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 75.4 112.517 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.65 18.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.682 2.255 . . . . 75.23 112.395 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.5 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 55.2 t30 -155.69 28.61 0.38 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 74.23 110.884 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -126.99 119.42 26.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.494 . . . . 73.31 110.9 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -96.32 140.23 31.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 74.21 110.961 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.683 ' HA ' HG23 ' A' ' 62' ' ' VAL . 85.9 m -93.76 115.02 27.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 70.33 111.173 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.3 t -102.24 139.06 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 63.02 111.124 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -120.49 140.85 50.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 61.54 110.924 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.509 HG22 ' CG1' ' A' ' 53' ' ' ILE . 99.1 t -138.3 136.06 44.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.486 . . . . 73.54 111.106 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.788 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -137.91 140.71 40.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 74.22 110.95 179.92 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.27 102.97 2.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 71.54 111.083 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 3.3 p90 -112.01 156.71 21.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 72.24 110.894 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.13 7.79 23.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.137 -0.483 . . . . 55.25 111.092 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -103.17 82.9 2.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 74.12 110.929 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 100.28 -135.04 11.93 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.739 . . . . 52.23 112.498 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -154.61 150.22 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.799 0.333 . . . . 73.41 110.954 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 2.9 pm0 -154.07 155.02 30.71 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.648 0.737 . . . . 53.32 110.874 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.81 4.2 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.676 2.25 . . . . 75.3 112.382 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.742 ' O ' HD12 ' A' ' 53' ' ' ILE . 2.1 m120 -134.99 62.88 55.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.577 0.703 . . . . 73.34 110.873 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 76.58 1.14 Allowed 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.661 2.241 . . . . 64.34 112.351 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.742 HD12 ' O ' ' A' ' 51' ' ' ASN . 3.9 mp -106.56 143.06 18.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 75.31 111.145 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -138.91 158.51 44.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 72.23 110.88 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.8 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -164.09 84.47 1.26 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.639 0.733 . . . . 52.21 111.143 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.676 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.72 121.93 8.62 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.675 2.25 . . . . 60.02 112.334 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -66.76 152.24 45.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.434 . . . . 72.0 110.9 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.0 -35.87 3.93 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.708 -0.758 . . . . 52.31 112.478 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.5 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -105.86 157.58 17.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.751 0.31 . . . . 74.12 111.114 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.715 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.3 mp0 -66.8 144.78 56.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 71.35 110.859 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.763 HG13 HG23 ' A' ' 55' ' ' VAL . 5.7 mm -130.56 124.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 62.33 111.195 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.683 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -113.73 90.24 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 73.31 111.133 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.59 ' HB2' HG12 ' A' ' 93' ' ' VAL . 64.1 m-85 -67.88 138.8 56.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 65.13 110.859 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.4 mttt -132.75 100.25 4.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 74.42 110.887 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.57 HD11 ' CE2' ' A' ' 74' ' ' PHE . 2.3 mp -106.87 141.63 21.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 71.25 111.151 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.2 t -154.67 138.02 15.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.183 -0.462 . . . . 73.13 111.14 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.411 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -142.8 159.58 56.36 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 74.03 110.854 -179.84 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.411 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.7 -51.68 0.38 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.678 2.252 . . . . 74.13 112.361 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -156.95 49.41 0.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 50.54 110.892 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.41 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.13 136.27 5.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 62.43 111.158 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 71.4 mt -86.21 142.53 12.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.186 -0.461 . . . . 71.11 111.115 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -118.3 -80.99 0.62 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.865 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 57.29 171.46 0.19 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.73 -0.748 . . . . 65.1 112.502 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.57 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.8 p90 -160.45 141.89 12.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.354 . . . . 63.0 110.927 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 7.1 t-80 -116.18 101.78 9.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 61.24 110.851 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.727 HG12 HG21 ' A' ' 81' ' ' ILE . 5.0 p -96.28 143.78 11.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 61.24 111.104 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -66.34 -172.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 72.11 110.938 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.89 -46.52 3.3 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.778 -0.725 . . . . 61.2 112.457 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.419 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.8 OUTLIER -146.7 165.68 28.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.751 0.31 . . . . 74.42 111.149 -179.82 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.419 ' H ' HG22 ' A' ' 79' ' ' THR . 3.8 m120 -79.48 58.36 2.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 75.12 110.947 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.727 HG21 HG12 ' A' ' 76' ' ' VAL . 12.9 tt -66.35 115.09 3.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 63.41 111.118 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.7 91.05 3.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.01 110.863 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.43 ' CG1' HG21 ' A' ' 93' ' ' VAL . 7.0 m -118.11 120.48 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 75.44 111.103 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -160.9 117.34 2.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.02 110.924 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.498 HG21 ' OG ' ' A' ' 91' ' ' SER . 96.2 t -140.35 127.73 23.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 75.03 111.134 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.419 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -51.07 160.06 0.91 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.601 0.715 . . . . 63.42 110.921 179.972 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.419 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 54.0 Cg_endo -69.73 155.47 65.96 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.724 2.283 . . . . 71.41 112.353 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.65 10.7 46.33 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.797 -0.716 . . . . 64.35 112.513 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -164.69 119.2 1.37 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.871 0.367 . . . . 74.34 110.867 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.428 HG12 ' O ' ' A' ' 9' ' ' GLU . 2.9 p -68.69 133.73 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 63.25 111.141 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.498 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -94.39 168.9 10.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 54.25 110.876 -179.87 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 90.5 m -144.4 105.46 4.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 71.24 111.119 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.59 HG12 ' HB2' ' A' ' 63' ' ' PHE . 9.0 p -118.58 141.21 39.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 62.51 111.125 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -110.6 101.55 10.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 71.31 110.879 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -145.97 119.26 8.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.228 -0.442 . . . . 64.42 110.905 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.5 t -117.28 142.97 46.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.489 . . . . 71.13 111.181 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.0 -175.93 4.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 63.11 110.915 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 20.5 mtpt -126.21 -12.45 6.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.16 -0.473 . . . . 74.12 110.917 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -148.19 162.22 31.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.601 0.715 . . . . 75.5 110.908 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 156.9 62.23 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.69 2.26 . . . . 73.21 112.344 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.2 133.64 1.51 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.743 -0.742 . . . . 60.44 112.523 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -99.4 128.49 45.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 74.33 110.897 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -144.13 131.08 20.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 74.31 110.889 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 7.1 ptt180 -147.94 83.41 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 74.15 110.858 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.0 mt -151.01 145.03 16.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 73.14 111.155 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.67 140.0 36.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 71.41 111.131 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 179.57 153.44 0.46 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 73.34 110.867 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 54.2 m-20 51.45 53.29 13.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 54.24 110.902 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.428 HE22 ' N ' ' A' ' 74' ' ' PHE . 39.9 mm-40 -98.6 62.5 1.41 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.225 -0.443 . . . . 73.43 110.96 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 69.43 -75.4 0.07 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.248 -0.433 . . . . 74.01 110.907 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 56.1 m -75.31 -24.81 57.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.13 -0.487 . . . . 54.45 110.853 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.02 43.29 9.93 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 63.31 112.529 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -52.82 171.25 0.06 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.911 0.386 . . . . 72.31 110.875 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 173.88 34.7 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.75 . . . . 71.21 112.444 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -179.33 37.93 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.754 0.311 . . . . 74.34 110.829 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -162.25 -67.8 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.244 -0.435 . . . . 71.15 110.905 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 27.9 p30 -58.19 -175.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 61.42 110.876 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 20.9 mmt -115.28 176.78 4.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 75.44 110.898 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -89.27 122.74 32.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.277 -0.42 . . . . 70.24 110.885 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.93 167.95 0.3 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.753 -0.736 . . . . 65.01 112.475 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.568 ' HB ' HD13 ' A' ' 53' ' ' ILE . 43.1 m -154.03 118.66 4.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.814 0.34 . . . . 74.32 111.146 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.596 HG13 HG21 ' A' ' 53' ' ' ILE . 4.3 mp -144.92 141.55 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 75.34 111.123 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.493 ' O ' HG12 ' A' ' 55' ' ' VAL . 85.1 t -131.29 133.95 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 72.4 111.135 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.8 HG22 HG13 ' A' ' 55' ' ' VAL . 97.4 t -103.9 134.93 43.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 54.41 111.093 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -117.87 130.66 56.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 65.33 110.846 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 73.41 110.856 179.973 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.83 0.348 . . . . 73.44 110.876 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 3.2 m 38.06 80.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 72.43 111.116 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.1 pt -111.81 78.2 2.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.602 0.715 . . . . 74.54 111.09 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 -170.76 0.41 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.639 2.226 . . . . 71.31 112.349 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.23 35.41 1.21 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 62.34 111.067 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 171.76 164.77 27.91 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.698 -0.763 . . . . 73.35 112.466 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.46 -166.39 0.23 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.832 0.349 . . . . 62.13 110.9 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.616 HD13 ' HB ' ' A' ' 90' ' ' VAL . 3.1 pp -54.82 178.18 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 53.33 110.916 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.425 ' N ' HD12 ' A' ' 8' ' ' LEU . 14.1 pt-20 -103.13 136.27 43.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 73.43 110.883 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -89.46 166.76 13.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 70.53 110.885 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 m -144.5 -179.31 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.459 . . . . 71.3 111.146 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -145.76 161.66 39.42 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.628 0.728 . . . . 65.0 110.904 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -4.47 14.09 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.687 2.258 . . . . 70.51 112.355 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.796 HG22 HG23 ' A' ' 15' ' ' THR . 33.9 m -48.47 -70.78 0.08 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 62.33 111.178 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.796 HG23 HG22 ' A' ' 14' ' ' THR . 30.5 p -150.92 35.26 0.6 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 72.03 111.17 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 14.0 p -69.56 -31.59 49.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 61.53 111.086 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.407 ' HB3' HD21 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -93.14 -5.09 51.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 75.52 110.889 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -104.53 -35.7 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 73.4 110.9 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -129.0 134.16 48.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 63.23 110.861 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.73 -160.3 13.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 64.21 112.5 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -26.27 27.71 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.746 2.297 . . . . 73.1 112.342 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 16.1 m-90 -87.17 -9.86 54.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.192 -0.458 . . . . 61.24 110.928 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.77 -59.46 2.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 54.15 111.134 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.62 144.38 28.5 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.605 0.717 . . . . 71.43 110.875 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -19.17 36.78 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.695 2.263 . . . . 72.3 112.39 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.75 -20.28 60.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 74.23 111.117 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mm-40 -87.28 6.82 31.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 73.32 110.868 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.43 -76.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 70.01 111.112 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.404 HG21 ' HB3' ' A' ' 54' ' ' GLU . 20.1 t -84.53 118.35 31.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 72.02 111.123 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.445 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 11.0 m -132.94 138.75 51.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 75.25 111.151 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.14 95.96 9.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 73.22 110.892 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.3 t -95.71 -35.82 11.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 65.31 111.163 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.79 -166.54 21.63 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.75 . . . . 62.13 112.507 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -44.93 1.77 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.677 2.251 . . . . 65.42 112.315 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -143.37 30.24 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 74.31 110.867 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -126.95 120.05 28.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 74.42 110.933 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -96.34 135.73 37.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 72.35 110.924 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.445 ' HB ' ' CG2' ' A' ' 30' ' ' VAL . 49.8 m -96.01 105.0 16.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.093 -0.503 . . . . 54.12 111.111 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -84.65 147.23 5.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 73.1 111.141 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -127.16 121.85 32.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 73.54 110.928 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.499 HG22 ' CG1' ' A' ' 53' ' ' ILE . 97.6 t -114.33 124.97 71.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 73.23 111.191 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.667 HD12 ' OE1' ' A' ' 49' ' ' GLN . 3.3 tm? -120.36 136.5 54.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 64.53 110.868 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.507 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -155.61 140.55 17.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 52.44 111.122 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -139.99 159.0 43.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 64.55 110.923 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.71 5.57 35.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 53.55 111.111 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -122.31 84.88 2.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 72.13 110.853 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.87 179.14 19.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.743 -0.742 . . . . 72.02 112.492 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -124.65 139.48 53.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.806 0.336 . . . . 63.2 110.922 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.667 ' OE1' HD12 ' A' ' 42' ' ' LEU . 5.4 mt-30 -142.17 162.09 47.24 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 73.2 110.875 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 179.9 3.37 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.675 2.25 . . . . 64.43 112.317 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.659 ' O ' HD12 ' A' ' 53' ' ' ILE . 4.6 m-80 -135.98 63.0 49.37 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.629 0.728 . . . . 63.33 110.909 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 73.77 1.32 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.643 2.229 . . . . 72.13 112.368 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.659 HD12 ' O ' ' A' ' 51' ' ' ASN . 4.5 mp -110.57 113.91 45.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.246 -0.434 . . . . 72.44 111.179 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.404 ' HB3' HG21 ' A' ' 29' ' ' VAL . 12.3 tt0 -110.07 135.43 50.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 74.41 110.908 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.857 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -138.9 81.76 21.58 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.665 0.745 . . . . 72.13 111.132 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.626 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.2 Cg_endo -69.71 129.01 16.9 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.731 2.287 . . . . 73.33 112.356 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.449 HE22 ' HA ' ' A' ' 126' ' ' GLU . 1.7 pm0 -73.44 152.2 40.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 71.12 110.897 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.61 -35.61 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.758 -0.734 . . . . 52.51 112.474 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.0 155.93 18.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 71.44 111.127 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.696 ' O ' HD13 ' A' ' 61' ' ' ILE . 40.4 mt-10 -67.18 144.51 55.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 75.03 110.896 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.696 HD13 ' O ' ' A' ' 60' ' ' GLU . 6.4 mm -128.83 119.61 50.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.455 . . . . 73.35 111.137 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.822 HG13 HG23 ' A' ' 92' ' ' THR . 55.1 t -107.55 91.22 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 74.42 111.143 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.571 ' HB2' HG12 ' A' ' 93' ' ' VAL . 65.3 m-85 -70.37 137.25 50.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 61.12 110.864 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -129.55 100.88 5.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 74.21 110.839 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.732 ' CG2' HG11 ' A' ' 85' ' ' VAL . 1.8 mp -100.31 155.29 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 73.53 111.11 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.4 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.3 t -169.99 139.21 1.83 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.166 -0.47 . . . . 72.02 111.148 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.4 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -143.46 161.78 45.43 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.688 0.756 . . . . 73.4 110.857 -179.86 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.4 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.72 -54.09 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.69 2.26 . . . . 70.22 112.392 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -159.16 38.3 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 71.3 110.878 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -138.73 135.16 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 72.42 111.114 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.514 HD13 ' HD3' ' A' ' 87' ' ' PRO . 28.7 mm -88.02 142.89 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 73.33 111.133 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 6.0 p80 -174.85 136.9 0.42 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 73.01 110.859 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -143.76 -149.62 5.12 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 62.34 112.494 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.468 ' CE2' HD11 ' A' ' 65' ' ' ILE . 7.9 p90 -159.29 138.19 11.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.923 0.392 . . . . 51.12 110.925 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 41.6 t60 -128.34 98.83 5.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 71.34 110.858 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.704 HG12 HG21 ' A' ' 81' ' ' ILE . 6.6 p -80.58 144.61 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 63.14 111.111 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.3 pm0 -67.77 -175.44 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 62.12 110.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.54 -51.1 4.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.715 -0.755 . . . . 74.13 112.474 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.7 m -131.46 153.34 49.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.321 . . . . 62.41 111.174 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -76.0 66.08 2.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 71.14 110.89 -179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.704 HG21 HG12 ' A' ' 76' ' ' VAL . 12.5 tt -77.57 113.11 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 70.32 111.09 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.03 98.35 6.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 52.01 110.885 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.9 m -121.25 120.31 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.158 -0.474 . . . . 72.22 111.15 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -125.09 96.02 4.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 62.54 110.885 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.732 HG11 ' CG2' ' A' ' 65' ' ' ILE . 5.8 p -86.83 144.37 9.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 63.01 111.072 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 6.1 mp -111.05 156.62 40.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.6 0.714 . . . . 72.31 110.935 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.514 ' HD3' HD13 ' A' ' 71' ' ' ILE . 54.1 Cg_endo -69.71 146.96 62.13 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.254 . . . . 74.42 112.365 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.22 8.96 86.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.734 -0.746 . . . . 20.31 112.467 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -146.69 173.61 12.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.918 0.39 . . . . 71.41 110.893 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.616 ' HB ' HD13 ' A' ' 8' ' ' LEU . 18.5 t -120.92 146.21 26.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 70.23 111.155 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.416 ' OG ' HD12 ' A' ' 65' ' ' ILE . 1.5 p -109.84 158.51 18.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 72.34 110.87 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.822 HG23 HG13 ' A' ' 62' ' ' VAL . 53.2 m -145.87 105.46 3.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.474 . . . . 63.33 111.128 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.571 HG12 ' HB2' ' A' ' 63' ' ' PHE . 7.6 p -123.11 136.23 60.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 71.14 111.143 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.2 mtm180 -105.86 92.47 4.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 74.12 110.827 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -134.66 115.17 13.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.452 . . . . 73.2 110.939 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 t -116.19 142.93 46.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 73.11 111.149 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.95 178.85 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 71.35 110.863 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.34 -21.94 7.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.118 -0.492 . . . . 72.55 110.912 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.97 158.3 74.15 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.592 0.71 . . . . 73.12 110.887 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 149.44 66.86 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.678 2.252 . . . . 74.2 112.363 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.87 156.67 9.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.752 . . . . 54.52 112.457 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.616 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -114.54 132.2 56.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.847 0.356 . . . . 63.24 110.868 -179.874 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -143.62 146.41 33.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.158 -0.473 . . . . 55.41 110.923 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.949 ' O ' HG22 ' A' ' 105' ' ' ILE . 13.9 ptt-85 -164.9 -164.58 0.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 74.32 110.863 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.949 HG22 ' O ' ' A' ' 104' ' ' ARG . 7.3 tt 58.2 158.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 61.32 111.118 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -119.28 140.05 44.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 61.14 111.16 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.525 ' HA ' HD23 ' A' ' 113' ' ' LEU . 56.7 m -141.67 -42.51 0.36 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.167 -0.47 . . . . 73.43 110.87 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 61.2 m-20 -125.43 76.03 1.52 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.183 -0.462 . . . . 73.43 110.886 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -122.62 -5.13 8.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 54.52 110.886 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 70.6 t80 63.41 155.39 0.05 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 75.32 110.889 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 7.2 t 65.76 15.34 10.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.112 -0.495 . . . . 64.13 110.854 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -159.89 -129.12 1.02 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.799 -0.715 . . . . 71.23 112.542 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.525 HD23 ' HA ' ' A' ' 107' ' ' CYS . 3.1 tm? 62.54 104.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.843 0.354 . . . . 75.25 110.888 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.06 -20.56 50.08 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.763 -0.732 . . . . 41.53 112.514 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -152.25 128.93 10.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.723 0.297 . . . . 74.4 110.876 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 14.0 mt-30 63.6 -169.35 0.19 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 75.32 110.909 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 63.76 97.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 74.14 110.915 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.27 175.32 5.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 74.13 110.853 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 -91.29 161.94 14.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 70.21 110.879 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.533 ' O ' HD12 ' A' ' 122' ' ' ILE . . . -130.68 103.88 0.58 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.71 -0.757 . . . . 40.0 112.465 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.644 ' O ' HD13 ' A' ' 53' ' ' ILE . 96.2 m -74.98 116.23 15.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.791 0.329 . . . . 75.13 111.166 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.533 HD12 ' O ' ' A' ' 120' ' ' GLY . 2.5 mp -140.25 132.92 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 65.14 111.069 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.616 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -134.3 141.13 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 73.0 111.093 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.857 HG22 HG13 ' A' ' 55' ' ' VAL . 62.1 t -103.75 130.73 53.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 61.11 111.138 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -104.1 128.72 51.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 70.24 110.917 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.449 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 116.23 -0.441 . . . . 75.42 110.853 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.2 mtp . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.799 0.333 . . . . 71.43 110.85 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 98.2 t -108.03 113.15 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 75.55 111.163 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 28.5 pt -151.16 153.75 33.14 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.622 0.725 . . . . 70.22 111.142 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.77 -176.96 1.66 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.651 2.234 . . . . 53.35 112.34 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.94 -24.96 16.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 50.0 111.085 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -173.62 129.22 1.62 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.749 -0.739 . . . . 74.32 112.526 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.07 163.75 0.11 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.79 0.328 . . . . 63.12 110.894 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.662 HD21 ' NH1' ' A' ' 10' ' ' ARG . 0.2 OUTLIER 61.31 164.38 0.08 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.259 -0.428 . . . . 55.33 110.905 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.622 ' N ' HD12 ' A' ' 8' ' ' LEU . 3.8 pm0 -132.46 130.36 40.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 75.33 110.892 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.662 ' NH1' HD21 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -86.43 142.67 28.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 62.45 110.848 -179.919 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.568 HG13 HG23 ' A' ' 90' ' ' VAL . 16.4 m -118.46 -176.64 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.167 -0.469 . . . . 65.52 111.106 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.444 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 16.5 p30 -142.92 157.39 61.22 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.605 0.717 . . . . 54.52 110.887 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 54.0 Cg_endo -69.77 -3.06 11.25 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.646 2.23 . . . . 75.41 112.379 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.82 HG22 HG23 ' A' ' 15' ' ' THR . 25.2 m -46.58 -69.98 0.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.452 . . . . 75.51 111.165 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.82 HG23 HG22 ' A' ' 14' ' ' THR . 25.9 p -149.71 24.83 0.86 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 65.43 111.165 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.2 p -63.68 -30.97 51.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 74.31 111.133 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.487 ' NH1' HD21 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -103.28 -5.38 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 74.44 110.879 -179.973 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 83.7 mm-40 -92.24 -37.42 12.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 71.11 110.942 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -141.89 133.42 26.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 72.3 110.898 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 126.97 -155.09 19.62 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.7 -0.762 . . . . 72.34 112.502 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.95 17.5 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.683 2.256 . . . . 72.45 112.351 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.442 ' HB3' HD23 ' A' ' 42' ' ' LEU . 12.2 m-90 -84.61 -13.98 50.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 73.32 110.916 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.78 -49.18 75.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.082 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -114.07 144.39 31.51 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.608 0.718 . . . . 75.14 110.862 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 -25.7 28.06 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.662 2.242 . . . . 61.43 112.318 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.22 -6.75 49.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 74.15 111.098 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 7.0 mm100 -102.47 9.67 39.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 72.44 110.881 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.92 -79.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 62.22 111.146 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.572 HG23 ' HB3' ' A' ' 37' ' ' TYR . 1.5 p -84.98 124.34 39.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 53.21 111.12 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.5 m -135.29 136.01 51.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 63.25 111.124 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -75.57 107.2 7.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 52.05 110.893 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 9.7 t -111.94 -32.95 6.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.218 -0.446 . . . . 55.02 111.141 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.76 -172.68 19.86 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.756 -0.735 . . . . 34.11 112.504 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -43.8 2.45 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.687 2.258 . . . . 73.23 112.357 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -140.96 35.27 1.75 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 64.31 110.876 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.5 pt20 -138.35 119.09 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 60.03 110.889 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.572 ' HB3' HG23 ' A' ' 29' ' ' VAL . 15.2 m-85 -96.79 137.34 36.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 71.42 110.95 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.741 ' HA ' HG23 ' A' ' 62' ' ' VAL . 81.2 m -95.74 105.71 17.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 73.45 111.147 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.463 ' HA ' ' HA ' ' A' ' 29' ' ' VAL . 9.9 t -92.66 138.52 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 64.13 111.12 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -120.75 114.82 22.2 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.191 -0.459 . . . . 72.32 110.951 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.485 HG22 HG13 ' A' ' 53' ' ' ILE . 64.4 t -104.14 130.79 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.14 -0.482 . . . . 73.15 111.102 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.487 HD21 ' NH1' ' A' ' 17' ' ' ARG . 1.7 tm? -125.07 121.52 34.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.47 . . . . 71.12 110.896 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -142.89 137.57 29.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.446 . . . . 62.43 111.088 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -145.52 159.94 42.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 74.04 110.858 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.82 5.55 32.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 54.33 111.108 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -110.26 70.59 0.73 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.45 110.831 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.07 -170.09 16.23 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.684 -0.77 . . . . 55.55 112.415 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.23 126.51 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.795 0.331 . . . . 72.41 110.929 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.46 ' HB3' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -136.42 161.0 64.62 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.567 0.699 . . . . 73.45 110.961 179.974 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.46 ' HD2' ' HB3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.76 178.68 4.32 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.707 2.271 . . . . 70.43 112.338 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.708 ' O ' HD12 ' A' ' 53' ' ' ILE . 1.1 m-80 -129.93 62.78 65.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.646 0.736 . . . . 64.5 110.905 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 75.56 1.23 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.657 2.238 . . . . 71.23 112.314 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.753 HD13 ' O ' ' A' ' 121' ' ' THR . 4.4 mp -106.89 98.18 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 64.11 111.133 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -82.14 129.6 34.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 61.41 110.889 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.69 ' O ' HG13 ' A' ' 124' ' ' VAL . 30.7 t -137.01 81.31 33.35 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.633 0.73 . . . . 75.1 111.118 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.596 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.8 123.05 9.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.702 2.268 . . . . 72.34 112.355 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.506 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.1 pm0 -69.29 155.18 40.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 71.45 110.933 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.36 -4.39 77.59 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.749 -0.739 . . . . 60.13 112.503 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.05 152.46 51.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.71 0.29 . . . . 75.1 111.129 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.68 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.0 mp0 -66.66 139.37 57.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.265 -0.425 . . . . 64.43 110.887 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.68 HD13 ' O ' ' A' ' 60' ' ' GLU . 7.2 mm -127.41 116.33 43.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.198 -0.456 . . . . 64.14 111.123 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -104.44 90.59 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 71.21 111.108 179.87 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -68.42 139.7 55.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 75.13 110.883 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -131.97 100.57 5.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 64.11 110.913 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.8 mp -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 73.32 111.122 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.1 t -168.44 140.49 2.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.135 -0.484 . . . . 72.4 111.137 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.451 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -149.52 161.14 32.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.705 0.764 . . . . 75.45 110.861 -179.883 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.424 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.78 -55.46 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 42.12 112.322 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -156.96 61.97 0.51 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 63.25 110.85 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.451 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.84 135.44 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 61.32 111.163 179.955 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 36.4 mm -69.81 130.5 34.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 64.11 111.128 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.66 ' HE2' HG23 ' A' ' 85' ' ' VAL . 9.2 p-80 -119.98 -175.79 3.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.236 -0.438 . . . . 51.22 110.885 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 170.9 12.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 33.22 112.502 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.5 p90 -153.23 141.25 20.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.845 0.355 . . . . 75.15 110.918 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 76.2 t60 -122.1 104.38 9.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 73.11 110.878 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.686 HG12 HG21 ' A' ' 81' ' ' ILE . 3.5 p -94.3 137.86 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 74.44 111.143 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -59.96 -175.98 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 61.41 110.904 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.13 -50.97 4.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 44.41 112.45 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.464 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -129.26 171.71 12.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.773 0.321 . . . . 73.22 111.111 -179.816 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.464 ' H ' HG22 ' A' ' 79' ' ' THR . 3.2 m-80 -93.17 47.61 1.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 73.44 110.852 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.686 HG21 HG12 ' A' ' 76' ' ' VAL . 12.5 tt -58.54 112.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 60.34 111.172 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.34 94.16 4.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 74.53 110.923 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.421 HG11 ' CG1' ' A' ' 93' ' ' VAL . 3.3 m -117.97 120.35 64.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 54.11 111.096 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -150.28 118.46 6.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 74.32 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.851 HG21 ' HB2' ' A' ' 91' ' ' SER . 5.0 m -140.73 146.88 23.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.155 -0.475 . . . . 73.32 111.14 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.27 161.94 75.5 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.554 0.692 . . . . 75.42 110.969 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 159.65 52.61 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.25 . . . . 72.11 112.309 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 86.4 13.28 68.36 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.749 -0.739 . . . . 74.42 112.493 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -146.21 138.43 25.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.903 0.383 . . . . 71.23 110.892 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.568 HG23 HG13 ' A' ' 11' ' ' VAL . 99.5 t -90.93 105.89 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 53.03 111.153 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.851 ' HB2' HG21 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -89.31 137.67 32.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 73.3 110.855 -179.839 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 92.9 m -110.01 105.51 14.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 74.23 111.172 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.421 ' CG1' HG11 ' A' ' 83' ' ' VAL . 44.7 t -98.19 147.95 6.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 71.54 111.104 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.61 110.93 15.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 70.21 110.882 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -156.68 122.64 4.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 72.05 110.887 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.8 t -123.39 135.55 54.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 64.43 111.152 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.79 -174.22 3.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 65.24 110.871 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -121.9 -26.4 4.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 72.11 110.915 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.1 mpp_? -134.51 161.41 63.89 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 70.04 110.88 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 154.22 67.89 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.652 2.235 . . . . 63.32 112.371 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.58 134.4 1.65 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.755 -0.736 . . . . 32.23 112.485 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.743 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -100.69 139.49 36.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 74.31 110.892 -179.883 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -143.82 132.82 22.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 74.24 110.915 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.36 94.07 2.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 61.13 110.86 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.8 tt -177.63 131.55 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 75.34 111.17 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.402 HD13 HD23 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -106.2 145.77 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 64.33 111.093 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -163.98 -74.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 54.35 110.874 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 6.4 m120 -81.09 106.67 13.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.466 . . . . 75.4 110.905 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -167.8 -77.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 74.32 110.914 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER 175.91 -168.49 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.427 . . . . 72.41 110.915 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 68.66 -76.4 0.06 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.148 -0.478 . . . . 60.22 110.9 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 153.61 95.31 0.11 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.748 -0.739 . . . . 70.2 112.5 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.496 ' C ' HD13 ' A' ' 113' ' ' LEU . 3.1 tm? -51.77 131.87 30.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.919 0.39 . . . . 73.5 110.88 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.444 ' H ' HD22 ' A' ' 113' ' ' LEU . . . 146.79 -101.77 0.24 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.73 -0.747 . . . . 70.53 112.499 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 19.0 m170 -94.09 40.3 1.08 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.744 0.307 . . . . 74.12 110.849 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -172.73 172.54 4.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.231 -0.44 . . . . 64.23 110.878 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 37.9 t-20 66.08 119.46 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 75.43 110.894 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -71.18 174.88 5.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 71.12 110.901 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -91.28 129.7 37.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 71.02 110.886 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.8 82.49 0.4 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.713 -0.756 . . . . 53.35 112.476 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.753 ' O ' HD13 ' A' ' 53' ' ' ILE . 6.7 m -80.7 115.02 19.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.826 0.346 . . . . 64.42 111.127 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.444 ' CG2' HG21 ' A' ' 55' ' ' VAL . 2.1 mp -149.14 139.12 16.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 74.34 111.177 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.743 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.5 p -127.5 135.92 61.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 64.32 111.182 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 55' ' ' VAL . 41.3 t -104.48 127.65 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 74.21 111.103 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 12.4 mmmm -102.22 133.6 46.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 70.21 110.872 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.506 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 75.21 110.919 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.541 ' O ' HG23 ' A' ' 3' ' ' ILE . 2.7 mtt . . . . . 0 C--O 1.23 0.079 0 CA-C-O 120.774 0.321 . . . . 73.24 110.875 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.588 HG22 ' O ' ' A' ' 2' ' ' VAL . 12.3 p 41.43 37.14 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 64.34 111.074 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.541 HG23 ' O ' ' A' ' 1' ' ' MET . 6.4 pt -122.52 77.97 46.28 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.592 0.71 . . . . 61.22 111.099 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -177.65 1.98 Allowed 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.689 2.259 . . . . 74.11 112.369 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -156.26 159.8 39.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.257 -0.429 . . . . 71.04 111.101 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 56.95 32.2 62.16 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.742 -0.742 . . . . 71.34 112.515 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -171.48 -168.97 0.66 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.745 0.307 . . . . 72.13 110.931 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.636 HD13 ' O ' ' A' ' 90' ' ' VAL . 0.8 OUTLIER -57.69 -172.98 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.231 -0.44 . . . . 73.54 110.913 179.941 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.48 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.8 OUTLIER -115.8 134.34 55.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 64.21 110.891 179.96 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 166.56 10.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 75.35 110.884 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.8 m -144.41 -179.09 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 71.35 111.074 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.68 162.04 40.66 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.603 0.716 . . . . 62.23 110.902 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -3.67 12.49 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.676 2.251 . . . . 65.45 112.331 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 28.0 m -46.09 -70.44 0.1 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.239 -0.437 . . . . 63.21 111.17 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 28.3 p -150.05 27.59 0.77 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 64.4 111.157 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.2 p -65.22 -30.77 51.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 73.22 111.13 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.428 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.7 OUTLIER -100.74 -15.74 17.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.148 -0.478 . . . . 63.33 110.863 -179.95 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -88.45 -33.04 17.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 61.04 110.898 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -141.35 135.12 30.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 73.03 110.913 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.44 -160.69 19.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.753 -0.737 . . . . 72.1 112.492 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -25.8 28.21 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.265 . . . . 53.24 112.343 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.733 ' HB3' HD13 ' A' ' 42' ' ' LEU . 14.5 m-90 -87.07 -12.6 46.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 75.32 110.95 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.86 -59.43 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.451 . . . . 73.43 111.093 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.42 144.55 28.45 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.556 0.693 . . . . 71.44 110.879 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -27.75 26.37 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.689 2.26 . . . . 75.41 112.359 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.41 -18.38 60.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 72.32 111.094 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 -87.82 7.64 29.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 70.14 110.939 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.14 -78.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 64.35 111.112 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 39' ' ' VAL . 1.8 p -93.1 124.93 45.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 74.23 111.113 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.2 m -119.67 149.86 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 64.43 111.108 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.65 121.99 27.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 72.21 110.963 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.462 HG21 ' OG1' ' A' ' 38' ' ' THR . 0.6 OUTLIER -121.91 -42.6 2.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 73.1 111.122 -179.881 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.47 170.65 13.81 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 61.5 112.488 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.695 2.264 . . . . 72.43 112.31 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -156.29 34.34 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 64.52 110.908 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -154.0 155.64 35.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.128 -0.487 . . . . 74.33 110.898 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -143.05 147.99 35.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 72.34 110.913 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.462 ' OG1' HG21 ' A' ' 32' ' ' THR . 52.0 m -101.37 104.22 15.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 72.53 111.127 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.573 HG11 HG23 ' A' ' 53' ' ' ILE . 6.7 t -85.18 135.13 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 72.44 111.137 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -117.12 121.66 41.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.18 -0.464 . . . . 72.41 110.933 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.0 m -122.73 143.9 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 55.44 111.131 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.733 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -138.69 143.85 39.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.479 . . . . 62.23 110.889 179.993 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -149.54 123.52 9.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 73.14 111.129 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -121.41 154.47 36.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 62.45 110.814 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.84 6.87 33.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 54.42 111.074 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -122.37 86.07 2.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 75.43 110.906 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.91 -165.92 12.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.755 -0.736 . . . . 62.34 112.54 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -136.3 143.43 44.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.842 0.353 . . . . 74.03 110.893 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.417 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.7 pm0 -145.37 155.59 53.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 72.13 110.901 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.417 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.9 Cg_endo -69.75 174.45 9.48 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.253 . . . . 63.31 112.35 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.73 ' O ' HD12 ' A' ' 53' ' ' ILE . 2.1 m-20 -127.99 62.37 56.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.631 0.729 . . . . 72.23 110.869 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 74.43 1.26 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.655 2.237 . . . . 73.1 112.343 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.73 HD12 ' O ' ' A' ' 51' ' ' ASN . 3.9 mp -110.58 113.89 45.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 54.43 111.154 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -108.59 119.47 39.61 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.491 . . . . 72.13 110.908 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.848 HG23 HG13 ' A' ' 61' ' ' ILE . 2.1 p -124.77 85.71 56.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.61 0.719 . . . . 74.14 111.125 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.619 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.4 Cg_endo -69.76 122.57 9.25 Favored 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 122.673 2.249 . . . . 72.31 112.347 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.57 150.45 48.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 64.01 110.881 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.81 -30.46 5.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 52.23 112.507 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.83 152.12 23.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.736 0.303 . . . . 54.21 111.119 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.63 ' O ' HD13 ' A' ' 61' ' ' ILE . 0.4 OUTLIER -68.82 142.36 54.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.456 . . . . 75.11 110.861 -179.897 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.848 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -126.87 124.16 64.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 62.11 111.106 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 1.042 HG13 HG23 ' A' ' 92' ' ' THR . 55.0 t -107.92 91.25 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 71.11 111.173 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -69.48 135.02 49.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 65.31 110.887 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -131.43 100.44 5.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 62.13 110.865 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.775 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.5 mp -97.17 156.07 3.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.264 -0.426 . . . . 73.12 111.098 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.607 HG23 HD12 ' A' ' 42' ' ' LEU . 7.2 t -166.01 137.9 3.86 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 43.44 111.141 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.639 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -152.21 159.76 32.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.646 0.736 . . . . 71.14 110.912 -179.876 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.76 -53.98 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.665 2.243 . . . . 71.21 112.403 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -154.88 65.84 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 73.24 110.864 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.639 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.4 135.55 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 74.32 111.126 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.2 mm -66.9 145.54 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 75.31 111.107 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.775 ' HB3' HG21 ' A' ' 65' ' ' ILE . 1.3 m-70 -108.75 -167.05 1.17 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 74.45 110.834 179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.84 120.73 3.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 41.12 112.513 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -121.16 142.84 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.904 0.383 . . . . 74.54 110.9 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -89.14 137.19 32.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 73.11 110.872 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.741 HG13 ' CE2' ' A' ' 103' ' ' TYR . 94.8 t -130.03 141.47 46.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 62.42 111.161 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.6 mt-10 -75.26 175.67 8.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 64.11 110.878 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.06 -51.65 4.14 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.676 -0.773 . . . . 64.34 112.514 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.25 147.24 51.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 74.11 111.156 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 7.8 m-80 -76.71 64.57 2.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 65.55 110.881 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.767 HD12 ' CD2' ' A' ' 95' ' ' TYR . 8.0 tt -58.23 125.94 15.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 73.2 111.176 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.7 89.67 3.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.853 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.575 HG11 HG21 ' A' ' 93' ' ' VAL . 3.7 m -115.87 120.65 65.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 73.42 111.158 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -155.79 114.51 3.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 72.12 110.838 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.652 HG21 ' OG ' ' A' ' 91' ' ' SER . 61.6 t -140.46 146.71 24.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 74.15 111.138 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.433 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.6 OUTLIER -69.69 155.68 93.06 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.585 0.707 . . . . 63.03 110.902 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.433 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 54.1 Cg_endo -69.74 159.8 52.09 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.234 . . . . 71.1 112.379 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.21 17.25 51.31 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.761 -0.733 . . . . 64.11 112.493 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -156.26 155.77 32.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.88 0.371 . . . . 73.13 110.886 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.636 ' O ' HD13 ' A' ' 8' ' ' LEU . 98.2 t -104.85 109.78 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 55.31 111.123 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.652 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.4 OUTLIER -83.83 169.46 15.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 73.11 110.879 -179.856 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 92' ' ' THR . . . . . 1.042 HG23 HG13 ' A' ' 62' ' ' VAL . 98.3 m -137.99 122.22 18.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.144 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.575 HG21 HG11 ' A' ' 83' ' ' VAL . 21.3 t -124.57 130.6 73.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 71.02 111.155 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.7 mmm180 -102.57 70.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 70.24 110.9 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.767 ' CD2' HD12 ' A' ' 81' ' ' ILE . 14.8 t80 -110.13 130.73 55.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.153 -0.476 . . . . 72.25 110.931 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.1 t -139.64 142.25 37.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.475 . . . . 63.02 111.133 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -97.0 -175.49 3.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 73.25 110.861 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.1 mttt -125.34 -12.52 6.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 35.13 110.899 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -145.81 162.14 37.24 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.557 0.694 . . . . 70.22 110.865 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 154.0 68.21 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.679 2.253 . . . . 61.03 112.347 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.45 141.17 3.05 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.727 -0.749 . . . . 23.23 112.483 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -106.59 130.14 54.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.808 0.337 . . . . 60.42 110.905 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' TYR . . . . . 0.741 ' CE2' HG13 ' A' ' 76' ' ' VAL . 4.3 p90 -144.04 146.32 32.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 73.01 110.922 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.494 ' HG2' HD12 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -155.17 -175.76 5.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 74.21 110.848 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.494 HD12 ' HG2' ' A' ' 104' ' ' ARG . 1.9 mp 65.62 150.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 72.41 111.195 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.477 HD13 ' N ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -109.68 145.75 15.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 55.31 111.167 179.881 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.477 ' N ' HD13 ' A' ' 106' ' ' ILE . 0.2 OUTLIER -175.07 33.44 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.166 -0.47 . . . . 64.54 110.904 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 34.1 t30 -174.84 60.43 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.138 -0.483 . . . . 73.14 110.866 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.459 ' HB2' HD11 ' A' ' 106' ' ' ILE . 0.0 OUTLIER -107.46 -175.39 2.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 70.33 110.899 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -121.33 69.76 0.92 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.205 -0.452 . . . . 61.31 110.942 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 35.9 t -176.95 -36.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.13 -0.487 . . . . 73.21 110.899 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 156.56 145.77 4.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.718 -0.753 . . . . 71.22 112.476 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.522 HD23 ' H ' ' A' ' 113' ' ' LEU . 2.1 pt? -127.83 133.49 49.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.879 0.371 . . . . 75.25 110.924 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 136.43 -107.49 0.61 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.719 -0.753 . . . . 64.25 112.454 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -51.91 -73.89 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.743 0.306 . . . . 72.33 110.861 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -71.1 -169.74 0.4 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 71.43 110.899 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.55 95.97 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.208 -0.451 . . . . 73.51 110.904 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.45 174.84 6.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 52.12 110.875 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -91.33 120.09 31.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 75.13 110.921 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -87.58 -179.78 47.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.747 -0.739 . . . . 72.24 112.531 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.722 ' O ' HD13 ' A' ' 53' ' ' ILE . 67.9 m -154.71 137.02 14.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.74 0.305 . . . . 73.54 111.164 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.446 ' CG2' HG11 ' A' ' 55' ' ' VAL . 2.8 mp -147.36 140.72 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 72.25 111.123 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 55' ' ' VAL . 50.2 t -128.41 129.28 68.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 35.51 111.116 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.776 HG22 HG13 ' A' ' 55' ' ' VAL . 87.9 t -103.59 136.86 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 75.35 111.082 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.3 mmmt -113.83 131.78 56.12 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 72.25 110.902 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 73.34 110.874 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.1 ptp . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.807 0.337 . . . . 71.42 110.843 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 63.0 t -116.28 86.07 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.237 -0.438 . . . . 74.22 111.123 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -138.08 77.79 36.12 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.635 0.731 . . . . 72.53 111.143 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -177.59 1.95 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.673 2.249 . . . . 62.24 112.356 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -167.56 161.58 13.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 73.42 111.111 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 109.31 -34.74 5.33 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.734 -0.746 . . . . 71.33 112.507 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -168.4 120.11 0.81 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.813 0.339 . . . . 65.43 110.898 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.638 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 62.07 162.51 0.08 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 53.42 110.885 179.899 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.638 ' N ' HD12 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -123.98 132.93 53.77 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.183 -0.462 . . . . 62.12 110.859 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.64 166.78 13.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 61.11 110.85 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 16' ' ' VAL . 35.9 m -150.02 140.6 16.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.178 -0.465 . . . . 62.11 111.104 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.1 162.84 19.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.578 0.704 . . . . 72.03 110.855 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.96 9.33 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.651 2.234 . . . . 60.1 112.384 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.464 HG22 HG23 ' A' ' 15' ' ' THR . 3.2 m -46.24 -67.43 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.207 -0.451 . . . . 74.13 111.168 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.464 HG23 HG22 ' A' ' 14' ' ' THR . 26.8 p -146.67 13.86 1.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 71.32 111.138 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 11' ' ' VAL . 12.6 p -50.64 -31.93 9.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 111.136 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.14 -17.41 14.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 74.32 110.883 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 22.1 mm100 -79.62 -31.21 41.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 74.44 110.94 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -149.24 140.48 23.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.231 -0.441 . . . . 72.31 110.884 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.19 -157.16 17.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.691 -0.766 . . . . 73.21 112.46 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 -30.6 22.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 50.21 112.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 14.9 m-90 -87.21 -7.48 57.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.226 -0.443 . . . . 62.15 110.921 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.29 -60.08 2.51 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 74.53 111.054 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.56 142.59 29.57 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.577 0.703 . . . . 75.32 110.916 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -28.38 25.07 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.666 2.244 . . . . 65.01 112.347 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.18 -11.69 60.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 73.03 111.115 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.5 mm-40 -95.35 24.71 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 74.31 110.935 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.503 ' HB2' ' HB2' ' A' ' 52' ' ' PRO . . . -56.58 -79.58 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 74.51 111.067 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.507 HG11 ' HB3' ' A' ' 54' ' ' GLU . 1.8 p -106.86 141.01 23.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 72.02 111.153 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 m -128.1 150.16 33.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 74.13 111.164 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.1 tp60 -89.1 118.79 29.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 72.33 110.925 -179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.9 t -121.06 -21.06 6.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 63.33 111.148 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.29 168.38 20.19 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 54.21 112.5 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.25 20.57 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.652 2.235 . . . . 65.22 112.33 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.507 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 18.0 t30 -159.33 23.25 0.19 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.445 . . . . 60.35 110.874 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -138.87 153.97 48.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 71.43 110.865 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -141.97 142.15 32.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 72.23 110.966 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.2 m -95.74 104.55 16.48 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.115 -0.493 . . . . 75.41 111.144 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 t -84.5 140.06 16.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 74.5 111.156 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.29 122.76 39.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 72.14 110.918 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.618 HG12 HD12 ' A' ' 53' ' ' ILE . 16.6 m -118.73 123.26 71.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.11 -0.495 . . . . 71.03 111.113 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.685 HD11 ' CD2' ' A' ' 44' ' ' PHE . 3.0 tm? -115.88 132.88 56.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 71.15 110.894 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.507 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -155.44 114.47 3.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 52.33 111.087 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.685 ' CD2' HD11 ' A' ' 42' ' ' LEU . 5.9 p90 -129.36 152.09 49.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 42.02 110.878 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.421 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -85.14 1.77 46.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.09 -0.504 . . . . 53.44 111.145 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -95.83 72.0 3.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 73.24 110.868 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.21 -150.88 17.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.754 -0.736 . . . . 73.43 112.471 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 p90 -136.37 150.93 49.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.36 . . . . 65.15 110.907 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -162.09 162.06 20.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.591 0.71 . . . . 73.51 110.904 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 157.36 60.63 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.281 . . . . 74.44 112.35 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -133.09 66.69 76.32 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.644 0.735 . . . . 62.34 110.877 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.503 ' HB2' ' HB2' ' A' ' 28' ' ' ALA . 53.8 Cg_endo -69.83 114.03 3.58 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.676 2.251 . . . . 73.33 112.367 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.618 HD12 HG12 ' A' ' 41' ' ' VAL . 1.5 mm -117.21 151.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 61.53 111.136 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.507 ' HB3' HG11 ' A' ' 29' ' ' VAL . 13.2 tt0 -155.25 120.62 4.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 71.3 110.929 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.923 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -139.7 82.03 18.75 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.651 0.739 . . . . 74.31 111.131 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.8 Cg_endo -69.81 123.67 10.31 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.698 2.266 . . . . 74.32 112.349 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.489 HE22 ' HA ' ' A' ' 126' ' ' GLU . 1.8 pm0 -69.23 155.11 40.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 72.32 110.96 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.41 -8.73 73.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 72.01 112.469 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.507 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -133.02 155.77 48.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 61.21 111.115 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.717 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.2 mt-10 -66.75 141.37 57.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 70.51 110.857 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.748 HG13 HG23 ' A' ' 55' ' ' VAL . 5.7 mm -130.14 119.18 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 54.12 111.106 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.553 HG13 ' OG1' ' A' ' 92' ' ' THR . 54.8 t -102.28 98.42 6.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 71.51 111.129 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.5 ' HB2' HG12 ' A' ' 93' ' ' VAL . 72.0 m-85 -76.97 126.34 30.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 75.42 110.851 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.9 mttt -120.32 100.09 6.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 63.32 110.911 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.474 ' HA ' HG23 ' A' ' 41' ' ' VAL . 1.8 mt -98.22 153.21 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 72.33 111.111 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 13.4 t -171.35 145.97 2.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 74.03 111.185 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.448 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -153.29 159.62 31.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.678 0.751 . . . . 74.03 110.854 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.438 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.76 -54.83 0.2 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.73 2.287 . . . . 63.1 112.325 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -156.53 60.55 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.238 -0.437 . . . . 72.43 110.884 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.448 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.29 136.35 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.459 . . . . 64.11 111.136 179.995 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.444 HG22 HD13 ' A' ' 113' ' ' LEU . 41.4 mm -67.08 144.2 14.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 65.53 111.09 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -136.98 158.11 45.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 74.02 110.827 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.71 129.83 1.11 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.779 -0.724 . . . . 71.14 112.515 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.0 p90 -117.47 141.93 47.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 74.23 110.862 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -112.1 90.74 3.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 75.42 110.846 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.722 ' HB ' HG21 ' A' ' 81' ' ' ILE . 27.6 t -73.36 145.53 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 74.22 111.115 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -75.66 -175.56 2.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 71.41 110.858 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.91 -51.38 4.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 55.24 112.437 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.45 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -132.41 179.28 6.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.777 0.322 . . . . 71.25 111.161 -179.846 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.45 ' H ' HG22 ' A' ' 79' ' ' THR . 11.2 m-80 -90.19 48.01 1.51 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 63.22 110.868 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.722 HG21 ' HB ' ' A' ' 76' ' ' VAL . 3.3 tp -63.14 111.0 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 64.43 111.139 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.87 122.73 46.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 64.43 110.852 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.2 m -143.51 120.1 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 34.3 111.126 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.661 ' CB ' HD21 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -159.25 112.59 2.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 43.21 110.888 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 23.5 t -140.5 144.28 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 73.05 111.142 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 1.4 mp -61.53 161.11 21.16 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.591 0.71 . . . . 54.53 110.919 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 159.53 53.11 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.667 2.245 . . . . 45.33 112.347 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.23 10.88 60.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.718 -0.753 . . . . 75.44 112.492 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -152.6 159.39 43.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.862 0.363 . . . . 74.35 110.869 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 95.7 t -98.43 143.34 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 62.44 111.138 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 7.3 p -121.3 97.24 5.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 61.22 110.899 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.553 ' OG1' HG13 ' A' ' 62' ' ' VAL . 1.2 t -85.63 141.33 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.116 -0.493 . . . . 54.51 111.167 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.5 HG12 ' HB2' ' A' ' 63' ' ' PHE . 12.6 p -154.24 150.3 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 72.44 111.136 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -109.6 116.4 31.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 62.33 110.894 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -151.45 114.96 4.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 74.3 110.945 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.6 t -116.55 136.24 53.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.14 -0.482 . . . . 62.02 111.123 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -87.06 -172.47 3.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 74.33 110.922 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.1 tttt -123.19 -26.14 4.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 61.34 110.909 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -140.71 162.06 50.97 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.708 . . . . 74.42 110.871 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 150.72 68.57 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 72.12 112.345 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.09 143.85 3.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.733 -0.746 . . . . 73.23 112.506 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.743 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -108.82 134.53 51.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.84 0.352 . . . . 73.52 110.906 -179.883 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 103' ' ' TYR . . . . . 0.604 ' CE2' HG13 ' A' ' 76' ' ' VAL . 2.1 p90 -143.54 131.53 21.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 73.15 110.933 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.39 111.27 5.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.08 -0.509 . . . . 74.51 110.867 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.0 tp -178.61 142.95 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 74.23 111.098 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.47 HD13 ' HA2' ' A' ' 114' ' ' GLY . 17.7 tt -130.38 126.39 61.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 42.05 111.11 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 178.98 170.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 73.21 110.913 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 51.63 30.41 6.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 73.21 110.925 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -100.58 -25.19 14.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.476 . . . . 64.05 110.893 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 63.14 -173.42 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 64.32 110.937 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER 57.07 25.77 11.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.48 . . . . 64.04 110.882 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 61.88 36.53 92.94 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.727 . . . . 73.32 112.501 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.661 HD21 ' CB ' ' A' ' 84' ' ' GLU . 1.3 mm? -70.82 -74.77 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.882 0.372 . . . . 71.1 110.95 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.47 ' HA2' HD13 ' A' ' 106' ' ' ILE . . . -87.0 90.16 1.66 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 61.13 112.482 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 1.8 m80 -128.11 -74.85 0.57 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.696 0.284 . . . . 74.13 110.884 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -117.03 -23.81 7.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 64.42 110.932 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -59.48 -179.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 45.53 110.927 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.504 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . 0.0 OUTLIER -71.53 174.47 6.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.481 . . . . 65.52 110.879 179.923 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 119' ' ' PHE . . . . . 0.435 ' CD2' HG22 ' A' ' 106' ' ' ILE . 11.2 m-85 -97.8 149.83 21.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.228 -0.442 . . . . 63.54 110.856 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -72.42 79.41 0.67 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.727 -0.749 . . . . 63.13 112.446 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.609 HG23 HG13 ' A' ' 53' ' ' ILE . 15.1 t -85.47 134.28 34.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.714 0.293 . . . . 53.13 111.21 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.582 HD12 ' C ' ' A' ' 121' ' ' THR . 3.3 mp -153.1 134.27 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.243 -0.435 . . . . 72.2 111.11 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.743 HG23 ' HB3' ' A' ' 102' ' ' GLU . 8.6 p -126.23 137.61 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 73.14 111.139 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.923 HG22 HG13 ' A' ' 55' ' ' VAL . 47.3 t -108.14 141.97 22.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 34.44 111.134 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.8 mmtt -116.33 132.42 56.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 75.43 110.937 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.489 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 71.41 110.875 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.1 tpt . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.813 0.34 . . . . 51.22 110.862 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.5 m -116.99 68.85 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 73.12 111.143 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -124.12 77.97 59.6 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.633 0.73 . . . . 75.0 111.174 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 -177.34 1.82 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.66 2.24 . . . . 74.33 112.354 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -152.4 80.55 1.24 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.454 . . . . 44.42 111.132 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -179.81 -57.25 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.707 -0.759 . . . . 53.23 112.449 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.5 tptt -172.32 152.13 2.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 63.42 110.878 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.71 HD13 ' O ' ' A' ' 90' ' ' VAL . 0.2 OUTLIER 62.08 162.35 0.08 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 74.25 110.915 179.954 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.635 ' N ' HD12 ' A' ' 8' ' ' LEU . 2.1 pt-20 -118.96 141.79 48.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 72.34 110.892 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -93.1 135.38 34.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 64.22 110.85 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.447 HG21 HG21 ' A' ' 16' ' ' VAL . 7.8 m -115.01 -179.22 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 60.52 111.133 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -147.04 162.63 32.22 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 71.34 110.867 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -4.33 13.79 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.677 2.251 . . . . 71.41 112.367 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.411 ' O ' HG23 ' A' ' 15' ' ' THR . 5.4 m -48.75 -66.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.24 -0.436 . . . . 75.5 111.112 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 14' ' ' THR . 3.2 p -155.59 37.35 0.37 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 71.42 111.149 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.447 HG21 HG21 ' A' ' 11' ' ' VAL . 8.4 p -77.19 -27.52 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.214 -0.448 . . . . 73.32 111.137 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 20.4 ptt85 -104.28 -10.76 17.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 75.24 110.853 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -94.35 -36.96 11.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.453 . . . . 72.32 110.927 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.87 133.88 40.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 55.43 110.883 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.02 -157.18 19.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 45.25 112.507 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -30.06 22.79 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 72.53 112.36 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.777 ' HB3' HD13 ' A' ' 42' ' ' LEU . 14.0 m-90 -86.82 -10.89 52.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 74.32 110.926 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.66 -59.32 3.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 75.23 111.112 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.63 144.85 29.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.612 0.72 . . . . 71.44 110.868 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -17.24 37.75 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.665 2.243 . . . . 71.03 112.322 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -24.09 59.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 72.02 111.132 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.7 mm-40 -90.05 10.54 23.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 72.23 110.931 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -78.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 74.12 111.15 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.614 HG11 ' CB ' ' A' ' 54' ' ' GLU . 2.1 p -108.2 128.71 63.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 71.13 111.149 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.01 144.04 28.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 64.01 111.139 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 2.1 tp-100 -75.48 121.45 22.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 73.31 110.905 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 t -119.95 -12.88 9.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 62.12 111.166 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.61 -167.66 12.15 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.751 -0.737 . . . . 72.32 112.496 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 -36.12 11.4 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 65.3 112.337 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -153.58 34.45 0.45 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 73.23 110.884 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -134.14 118.09 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 72.21 110.889 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -97.66 138.47 35.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.94 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 55.9 m -95.66 102.59 14.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 72.34 111.13 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.9 t -84.24 146.33 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 75.04 111.156 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -126.8 124.06 38.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.143 -0.48 . . . . 64.4 110.962 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.457 HG22 HD12 ' A' ' 53' ' ' ILE . 92.1 t -125.37 138.67 53.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.491 . . . . 70.21 111.121 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.777 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -138.61 141.84 39.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.166 -0.47 . . . . 74.02 110.94 179.951 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.68 109.11 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 45.54 111.065 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -122.77 153.43 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 74.25 110.852 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.26 4.3 35.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 75.21 111.13 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -95.24 78.11 3.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.937 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.59 -139.92 14.75 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 71.23 112.489 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -148.42 150.06 32.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.845 0.355 . . . . 53.03 110.943 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -158.19 162.55 26.69 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.571 0.701 . . . . 73.44 110.963 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 157.03 61.78 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.722 2.281 . . . . 73.54 112.317 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.49 66.08 76.11 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.598 0.713 . . . . 45.04 110.847 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.526 ' C ' HD13 ' A' ' 53' ' ' ILE . 53.1 Cg_endo -69.85 118.36 5.64 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.693 2.262 . . . . 63.5 112.302 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.618 HG21 ' HA ' ' A' ' 122' ' ' ILE . 2.4 mm -124.55 151.51 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 73.42 111.123 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.614 ' CB ' HG11 ' A' ' 29' ' ' VAL . 8.3 tt0 -155.22 115.66 3.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 75.4 110.836 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.686 ' O ' HG13 ' A' ' 124' ' ' VAL . 21.2 t -131.34 82.02 63.61 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.647 0.737 . . . . 71.23 111.145 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.729 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.75 121.87 8.56 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.692 2.261 . . . . 71.14 112.368 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -68.3 152.85 44.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.253 -0.43 . . . . 65.12 110.933 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.95 -36.33 3.7 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 73.11 112.495 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.77 158.06 17.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.8 0.333 . . . . 62.12 111.066 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.672 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.5 mt-10 -67.87 144.53 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.45 . . . . 63.24 110.922 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.729 HD12 ' HD2' ' A' ' 56' ' ' PRO . 5.7 mm -128.21 120.01 52.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 72.11 111.114 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.985 HG13 HG23 ' A' ' 92' ' ' THR . 55.2 t -103.9 91.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 71.34 111.128 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.618 ' HB2' HG12 ' A' ' 93' ' ' VAL . 90.5 m-85 -69.61 134.95 49.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 71.31 110.906 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.421 ' HD3' HG21 ' A' ' 90' ' ' VAL . 15.6 mttt -131.53 100.16 5.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.153 -0.476 . . . . 64.14 110.877 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.584 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.8 mp -107.11 143.32 17.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 54.02 111.156 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.5 t -156.38 136.18 12.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 74.23 111.166 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.404 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -142.95 161.51 48.3 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.699 0.761 . . . . 73.4 110.853 -179.86 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.404 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.0 Cg_endo -69.77 -50.81 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.671 2.247 . . . . 50.34 112.385 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -155.78 49.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 62.2 110.842 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.21 135.94 3.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.146 -0.479 . . . . 71.51 111.117 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 95.0 mt -86.45 105.64 14.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.14 111.147 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.408 ' O ' HG21 ' A' ' 65' ' ' ILE . 76.0 t60 -99.46 69.65 1.67 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 53.41 110.901 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.15 155.5 21.07 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.73 -0.748 . . . . 41.14 112.466 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.584 ' CE2' HD11 ' A' ' 65' ' ' ILE . 3.3 p90 -128.61 142.82 50.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.883 0.373 . . . . 72.3 110.886 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -118.56 94.1 4.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 74.15 110.854 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.529 HG13 ' CE2' ' A' ' 103' ' ' TYR . 10.1 t -74.11 140.9 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 75.53 111.147 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 pm0 -75.3 -176.05 2.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 72.43 110.869 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.7 -51.86 4.61 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.723 -0.751 . . . . 61.11 112.491 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.406 HG22 ' N ' ' A' ' 80' ' ' ASN . 10.7 m -124.02 157.16 35.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.813 0.34 . . . . 75.53 111.174 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.406 ' N ' HG22 ' A' ' 79' ' ' THR . 1.1 m120 -77.15 60.06 1.84 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 61.04 110.874 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.552 ' O ' HG23 ' A' ' 81' ' ' ILE . 11.5 tt -78.51 116.53 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 53.33 111.137 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -123.19 96.69 5.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 75.41 110.85 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.6 m -114.39 119.89 62.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 70.14 111.105 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.64 117.36 7.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.14 -0.482 . . . . 62.22 110.886 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.81 HG11 ' HB2' ' A' ' 91' ' ' SER . 7.6 p -140.62 128.29 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 63.2 111.117 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -57.52 157.91 12.5 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.59 0.71 . . . . 63.55 110.959 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 159.16 54.46 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.685 2.256 . . . . 62.22 112.339 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.1 11.73 59.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 72.01 112.511 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -163.86 118.19 1.53 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.897 0.379 . . . . 71.4 110.897 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.71 ' O ' HD13 ' A' ' 8' ' ' LEU . 3.5 p -68.8 143.28 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 74.45 111.129 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.81 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.3 OUTLIER -107.09 169.29 8.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 70.42 110.814 -179.854 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.985 HG23 HG13 ' A' ' 62' ' ' VAL . 87.8 m -145.45 111.28 5.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.121 -0.491 . . . . 73.14 111.112 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.618 HG12 ' HB2' ' A' ' 63' ' ' PHE . 8.0 p -124.45 150.7 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 71.13 111.131 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -114.93 97.49 6.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.831 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.544 ' CD2' HD12 ' A' ' 81' ' ' ILE . 40.5 t80 -139.9 110.08 6.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 73.33 110.947 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.1 t -110.68 143.5 41.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 71.4 111.177 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.6 -178.89 5.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.258 -0.428 . . . . 74.21 110.853 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.7 mttt -119.85 -12.9 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 73.13 110.927 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.16 161.66 31.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.62 0.724 . . . . 75.01 110.831 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.67 152.43 69.75 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 2.26 . . . . 64.42 112.384 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 159.4 130.43 1.14 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.785 -0.722 . . . . 52.22 112.494 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -99.22 130.46 45.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 72.35 110.866 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' TYR . . . . . 0.529 ' CE2' HG13 ' A' ' 76' ' ' VAL . 1.0 OUTLIER -135.42 146.39 48.23 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.197 -0.456 . . . . 74.2 110.93 -179.872 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.942 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.7 OUTLIER -148.22 -163.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 71.32 110.907 179.99 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.942 HG22 ' O ' ' A' ' 104' ' ' ARG . 1.2 tt 58.94 158.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 73.34 111.129 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.56 138.41 43.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 72.14 111.157 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 6.9 t -171.61 71.44 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.225 -0.443 . . . . 73.53 110.864 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -179.68 -37.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 75.0 110.886 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -57.25 179.73 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 71.21 110.92 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 1.6 p90 -104.56 -20.06 13.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 73.31 110.94 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -52.1 -63.41 1.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.142 -0.481 . . . . 72.24 110.88 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -178.04 -156.73 17.26 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.735 -0.745 . . . . 34.05 112.47 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.515 ' O ' HD12 ' A' ' 113' ' ' LEU . 3.4 pp -162.7 26.49 0.1 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.853 0.359 . . . . 73.44 110.935 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -168.42 -89.46 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.774 -0.727 . . . . 41.15 112.505 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 15.8 p80 -64.64 -14.74 59.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.739 0.304 . . . . 65.24 110.869 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 -61.9 -164.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 75.21 110.871 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -56.33 -175.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 74.5 110.92 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 1.2 mtt -69.47 175.29 4.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.43 110.876 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' PHE . . . . . 0.401 ' HB3' ' HA ' ' A' ' 105' ' ' ILE . 19.0 m-85 -91.19 167.62 12.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 63.31 110.878 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -101.48 166.1 18.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.695 -0.764 . . . . 72.14 112.49 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.586 ' C ' HD12 ' A' ' 122' ' ' ILE . 68.7 m -154.93 127.6 8.02 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.771 0.32 . . . . 65.32 111.118 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.618 ' HA ' HG21 ' A' ' 53' ' ' ILE . 4.3 mp -150.01 143.66 17.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 72.34 111.136 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 m -134.47 140.74 45.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 73.33 111.133 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.686 HG13 ' O ' ' A' ' 55' ' ' VAL . 58.5 t -113.68 126.03 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 73.5 111.17 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 11.3 mmmm -108.92 141.51 40.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 61.24 110.909 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.209 -0.451 . . . . 72.55 110.928 179.963 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.8 mmt . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.866 0.365 . . . . 62.35 110.914 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.3 p -154.07 128.02 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.217 -0.447 . . . . 74.54 111.121 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.9 pt -129.43 153.71 80.63 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.642 0.734 . . . . 74.34 111.155 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -177.3 1.81 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.699 2.266 . . . . 71.5 112.328 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -162.09 74.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 72.23 111.062 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.26 -17.74 54.58 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.791 -0.719 . . . . 45.34 112.463 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.515 ' HE2' HD23 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -104.04 -172.22 2.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.758 0.313 . . . . 71.43 110.905 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.596 HD13 ' O ' ' A' ' 90' ' ' VAL . 2.3 pp -58.74 -174.78 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.266 -0.425 . . . . 62.21 110.922 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.532 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.3 OUTLIER -86.39 131.02 34.3 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.227 -0.442 . . . . 75.12 110.867 179.971 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -104.52 143.98 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 72.01 110.904 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.514 HG21 ' OG1' ' A' ' 66' ' ' THR . 17.0 m -110.64 -177.55 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 73.44 111.138 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.416 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 4.9 p30 -143.79 156.18 59.31 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.626 0.727 . . . . 70.15 110.87 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.81 -3.58 12.34 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.652 2.235 . . . . 41.12 112.338 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 3.7 m -47.56 -63.74 0.97 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.237 -0.438 . . . . 63.51 111.14 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -155.67 29.04 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.244 -0.435 . . . . 61.44 111.133 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.4 p -64.57 -30.23 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.435 . . . . 65.25 111.12 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.453 ' HB3' HD21 ' A' ' 42' ' ' LEU . 4.0 ptt-85 -101.17 -6.63 24.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.35 110.874 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 11.3 mm-40 -97.43 -37.46 9.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 75.5 110.924 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -135.11 133.93 39.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 71.1 110.852 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.05 -158.76 18.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.717 -0.754 . . . . 72.23 112.466 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -29.02 24.71 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.657 2.238 . . . . 72.32 112.364 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.783 ' HB3' HD13 ' A' ' 42' ' ' LEU . 15.0 m-90 -87.12 -11.42 50.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.26 -0.427 . . . . 64.43 110.893 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.36 -59.16 5.07 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.267 -0.424 . . . . 74.13 111.074 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.91 143.63 26.99 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.598 0.713 . . . . 75.12 110.885 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -22.69 31.51 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.735 2.29 . . . . 72.43 112.288 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.8 -7.27 51.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.271 -0.422 . . . . 23.02 111.104 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 8.9 mm100 -104.73 5.27 33.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 71.44 110.887 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -77.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 62.23 111.1 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.3 p -103.39 108.4 24.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 74.43 111.109 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -114.91 149.86 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 74.14 111.138 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -67.96 122.32 17.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 60.23 110.895 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.572 HG23 ' HG3' ' A' ' 36' ' ' GLN . 1.7 t -119.73 -33.55 3.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 51.32 111.132 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.06 175.85 17.94 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 60.52 112.493 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.67 24.21 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.721 2.281 . . . . 74.12 112.336 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -161.03 34.79 0.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 74.14 110.895 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.572 ' HG3' HG23 ' A' ' 32' ' ' THR . 0.2 OUTLIER -150.91 160.29 44.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 64.31 110.94 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -143.12 144.32 32.18 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.244 -0.435 . . . . 73.4 110.906 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.2 m -97.62 103.14 15.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 64.3 111.142 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.9 t -85.05 137.67 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 62.35 111.18 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -120.26 113.12 19.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 73.35 110.966 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.494 HG22 HG13 ' A' ' 53' ' ' ILE . 59.1 t -110.42 133.82 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 74.13 111.122 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.783 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.6 OUTLIER -139.31 139.36 37.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 53.51 110.868 -179.982 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.648 ' HB3' ' CE1' ' A' ' 72' ' ' HIS . . . -155.16 122.66 5.63 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 74.22 111.107 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -121.56 145.57 47.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 75.31 110.874 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.32 48.12 1.57 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.474 . . . . 72.51 111.117 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -120.9 -50.7 2.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 64.02 110.879 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -133.71 -119.01 1.95 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.773 -0.727 . . . . 75.32 112.54 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -150.17 136.68 19.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 74.34 110.894 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -130.39 159.41 70.76 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.578 0.704 . . . . 61.23 110.939 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -176.97 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.672 2.248 . . . . 62.3 112.367 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.514 ' C ' HD12 ' A' ' 53' ' ' ILE . 1.0 OUTLIER -137.57 62.5 36.23 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.672 0.748 . . . . 52.42 110.926 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 6.45 1.3 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.67 2.247 . . . . 74.54 112.313 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.935 HD13 HG22 ' A' ' 121' ' ' THR . 4.7 mp -48.39 131.28 5.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 75.13 111.136 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.445 ' HB3' HG11 ' A' ' 29' ' ' VAL . 10.6 tt0 -140.18 149.6 43.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 52.34 110.883 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 61' ' ' ILE . 86.9 t -151.0 81.96 6.09 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.618 0.723 . . . . 60.23 111.132 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.69 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.5 Cg_endo -69.79 123.08 9.74 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.647 2.232 . . . . 71.33 112.332 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.479 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.0 pm0 -70.1 155.3 40.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 65.24 110.923 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.54 -9.67 70.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.729 -0.748 . . . . 70.23 112.469 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.36 154.35 50.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.759 0.314 . . . . 71.02 111.125 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.681 ' O ' HD13 ' A' ' 61' ' ' ILE . 20.9 mt-10 -64.88 144.55 57.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 75.44 110.944 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.737 HG13 HG13 ' A' ' 55' ' ' VAL . 7.6 mm -129.44 115.16 33.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 65.13 111.127 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.593 HG13 ' OG1' ' A' ' 92' ' ' THR . 77.2 t -99.06 97.72 6.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 44.33 111.122 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.514 ' HB2' HG12 ' A' ' 93' ' ' VAL . 87.9 m-85 -75.85 132.06 40.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 70.41 110.872 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -130.82 100.06 5.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.931 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.38 153.24 4.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 75.51 111.11 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.771 HG23 HD12 ' A' ' 42' ' ' LEU . 9.5 t -167.1 128.66 1.62 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 72.23 111.134 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.473 ' HB2' HG23 ' A' ' 70' ' ' VAL . 0.1 OUTLIER -140.25 166.16 25.39 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.637 0.732 . . . . 74.33 110.84 -179.875 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' CB ' ' A' ' 67' ' ' SER . 54.4 Cg_endo -69.72 -54.8 0.2 Allowed 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.668 2.245 . . . . 72.1 112.389 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -158.7 57.22 0.44 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 74.32 110.917 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.473 HG23 ' HB2' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.62 140.23 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.142 -0.481 . . . . 71.44 111.108 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.463 HD13 ' HD3' ' A' ' 87' ' ' PRO . 35.0 mm -85.3 150.82 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 74.1 111.101 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.648 ' CE1' ' HB3' ' A' ' 43' ' ' ALA . 11.9 m170 -115.69 -84.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.472 . . . . 74.43 110.903 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.88 98.85 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.743 -0.741 . . . . 73.05 112.492 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -106.31 142.47 35.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 74.35 110.89 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -110.8 142.39 42.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 75.55 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.4 t -135.89 136.19 50.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 62.02 111.142 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -64.21 -177.2 0.26 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.181 -0.463 . . . . 74.34 110.925 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 84.32 -51.22 4.53 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.747 -0.74 . . . . 60.14 112.479 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.1 m -135.12 160.94 36.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.774 0.321 . . . . 74.02 111.202 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -86.01 76.58 9.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 64.03 110.893 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.451 ' O ' HG23 ' A' ' 81' ' ' ILE . 4.8 tt -85.01 121.81 37.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 72.45 111.11 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -116.5 95.42 5.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 73.42 110.878 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.8 m -115.63 120.37 64.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 63.03 111.147 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -156.59 110.02 2.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.2 -0.454 . . . . 71.31 110.874 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.759 HG11 ' HB2' ' A' ' 91' ' ' SER . 13.8 p -140.74 147.11 23.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 62.54 111.12 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.28 161.1 80.26 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.567 0.699 . . . . 62.32 110.905 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.463 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.6 Cg_endo -69.75 159.64 52.67 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.654 2.236 . . . . 74.14 112.333 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.39 85.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.722 -0.751 . . . . 75.11 112.469 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -139.37 145.25 38.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.932 0.396 . . . . 74.53 110.889 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.596 ' O ' HD13 ' A' ' 8' ' ' LEU . 21.2 t -99.3 110.66 27.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.165 -0.47 . . . . 72.25 111.157 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.759 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -91.37 165.97 13.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 51.33 110.846 -179.851 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.593 ' OG1' HG13 ' A' ' 62' ' ' VAL . 1.4 t -144.19 140.15 29.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 43.21 111.168 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.514 HG12 ' HB2' ' A' ' 63' ' ' PHE . 9.9 p -153.79 127.55 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 73.11 111.126 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.0 mtm180 -93.95 111.11 22.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 73.14 110.885 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -145.75 118.45 8.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.429 . . . . 73.12 110.872 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.3 t -114.39 132.03 56.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 71.44 111.161 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -177.59 6.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 73.42 110.854 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.3 ttpt -121.52 -24.28 5.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 61.42 110.901 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.49 160.21 57.69 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.613 0.721 . . . . 65.35 110.899 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 127.85 15.16 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.689 2.26 . . . . 72.21 112.313 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.12 146.33 14.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 63.44 112.521 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -105.57 135.71 46.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.84 0.352 . . . . 74.34 110.881 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -143.97 148.87 35.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.169 -0.469 . . . . 73.13 110.947 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.421 ' C ' HD12 ' A' ' 105' ' ' ILE . 30.6 ttp85 -168.78 157.9 8.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 65.52 110.882 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.421 HD12 ' C ' ' A' ' 104' ' ' ARG . 2.0 mp 66.79 147.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.176 -0.466 . . . . 74.44 111.096 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.86 136.85 31.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 74.12 111.11 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -179.89 36.75 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.171 -0.468 . . . . 74.34 110.9 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -175.72 63.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.185 -0.461 . . . . 71.31 110.902 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -174.03 -170.14 0.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 62.33 110.924 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 5.3 t80 -67.2 89.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 60.43 110.971 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -179.24 -60.15 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.127 -0.488 . . . . 52.51 110.847 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.73 19.08 58.77 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.81 -0.71 . . . . 74.0 112.485 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.531 ' O ' HD23 ' A' ' 113' ' ' LEU . 1.6 tt 52.14 86.56 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.81 0.338 . . . . 74.43 110.899 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -110.25 -135.91 7.18 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.756 -0.735 . . . . 73.45 112.541 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 36.0 p-80 -126.68 26.46 6.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.686 0.279 . . . . 74.12 110.827 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -145.83 46.19 1.27 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 72.43 110.924 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -145.62 173.55 11.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 73.4 110.904 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 10.1 mmt -134.22 174.44 10.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 45.04 110.91 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -100.62 159.85 14.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 74.33 110.904 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -151.69 110.65 0.47 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 41.42 112.465 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.935 HG22 HD13 ' A' ' 53' ' ' ILE . 0.8 OUTLIER -86.77 152.92 22.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.73 0.3 . . . . 64.41 111.197 -179.907 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.658 HG13 HG21 ' A' ' 53' ' ' ILE . 4.4 mp -149.06 120.53 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 55.21 111.13 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.494 HG12 ' O ' ' A' ' 53' ' ' ILE . 3.0 p -114.83 127.14 72.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 74.41 111.089 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.711 HG13 ' O ' ' A' ' 55' ' ' VAL . 42.7 t -97.88 131.2 45.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 74.32 111.149 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 15.2 mmmt -104.97 128.53 53.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 64.1 110.86 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.479 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 60.22 110.884 179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.521 ' HG3' HG13 ' A' ' 2' ' ' VAL . 5.5 ptm . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.761 0.315 . . . . 74.3 110.877 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.521 HG13 ' HG3' ' A' ' 1' ' ' MET . 25.0 m -114.12 139.37 40.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.261 -0.427 . . . . 75.22 111.111 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.4 pt -150.96 77.88 7.51 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.594 0.712 . . . . 74.12 111.133 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -178.14 2.2 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.73 2.287 . . . . 65.53 112.346 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -152.74 91.82 1.6 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 65.32 111.098 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 169.86 -119.69 0.83 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 72.23 112.521 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.07 157.03 17.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.814 0.34 . . . . 75.24 110.879 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.699 HD13 ' O ' ' A' ' 90' ' ' VAL . 0.2 OUTLIER 61.49 163.75 0.08 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.23 -0.441 . . . . 73.12 110.909 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.631 ' N ' HD12 ' A' ' 8' ' ' LEU . 1.0 OUTLIER -119.22 141.38 48.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 71.54 110.869 179.934 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -86.02 137.97 32.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 71.21 110.867 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.453 HG21 ' OG1' ' A' ' 66' ' ' THR . 17.1 m -120.72 -177.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.131 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.447 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 33.8 p30 -144.16 156.75 57.88 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.596 0.712 . . . . 72.03 110.882 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.6 Cg_endo -69.76 -2.28 9.9 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.674 2.249 . . . . 73.31 112.356 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.75 HG22 HG23 ' A' ' 15' ' ' THR . 26.6 m -45.24 -65.24 0.56 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.223 -0.444 . . . . 72.44 111.124 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.75 HG23 HG22 ' A' ' 14' ' ' THR . 38.2 p -150.26 17.84 0.84 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 71.12 111.121 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.4 p -57.17 -25.8 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 64.3 111.145 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.5 ptt85 -106.71 -8.05 17.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 73.12 110.851 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 6.6 mm-40 -94.03 -32.22 13.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.4 110.92 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.471 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 7.8 pt-20 -142.56 144.19 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 74.35 110.902 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.96 -156.56 15.58 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.765 -0.731 . . . . 33.41 112.482 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.454 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.3 Cg_endo -69.77 -35.94 11.69 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.661 2.24 . . . . 65.34 112.328 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.403 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 13.5 m-90 -84.66 -7.25 59.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.213 -0.449 . . . . 70.34 110.92 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.471 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -62.02 -54.19 45.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.24 -0.437 . . . . 52.13 111.105 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.68 141.99 30.89 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.653 0.74 . . . . 75.04 110.855 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.673 2.248 . . . . 72.31 112.372 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.59 -36.99 65.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 64.21 111.06 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.454 ' HG3' ' HA ' ' A' ' 21' ' ' PRO . 5.0 pm0 -95.31 33.06 1.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.4 110.929 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.478 ' HB2' ' HG2' ' A' ' 52' ' ' PRO . . . -55.73 -76.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 73.22 111.101 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.734 HG11 ' CB ' ' A' ' 54' ' ' GLU . 2.3 p -101.88 129.79 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 62.34 111.103 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -142.33 139.99 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 73.32 111.151 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -72.4 123.34 22.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 75.33 110.903 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -120.28 -10.45 9.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 75.24 111.165 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.98 -168.83 12.46 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 51.5 112.479 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -33.8 16.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.654 2.236 . . . . 50.34 112.368 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -154.31 28.7 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 73.04 110.896 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -126.83 119.43 26.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 42.02 110.912 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 63.0 m-85 -96.37 134.7 39.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 74.25 110.906 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.689 ' HA ' HG23 ' A' ' 62' ' ' VAL . 92.5 m -93.84 104.23 16.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 64.13 111.119 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.1 t -86.85 132.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 71.31 111.096 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -118.07 115.66 25.3 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.19 -0.459 . . . . 75.1 110.917 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.473 HG12 HD12 ' A' ' 53' ' ' ILE . 15.8 m -114.05 119.71 61.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 72.04 111.131 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.49 ' C ' HD13 ' A' ' 42' ' ' LEU . 3.2 tm? -114.97 132.86 56.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 73.13 110.927 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.46 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -154.59 131.28 10.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 75.3 111.066 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.404 ' CD2' HD11 ' A' ' 42' ' ' LEU . 2.9 p90 -127.1 163.03 24.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 75.13 110.868 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.799 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -87.03 2.9 48.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.098 -0.501 . . . . 71.21 111.124 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 3.5 p90 -122.3 84.43 2.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 73.12 110.865 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.01 158.72 12.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 75.31 112.464 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -111.77 120.8 43.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.798 0.332 . . . . 73.4 110.976 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -127.08 162.36 48.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 60.24 110.883 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 162.49 41.87 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.659 2.239 . . . . 62.43 112.34 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 -137.95 67.19 48.8 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.614 0.721 . . . . 72.45 110.851 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.478 ' HG2' ' HB2' ' A' ' 28' ' ' ALA . 53.9 Cg_endo -69.81 98.99 0.72 Allowed 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.643 2.228 . . . . 73.22 112.35 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.545 HG13 HG23 ' A' ' 121' ' ' THR . 1.5 mm -100.57 157.44 4.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 75.34 111.131 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.734 ' CB ' HG11 ' A' ' 29' ' ' VAL . 16.4 tt0 -155.42 122.08 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.909 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.957 HG12 HG21 ' A' ' 61' ' ' ILE . 6.0 m -142.68 86.6 9.53 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.612 0.72 . . . . 72.15 111.137 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.549 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.8 Cg_endo -69.76 122.74 9.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.689 2.259 . . . . 73.31 112.344 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.06 155.75 23.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 64.51 110.904 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.98 -0.97 76.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.694 -0.765 . . . . 72.44 112.484 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.95 150.4 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.787 0.327 . . . . 74.23 111.086 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.676 ' O ' HD13 ' A' ' 61' ' ' ILE . 2.6 mp0 -68.14 138.23 55.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 65.24 110.883 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.957 HG21 HG12 ' A' ' 55' ' ' VAL . 5.0 mm -128.28 117.78 46.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 53.14 111.139 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.689 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -104.23 94.2 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 71.52 111.145 179.841 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.663 ' CZ ' HG11 ' A' ' 55' ' ' VAL . 40.2 m-85 -64.52 142.86 58.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 74.23 110.899 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -133.36 98.36 4.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.917 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.676 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.3 mp -106.8 137.01 39.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.26 -0.427 . . . . 73.31 111.15 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.453 ' OG1' HG21 ' A' ' 11' ' ' VAL . 6.5 t -154.96 134.62 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 70.04 111.121 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.415 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -146.2 161.38 39.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.688 0.756 . . . . 64.31 110.852 -179.893 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.5 Cg_endo -69.72 -52.98 0.3 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.699 2.266 . . . . 73.4 112.308 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -158.31 53.61 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 62.51 110.856 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.799 HG11 ' HB2' ' A' ' 45' ' ' ALA . 0.0 OUTLIER -155.12 140.95 11.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 71.41 111.121 179.977 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.572 HD13 ' HD3' ' A' ' 87' ' ' PRO . 30.5 mm -85.83 151.23 3.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 52.02 111.132 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.564 ' HB3' HG21 ' A' ' 65' ' ' ILE . 78.2 t60 -125.47 -83.93 0.63 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.17 -0.468 . . . . 61.35 110.872 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 61.13 158.57 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.724 -0.751 . . . . 71.34 112.504 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.676 ' CE2' HD11 ' A' ' 65' ' ' ILE . 0.8 OUTLIER -145.76 141.9 28.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.928 0.394 . . . . 65.32 110.859 -179.864 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.651 ' HB3' HG23 ' A' ' 105' ' ' ILE . 31.0 t-80 -104.35 140.29 38.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 70.51 110.844 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.62 HG22 ' CE2' ' A' ' 103' ' ' TYR . 94.1 t -126.31 134.66 65.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 71.02 111.154 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -75.14 169.69 17.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 75.42 110.887 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.33 -51.28 4.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 51.33 112.504 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.3 m -116.29 151.47 35.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 74.3 111.109 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -86.04 58.79 5.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.909 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.504 HD12 ' CD2' ' A' ' 95' ' ' TYR . 7.7 tt -62.87 126.11 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 70.11 111.121 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -116.53 90.9 3.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 74.44 110.896 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.581 HG11 HG11 ' A' ' 93' ' ' VAL . 3.6 m -115.74 120.06 63.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 74.3 111.1 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -155.71 114.66 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 74.14 110.834 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.581 HG21 ' HB3' ' A' ' 91' ' ' SER . 94.3 t -140.2 145.04 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 65.42 111.104 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.1 mp -79.79 159.91 70.35 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.644 0.735 . . . . 60.33 110.904 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.572 ' HD3' HD13 ' A' ' 71' ' ' ILE . 54.0 Cg_endo -69.74 159.7 52.43 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.687 2.258 . . . . 73.4 112.354 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.58 10.02 48.49 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.75 -0.738 . . . . 74.24 112.519 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -169.36 126.24 0.91 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.891 0.376 . . . . 71.24 110.888 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.699 ' O ' HD13 ' A' ' 8' ' ' LEU . 2.4 p -65.17 118.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 70.33 111.158 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.581 ' HB3' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -81.57 166.7 20.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 64.14 110.894 -179.852 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 97.8 m -136.27 134.86 38.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.43 111.174 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.581 HG11 HG11 ' A' ' 83' ' ' VAL . 16.2 t -144.48 131.5 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 72.33 111.116 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -109.58 95.1 5.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 75.02 110.904 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.504 ' CD2' HD12 ' A' ' 81' ' ' ILE . 41.5 t80 -136.13 127.25 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.196 -0.456 . . . . 71.23 110.874 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.8 t -128.2 143.27 51.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 70.3 111.145 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -100.75 -173.26 2.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 72.02 110.907 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.03 -24.43 4.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.141 -0.482 . . . . 70.34 110.855 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -132.39 162.16 58.72 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.613 0.72 . . . . 74.43 110.895 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 155.45 65.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.711 2.274 . . . . 64.03 112.358 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.46 133.15 2.34 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.74 -0.743 . . . . 74.43 112.433 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -97.24 144.09 27.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.863 0.363 . . . . 75.35 110.866 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' TYR . . . . . 0.62 ' CE2' HG22 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -137.74 132.63 33.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 72.31 110.949 -179.885 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.82 120.98 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 73.24 110.853 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.651 HG23 ' HB3' ' A' ' 75' ' ' HIS . 5.6 tt -178.22 137.32 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 75.25 111.136 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.442 HD13 ' N ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -141.08 142.93 28.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 44.01 111.106 179.881 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.699 ' HA ' HD13 ' A' ' 113' ' ' LEU . 6.3 p -179.96 -42.32 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.456 . . . . 51.42 110.848 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -153.7 127.52 8.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.446 . . . . 51.34 110.853 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -131.39 -40.14 1.13 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 64.42 110.912 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -175.48 -40.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.144 -0.48 . . . . 75.11 110.874 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.8 t -94.46 -39.86 10.2 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.143 -0.48 . . . . 75.24 110.896 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 139.49 -129.42 4.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.712 -0.756 . . . . 52.44 112.482 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.699 HD13 ' HA ' ' A' ' 107' ' ' CYS . 2.6 pt? -173.12 -169.88 0.59 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.861 0.362 . . . . 74.25 110.886 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 162.76 -171.22 38.52 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.761 -0.733 . . . . 62.23 112.464 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 40.6 p-80 -57.16 -24.25 53.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.773 0.32 . . . . 75.31 110.867 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 21.7 mt-30 -103.69 70.1 1.0 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.44 . . . . 73.05 110.892 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -155.67 100.96 2.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 72.55 110.922 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -71.57 173.88 7.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 72.41 110.873 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -92.17 120.1 32.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 62.33 110.888 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.42 ' HA3' ' HB3' ' A' ' 74' ' ' PHE . . . -81.87 92.26 1.53 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.742 -0.742 . . . . 72.23 112.485 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.602 ' O ' HD13 ' A' ' 122' ' ' ILE . 13.4 t -86.48 154.14 21.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.794 0.331 . . . . 74.1 111.107 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 121' ' ' THR . 5.9 mm -141.52 148.24 21.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.51 111.121 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.405 ' O ' HG22 ' A' ' 55' ' ' VAL . 71.3 t -135.07 115.46 18.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.143 -0.481 . . . . 55.33 111.146 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.847 HG22 HG23 ' A' ' 55' ' ' VAL . 95.9 t -102.25 121.69 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 74.42 111.112 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.1 mmmt -106.22 138.73 41.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 64.04 110.878 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.222 -0.445 . . . . 73.22 110.868 179.996 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 ptt? . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.797 0.332 . . . . 63.42 110.819 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.0 t -79.33 78.29 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 72.34 111.14 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.9 pt -145.23 78.58 12.2 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 72.44 111.144 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -177.59 1.93 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.726 2.284 . . . . 70.4 112.356 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -170.49 -37.72 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.218 -0.446 . . . . 71.34 111.148 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -52.53 -50.96 46.14 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 71.33 112.464 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 41.5 tptt -171.13 154.23 3.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.792 0.33 . . . . 73.24 110.901 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.624 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.81 163.29 0.08 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.441 . . . . 63.41 110.939 179.942 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.624 ' N ' HD12 ' A' ' 8' ' ' LEU . 15.8 mp0 -119.41 136.54 54.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.474 . . . . 74.24 110.921 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.616 ' HD2' HD11 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -99.71 149.46 23.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 75.32 110.866 -179.884 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.601 HG21 HG21 ' A' ' 16' ' ' VAL . 13.8 m -147.39 -178.29 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 51.44 111.125 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -144.3 162.31 40.47 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.618 0.723 . . . . 73.31 110.858 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -4.59 14.34 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.633 2.222 . . . . 74.13 112.317 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.408 ' O ' HG23 ' A' ' 15' ' ' THR . 4.6 m -48.83 -67.14 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.431 . . . . 72.31 111.105 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.408 HG23 ' O ' ' A' ' 14' ' ' THR . 3.1 p -155.46 38.27 0.38 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 61.21 111.179 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.601 HG21 HG21 ' A' ' 11' ' ' VAL . 11.8 p -76.22 -31.97 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 75.44 111.139 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.476 ' HB3' HD11 ' A' ' 42' ' ' LEU . 7.4 ptt-85 -97.25 -11.61 23.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 74.41 110.894 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.6 mm-40 -95.53 -37.32 10.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.893 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -132.65 134.17 44.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 73.22 110.869 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.57 -158.95 18.23 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.764 -0.731 . . . . 74.33 112.506 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -26.86 26.93 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.623 2.215 . . . . 62.54 112.373 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.732 ' HB3' HD13 ' A' ' 42' ' ' LEU . 13.3 m-90 -87.39 -13.34 43.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 64.43 110.91 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.18 -59.67 2.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.267 -0.424 . . . . 73.33 111.054 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.18 144.07 29.34 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.623 0.725 . . . . 75.52 110.833 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -28.97 24.7 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.62 2.213 . . . . 60.2 112.369 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.4 -16.98 60.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 70.15 111.089 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.2 mm-40 -88.36 8.3 28.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 74.4 110.947 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.39 -78.4 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 71.21 111.08 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.1 p -103.02 126.51 57.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 64.43 111.114 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -134.97 150.13 29.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 44.53 111.083 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -71.02 121.03 17.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 63.21 110.892 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.552 HG23 ' HG3' ' A' ' 36' ' ' GLN . 1.7 t -120.13 -33.05 4.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 75.34 111.153 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.79 178.49 16.49 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.706 -0.759 . . . . 74.22 112.476 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -18.14 37.33 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.727 2.284 . . . . 71.52 112.368 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 -153.3 30.08 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.196 -0.456 . . . . 71.21 110.872 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.552 ' HG3' HG23 ' A' ' 32' ' ' THR . 3.0 pt20 -140.96 157.46 45.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 62.44 110.919 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -140.56 138.39 34.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 75.34 110.95 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.753 ' HA ' HG23 ' A' ' 62' ' ' VAL . 75.4 m -92.98 103.86 16.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 75.51 111.143 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 t -90.25 140.39 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 64.45 111.158 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -124.14 120.44 32.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.01 110.893 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.658 HG23 HG23 ' A' ' 65' ' ' ILE . 4.5 m -121.61 146.52 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 74.43 111.129 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.732 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -139.1 143.94 38.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.166 -0.47 . . . . 72.41 110.935 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.84 106.2 3.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.441 . . . . 72.23 111.102 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.6 p90 -129.07 144.99 51.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 65.22 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.62 0.36 52.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 52.42 111.132 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.55 33.97 1.37 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 74.21 110.848 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.75 -141.73 8.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.743 -0.741 . . . . 51.25 112.494 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -155.48 155.17 33.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 71.21 110.899 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.412 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -156.66 156.2 29.62 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.607 0.718 . . . . 75.3 110.883 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.412 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.4 Cg_endo -69.82 -179.78 3.18 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 65.14 112.334 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.438 ' HB3' ' HB ' ' A' ' 121' ' ' THR . 0.4 OUTLIER -131.94 61.36 57.59 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.609 0.719 . . . . 73.44 110.881 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 7.16 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.659 2.24 . . . . 75.32 112.359 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.646 HG21 HG13 ' A' ' 122' ' ' ILE . 3.7 mp -46.86 143.34 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 61.13 111.121 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -144.18 164.69 29.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 64.53 110.891 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.879 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -165.4 82.87 1.11 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 72.22 111.15 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.589 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.72 122.49 9.18 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 75.13 112.354 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.506 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.7 pm0 -68.25 154.9 40.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 72.43 110.89 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.59 -7.87 77.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.771 -0.728 . . . . 62.21 112.451 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.03 159.03 41.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.768 0.318 . . . . 65.12 111.064 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.754 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.4 mp0 -71.76 140.71 49.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 73.31 110.917 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.778 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -129.56 115.48 34.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 53.31 111.169 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.753 HG23 ' HA ' ' A' ' 38' ' ' THR . 1.1 m -103.76 90.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 73.12 111.107 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.522 ' HB2' HG12 ' A' ' 93' ' ' VAL . 71.4 m-85 -66.45 140.87 58.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.913 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -132.42 98.61 4.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 71.13 110.931 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.658 HG23 HG23 ' A' ' 41' ' ' VAL . 1.4 mp -97.72 158.41 3.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 71.24 111.157 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.2 t -168.73 135.59 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 72.35 111.144 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.63 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -139.72 159.93 63.11 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.669 0.747 . . . . 50.41 110.858 -179.847 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.416 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.1 Cg_endo -69.71 -52.77 0.31 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.697 2.265 . . . . 70.11 112.398 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -153.02 41.11 0.56 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 53.54 110.847 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.63 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -142.3 135.07 27.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.229 -0.441 . . . . 73.15 111.125 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.42 HG22 ' ND2' ' A' ' 117' ' ' ASN . 43.9 mt -72.95 146.39 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 72.01 111.134 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.588 ' CB ' HG21 ' A' ' 65' ' ' ILE . 30.6 p80 -113.65 -168.16 1.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 71.32 110.848 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.87 118.16 2.06 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.743 -0.742 . . . . 35.4 112.51 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -117.63 144.38 45.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 63.22 110.842 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 32.9 t-80 -106.03 130.19 53.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 75.21 110.839 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.676 HG12 HG21 ' A' ' 81' ' ' ILE . 2.4 p -131.71 128.82 60.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.472 . . . . 63.51 111.089 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -58.08 -177.53 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 63.21 110.874 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.3 -47.6 1.95 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.738 -0.744 . . . . 74.11 112.444 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.409 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -147.28 179.49 7.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.857 0.36 . . . . 73.12 111.086 -179.803 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.409 ' H ' HG22 ' A' ' 79' ' ' THR . 4.2 m120 -92.31 78.88 5.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 74.13 110.896 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.676 HG21 HG12 ' A' ' 76' ' ' VAL . 6.8 tt -88.56 123.43 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 71.21 111.102 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -122.67 92.56 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 72.2 110.919 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.6 m -116.48 119.92 63.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 51.0 111.174 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -165.44 111.15 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 61.32 110.906 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.414 HG21 ' OG ' ' A' ' 91' ' ' SER . 86.2 t -140.63 140.81 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 70.44 111.133 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.0 mp -56.88 160.77 5.46 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.567 0.699 . . . . 72.34 110.928 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 160.68 48.83 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.672 2.248 . . . . 60.1 112.375 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.2 17.24 56.14 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.742 -0.742 . . . . 43.41 112.504 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -159.79 157.47 29.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.881 0.372 . . . . 74.31 110.886 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 86.1 t -102.92 133.5 46.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 54.11 111.107 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.414 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.6 OUTLIER -109.53 115.29 29.64 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.845 -179.871 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.5 m -94.46 124.43 38.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.062 -0.517 . . . . 74.21 111.158 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.522 HG12 ' HB2' ' A' ' 63' ' ' PHE . 10.7 p -134.67 137.66 50.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 74.32 111.197 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -103.24 108.56 19.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.154 -0.476 . . . . 70.42 110.902 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -141.35 112.26 7.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 74.11 110.909 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -112.86 137.31 51.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.47 . . . . 61.42 111.109 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.32 -175.28 3.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 71.24 110.919 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.5 mtmm -123.63 -12.78 7.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.871 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.6 mpp_? -150.87 161.79 28.94 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.603 0.716 . . . . 75.3 110.904 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.83 64.95 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.763 2.309 . . . . 71.44 112.331 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.92 141.58 3.18 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.733 -0.746 . . . . 62.53 112.493 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -106.18 128.84 54.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 62.22 110.898 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 5.9 p90 -143.98 146.19 32.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.155 -0.475 . . . . 72.01 110.947 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.92 -176.52 5.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 73.11 110.846 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.406 HG22 ' N ' ' A' ' 106' ' ' ILE . 18.9 mm 66.37 155.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 73.11 111.103 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.654 HG22 ' HD2' ' A' ' 119' ' ' PHE . 0.0 OUTLIER -110.81 145.73 16.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 74.43 111.096 179.866 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.479 ' N ' HD13 ' A' ' 106' ' ' ILE . 1.8 t -170.95 137.31 1.19 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.169 -0.469 . . . . 72.31 110.861 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 69.53 -75.27 0.07 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 63.35 110.921 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 59.22 172.03 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 71.42 110.922 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 8.1 t80 -77.06 64.31 2.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.237 -0.438 . . . . 75.22 110.91 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 75.38 46.28 0.12 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 55.02 110.852 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -132.09 -133.16 3.41 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.774 -0.727 . . . . 63.35 112.484 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.613 HD13 ' CD1' ' A' ' 106' ' ' ILE . 52.2 tp 61.99 -85.31 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.899 0.38 . . . . 71.31 110.887 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 47.48 53.19 12.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 61.21 112.458 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 20.0 m170 50.92 32.67 7.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.786 0.327 . . . . 72.43 110.889 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -154.02 -165.02 2.0 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.201 -0.454 . . . . 72.21 110.912 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ASN . . . . . 0.42 ' ND2' HG22 ' A' ' 71' ' ' ILE . 2.5 t-20 67.45 120.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 71.13 110.91 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 5.8 mmm -71.52 174.55 6.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 71.21 110.817 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' PHE . . . . . 0.654 ' HD2' HG22 ' A' ' 106' ' ' ILE . 0.1 OUTLIER -130.64 167.7 18.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 75.45 110.885 -179.911 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -150.14 156.07 26.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 63.42 112.5 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.535 ' O ' HD13 ' A' ' 53' ' ' ILE . 4.2 m -85.16 145.23 27.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.777 0.322 . . . . 73.31 111.152 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.646 HG13 HG21 ' A' ' 53' ' ' ILE . 4.6 mp -146.77 120.4 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 75.25 111.174 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 55' ' ' VAL . 2.6 p -116.41 142.2 31.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 73.32 111.103 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.879 HG22 HG13 ' A' ' 55' ' ' VAL . 60.5 t -106.05 122.17 59.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.162 -0.472 . . . . 74.2 111.161 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -90.39 134.94 34.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 75.31 110.936 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.506 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 71.53 110.897 179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.554 ' HG3' HG12 ' A' ' 2' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.817 0.342 . . . . 74.53 110.849 . . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.554 HG12 ' HG3' ' A' ' 1' ' ' MET . 2.5 p -162.2 95.05 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.266 -0.425 . . . . 52.24 111.134 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -153.15 78.08 5.97 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.551 0.691 . . . . 74.01 111.121 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 -177.4 1.84 Allowed 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.721 2.28 . . . . 75.41 112.319 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -168.21 126.48 1.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 52.52 111.101 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 132.81 -57.47 0.71 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.772 -0.728 . . . . 33.42 112.507 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -152.53 133.03 13.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.82 0.343 . . . . 72.44 110.898 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.608 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.23 164.37 0.08 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 64.15 110.913 179.952 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.608 ' N ' HD12 ' A' ' 8' ' ' LEU . 25.2 mp0 -129.64 135.99 49.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 73.51 110.888 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.485 ' HD2' HD11 ' A' ' 8' ' ' LEU . 0.4 OUTLIER -92.59 137.71 32.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 73.24 110.863 -179.885 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.47 HG21 HG21 ' A' ' 16' ' ' VAL . 12.5 m -136.32 -177.94 2.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 65.32 111.127 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -143.93 162.52 40.47 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.589 0.709 . . . . 70.14 110.897 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -4.12 13.38 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.697 2.265 . . . . 73.45 112.355 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.425 ' O ' HG23 ' A' ' 15' ' ' THR . 23.3 m -47.64 -70.04 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 70.43 111.126 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.425 HG23 ' O ' ' A' ' 14' ' ' THR . 3.7 p -155.96 38.74 0.36 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 73.42 111.147 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.581 HG22 ' CE3' ' A' ' 22' ' ' TRP . 13.4 p -75.52 -42.25 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.253 -0.431 . . . . 73.5 111.13 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.548 ' HB2' HD22 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -108.97 11.25 26.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 74.32 110.868 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 11.6 mm100 -105.55 -33.26 8.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 71.34 110.879 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.47 ' CG ' ' O ' ' A' ' 19' ' ' GLU . 28.5 tt0 -142.55 13.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 74.31 110.859 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -103.35 -154.85 24.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.741 -0.742 . . . . 75.23 112.487 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.462 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.2 Cg_endo -69.75 -23.06 31.26 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.684 2.256 . . . . 62.21 112.351 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.581 ' CE3' HG22 ' A' ' 16' ' ' VAL . 18.2 m-90 -91.03 -7.27 52.35 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 73.44 110.939 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.18 -44.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 51.41 111.132 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.43 137.71 20.74 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.61 0.719 . . . . 73.4 110.892 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -17.83 37.14 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.692 2.261 . . . . 61.23 112.314 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.19 -37.8 69.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 31.43 111.134 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 15.0 mm100 -84.79 4.9 30.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 72.32 110.911 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.65 -73.29 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 50.03 111.107 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.475 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.0 p -105.93 123.01 60.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.235 -0.439 . . . . 60.35 111.105 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.6 t -137.76 150.35 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.457 . . . . 72.24 111.126 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.423 ' NE2' ' CD2' ' A' ' 37' ' ' TYR . 1.3 mm-40 -75.67 121.29 22.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 70.41 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.4 p -121.31 -41.6 2.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.433 . . . . 75.53 111.163 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.73 -166.74 34.8 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.734 -0.746 . . . . 60.52 112.515 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -36.76 10.21 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.673 2.248 . . . . 64.23 112.378 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ASN . . . . . 0.502 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 63.8 t30 -152.7 28.95 0.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.249 -0.432 . . . . 73.03 110.861 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 127.53 44.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 74.23 110.893 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.423 ' CD2' ' NE2' ' A' ' 31' ' ' GLN . 18.0 m-85 -96.66 135.62 38.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 73.32 110.899 -179.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.78 ' HA ' HG23 ' A' ' 62' ' ' VAL . 51.7 m -92.01 102.36 14.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.114 -0.493 . . . . 52.01 111.162 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.424 HG11 HG23 ' A' ' 53' ' ' ILE . 12.5 t -85.75 139.01 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 64.23 111.099 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -120.2 100.61 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 75.03 110.927 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.497 HG12 HG12 ' A' ' 53' ' ' ILE . 15.4 m -96.33 142.43 13.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.104 -0.498 . . . . 70.42 111.108 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.568 HD21 ' CE2' ' A' ' 44' ' ' PHE . 15.1 tp -130.31 144.21 51.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.925 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.58 ' HB1' ' HG2' ' A' ' 118' ' ' MET . . . -154.52 98.57 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 63.33 111.132 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.568 ' CE2' HD21 ' A' ' 42' ' ' LEU . 3.1 p90 -113.88 155.96 24.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 71.24 110.854 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.76 31.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 62.21 111.103 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -105.73 75.36 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 54.33 110.866 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.43 -162.37 17.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.713 -0.756 . . . . 53.11 112.491 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 34.1 p90 -126.67 151.88 47.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.834 0.349 . . . . 73.21 110.926 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -136.08 159.97 68.95 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.64 0.733 . . . . 63.25 110.889 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -176.38 1.48 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.701 2.267 . . . . 74.3 112.316 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.478 ' CB ' HG21 ' A' ' 121' ' ' THR . 1.6 m120 -138.11 62.16 30.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.615 0.721 . . . . 72.25 110.856 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 6.27 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.719 2.28 . . . . 65.12 112.334 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.645 HG21 HG13 ' A' ' 122' ' ' ILE . 3.6 mp -48.4 107.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 74.23 111.094 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.475 ' HB3' HG11 ' A' ' 29' ' ' VAL . 39.7 tt0 -110.75 140.19 45.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.14 110.9 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 1.0 HG12 HG21 ' A' ' 61' ' ' ILE . 3.0 m -140.59 86.36 12.32 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.655 0.74 . . . . 73.52 111.152 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.658 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.0 Cg_endo -69.74 121.92 8.61 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.686 2.258 . . . . 64.11 112.374 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.95 153.33 42.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 71.02 110.906 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.8 -9.59 75.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 71.14 112.52 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.502 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -133.58 154.72 50.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.741 0.305 . . . . 74.03 111.12 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.713 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.6 mm-40 -67.09 144.4 56.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 70.03 110.899 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 1.0 HG21 HG12 ' A' ' 55' ' ' VAL . 6.7 mm -129.12 101.03 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 64.4 111.142 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.78 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.4 OUTLIER -89.19 100.1 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 63.52 111.104 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.476 ' HZ ' HG11 ' A' ' 55' ' ' VAL . 70.0 m-85 -72.89 141.6 47.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 62.51 110.911 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -132.62 99.21 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 75.03 110.901 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.598 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.4 mp -98.37 153.92 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 72.52 111.081 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -169.18 136.62 1.83 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 62.43 111.127 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.491 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -148.22 159.44 39.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.67 0.748 . . . . 63.53 110.857 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.403 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.4 Cg_endo -69.81 -55.14 0.19 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.659 2.239 . . . . 73.35 112.352 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -156.3 62.89 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 72.32 110.866 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.491 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.28 136.15 4.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 63.21 111.162 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.2 mm -71.12 143.7 14.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 73.3 111.124 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.598 ' CG ' HG21 ' A' ' 65' ' ' ILE . 24.8 p80 -125.55 -168.89 1.91 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 74.24 110.852 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.18 132.89 3.49 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 65.2 112.439 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -126.35 142.04 51.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 65.23 110.903 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -103.93 89.28 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 75.24 110.902 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.787 HG13 ' CE2' ' A' ' 103' ' ' TYR . 15.6 t -74.63 131.81 34.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 63.43 111.138 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -68.14 178.36 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 71.31 110.908 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.96 -51.05 1.71 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.729 -0.748 . . . . 65.32 112.495 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.435 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -140.0 179.51 6.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.822 0.344 . . . . 52.23 111.142 -179.831 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.435 ' H ' HG22 ' A' ' 79' ' ' THR . 22.5 m120 -87.94 67.42 9.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 70.11 110.871 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.467 ' O ' HG23 ' A' ' 81' ' ' ILE . 13.2 tt -76.86 119.71 25.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 74.24 111.134 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -116.35 103.32 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 74.31 110.933 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.519 HG11 HG21 ' A' ' 93' ' ' VAL . 2.8 m -125.59 120.52 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.44 111.195 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -155.33 113.45 3.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 73.32 110.878 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.668 HG21 ' OG ' ' A' ' 91' ' ' SER . 60.9 t -140.85 147.31 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 71.13 111.099 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.492 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -73.48 158.68 86.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.632 0.73 . . . . 73.21 110.954 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.6 Cg_endo -69.82 159.79 52.05 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.686 2.258 . . . . 63.34 112.333 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.41 17.35 50.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.767 -0.73 . . . . 32.4 112.479 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -165.24 138.48 4.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.947 0.403 . . . . 71.52 110.858 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.38 137.69 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.137 -0.483 . . . . 70.22 111.081 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.668 ' OG ' HG21 ' A' ' 85' ' ' VAL . 3.5 t -119.98 131.7 55.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.113 -0.494 . . . . 62.43 110.847 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.4 t -96.92 145.76 25.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 54.41 111.119 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.519 HG21 HG11 ' A' ' 83' ' ' VAL . 40.1 t -145.99 125.6 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 73.23 111.139 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -102.99 115.43 30.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 71.21 110.89 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -162.27 109.62 1.33 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 62.55 110.908 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -107.72 143.04 36.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.487 . . . . 74.43 111.115 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.41 174.91 6.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 64.34 110.858 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -119.72 -20.36 7.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.489 . . . . 65.54 110.858 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -139.35 158.48 68.79 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.653 0.74 . . . . 75.51 110.814 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.424 ' HA ' ' HB ' ' A' ' 124' ' ' VAL . 53.7 Cg_endo -69.76 158.07 58.22 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.656 2.237 . . . . 74.35 112.355 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 156.27 136.53 2.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 54.24 112.497 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.507 ' HB3' HG23 ' A' ' 123' ' ' VAL . 1.5 pm0 -101.67 134.75 44.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 74.42 110.892 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' TYR . . . . . 0.787 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.7 OUTLIER -143.9 127.24 16.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 73.44 110.951 -179.82 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.8 105.96 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 75.13 110.901 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 6.3 tt 179.8 142.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 62.41 111.103 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.448 HD11 ' SG ' ' A' ' 111' ' ' CYS . 0.0 OUTLIER -122.84 141.51 42.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 72.44 111.125 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.433 ' N ' HD13 ' A' ' 106' ' ' ILE . 5.4 p 179.4 -42.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 51.33 110.848 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -89.57 62.37 5.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 54.23 110.881 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -178.69 136.82 0.15 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 73.11 110.909 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -72.06 121.1 18.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 74.4 110.91 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.448 ' SG ' HD11 ' A' ' 106' ' ' ILE . 6.3 p -179.85 34.47 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.122 -0.49 . . . . 75.02 110.906 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 53.98 66.12 2.99 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.733 -0.746 . . . . 71.11 112.471 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.434 ' O ' HD23 ' A' ' 113' ' ' LEU . 1.2 tt -51.8 108.97 0.31 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.839 0.352 . . . . 41.33 110.897 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 149.99 -89.73 0.14 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.794 -0.717 . . . . 74.53 112.5 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -113.58 -28.6 7.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.719 0.295 . . . . 74.52 110.859 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -54.5 -27.02 35.07 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 62.43 110.925 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -144.75 -169.41 3.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 71.15 110.856 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.58 ' HG2' ' HB1' ' A' ' 43' ' ' ALA . 0.5 OUTLIER -134.99 177.99 7.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 64.14 110.907 179.865 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 -88.07 119.3 28.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.228 -0.442 . . . . 75.2 110.928 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.9 173.15 23.36 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.728 -0.749 . . . . 42.21 112.53 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.557 ' O ' HD13 ' A' ' 53' ' ' ILE . 46.3 m -154.41 119.98 5.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.779 0.323 . . . . 62.02 111.201 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.645 HG13 HG21 ' A' ' 53' ' ' ILE . 4.6 mp -141.73 119.46 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 64.34 111.158 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.507 HG23 ' HB3' ' A' ' 102' ' ' GLU . 9.0 p -116.44 136.88 52.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 71.11 111.125 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 55' ' ' VAL . 35.5 t -100.67 128.1 53.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 30.31 111.169 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.6 mmtt -111.99 132.55 54.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 71.23 110.896 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.207 -0.451 . . . . 64.0 110.926 179.961 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.839 0.352 . . . . 71.42 110.88 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 20.6 t -127.31 66.41 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 75.31 111.106 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.6 pt -112.18 78.38 2.43 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.603 0.715 . . . . 73.32 111.109 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -176.47 1.5 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.695 2.263 . . . . 75.33 112.31 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -86.72 -169.46 2.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.229 -0.441 . . . . 62.21 111.068 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.61 26.8 74.09 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 72.55 112.471 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.43 170.04 0.15 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.851 0.358 . . . . 73.34 110.877 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.627 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.56 163.79 0.08 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 73.03 110.922 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.627 ' N ' HD12 ' A' ' 8' ' ' LEU . 0.4 OUTLIER -120.28 138.17 53.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 72.31 110.908 179.919 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.44 ' HD2' HD11 ' A' ' 8' ' ' LEU . 2.9 mpt_? -93.77 127.91 39.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 73.22 110.892 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.437 HG21 HG21 ' A' ' 16' ' ' VAL . 7.1 m -110.8 -178.79 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 63.22 111.153 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -144.41 162.17 40.81 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.593 0.711 . . . . 74.04 110.909 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -3.32 11.81 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.705 2.27 . . . . 43.31 112.306 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 26.9 m -44.92 -70.14 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 63.35 111.09 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 27.6 p -149.62 22.97 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 74.42 111.148 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.437 HG21 HG21 ' A' ' 11' ' ' VAL . 10.6 p -61.42 -23.75 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 74.35 111.106 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.518 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.6 OUTLIER -105.91 -19.88 13.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 72.31 110.844 -179.939 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -85.29 -28.29 25.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 61.1 110.912 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.402 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 4.9 pt-20 -145.06 146.66 31.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.467 . . . . 74.11 110.864 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.64 -158.91 14.02 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.794 -0.717 . . . . 31.34 112.453 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.46 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.0 Cg_endo -69.73 -30.26 22.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.665 2.243 . . . . 72.3 112.373 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.729 ' HB3' HD13 ' A' ' 42' ' ' LEU . 17.2 m-90 -85.86 -8.36 58.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.196 -0.457 . . . . 74.12 110.887 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.402 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -72.63 -59.63 2.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 33.22 111.103 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.54 145.8 34.09 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.588 0.709 . . . . 74.44 110.891 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.644 2.229 . . . . 64.33 112.36 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.0 -22.62 60.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 74.12 111.089 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -116.42 30.86 7.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 54.13 110.916 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.35 -57.01 3.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 74.43 111.097 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.78 HG21 ' HB3' ' A' ' 54' ' ' GLU . 21.9 t -113.18 101.89 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 74.02 111.124 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.9 t -117.14 148.87 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 75.32 111.119 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.452 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -80.39 117.4 21.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 64.24 110.915 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 32' ' ' THR . . . . . 0.449 HG21 ' OG1' ' A' ' 38' ' ' THR . 15.9 p -105.79 -43.6 4.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 65.03 111.131 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.13 -173.24 22.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.79 -0.719 . . . . 73.31 112.501 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -5.61 16.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.7 2.267 . . . . 74.23 112.307 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -175.41 30.15 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 74.31 110.845 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLN . . . . . 0.412 ' HG3' ' HB2' ' A' ' 60' ' ' GLU . 4.6 mp0 -126.62 118.42 24.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 74.33 110.91 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.452 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 54.2 m-85 -98.93 130.4 45.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 74.31 110.94 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.449 ' OG1' HG21 ' A' ' 32' ' ' THR . 24.7 m -95.62 105.65 17.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.11 -0.496 . . . . 71.01 111.157 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.437 HG13 HG22 ' A' ' 29' ' ' VAL . 18.3 t -88.02 146.3 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 75.04 111.128 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -127.27 106.65 9.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 74.54 110.947 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.532 HG12 ' CG1' ' A' ' 53' ' ' ILE . 16.2 m -107.08 142.76 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 60.43 111.096 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.729 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.6 OUTLIER -139.41 143.27 37.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 74.45 110.858 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.35 114.76 3.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 71.3 111.083 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.507 ' CD2' HD21 ' A' ' 42' ' ' LEU . 4.1 p90 -127.67 155.06 44.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 75.42 110.905 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.9 4.21 38.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.465 . . . . 53.14 111.103 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -104.25 74.76 1.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 72.41 110.861 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 109.37 -160.11 13.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.726 -0.749 . . . . 75.55 112.544 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 11.4 p90 -135.25 144.94 47.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.793 0.33 . . . . 73.14 110.948 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -143.69 162.3 42.21 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.609 0.718 . . . . 45.23 110.883 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -176.09 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.63 2.22 . . . . 72.12 112.338 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.678 ' O ' HD12 ' A' ' 53' ' ' ILE . 62.9 m-20 -130.79 59.93 49.46 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.622 0.725 . . . . 73.13 110.884 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 73.84 1.31 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.7 2.267 . . . . 64.11 112.353 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.7 HG21 HG13 ' A' ' 122' ' ' ILE . 4.1 mp -117.14 122.71 70.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 75.15 111.086 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.78 ' HB3' HG21 ' A' ' 29' ' ' VAL . 10.5 tt0 -125.75 129.3 49.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.879 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 124' ' ' VAL . 2.6 p -136.51 80.47 38.69 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.635 0.731 . . . . 54.41 111.098 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.446 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.74 122.92 9.59 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.701 2.268 . . . . 75.35 112.321 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.473 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.4 pm0 -67.49 154.71 40.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.237 -0.438 . . . . 74.23 110.932 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.33 -10.34 71.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 54.51 112.49 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.28 143.11 48.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 73.04 111.087 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.559 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.9 mp0 -61.15 135.19 57.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 71.21 110.867 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.651 HG13 HG23 ' A' ' 55' ' ' VAL . 12.4 mm -122.62 123.5 68.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.118 -0.492 . . . . 73.43 111.135 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.963 HG13 HG23 ' A' ' 92' ' ' THR . 41.9 t -101.9 92.23 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.42 111.134 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.79 138.33 54.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 73.43 110.873 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -131.15 102.01 5.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 74.55 110.91 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 74' ' ' PHE . 1.6 mp -102.92 139.84 22.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 71.52 111.146 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 10.1 t -158.62 137.74 11.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 53.54 111.163 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.457 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -141.59 160.93 54.78 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.674 0.75 . . . . 64.31 110.865 -179.875 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.457 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.86 -54.39 0.22 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.655 2.237 . . . . 52.14 112.349 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -157.32 59.03 0.51 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 44.44 110.882 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.407 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.93 135.97 4.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 73.42 111.17 179.983 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 mm -67.4 144.97 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 73.11 111.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.4 ' HB2' HG21 ' A' ' 65' ' ' ILE . 9.1 p80 -132.96 -176.58 4.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 72.43 110.848 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.62 132.66 3.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.741 -0.742 . . . . 60.2 112.455 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.504 ' CZ ' HD11 ' A' ' 65' ' ' ILE . 1.8 p90 -121.03 144.3 48.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.845 0.355 . . . . 64.32 110.891 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.42 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 9.7 p80 -103.82 88.17 2.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 72.45 110.881 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.784 HG13 ' CE2' ' A' ' 103' ' ' TYR . 10.9 t -74.94 115.67 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 62.01 111.125 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.89 177.45 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 74.11 110.91 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.41 -49.07 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.788 -0.72 . . . . 62.22 112.489 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.437 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -134.46 179.38 6.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.751 0.31 . . . . 70.02 111.163 -179.905 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.437 ' H ' HG22 ' A' ' 79' ' ' THR . 24.4 m120 -88.35 50.36 1.96 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 70.41 110.882 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.494 ' O ' HG23 ' A' ' 81' ' ' ILE . 6.2 tp -60.94 116.04 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 71.34 111.1 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -116.9 100.82 8.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 42.54 110.876 179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.605 HG11 HG21 ' A' ' 93' ' ' VAL . 3.4 m -121.86 124.13 70.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 73.04 111.13 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -164.61 108.62 0.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 71.03 110.856 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.591 HG21 ' OG ' ' A' ' 91' ' ' SER . 45.1 t -140.4 146.49 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 44.13 111.189 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.74 161.23 62.68 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.58 0.705 . . . . 72.01 110.948 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.94 51.54 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.73 2.287 . . . . 71.43 112.305 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.37 5.48 75.67 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.75 -0.738 . . . . 50.01 112.515 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -147.9 117.95 7.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.899 0.38 . . . . 73.24 110.872 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.497 HG12 ' O ' ' A' ' 9' ' ' GLU . 3.8 p -77.94 118.98 25.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 70.42 111.104 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.591 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -94.85 134.05 37.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.11 -0.495 . . . . 74.02 110.835 -179.835 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.963 HG23 HG13 ' A' ' 62' ' ' VAL . 74.2 m -98.84 109.39 22.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 70.42 111.15 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.605 HG21 HG11 ' A' ' 83' ' ' VAL . 39.7 t -106.86 148.33 11.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 61.3 111.138 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -121.05 107.52 12.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.476 . . . . 74.54 110.831 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -153.18 130.39 11.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 52.34 110.949 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 29.7 m -139.95 141.57 36.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 75.34 111.143 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -96.57 -176.42 3.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 74.2 110.907 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -123.15 -12.55 7.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 61.11 110.905 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.95 162.85 51.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.647 0.737 . . . . 74.35 110.863 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 149.54 66.92 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.686 2.257 . . . . 64.34 112.328 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.4 136.92 2.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 61.52 112.459 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.711 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.5 OUTLIER -109.41 132.82 53.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.847 0.356 . . . . 70.23 110.875 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 103' ' ' TYR . . . . . 0.784 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.9 OUTLIER -143.27 137.17 28.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.181 -0.463 . . . . 52.21 110.895 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.93 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.17 -164.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 73.23 110.877 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.93 HG22 ' O ' ' A' ' 104' ' ' ARG . 7.7 tt 57.55 158.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 75.43 111.097 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.441 HD13 ' N ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -119.91 145.32 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 60.31 111.118 179.88 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.441 ' N ' HD13 ' A' ' 106' ' ' ILE . 0.1 OUTLIER -179.29 35.19 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.172 -0.467 . . . . 73.12 110.923 179.979 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -159.95 80.75 0.71 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 73.21 110.858 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 4.1 mp0 -160.37 -44.05 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 73.42 110.901 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER 63.35 94.38 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 71.41 110.932 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -179.58 34.53 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.087 -0.506 . . . . 74.55 110.894 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 103.02 26.06 7.22 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.746 -0.74 . . . . 70.33 112.495 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.513 HD12 ' N ' ' A' ' 114' ' ' GLY . 2.9 pp -60.71 -170.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.878 0.37 . . . . 61.25 110.861 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.513 ' N ' HD12 ' A' ' 113' ' ' LEU . . . 80.52 -85.64 1.34 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.752 -0.737 . . . . 43.03 112.475 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -75.14 -25.02 58.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.776 0.322 . . . . 74.13 110.851 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -117.32 -169.68 1.71 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 73.01 110.975 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 5.6 t-20 63.61 106.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.448 . . . . 62.51 110.899 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 1.1 ptp -71.49 173.12 8.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.158 -0.474 . . . . 65.23 110.913 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -92.16 125.9 37.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 63.23 110.886 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -81.8 179.5 53.33 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.727 -0.749 . . . . 53.12 112.437 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.567 ' O ' HD13 ' A' ' 53' ' ' ILE . 55.1 m -155.24 117.24 4.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.775 0.321 . . . . 73.43 111.169 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.7 HG13 HG21 ' A' ' 53' ' ' ILE . 5.1 mp -146.48 129.66 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 64.42 111.115 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.711 HG23 ' HB3' ' A' ' 102' ' ' GLU . 9.9 p -132.27 137.06 55.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 71.42 111.119 179.816 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.679 HG13 ' O ' ' A' ' 55' ' ' VAL . 15.7 t -99.73 125.18 53.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 72.03 111.115 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.6 mmmt -99.26 130.68 45.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 71.34 110.879 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.473 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 61.5 110.863 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.087 0 CA-C-O 120.833 0.349 . . . . 72.45 110.912 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.3 t 60.89 84.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 75.41 111.148 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.8 pt -120.32 153.47 55.9 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.619 0.723 . . . . 72.31 111.12 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 -176.73 1.56 Allowed 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.664 2.243 . . . . 54.32 112.374 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.1 -62.97 1.22 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 74.4 111.107 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -154.44 19.32 0.61 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.752 -0.737 . . . . 61.0 112.512 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.16 146.04 2.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.786 0.327 . . . . 73.21 110.932 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.697 HD13 ' O ' ' A' ' 90' ' ' VAL . 0.2 OUTLIER 61.16 164.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.247 -0.433 . . . . 64.45 110.925 179.934 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.617 ' N ' HD12 ' A' ' 8' ' ' LEU . 2.1 mt-10 -120.45 143.56 48.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 75.41 110.919 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.12 136.74 38.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 73.41 110.85 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.518 HG21 HG21 ' A' ' 16' ' ' VAL . 15.2 m -128.46 -178.66 2.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 64.34 111.103 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 161.94 41.54 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.647 0.737 . . . . 64.14 110.854 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -4.71 14.58 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.735 2.29 . . . . 62.01 112.359 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.407 ' O ' HG23 ' A' ' 15' ' ' THR . 4.2 m -48.44 -66.92 0.32 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.185 -0.461 . . . . 74.35 111.138 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 14' ' ' THR . 2.8 p -155.62 37.59 0.37 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.446 . . . . 63.15 111.163 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.518 HG21 HG21 ' A' ' 11' ' ' VAL . 14.7 p -74.29 -34.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 75.11 111.119 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.427 ' HB3' HD11 ' A' ' 42' ' ' LEU . 11.5 ptt85 -95.17 -10.73 29.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 73.45 110.865 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 -97.69 -35.08 10.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 62.41 110.892 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -131.86 136.95 47.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 63.24 110.906 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 118.21 -159.5 14.25 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 11.21 112.495 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -26.89 26.94 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.63 2.22 . . . . 62.15 112.325 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.748 ' HB3' HD13 ' A' ' 42' ' ' LEU . 15.7 m-90 -86.37 -10.94 53.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.235 -0.439 . . . . 71.54 110.929 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.9 -59.0 3.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 61.14 111.079 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.85 144.61 29.7 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.573 0.702 . . . . 73.31 110.898 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -15.32 37.02 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.686 2.257 . . . . 62.21 112.349 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.29 -6.46 48.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 31.04 111.117 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 8.3 mm100 -106.39 6.49 30.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 72.54 110.883 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -51.95 -76.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 70.54 111.07 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.451 HG13 ' HB3' ' A' ' 37' ' ' TYR . 14.2 t -83.13 130.75 35.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 74.34 111.131 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 32.3 t -144.67 114.35 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 73.43 111.109 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -60.03 116.51 4.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 74.34 110.904 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.4 t -119.9 -38.74 2.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 63.43 111.136 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.91 173.61 18.82 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.732 . . . . 24.35 112.539 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.04 3.57 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.726 2.284 . . . . 64.21 112.339 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 53.2 t30 67.78 34.96 4.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 74.33 110.898 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -145.48 156.96 44.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 62.14 110.901 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.451 ' HB3' HG13 ' A' ' 29' ' ' VAL . 43.1 m-85 -143.16 141.27 31.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 74.55 110.955 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.528 HG23 ' HE3' ' A' ' 64' ' ' LYS . 54.4 m -94.86 104.87 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.117 -0.492 . . . . 74.21 111.152 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.466 HG11 HG23 ' A' ' 53' ' ' ILE . 15.7 t -87.35 152.62 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 51.24 111.097 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -127.2 140.25 52.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 64.11 110.913 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.593 HG22 ' CG1' ' A' ' 53' ' ' ILE . 60.0 t -139.1 137.98 41.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 63.54 111.106 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.748 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.4 OUTLIER -138.42 141.49 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 73.3 110.873 179.92 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.58 101.18 2.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 73.1 111.104 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -116.57 147.35 41.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 74.44 110.857 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.23 0.26 52.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 73.44 111.115 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -94.19 39.28 1.08 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 75.44 110.908 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.63 -137.93 8.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 64.51 112.526 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 31.1 t80 -155.24 160.6 40.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.802 0.334 . . . . 74.23 110.959 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -165.23 162.18 14.07 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.581 0.705 . . . . 73.04 110.912 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 176.74 6.37 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.703 2.269 . . . . 72.14 112.348 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.639 ' C ' HD12 ' A' ' 53' ' ' ILE . 6.6 m120 -133.89 63.25 62.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.616 0.722 . . . . 53.51 110.85 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 72.1 1.48 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.268 . . . . 74.4 112.372 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.722 HG21 HG13 ' A' ' 122' ' ' ILE . 4.9 mp -106.41 121.55 59.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 70.14 111.152 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -120.0 115.4 23.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 75.31 110.893 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.862 HG13 HG22 ' A' ' 124' ' ' VAL . 2.6 p -123.35 78.47 53.56 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.621 0.724 . . . . 54.42 111.15 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.721 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.73 123.02 9.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.704 2.27 . . . . 64.14 112.342 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.507 HE22 ' HA ' ' A' ' 126' ' ' GLU . 1.1 pm0 -68.61 154.72 41.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.267 -0.424 . . . . 61.14 110.875 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.1 -6.28 76.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 73.41 112.517 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.31 156.44 47.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.76 0.314 . . . . 72.03 111.072 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.742 ' O ' HD13 ' A' ' 61' ' ' ILE . 6.3 mt-10 -67.42 138.53 56.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.915 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.742 HD13 ' O ' ' A' ' 60' ' ' GLU . 4.4 mm -130.87 114.8 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 41.31 111.118 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 92' ' ' THR . 39.5 t -101.23 94.29 3.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 75.35 111.123 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -70.47 132.61 45.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 74.44 110.884 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.528 ' HE3' HG23 ' A' ' 38' ' ' THR . 36.2 mttt -128.74 99.74 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 75.23 110.914 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.502 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.8 mp -104.22 158.63 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 72.22 111.159 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.414 ' N ' HG22 ' A' ' 65' ' ' ILE . 7.9 t -167.01 141.91 4.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 62.13 111.144 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.586 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -148.48 158.46 40.5 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.686 0.755 . . . . 62.51 110.852 -179.88 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.45 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.6 Cg_endo -69.8 -55.48 0.17 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.725 2.283 . . . . 74.12 112.31 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -154.91 68.39 0.7 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.852 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.586 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.2 -171.15 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.215 -0.448 . . . . 74.22 111.143 -179.992 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.509 HD13 ' O ' ' A' ' 70' ' ' VAL . 30.9 mm -138.11 140.49 40.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 71.14 111.126 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.502 ' CG ' HG21 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -115.23 -85.46 0.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 73.3 110.848 179.917 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 53.85 94.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.71 -0.757 . . . . 31.34 112.48 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -100.14 143.09 30.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 70.13 110.868 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 3.6 t60 -120.22 142.84 48.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 73.04 110.846 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.806 HG11 ' CZ ' ' A' ' 95' ' ' TYR . 4.9 p -127.78 122.83 59.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 71.34 111.112 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -52.16 160.85 0.7 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 74.04 110.897 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.15 -51.93 4.55 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.786 -0.721 . . . . 41.14 112.467 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.85 160.91 14.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.827 0.346 . . . . 73.24 111.132 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -101.03 35.49 2.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.466 . . . . 71.24 110.924 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.635 HG21 HG12 ' A' ' 76' ' ' VAL . 20.0 tt -54.73 124.91 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 75.03 111.117 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -123.76 82.75 2.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 74.24 110.897 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.447 HG11 HG11 ' A' ' 93' ' ' VAL . 5.1 m -110.33 119.33 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 62.51 111.106 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -165.39 103.32 0.73 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 62.42 110.896 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 18.1 m -140.36 139.37 35.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.148 -0.478 . . . . 75.1 111.13 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.7 mp -59.88 163.39 7.63 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.583 0.706 . . . . 72.45 110.936 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 159.93 51.6 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.669 2.246 . . . . 50.43 112.343 179.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.5 17.38 57.1 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 71.31 112.469 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -158.42 143.45 16.35 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 74.34 110.881 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.697 ' O ' HD13 ' A' ' 8' ' ' LEU . 52.3 t -81.42 146.12 7.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.136 -0.484 . . . . 74.13 111.115 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -103.82 158.08 16.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.44 110.891 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 62' ' ' VAL . 26.6 m -147.28 123.23 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 75.33 111.164 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.447 HG11 HG11 ' A' ' 83' ' ' VAL . 9.4 p -153.15 136.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 51.33 111.126 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.0 mtm180 -96.33 81.46 3.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 75.02 110.84 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.806 ' CZ ' HG11 ' A' ' 76' ' ' VAL . 2.9 t80 -106.11 121.89 45.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.209 -0.451 . . . . 72.5 110.935 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 t -133.74 138.46 45.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 70.13 111.135 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.43 -168.9 1.68 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.899 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.5 mtpt -123.12 -27.12 4.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 70.42 110.917 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ARG . . . . . 0.437 ' HB3' ' HD2' ' A' ' 100' ' ' PRO . 13.3 mmt180 -129.18 156.07 78.87 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 73.04 110.916 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' PRO . . . . . 0.437 ' HD2' ' HB3' ' A' ' 99' ' ' ARG . 54.0 Cg_endo -69.72 152.08 69.43 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.672 2.248 . . . . 52.33 112.329 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.7 150.49 6.84 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.758 -0.734 . . . . 70.34 112.485 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.691 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -112.63 127.74 56.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.885 0.374 . . . . 63.31 110.867 -179.879 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -143.93 136.46 26.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 72.51 110.911 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.914 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.1 OUTLIER -144.38 -167.29 2.59 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.119 -0.492 . . . . 74.23 110.885 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.914 HG22 ' O ' ' A' ' 104' ' ' ARG . 0.6 OUTLIER 56.93 159.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 55.12 111.074 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.408 HG22 ' CD1' ' A' ' 119' ' ' PHE . 7.0 tt -104.66 134.81 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 75.22 111.121 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 26.4 m -141.45 -42.3 0.37 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 64.34 110.858 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -106.64 126.03 51.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 63.14 110.914 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -175.46 -51.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 73.52 110.916 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 2.4 t80 63.33 83.83 0.16 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 65.12 110.93 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -179.49 -34.97 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 61.24 110.869 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 178.2 33.01 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.728 -0.748 . . . . 35.2 112.49 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -70.27 -179.5 2.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.849 0.357 . . . . 63.31 110.935 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.7 -114.85 4.62 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.748 -0.739 . . . . 63.3 112.481 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 59.1 t-80 -68.11 -29.3 68.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.767 0.317 . . . . 73.25 110.881 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -106.7 -175.62 2.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 75.33 110.877 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 63.88 104.63 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.167 -0.469 . . . . 71.2 110.883 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -70.96 174.59 5.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 42.45 110.865 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' PHE . . . . . 0.408 ' CD1' HG22 ' A' ' 106' ' ' ILE . 1.2 p90 -141.63 167.66 21.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 73.53 110.907 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -143.6 162.21 27.69 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 74.23 112.513 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.568 ' O ' HD13 ' A' ' 53' ' ' ILE . 28.6 m -85.81 141.19 29.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.775 0.321 . . . . 73.34 111.161 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.722 HG13 HG21 ' A' ' 53' ' ' ILE . 4.8 mp -147.88 109.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 73.35 111.112 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.691 HG23 ' HB3' ' A' ' 102' ' ' GLU . 8.6 p -114.97 140.65 35.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 75.24 111.091 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.862 HG22 HG13 ' A' ' 55' ' ' VAL . 68.9 t -104.16 118.49 51.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 74.51 111.125 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 5.1 mmmt -89.98 131.21 35.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 70.24 110.912 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.507 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 72.23 110.906 179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.2 mtt . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.848 0.356 . . . . 73.3 110.91 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 40.0 t -85.85 73.16 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 51.54 111.119 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.3 pt -140.62 78.0 21.9 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.588 0.708 . . . . 72.43 111.082 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.76 -178.14 2.21 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.679 2.253 . . . . 71.55 112.357 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.99 175.06 10.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 62.24 111.137 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.13 -61.18 2.23 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.757 -0.735 . . . . 53.21 112.491 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -174.41 156.16 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.789 0.328 . . . . 72.12 110.922 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.617 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.65 163.68 0.08 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.249 -0.432 . . . . 71.23 110.871 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.617 ' N ' HD12 ' A' ' 8' ' ' LEU . 0.5 OUTLIER -127.58 143.7 51.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 62.15 110.9 179.916 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.95 124.14 34.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 74.34 110.92 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 16' ' ' VAL . 13.9 m -111.4 -178.99 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.456 . . . . 74.4 111.146 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -145.59 162.27 37.21 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.594 0.711 . . . . 72.02 110.887 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 -4.03 13.19 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.688 2.258 . . . . 71.53 112.339 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.411 ' O ' HG23 ' A' ' 15' ' ' THR . 1.9 m -46.93 -65.2 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 71.43 111.166 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 14' ' ' THR . 2.0 p -155.63 32.54 0.36 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.237 -0.438 . . . . 72.44 111.127 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 11' ' ' VAL . 13.9 p -70.96 -29.14 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.232 -0.44 . . . . 63.13 111.125 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.8 ptt-85 -97.55 -9.03 27.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.879 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -101.41 -31.9 10.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 73.33 110.918 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -132.8 134.82 45.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 74.12 110.908 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.98 -158.56 14.62 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.782 -0.723 . . . . 73.2 112.542 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.446 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 53.8 Cg_endo -69.78 -28.81 24.68 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.693 2.262 . . . . 64.34 112.377 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.446 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 18.5 m-90 -87.01 -5.67 59.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 75.31 110.921 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.5 -59.34 2.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.246 -0.434 . . . . 55.44 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -113.93 144.68 32.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.554 0.692 . . . . 65.2 110.891 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -5.02 15.23 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.683 2.256 . . . . 70.12 112.384 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.77 -19.0 61.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.128 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.24 31.16 6.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 74.21 110.929 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.2 -73.1 0.13 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.05 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.655 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.0 p -111.63 106.54 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.441 . . . . 65.02 111.157 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -117.45 149.92 19.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 64.35 111.157 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -79.64 124.21 28.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 73.24 110.94 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.7 t -119.19 -14.83 9.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 52.11 111.136 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.42 -170.93 12.81 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 73.22 112.484 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -36.02 11.42 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.252 . . . . 72.14 112.33 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 20.2 t30 -149.76 34.61 0.69 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.225 -0.443 . . . . 61.24 110.861 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -137.33 117.44 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 73.4 110.91 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -98.24 143.13 29.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 74.23 110.918 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 51.9 m -99.05 102.21 13.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 73.33 111.158 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 t -83.53 143.15 12.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 75.52 111.117 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -125.0 112.7 16.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.196 -0.456 . . . . 73.01 110.937 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.5 HG22 HD12 ' A' ' 53' ' ' ILE . 85.4 t -109.53 125.9 66.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.12 -0.491 . . . . 63.01 111.107 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.692 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.5 tm? -115.64 137.18 52.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 74.21 110.928 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.692 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.05 117.56 4.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 72.11 111.082 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -145.38 140.54 27.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 53.33 110.885 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.4 27.03 1.31 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 74.31 111.124 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -120.92 25.26 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 73.43 110.886 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 169.32 -146.9 10.53 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.816 -0.707 . . . . 52.22 112.523 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -155.57 116.4 3.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.798 0.332 . . . . 74.32 110.914 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.457 ' HG3' ' HD2' ' A' ' 50' ' ' PRO . 2.1 mp0 -134.65 163.32 52.02 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.591 0.71 . . . . 75.14 110.919 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.457 ' HD2' ' HG3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.79 162.15 43.19 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.64 2.226 . . . . 74.34 112.362 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 -124.29 64.34 36.81 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.586 0.708 . . . . 73.32 110.917 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.601 ' C ' HD13 ' A' ' 53' ' ' ILE . 54.3 Cg_endo -69.72 113.18 3.28 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.669 2.246 . . . . 74.54 112.375 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.601 HD13 ' C ' ' A' ' 52' ' ' PRO . 1.5 mm -126.13 144.99 34.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 71.22 111.161 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.655 ' HB3' HG11 ' A' ' 29' ' ' VAL . 24.0 tt0 -155.23 115.6 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 74.14 110.918 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 1.002 HG12 HG21 ' A' ' 61' ' ' ILE . 2.7 m -130.75 84.29 59.08 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.63 0.729 . . . . 73.34 111.127 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.703 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.77 122.62 9.3 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 73.02 112.369 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.7 154.56 38.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 53.45 110.9 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.62 -8.39 72.34 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 72.43 112.476 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.16 157.32 45.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.714 0.292 . . . . 51.1 111.142 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.728 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.0 mt-10 -70.19 144.7 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 71.4 110.915 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 1.002 HG21 HG12 ' A' ' 55' ' ' VAL . 5.4 mm -128.79 105.35 12.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 52.54 111.112 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.622 HG13 HG23 ' A' ' 92' ' ' THR . 25.4 t -84.74 100.68 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 73.24 111.074 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.478 ' CZ ' HG11 ' A' ' 55' ' ' VAL . 96.0 m-85 -76.89 135.15 38.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.1 110.876 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.47 ' HD3' HG21 ' A' ' 90' ' ' VAL . 8.7 mttt -132.28 100.19 4.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 62.32 110.93 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.508 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.6 mp -109.08 141.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 55.42 111.115 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 7.8 t -155.92 135.3 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 72.13 111.135 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.44 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -141.96 161.1 53.02 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.7 0.762 . . . . 54.03 110.826 -179.867 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.419 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.0 Cg_endo -69.74 -53.34 0.28 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.674 2.249 . . . . 51.4 112.365 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -156.67 57.82 0.55 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 71.14 110.823 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.44 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.49 141.43 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.254 -0.43 . . . . 75.13 111.126 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 72' ' ' HIS . 25.1 mm -85.35 155.18 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 71.53 111.093 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.508 ' CG ' HG21 ' A' ' 65' ' ' ILE . 0.2 OUTLIER -123.75 -86.28 0.64 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.121 -0.49 . . . . 71.12 110.857 179.872 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.04 101.6 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.721 -0.752 . . . . 62.14 112.469 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.479 ' CE2' HD11 ' A' ' 65' ' ' ILE . 2.5 p90 -103.5 144.94 30.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.917 0.389 . . . . 74.34 110.854 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -106.0 142.25 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 71.33 110.884 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.747 ' HB ' HG21 ' A' ' 81' ' ' ILE . 44.3 t -137.53 143.6 33.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 52.23 111.131 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -73.2 -175.7 1.94 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.478 . . . . 64.11 110.912 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.09 -51.09 3.98 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.75 -0.738 . . . . 52.12 112.493 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.442 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -142.14 179.5 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.828 0.347 . . . . 62.0 111.127 -179.862 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.442 ' H ' HG22 ' A' ' 79' ' ' THR . 6.8 t-20 -88.17 61.05 6.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 65.21 110.891 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.747 HG21 ' HB ' ' A' ' 76' ' ' VAL . 4.8 tp -71.16 99.72 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 73.11 111.13 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -110.4 112.11 23.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 72.24 110.919 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.808 HG11 HG21 ' A' ' 93' ' ' VAL . 1.5 m -130.82 122.93 53.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.457 . . . . 72.52 111.161 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -152.64 112.79 4.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 71.44 110.874 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.631 HG21 ' OG ' ' A' ' 91' ' ' SER . 57.3 t -140.55 144.28 27.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 60.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.27 160.06 80.54 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.631 0.729 . . . . 71.33 110.899 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.424 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.4 Cg_endo -69.76 159.82 51.97 Favored 'Trans proline' 0 C--N 1.34 0.126 0 C-N-CA 122.708 2.272 . . . . 53.31 112.28 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.61 -1.27 56.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 74.34 112.465 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -147.0 156.75 43.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.884 0.374 . . . . 74.45 110.891 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.546 HG12 ' O ' ' A' ' 9' ' ' GLU . 2.1 p -105.55 113.9 43.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 71.03 111.119 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.631 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -80.54 168.2 19.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 34.43 110.876 -179.87 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 92' ' ' THR . . . . . 0.622 HG23 HG13 ' A' ' 62' ' ' VAL . 96.5 m -134.5 139.35 45.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 65.34 111.129 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.808 HG21 HG11 ' A' ' 83' ' ' VAL . 9.9 t -143.45 137.63 25.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.236 -0.438 . . . . 71.01 111.128 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.04 72.63 0.79 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.469 . . . . 71.51 110.886 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -108.41 141.17 40.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 74.51 110.924 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.1 t -140.06 143.19 36.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.137 -0.483 . . . . 63.21 111.162 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -101.1 177.18 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 70.35 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.34 -12.79 8.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.462 . . . . 71.54 110.877 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -144.57 162.03 41.01 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.653 0.74 . . . . 74.3 110.914 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 155.58 65.62 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.73 2.287 . . . . 62.25 112.314 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 162.27 135.37 1.8 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.773 -0.727 . . . . 74.32 112.53 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.841 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -108.92 124.89 51.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.866 0.365 . . . . 74.14 110.901 -179.896 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -136.04 135.27 39.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.198 -0.456 . . . . 71.21 110.954 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.95 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.5 OUTLIER -144.24 -177.56 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 60.11 110.858 -179.95 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.95 HG22 ' O ' ' A' ' 104' ' ' ARG . 6.6 tt 59.79 158.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 73.13 111.122 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.33 140.26 34.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 72.04 111.164 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -177.96 47.55 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.195 -0.457 . . . . 72.51 110.894 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -177.36 50.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.162 -0.472 . . . . 74.53 110.904 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -174.12 177.57 2.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.458 . . . . 65.33 110.882 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -114.43 121.18 42.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 74.42 110.901 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -169.37 -40.99 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.117 -0.492 . . . . 50.12 110.88 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 166.39 -43.13 0.27 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.731 -0.747 . . . . 74.25 112.53 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.401 HD23 ' N ' ' A' ' 114' ' ' GLY . 0.4 OUTLIER 62.56 164.38 0.1 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.849 0.357 . . . . 64.53 110.905 -179.939 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.401 ' N ' HD23 ' A' ' 113' ' ' LEU . . . 52.59 -112.54 2.16 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.748 -0.739 . . . . 70.03 112.498 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 52.8 p-80 -79.96 175.84 10.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.738 0.304 . . . . 75.41 110.893 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 69.14 -75.57 0.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.25 -0.432 . . . . 73.12 110.953 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 35.5 t30 -71.83 124.59 25.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 51.51 110.896 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.553 ' SD ' ' HB1' ' A' ' 43' ' ' ALA . 21.8 mmt -71.35 174.75 6.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 64.22 110.847 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -90.89 152.77 20.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.237 -0.438 . . . . 71.12 110.899 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -101.08 73.42 0.38 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.698 -0.763 . . . . 74.15 112.484 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.557 ' C ' HD12 ' A' ' 122' ' ' ILE . 99.4 m -74.38 124.84 27.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.741 0.305 . . . . 63.42 111.138 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.576 HG13 HG21 ' A' ' 53' ' ' ILE . 3.1 mp -153.41 138.08 9.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 73.12 111.131 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.841 HG23 ' HB3' ' A' ' 102' ' ' GLU . 11.5 p -134.22 134.69 55.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 71.12 111.151 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.742 HG22 HG23 ' A' ' 55' ' ' VAL . 48.1 t -103.61 129.13 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 73.41 111.152 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt -107.19 129.1 54.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.134 -0.484 . . . . 63.31 110.885 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 64.51 110.878 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.863 0.363 . . . . 74.22 110.85 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.404 HG21 ' HB3' ' A' ' 12' ' ' ASP . 90.4 t -81.15 99.91 4.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 75.24 111.136 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 31.3 pt -95.78 153.81 39.24 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.665 0.745 . . . . 74.51 111.081 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -178.73 2.48 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.624 2.216 . . . . 70.53 112.395 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -173.35 76.54 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 60.21 111.103 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.78 -18.7 56.93 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.693 -0.765 . . . . 63.25 112.477 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.15 -177.51 3.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.809 0.338 . . . . 74.1 110.913 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.591 HD13 ' O ' ' A' ' 90' ' ' VAL . 3.2 pp -60.76 -175.44 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.21 -0.45 . . . . 71.12 110.927 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.54 ' O ' HD12 ' A' ' 8' ' ' LEU . 4.0 mm-40 -64.89 123.16 18.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 73.1 110.877 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.67 139.26 40.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 74.04 110.874 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.8 m -130.1 -177.55 2.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 73.35 111.124 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.411 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 55.9 p-10 -144.07 155.47 58.6 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.563 0.697 . . . . 73.01 110.893 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.4 Cg_endo -69.84 -3.94 13.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.656 2.237 . . . . 73.53 112.351 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.43 ' O ' HG23 ' A' ' 15' ' ' THR . 23.2 m -49.07 -64.7 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 44.23 111.092 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.43 HG23 ' O ' ' A' ' 14' ' ' THR . 2.7 p -156.04 34.91 0.34 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 62.21 111.15 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 p -70.59 -29.19 37.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 61.33 111.069 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.552 ' HB3' HD21 ' A' ' 42' ' ' LEU . 7.2 ptt-85 -98.74 -7.91 26.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 71.43 110.879 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -101.62 -34.79 9.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 73.15 110.927 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.51 133.2 46.07 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 73.53 110.891 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 120.25 -158.15 15.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.747 -0.74 . . . . 62.11 112.507 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -30.11 22.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.73 2.287 . . . . 74.0 112.321 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.416 ' HB3' HD23 ' A' ' 42' ' ' LEU . 13.5 m-90 -84.89 -10.21 57.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.279 -0.418 . . . . 74.1 110.921 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.85 -59.46 2.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 74.41 111.072 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.76 144.64 28.21 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.64 0.733 . . . . 72.33 110.815 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -26.35 27.8 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.686 2.257 . . . . 75.32 112.335 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.02 -18.31 60.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.262 -0.426 . . . . 52.32 111.093 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 19.0 mm-40 -87.35 6.85 31.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 75.22 110.887 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.87 -77.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.266 -0.424 . . . . 62.55 111.084 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.54 116.95 23.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 71.34 111.131 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.0 t -145.77 131.06 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 71.5 111.167 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.59 125.47 26.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 72.23 110.877 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.2 t -117.46 -41.39 2.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 72.24 111.148 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.73 -164.11 18.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 73.35 112.482 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -43.99 2.37 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.7 2.266 . . . . 41.51 112.372 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -141.27 34.45 1.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 73.31 110.908 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -131.4 119.71 22.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 71.31 110.847 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -97.0 140.93 30.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 62.4 110.919 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.694 ' HA ' HG23 ' A' ' 62' ' ' VAL . 96.7 m -93.79 122.45 36.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 61.22 111.137 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.907 HG11 HG23 ' A' ' 53' ' ' ILE . 18.5 t -109.05 108.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 60.44 111.107 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.408 ' CZ ' HG21 ' A' ' 38' ' ' THR . 66.6 m-85 -94.18 105.45 17.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 73.21 110.924 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.602 HG22 ' CG1' ' A' ' 53' ' ' ILE . 59.8 t -98.73 132.65 43.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.082 -0.508 . . . . 71.44 111.167 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.643 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.6 tm? -123.85 133.82 53.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.226 -0.443 . . . . 74.13 110.91 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.643 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.06 132.01 10.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 74.41 111.083 179.83 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -145.26 147.54 32.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 72.41 110.912 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.74 50.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.179 -0.464 . . . . 71.51 111.133 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -95.72 34.05 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 73.31 110.86 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.49 -138.56 6.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.75 -0.738 . . . . 65.05 112.505 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -155.17 157.02 36.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.801 0.334 . . . . 65.41 110.957 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -165.33 162.05 13.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.582 0.706 . . . . 73.31 110.938 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 178.64 4.34 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.677 2.251 . . . . 75.11 112.37 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.63 ' C ' HD12 ' A' ' 53' ' ' ILE . 8.0 m-80 -138.41 63.46 34.78 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.602 0.715 . . . . 73.34 110.869 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 73.1 1.36 Allowed 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.719 2.279 . . . . 65.4 112.361 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.907 HG23 HG11 ' A' ' 39' ' ' VAL . 4.8 mp -106.73 136.44 41.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 71.13 111.13 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -133.13 118.05 18.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.169 -0.469 . . . . 63.21 110.891 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.719 ' O ' HG13 ' A' ' 124' ' ' VAL . 19.6 t -119.9 82.8 28.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 73.11 111.146 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.688 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.73 122.06 8.75 Favored 'Trans proline' 0 N--CA 1.465 -0.173 0 C-N-CA 122.718 2.279 . . . . 72.34 112.358 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.514 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.2 pm0 -69.79 153.03 43.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 43.24 110.914 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.27 -4.62 83.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 64.51 112.484 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.42 156.24 48.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 62.01 111.112 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.726 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.8 mp0 -66.71 140.6 57.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 74.24 110.897 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.726 HD13 ' O ' ' A' ' 60' ' ' GLU . 5.6 mm -130.23 115.01 30.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.134 -0.485 . . . . 72.43 111.116 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.694 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -103.0 90.95 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.17 -0.468 . . . . 71.1 111.161 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.663 ' HB2' HG12 ' A' ' 93' ' ' VAL . 72.2 m-85 -68.13 138.81 56.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 74.13 110.864 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.442 ' HD3' HG21 ' A' ' 90' ' ' VAL . 5.4 mttt -131.83 99.36 4.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 72.44 110.943 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.5 mp -106.76 142.55 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 63.24 111.152 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.429 ' O ' HG23 ' A' ' 66' ' ' THR . 14.2 t -153.81 128.29 9.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 72.22 111.155 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.687 ' CB ' HG23 ' A' ' 70' ' ' VAL . 1.0 OUTLIER -131.33 160.23 68.08 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.677 0.751 . . . . 65.11 110.854 -179.847 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.533 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.72 -53.2 0.28 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.708 2.272 . . . . 62.11 112.343 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ASP . . . . . 0.422 ' HA ' ' HG3' ' A' ' 87' ' ' PRO . 3.7 m-20 -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 73.23 110.888 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.687 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.9 133.41 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 65.41 111.16 179.984 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.706 HG22 ' H ' ' A' ' 72' ' ' HIS . 10.1 mm -91.73 172.53 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 62.32 111.105 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.706 ' H ' HG22 ' A' ' 71' ' ' ILE . 0.1 OUTLIER 76.28 148.86 0.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.124 -0.489 . . . . 73.32 110.896 179.915 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -121.12 -94.68 1.37 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.731 -0.747 . . . . 62.23 112.489 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.519 ' CG ' HD11 ' A' ' 122' ' ' ILE . 3.6 p90 -152.02 149.33 28.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.897 0.38 . . . . 73.11 110.871 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.8 p-80 -114.73 143.1 45.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 75.33 110.836 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.728 HG12 ' CG2' ' A' ' 81' ' ' ILE . 5.9 p -119.67 145.07 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 65.12 111.141 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.3 172.55 12.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 73.04 110.886 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.51 -52.05 4.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.731 -0.747 . . . . 71.33 112.479 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 16.8 m -123.1 154.13 39.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.333 . . . . 64.31 111.139 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -88.41 65.87 8.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 60.52 110.903 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.728 ' CG2' HG12 ' A' ' 76' ' ' VAL . 0.7 OUTLIER -57.03 134.12 21.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.195 -0.457 . . . . 64.3 111.169 179.922 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.37 81.62 1.61 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 75.3 110.87 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.454 ' O ' HG23 ' A' ' 83' ' ' VAL . 19.6 m -116.63 117.73 56.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 72.22 111.141 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -166.88 117.8 0.92 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 72.43 110.893 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.0 m -140.18 137.4 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 65.33 111.089 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.08 156.44 1.79 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.576 0.703 . . . . 73.34 110.961 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.487 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.1 Cg_endo -69.83 159.21 54.21 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.671 2.247 . . . . 72.22 112.316 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 87.39 3.36 81.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.71 -0.757 . . . . 74.42 112.523 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLU . . . . . 0.419 ' HB3' HD11 ' A' ' 8' ' ' LEU . 26.6 mt-10 -148.59 117.56 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 72.01 110.876 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.591 ' O ' HD13 ' A' ' 8' ' ' LEU . 1.7 p -60.33 137.19 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 74.45 111.138 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.58 163.91 17.17 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 73.52 110.899 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.6 m -146.69 104.83 3.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 54.02 111.135 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.663 HG12 ' HB2' ' A' ' 63' ' ' PHE . 4.4 p -130.07 154.36 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 74.32 111.14 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -122.67 100.4 6.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 73.32 110.912 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.412 ' CD2' HD12 ' A' ' 81' ' ' ILE . 49.9 t80 -134.81 108.31 7.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.19 -0.459 . . . . 70.04 110.885 -179.789 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.8 t -103.94 135.54 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 75.53 111.184 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.474 ' HD2' HG21 ' A' ' 124' ' ' VAL . 0.1 OUTLIER -93.44 -177.57 4.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 62.54 110.828 -179.942 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.7 mtmt -125.72 -22.03 4.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 62.04 110.897 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.14 158.92 72.75 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.587 0.708 . . . . 71.21 110.868 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 152.89 69.3 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.696 2.264 . . . . 73.24 112.343 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 168.64 143.43 3.83 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 63.1 112.475 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.693 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -110.27 133.09 53.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.832 0.348 . . . . 44.32 110.92 -179.918 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 103' ' ' TYR . . . . . 0.477 ' CZ ' HG23 ' A' ' 76' ' ' VAL . 1.2 p90 -143.78 136.63 27.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.148 -0.478 . . . . 75.43 110.921 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.912 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.49 -167.82 2.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 63.3 110.894 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.912 HG22 ' O ' ' A' ' 104' ' ' ARG . 8.5 tt 56.64 159.32 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 52.11 111.118 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.47 142.64 29.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 63.22 111.112 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 5.8 p 179.53 -42.64 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 74.53 110.937 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -100.82 81.25 2.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 73.33 110.854 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -129.42 -76.11 0.55 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.213 -0.449 . . . . 72.43 110.927 179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 9.4 t80 179.69 -47.34 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 74.3 110.893 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -92.58 97.71 10.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.136 -0.484 . . . . 75.14 110.881 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -45.98 105.22 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.728 -0.749 . . . . 72.32 112.514 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.685 HD23 ' ND2' ' A' ' 117' ' ' ASN . 13.6 tp -142.77 137.82 30.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.891 0.376 . . . . 74.52 110.917 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -122.59 -11.5 5.48 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.769 -0.729 . . . . 61.3 112.461 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -130.82 -169.4 2.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.705 0.288 . . . . 72.13 110.883 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 67.85 -77.88 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 71.43 110.892 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' ASN . . . . . 0.685 ' ND2' HD23 ' A' ' 113' ' ' LEU . 28.1 p30 -57.32 -176.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 63.43 110.904 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.25 175.57 6.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 74.0 110.879 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -90.89 120.26 31.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 74.24 110.868 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -77.18 170.35 55.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.731 -0.747 . . . . 60.54 112.537 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.658 ' O ' HD13 ' A' ' 53' ' ' ILE . 52.3 m -154.7 121.36 5.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.792 0.33 . . . . 65.11 111.2 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.539 HD12 ' C ' ' A' ' 121' ' ' THR . 4.8 mp -146.82 139.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 61.0 111.098 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.693 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -134.81 135.08 53.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 71.32 111.174 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.719 HG13 ' O ' ' A' ' 55' ' ' VAL . 57.4 t -102.65 123.94 56.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 43.14 111.147 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.1 mmtt -98.29 134.25 41.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 72.34 110.918 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.514 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 71.53 110.892 179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.545 ' O ' HG23 ' A' ' 3' ' ' ILE . 14.0 mmt . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.788 0.328 . . . . 64.32 110.902 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.592 HG22 ' O ' ' A' ' 2' ' ' VAL . 12.1 p 41.51 37.01 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 70.4 111.15 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.545 HG23 ' O ' ' A' ' 1' ' ' MET . 6.9 pt -112.53 78.6 2.75 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.622 0.725 . . . . 73.21 111.133 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 -178.81 2.5 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.71 2.273 . . . . 61.03 112.361 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -150.48 92.03 1.81 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.459 . . . . 34.35 111.086 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 166.56 62.0 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.719 -0.753 . . . . 43.44 112.5 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 66.0 146.73 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.814 0.34 . . . . 63.24 110.877 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.596 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.1 164.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 73.13 110.895 179.917 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.596 ' N ' HD12 ' A' ' 8' ' ' LEU . 2.0 mt-10 -126.97 148.23 50.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 71.52 110.87 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.549 ' NH1' HD21 ' A' ' 8' ' ' LEU . 3.3 mpt_? -99.02 121.42 40.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 63.11 110.87 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.436 HG21 ' OG1' ' A' ' 66' ' ' THR . 15.7 m -118.61 -179.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 63.33 111.16 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.99 162.16 39.22 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.688 0.756 . . . . 74.34 110.799 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.85 -2.96 11.12 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.662 2.241 . . . . 73.55 112.349 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -44.86 -62.78 1.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 74.54 111.15 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.8 23.87 0.39 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 72.4 111.166 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.411 HG21 HG21 ' A' ' 11' ' ' VAL . 10.0 p -65.89 -30.98 51.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 72.52 111.098 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.676 ' CB ' HD11 ' A' ' 42' ' ' LEU . 0.2 OUTLIER -106.3 -6.93 18.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 73.33 110.886 -179.978 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -95.24 -36.44 11.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 72.11 110.894 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -140.94 132.28 26.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 75.01 110.85 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.91 -156.95 21.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 73.42 112.487 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.463 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.8 Cg_endo -69.76 -32.91 17.65 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 70.21 112.356 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.786 ' O ' HD12 ' A' ' 42' ' ' LEU . 10.5 m-90 -84.92 -17.87 36.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.445 . . . . 75.44 110.951 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.45 -61.33 2.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 75.51 111.092 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.69 144.36 29.41 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.612 0.72 . . . . 73.42 110.828 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -11.37 30.69 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.692 2.262 . . . . 61.45 112.32 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.69 -27.52 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 63.01 111.119 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.463 ' HG3' ' HA ' ' A' ' 21' ' ' PRO . 3.5 pm0 -111.04 31.84 5.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 74.34 110.862 -179.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.77 -41.82 29.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 43.11 111.1 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.701 HG21 ' CB ' ' A' ' 54' ' ' GLU . 60.3 t -114.64 130.33 69.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 65.42 111.113 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -146.87 137.87 18.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.096 -0.502 . . . . 61.13 111.064 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -79.68 115.87 19.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 75.33 110.937 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -113.79 -21.06 10.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 73.12 111.142 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.27 -167.48 14.05 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 61.12 112.511 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.94 3.88 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.715 2.277 . . . . 75.32 112.363 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -148.42 29.73 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 71.44 110.876 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -126.95 116.32 20.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 75.32 110.891 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -95.75 140.33 30.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 71.44 110.966 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.716 ' HA ' HG23 ' A' ' 62' ' ' VAL . 88.0 m -92.38 109.9 21.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 72.43 111.176 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 t -89.93 130.07 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 75.34 111.108 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -113.98 105.13 12.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 74.23 110.956 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.554 HG12 HD12 ' A' ' 53' ' ' ILE . 25.0 m -100.15 147.01 8.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.145 -0.48 . . . . 74.42 111.158 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.786 HD12 ' O ' ' A' ' 22' ' ' TRP . 0.3 OUTLIER -133.67 133.16 41.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.245 -0.434 . . . . 65.31 110.948 179.961 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.78 98.72 1.94 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 63.44 111.083 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.507 ' HD1' HD22 ' A' ' 42' ' ' LEU . 52.5 p90 -123.85 143.03 50.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.855 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.86 0.17 53.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 74.41 111.114 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -97.2 66.33 2.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 73.1 110.871 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.28 -137.07 10.47 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.455 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -155.17 150.27 26.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.861 0.363 . . . . 72.2 110.924 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -165.32 163.29 13.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.583 0.706 . . . . 72.44 110.925 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 176.08 7.28 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.618 2.212 . . . . 70.33 112.335 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.441 ' O ' HG12 ' A' ' 53' ' ' ILE . 4.1 m120 -129.86 62.72 65.3 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.623 0.725 . . . . 71.31 110.914 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.662 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.7 Cg_endo -69.73 111.15 2.72 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 53.44 112.342 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.669 HG21 HG13 ' A' ' 122' ' ' ILE . 1.1 mm -130.66 151.58 36.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 71.53 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.701 ' CB ' HG21 ' A' ' 29' ' ' VAL . 6.3 tt0 -156.06 115.77 3.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 60.32 110.866 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.678 ' O ' HG13 ' A' ' 124' ' ' VAL . 6.3 t -135.37 76.44 56.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.699 . . . . 61.33 111.139 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.638 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.2 Cg_endo -69.8 121.55 8.23 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.695 2.263 . . . . 65.42 112.329 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.507 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.5 pm0 -66.5 155.29 38.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.239 -0.437 . . . . 74.54 110.949 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.56 -13.32 65.85 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 24.23 112.49 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.43 154.48 50.74 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 63.35 111.077 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.693 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.1 mt-10 -64.69 136.08 56.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 75.25 110.906 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.693 HD13 ' O ' ' A' ' 60' ' ' GLU . 8.1 mm -127.25 96.21 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 75.12 111.11 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.716 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.2 OUTLIER -84.46 102.18 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 71.4 111.143 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -73.49 139.62 45.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 71.41 110.922 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 15.8 mttt -131.83 98.78 4.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.472 . . . . 75.33 110.928 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.747 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.3 mp -97.56 157.29 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 73.02 111.147 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.436 ' OG1' HG21 ' A' ' 11' ' ' VAL . 12.3 t -170.24 126.21 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 42.25 111.164 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.661 ' HB3' HG22 ' A' ' 70' ' ' VAL . 3.6 m -127.44 161.99 51.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.656 0.741 . . . . 63.24 110.879 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -51.8 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.645 2.23 . . . . 74.1 112.334 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -155.52 29.52 0.38 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 63.44 110.809 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.661 HG22 ' HB3' ' A' ' 67' ' ' SER . 25.9 m -128.37 144.35 38.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 71.12 111.109 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.535 HD13 ' HD3' ' A' ' 87' ' ' PRO . 24.1 mm -69.73 157.2 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.479 . . . . 71.23 111.13 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.747 ' HB3' HG21 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -114.7 -164.4 0.94 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.18 -0.464 . . . . 73.5 110.865 179.888 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.71 130.48 3.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.815 -0.707 . . . . 42.31 112.479 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.572 ' CE1' HG21 ' A' ' 83' ' ' VAL . 1.5 p90 -136.76 144.39 43.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.884 0.373 . . . . 74.14 110.91 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 36.8 t-80 -93.66 133.6 36.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.119 -0.492 . . . . 65.2 110.822 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.721 HG13 ' CE2' ' A' ' 103' ' ' TYR . 87.0 t -126.72 143.27 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 73.2 111.117 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -75.52 177.01 7.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 74.43 110.856 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.74 -51.59 4.57 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 61.21 112.489 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.1 m -140.64 154.12 46.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.797 0.332 . . . . 62.51 111.106 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -76.6 64.58 2.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 73.3 110.88 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 11.3 tt -54.9 128.29 14.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.469 . . . . 73.24 111.124 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -115.58 97.06 5.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 64.41 110.869 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.572 HG21 ' CE1' ' A' ' 74' ' ' PHE . 3.5 m -125.48 120.44 57.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 42.4 111.075 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -154.33 115.72 4.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 74.53 110.832 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.661 HG21 ' CB ' ' A' ' 91' ' ' SER . 94.1 t -139.28 146.53 25.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.485 . . . . 73.42 111.16 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.416 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -75.65 157.99 83.54 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.586 0.708 . . . . 73.44 110.923 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.535 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.3 Cg_endo -69.78 153.8 68.43 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.719 2.28 . . . . 74.31 112.321 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.69 7.06 59.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.752 -0.737 . . . . 74.03 112.496 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -156.75 141.94 17.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.873 0.368 . . . . 72.23 110.878 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 3.6 p -95.69 126.3 48.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 71.52 111.122 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.661 ' CB ' HG21 ' A' ' 85' ' ' VAL . 0.8 OUTLIER -87.5 177.36 7.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 71.23 110.798 -179.829 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 98.8 m -144.82 105.48 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 63.44 111.139 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.509 HG11 HG11 ' A' ' 83' ' ' VAL . 9.8 p -134.82 137.8 50.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 74.42 111.109 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -113.27 139.9 48.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 75.25 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -166.06 94.8 0.57 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.245 -0.434 . . . . 75.13 110.955 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -84.33 143.76 29.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 74.43 111.113 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.12 -169.41 2.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.43 110.889 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mttt -124.93 -28.26 3.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 62.53 110.897 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.17 158.87 70.21 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.605 0.717 . . . . 75.43 110.841 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 147.74 63.44 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.722 2.281 . . . . 74.44 112.342 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.27 153.58 8.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 43.35 112.484 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -116.74 132.2 56.75 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.826 0.346 . . . . 75.43 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' TYR . . . . . 0.721 ' CE2' HG13 ' A' ' 76' ' ' VAL . 2.4 p90 -143.83 141.18 30.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 65.01 110.9 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.85 177.43 8.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.491 . . . . 74.33 110.91 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.468 HD13 ' HB3' ' A' ' 119' ' ' PHE . 20.3 mm 67.48 146.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.213 -0.449 . . . . 74.13 111.184 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.467 HD12 HD23 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -108.17 143.56 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 75.42 111.133 179.866 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 4.9 p -127.08 84.19 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.156 -0.475 . . . . 55.1 110.865 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.4 m120 72.3 -69.31 0.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 74.32 110.892 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 59.91 20.33 9.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 72.41 110.909 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 1.2 m-30 62.67 82.3 0.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.17 -0.468 . . . . 73.35 110.91 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 179.63 -70.16 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.095 -0.502 . . . . 72.11 110.901 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 161.96 74.33 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.741 -0.742 . . . . 55.45 112.507 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.478 ' C ' HD13 ' A' ' 113' ' ' LEU . 3.1 tm? -51.75 120.62 5.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.81 0.338 . . . . 72.55 110.97 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 152.12 -117.33 0.81 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.71 -0.757 . . . . 53.34 112.495 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 19.4 p80 -91.16 48.43 1.5 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.762 0.315 . . . . 73.23 110.878 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -151.17 19.74 0.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 64.15 110.916 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -179.9 -176.36 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 71.31 110.935 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -142.8 175.06 10.11 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.197 -0.456 . . . . 75.42 110.876 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' PHE . . . . . 0.468 ' HB3' HD13 ' A' ' 105' ' ' ILE . 11.4 m-85 -91.06 123.37 34.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 74.2 110.873 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -123.22 124.11 5.52 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.716 -0.754 . . . . 32.24 112.494 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.665 HG23 HG13 ' A' ' 53' ' ' ILE . 12.5 t -86.47 154.24 21.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.793 0.33 . . . . 70.54 111.114 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.669 HG13 HG21 ' A' ' 53' ' ' ILE . 2.9 mp -153.79 137.33 8.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.205 -0.452 . . . . 73.32 111.126 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.5 p -127.55 139.03 53.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 52.34 111.094 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.678 HG13 ' O ' ' A' ' 55' ' ' VAL . 49.1 t -109.27 117.17 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 73.52 111.162 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -86.98 138.76 31.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 74.14 110.888 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.507 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.447 . . . . 65.34 110.911 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 ptm . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.851 0.358 . . . . 70.04 110.899 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 32.8 m -88.93 137.21 21.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 44.22 111.136 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.9 pt -153.03 78.45 5.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.615 0.721 . . . . 53.42 111.131 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -177.49 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.688 2.259 . . . . 61.24 112.396 179.851 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -147.94 60.11 1.12 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 72.41 111.085 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -146.47 -78.83 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.756 -0.735 . . . . 74.1 112.465 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.06 127.92 55.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.86 0.362 . . . . 62.41 110.887 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 48.29 -168.76 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 75.42 110.894 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -123.02 131.91 53.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 73.44 110.91 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -96.04 145.18 25.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.494 . . . . 70.13 110.853 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.1 m -136.64 -178.58 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 62.43 111.14 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.13 161.98 42.51 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.641 0.734 . . . . 75.41 110.876 179.883 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 -3.5 12.14 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.692 2.261 . . . . 63.31 112.362 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 25.8 m -44.96 -70.21 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 42.42 111.165 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 25.6 p -149.59 24.1 0.88 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 64.31 111.152 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.6 p -62.85 -26.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 55.12 111.118 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -106.07 -17.21 14.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 70.05 110.865 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -83.91 -35.9 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 64.4 110.923 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 -142.38 140.82 32.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 73.43 110.895 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.24 -158.53 17.86 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.732 -0.747 . . . . 64.24 112.476 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.72 -30.97 21.63 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 72.33 112.398 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 12.2 m-90 -84.6 -13.91 50.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.942 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.88 -59.42 3.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 63.34 111.105 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.01 147.63 34.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.565 0.698 . . . . 64.34 110.876 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -26.67 27.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.667 2.244 . . . . 72.25 112.361 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -80.14 -1.12 38.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 72.41 111.069 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.8 mm-40 -105.27 5.07 31.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 52.34 110.953 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.3 -74.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 73.45 111.099 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 1.066 HG22 HG12 ' A' ' 39' ' ' VAL . 48.0 t -71.91 126.78 33.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.436 . . . . 71.0 111.127 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.45 ' O ' HG23 ' A' ' 30' ' ' VAL . 19.0 m -150.34 127.01 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 73.03 111.13 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 -76.28 114.44 14.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.459 . . . . 52.43 110.926 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.2 t -120.05 -13.17 9.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.263 -0.426 . . . . 71.32 111.116 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.36 -173.25 13.78 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.753 -0.737 . . . . 62.11 112.514 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -36.72 10.34 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 73.35 112.336 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -150.86 34.35 0.6 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 72.1 110.863 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -134.55 117.8 16.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 71.54 110.945 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -98.58 134.33 41.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 75.02 110.947 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.783 ' HA ' HG23 ' A' ' 62' ' ' VAL . 56.7 m -95.07 115.04 26.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.482 . . . . 74.34 111.136 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 1.066 HG12 HG22 ' A' ' 29' ' ' VAL . 34.6 m -110.33 126.62 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 75.13 111.131 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 84.8 m-85 -103.13 113.78 27.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.198 -0.455 . . . . 75.12 110.859 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.517 HG12 ' CG1' ' A' ' 53' ' ' ILE . 15.8 m -97.5 131.4 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.11 -0.496 . . . . 71.4 111.126 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.736 HD11 ' CD2' ' A' ' 44' ' ' PHE . 3.2 tm? -120.19 135.66 54.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 71.11 110.89 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.527 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -156.44 113.98 3.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 73.12 111.065 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.736 ' CD2' HD11 ' A' ' 42' ' ' LEU . 7.0 p90 -128.5 151.08 49.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 73.11 110.889 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.47 1.44 48.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 75.23 111.074 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -92.15 75.65 5.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.261 -0.427 . . . . 73.41 110.852 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.46 -127.75 9.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 73.12 112.499 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -141.67 162.34 35.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.824 0.345 . . . . 74.4 110.909 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.405 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 1.8 pm0 -161.07 155.93 20.24 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 73.34 110.93 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.74 -176.23 1.41 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.675 2.25 . . . . 63.23 112.337 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.656 ' O ' HD12 ' A' ' 53' ' ' ILE . 4.1 m120 -130.28 60.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.605 0.717 . . . . 64.24 110.881 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 73.94 1.32 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.675 2.25 . . . . 61.24 112.35 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.656 HD12 ' O ' ' A' ' 51' ' ' ASN . 2.9 mp -125.84 132.39 70.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 73.23 111.146 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -131.62 156.69 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 61.13 110.906 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.836 HG13 HG22 ' A' ' 124' ' ' VAL . 2.9 p -157.47 77.88 3.72 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.619 0.723 . . . . 70.21 111.148 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.769 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.76 121.46 8.15 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.696 2.264 . . . . 73.23 112.356 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.453 HE22 ' HA ' ' A' ' 126' ' ' GLU . 1.1 pm0 -68.26 154.24 42.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 65.24 110.924 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.94 -10.16 69.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.76 -0.733 . . . . 73.11 112.493 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.5 159.9 39.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.773 0.32 . . . . 60.43 111.106 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.63 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.8 mp0 -72.57 141.34 48.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.43 110.895 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.769 HD12 ' HD2' ' A' ' 56' ' ' PRO . 3.8 mm -125.96 119.48 54.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.169 -0.469 . . . . 71.32 111.124 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.783 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -110.19 90.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 55.13 111.087 179.905 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.505 ' CD2' HG21 ' A' ' 39' ' ' VAL . 38.7 m-85 -74.81 144.18 43.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 72.31 110.872 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.402 ' HD3' HG11 ' A' ' 90' ' ' VAL . 0.1 OUTLIER -127.41 100.81 6.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 73.15 110.908 179.956 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.9 mt -94.23 147.3 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 74.32 111.125 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -166.12 136.93 3.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 71.12 111.146 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.457 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -146.34 160.61 41.73 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.698 0.761 . . . . 74.05 110.835 -179.883 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.403 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.6 Cg_endo -69.79 -54.87 0.2 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.674 2.249 . . . . 72.45 112.353 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -156.88 61.43 0.52 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 73.21 110.854 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.457 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.16 135.9 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 53.15 111.112 179.98 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.0 mm -73.61 145.17 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 75.21 111.142 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -126.56 -168.57 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 64.35 110.876 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 133.31 115.21 1.59 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 63.44 112.475 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -111.03 142.71 42.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.842 0.354 . . . . 72.12 110.879 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.614 ' CG ' HE22 ' A' ' 109' ' ' GLN . 30.3 p-80 -115.17 142.63 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 74.55 110.816 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 16.6 t -133.68 147.66 30.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 72.1 111.126 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -70.01 -178.65 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 64.01 110.907 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.53 -51.17 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.721 -0.752 . . . . 71.43 112.5 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.1 m -136.89 153.86 50.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.789 0.328 . . . . 75.02 111.16 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -77.39 60.44 2.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 70.53 110.9 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.467 ' O ' HG23 ' A' ' 81' ' ' ILE . 7.2 tt -69.58 115.26 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 71.34 111.123 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.78 104.25 11.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.48 . . . . 74.03 110.883 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.452 HG11 ' CG2' ' A' ' 93' ' ' VAL . 3.6 m -125.79 120.14 56.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 60.44 111.139 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.5 pp20? -157.23 117.23 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 72.24 110.867 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -140.35 146.54 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 62.1 111.113 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.402 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -64.21 158.49 64.06 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.619 0.723 . . . . 73.3 110.922 179.966 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.402 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 54.0 Cg_endo -69.77 152.86 69.37 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.235 . . . . 71.52 112.332 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.62 11.46 63.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.757 -0.735 . . . . 64.02 112.463 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -145.83 118.17 8.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 74.44 110.952 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.402 HG11 ' HD3' ' A' ' 64' ' ' LYS . 39.2 t -63.43 105.59 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 63.25 111.173 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 66.0 p -91.98 114.33 26.84 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 51.11 110.867 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.3 t -81.83 145.99 30.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 61.43 111.17 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.452 ' CG2' HG11 ' A' ' 83' ' ' VAL . 87.2 t -139.94 117.85 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 71.34 111.107 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.0 mmm180 -102.8 107.91 18.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 73.34 110.894 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -155.95 141.38 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 61.25 110.938 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.5 t -135.14 143.63 46.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 74.43 111.102 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -95.56 -175.5 3.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 62.01 110.88 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -123.06 -12.27 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.116 -0.493 . . . . 73.15 110.876 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.83 161.93 28.09 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.646 0.736 . . . . 70.4 110.835 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 156.7 62.68 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 64.55 112.316 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.0 132.51 1.37 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 64.32 112.51 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -101.79 132.84 47.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.889 0.376 . . . . 62.44 110.918 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -143.8 129.61 19.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.49 . . . . 63.3 110.913 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.0 95.3 2.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.501 . . . . 71.52 110.843 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.5 tt -178.19 143.77 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 73.11 111.118 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -118.1 144.59 25.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 64.02 111.106 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 55.3 m -114.42 -75.81 0.59 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.468 . . . . 62.43 110.889 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -134.38 -39.46 0.82 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 74.43 110.929 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' GLN . . . . . 0.614 HE22 ' CG ' ' A' ' 75' ' ' HIS . 11.8 mm-40 71.32 -70.02 0.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 73.44 110.923 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 73.6 t80 -152.68 -74.38 0.14 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.177 -0.465 . . . . 52.23 110.958 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.8 t -52.51 -35.35 52.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.056 -0.52 . . . . 55.21 110.879 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 109.91 59.63 0.51 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.763 -0.732 . . . . 71.34 112.487 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.611 HD12 ' HB2' ' A' ' 117' ' ' ASN . 11.2 tp 57.5 95.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.889 0.376 . . . . 62.42 110.917 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -60.15 -169.61 0.44 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.714 -0.755 . . . . 73.44 112.479 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 73.6 t60 -55.95 -25.65 44.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.725 0.298 . . . . 73.12 110.858 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -133.4 -68.9 0.56 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 75.42 110.938 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' ASN . . . . . 0.611 ' HB2' HD12 ' A' ' 113' ' ' LEU . 0.1 OUTLIER 61.99 102.54 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 74.55 110.86 -179.986 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.44 174.33 6.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 52.24 110.868 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -91.78 121.97 33.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 73.32 110.9 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.416 ' C ' HD12 ' A' ' 122' ' ' ILE . . . -69.3 84.86 0.24 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.725 -0.75 . . . . 72.32 112.495 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.633 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.4 m -75.21 117.73 17.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.768 0.318 . . . . 55.04 111.161 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.579 HG13 HG21 ' A' ' 53' ' ' ILE . 3.7 mp -147.55 140.17 18.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 75.42 111.12 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.478 ' O ' HG12 ' A' ' 55' ' ' VAL . 5.6 m -134.46 138.33 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 71.41 111.099 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.836 HG22 HG13 ' A' ' 55' ' ' VAL . 44.0 t -104.05 125.15 58.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 72.22 111.116 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 31.2 mmtt -107.19 133.83 51.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 65.54 110.91 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.453 ' HA ' HE22 ' A' ' 57' ' ' GLN . 22.3 mt-10 . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 72.43 110.865 179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.454 ' O ' HG23 ' A' ' 3' ' ' ILE . 4.2 mmt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.832 0.349 . . . . 41.44 110.876 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 35.5 m 40.14 44.51 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 61.01 111.115 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.454 HG23 ' O ' ' A' ' 1' ' ' MET . 8.0 pt -109.92 81.33 2.02 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.596 0.713 . . . . 75.42 111.108 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -173.22 0.68 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.645 2.23 . . . . 74.05 112.391 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.56 144.47 31.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 54.52 111.093 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 63.53 95.83 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.702 -0.761 . . . . 72.12 112.521 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.29 164.29 0.11 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.838 0.352 . . . . 73.35 110.915 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.3 tp 65.86 121.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 70.54 110.938 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -121.16 117.1 26.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.201 -0.454 . . . . 52.41 110.856 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -84.3 144.33 28.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.492 . . . . 74.21 110.892 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.435 ' HB ' HG21 ' A' ' 16' ' ' VAL . 13.3 m -134.24 -177.37 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 72.1 111.111 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.463 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 21.4 p30 -143.77 157.72 57.75 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.586 0.708 . . . . 74.42 110.855 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.463 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.75 -2.8 10.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.243 . . . . 75.14 112.313 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.606 HG22 HG23 ' A' ' 15' ' ' THR . 9.7 m -48.26 -67.72 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 74.33 111.147 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.606 HG23 HG22 ' A' ' 14' ' ' THR . 38.4 p -151.0 30.24 0.64 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.45 . . . . 72.42 111.131 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.435 HG21 ' HB ' ' A' ' 11' ' ' VAL . 4.9 p -78.83 -24.96 13.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.24 -0.436 . . . . 72.53 111.113 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.505 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.9 OUTLIER -98.65 -18.23 18.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 75.42 110.892 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.9 mm-40 -100.92 -31.42 11.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 63.33 110.896 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -129.28 138.68 51.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 73.41 110.874 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 116.68 -161.78 12.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 41.24 112.494 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -27.77 25.87 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 2.239 . . . . 70.03 112.375 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.449 ' HB3' HD23 ' A' ' 42' ' ' LEU . 13.5 m-90 -84.45 -17.48 39.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 75.54 110.916 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.64 -59.8 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 53.45 111.124 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.45 143.0 25.91 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.605 0.717 . . . . 60.32 110.86 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -14.99 37.04 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 62.51 112.353 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -6.58 48.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 75.2 111.131 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 9.2 mm100 -108.26 5.8 26.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 64.03 110.965 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.76 -78.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.213 -0.449 . . . . 71.12 111.123 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -81.92 125.88 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 61.04 111.113 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.45 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 25.1 m -141.66 142.62 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 55.25 111.154 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -82.31 110.52 17.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 70.43 110.928 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.7 t -108.89 -41.3 4.78 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 74.3 111.138 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.9 175.61 19.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.47 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 116.53 4.6 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.727 2.285 . . . . 74.11 112.34 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 66.97 35.31 4.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 73.44 110.866 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -147.87 152.6 37.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.218 -0.446 . . . . 74.35 110.941 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -141.72 140.96 33.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.222 -0.445 . . . . 65.3 110.957 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.79 ' HA ' HG23 ' A' ' 62' ' ' VAL . 28.8 m -90.95 117.55 29.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 74.04 111.18 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 t -100.35 107.4 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 71.01 111.14 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.465 ' CZ ' HG21 ' A' ' 38' ' ' THR . 70.7 m-85 -88.45 127.38 35.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.189 -0.46 . . . . 73.52 110.913 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.836 HG22 HD12 ' A' ' 53' ' ' ILE . 77.0 t -119.82 108.04 22.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.109 -0.496 . . . . 75.05 111.119 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.505 HD11 ' HB3' ' A' ' 17' ' ' ARG . 0.7 OUTLIER -101.5 126.57 48.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 65.11 110.904 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -152.87 128.44 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 53.02 111.145 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -145.78 147.01 31.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.44 . . . . 74.31 110.9 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.77 31.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 74.44 111.088 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -104.63 54.84 0.72 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 61.03 110.876 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 131.67 -139.16 10.71 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 53.02 112.445 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -154.98 151.46 28.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.854 0.359 . . . . 73.41 110.926 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -165.68 162.98 12.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.576 0.703 . . . . 60.03 110.901 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 154.04 68.2 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.697 2.264 . . . . 72.42 112.332 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -128.22 66.4 72.67 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.574 0.702 . . . . 73.44 110.921 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.626 ' O ' HD13 ' A' ' 53' ' ' ILE . 54.3 Cg_endo -69.72 115.21 3.98 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.707 2.271 . . . . 52.35 112.374 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.836 HD12 HG22 ' A' ' 41' ' ' VAL . 2.6 mm -125.82 146.47 31.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 73.42 111.1 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -155.1 118.03 4.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 71.22 110.885 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.83 HG23 HG13 ' A' ' 61' ' ' ILE . 2.1 p -132.72 85.32 47.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.669 0.747 . . . . 44.12 111.123 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.4 Cg_endo -69.84 123.13 9.78 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.625 2.217 . . . . 73.21 112.363 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.35 145.98 55.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 74.53 110.865 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.41 -28.31 9.22 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 74.2 112.51 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.6 156.86 17.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.74 0.305 . . . . 72.32 111.103 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.729 ' O ' HD13 ' A' ' 61' ' ' ILE . 2.2 mt-10 -66.4 142.13 57.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 64.25 110.916 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.83 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -131.89 119.95 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 73.31 111.145 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.79 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.3 OUTLIER -114.01 89.44 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 54.43 111.142 179.847 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -66.61 137.18 56.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 65.44 110.92 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' LYS . . . . . 0.566 ' HD3' HG11 ' A' ' 90' ' ' VAL . 8.6 mttm -133.77 100.65 4.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 64.1 110.898 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.582 HD11 ' CE2' ' A' ' 74' ' ' PHE . 2.6 mp -102.17 157.86 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.444 . . . . 74.53 111.119 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.415 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.7 t -165.48 142.19 5.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 64.41 111.163 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.457 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -151.27 162.18 27.54 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 74.12 110.862 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HD3' ' CZ ' ' A' ' 17' ' ' ARG . 53.8 Cg_endo -69.76 -55.68 0.17 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.729 2.286 . . . . 72.54 112.348 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -155.93 60.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.458 . . . . 74.13 110.832 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.457 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.05 134.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 70.42 111.132 179.986 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.8 mm -64.8 145.06 14.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.142 -0.481 . . . . 70.15 111.118 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.574 ' HB2' HG21 ' A' ' 65' ' ' ILE . 9.5 p-80 -140.79 115.49 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.474 . . . . 71.43 110.848 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.26 132.58 3.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 60.43 112.496 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.582 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.9 p90 -117.15 142.64 46.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.829 0.347 . . . . 74.13 110.866 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.6 t-80 -126.05 105.17 8.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 74.32 110.882 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.458 HG12 HG21 ' A' ' 81' ' ' ILE . 4.9 p -97.06 144.95 9.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 43.13 111.102 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -61.16 -175.44 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 71.0 110.92 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 90.36 -51.08 3.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.702 -0.761 . . . . 71.21 112.514 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.425 HG22 ' N ' ' A' ' 80' ' ' ASN . 7.4 m -140.18 158.85 43.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.791 0.329 . . . . 71.12 111.182 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.425 ' N ' HG22 ' A' ' 79' ' ' THR . 3.5 m120 -76.17 60.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 73.03 110.892 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.518 ' O ' HG23 ' A' ' 81' ' ' ILE . 13.4 tt -72.4 110.08 5.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 73.22 111.104 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.12 97.88 6.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 51.4 110.88 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.48 HG11 HG21 ' A' ' 93' ' ' VAL . 2.6 m -118.23 119.9 62.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 74.03 111.11 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -150.71 115.52 5.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 74.51 110.894 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.714 HG11 ' HB2' ' A' ' 91' ' ' SER . 7.3 p -140.67 146.52 24.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 72.01 111.094 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.2 mp -69.71 160.04 81.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.647 0.737 . . . . 51.54 110.915 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 160.29 50.27 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.657 2.238 . . . . 73.31 112.372 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.31 17.71 54.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.775 -0.726 . . . . 54.35 112.474 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -163.38 135.58 5.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.875 0.369 . . . . 73.24 110.909 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.566 HG11 ' HD3' ' A' ' 64' ' ' LYS . 61.9 t -76.37 138.06 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 70.44 111.13 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.714 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -115.2 107.74 15.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 72.34 110.862 -179.836 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.2 m -81.73 120.02 24.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 73.31 111.131 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.48 HG21 HG11 ' A' ' 83' ' ' VAL . 46.7 t -120.61 122.79 68.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.269 -0.423 . . . . 74.14 111.148 179.887 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.4 mmm180 -100.85 102.45 13.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 55.34 110.88 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 52.9 t80 -151.93 120.41 6.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 62.34 110.921 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.3 t -114.93 139.91 49.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.105 -0.498 . . . . 64.41 111.156 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -90.96 -170.1 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 72.44 110.863 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 25.5 mttt -129.44 -25.52 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 70.43 110.896 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.1 mtp180 -135.98 154.64 77.78 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 74.41 110.832 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 156.84 62.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.651 2.234 . . . . 71.04 112.318 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.19 133.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 44.43 112.48 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.57 128.73 38.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.832 0.349 . . . . 72.1 110.871 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.3 p90 -143.87 132.04 21.85 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 72.22 110.911 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 43.5 mtm180 -144.88 -176.59 5.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 64.22 110.892 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.0 mt 66.35 144.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 70.13 111.157 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.456 HD13 ' N ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -103.68 145.05 13.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 74.24 111.15 179.819 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.456 ' N ' HD13 ' A' ' 106' ' ' ILE . 9.0 t -104.46 -67.24 0.91 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 62.31 110.894 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -146.81 102.29 3.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 63.15 110.866 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -97.72 25.83 5.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 74.51 110.864 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 59.11 175.67 0.07 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.236 -0.438 . . . . 71.14 110.903 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER 63.18 25.64 14.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.12 -0.491 . . . . 70.22 110.89 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.6 95.92 0.39 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.721 -0.752 . . . . 72.13 112.499 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.53 HD12 ' N ' ' A' ' 114' ' ' GLY . 0.8 OUTLIER -66.06 -178.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.889 0.376 . . . . 71.32 110.899 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.53 ' N ' HD12 ' A' ' 113' ' ' LEU . . . 88.53 -117.31 4.81 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.772 -0.727 . . . . 65.33 112.481 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 31.3 m170 -52.51 148.17 7.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.748 0.308 . . . . 63.4 110.88 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 61.83 55.35 2.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 75.12 110.902 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -179.25 93.98 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 74.23 110.869 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -71.66 174.45 6.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 72.44 110.904 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -91.84 121.1 33.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.228 -0.442 . . . . 71.22 110.909 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -83.8 176.57 52.21 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.752 -0.737 . . . . 71.35 112.503 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.764 HG23 HG13 ' A' ' 53' ' ' ILE . 9.9 t -154.56 136.8 14.84 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.746 0.307 . . . . 73.11 111.135 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.55 HD12 ' C ' ' A' ' 121' ' ' THR . 3.7 mp -150.33 142.01 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.234 -0.439 . . . . 75.2 111.157 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.48 ' O ' HG12 ' A' ' 55' ' ' VAL . 28.0 t -132.97 130.19 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 75.05 111.121 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.824 HG22 HG13 ' A' ' 55' ' ' VAL . 42.5 t -103.07 130.38 53.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 64.44 111.135 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -108.18 134.15 51.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 75.51 110.901 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.34 110.894 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.815 0.341 . . . . 73.11 110.844 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' VAL . . . . . 0.507 HG22 ' O ' ' A' ' 2' ' ' VAL . 2.4 p 38.15 82.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.234 -0.439 . . . . 63.14 111.098 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.473 HD13 ' H ' ' A' ' 3' ' ' ILE . 0.2 OUTLIER -117.31 153.29 49.99 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.642 0.734 . . . . 53.53 111.125 179.889 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -176.94 1.64 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.663 2.242 . . . . 74.21 112.392 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.99 68.3 1.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.453 . . . . 44.31 111.089 179.862 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 127.62 -93.21 0.37 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.787 -0.72 . . . . 50.25 112.514 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.96 161.65 14.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.818 0.342 . . . . 63.23 110.914 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.798 HD11 ' HD2' ' A' ' 10' ' ' ARG . 0.2 OUTLIER 61.41 164.29 0.08 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 63.32 110.891 179.937 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.615 ' N ' HD12 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -128.35 131.53 48.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 71.33 110.911 179.933 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.798 ' HD2' HD11 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -90.07 154.09 20.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 70.13 110.895 -179.913 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 16' ' ' VAL . 10.6 m -126.74 -178.05 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 73.13 111.165 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.464 ' OD1' HG21 ' A' ' 2' ' ' VAL . 0.4 OUTLIER -143.81 161.74 44.6 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.591 0.71 . . . . 62.43 110.867 179.914 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -4.24 13.64 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.695 2.264 . . . . 74.23 112.379 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.721 HG22 HG23 ' A' ' 15' ' ' THR . 42.2 m -48.46 -71.0 0.07 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.198 -0.455 . . . . 75.53 111.157 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.721 HG23 HG22 ' A' ' 14' ' ' THR . 44.8 p -151.59 36.68 0.57 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 62.35 111.159 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 11' ' ' VAL . 10.0 p -78.93 -25.58 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 64.41 111.129 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -97.52 -18.2 19.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 71.51 110.834 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -101.43 -28.4 12.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.445 . . . . 72.45 110.923 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.33 133.17 42.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 73.23 110.914 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.88 -158.67 17.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 74.32 112.473 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.474 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.4 Cg_endo -69.75 -34.65 14.17 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.72 2.28 . . . . 65.53 112.342 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.437 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 14.9 m-90 -84.98 -6.95 59.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 64.52 110.912 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -59.12 4.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 51.21 111.106 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.99 141.7 25.37 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.592 0.71 . . . . 73.3 110.896 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -7.17 20.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 62.31 112.311 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.06 -25.5 60.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 72.22 111.094 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.474 ' HG3' ' HA ' ' A' ' 21' ' ' PRO . 3.7 pm0 -110.99 34.21 4.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 72.03 110.919 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.59 -69.03 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 63.04 111.115 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.561 HG11 ' CB ' ' A' ' 54' ' ' GLU . 1.6 p -111.33 125.18 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.448 . . . . 63.53 111.097 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.97 151.46 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 65.35 111.179 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLN . . . . . 0.433 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -72.69 119.29 16.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 74.32 110.879 -179.974 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.2 p -120.94 -42.58 2.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.157 -0.474 . . . . 55.34 111.137 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.39 -168.22 16.83 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.749 -0.739 . . . . 74.2 112.504 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 109.8 2.4 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 73.33 112.354 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.9 t30 49.92 30.58 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 71.43 110.878 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.43 120.98 26.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.177 -0.465 . . . . 72.44 110.891 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' TYR . . . . . 0.433 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 39.7 m-85 -94.43 141.97 27.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 61.2 110.924 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.419 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 21.9 m -99.66 99.78 10.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 72.21 111.16 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.34 131.57 33.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 61.03 111.087 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -113.63 100.69 8.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.176 -0.465 . . . . 73.22 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.753 HG12 HD12 ' A' ' 53' ' ' ILE . 34.8 m -97.45 129.94 46.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 74.01 111.141 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 18.5 tp -124.24 138.54 54.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 70.34 110.928 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.741 ' HB3' ' CE1' ' A' ' 72' ' ' HIS . . . -155.68 123.41 5.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.467 . . . . 74.34 111.094 179.833 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -143.09 144.1 32.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 72.45 110.876 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.13 4.89 32.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 51.14 111.114 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -103.34 72.9 1.18 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 61.33 110.846 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 115.08 -141.69 17.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 70.13 112.522 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -152.89 148.4 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.807 0.337 . . . . 72.24 110.938 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -165.15 162.97 13.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 73.04 110.913 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 158.58 56.53 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.686 2.257 . . . . 64.12 112.374 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -131.88 67.02 79.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.704 0.764 . . . . 64.51 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.724 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.9 Cg_endo -69.76 119.56 6.49 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 55.31 112.336 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.806 HG13 HG23 ' A' ' 121' ' ' THR . 1.5 mm -131.27 124.13 54.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 74.13 111.106 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.561 ' CB ' HG11 ' A' ' 29' ' ' VAL . 8.6 tt0 -131.24 116.38 17.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 73.01 110.891 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.731 HG13 HG21 ' A' ' 61' ' ' ILE . 5.7 t -130.1 80.6 70.59 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.63 0.729 . . . . 71.25 111.12 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.551 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.7 121.12 7.82 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.746 2.298 . . . . 74.5 112.331 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.508 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.5 pm0 -68.12 155.57 39.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 72.22 110.929 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.52 -6.53 76.81 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.754 -0.736 . . . . 74.0 112.481 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.82 155.34 49.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 73.3 111.094 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.763 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.5 mt-10 -64.84 143.42 57.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 71.01 110.897 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.763 HD13 ' O ' ' A' ' 60' ' ' GLU . 8.6 mm -131.65 124.53 54.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 44.21 111.124 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 1.018 HG13 HG23 ' A' ' 92' ' ' THR . 46.8 t -111.22 93.48 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 75.32 111.146 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -71.82 137.06 47.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 65.31 110.858 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -132.28 99.52 4.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 65.44 110.907 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.411 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.6 mp -98.03 153.53 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 70.35 111.147 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.2 t -171.77 137.77 1.03 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 60.15 111.165 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.447 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -142.44 162.21 45.97 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.708 0.766 . . . . 52.43 110.843 -179.836 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.426 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.8 Cg_endo -69.71 -52.01 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 65.13 112.322 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -155.91 36.67 0.35 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 64.5 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.447 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -140.17 -179.24 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 72.12 111.139 -179.961 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ILE . . . . . 0.634 HG23 ' O ' ' A' ' 85' ' ' VAL . 33.1 mt -144.91 156.68 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.201 -0.454 . . . . 74.21 111.183 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.741 ' CE1' ' HB3' ' A' ' 43' ' ' ALA . 35.6 p-80 -168.52 98.17 0.41 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 73.33 110.835 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -95.02 135.72 12.56 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 73.13 112.504 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.608 ' CE1' HG21 ' A' ' 83' ' ' VAL . 9.3 p90 -99.05 142.1 30.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.876 0.369 . . . . 72.51 110.872 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.9 p80 -125.24 142.69 51.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 73.32 110.897 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.697 HG11 ' CE1' ' A' ' 97' ' ' PHE . 21.2 t -131.83 147.56 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 75.42 111.134 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -71.49 -175.44 1.3 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 74.43 110.867 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.12 -51.45 4.58 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 73.23 112.49 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.6 m -135.52 151.35 50.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.782 0.325 . . . . 72.55 111.153 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.5 m-80 -74.13 70.13 1.56 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 71.24 110.871 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.547 ' O ' HG23 ' A' ' 81' ' ' ILE . 14.1 tt -87.77 104.37 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 72.44 111.099 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -115.83 103.85 11.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 64.43 110.893 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.765 HG11 HG21 ' A' ' 93' ' ' VAL . 0.9 OUTLIER -114.32 120.62 64.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 62.44 111.113 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.32 121.09 17.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 70.34 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.634 ' O ' HG23 ' A' ' 71' ' ' ILE . 13.7 p -139.36 147.64 24.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 63.42 111.142 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.504 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -90.58 163.92 28.63 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.594 0.712 . . . . 73.05 110.911 179.927 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.504 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.5 Cg_endo -69.77 147.77 63.56 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.682 2.254 . . . . 72.03 112.317 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.01 9.18 58.51 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.754 -0.736 . . . . 73.23 112.492 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -146.34 173.68 12.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.869 0.366 . . . . 72.3 110.876 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.53 ' O ' HD13 ' A' ' 8' ' ' LEU . 17.5 t -129.37 119.49 48.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 71.31 111.117 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -103.75 133.66 48.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 54.21 110.822 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' THR . . . . . 1.018 HG23 HG13 ' A' ' 62' ' ' VAL . 60.7 m -103.13 131.87 49.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 71.52 111.12 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.765 HG21 HG11 ' A' ' 83' ' ' VAL . 19.0 t -125.26 127.6 72.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 72.45 111.114 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -107.78 92.6 4.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 52.35 110.858 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -140.77 133.43 28.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.157 -0.474 . . . . 75.04 110.902 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.7 t -123.16 140.19 53.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 71.23 111.159 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' PHE . . . . . 0.697 ' CE1' HG11 ' A' ' 76' ' ' VAL . 75.2 m-85 -96.3 -174.82 3.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 74.33 110.861 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -125.89 -29.02 3.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 72.2 110.928 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.35 155.59 81.28 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.597 0.713 . . . . 71.11 110.897 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 170.56 16.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.647 2.231 . . . . 64.12 112.351 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 154.99 133.32 1.71 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 70.0 112.479 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.13 125.54 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 65.51 110.903 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.75 146.61 33.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 73.45 110.94 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.23 97.89 1.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.15 110.838 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.4 tt -175.51 151.96 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.151 -0.477 . . . . 74.31 111.118 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.567 ' O ' HD13 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -114.43 141.47 30.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 73.34 111.189 179.822 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.404 ' N ' HD13 ' A' ' 106' ' ' ILE . 24.9 t -179.07 -74.36 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 74.31 110.907 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 45.2 m-20 -62.52 94.7 0.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.461 . . . . 74.21 110.886 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -170.2 -173.58 1.53 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 74.52 110.914 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 6.2 t80 -119.56 68.88 0.82 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.454 . . . . 72.32 110.918 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -151.98 -49.19 0.11 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 72.54 110.897 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 127.57 104.03 1.25 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.746 -0.74 . . . . 71.33 112.467 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.567 HD13 ' O ' ' A' ' 106' ' ' ILE . 21.1 tp -51.36 149.09 4.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.835 0.35 . . . . 74.23 110.885 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.537 ' H ' HD12 ' A' ' 113' ' ' LEU . . . 90.5 -157.8 25.9 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.696 -0.764 . . . . 73.14 112.489 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 58.36 -165.71 0.17 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.773 0.321 . . . . 75.13 110.859 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -51.44 -26.95 8.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 63.14 110.943 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -53.63 101.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.47 . . . . 61.43 110.883 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' MET . . . . . 0.465 ' SD ' ' HB1' ' A' ' 43' ' ' ALA . 0.3 OUTLIER -76.16 177.03 7.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 52.31 110.884 179.903 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -89.71 120.21 30.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.245 -0.434 . . . . 71.42 110.872 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -72.28 -175.93 26.98 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 53.1 112.472 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.806 HG23 HG13 ' A' ' 53' ' ' ILE . 4.8 t -154.88 146.82 23.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.763 0.316 . . . . 53.14 111.168 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.603 HG13 HG21 ' A' ' 53' ' ' ILE . 2.1 mp -153.9 137.63 8.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 71.53 111.121 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 26.9 t -126.14 122.58 61.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 74.23 111.149 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.652 HG13 ' O ' ' A' ' 55' ' ' VAL . 44.3 t -101.52 112.1 33.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 75.24 111.119 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 17.8 mmmt -84.45 135.26 34.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 54.53 110.897 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.508 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 74.43 110.945 179.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.804 0.335 . . . . 45.45 110.859 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.1 m -111.28 139.01 37.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 44.23 111.163 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -150.46 77.93 7.89 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.639 0.733 . . . . 63.43 111.124 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -177.51 1.91 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.692 2.262 . . . . 61.31 112.33 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -145.0 -70.77 0.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.475 . . . . 61.41 111.108 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -101.14 17.55 55.78 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.766 -0.731 . . . . 32.43 112.446 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' LYS . . . . . 0.429 ' HE3' HD23 ' A' ' 8' ' ' LEU . 13.1 mmmt -115.08 178.93 4.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.831 0.348 . . . . 63.52 110.88 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.429 HD23 ' HE3' ' A' ' 7' ' ' LYS . 0.5 OUTLIER -63.77 -174.06 0.09 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.22 -0.446 . . . . 63.54 110.948 179.905 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.406 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.8 OUTLIER -78.53 129.37 34.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.438 . . . . 71.21 110.885 179.96 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.54 168.46 10.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 75.34 110.851 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.87 ' CG1' HG21 ' A' ' 16' ' ' VAL . 1.4 t -141.54 166.71 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 60.44 111.098 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ASP . . . . . 0.427 ' H ' HG12 ' A' ' 11' ' ' VAL . 55.9 p-10 -161.12 153.45 16.97 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.594 0.711 . . . . 73.44 110.843 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -4.34 13.85 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.684 2.256 . . . . 71.1 112.326 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.459 ' O ' HG23 ' A' ' 15' ' ' THR . 40.6 m -44.44 -72.23 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 65.24 111.094 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 14' ' ' THR . 6.7 p -156.62 33.08 0.31 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 52.34 111.144 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.87 HG21 ' CG1' ' A' ' 11' ' ' VAL . 4.9 p -78.58 -19.92 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 74.04 111.105 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -100.68 -9.38 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 60.02 110.896 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -103.53 -32.87 9.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 63.14 110.881 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -140.16 125.98 19.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 73.54 110.861 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 132.26 -155.99 21.78 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.741 . . . . 24.22 112.515 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -37.83 8.65 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.723 2.282 . . . . 71.52 112.349 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' TRP . . . . . 0.483 ' HE3' HG22 ' A' ' 16' ' ' VAL . 7.8 m-90 -84.51 -12.57 53.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.211 -0.449 . . . . 72.11 110.917 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.79 -59.54 4.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 75.31 111.087 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.21 142.84 25.37 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 51.3 110.88 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 -22.83 31.81 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.644 2.229 . . . . 61.52 112.376 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.51 -17.56 61.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 75.25 111.097 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 3.5 mm100 -89.35 10.13 23.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 75.24 110.929 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.26 -77.53 0.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 50.42 111.083 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.435 HG21 ' HB3' ' A' ' 54' ' ' GLU . 21.1 t -84.38 122.06 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 72.4 111.165 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.8 131.62 53.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.451 . . . . 62.15 111.106 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -71.31 118.28 13.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 72.31 110.899 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.0 t -119.38 -41.49 2.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 71.2 111.175 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.34 171.2 13.72 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.765 -0.731 . . . . 32.34 112.487 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -10.21 28.02 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.685 2.257 . . . . 72.03 112.358 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -157.69 34.81 0.26 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.283 -0.417 . . . . 63.4 110.883 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -151.29 160.04 44.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 63.51 110.896 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.7 m-85 -143.31 146.64 33.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.252 -0.431 . . . . 75.43 110.941 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 99.5 m -97.23 121.99 39.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.119 -0.491 . . . . 74.11 111.165 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 17.9 t -100.37 134.58 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 72.24 111.137 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -120.65 100.51 7.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 73.3 110.932 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.495 HG12 HG13 ' A' ' 53' ' ' ILE . 32.8 m -98.78 128.53 50.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 74.1 111.129 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.706 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.8 tm? -120.74 138.23 54.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 71.24 110.928 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.706 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.22 137.04 14.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 73.12 111.049 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PHE . . . . . 0.427 ' HD2' HD11 ' A' ' 42' ' ' LEU . 2.9 p90 -145.29 150.06 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 73.31 110.918 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.41 18.69 4.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 54.42 111.118 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -84.34 -61.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 60.42 110.868 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -127.44 -122.43 2.52 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.786 -0.721 . . . . 75.23 112.488 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -143.91 145.02 31.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.869 0.366 . . . . 74.33 110.904 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLN . . . . . 0.427 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.0 pm0 -154.37 156.09 31.4 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.56 0.695 . . . . 74.53 110.892 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.2 Cg_endo -69.79 177.38 5.65 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.632 2.222 . . . . 75.23 112.343 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.712 ' O ' HD12 ' A' ' 53' ' ' ILE . 8.5 m-20 -131.23 62.3 64.39 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.592 0.71 . . . . 61.15 110.905 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 70.77 1.56 Allowed 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.661 2.241 . . . . 74.25 112.377 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.712 HD12 ' O ' ' A' ' 51' ' ' ASN . 4.3 mp -105.88 128.29 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 75.11 111.151 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.435 ' HB3' HG21 ' A' ' 29' ' ' VAL . 11.2 tt0 -126.3 135.11 51.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.468 . . . . 73.43 110.878 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.741 HG13 HG22 ' A' ' 124' ' ' VAL . 2.5 p -140.12 81.95 17.79 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.657 0.741 . . . . 74.4 111.08 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.59 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.74 123.55 10.22 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.715 2.277 . . . . 61.25 112.328 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.452 HE22 ' HA ' ' A' ' 126' ' ' GLU . 1.3 pm0 -66.87 152.37 45.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 71.44 110.951 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.42 -36.51 3.7 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 61.23 112.49 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -106.22 150.12 26.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.749 0.309 . . . . 61.14 111.129 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.619 ' O ' HD13 ' A' ' 61' ' ' ILE . 18.1 mt-10 -66.42 142.07 57.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 55.32 110.901 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.717 HG13 HG23 ' A' ' 55' ' ' VAL . 5.8 mm -126.25 119.43 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 45.35 111.116 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 1.091 HG13 HG23 ' A' ' 92' ' ' THR . 64.3 t -98.33 92.08 2.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 73.52 111.118 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.506 ' HB2' HG12 ' A' ' 93' ' ' VAL . 66.9 m-85 -70.9 136.59 48.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.906 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 8.7 mttt -132.09 98.64 4.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 64.54 110.908 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.715 HD11 ' CZ ' ' A' ' 74' ' ' PHE . 1.6 mp -103.17 137.5 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 71.23 111.11 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' THR . . . . . 0.419 ' OG1' HG11 ' A' ' 11' ' ' VAL . 4.2 t -155.73 135.89 12.99 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 75.43 111.123 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.449 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -135.87 161.19 64.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.633 0.73 . . . . 75.31 110.859 -179.863 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.8 Cg_endo -69.68 -53.95 0.25 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.675 2.25 . . . . 72.11 112.361 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -156.83 56.15 0.54 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 74.54 110.866 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.01 136.23 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 63.2 111.152 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.4 mm -64.33 149.14 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.164 -0.471 . . . . 74.45 111.115 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.582 ' HB2' HG21 ' A' ' 65' ' ' ILE . 2.4 p-80 -133.11 -178.5 4.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 65.54 110.886 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 135.37 139.69 4.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 35.45 112.485 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.715 ' CZ ' HD11 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -130.57 144.68 51.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.894 0.378 . . . . 73.2 110.837 -179.845 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 18.2 t60 -101.06 142.13 32.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.106 -0.497 . . . . 72.3 110.863 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.612 HG22 ' CD2' ' A' ' 103' ' ' TYR . 58.2 t -131.84 138.13 53.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 62.02 111.118 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -75.51 179.45 5.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 73.24 110.862 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.14 -52.03 4.57 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.781 -0.723 . . . . 74.13 112.48 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.62 179.7 4.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.82 0.343 . . . . 75.03 111.123 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -105.77 65.5 0.71 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 61.13 110.893 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.58 HD12 ' CD2' ' A' ' 95' ' ' TYR . 7.5 tt -72.47 121.68 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 73.51 111.159 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -117.07 90.47 3.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 110.827 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 5.1 m -115.05 118.41 58.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 62.02 111.126 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -166.72 104.73 0.59 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.145 -0.48 . . . . 71.15 110.878 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.545 HG23 ' HE2' ' A' ' 72' ' ' HIS . 2.4 m -140.64 146.61 23.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 72.54 111.109 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.422 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -57.8 159.78 9.36 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.559 0.695 . . . . 72.24 110.915 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 87' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 53.9 Cg_endo -69.74 159.67 52.55 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.71 2.274 . . . . 73.32 112.343 179.864 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 90.82 4.51 69.53 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.695 -0.764 . . . . 21.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -147.19 117.81 7.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.872 0.368 . . . . 73.53 110.928 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 1.8 p -74.49 130.04 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 62.04 111.134 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.54 ' HB2' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -102.17 112.26 24.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 75.25 110.816 -179.812 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 92' ' ' THR . . . . . 1.091 HG23 HG13 ' A' ' 62' ' ' VAL . 52.7 m -90.12 115.72 27.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 65.31 111.117 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 63' ' ' PHE . 8.6 p -128.75 152.22 36.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 55.14 111.117 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.82 103.02 11.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 70.52 110.901 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.58 ' CD2' HD12 ' A' ' 81' ' ' ILE . 9.0 t80 -134.28 114.95 13.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 75.14 110.92 -179.876 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.0 t -129.09 134.85 48.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.117 -0.492 . . . . 65.44 111.109 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -90.85 -176.73 4.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 54.44 110.849 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -121.25 -13.04 8.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 73.21 110.947 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.73 162.74 49.28 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.634 0.731 . . . . 52.23 110.87 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 150.05 67.45 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.686 2.257 . . . . 75.32 112.318 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.73 157.47 10.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.727 -0.749 . . . . 54.44 112.49 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.765 ' HB3' HG23 ' A' ' 123' ' ' VAL . 3.8 pm0 -120.26 125.17 47.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.872 0.368 . . . . 65.23 110.855 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' TYR . . . . . 0.612 ' CD2' HG22 ' A' ' 76' ' ' VAL . 1.0 OUTLIER -133.01 146.64 51.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.483 . . . . 72.15 110.885 -179.838 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ARG . . . . . 0.417 ' O ' ' HB ' ' A' ' 105' ' ' ILE . 0.4 OUTLIER -174.3 -162.11 0.13 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 74.32 110.83 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.417 ' HB ' ' O ' ' A' ' 104' ' ' ARG . 21.2 mm 75.28 117.79 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 71.34 111.161 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.477 HG23 ' N ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -85.2 -175.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 64.24 111.144 179.849 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.477 ' N ' HG23 ' A' ' 106' ' ' ILE . 2.9 t 79.8 42.97 0.06 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.185 -0.462 . . . . 71.12 110.871 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ASN . . . . . 0.48 ' O ' ' N ' ' A' ' 110' ' ' TYR . 8.2 m-20 -154.16 -81.38 0.09 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 70.13 110.928 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 17.9 mp0 50.49 -87.76 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 72.31 110.912 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' TYR . . . . . 0.48 ' N ' ' O ' ' A' ' 108' ' ' ASN . 87.2 t80 -134.96 -39.1 0.78 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 74.53 110.938 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.2 m -114.83 -33.8 5.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.105 -0.498 . . . . 44.53 110.843 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 103.88 122.8 5.15 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.746 -0.74 . . . . 23.44 112.519 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -131.54 -78.76 0.52 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.852 0.358 . . . . 71.5 110.932 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 44.88 -153.17 0.55 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.722 -0.751 . . . . 65.44 112.47 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 15.1 t-160 53.66 67.57 0.98 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.745 0.307 . . . . 74.11 110.9 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -179.47 -79.04 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.456 . . . . 75.13 110.887 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 10.4 p-10 -95.78 179.77 4.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 74.14 110.912 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.88 175.41 7.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 73.33 110.86 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -90.56 133.48 35.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.245 -0.434 . . . . 73.4 110.868 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -73.15 -173.78 26.09 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 61.12 112.457 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.607 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.6 m -156.41 126.04 6.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.751 0.31 . . . . 63.5 111.166 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.637 HG13 HG21 ' A' ' 53' ' ' ILE . 5.3 mp -145.35 117.24 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 61.2 111.144 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.765 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -121.65 141.49 41.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 72.14 111.094 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' VAL . . . . . 0.741 HG22 HG13 ' A' ' 55' ' ' VAL . 87.0 t -101.5 136.59 32.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 74.0 111.163 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -114.49 125.72 54.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 62.21 110.869 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.452 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 74.0 110.871 179.964 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.5 mmm . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.857 0.361 . . . . 63.12 110.884 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 17.3 m -68.62 136.63 26.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.21 -0.45 . . . . 73.13 111.095 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.8 pt -108.14 153.59 41.74 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.603 0.716 . . . . 63.13 111.149 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -176.26 1.43 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.731 2.288 . . . . 71.44 112.323 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -150.49 84.75 1.37 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 73.32 111.097 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.21 -101.31 1.84 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.695 -0.764 . . . . 73.32 112.51 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.35 158.41 19.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.787 0.327 . . . . 71.32 110.886 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.61 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.33 164.34 0.08 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.222 -0.445 . . . . 73.55 110.956 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLU . . . . . 0.61 ' N ' HD12 ' A' ' 8' ' ' LEU . 1.6 mm-40 -123.44 148.26 46.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 74.52 110.896 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ARG . . . . . 0.589 ' HD2' HD11 ' A' ' 8' ' ' LEU . 3.7 mpt_? -105.01 121.36 43.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 61.55 110.863 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.462 ' HB ' HG21 ' A' ' 16' ' ' VAL . 5.6 m -113.49 -179.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 75.42 111.17 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 162.63 38.29 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.571 0.7 . . . . 71.22 110.891 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -2.78 10.78 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.656 2.237 . . . . 65.31 112.36 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.751 HG22 HG23 ' A' ' 15' ' ' THR . 29.1 m -44.75 -67.34 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.231 -0.441 . . . . 62.32 111.109 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' THR . . . . . 0.751 HG23 HG22 ' A' ' 14' ' ' THR . 43.4 p -150.67 21.29 0.81 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 54.21 111.142 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.462 HG21 ' HB ' ' A' ' 11' ' ' VAL . 1.3 p -77.65 -16.88 14.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 71.11 111.157 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ARG . . . . . 0.431 ' NE ' ' HD3' ' A' ' 68' ' ' PRO . 0.0 OUTLIER -106.66 -25.0 11.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 72.31 110.876 -179.951 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -92.6 -24.24 18.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 74.11 110.92 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.458 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 11.3 tt0 -143.58 147.32 34.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 61.35 110.928 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.01 -158.74 14.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.73 -0.748 . . . . 75.32 112.489 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.42 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.9 Cg_endo -69.81 -33.9 15.48 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.678 2.252 . . . . 71.53 112.332 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 11.8 m-90 -83.2 -12.87 56.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.256 -0.429 . . . . 74.54 110.898 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.458 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -62.44 -57.13 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.256 -0.429 . . . . 51.01 111.134 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.34 142.22 25.19 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.564 0.697 . . . . 64.23 110.927 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -6.73 19.3 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.708 2.272 . . . . 72.54 112.359 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.79 -12.87 61.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 64.1 111.109 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLN . . . . . 0.42 ' HG3' ' HA ' ' A' ' 21' ' ' PRO . 17.6 mm-40 -99.0 14.4 29.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.443 . . . . 74.51 110.93 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ALA . . . . . 0.458 ' HB2' ' HG2' ' A' ' 52' ' ' PRO . . . -65.0 -14.84 61.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.463 . . . . 71.13 111.089 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.522 HG22 ' HB3' ' A' ' 54' ' ' GLU . 7.0 t -145.21 119.31 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 74.24 111.092 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.766 HG13 ' HB ' ' A' ' 38' ' ' THR . 1.6 p -144.21 140.92 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 60.25 111.153 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.33 100.88 13.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 74.04 110.87 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.4 t -98.07 -34.46 10.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.232 -0.44 . . . . 61.13 111.147 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.71 -168.44 17.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 74.43 112.472 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -37.83 8.56 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.654 2.236 . . . . 54.2 112.334 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -148.27 34.68 0.8 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 73.45 110.864 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -135.41 119.87 18.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 65.32 110.893 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -95.87 140.89 29.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 73.5 110.983 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.766 ' HB ' HG13 ' A' ' 30' ' ' VAL . 22.3 m -94.81 107.82 19.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 70.42 111.141 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.1 t -89.25 130.0 39.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.224 -0.444 . . . . 61.22 111.137 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' TYR . . . . . 0.409 ' CD2' ' HB2' ' A' ' 21' ' ' PRO . 49.0 m-85 -116.03 113.15 22.81 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 74.3 110.909 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 41' ' ' VAL . 31.2 m -111.35 125.1 68.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 71.24 111.117 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.416 HD11 ' CZ ' ' A' ' 17' ' ' ARG . 2.9 tm? -121.92 126.28 48.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.122 -0.49 . . . . 60.23 110.907 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -144.54 144.96 31.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 53.21 111.115 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 12.2 p90 -136.65 152.74 50.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 73.15 110.908 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ALA . . . . . 0.553 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -87.77 12.2 13.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 72.4 111.063 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -120.48 66.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 72.5 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 123.31 -147.88 16.71 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.747 -0.739 . . . . 62.44 112.507 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -150.71 155.88 40.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 64.32 110.929 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -164.48 162.54 15.31 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.624 0.726 . . . . 62.22 110.916 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 140.09 41.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.696 2.264 . . . . 70.2 112.354 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASN . . . . . 0.621 ' O ' HD12 ' A' ' 53' ' ' ILE . 14.3 m-20 -131.61 68.19 80.67 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.624 0.726 . . . . 73.51 110.879 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PRO . . . . . 0.458 ' HG2' ' HB2' ' A' ' 28' ' ' ALA . 53.5 Cg_endo -69.75 72.75 1.42 Allowed 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.707 2.271 . . . . 71.3 112.363 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ILE . . . . . 0.731 HD13 ' O ' ' A' ' 121' ' ' THR . 2.6 mp -77.37 91.34 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 73.4 111.1 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLU . . . . . 0.522 ' HB3' HG22 ' A' ' 29' ' ' VAL . 9.1 tt0 -83.48 138.54 33.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.882 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' VAL . . . . . 0.586 HG13 HG21 ' A' ' 61' ' ' ILE . 6.5 t -143.93 85.79 8.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.593 0.711 . . . . 70.2 111.101 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' PRO . . . . . 0.675 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.78 122.95 9.62 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.669 2.246 . . . . 74.2 112.335 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLN . . . . . 0.508 HE22 ' HA ' ' A' ' 126' ' ' GLU . 2.6 pm0 -70.55 153.09 43.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 72.42 110.901 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.84 -35.83 3.85 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.72 -0.752 . . . . 54.31 112.51 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.86 155.09 19.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.747 0.308 . . . . 73.44 111.112 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.678 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.9 mp0 -65.52 143.8 57.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 73.52 110.886 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ILE . . . . . 0.678 HD13 ' O ' ' A' ' 60' ' ' GLU . 6.6 mm -128.73 118.69 47.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 70.4 111.142 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' VAL . . . . . 0.756 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -107.77 90.06 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 53.53 111.156 179.882 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -65.08 142.03 58.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 70.3 110.884 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -132.63 99.77 4.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 64.52 110.92 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ILE . . . . . 0.697 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.3 mp -102.77 145.65 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 65.24 111.128 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.9 t -161.24 132.57 5.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 75.22 111.154 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' SER . . . . . 0.647 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -145.13 163.97 29.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.674 0.749 . . . . 72.41 110.905 -179.868 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 68' ' ' PRO . . . . . 0.605 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.1 Cg_endo -69.73 -56.36 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.701 2.268 . . . . 62.41 112.385 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -152.87 67.91 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 74.01 110.905 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.784 HG12 ' HB3' ' A' ' 116' ' ' GLN . 0.0 OUTLIER -158.3 134.86 2.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 65.34 111.138 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.02 143.75 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 52.41 111.072 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' HIS . . . . . 0.697 ' HB3' HG21 ' A' ' 65' ' ' ILE . 0.9 OUTLIER -108.75 -166.32 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.128 -0.487 . . . . 75.15 110.864 179.864 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.64 122.45 3.51 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.771 -0.728 . . . . 71.02 112.497 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' PHE . . . . . 0.452 ' CE2' HD11 ' A' ' 65' ' ' ILE . 0.3 OUTLIER -119.87 142.38 48.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.916 0.389 . . . . 62.42 110.898 -179.911 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -93.41 135.63 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.123 -0.489 . . . . 71.53 110.876 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.691 HG13 ' CE2' ' A' ' 103' ' ' TYR . 59.1 t -137.19 142.88 36.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 65.54 111.172 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -75.5 -176.31 3.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 62.03 110.871 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 87.47 -50.91 4.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.777 -0.725 . . . . 61.21 112.474 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.455 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -142.82 173.44 11.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 43.21 111.099 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ASN . . . . . 0.455 ' H ' HG22 ' A' ' 79' ' ' THR . 28.6 m120 -85.41 59.43 5.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 75.54 110.884 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ILE . . . . . 0.471 ' O ' HG23 ' A' ' 81' ' ' ILE . 6.4 tp -56.69 116.87 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 51.34 111.101 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.23 100.42 8.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 74.52 110.907 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.486 HG11 HG21 ' A' ' 93' ' ' VAL . 5.7 m -127.29 122.87 60.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 74.15 111.154 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -160.6 114.68 2.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 71.11 110.895 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.721 HG21 ' OG ' ' A' ' 91' ' ' SER . 96.7 t -140.36 145.09 26.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 64.31 111.158 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.22 156.65 89.56 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.609 0.719 . . . . 74.31 110.907 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 160.71 48.7 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.728 2.285 . . . . 64.24 112.347 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 97.84 -0.13 59.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 71.23 112.469 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -146.15 156.7 43.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.889 0.376 . . . . 73.34 110.862 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.43 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 1.6 p -105.7 108.75 25.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 54.52 111.128 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.721 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -80.22 164.77 22.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.882 -179.865 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 77.7 m -129.24 105.21 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 62.44 111.134 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.486 HG21 HG11 ' A' ' 83' ' ' VAL . 24.6 t -101.79 130.81 50.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.239 -0.437 . . . . 63.31 111.14 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -110.44 92.45 4.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 72.1 110.851 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.2 t80 -143.01 114.08 7.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 74.02 110.927 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.7 t -113.87 142.9 45.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 65.34 111.143 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.08 179.98 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 74.42 110.842 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -121.08 -12.77 8.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.922 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.9 mpp_? -149.05 162.03 30.45 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.564 0.697 . . . . 73.31 110.913 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 153.63 68.67 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.731 2.287 . . . . 75.14 112.313 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 157.18 131.12 1.3 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.725 -0.75 . . . . 71.12 112.435 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.432 ' CG ' HG23 ' A' ' 123' ' ' VAL . 23.0 mt-10 -101.75 138.76 38.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.865 0.364 . . . . 71.21 110.865 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' TYR . . . . . 0.691 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.3 OUTLIER -143.87 140.6 29.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.135 -0.484 . . . . 74.42 110.921 -179.898 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 46.3 mtm180 -144.89 72.79 1.34 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 73.22 110.895 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 55.8 mt -151.05 144.27 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.226 -0.443 . . . . 73.34 111.124 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.682 ' CD1' HD12 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -133.87 142.17 42.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 73.51 111.145 179.861 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 107' ' ' CYS . . . . . 0.465 ' N ' HD13 ' A' ' 106' ' ' ILE . 34.7 t -177.78 113.89 0.08 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 74.14 110.89 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 56.96 94.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 73.25 110.922 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -92.81 42.92 1.11 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 73.32 110.945 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 41.3 t80 70.05 -71.83 0.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 65.4 110.918 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 8.5 p -52.92 -39.49 62.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 73.43 110.889 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 138.73 103.11 0.58 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.724 -0.75 . . . . 43.23 112.474 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.682 HD12 ' CD1' ' A' ' 106' ' ' ILE . 1.4 tt -51.7 140.69 18.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.872 0.368 . . . . 71.35 110.962 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -131.72 -162.55 10.51 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.753 . . . . 51.34 112.447 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 62.0 m170 -96.25 164.59 12.6 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.735 0.303 . . . . 74.35 110.883 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLN . . . . . 0.784 ' HB3' HG12 ' A' ' 70' ' ' VAL . 60.5 mm-40 63.67 16.24 9.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 74.21 110.936 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -94.9 130.99 41.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 72.51 110.891 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -71.32 175.4 5.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 74.14 110.911 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 30.9 m-85 -90.5 167.39 12.62 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.432 . . . . 74.31 110.886 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -79.45 53.6 4.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.768 -0.73 . . . . 71.03 112.494 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.731 ' O ' HD13 ' A' ' 53' ' ' ILE . 86.5 m -75.0 112.45 11.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.784 0.326 . . . . 71.11 111.155 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ILE . . . . . 0.535 HG23 ' CG2' ' A' ' 55' ' ' VAL . 1.4 mp -153.34 136.51 7.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 43.54 111.102 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' VAL . . . . . 0.432 HG23 ' CG ' ' A' ' 102' ' ' GLU . 1.9 p -117.78 126.56 74.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 71.21 111.133 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 61.9 t -101.14 117.68 46.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 74.04 111.109 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.0 mmmt -93.59 137.54 32.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 72.21 110.907 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLU . . . . . 0.508 ' HA ' HE22 ' A' ' 57' ' ' GLN . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 64.15 110.924 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.428 ' O ' HG12 ' A' ' 90' ' ' VAL . 0.9 OUTLIER . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.869 0.366 . . . . 63.33 110.89 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.94 131.47 44.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 74.23 110.825 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.4 m -120.91 -177.18 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 73.42 111.124 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.43 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 25.1 p30 -143.42 156.7 60.43 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 74.04 110.874 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.43 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.9 Cg_endo -69.79 -3.08 11.3 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.655 2.237 . . . . 73.23 112.358 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.696 HG22 HG23 ' A' ' 15' ' ' THR . 12.4 m -46.76 -68.3 0.2 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.205 -0.452 . . . . 61.41 111.124 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.696 HG23 HG22 ' A' ' 14' ' ' THR . 24.4 p -150.02 26.07 0.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.451 . . . . 75.51 111.133 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.4 p -65.39 -29.1 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.26 -0.427 . . . . 75.23 111.102 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.9 ptt180 -102.53 -7.91 21.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 74.11 110.884 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.3 mt-30 -96.81 -37.67 10.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 63.55 110.914 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.84 133.68 41.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 71.32 110.877 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.11 -156.91 18.39 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.753 -0.737 . . . . 74.12 112.494 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -30.79 21.72 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.741 2.294 . . . . 62.34 112.333 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.788 ' HB3' HD13 ' A' ' 42' ' ' LEU . 13.5 m-90 -85.95 -12.53 50.24 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 61.22 110.922 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.62 -58.98 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 64.41 111.095 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.89 146.5 34.24 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.593 0.711 . . . . 75.12 110.867 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -14.17 35.62 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.664 2.243 . . . . 71.55 112.349 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.13 -24.43 59.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 73.02 111.056 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 mm-40 -86.34 5.01 36.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 64.44 110.87 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.39 -76.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.43 111.085 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 12.3 t -89.71 115.6 29.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 71.21 111.144 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.34 119.02 4.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 75.41 111.138 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.427 HE22 ' N ' ' A' ' 36' ' ' GLN . 11.9 tp60 -68.06 123.37 20.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 70.54 110.876 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.4 p -120.18 -11.55 9.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 74.55 111.111 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.9 -169.33 12.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 75.4 112.517 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.65 18.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.682 2.255 . . . . 75.23 112.395 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.5 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 55.2 t30 -155.69 28.61 0.38 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 74.23 110.884 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.427 ' N ' HE22 ' A' ' 31' ' ' GLN . 1.5 pt20 -126.99 119.42 26.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.494 . . . . 73.31 110.9 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -96.32 140.23 31.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 74.21 110.961 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.683 ' HA ' HG23 ' A' ' 62' ' ' VAL . 85.9 m -93.76 115.02 27.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 70.33 111.173 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.3 t -102.24 139.06 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 63.02 111.124 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -120.49 140.85 50.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 61.54 110.924 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.509 HG22 ' CG1' ' A' ' 53' ' ' ILE . 99.1 t -138.3 136.06 44.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.486 . . . . 73.54 111.106 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.788 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -137.91 140.71 40.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 74.22 110.95 179.92 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.27 102.97 2.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 71.54 111.083 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 3.3 p90 -112.01 156.71 21.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 72.24 110.894 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.13 7.79 23.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.137 -0.483 . . . . 55.25 111.092 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -103.17 82.9 2.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 74.12 110.929 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 100.28 -135.04 11.93 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.739 . . . . 52.23 112.498 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -154.61 150.22 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.799 0.333 . . . . 73.41 110.954 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 2.9 pm0 -154.07 155.02 30.71 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.648 0.737 . . . . 53.32 110.874 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.81 4.2 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.676 2.25 . . . . 75.3 112.382 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.742 ' O ' HD12 ' A' ' 53' ' ' ILE . 2.1 m120 -134.99 62.88 55.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.577 0.703 . . . . 73.34 110.873 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 76.58 1.14 Allowed 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.661 2.241 . . . . 64.34 112.351 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.742 HD12 ' O ' ' A' ' 51' ' ' ASN . 3.9 mp -106.56 143.06 18.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 75.31 111.145 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -138.91 158.51 44.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 72.23 110.88 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.8 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -164.09 84.47 1.26 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.639 0.733 . . . . 52.21 111.143 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.676 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.72 121.93 8.62 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.675 2.25 . . . . 60.02 112.334 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -66.76 152.24 45.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.434 . . . . 72.0 110.9 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.0 -35.87 3.93 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.708 -0.758 . . . . 52.31 112.478 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.5 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -105.86 157.58 17.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.751 0.31 . . . . 74.12 111.114 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.715 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.3 mp0 -66.8 144.78 56.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 71.35 110.859 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.763 HG13 HG23 ' A' ' 55' ' ' VAL . 5.7 mm -130.56 124.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 62.33 111.195 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.683 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -113.73 90.24 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 73.31 111.133 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.59 ' HB2' HG12 ' A' ' 93' ' ' VAL . 64.1 m-85 -67.88 138.8 56.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 65.13 110.859 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.4 mttt -132.75 100.25 4.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 74.42 110.887 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.57 HD11 ' CE2' ' A' ' 74' ' ' PHE . 2.3 mp -106.87 141.63 21.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 71.25 111.151 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.2 t -154.67 138.02 15.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.183 -0.462 . . . . 73.13 111.14 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.411 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -142.8 159.58 56.36 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 74.03 110.854 -179.84 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.411 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.7 -51.68 0.38 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.678 2.252 . . . . 74.13 112.361 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -156.95 49.41 0.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 50.54 110.892 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.41 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.13 136.27 5.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 62.43 111.158 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 71.4 mt -86.21 142.53 12.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.186 -0.461 . . . . 71.11 111.115 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -118.3 -80.99 0.62 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.865 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 57.29 171.46 0.19 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.73 -0.748 . . . . 65.1 112.502 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.57 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.8 p90 -160.45 141.89 12.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.354 . . . . 63.0 110.927 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 7.1 t-80 -116.18 101.78 9.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 61.24 110.851 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.727 HG12 HG21 ' A' ' 81' ' ' ILE . 5.0 p -96.28 143.78 11.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 61.24 111.104 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -66.34 -172.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 72.11 110.938 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.89 -46.52 3.3 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.778 -0.725 . . . . 61.2 112.457 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.419 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.8 OUTLIER -146.7 165.68 28.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.751 0.31 . . . . 74.42 111.149 -179.82 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.419 ' H ' HG22 ' A' ' 79' ' ' THR . 2.0 m-80 -79.48 58.36 2.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 75.12 110.947 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.727 HG21 HG12 ' A' ' 76' ' ' VAL . 12.9 tt -66.35 115.09 3.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 63.41 111.118 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.7 91.05 3.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.01 110.863 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.43 ' CG1' HG21 ' A' ' 93' ' ' VAL . 7.0 m -118.11 120.48 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 75.44 111.103 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -160.9 117.34 2.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.02 110.924 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.498 HG21 ' OG ' ' A' ' 91' ' ' SER . 96.2 t -140.35 127.73 23.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 75.03 111.134 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.419 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -51.07 160.06 0.91 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.601 0.715 . . . . 63.42 110.921 179.972 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.419 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 54.0 Cg_endo -69.73 155.47 65.96 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.724 2.283 . . . . 71.41 112.353 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.65 10.7 46.33 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.797 -0.716 . . . . 64.35 112.513 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -164.69 119.2 1.37 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.871 0.367 . . . . 74.34 110.867 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.428 HG12 ' O ' ' A' ' 9' ' ' GLU . 2.9 p -68.69 133.73 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 63.25 111.141 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.498 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -94.39 168.9 10.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 54.25 110.876 -179.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 90.5 m -144.4 105.46 4.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 71.24 111.119 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.59 HG12 ' HB2' ' A' ' 63' ' ' PHE . 9.0 p -118.58 141.21 39.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 62.51 111.125 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -110.6 101.55 10.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 71.31 110.879 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -145.97 119.26 8.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.228 -0.442 . . . . 64.42 110.905 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.5 t -117.28 142.97 46.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.489 . . . . 71.13 111.181 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.0 -175.93 4.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 63.11 110.915 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 20.5 mtpt -126.21 -12.45 6.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.16 -0.473 . . . . 74.12 110.917 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -148.19 162.22 31.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.601 0.715 . . . . 75.5 110.908 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 156.9 62.23 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.69 2.26 . . . . 73.21 112.344 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.2 133.64 1.51 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.743 -0.742 . . . . 60.44 112.523 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -99.4 128.49 45.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 74.33 110.897 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -144.13 131.08 20.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 74.31 110.889 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 7.1 ptt180 -147.94 83.41 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 74.15 110.858 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.0 mt -151.01 145.03 16.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 73.14 111.155 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 71.41 111.131 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.568 ' HB ' HD13 ' A' ' 53' ' ' ILE . 43.1 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.814 0.34 . . . . 74.32 111.146 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.596 HG13 HG21 ' A' ' 53' ' ' ILE . 4.3 mp -144.92 141.55 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 75.34 111.123 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.493 ' O ' HG12 ' A' ' 55' ' ' VAL . 85.1 t -131.29 133.95 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 72.4 111.135 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.8 HG22 HG13 ' A' ' 55' ' ' VAL . 97.4 t -103.9 134.93 43.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 54.41 111.093 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -117.87 130.66 56.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 65.33 110.846 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 73.41 110.856 179.973 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.1 pt-20 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.851 0.358 . . . . 73.43 110.883 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -89.46 166.76 13.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 70.53 110.885 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 m -144.5 -179.31 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.459 . . . . 71.3 111.146 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -145.76 161.66 39.42 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.628 0.728 . . . . 65.0 110.904 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -4.47 14.09 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.687 2.258 . . . . 70.51 112.355 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.796 HG22 HG23 ' A' ' 15' ' ' THR . 33.9 m -48.47 -70.78 0.08 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 62.33 111.178 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.796 HG23 HG22 ' A' ' 14' ' ' THR . 30.5 p -150.92 35.26 0.6 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 72.03 111.17 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 14.0 p -69.56 -31.59 49.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 61.53 111.086 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.407 ' HB3' HD21 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -93.14 -5.09 51.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 75.52 110.889 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -104.53 -35.7 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 73.4 110.9 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -129.0 134.16 48.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 63.23 110.861 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.73 -160.3 13.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 64.21 112.5 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -26.27 27.71 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.746 2.297 . . . . 73.1 112.342 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 16.1 m-90 -87.17 -9.86 54.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.192 -0.458 . . . . 61.24 110.928 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.77 -59.46 2.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 54.15 111.134 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.62 144.38 28.5 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.605 0.717 . . . . 71.43 110.875 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -19.17 36.78 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.695 2.263 . . . . 72.3 112.39 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.75 -20.28 60.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 74.23 111.117 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mm-40 -87.28 6.82 31.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 73.32 110.868 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.43 -76.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 70.01 111.112 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.404 HG21 ' HB3' ' A' ' 54' ' ' GLU . 20.1 t -84.53 118.35 31.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 72.02 111.123 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.445 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 11.0 m -132.94 138.75 51.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 75.25 111.151 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.14 95.96 9.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 73.22 110.892 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.3 t -95.71 -35.82 11.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 65.31 111.163 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.79 -166.54 21.63 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.75 . . . . 62.13 112.507 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -44.93 1.77 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.677 2.251 . . . . 65.42 112.315 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -143.37 30.24 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 74.31 110.867 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -126.95 120.05 28.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 74.42 110.933 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -96.34 135.73 37.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 72.35 110.924 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.445 ' HB ' ' CG2' ' A' ' 30' ' ' VAL . 49.8 m -96.01 105.0 16.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.093 -0.503 . . . . 54.12 111.111 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -84.65 147.23 5.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 73.1 111.141 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -127.16 121.85 32.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 73.54 110.928 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.499 HG22 ' CG1' ' A' ' 53' ' ' ILE . 97.6 t -114.33 124.97 71.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 73.23 111.191 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.667 HD12 ' OE1' ' A' ' 49' ' ' GLN . 3.3 tm? -120.36 136.5 54.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 64.53 110.868 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.507 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -155.61 140.55 17.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 52.44 111.122 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -139.99 159.0 43.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 64.55 110.923 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.71 5.57 35.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 53.55 111.111 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -122.31 84.88 2.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 72.13 110.853 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.87 179.14 19.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.743 -0.742 . . . . 72.02 112.492 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -124.65 139.48 53.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.806 0.336 . . . . 63.2 110.922 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.667 ' OE1' HD12 ' A' ' 42' ' ' LEU . 5.4 mt-30 -142.17 162.09 47.24 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 73.2 110.875 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 179.9 3.37 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.675 2.25 . . . . 64.43 112.317 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.659 ' O ' HD12 ' A' ' 53' ' ' ILE . 4.6 m-80 -135.98 63.0 49.37 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.629 0.728 . . . . 63.33 110.909 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 73.77 1.32 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.643 2.229 . . . . 72.13 112.368 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.659 HD12 ' O ' ' A' ' 51' ' ' ASN . 4.5 mp -110.57 113.91 45.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.246 -0.434 . . . . 72.44 111.179 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.404 ' HB3' HG21 ' A' ' 29' ' ' VAL . 12.3 tt0 -110.07 135.43 50.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 74.41 110.908 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.857 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -138.9 81.76 21.58 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.665 0.745 . . . . 72.13 111.132 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.626 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.2 Cg_endo -69.71 129.01 16.9 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.731 2.287 . . . . 73.33 112.356 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.44 152.2 40.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 71.12 110.897 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.61 -35.61 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.758 -0.734 . . . . 52.51 112.474 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.0 155.93 18.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 71.44 111.127 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.696 ' O ' HD13 ' A' ' 61' ' ' ILE . 40.4 mt-10 -67.18 144.51 55.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 75.03 110.896 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.696 HD13 ' O ' ' A' ' 60' ' ' GLU . 6.4 mm -128.83 119.61 50.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.455 . . . . 73.35 111.137 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.822 HG13 HG23 ' A' ' 92' ' ' THR . 55.1 t -107.55 91.22 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 74.42 111.143 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.571 ' HB2' HG12 ' A' ' 93' ' ' VAL . 65.3 m-85 -70.37 137.25 50.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 61.12 110.864 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -129.55 100.88 5.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 74.21 110.839 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.732 ' CG2' HG11 ' A' ' 85' ' ' VAL . 1.8 mp -100.31 155.29 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 73.53 111.11 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.4 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.3 t -169.99 139.21 1.83 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.166 -0.47 . . . . 72.02 111.148 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.4 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -143.46 161.78 45.43 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.688 0.756 . . . . 73.4 110.857 -179.86 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.4 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.72 -54.09 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.69 2.26 . . . . 70.22 112.392 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -159.16 38.3 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 71.3 110.878 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -138.73 135.16 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 72.42 111.114 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.514 HD13 ' HD3' ' A' ' 87' ' ' PRO . 28.7 mm -88.02 142.89 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 73.33 111.133 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 21.5 p-80 -174.85 136.9 0.42 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 73.01 110.859 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -143.76 -149.62 5.12 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 62.34 112.494 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.468 ' CE2' HD11 ' A' ' 65' ' ' ILE . 7.9 p90 -159.29 138.19 11.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.923 0.392 . . . . 51.12 110.925 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 41.6 t60 -128.34 98.83 5.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 71.34 110.858 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.704 HG12 HG21 ' A' ' 81' ' ' ILE . 6.6 p -80.58 144.61 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 63.14 111.111 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.3 pm0 -67.77 -175.44 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 62.12 110.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.54 -51.1 4.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.715 -0.755 . . . . 74.13 112.474 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.7 m -131.46 153.34 49.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.321 . . . . 62.41 111.174 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.462 ' H ' ' ND2' ' A' ' 80' ' ' ASN . 2.5 p30 -76.0 66.08 2.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 71.14 110.89 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.704 HG21 HG12 ' A' ' 76' ' ' VAL . 12.5 tt -77.57 113.11 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 70.32 111.09 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.03 98.35 6.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 52.01 110.885 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.9 m -121.25 120.31 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.158 -0.474 . . . . 72.22 111.15 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -125.09 96.02 4.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 62.54 110.885 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.732 HG11 ' CG2' ' A' ' 65' ' ' ILE . 5.8 p -86.83 144.37 9.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 63.01 111.072 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 6.1 mp -111.05 156.62 40.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.6 0.714 . . . . 72.31 110.935 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.514 ' HD3' HD13 ' A' ' 71' ' ' ILE . 54.1 Cg_endo -69.71 146.96 62.13 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.254 . . . . 74.42 112.365 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.22 8.96 86.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.734 -0.746 . . . . 20.31 112.467 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -146.69 173.61 12.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.918 0.39 . . . . 71.41 110.893 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 18.5 t -120.92 146.21 26.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 70.23 111.155 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.416 ' OG ' HD12 ' A' ' 65' ' ' ILE . 1.5 p -109.84 158.51 18.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 72.34 110.87 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.822 HG23 HG13 ' A' ' 62' ' ' VAL . 53.2 m -145.87 105.46 3.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.474 . . . . 63.33 111.128 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.571 HG12 ' HB2' ' A' ' 63' ' ' PHE . 7.6 p -123.11 136.23 60.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 71.14 111.143 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.2 mtm180 -105.86 92.47 4.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 74.12 110.827 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -134.66 115.17 13.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.452 . . . . 73.2 110.939 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 t -116.19 142.93 46.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 73.11 111.149 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.95 178.85 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 71.35 110.863 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.34 -21.94 7.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.118 -0.492 . . . . 72.55 110.912 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.97 158.3 74.15 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.592 0.71 . . . . 73.12 110.887 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 149.44 66.86 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.678 2.252 . . . . 74.2 112.363 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.87 156.67 9.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.752 . . . . 54.52 112.457 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.616 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -114.54 132.2 56.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.847 0.356 . . . . 63.24 110.868 -179.874 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -143.62 146.41 33.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.158 -0.473 . . . . 55.41 110.923 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.949 ' O ' HG22 ' A' ' 105' ' ' ILE . 13.9 ptt-85 -164.9 -164.58 0.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 74.32 110.863 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.949 HG22 ' O ' ' A' ' 104' ' ' ARG . 7.3 tt 58.2 158.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 61.32 111.118 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 61.14 111.16 179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.644 ' O ' HD13 ' A' ' 53' ' ' ILE . 96.2 m . . . . . 0 C--O 1.232 0.165 0 CA-C-O 120.791 0.329 . . . . 75.13 111.166 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.511 HG13 HG21 ' A' ' 53' ' ' ILE . 2.5 mp -140.25 132.92 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 65.14 111.069 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.616 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -134.3 141.13 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 73.0 111.093 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.857 HG22 HG13 ' A' ' 55' ' ' VAL . 62.1 t -103.75 130.73 53.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 61.11 111.138 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -104.1 128.72 51.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 70.24 110.917 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 116.23 -0.441 . . . . 75.42 110.853 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 3.8 pm0 . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.815 0.341 . . . . 75.33 110.892 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.43 142.67 28.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 62.45 110.848 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.568 HG13 HG23 ' A' ' 90' ' ' VAL . 16.4 m -118.46 -176.64 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.167 -0.469 . . . . 65.52 111.106 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.444 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 16.5 p30 -142.92 157.39 61.22 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.605 0.717 . . . . 54.52 110.887 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 54.0 Cg_endo -69.77 -3.06 11.25 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.646 2.23 . . . . 75.41 112.379 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.82 HG22 HG23 ' A' ' 15' ' ' THR . 25.2 m -46.58 -69.98 0.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.452 . . . . 75.51 111.165 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.82 HG23 HG22 ' A' ' 14' ' ' THR . 25.9 p -149.71 24.83 0.86 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 65.43 111.165 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.2 p -63.68 -30.97 51.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 74.31 111.133 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.487 ' NH1' HD21 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -103.28 -5.38 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 74.44 110.879 -179.973 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 83.7 mm-40 -92.24 -37.42 12.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 71.11 110.942 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -141.89 133.42 26.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 72.3 110.898 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 126.97 -155.09 19.62 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.7 -0.762 . . . . 72.34 112.502 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.95 17.5 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.683 2.256 . . . . 72.45 112.351 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.442 ' HB3' HD23 ' A' ' 42' ' ' LEU . 12.2 m-90 -84.61 -13.98 50.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 73.32 110.916 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.78 -49.18 75.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.082 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -114.07 144.39 31.51 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.608 0.718 . . . . 75.14 110.862 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 -25.7 28.06 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.662 2.242 . . . . 61.43 112.318 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.22 -6.75 49.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 74.15 111.098 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 24.0 mm-40 -102.47 9.67 39.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 72.44 110.881 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.92 -79.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 62.22 111.146 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.572 HG23 ' HB3' ' A' ' 37' ' ' TYR . 1.5 p -84.98 124.34 39.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 53.21 111.12 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.5 m -135.29 136.01 51.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 63.25 111.124 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -75.57 107.2 7.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 52.05 110.893 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 9.7 t -111.94 -32.95 6.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.218 -0.446 . . . . 55.02 111.141 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.76 -172.68 19.86 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.756 -0.735 . . . . 34.11 112.504 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -43.8 2.45 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.687 2.258 . . . . 73.23 112.357 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -140.96 35.27 1.75 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 64.31 110.876 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.35 119.09 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 60.03 110.889 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.572 ' HB3' HG23 ' A' ' 29' ' ' VAL . 15.2 m-85 -96.79 137.34 36.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 71.42 110.95 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.741 ' HA ' HG23 ' A' ' 62' ' ' VAL . 81.2 m -95.74 105.71 17.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 73.45 111.147 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.463 ' HA ' ' HA ' ' A' ' 29' ' ' VAL . 9.9 t -92.66 138.52 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 64.13 111.12 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -120.75 114.82 22.2 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.191 -0.459 . . . . 72.32 110.951 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.485 HG22 HG13 ' A' ' 53' ' ' ILE . 64.4 t -104.14 130.79 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.14 -0.482 . . . . 73.15 111.102 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.487 HD21 ' NH1' ' A' ' 17' ' ' ARG . 1.7 tm? -125.07 121.52 34.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.47 . . . . 71.12 110.896 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -142.89 137.57 29.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.446 . . . . 62.43 111.088 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -145.52 159.94 42.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 74.04 110.858 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.82 5.55 32.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 54.33 111.108 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -110.26 70.59 0.73 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.45 110.831 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.07 -170.09 16.23 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.684 -0.77 . . . . 55.55 112.415 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.23 126.51 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.795 0.331 . . . . 72.41 110.929 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.46 ' HB3' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -136.42 161.0 64.62 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.567 0.699 . . . . 73.45 110.961 179.974 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.46 ' HD2' ' HB3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.76 178.68 4.32 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.707 2.271 . . . . 70.43 112.338 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.708 ' O ' HD12 ' A' ' 53' ' ' ILE . 1.1 m-80 -129.93 62.78 65.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.646 0.736 . . . . 64.5 110.905 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 75.56 1.23 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.657 2.238 . . . . 71.23 112.314 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.753 HD13 ' O ' ' A' ' 121' ' ' THR . 4.4 mp -106.89 98.18 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 64.11 111.133 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -82.14 129.6 34.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 61.41 110.889 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.69 ' O ' HG13 ' A' ' 124' ' ' VAL . 30.7 t -137.01 81.31 33.35 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.633 0.73 . . . . 75.1 111.118 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.596 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.8 123.05 9.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.702 2.268 . . . . 72.34 112.355 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.29 155.18 40.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 71.45 110.933 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.36 -4.39 77.59 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.749 -0.739 . . . . 60.13 112.503 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.05 152.46 51.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.71 0.29 . . . . 75.1 111.129 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.68 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.0 mp0 -66.66 139.37 57.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.265 -0.425 . . . . 64.43 110.887 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.68 HD13 ' O ' ' A' ' 60' ' ' GLU . 7.2 mm -127.41 116.33 43.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.198 -0.456 . . . . 64.14 111.123 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -104.44 90.59 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 71.21 111.108 179.87 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -68.42 139.7 55.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 75.13 110.883 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -131.97 100.57 5.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 64.11 110.913 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.8 mp -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 73.32 111.122 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.1 t -168.44 140.49 2.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.135 -0.484 . . . . 72.4 111.137 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.451 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -149.52 161.14 32.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.705 0.764 . . . . 75.45 110.861 -179.883 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.424 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.78 -55.46 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 42.12 112.322 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -156.96 61.97 0.51 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 63.25 110.85 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.451 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.84 135.44 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 61.32 111.163 179.955 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 36.4 mm -69.81 130.5 34.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 64.11 111.128 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.66 ' HE2' HG23 ' A' ' 85' ' ' VAL . 9.2 p-80 -119.98 -175.79 3.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.236 -0.438 . . . . 51.22 110.885 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 170.9 12.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 33.22 112.502 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.5 p90 -153.23 141.25 20.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.845 0.355 . . . . 75.15 110.918 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 76.2 t60 -122.1 104.38 9.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 73.11 110.878 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.686 HG12 HG21 ' A' ' 81' ' ' ILE . 3.5 p -94.3 137.86 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 74.44 111.143 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -59.96 -175.98 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 61.41 110.904 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.13 -50.97 4.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 44.41 112.45 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.464 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -129.26 171.71 12.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.773 0.321 . . . . 73.22 111.111 -179.816 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.464 ' H ' HG22 ' A' ' 79' ' ' THR . 3.2 m-80 -93.17 47.61 1.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 73.44 110.852 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.686 HG21 HG12 ' A' ' 76' ' ' VAL . 12.5 tt -58.54 112.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 60.34 111.172 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.34 94.16 4.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 74.53 110.923 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.421 HG11 ' CG1' ' A' ' 93' ' ' VAL . 3.3 m -117.97 120.35 64.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 54.11 111.096 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -150.28 118.46 6.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 74.32 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.851 HG21 ' HB2' ' A' ' 91' ' ' SER . 5.0 m -140.73 146.88 23.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.155 -0.475 . . . . 73.32 111.14 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.27 161.94 75.5 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.554 0.692 . . . . 75.42 110.969 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 159.65 52.61 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.25 . . . . 72.11 112.309 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 86.4 13.28 68.36 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.749 -0.739 . . . . 74.42 112.493 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -146.21 138.43 25.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.903 0.383 . . . . 71.23 110.892 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.568 HG23 HG13 ' A' ' 11' ' ' VAL . 99.5 t -90.93 105.89 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 53.03 111.153 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.851 ' HB2' HG21 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -89.31 137.67 32.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 73.3 110.855 -179.839 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 92.9 m -110.01 105.51 14.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 74.23 111.172 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.421 ' CG1' HG11 ' A' ' 83' ' ' VAL . 44.7 t -98.19 147.95 6.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 71.54 111.104 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.61 110.93 15.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 70.21 110.882 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -156.68 122.64 4.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 72.05 110.887 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.8 t -123.39 135.55 54.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 64.43 111.152 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.79 -174.22 3.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 65.24 110.871 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -121.9 -26.4 4.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 72.11 110.915 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.1 mpp_? -134.51 161.41 63.89 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 70.04 110.88 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 154.22 67.89 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.652 2.235 . . . . 63.32 112.371 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.58 134.4 1.65 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.755 -0.736 . . . . 32.23 112.485 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.743 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -100.69 139.49 36.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 74.31 110.892 -179.883 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -143.82 132.82 22.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 74.24 110.915 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.36 94.07 2.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 61.13 110.86 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.8 tt -177.63 131.55 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 75.34 111.17 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 64.33 111.093 179.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.753 ' O ' HD13 ' A' ' 53' ' ' ILE . 6.7 m . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.826 0.346 . . . . 64.42 111.127 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.444 ' CG2' HG21 ' A' ' 55' ' ' VAL . 2.1 mp -149.14 139.12 16.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 74.34 111.177 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.743 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.5 p -127.5 135.92 61.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 64.32 111.182 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 55' ' ' VAL . 41.3 t -104.48 127.65 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 74.21 111.103 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 12.4 mmmm -102.22 133.6 46.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 70.21 110.872 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 75.21 110.919 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.822 0.344 . . . . 64.21 110.891 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 166.56 10.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 75.35 110.884 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.8 m -144.41 -179.09 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 71.35 111.074 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.68 162.04 40.66 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.603 0.716 . . . . 62.23 110.902 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -3.67 12.49 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.676 2.251 . . . . 65.45 112.331 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 28.0 m -46.09 -70.44 0.1 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.239 -0.437 . . . . 63.21 111.17 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 28.3 p -150.05 27.59 0.77 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 64.4 111.157 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.2 p -65.22 -30.77 51.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 73.22 111.13 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.428 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.7 OUTLIER -100.74 -15.74 17.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.148 -0.478 . . . . 63.33 110.863 -179.95 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -88.45 -33.04 17.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 61.04 110.898 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -141.35 135.12 30.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 73.03 110.913 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.44 -160.69 19.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.753 -0.737 . . . . 72.1 112.492 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -25.8 28.21 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.265 . . . . 53.24 112.343 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.733 ' HB3' HD13 ' A' ' 42' ' ' LEU . 14.5 m-90 -87.07 -12.6 46.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 75.32 110.95 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.86 -59.43 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.451 . . . . 73.43 111.093 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.42 144.55 28.45 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.556 0.693 . . . . 71.44 110.879 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -27.75 26.37 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.689 2.26 . . . . 75.41 112.359 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.41 -18.38 60.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 72.32 111.094 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 -87.82 7.64 29.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 70.14 110.939 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.14 -78.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 64.35 111.112 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 39' ' ' VAL . 1.8 p -93.1 124.93 45.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 74.23 111.113 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.2 m -119.67 149.86 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 64.43 111.108 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.65 121.99 27.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 72.21 110.963 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.462 HG21 ' OG1' ' A' ' 38' ' ' THR . 0.6 OUTLIER -121.91 -42.6 2.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 73.1 111.122 -179.881 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.47 170.65 13.81 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 61.5 112.488 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.695 2.264 . . . . 72.43 112.31 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -156.29 34.34 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 64.52 110.908 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -154.0 155.64 35.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.128 -0.487 . . . . 74.33 110.898 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -143.05 147.99 35.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 72.34 110.913 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.462 ' OG1' HG21 ' A' ' 32' ' ' THR . 52.0 m -101.37 104.22 15.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 72.53 111.127 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.573 HG11 HG23 ' A' ' 53' ' ' ILE . 6.7 t -85.18 135.13 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 72.44 111.137 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -117.12 121.66 41.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.18 -0.464 . . . . 72.41 110.933 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.0 m -122.73 143.9 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 55.44 111.131 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.733 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -138.69 143.85 39.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.479 . . . . 62.23 110.889 179.993 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -149.54 123.52 9.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 73.14 111.129 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -121.41 154.47 36.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 62.45 110.814 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.84 6.87 33.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 54.42 111.074 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -122.37 86.07 2.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 75.43 110.906 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.91 -165.92 12.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.755 -0.736 . . . . 62.34 112.54 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -136.3 143.43 44.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.842 0.353 . . . . 74.03 110.893 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.417 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.7 pm0 -145.37 155.59 53.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 72.13 110.901 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.417 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.9 Cg_endo -69.75 174.45 9.48 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.253 . . . . 63.31 112.35 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.73 ' O ' HD12 ' A' ' 53' ' ' ILE . 2.1 m-20 -127.99 62.37 56.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.631 0.729 . . . . 72.23 110.869 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 74.43 1.26 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.655 2.237 . . . . 73.1 112.343 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.73 HD12 ' O ' ' A' ' 51' ' ' ASN . 3.9 mp -110.58 113.89 45.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 54.43 111.154 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -108.59 119.47 39.61 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.491 . . . . 72.13 110.908 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.848 HG23 HG13 ' A' ' 61' ' ' ILE . 2.1 p -124.77 85.71 56.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.61 0.719 . . . . 74.14 111.125 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.619 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.4 Cg_endo -69.76 122.57 9.25 Favored 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 122.673 2.249 . . . . 72.31 112.347 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.57 150.45 48.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 64.01 110.881 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.81 -30.46 5.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 52.23 112.507 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.83 152.12 23.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.736 0.303 . . . . 54.21 111.119 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.63 ' O ' HD13 ' A' ' 61' ' ' ILE . 0.4 OUTLIER -68.82 142.36 54.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.456 . . . . 75.11 110.861 -179.897 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.848 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -126.87 124.16 64.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 62.11 111.106 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 1.042 HG13 HG23 ' A' ' 92' ' ' THR . 55.0 t -107.92 91.25 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 71.11 111.173 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -69.48 135.02 49.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 65.31 110.887 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -131.43 100.44 5.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 62.13 110.865 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.775 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.5 mp -97.17 156.07 3.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.264 -0.426 . . . . 73.12 111.098 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.607 HG23 HD12 ' A' ' 42' ' ' LEU . 7.2 t -166.01 137.9 3.86 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 43.44 111.141 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.639 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -152.21 159.76 32.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.646 0.736 . . . . 71.14 110.912 -179.876 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.76 -53.98 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.665 2.243 . . . . 71.21 112.403 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -154.88 65.84 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 73.24 110.864 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.639 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.4 135.55 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 74.32 111.126 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.2 mm -66.9 145.54 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 75.31 111.107 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.775 ' HB3' HG21 ' A' ' 65' ' ' ILE . 0.3 OUTLIER -108.75 -167.05 1.17 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 74.45 110.834 179.85 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.84 120.73 3.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 41.12 112.513 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -121.16 142.84 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.904 0.383 . . . . 74.54 110.9 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -89.14 137.19 32.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 73.11 110.872 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.741 HG13 ' CE2' ' A' ' 103' ' ' TYR . 94.8 t -130.03 141.47 46.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 62.42 111.161 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.6 mt-10 -75.26 175.67 8.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 64.11 110.878 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.06 -51.65 4.14 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.676 -0.773 . . . . 64.34 112.514 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.25 147.24 51.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 74.11 111.156 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -76.71 64.57 2.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 65.55 110.881 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.767 HD12 ' CD2' ' A' ' 95' ' ' TYR . 8.0 tt -58.23 125.94 15.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 73.2 111.176 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.7 89.67 3.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.853 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.575 HG11 HG21 ' A' ' 93' ' ' VAL . 3.7 m -115.87 120.65 65.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 73.42 111.158 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -155.79 114.51 3.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 72.12 110.838 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.652 HG21 ' OG ' ' A' ' 91' ' ' SER . 61.6 t -140.46 146.71 24.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 74.15 111.138 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.433 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.6 OUTLIER -69.69 155.68 93.06 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.585 0.707 . . . . 63.03 110.902 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.433 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 54.1 Cg_endo -69.74 159.8 52.09 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.234 . . . . 71.1 112.379 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.21 17.25 51.31 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.761 -0.733 . . . . 64.11 112.493 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -156.26 155.77 32.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.88 0.371 . . . . 73.13 110.886 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.4 HG21 ' HH2' ' A' ' 22' ' ' TRP . 98.2 t -104.85 109.78 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 55.31 111.123 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.652 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.4 OUTLIER -83.83 169.46 15.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 73.11 110.879 -179.856 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 1.042 HG23 HG13 ' A' ' 62' ' ' VAL . 98.3 m -137.99 122.22 18.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.144 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.575 HG21 HG11 ' A' ' 83' ' ' VAL . 21.3 t -124.57 130.6 73.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 71.02 111.155 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.7 mmm180 -102.57 70.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 70.24 110.9 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.767 ' CD2' HD12 ' A' ' 81' ' ' ILE . 14.8 t80 -110.13 130.73 55.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.153 -0.476 . . . . 72.25 110.931 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.1 t -139.64 142.25 37.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.475 . . . . 63.02 111.133 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -97.0 -175.49 3.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 73.25 110.861 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.1 mttt -125.34 -12.52 6.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 35.13 110.899 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -145.81 162.14 37.24 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.557 0.694 . . . . 70.22 110.865 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 154.0 68.21 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.679 2.253 . . . . 61.03 112.347 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.45 141.17 3.05 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.727 -0.749 . . . . 23.23 112.483 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -106.59 130.14 54.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.808 0.337 . . . . 60.42 110.905 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . 0.741 ' CE2' HG13 ' A' ' 76' ' ' VAL . 4.3 p90 -144.04 146.32 32.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 73.01 110.922 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.494 ' HG2' HD12 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -155.17 -175.76 5.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 74.21 110.848 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.494 HD12 ' HG2' ' A' ' 104' ' ' ARG . 1.9 mp 65.62 150.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 72.41 111.195 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 55.31 111.167 179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.722 ' O ' HD13 ' A' ' 53' ' ' ILE . 67.9 m . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.74 0.305 . . . . 73.54 111.164 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.446 ' CG2' HG11 ' A' ' 55' ' ' VAL . 2.8 mp -147.36 140.72 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 72.25 111.123 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 55' ' ' VAL . 50.2 t -128.41 129.28 68.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 35.51 111.116 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.776 HG22 HG13 ' A' ' 55' ' ' VAL . 87.9 t -103.59 136.86 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 75.35 111.082 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.3 mmmt -113.83 131.78 56.12 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 72.25 110.902 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 73.34 110.874 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.874 0.369 . . . . 62.12 110.859 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.64 166.78 13.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 61.11 110.85 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 16' ' ' VAL . 35.9 m -150.02 140.6 16.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.178 -0.465 . . . . 62.11 111.104 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.1 162.84 19.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.578 0.704 . . . . 72.03 110.855 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.96 9.33 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.651 2.234 . . . . 60.1 112.384 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.464 HG22 HG23 ' A' ' 15' ' ' THR . 3.2 m -46.24 -67.43 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.207 -0.451 . . . . 74.13 111.168 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.464 HG23 HG22 ' A' ' 14' ' ' THR . 26.8 p -146.67 13.86 1.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 71.32 111.138 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 11' ' ' VAL . 12.6 p -50.64 -31.93 9.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 111.136 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.14 -17.41 14.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 74.32 110.883 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 22.1 mm100 -79.62 -31.21 41.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 74.44 110.94 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -149.24 140.48 23.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.231 -0.441 . . . . 72.31 110.884 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.19 -157.16 17.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.691 -0.766 . . . . 73.21 112.46 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 -30.6 22.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 50.21 112.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 14.9 m-90 -87.21 -7.48 57.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.226 -0.443 . . . . 62.15 110.921 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.29 -60.08 2.51 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 74.53 111.054 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.56 142.59 29.57 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.577 0.703 . . . . 75.32 110.916 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -28.38 25.07 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.666 2.244 . . . . 65.01 112.347 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.18 -11.69 60.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 73.03 111.115 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.5 mm-40 -95.35 24.71 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 74.31 110.935 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.503 ' HB2' ' HB2' ' A' ' 52' ' ' PRO . . . -56.58 -79.58 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 74.51 111.067 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.507 HG11 ' HB3' ' A' ' 54' ' ' GLU . 1.8 p -106.86 141.01 23.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 72.02 111.153 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 m -128.1 150.16 33.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 74.13 111.164 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.1 118.79 29.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 72.33 110.925 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.9 t -121.06 -21.06 6.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 63.33 111.148 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.29 168.38 20.19 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 54.21 112.5 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.25 20.57 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.652 2.235 . . . . 65.22 112.33 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.507 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 18.0 t30 -159.33 23.25 0.19 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.445 . . . . 60.35 110.874 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -138.87 153.97 48.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 71.43 110.865 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -141.97 142.15 32.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 72.23 110.966 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.2 m -95.74 104.55 16.48 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.115 -0.493 . . . . 75.41 111.144 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 t -84.5 140.06 16.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 74.5 111.156 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.29 122.76 39.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 72.14 110.918 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.618 HG12 HD12 ' A' ' 53' ' ' ILE . 16.6 m -118.73 123.26 71.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.11 -0.495 . . . . 71.03 111.113 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.685 HD11 ' CD2' ' A' ' 44' ' ' PHE . 3.0 tm? -115.88 132.88 56.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 71.15 110.894 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.507 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -155.44 114.47 3.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 52.33 111.087 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.685 ' CD2' HD11 ' A' ' 42' ' ' LEU . 5.9 p90 -129.36 152.09 49.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 42.02 110.878 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.421 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -85.14 1.77 46.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.09 -0.504 . . . . 53.44 111.145 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -95.83 72.0 3.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 73.24 110.868 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.21 -150.88 17.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.754 -0.736 . . . . 73.43 112.471 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 p90 -136.37 150.93 49.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.36 . . . . 65.15 110.907 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -162.09 162.06 20.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.591 0.71 . . . . 73.51 110.904 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 157.36 60.63 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.281 . . . . 74.44 112.35 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -133.09 66.69 76.32 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.644 0.735 . . . . 62.34 110.877 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.503 ' HB2' ' HB2' ' A' ' 28' ' ' ALA . 53.8 Cg_endo -69.83 114.03 3.58 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.676 2.251 . . . . 73.33 112.367 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.618 HD12 HG12 ' A' ' 41' ' ' VAL . 1.5 mm -117.21 151.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 61.53 111.136 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.507 ' HB3' HG11 ' A' ' 29' ' ' VAL . 13.2 tt0 -155.25 120.62 4.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 71.3 110.929 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.923 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -139.7 82.03 18.75 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.651 0.739 . . . . 74.31 111.131 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.8 Cg_endo -69.81 123.67 10.31 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.698 2.266 . . . . 74.32 112.349 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.23 155.11 40.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 72.32 110.96 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.41 -8.73 73.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 72.01 112.469 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.507 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -133.02 155.77 48.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 61.21 111.115 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.717 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.2 mt-10 -66.75 141.37 57.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 70.51 110.857 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.748 HG13 HG23 ' A' ' 55' ' ' VAL . 5.7 mm -130.14 119.18 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 54.12 111.106 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.553 HG13 ' OG1' ' A' ' 92' ' ' THR . 54.8 t -102.28 98.42 6.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 71.51 111.129 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.5 ' HB2' HG12 ' A' ' 93' ' ' VAL . 72.0 m-85 -76.97 126.34 30.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 75.42 110.851 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.9 mttt -120.32 100.09 6.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 63.32 110.911 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.474 ' HA ' HG23 ' A' ' 41' ' ' VAL . 1.8 mt -98.22 153.21 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 72.33 111.111 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 13.4 t -171.35 145.97 2.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 74.03 111.185 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.448 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -153.29 159.62 31.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.678 0.751 . . . . 74.03 110.854 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.438 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.76 -54.83 0.2 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.73 2.287 . . . . 63.1 112.325 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -156.53 60.55 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.238 -0.437 . . . . 72.43 110.884 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.448 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.29 136.35 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.459 . . . . 64.11 111.136 179.995 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 41.4 mm -67.08 144.2 14.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 65.53 111.09 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -136.98 158.11 45.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 74.02 110.827 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.71 129.83 1.11 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.779 -0.724 . . . . 71.14 112.515 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.0 p90 -117.47 141.93 47.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 74.23 110.862 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -112.1 90.74 3.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 75.42 110.846 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.722 ' HB ' HG21 ' A' ' 81' ' ' ILE . 27.6 t -73.36 145.53 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 74.22 111.115 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -75.66 -175.56 2.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 71.41 110.858 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.91 -51.38 4.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 55.24 112.437 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.45 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -132.41 179.28 6.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.777 0.322 . . . . 71.25 111.161 -179.846 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.45 ' H ' HG22 ' A' ' 79' ' ' THR . 11.2 m-80 -90.19 48.01 1.51 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 63.22 110.868 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.722 HG21 ' HB ' ' A' ' 76' ' ' VAL . 3.3 tp -63.14 111.0 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 64.43 111.139 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.87 122.73 46.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 64.43 110.852 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.2 m -143.51 120.1 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 34.3 111.126 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -159.25 112.59 2.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 43.21 110.888 179.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 23.5 t -140.5 144.28 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 73.05 111.142 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 1.4 mp -61.53 161.11 21.16 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.591 0.71 . . . . 54.53 110.919 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 159.53 53.11 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.667 2.245 . . . . 45.33 112.347 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.23 10.88 60.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.718 -0.753 . . . . 75.44 112.492 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -152.6 159.39 43.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.862 0.363 . . . . 74.35 110.869 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 95.7 t -98.43 143.34 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 62.44 111.138 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 7.3 p -121.3 97.24 5.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 61.22 110.899 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.553 ' OG1' HG13 ' A' ' 62' ' ' VAL . 1.2 t -85.63 141.33 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.116 -0.493 . . . . 54.51 111.167 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.5 HG12 ' HB2' ' A' ' 63' ' ' PHE . 12.6 p -154.24 150.3 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 72.44 111.136 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -109.6 116.4 31.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 62.33 110.894 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -151.45 114.96 4.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 74.3 110.945 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.6 t -116.55 136.24 53.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.14 -0.482 . . . . 62.02 111.123 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -87.06 -172.47 3.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 74.33 110.922 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.1 tttt -123.19 -26.14 4.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 61.34 110.909 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -140.71 162.06 50.97 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.708 . . . . 74.42 110.871 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 150.72 68.57 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 72.12 112.345 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.09 143.85 3.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.733 -0.746 . . . . 73.23 112.506 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.743 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -108.82 134.53 51.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.84 0.352 . . . . 73.52 110.906 -179.883 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . 0.604 ' CE2' HG13 ' A' ' 76' ' ' VAL . 2.1 p90 -143.54 131.53 21.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 73.15 110.933 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.39 111.27 5.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.08 -0.509 . . . . 74.51 110.867 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.0 tp -178.61 142.95 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 74.23 111.098 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.437 HG23 ' O ' ' A' ' 106' ' ' ILE . 17.7 tt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 42.05 111.11 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.609 HG23 HG13 ' A' ' 53' ' ' ILE . 15.1 t . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.714 0.293 . . . . 53.13 111.21 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.582 HD12 ' C ' ' A' ' 121' ' ' THR . 3.3 mp -153.1 134.27 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.243 -0.435 . . . . 72.2 111.11 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.743 HG23 ' HB3' ' A' ' 102' ' ' GLU . 8.6 p -126.23 137.61 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 73.14 111.139 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.923 HG22 HG13 ' A' ' 55' ' ' VAL . 47.3 t -108.14 141.97 22.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 34.44 111.134 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.8 mmtt -116.33 132.42 56.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 75.43 110.937 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 71.41 110.875 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.477 ' O ' HG12 ' A' ' 90' ' ' VAL . 2.1 pt-20 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.839 0.352 . . . . 72.34 110.892 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -93.1 135.38 34.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 64.22 110.85 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.447 HG21 HG21 ' A' ' 16' ' ' VAL . 7.8 m -115.01 -179.22 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 60.52 111.133 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -147.04 162.63 32.22 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 71.34 110.867 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -4.33 13.79 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.677 2.251 . . . . 71.41 112.367 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.411 ' O ' HG23 ' A' ' 15' ' ' THR . 5.4 m -48.75 -66.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.24 -0.436 . . . . 75.5 111.112 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 14' ' ' THR . 3.2 p -155.59 37.35 0.37 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 71.42 111.149 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.447 HG21 HG21 ' A' ' 11' ' ' VAL . 8.4 p -77.19 -27.52 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.214 -0.448 . . . . 73.32 111.137 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 20.4 ptt85 -104.28 -10.76 17.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 75.24 110.853 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -94.35 -36.96 11.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.453 . . . . 72.32 110.927 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.87 133.88 40.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 55.43 110.883 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.02 -157.18 19.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 45.25 112.507 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -30.06 22.79 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 72.53 112.36 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.777 ' HB3' HD13 ' A' ' 42' ' ' LEU . 14.0 m-90 -86.82 -10.89 52.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 74.32 110.926 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.66 -59.32 3.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 75.23 111.112 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.63 144.85 29.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.612 0.72 . . . . 71.44 110.868 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -17.24 37.75 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.665 2.243 . . . . 71.03 112.322 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -24.09 59.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 72.02 111.132 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.7 mm-40 -90.05 10.54 23.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 72.23 110.931 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -78.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 74.12 111.15 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.614 HG11 ' CB ' ' A' ' 54' ' ' GLU . 2.1 p -108.2 128.71 63.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 71.13 111.149 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.01 144.04 28.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 64.01 111.139 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.0 tp60 -75.48 121.45 22.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 73.31 110.905 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 t -119.95 -12.88 9.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 62.12 111.166 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.61 -167.66 12.15 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.751 -0.737 . . . . 72.32 112.496 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 -36.12 11.4 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 65.3 112.337 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -153.58 34.45 0.45 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 73.23 110.884 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.14 118.09 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 72.21 110.889 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -97.66 138.47 35.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.94 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 55.9 m -95.66 102.59 14.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 72.34 111.13 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.9 t -84.24 146.33 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 75.04 111.156 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -126.8 124.06 38.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.143 -0.48 . . . . 64.4 110.962 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.457 HG22 HD12 ' A' ' 53' ' ' ILE . 92.1 t -125.37 138.67 53.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.491 . . . . 70.21 111.121 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.777 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -138.61 141.84 39.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.166 -0.47 . . . . 74.02 110.94 179.951 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.68 109.11 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 45.54 111.065 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -122.77 153.43 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 74.25 110.852 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.26 4.3 35.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 75.21 111.13 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -95.24 78.11 3.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.937 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.59 -139.92 14.75 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 71.23 112.489 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -148.42 150.06 32.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.845 0.355 . . . . 53.03 110.943 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -158.19 162.55 26.69 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.571 0.701 . . . . 73.44 110.963 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 157.03 61.78 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.722 2.281 . . . . 73.54 112.317 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.49 66.08 76.11 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.598 0.713 . . . . 45.04 110.847 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.526 ' C ' HD13 ' A' ' 53' ' ' ILE . 53.1 Cg_endo -69.85 118.36 5.64 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.693 2.262 . . . . 63.5 112.302 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.618 HG21 ' HA ' ' A' ' 122' ' ' ILE . 2.4 mm -124.55 151.51 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 73.42 111.123 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.614 ' CB ' HG11 ' A' ' 29' ' ' VAL . 8.3 tt0 -155.22 115.66 3.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 75.4 110.836 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.686 ' O ' HG13 ' A' ' 124' ' ' VAL . 21.2 t -131.34 82.02 63.61 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.647 0.737 . . . . 71.23 111.145 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.729 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.75 121.87 8.56 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.692 2.261 . . . . 71.14 112.368 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -68.3 152.85 44.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.253 -0.43 . . . . 65.12 110.933 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.95 -36.33 3.7 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 73.11 112.495 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.77 158.06 17.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.8 0.333 . . . . 62.12 111.066 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.672 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.5 mt-10 -67.87 144.53 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.45 . . . . 63.24 110.922 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.729 HD12 ' HD2' ' A' ' 56' ' ' PRO . 5.7 mm -128.21 120.01 52.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 72.11 111.114 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.985 HG13 HG23 ' A' ' 92' ' ' THR . 55.2 t -103.9 91.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 71.34 111.128 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.618 ' HB2' HG12 ' A' ' 93' ' ' VAL . 90.5 m-85 -69.61 134.95 49.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 71.31 110.906 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.421 ' HD3' HG21 ' A' ' 90' ' ' VAL . 15.6 mttt -131.53 100.16 5.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.153 -0.476 . . . . 64.14 110.877 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.584 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.8 mp -107.11 143.32 17.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 54.02 111.156 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.5 t -156.38 136.18 12.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 74.23 111.166 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.404 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -142.95 161.51 48.3 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.699 0.761 . . . . 73.4 110.853 -179.86 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.404 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.0 Cg_endo -69.77 -50.81 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.671 2.247 . . . . 50.34 112.385 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -155.78 49.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 62.2 110.842 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.21 135.94 3.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.146 -0.479 . . . . 71.51 111.117 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 95.0 mt -86.45 105.64 14.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.14 111.147 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.408 ' O ' HG21 ' A' ' 65' ' ' ILE . 44.8 t-80 -99.46 69.65 1.67 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 53.41 110.901 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.15 155.5 21.07 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.73 -0.748 . . . . 41.14 112.466 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.584 ' CE2' HD11 ' A' ' 65' ' ' ILE . 3.3 p90 -128.61 142.82 50.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.883 0.373 . . . . 72.3 110.886 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -118.56 94.1 4.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 74.15 110.854 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.529 HG13 ' CE2' ' A' ' 103' ' ' TYR . 10.1 t -74.11 140.9 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 75.53 111.147 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 pm0 -75.3 -176.05 2.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 72.43 110.869 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.7 -51.86 4.61 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.723 -0.751 . . . . 61.11 112.491 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.406 HG22 ' N ' ' A' ' 80' ' ' ASN . 10.7 m -124.02 157.16 35.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.813 0.34 . . . . 75.53 111.174 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.406 ' N ' HG22 ' A' ' 79' ' ' THR . 1.1 m120 -77.15 60.06 1.84 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 61.04 110.874 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.552 ' O ' HG23 ' A' ' 81' ' ' ILE . 11.5 tt -78.51 116.53 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 53.33 111.137 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -123.19 96.69 5.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 75.41 110.85 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.6 m -114.39 119.89 62.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 70.14 111.105 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.64 117.36 7.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.14 -0.482 . . . . 62.22 110.886 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.81 HG11 ' HB2' ' A' ' 91' ' ' SER . 7.6 p -140.62 128.29 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 63.2 111.117 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -57.52 157.91 12.5 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.59 0.71 . . . . 63.55 110.959 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 159.16 54.46 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.685 2.256 . . . . 62.22 112.339 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.1 11.73 59.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 72.01 112.511 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -163.86 118.19 1.53 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.897 0.379 . . . . 71.4 110.897 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.477 HG12 ' O ' ' A' ' 9' ' ' GLU . 3.5 p -68.8 143.28 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 74.45 111.129 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.81 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.3 OUTLIER -107.09 169.29 8.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 70.42 110.814 -179.854 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.985 HG23 HG13 ' A' ' 62' ' ' VAL . 87.8 m -145.45 111.28 5.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.121 -0.491 . . . . 73.14 111.112 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.618 HG12 ' HB2' ' A' ' 63' ' ' PHE . 8.0 p -124.45 150.7 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 71.13 111.131 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -114.93 97.49 6.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.831 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.544 ' CD2' HD12 ' A' ' 81' ' ' ILE . 40.5 t80 -139.9 110.08 6.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 73.33 110.947 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.1 t -110.68 143.5 41.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 71.4 111.177 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.6 -178.89 5.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.258 -0.428 . . . . 74.21 110.853 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.7 mttt -119.85 -12.9 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 73.13 110.927 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.16 161.66 31.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.62 0.724 . . . . 75.01 110.831 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.67 152.43 69.75 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 2.26 . . . . 64.42 112.384 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 159.4 130.43 1.14 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.785 -0.722 . . . . 52.22 112.494 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -99.22 130.46 45.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 72.35 110.866 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . 0.529 ' CE2' HG13 ' A' ' 76' ' ' VAL . 1.0 OUTLIER -135.42 146.39 48.23 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.197 -0.456 . . . . 74.2 110.93 -179.872 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.942 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.7 OUTLIER -148.22 -163.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 71.32 110.907 179.99 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.942 HG22 ' O ' ' A' ' 104' ' ' ARG . 1.2 tt 58.94 158.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 73.34 111.129 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 72.14 111.157 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.586 ' C ' HD12 ' A' ' 122' ' ' ILE . 68.7 m . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.771 0.32 . . . . 65.32 111.118 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.618 ' HA ' HG21 ' A' ' 53' ' ' ILE . 4.3 mp -150.01 143.66 17.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 72.34 111.136 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 m -134.47 140.74 45.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 73.33 111.133 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.686 HG13 ' O ' ' A' ' 55' ' ' VAL . 58.5 t -113.68 126.03 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 73.5 111.17 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 11.3 mmmm -108.92 141.51 40.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 61.24 110.909 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.209 -0.451 . . . . 72.55 110.928 179.963 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.803 0.335 . . . . 75.12 110.867 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -104.52 143.98 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 72.01 110.904 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.514 HG21 ' OG1' ' A' ' 66' ' ' THR . 17.0 m -110.64 -177.55 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 73.44 111.138 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.416 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 4.9 p30 -143.79 156.18 59.31 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.626 0.727 . . . . 70.15 110.87 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.81 -3.58 12.34 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.652 2.235 . . . . 41.12 112.338 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 3.7 m -47.56 -63.74 0.97 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.237 -0.438 . . . . 63.51 111.14 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -155.67 29.04 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.244 -0.435 . . . . 61.44 111.133 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.4 p -64.57 -30.23 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.435 . . . . 65.25 111.12 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.453 ' HB3' HD21 ' A' ' 42' ' ' LEU . 4.0 ptt-85 -101.17 -6.63 24.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.35 110.874 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 11.3 mm-40 -97.43 -37.46 9.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 75.5 110.924 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -135.11 133.93 39.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 71.1 110.852 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.05 -158.76 18.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.717 -0.754 . . . . 72.23 112.466 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -29.02 24.71 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.657 2.238 . . . . 72.32 112.364 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.783 ' HB3' HD13 ' A' ' 42' ' ' LEU . 15.0 m-90 -87.12 -11.42 50.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.26 -0.427 . . . . 64.43 110.893 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.36 -59.16 5.07 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.267 -0.424 . . . . 74.13 111.074 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.91 143.63 26.99 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.598 0.713 . . . . 75.12 110.885 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -22.69 31.51 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.735 2.29 . . . . 72.43 112.288 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.8 -7.27 51.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.271 -0.422 . . . . 23.02 111.104 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 31.7 mm-40 -104.73 5.27 33.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 71.44 110.887 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -77.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 62.23 111.1 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.3 p -103.39 108.4 24.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 74.43 111.109 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -114.91 149.86 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 74.14 111.138 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -67.96 122.32 17.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 60.23 110.895 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.572 HG23 ' HG3' ' A' ' 36' ' ' GLN . 1.7 t -119.73 -33.55 3.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 51.32 111.132 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.06 175.85 17.94 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 60.52 112.493 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.67 24.21 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.721 2.281 . . . . 74.12 112.336 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -161.03 34.79 0.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 74.14 110.895 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.572 ' HG3' HG23 ' A' ' 32' ' ' THR . 0.2 OUTLIER -150.91 160.29 44.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 64.31 110.94 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -143.12 144.32 32.18 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.244 -0.435 . . . . 73.4 110.906 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.2 m -97.62 103.14 15.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 64.3 111.142 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.9 t -85.05 137.67 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 62.35 111.18 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -120.26 113.12 19.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 73.35 110.966 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.494 HG22 HG13 ' A' ' 53' ' ' ILE . 59.1 t -110.42 133.82 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 74.13 111.122 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.783 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.6 OUTLIER -139.31 139.36 37.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 53.51 110.868 -179.982 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.648 ' HB3' ' CE1' ' A' ' 72' ' ' HIS . . . -155.16 122.66 5.63 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 74.22 111.107 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -121.56 145.57 47.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 75.31 110.874 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.32 48.12 1.57 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.474 . . . . 72.51 111.117 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -120.9 -50.7 2.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 64.02 110.879 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -133.71 -119.01 1.95 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.773 -0.727 . . . . 75.32 112.54 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -150.17 136.68 19.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 74.34 110.894 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -130.39 159.41 70.76 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.578 0.704 . . . . 61.23 110.939 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -176.97 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.672 2.248 . . . . 62.3 112.367 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.514 ' C ' HD12 ' A' ' 53' ' ' ILE . 1.0 OUTLIER -137.57 62.5 36.23 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.672 0.748 . . . . 52.42 110.926 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 6.45 1.3 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.67 2.247 . . . . 74.54 112.313 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.935 HD13 HG22 ' A' ' 121' ' ' THR . 4.7 mp -48.39 131.28 5.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 75.13 111.136 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.445 ' HB3' HG11 ' A' ' 29' ' ' VAL . 10.6 tt0 -140.18 149.6 43.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 52.34 110.883 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 61' ' ' ILE . 86.9 t -151.0 81.96 6.09 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.618 0.723 . . . . 60.23 111.132 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.69 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.5 Cg_endo -69.79 123.08 9.74 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.647 2.232 . . . . 71.33 112.332 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.1 155.3 40.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 65.24 110.923 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.54 -9.67 70.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.729 -0.748 . . . . 70.23 112.469 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.36 154.35 50.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.759 0.314 . . . . 71.02 111.125 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.681 ' O ' HD13 ' A' ' 61' ' ' ILE . 20.9 mt-10 -64.88 144.55 57.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 75.44 110.944 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.737 HG13 HG13 ' A' ' 55' ' ' VAL . 7.6 mm -129.44 115.16 33.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 65.13 111.127 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.593 HG13 ' OG1' ' A' ' 92' ' ' THR . 77.2 t -99.06 97.72 6.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 44.33 111.122 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.514 ' HB2' HG12 ' A' ' 93' ' ' VAL . 87.9 m-85 -75.85 132.06 40.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 70.41 110.872 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -130.82 100.06 5.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.931 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.38 153.24 4.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 75.51 111.11 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.771 HG23 HD12 ' A' ' 42' ' ' LEU . 9.5 t -167.1 128.66 1.62 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 72.23 111.134 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.473 ' HB2' HG23 ' A' ' 70' ' ' VAL . 0.1 OUTLIER -140.25 166.16 25.39 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.637 0.732 . . . . 74.33 110.84 -179.875 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' CB ' ' A' ' 67' ' ' SER . 54.4 Cg_endo -69.72 -54.8 0.2 Allowed 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.668 2.245 . . . . 72.1 112.389 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -158.7 57.22 0.44 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 74.32 110.917 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.473 HG23 ' HB2' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.62 140.23 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.142 -0.481 . . . . 71.44 111.108 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.463 HD13 ' HD3' ' A' ' 87' ' ' PRO . 35.0 mm -85.3 150.82 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 74.1 111.101 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.648 ' CE1' ' HB3' ' A' ' 43' ' ' ALA . 11.9 m170 -115.69 -84.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.472 . . . . 74.43 110.903 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.88 98.85 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.743 -0.741 . . . . 73.05 112.492 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -106.31 142.47 35.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 74.35 110.89 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -110.8 142.39 42.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 75.55 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.4 t -135.89 136.19 50.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 62.02 111.142 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -64.21 -177.2 0.26 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.181 -0.463 . . . . 74.34 110.925 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 84.32 -51.22 4.53 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.747 -0.74 . . . . 60.14 112.479 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.1 m -135.12 160.94 36.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.774 0.321 . . . . 74.02 111.202 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -86.01 76.58 9.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 64.03 110.893 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.451 ' O ' HG23 ' A' ' 81' ' ' ILE . 4.8 tt -85.01 121.81 37.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 72.45 111.11 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -116.5 95.42 5.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 73.42 110.878 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.8 m -115.63 120.37 64.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 63.03 111.147 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -156.59 110.02 2.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.2 -0.454 . . . . 71.31 110.874 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.759 HG11 ' HB2' ' A' ' 91' ' ' SER . 13.8 p -140.74 147.11 23.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 62.54 111.12 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.28 161.1 80.26 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.567 0.699 . . . . 62.32 110.905 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.463 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.6 Cg_endo -69.75 159.64 52.67 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.654 2.236 . . . . 74.14 112.333 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.39 85.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.722 -0.751 . . . . 75.11 112.469 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -139.37 145.25 38.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.932 0.396 . . . . 74.53 110.889 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.504 HG23 HG13 ' A' ' 11' ' ' VAL . 21.2 t -99.3 110.66 27.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.165 -0.47 . . . . 72.25 111.157 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.759 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -91.37 165.97 13.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 51.33 110.846 -179.851 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.593 ' OG1' HG13 ' A' ' 62' ' ' VAL . 1.4 t -144.19 140.15 29.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 43.21 111.168 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.514 HG12 ' HB2' ' A' ' 63' ' ' PHE . 9.9 p -153.79 127.55 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 73.11 111.126 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.0 mtm180 -93.95 111.11 22.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 73.14 110.885 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -145.75 118.45 8.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.429 . . . . 73.12 110.872 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.3 t -114.39 132.03 56.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 71.44 111.161 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -177.59 6.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 73.42 110.854 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.3 ttpt -121.52 -24.28 5.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 61.42 110.901 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.49 160.21 57.69 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.613 0.721 . . . . 65.35 110.899 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 127.85 15.16 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.689 2.26 . . . . 72.21 112.313 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.12 146.33 14.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 63.44 112.521 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -105.57 135.71 46.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.84 0.352 . . . . 74.34 110.881 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -143.97 148.87 35.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.169 -0.469 . . . . 73.13 110.947 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.421 ' C ' HD12 ' A' ' 105' ' ' ILE . 30.6 ttp85 -168.78 157.9 8.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 65.52 110.882 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.421 HD12 ' C ' ' A' ' 104' ' ' ARG . 2.0 mp 66.79 147.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.176 -0.466 . . . . 74.44 111.096 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 74.12 111.11 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.935 HG22 HD13 ' A' ' 53' ' ' ILE . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.73 0.3 . . . . 64.41 111.197 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.658 HG13 HG21 ' A' ' 53' ' ' ILE . 4.4 mp -149.06 120.53 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 55.21 111.13 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.494 HG12 ' O ' ' A' ' 53' ' ' ILE . 3.0 p -114.83 127.14 72.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 74.41 111.089 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.711 HG13 ' O ' ' A' ' 55' ' ' VAL . 42.7 t -97.88 131.2 45.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 74.32 111.149 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 15.2 mmmt -104.97 128.53 53.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 64.1 110.86 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 60.22 110.884 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.43 ' O ' HG12 ' A' ' 90' ' ' VAL . 1.0 OUTLIER . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.87 0.367 . . . . 71.54 110.869 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -86.02 137.97 32.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 71.21 110.867 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.453 HG21 ' OG1' ' A' ' 66' ' ' THR . 17.1 m -120.72 -177.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.131 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.447 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 33.8 p30 -144.16 156.75 57.88 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.596 0.712 . . . . 72.03 110.882 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.6 Cg_endo -69.76 -2.28 9.9 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.674 2.249 . . . . 73.31 112.356 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.75 HG22 HG23 ' A' ' 15' ' ' THR . 26.6 m -45.24 -65.24 0.56 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.223 -0.444 . . . . 72.44 111.124 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.75 HG23 HG22 ' A' ' 14' ' ' THR . 38.2 p -150.26 17.84 0.84 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 71.12 111.121 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.4 p -57.17 -25.8 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 64.3 111.145 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.442 HH12 ' NE2' ' A' ' 18' ' ' GLN . 3.5 ptt85 -106.71 -8.05 17.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 73.12 110.851 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.442 ' NE2' HH12 ' A' ' 17' ' ' ARG . 0.8 OUTLIER -94.03 -32.22 13.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.4 110.92 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.471 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 7.8 pt-20 -142.56 144.19 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 74.35 110.902 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.96 -156.56 15.58 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.765 -0.731 . . . . 33.41 112.482 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.454 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.3 Cg_endo -69.77 -35.94 11.69 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.661 2.24 . . . . 65.34 112.328 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.403 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 13.5 m-90 -84.66 -7.25 59.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.213 -0.449 . . . . 70.34 110.92 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.471 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -62.02 -54.19 45.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.24 -0.437 . . . . 52.13 111.105 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.68 141.99 30.89 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.653 0.74 . . . . 75.04 110.855 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.673 2.248 . . . . 72.31 112.372 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.59 -36.99 65.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 64.21 111.06 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.471 HE21 ' N ' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -95.31 33.06 1.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.4 110.929 -179.962 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.478 ' HB2' ' HG2' ' A' ' 52' ' ' PRO . . . -55.73 -76.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 73.22 111.101 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.734 HG11 ' CB ' ' A' ' 54' ' ' GLU . 2.3 p -101.88 129.79 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 62.34 111.103 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -142.33 139.99 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 73.32 111.151 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.425 HE22 ' N ' ' A' ' 36' ' ' GLN . 13.0 tp60 -72.4 123.34 22.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 75.33 110.903 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -120.28 -10.45 9.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 75.24 111.165 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.98 -168.83 12.46 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 51.5 112.479 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -33.8 16.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.654 2.236 . . . . 50.34 112.368 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -154.31 28.7 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 73.04 110.896 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.425 ' N ' HE22 ' A' ' 31' ' ' GLN . 1.4 pt20 -126.83 119.43 26.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 42.02 110.912 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 63.0 m-85 -96.37 134.7 39.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 74.25 110.906 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.689 ' HA ' HG23 ' A' ' 62' ' ' VAL . 92.5 m -93.84 104.23 16.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 64.13 111.119 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.1 t -86.85 132.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 71.31 111.096 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -118.07 115.66 25.3 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.19 -0.459 . . . . 75.1 110.917 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.473 HG12 HD12 ' A' ' 53' ' ' ILE . 15.8 m -114.05 119.71 61.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 72.04 111.131 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.49 ' C ' HD13 ' A' ' 42' ' ' LEU . 3.2 tm? -114.97 132.86 56.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 73.13 110.927 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.46 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -154.59 131.28 10.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 75.3 111.066 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.404 ' CD2' HD11 ' A' ' 42' ' ' LEU . 2.9 p90 -127.1 163.03 24.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 75.13 110.868 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.799 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -87.03 2.9 48.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.098 -0.501 . . . . 71.21 111.124 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 3.5 p90 -122.3 84.43 2.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 73.12 110.865 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.01 158.72 12.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 75.31 112.464 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -111.77 120.8 43.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.798 0.332 . . . . 73.4 110.976 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -127.08 162.36 48.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 60.24 110.883 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 162.49 41.87 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.659 2.239 . . . . 62.43 112.34 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 -137.95 67.19 48.8 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.614 0.721 . . . . 72.45 110.851 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.478 ' HG2' ' HB2' ' A' ' 28' ' ' ALA . 53.9 Cg_endo -69.81 98.99 0.72 Allowed 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.643 2.228 . . . . 73.22 112.35 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.545 HG13 HG23 ' A' ' 121' ' ' THR . 1.5 mm -100.57 157.44 4.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 75.34 111.131 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.734 ' CB ' HG11 ' A' ' 29' ' ' VAL . 16.4 tt0 -155.42 122.08 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.909 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.957 HG12 HG21 ' A' ' 61' ' ' ILE . 6.0 m -142.68 86.6 9.53 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.612 0.72 . . . . 72.15 111.137 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.549 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.8 Cg_endo -69.76 122.74 9.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.689 2.259 . . . . 73.31 112.344 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.06 155.75 23.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 64.51 110.904 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.98 -0.97 76.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.694 -0.765 . . . . 72.44 112.484 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.95 150.4 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.787 0.327 . . . . 74.23 111.086 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.676 ' O ' HD13 ' A' ' 61' ' ' ILE . 2.6 mp0 -68.14 138.23 55.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 65.24 110.883 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.957 HG21 HG12 ' A' ' 55' ' ' VAL . 5.0 mm -128.28 117.78 46.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 53.14 111.139 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.689 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -104.23 94.2 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 71.52 111.145 179.841 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.663 ' CZ ' HG11 ' A' ' 55' ' ' VAL . 40.2 m-85 -64.52 142.86 58.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 74.23 110.899 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -133.36 98.36 4.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.917 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.676 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.3 mp -106.8 137.01 39.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.26 -0.427 . . . . 73.31 111.15 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.453 ' OG1' HG21 ' A' ' 11' ' ' VAL . 6.5 t -154.96 134.62 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 70.04 111.121 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.415 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -146.2 161.38 39.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.688 0.756 . . . . 64.31 110.852 -179.893 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.5 Cg_endo -69.72 -52.98 0.3 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.699 2.266 . . . . 73.4 112.308 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -158.31 53.61 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 62.51 110.856 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.799 HG11 ' HB2' ' A' ' 45' ' ' ALA . 0.0 OUTLIER -155.12 140.95 11.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 71.41 111.121 179.977 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.572 HD13 ' HD3' ' A' ' 87' ' ' PRO . 30.5 mm -85.83 151.23 3.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 52.02 111.132 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.564 ' HB3' HG21 ' A' ' 65' ' ' ILE . 78.2 t60 -125.47 -83.93 0.63 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.17 -0.468 . . . . 61.35 110.872 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 61.13 158.57 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.724 -0.751 . . . . 71.34 112.504 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.676 ' CE2' HD11 ' A' ' 65' ' ' ILE . 0.8 OUTLIER -145.76 141.9 28.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.928 0.394 . . . . 65.32 110.859 -179.864 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.651 ' HB3' HG23 ' A' ' 105' ' ' ILE . 31.0 t-80 -104.35 140.29 38.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 70.51 110.844 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.62 HG22 ' CE2' ' A' ' 103' ' ' TYR . 94.1 t -126.31 134.66 65.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 71.02 111.154 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -75.14 169.69 17.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 75.42 110.887 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.33 -51.28 4.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 51.33 112.504 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.3 m -116.29 151.47 35.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 74.3 111.109 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -86.04 58.79 5.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.909 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.504 HD12 ' CD2' ' A' ' 95' ' ' TYR . 7.7 tt -62.87 126.11 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 70.11 111.121 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -116.53 90.9 3.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 74.44 110.896 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.581 HG11 HG11 ' A' ' 93' ' ' VAL . 3.6 m -115.74 120.06 63.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 74.3 111.1 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -155.71 114.66 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 74.14 110.834 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.581 HG21 ' HB3' ' A' ' 91' ' ' SER . 94.3 t -140.2 145.04 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 65.42 111.104 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.1 mp -79.79 159.91 70.35 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.644 0.735 . . . . 60.33 110.904 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.572 ' HD3' HD13 ' A' ' 71' ' ' ILE . 54.0 Cg_endo -69.74 159.7 52.43 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.687 2.258 . . . . 73.4 112.354 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.58 10.02 48.49 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.75 -0.738 . . . . 74.24 112.519 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -169.36 126.24 0.91 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.891 0.376 . . . . 71.24 110.888 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.43 HG12 ' O ' ' A' ' 9' ' ' GLU . 2.4 p -65.17 118.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 70.33 111.158 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.581 ' HB3' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -81.57 166.7 20.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 64.14 110.894 -179.852 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 97.8 m -136.27 134.86 38.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.43 111.174 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.581 HG11 HG11 ' A' ' 83' ' ' VAL . 16.2 t -144.48 131.5 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 72.33 111.116 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -109.58 95.1 5.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 75.02 110.904 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.504 ' CD2' HD12 ' A' ' 81' ' ' ILE . 41.5 t80 -136.13 127.25 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.196 -0.456 . . . . 71.23 110.874 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.8 t -128.2 143.27 51.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 70.3 111.145 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -100.75 -173.26 2.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 72.02 110.907 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.03 -24.43 4.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.141 -0.482 . . . . 70.34 110.855 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -132.39 162.16 58.72 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.613 0.72 . . . . 74.43 110.895 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 155.45 65.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.711 2.274 . . . . 64.03 112.358 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.46 133.15 2.34 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.74 -0.743 . . . . 74.43 112.433 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -97.24 144.09 27.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.863 0.363 . . . . 75.35 110.866 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . 0.62 ' CE2' HG22 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -137.74 132.63 33.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 72.31 110.949 -179.885 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.82 120.98 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 73.24 110.853 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.651 HG23 ' HB3' ' A' ' 75' ' ' HIS . 5.6 tt -178.22 137.32 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 75.25 111.136 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 44.01 111.106 179.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.602 ' O ' HD13 ' A' ' 122' ' ' ILE . 13.4 t . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.794 0.331 . . . . 74.1 111.107 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 121' ' ' THR . 5.9 mm -141.52 148.24 21.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.51 111.121 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.405 ' O ' HG22 ' A' ' 55' ' ' VAL . 71.3 t -135.07 115.46 18.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.143 -0.481 . . . . 55.33 111.146 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.847 HG22 HG23 ' A' ' 55' ' ' VAL . 95.9 t -102.25 121.69 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 74.42 111.112 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.1 mmmt -106.22 138.73 41.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 64.04 110.878 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.222 -0.445 . . . . 73.22 110.868 179.996 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 15.8 mp0 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.856 0.36 . . . . 74.24 110.921 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.71 149.46 23.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 75.32 110.866 -179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.601 HG21 HG21 ' A' ' 16' ' ' VAL . 13.8 m -147.39 -178.29 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 51.44 111.125 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -144.3 162.31 40.47 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.618 0.723 . . . . 73.31 110.858 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -4.59 14.34 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.633 2.222 . . . . 74.13 112.317 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.408 ' O ' HG23 ' A' ' 15' ' ' THR . 4.6 m -48.83 -67.14 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.431 . . . . 72.31 111.105 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.408 HG23 ' O ' ' A' ' 14' ' ' THR . 3.1 p -155.46 38.27 0.38 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 61.21 111.179 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.601 HG21 HG21 ' A' ' 11' ' ' VAL . 11.8 p -76.22 -31.97 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 75.44 111.139 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.476 ' HB3' HD11 ' A' ' 42' ' ' LEU . 7.4 ptt-85 -97.25 -11.61 23.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 74.41 110.894 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.6 mm-40 -95.53 -37.32 10.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.893 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -132.65 134.17 44.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 73.22 110.869 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.57 -158.95 18.23 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.764 -0.731 . . . . 74.33 112.506 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -26.86 26.93 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.623 2.215 . . . . 62.54 112.373 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.732 ' HB3' HD13 ' A' ' 42' ' ' LEU . 13.3 m-90 -87.39 -13.34 43.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 64.43 110.91 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.18 -59.67 2.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.267 -0.424 . . . . 73.33 111.054 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.18 144.07 29.34 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.623 0.725 . . . . 75.52 110.833 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -28.97 24.7 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.62 2.213 . . . . 60.2 112.369 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.4 -16.98 60.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 70.15 111.089 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.2 mm-40 -88.36 8.3 28.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 74.4 110.947 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.39 -78.4 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 71.21 111.08 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.1 p -103.02 126.51 57.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 64.43 111.114 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -134.97 150.13 29.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 44.53 111.083 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -71.02 121.03 17.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 63.21 110.892 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.552 HG23 ' HG3' ' A' ' 36' ' ' GLN . 1.7 t -120.13 -33.05 4.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 75.34 111.153 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.79 178.49 16.49 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.706 -0.759 . . . . 74.22 112.476 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -18.14 37.33 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.727 2.284 . . . . 71.52 112.368 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 -153.3 30.08 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.196 -0.456 . . . . 71.21 110.872 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.552 ' HG3' HG23 ' A' ' 32' ' ' THR . 0.1 OUTLIER -140.96 157.46 45.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 62.44 110.919 179.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -140.56 138.39 34.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 75.34 110.95 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.753 ' HA ' HG23 ' A' ' 62' ' ' VAL . 75.4 m -92.98 103.86 16.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 75.51 111.143 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 t -90.25 140.39 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 64.45 111.158 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -124.14 120.44 32.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.01 110.893 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.658 HG23 HG23 ' A' ' 65' ' ' ILE . 4.5 m -121.61 146.52 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 74.43 111.129 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.732 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -139.1 143.94 38.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.166 -0.47 . . . . 72.41 110.935 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.84 106.2 3.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.441 . . . . 72.23 111.102 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.6 p90 -129.07 144.99 51.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 65.22 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.62 0.36 52.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 52.42 111.132 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.55 33.97 1.37 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 74.21 110.848 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.75 -141.73 8.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.743 -0.741 . . . . 51.25 112.494 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -155.48 155.17 33.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 71.21 110.899 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.412 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -156.66 156.2 29.62 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.607 0.718 . . . . 75.3 110.883 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.412 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.4 Cg_endo -69.82 -179.78 3.18 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 65.14 112.334 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.438 ' HB3' ' HB ' ' A' ' 121' ' ' THR . 0.4 OUTLIER -131.94 61.36 57.59 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.609 0.719 . . . . 73.44 110.881 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 7.16 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.659 2.24 . . . . 75.32 112.359 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.646 HG21 HG13 ' A' ' 122' ' ' ILE . 3.7 mp -46.86 143.34 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 61.13 111.121 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -144.18 164.69 29.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 64.53 110.891 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.879 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -165.4 82.87 1.11 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 72.22 111.15 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.589 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.72 122.49 9.18 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 75.13 112.354 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.25 154.9 40.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 72.43 110.89 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.59 -7.87 77.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.771 -0.728 . . . . 62.21 112.451 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.03 159.03 41.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.768 0.318 . . . . 65.12 111.064 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.754 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.4 mp0 -71.76 140.71 49.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 73.31 110.917 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.778 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -129.56 115.48 34.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 53.31 111.169 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.753 HG23 ' HA ' ' A' ' 38' ' ' THR . 1.1 m -103.76 90.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 73.12 111.107 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.522 ' HB2' HG12 ' A' ' 93' ' ' VAL . 71.4 m-85 -66.45 140.87 58.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.913 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -132.42 98.61 4.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 71.13 110.931 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.658 HG23 HG23 ' A' ' 41' ' ' VAL . 1.4 mp -97.72 158.41 3.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 71.24 111.157 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.2 t -168.73 135.59 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 72.35 111.144 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.63 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -139.72 159.93 63.11 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.669 0.747 . . . . 50.41 110.858 -179.847 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.416 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.1 Cg_endo -69.71 -52.77 0.31 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.697 2.265 . . . . 70.11 112.398 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -153.02 41.11 0.56 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 53.54 110.847 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.63 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -142.3 135.07 27.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.229 -0.441 . . . . 73.15 111.125 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.9 mt -72.95 146.39 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 72.01 111.134 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.588 ' CB ' HG21 ' A' ' 65' ' ' ILE . 30.6 p80 -113.65 -168.16 1.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 71.32 110.848 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.87 118.16 2.06 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.743 -0.742 . . . . 35.4 112.51 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -117.63 144.38 45.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 63.22 110.842 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 32.9 t-80 -106.03 130.19 53.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 75.21 110.839 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.676 HG12 HG21 ' A' ' 81' ' ' ILE . 2.4 p -131.71 128.82 60.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.472 . . . . 63.51 111.089 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -58.08 -177.53 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 63.21 110.874 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.3 -47.6 1.95 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.738 -0.744 . . . . 74.11 112.444 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.409 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -147.28 179.49 7.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.857 0.36 . . . . 73.12 111.086 -179.803 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.409 ' H ' HG22 ' A' ' 79' ' ' THR . 4.2 m120 -92.31 78.88 5.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 74.13 110.896 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.676 HG21 HG12 ' A' ' 76' ' ' VAL . 6.8 tt -88.56 123.43 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 71.21 111.102 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -122.67 92.56 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 72.2 110.919 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.6 m -116.48 119.92 63.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 51.0 111.174 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -165.44 111.15 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 61.32 110.906 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.414 HG21 ' OG ' ' A' ' 91' ' ' SER . 86.2 t -140.63 140.81 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 70.44 111.133 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.0 mp -56.88 160.77 5.46 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.567 0.699 . . . . 72.34 110.928 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 160.68 48.83 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.672 2.248 . . . . 60.1 112.375 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.2 17.24 56.14 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.742 -0.742 . . . . 43.41 112.504 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -159.79 157.47 29.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.881 0.372 . . . . 74.31 110.886 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 86.1 t -102.92 133.5 46.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 54.11 111.107 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.414 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.6 OUTLIER -109.53 115.29 29.64 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.845 -179.871 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.5 m -94.46 124.43 38.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.062 -0.517 . . . . 74.21 111.158 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.522 HG12 ' HB2' ' A' ' 63' ' ' PHE . 10.7 p -134.67 137.66 50.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 74.32 111.197 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -103.24 108.56 19.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.154 -0.476 . . . . 70.42 110.902 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -141.35 112.26 7.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 74.11 110.909 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -112.86 137.31 51.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.47 . . . . 61.42 111.109 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.32 -175.28 3.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 71.24 110.919 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.5 mtmm -123.63 -12.78 7.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.871 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.6 mpp_? -150.87 161.79 28.94 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.603 0.716 . . . . 75.3 110.904 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.83 64.95 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.763 2.309 . . . . 71.44 112.331 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.92 141.58 3.18 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.733 -0.746 . . . . 62.53 112.493 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -106.18 128.84 54.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 62.22 110.898 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 5.9 p90 -143.98 146.19 32.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.155 -0.475 . . . . 72.01 110.947 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.92 -176.52 5.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 73.11 110.846 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.406 HG22 ' N ' ' A' ' 106' ' ' ILE . 18.9 mm 66.37 155.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 73.11 111.103 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.418 ' C ' HD13 ' A' ' 106' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 74.43 111.096 179.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.535 ' O ' HD13 ' A' ' 53' ' ' ILE . 4.2 m . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.777 0.322 . . . . 73.31 111.152 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.646 HG13 HG21 ' A' ' 53' ' ' ILE . 4.6 mp -146.77 120.4 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 75.25 111.174 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 55' ' ' VAL . 2.6 p -116.41 142.2 31.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 73.32 111.103 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.879 HG22 HG13 ' A' ' 55' ' ' VAL . 60.5 t -106.05 122.17 59.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.162 -0.472 . . . . 74.2 111.161 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -90.39 134.94 34.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 75.31 110.936 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 71.53 110.897 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 25.2 mp0 . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.859 0.361 . . . . 73.51 110.888 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -92.59 137.71 32.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 73.24 110.863 -179.885 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.47 HG21 HG21 ' A' ' 16' ' ' VAL . 12.5 m -136.32 -177.94 2.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 65.32 111.127 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -143.93 162.52 40.47 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.589 0.709 . . . . 70.14 110.897 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -4.12 13.38 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.697 2.265 . . . . 73.45 112.355 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.425 ' O ' HG23 ' A' ' 15' ' ' THR . 23.3 m -47.64 -70.04 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 70.43 111.126 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.425 HG23 ' O ' ' A' ' 14' ' ' THR . 3.7 p -155.96 38.74 0.36 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 73.42 111.147 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.581 HG22 ' CE3' ' A' ' 22' ' ' TRP . 13.4 p -75.52 -42.25 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.253 -0.431 . . . . 73.5 111.13 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.548 ' HB2' HD22 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -108.97 11.25 26.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 74.32 110.868 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 16.7 mm-40 -105.55 -33.26 8.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 71.34 110.879 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.47 ' CG ' ' O ' ' A' ' 19' ' ' GLU . 28.5 tt0 -142.55 13.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 74.31 110.859 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -103.35 -154.85 24.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.741 -0.742 . . . . 75.23 112.487 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.462 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.2 Cg_endo -69.75 -23.06 31.26 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.684 2.256 . . . . 62.21 112.351 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.581 ' CE3' HG22 ' A' ' 16' ' ' VAL . 18.2 m-90 -91.03 -7.27 52.35 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 73.44 110.939 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.18 -44.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 51.41 111.132 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.43 137.71 20.74 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.61 0.719 . . . . 73.4 110.892 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -17.83 37.14 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.692 2.261 . . . . 61.23 112.314 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.19 -37.8 69.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 31.43 111.134 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 57.3 mm-40 -84.79 4.9 30.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 72.32 110.911 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.65 -73.29 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 50.03 111.107 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.475 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.0 p -105.93 123.01 60.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.235 -0.439 . . . . 60.35 111.105 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.6 t -137.76 150.35 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.457 . . . . 72.24 111.126 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -75.67 121.29 22.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 70.41 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.4 p -121.31 -41.6 2.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.433 . . . . 75.53 111.163 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.73 -166.74 34.8 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.734 -0.746 . . . . 60.52 112.515 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -36.76 10.21 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.673 2.248 . . . . 64.23 112.378 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . 0.502 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 63.8 t30 -152.7 28.95 0.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.249 -0.432 . . . . 73.03 110.861 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 127.53 44.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 74.23 110.893 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 18.0 m-85 -96.66 135.62 38.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 73.32 110.899 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.78 ' HA ' HG23 ' A' ' 62' ' ' VAL . 51.7 m -92.01 102.36 14.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.114 -0.493 . . . . 52.01 111.162 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.424 HG11 HG23 ' A' ' 53' ' ' ILE . 12.5 t -85.75 139.01 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 64.23 111.099 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -120.2 100.61 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 75.03 110.927 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.497 HG12 HG12 ' A' ' 53' ' ' ILE . 15.4 m -96.33 142.43 13.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.104 -0.498 . . . . 70.42 111.108 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.568 HD21 ' CE2' ' A' ' 44' ' ' PHE . 15.1 tp -130.31 144.21 51.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.925 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.42 ' H ' HD12 ' A' ' 42' ' ' LEU . . . -154.52 98.57 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 63.33 111.132 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.568 ' CE2' HD21 ' A' ' 42' ' ' LEU . 3.1 p90 -113.88 155.96 24.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 71.24 110.854 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.76 31.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 62.21 111.103 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -105.73 75.36 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 54.33 110.866 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.43 -162.37 17.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.713 -0.756 . . . . 53.11 112.491 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 34.1 p90 -126.67 151.88 47.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.834 0.349 . . . . 73.21 110.926 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.438 ' H ' ' NE2' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -136.08 159.97 68.95 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.64 0.733 . . . . 63.25 110.889 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -176.38 1.48 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.701 2.267 . . . . 74.3 112.316 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.478 ' CB ' HG21 ' A' ' 121' ' ' THR . 1.6 m120 -138.11 62.16 30.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.615 0.721 . . . . 72.25 110.856 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 6.27 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.719 2.28 . . . . 65.12 112.334 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.645 HG21 HG13 ' A' ' 122' ' ' ILE . 3.6 mp -48.4 107.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 74.23 111.094 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.475 ' HB3' HG11 ' A' ' 29' ' ' VAL . 39.7 tt0 -110.75 140.19 45.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.14 110.9 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 1.0 HG12 HG21 ' A' ' 61' ' ' ILE . 3.0 m -140.59 86.36 12.32 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.655 0.74 . . . . 73.52 111.152 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.658 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.0 Cg_endo -69.74 121.92 8.61 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.686 2.258 . . . . 64.11 112.374 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.95 153.33 42.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 71.02 110.906 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.8 -9.59 75.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 71.14 112.52 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.502 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -133.58 154.72 50.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.741 0.305 . . . . 74.03 111.12 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.713 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.6 mm-40 -67.09 144.4 56.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 70.03 110.899 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 1.0 HG21 HG12 ' A' ' 55' ' ' VAL . 6.7 mm -129.12 101.03 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 64.4 111.142 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.78 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.4 OUTLIER -89.19 100.1 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 63.52 111.104 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.476 ' HZ ' HG11 ' A' ' 55' ' ' VAL . 70.0 m-85 -72.89 141.6 47.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 62.51 110.911 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -132.62 99.21 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 75.03 110.901 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.598 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.4 mp -98.37 153.92 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 72.52 111.081 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -169.18 136.62 1.83 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 62.43 111.127 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.491 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -148.22 159.44 39.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.67 0.748 . . . . 63.53 110.857 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.403 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.4 Cg_endo -69.81 -55.14 0.19 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.659 2.239 . . . . 73.35 112.352 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -156.3 62.89 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 72.32 110.866 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.491 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.28 136.15 4.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 63.21 111.162 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.2 mm -71.12 143.7 14.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 73.3 111.124 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.598 ' CG ' HG21 ' A' ' 65' ' ' ILE . 9.5 p-80 -125.55 -168.89 1.91 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 74.24 110.852 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.18 132.89 3.49 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 65.2 112.439 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -126.35 142.04 51.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 65.23 110.903 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -103.93 89.28 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 75.24 110.902 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.787 HG13 ' CE2' ' A' ' 103' ' ' TYR . 15.6 t -74.63 131.81 34.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 63.43 111.138 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -68.14 178.36 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 71.31 110.908 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.96 -51.05 1.71 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.729 -0.748 . . . . 65.32 112.495 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.435 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -140.0 179.51 6.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.822 0.344 . . . . 52.23 111.142 -179.831 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.435 ' H ' HG22 ' A' ' 79' ' ' THR . 22.5 m120 -87.94 67.42 9.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 70.11 110.871 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.467 ' O ' HG23 ' A' ' 81' ' ' ILE . 13.2 tt -76.86 119.71 25.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 74.24 111.134 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -116.35 103.32 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 74.31 110.933 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.519 HG11 HG21 ' A' ' 93' ' ' VAL . 2.8 m -125.59 120.52 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.44 111.195 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -155.33 113.45 3.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 73.32 110.878 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.668 HG21 ' OG ' ' A' ' 91' ' ' SER . 60.9 t -140.85 147.31 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 71.13 111.099 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.492 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -73.48 158.68 86.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.632 0.73 . . . . 73.21 110.954 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.6 Cg_endo -69.82 159.79 52.05 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.686 2.258 . . . . 63.34 112.333 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.41 17.35 50.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.767 -0.73 . . . . 32.4 112.479 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -165.24 138.48 4.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.947 0.403 . . . . 71.52 110.858 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.38 137.69 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.137 -0.483 . . . . 70.22 111.081 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.668 ' OG ' HG21 ' A' ' 85' ' ' VAL . 3.5 t -119.98 131.7 55.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.113 -0.494 . . . . 62.43 110.847 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.4 t -96.92 145.76 25.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 54.41 111.119 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.519 HG21 HG11 ' A' ' 83' ' ' VAL . 40.1 t -145.99 125.6 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 73.23 111.139 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -102.99 115.43 30.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 71.21 110.89 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -162.27 109.62 1.33 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 62.55 110.908 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -107.72 143.04 36.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.487 . . . . 74.43 111.115 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.41 174.91 6.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 64.34 110.858 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -119.72 -20.36 7.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.489 . . . . 65.54 110.858 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -139.35 158.48 68.79 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.653 0.74 . . . . 75.51 110.814 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.424 ' HA ' ' HB ' ' A' ' 124' ' ' VAL . 53.7 Cg_endo -69.76 158.07 58.22 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.656 2.237 . . . . 74.35 112.355 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 156.27 136.53 2.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 54.24 112.497 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.507 ' HB3' HG23 ' A' ' 123' ' ' VAL . 1.5 pm0 -101.67 134.75 44.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 74.42 110.892 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . 0.787 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.7 OUTLIER -143.9 127.24 16.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 73.44 110.951 -179.82 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.8 105.96 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 75.13 110.901 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 6.3 tt 179.8 142.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 62.41 111.103 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 72.44 111.125 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.557 ' O ' HD13 ' A' ' 53' ' ' ILE . 46.3 m . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.779 0.323 . . . . 62.02 111.201 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.645 HG13 HG21 ' A' ' 53' ' ' ILE . 4.6 mp -141.73 119.46 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 64.34 111.158 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.507 HG23 ' HB3' ' A' ' 102' ' ' GLU . 9.0 p -116.44 136.88 52.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 71.11 111.125 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 55' ' ' VAL . 35.5 t -100.67 128.1 53.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 30.31 111.169 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.6 mmtt -111.99 132.55 54.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 71.23 110.896 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.207 -0.451 . . . . 64.0 110.926 179.961 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.497 ' O ' HG12 ' A' ' 90' ' ' VAL . 0.4 OUTLIER . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.821 0.343 . . . . 72.31 110.908 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.9 mpt_? -93.77 127.91 39.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 73.22 110.892 -179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.437 HG21 HG21 ' A' ' 16' ' ' VAL . 7.1 m -110.8 -178.79 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 63.22 111.153 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -144.41 162.17 40.81 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.593 0.711 . . . . 74.04 110.909 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -3.32 11.81 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.705 2.27 . . . . 43.31 112.306 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 26.9 m -44.92 -70.14 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 63.35 111.09 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 27.6 p -149.62 22.97 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 74.42 111.148 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.437 HG21 HG21 ' A' ' 11' ' ' VAL . 10.6 p -61.42 -23.75 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 74.35 111.106 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.518 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.6 OUTLIER -105.91 -19.88 13.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 72.31 110.844 -179.939 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -85.29 -28.29 25.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 61.1 110.912 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.402 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 4.9 pt-20 -145.06 146.66 31.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.467 . . . . 74.11 110.864 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.64 -158.91 14.02 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.794 -0.717 . . . . 31.34 112.453 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.46 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.0 Cg_endo -69.73 -30.26 22.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.665 2.243 . . . . 72.3 112.373 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.729 ' HB3' HD13 ' A' ' 42' ' ' LEU . 17.2 m-90 -85.86 -8.36 58.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.196 -0.457 . . . . 74.12 110.887 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.402 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -72.63 -59.63 2.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 33.22 111.103 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.54 145.8 34.09 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.588 0.709 . . . . 74.44 110.891 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.644 2.229 . . . . 64.33 112.36 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.0 -22.62 60.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 74.12 111.089 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -116.42 30.86 7.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 54.13 110.916 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.35 -57.01 3.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 74.43 111.097 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.78 HG21 ' HB3' ' A' ' 54' ' ' GLU . 21.9 t -113.18 101.89 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 74.02 111.124 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.9 t -117.14 148.87 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 75.32 111.119 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.452 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -80.39 117.4 21.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 64.24 110.915 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . 0.449 HG21 ' OG1' ' A' ' 38' ' ' THR . 15.9 p -105.79 -43.6 4.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 65.03 111.131 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.13 -173.24 22.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.79 -0.719 . . . . 73.31 112.501 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -5.61 16.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.7 2.267 . . . . 74.23 112.307 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -175.41 30.15 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 74.31 110.845 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . 0.412 ' HG3' ' HB2' ' A' ' 60' ' ' GLU . 4.6 mp0 -126.62 118.42 24.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 74.33 110.91 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.452 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 54.2 m-85 -98.93 130.4 45.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 74.31 110.94 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.449 ' OG1' HG21 ' A' ' 32' ' ' THR . 24.7 m -95.62 105.65 17.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.11 -0.496 . . . . 71.01 111.157 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.437 HG13 HG22 ' A' ' 29' ' ' VAL . 18.3 t -88.02 146.3 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 75.04 111.128 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -127.27 106.65 9.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 74.54 110.947 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.532 HG12 ' CG1' ' A' ' 53' ' ' ILE . 16.2 m -107.08 142.76 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 60.43 111.096 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.729 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.6 OUTLIER -139.41 143.27 37.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 74.45 110.858 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.35 114.76 3.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 71.3 111.083 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.507 ' CD2' HD21 ' A' ' 42' ' ' LEU . 4.1 p90 -127.67 155.06 44.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 75.42 110.905 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.9 4.21 38.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.465 . . . . 53.14 111.103 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -104.25 74.76 1.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 72.41 110.861 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 109.37 -160.11 13.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.726 -0.749 . . . . 75.55 112.544 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 11.4 p90 -135.25 144.94 47.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.793 0.33 . . . . 73.14 110.948 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -143.69 162.3 42.21 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.609 0.718 . . . . 45.23 110.883 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -176.09 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.63 2.22 . . . . 72.12 112.338 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.678 ' O ' HD12 ' A' ' 53' ' ' ILE . 62.9 m-20 -130.79 59.93 49.46 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.622 0.725 . . . . 73.13 110.884 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 73.84 1.31 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.7 2.267 . . . . 64.11 112.353 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.7 HG21 HG13 ' A' ' 122' ' ' ILE . 4.1 mp -117.14 122.71 70.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 75.15 111.086 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.78 ' HB3' HG21 ' A' ' 29' ' ' VAL . 10.5 tt0 -125.75 129.3 49.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.879 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 124' ' ' VAL . 2.6 p -136.51 80.47 38.69 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.635 0.731 . . . . 54.41 111.098 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.446 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.74 122.92 9.59 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.701 2.268 . . . . 75.35 112.321 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . 0.481 ' NE2' HG12 ' A' ' 124' ' ' VAL . 0.0 OUTLIER -67.49 154.71 40.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.237 -0.438 . . . . 74.23 110.932 179.954 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.33 -10.34 71.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 54.51 112.49 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.28 143.11 48.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 73.04 111.087 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.559 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.9 mp0 -61.15 135.19 57.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 71.21 110.867 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.651 HG13 HG23 ' A' ' 55' ' ' VAL . 12.4 mm -122.62 123.5 68.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.118 -0.492 . . . . 73.43 111.135 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.963 HG13 HG23 ' A' ' 92' ' ' THR . 41.9 t -101.9 92.23 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.42 111.134 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.79 138.33 54.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 73.43 110.873 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -131.15 102.01 5.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 74.55 110.91 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 74' ' ' PHE . 1.6 mp -102.92 139.84 22.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 71.52 111.146 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 10.1 t -158.62 137.74 11.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 53.54 111.163 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.457 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -141.59 160.93 54.78 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.674 0.75 . . . . 64.31 110.865 -179.875 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.457 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.86 -54.39 0.22 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.655 2.237 . . . . 52.14 112.349 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -157.32 59.03 0.51 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 44.44 110.882 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.407 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.93 135.97 4.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 73.42 111.17 179.983 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 mm -67.4 144.97 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 73.11 111.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.4 ' HB2' HG21 ' A' ' 65' ' ' ILE . 9.1 p80 -132.96 -176.58 4.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 72.43 110.848 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.62 132.66 3.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.741 -0.742 . . . . 60.2 112.455 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.504 ' CZ ' HD11 ' A' ' 65' ' ' ILE . 1.8 p90 -121.03 144.3 48.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.845 0.355 . . . . 64.32 110.891 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.42 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 9.7 p80 -103.82 88.17 2.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 72.45 110.881 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.784 HG13 ' CE2' ' A' ' 103' ' ' TYR . 10.9 t -74.94 115.67 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 62.01 111.125 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.89 177.45 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 74.11 110.91 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.41 -49.07 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.788 -0.72 . . . . 62.22 112.489 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.437 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -134.46 179.38 6.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.751 0.31 . . . . 70.02 111.163 -179.905 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.437 ' H ' HG22 ' A' ' 79' ' ' THR . 24.4 m120 -88.35 50.36 1.96 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 70.41 110.882 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.494 ' O ' HG23 ' A' ' 81' ' ' ILE . 6.2 tp -60.94 116.04 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 71.34 111.1 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -116.9 100.82 8.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 42.54 110.876 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.605 HG11 HG21 ' A' ' 93' ' ' VAL . 3.4 m -121.86 124.13 70.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 73.04 111.13 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -164.61 108.62 0.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 71.03 110.856 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.591 HG21 ' OG ' ' A' ' 91' ' ' SER . 45.1 t -140.4 146.49 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 44.13 111.189 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.74 161.23 62.68 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.58 0.705 . . . . 72.01 110.948 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.94 51.54 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.73 2.287 . . . . 71.43 112.305 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.37 5.48 75.67 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.75 -0.738 . . . . 50.01 112.515 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -147.9 117.95 7.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.899 0.38 . . . . 73.24 110.872 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.497 HG12 ' O ' ' A' ' 9' ' ' GLU . 3.8 p -77.94 118.98 25.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 70.42 111.104 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.591 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -94.85 134.05 37.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.11 -0.495 . . . . 74.02 110.835 -179.835 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.963 HG23 HG13 ' A' ' 62' ' ' VAL . 74.2 m -98.84 109.39 22.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 70.42 111.15 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.605 HG21 HG11 ' A' ' 83' ' ' VAL . 39.7 t -106.86 148.33 11.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 61.3 111.138 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -121.05 107.52 12.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.476 . . . . 74.54 110.831 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -153.18 130.39 11.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 52.34 110.949 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 29.7 m -139.95 141.57 36.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 75.34 111.143 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -96.57 -176.42 3.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 74.2 110.907 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -123.15 -12.55 7.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 61.11 110.905 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.95 162.85 51.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.647 0.737 . . . . 74.35 110.863 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 149.54 66.92 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.686 2.257 . . . . 64.34 112.328 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.4 136.92 2.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 61.52 112.459 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.711 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.5 OUTLIER -109.41 132.82 53.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.847 0.356 . . . . 70.23 110.875 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . 0.784 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.9 OUTLIER -143.27 137.17 28.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.181 -0.463 . . . . 52.21 110.895 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.93 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.17 -164.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 73.23 110.877 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.93 HG22 ' O ' ' A' ' 104' ' ' ARG . 7.7 tt 57.55 158.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 75.43 111.097 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 60.31 111.118 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.567 ' O ' HD13 ' A' ' 53' ' ' ILE . 55.1 m . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.775 0.321 . . . . 73.43 111.169 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.7 HG13 HG21 ' A' ' 53' ' ' ILE . 5.1 mp -146.48 129.66 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 64.42 111.115 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.711 HG23 ' HB3' ' A' ' 102' ' ' GLU . 9.9 p -132.27 137.06 55.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 71.42 111.119 179.816 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.679 HG13 ' O ' ' A' ' 55' ' ' VAL . 15.7 t -99.73 125.18 53.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 72.03 111.115 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.6 mmmt -99.26 130.68 45.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 71.34 110.879 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 61.5 110.863 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.847 0.356 . . . . 75.41 110.919 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.12 136.74 38.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 73.41 110.85 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.518 HG21 HG21 ' A' ' 16' ' ' VAL . 15.2 m -128.46 -178.66 2.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 64.34 111.103 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 161.94 41.54 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.647 0.737 . . . . 64.14 110.854 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -4.71 14.58 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.735 2.29 . . . . 62.01 112.359 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.407 ' O ' HG23 ' A' ' 15' ' ' THR . 4.2 m -48.44 -66.92 0.32 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.185 -0.461 . . . . 74.35 111.138 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 14' ' ' THR . 2.8 p -155.62 37.59 0.37 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.446 . . . . 63.15 111.163 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.518 HG21 HG21 ' A' ' 11' ' ' VAL . 14.7 p -74.29 -34.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 75.11 111.119 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.427 ' HB3' HD11 ' A' ' 42' ' ' LEU . 11.5 ptt85 -95.17 -10.73 29.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 73.45 110.865 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 -97.69 -35.08 10.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 62.41 110.892 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -131.86 136.95 47.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 63.24 110.906 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 118.21 -159.5 14.25 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 11.21 112.495 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -26.89 26.94 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.63 2.22 . . . . 62.15 112.325 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.748 ' HB3' HD13 ' A' ' 42' ' ' LEU . 15.7 m-90 -86.37 -10.94 53.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.235 -0.439 . . . . 71.54 110.929 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.9 -59.0 3.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 61.14 111.079 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.85 144.61 29.7 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.573 0.702 . . . . 73.31 110.898 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -15.32 37.02 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.686 2.257 . . . . 62.21 112.349 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.29 -6.46 48.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 31.04 111.117 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.8 mm-40 -106.39 6.49 30.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 72.54 110.883 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -51.95 -76.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 70.54 111.07 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.451 HG13 ' HB3' ' A' ' 37' ' ' TYR . 14.2 t -83.13 130.75 35.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 74.34 111.131 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 32.3 t -144.67 114.35 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 73.43 111.109 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -60.03 116.51 4.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 74.34 110.904 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.4 t -119.9 -38.74 2.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 63.43 111.136 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.91 173.61 18.82 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.732 . . . . 24.35 112.539 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.04 3.57 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.726 2.284 . . . . 64.21 112.339 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 53.2 t30 67.78 34.96 4.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 74.33 110.898 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -145.48 156.96 44.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 62.14 110.901 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.451 ' HB3' HG13 ' A' ' 29' ' ' VAL . 43.1 m-85 -143.16 141.27 31.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 74.55 110.955 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.528 HG23 ' HE3' ' A' ' 64' ' ' LYS . 54.4 m -94.86 104.87 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.117 -0.492 . . . . 74.21 111.152 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.466 HG11 HG23 ' A' ' 53' ' ' ILE . 15.7 t -87.35 152.62 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 51.24 111.097 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -127.2 140.25 52.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 64.11 110.913 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.593 HG22 ' CG1' ' A' ' 53' ' ' ILE . 60.0 t -139.1 137.98 41.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 63.54 111.106 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.748 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.4 OUTLIER -138.42 141.49 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 73.3 110.873 179.92 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.58 101.18 2.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 73.1 111.104 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -116.57 147.35 41.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 74.44 110.857 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.23 0.26 52.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 73.44 111.115 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -94.19 39.28 1.08 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 75.44 110.908 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.63 -137.93 8.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 64.51 112.526 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 31.1 t80 -155.24 160.6 40.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.802 0.334 . . . . 74.23 110.959 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -165.23 162.18 14.07 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.581 0.705 . . . . 73.04 110.912 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 176.74 6.37 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.703 2.269 . . . . 72.14 112.348 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.639 ' C ' HD12 ' A' ' 53' ' ' ILE . 6.6 m120 -133.89 63.25 62.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.616 0.722 . . . . 53.51 110.85 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 72.1 1.48 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.268 . . . . 74.4 112.372 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.722 HG21 HG13 ' A' ' 122' ' ' ILE . 4.9 mp -106.41 121.55 59.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 70.14 111.152 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -120.0 115.4 23.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 75.31 110.893 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.862 HG13 HG22 ' A' ' 124' ' ' VAL . 2.6 p -123.35 78.47 53.56 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.621 0.724 . . . . 54.42 111.15 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.721 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.73 123.02 9.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.704 2.27 . . . . 64.14 112.342 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -68.61 154.72 41.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.267 -0.424 . . . . 61.14 110.875 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.1 -6.28 76.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 73.41 112.517 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.31 156.44 47.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.76 0.314 . . . . 72.03 111.072 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.742 ' O ' HD13 ' A' ' 61' ' ' ILE . 6.3 mt-10 -67.42 138.53 56.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.915 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.742 HD13 ' O ' ' A' ' 60' ' ' GLU . 4.4 mm -130.87 114.8 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 41.31 111.118 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 92' ' ' THR . 39.5 t -101.23 94.29 3.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 75.35 111.123 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -70.47 132.61 45.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 74.44 110.884 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.528 ' HE3' HG23 ' A' ' 38' ' ' THR . 36.2 mttt -128.74 99.74 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 75.23 110.914 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.502 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.8 mp -104.22 158.63 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 72.22 111.159 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.414 ' N ' HG22 ' A' ' 65' ' ' ILE . 7.9 t -167.01 141.91 4.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 62.13 111.144 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.586 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -148.48 158.46 40.5 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.686 0.755 . . . . 62.51 110.852 -179.88 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.45 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.6 Cg_endo -69.8 -55.48 0.17 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.725 2.283 . . . . 74.12 112.31 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -154.91 68.39 0.7 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.852 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.586 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.2 -171.15 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.215 -0.448 . . . . 74.22 111.143 -179.992 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.509 HD13 ' O ' ' A' ' 70' ' ' VAL . 30.9 mm -138.11 140.49 40.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 71.14 111.126 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.502 ' CG ' HG21 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -115.23 -85.46 0.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 73.3 110.848 179.917 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 53.85 94.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.71 -0.757 . . . . 31.34 112.48 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -100.14 143.09 30.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 70.13 110.868 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -120.22 142.84 48.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 73.04 110.846 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.806 HG11 ' CZ ' ' A' ' 95' ' ' TYR . 4.9 p -127.78 122.83 59.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 71.34 111.112 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -52.16 160.85 0.7 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 74.04 110.897 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.15 -51.93 4.55 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.786 -0.721 . . . . 41.14 112.467 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.85 160.91 14.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.827 0.346 . . . . 73.24 111.132 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -101.03 35.49 2.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.466 . . . . 71.24 110.924 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.635 HG21 HG12 ' A' ' 76' ' ' VAL . 20.0 tt -54.73 124.91 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 75.03 111.117 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -123.76 82.75 2.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 74.24 110.897 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.447 HG11 HG11 ' A' ' 93' ' ' VAL . 5.1 m -110.33 119.33 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 62.51 111.106 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -165.39 103.32 0.73 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 62.42 110.896 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 18.1 m -140.36 139.37 35.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.148 -0.478 . . . . 75.1 111.13 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.7 mp -59.88 163.39 7.63 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.583 0.706 . . . . 72.45 110.936 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 159.93 51.6 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.669 2.246 . . . . 50.43 112.343 179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.5 17.38 57.1 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 71.31 112.469 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -158.42 143.45 16.35 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 74.34 110.881 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 52.3 t -81.42 146.12 7.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.136 -0.484 . . . . 74.13 111.115 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -103.82 158.08 16.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.44 110.891 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 62' ' ' VAL . 26.6 m -147.28 123.23 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 75.33 111.164 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.447 HG11 HG11 ' A' ' 83' ' ' VAL . 9.4 p -153.15 136.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 51.33 111.126 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.0 mtm180 -96.33 81.46 3.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 75.02 110.84 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.806 ' CZ ' HG11 ' A' ' 76' ' ' VAL . 2.9 t80 -106.11 121.89 45.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.209 -0.451 . . . . 72.5 110.935 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 t -133.74 138.46 45.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 70.13 111.135 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.43 -168.9 1.68 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.899 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.5 mtpt -123.12 -27.12 4.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 70.42 110.917 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . 0.437 ' HB3' ' HD2' ' A' ' 100' ' ' PRO . 13.3 mmt180 -129.18 156.07 78.87 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 73.04 110.916 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . 0.437 ' HD2' ' HB3' ' A' ' 99' ' ' ARG . 54.0 Cg_endo -69.72 152.08 69.43 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.672 2.248 . . . . 52.33 112.329 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.7 150.49 6.84 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.758 -0.734 . . . . 70.34 112.485 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.691 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -112.63 127.74 56.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.885 0.374 . . . . 63.31 110.867 -179.879 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -143.93 136.46 26.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 72.51 110.911 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.914 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.1 OUTLIER -144.38 -167.29 2.59 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.119 -0.492 . . . . 74.23 110.885 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.914 HG22 ' O ' ' A' ' 104' ' ' ARG . 0.6 OUTLIER 56.93 159.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 55.12 111.074 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 7.0 tt . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 75.22 111.121 179.861 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.568 ' O ' HD13 ' A' ' 53' ' ' ILE . 28.6 m . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.775 0.321 . . . . 73.34 111.161 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.722 HG13 HG21 ' A' ' 53' ' ' ILE . 4.8 mp -147.88 109.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 73.35 111.112 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.691 HG23 ' HB3' ' A' ' 102' ' ' GLU . 8.6 p -114.97 140.65 35.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 75.24 111.091 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.862 HG22 HG13 ' A' ' 55' ' ' VAL . 68.9 t -104.16 118.49 51.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 74.51 111.125 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 5.1 mmmt -89.98 131.21 35.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 70.24 110.912 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 72.23 110.906 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.546 ' O ' HG12 ' A' ' 90' ' ' VAL . 0.5 OUTLIER . . . . . 0 C--O 1.23 0.076 0 CA-C-O 120.822 0.344 . . . . 62.15 110.9 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.95 124.14 34.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 74.34 110.92 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 16' ' ' VAL . 13.9 m -111.4 -178.99 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.456 . . . . 74.4 111.146 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -145.59 162.27 37.21 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.594 0.711 . . . . 72.02 110.887 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 -4.03 13.19 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.688 2.258 . . . . 71.53 112.339 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.411 ' O ' HG23 ' A' ' 15' ' ' THR . 1.9 m -46.93 -65.2 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 71.43 111.166 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 14' ' ' THR . 2.0 p -155.63 32.54 0.36 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.237 -0.438 . . . . 72.44 111.127 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 11' ' ' VAL . 13.9 p -70.96 -29.14 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.232 -0.44 . . . . 63.13 111.125 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.8 ptt-85 -97.55 -9.03 27.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.879 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -101.41 -31.9 10.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 73.33 110.918 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -132.8 134.82 45.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 74.12 110.908 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.98 -158.56 14.62 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.782 -0.723 . . . . 73.2 112.542 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.446 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 53.8 Cg_endo -69.78 -28.81 24.68 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.693 2.262 . . . . 64.34 112.377 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.446 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 18.5 m-90 -87.01 -5.67 59.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 75.31 110.921 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.5 -59.34 2.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.246 -0.434 . . . . 55.44 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -113.93 144.68 32.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.554 0.692 . . . . 65.2 110.891 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -5.02 15.23 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.683 2.256 . . . . 70.12 112.384 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.77 -19.0 61.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.128 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.24 31.16 6.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 74.21 110.929 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.2 -73.1 0.13 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.05 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.655 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.0 p -111.63 106.54 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.441 . . . . 65.02 111.157 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -117.45 149.92 19.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 64.35 111.157 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -79.64 124.21 28.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 73.24 110.94 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.7 t -119.19 -14.83 9.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 52.11 111.136 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.42 -170.93 12.81 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 73.22 112.484 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -36.02 11.42 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.252 . . . . 72.14 112.33 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 20.2 t30 -149.76 34.61 0.69 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.225 -0.443 . . . . 61.24 110.861 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -137.33 117.44 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 73.4 110.91 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -98.24 143.13 29.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 74.23 110.918 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 51.9 m -99.05 102.21 13.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 73.33 111.158 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 t -83.53 143.15 12.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 75.52 111.117 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -125.0 112.7 16.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.196 -0.456 . . . . 73.01 110.937 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.5 HG22 HD12 ' A' ' 53' ' ' ILE . 85.4 t -109.53 125.9 66.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.12 -0.491 . . . . 63.01 111.107 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.692 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.5 tm? -115.64 137.18 52.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 74.21 110.928 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.692 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.05 117.56 4.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 72.11 111.082 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -145.38 140.54 27.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 53.33 110.885 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.4 27.03 1.31 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 74.31 111.124 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -120.92 25.26 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 73.43 110.886 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 169.32 -146.9 10.53 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.816 -0.707 . . . . 52.22 112.523 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -155.57 116.4 3.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.798 0.332 . . . . 74.32 110.914 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.457 ' HG3' ' HD2' ' A' ' 50' ' ' PRO . 2.1 mp0 -134.65 163.32 52.02 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.591 0.71 . . . . 75.14 110.919 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.457 ' HD2' ' HG3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.79 162.15 43.19 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.64 2.226 . . . . 74.34 112.362 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 -124.29 64.34 36.81 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.586 0.708 . . . . 73.32 110.917 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.601 ' C ' HD13 ' A' ' 53' ' ' ILE . 54.3 Cg_endo -69.72 113.18 3.28 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.669 2.246 . . . . 74.54 112.375 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.601 HD13 ' C ' ' A' ' 52' ' ' PRO . 1.5 mm -126.13 144.99 34.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 71.22 111.161 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.655 ' HB3' HG11 ' A' ' 29' ' ' VAL . 24.0 tt0 -155.23 115.6 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 74.14 110.918 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 1.002 HG12 HG21 ' A' ' 61' ' ' ILE . 2.7 m -130.75 84.29 59.08 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.63 0.729 . . . . 73.34 111.127 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.703 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.77 122.62 9.3 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 73.02 112.369 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.7 154.56 38.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 53.45 110.9 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.62 -8.39 72.34 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 72.43 112.476 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.16 157.32 45.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.714 0.292 . . . . 51.1 111.142 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.728 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.0 mt-10 -70.19 144.7 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 71.4 110.915 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 1.002 HG21 HG12 ' A' ' 55' ' ' VAL . 5.4 mm -128.79 105.35 12.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 52.54 111.112 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.622 HG13 HG23 ' A' ' 92' ' ' THR . 25.4 t -84.74 100.68 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 73.24 111.074 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.478 ' CZ ' HG11 ' A' ' 55' ' ' VAL . 96.0 m-85 -76.89 135.15 38.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.1 110.876 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.47 ' HD3' HG21 ' A' ' 90' ' ' VAL . 8.7 mttt -132.28 100.19 4.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 62.32 110.93 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.508 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.6 mp -109.08 141.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 55.42 111.115 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 7.8 t -155.92 135.3 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 72.13 111.135 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.44 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -141.96 161.1 53.02 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.7 0.762 . . . . 54.03 110.826 -179.867 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.419 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.0 Cg_endo -69.74 -53.34 0.28 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.674 2.249 . . . . 51.4 112.365 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -156.67 57.82 0.55 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 71.14 110.823 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.44 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.49 141.43 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.254 -0.43 . . . . 75.13 111.126 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 72' ' ' HIS . 25.1 mm -85.35 155.18 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 71.53 111.093 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.508 ' CG ' HG21 ' A' ' 65' ' ' ILE . 0.2 OUTLIER -123.75 -86.28 0.64 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.121 -0.49 . . . . 71.12 110.857 179.872 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.04 101.6 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.721 -0.752 . . . . 62.14 112.469 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.479 ' CE2' HD11 ' A' ' 65' ' ' ILE . 2.5 p90 -103.5 144.94 30.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.917 0.389 . . . . 74.34 110.854 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -106.0 142.25 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 71.33 110.884 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.747 ' HB ' HG21 ' A' ' 81' ' ' ILE . 44.3 t -137.53 143.6 33.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 52.23 111.131 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -73.2 -175.7 1.94 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.478 . . . . 64.11 110.912 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.09 -51.09 3.98 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.75 -0.738 . . . . 52.12 112.493 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.442 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -142.14 179.5 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.828 0.347 . . . . 62.0 111.127 -179.862 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.442 ' H ' HG22 ' A' ' 79' ' ' THR . 6.8 t-20 -88.17 61.05 6.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 65.21 110.891 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.747 HG21 ' HB ' ' A' ' 76' ' ' VAL . 4.8 tp -71.16 99.72 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 73.11 111.13 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -110.4 112.11 23.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 72.24 110.919 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.808 HG11 HG21 ' A' ' 93' ' ' VAL . 1.5 m -130.82 122.93 53.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.457 . . . . 72.52 111.161 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -152.64 112.79 4.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 71.44 110.874 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.631 HG21 ' OG ' ' A' ' 91' ' ' SER . 57.3 t -140.55 144.28 27.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 60.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.27 160.06 80.54 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.631 0.729 . . . . 71.33 110.899 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.424 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.4 Cg_endo -69.76 159.82 51.97 Favored 'Trans proline' 0 C--N 1.34 0.126 0 C-N-CA 122.708 2.272 . . . . 53.31 112.28 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.61 -1.27 56.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 74.34 112.465 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -147.0 156.75 43.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.884 0.374 . . . . 74.45 110.891 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.546 HG12 ' O ' ' A' ' 9' ' ' GLU . 2.1 p -105.55 113.9 43.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 71.03 111.119 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.631 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -80.54 168.2 19.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 34.43 110.876 -179.87 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 0.622 HG23 HG13 ' A' ' 62' ' ' VAL . 96.5 m -134.5 139.35 45.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 65.34 111.129 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.808 HG21 HG11 ' A' ' 83' ' ' VAL . 9.9 t -143.45 137.63 25.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.236 -0.438 . . . . 71.01 111.128 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.04 72.63 0.79 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.469 . . . . 71.51 110.886 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -108.41 141.17 40.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 74.51 110.924 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.1 t -140.06 143.19 36.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.137 -0.483 . . . . 63.21 111.162 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -101.1 177.18 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 70.35 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.34 -12.79 8.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.462 . . . . 71.54 110.877 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -144.57 162.03 41.01 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.653 0.74 . . . . 74.3 110.914 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 155.58 65.62 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.73 2.287 . . . . 62.25 112.314 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 162.27 135.37 1.8 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.773 -0.727 . . . . 74.32 112.53 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.841 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -108.92 124.89 51.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.866 0.365 . . . . 74.14 110.901 -179.896 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -136.04 135.27 39.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.198 -0.456 . . . . 71.21 110.954 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.95 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.5 OUTLIER -144.24 -177.56 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 60.11 110.858 -179.95 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.95 HG22 ' O ' ' A' ' 104' ' ' ARG . 6.6 tt 59.79 158.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 73.13 111.122 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 72.04 111.164 179.818 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.557 ' C ' HD12 ' A' ' 122' ' ' ILE . 99.4 m . . . . . 0 C--O 1.232 0.133 0 CA-C-O 120.741 0.305 . . . . 63.42 111.138 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.576 HG13 HG21 ' A' ' 53' ' ' ILE . 3.1 mp -153.41 138.08 9.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 73.12 111.131 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.841 HG23 ' HB3' ' A' ' 102' ' ' GLU . 11.5 p -134.22 134.69 55.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 71.12 111.151 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.742 HG22 HG23 ' A' ' 55' ' ' VAL . 48.1 t -103.61 129.13 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 73.41 111.152 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt -107.19 129.1 54.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.134 -0.484 . . . . 63.31 110.885 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 64.51 110.878 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.45 ' O ' HG12 ' A' ' 90' ' ' VAL . 4.0 mm-40 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 120.828 0.347 . . . . 73.1 110.877 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.67 139.26 40.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 74.04 110.874 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.8 m -130.1 -177.55 2.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 73.35 111.124 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.411 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 55.9 p-10 -144.07 155.47 58.6 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.563 0.697 . . . . 73.01 110.893 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.4 Cg_endo -69.84 -3.94 13.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.656 2.237 . . . . 73.53 112.351 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.43 ' O ' HG23 ' A' ' 15' ' ' THR . 23.2 m -49.07 -64.7 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 44.23 111.092 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.43 HG23 ' O ' ' A' ' 14' ' ' THR . 2.7 p -156.04 34.91 0.34 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 62.21 111.15 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 p -70.59 -29.19 37.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 61.33 111.069 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.552 ' HB3' HD21 ' A' ' 42' ' ' LEU . 7.2 ptt-85 -98.74 -7.91 26.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 71.43 110.879 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -101.62 -34.79 9.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 73.15 110.927 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.51 133.2 46.07 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 73.53 110.891 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 120.25 -158.15 15.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.747 -0.74 . . . . 62.11 112.507 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -30.11 22.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.73 2.287 . . . . 74.0 112.321 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.416 ' HB3' HD23 ' A' ' 42' ' ' LEU . 13.5 m-90 -84.89 -10.21 57.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.279 -0.418 . . . . 74.1 110.921 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.85 -59.46 2.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 74.41 111.072 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.76 144.64 28.21 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.64 0.733 . . . . 72.33 110.815 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -26.35 27.8 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.686 2.257 . . . . 75.32 112.335 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.02 -18.31 60.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.262 -0.426 . . . . 52.32 111.093 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 19.0 mm-40 -87.35 6.85 31.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 75.22 110.887 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.87 -77.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.266 -0.424 . . . . 62.55 111.084 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.54 116.95 23.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 71.34 111.131 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.0 t -145.77 131.06 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 71.5 111.167 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.59 125.47 26.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 72.23 110.877 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.2 t -117.46 -41.39 2.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 72.24 111.148 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.73 -164.11 18.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 73.35 112.482 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -43.99 2.37 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.7 2.266 . . . . 41.51 112.372 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -141.27 34.45 1.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 73.31 110.908 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -131.4 119.71 22.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 71.31 110.847 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -97.0 140.93 30.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 62.4 110.919 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.694 ' HA ' HG23 ' A' ' 62' ' ' VAL . 96.7 m -93.79 122.45 36.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 61.22 111.137 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.907 HG11 HG23 ' A' ' 53' ' ' ILE . 18.5 t -109.05 108.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 60.44 111.107 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.408 ' CZ ' HG21 ' A' ' 38' ' ' THR . 66.6 m-85 -94.18 105.45 17.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 73.21 110.924 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.602 HG22 ' CG1' ' A' ' 53' ' ' ILE . 59.8 t -98.73 132.65 43.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.082 -0.508 . . . . 71.44 111.167 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.643 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.6 tm? -123.85 133.82 53.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.226 -0.443 . . . . 74.13 110.91 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.643 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.06 132.01 10.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 74.41 111.083 179.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -145.26 147.54 32.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 72.41 110.912 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.74 50.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.179 -0.464 . . . . 71.51 111.133 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -95.72 34.05 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 73.31 110.86 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.49 -138.56 6.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.75 -0.738 . . . . 65.05 112.505 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -155.17 157.02 36.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.801 0.334 . . . . 65.41 110.957 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -165.33 162.05 13.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.582 0.706 . . . . 73.31 110.938 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 178.64 4.34 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.677 2.251 . . . . 75.11 112.37 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.63 ' C ' HD12 ' A' ' 53' ' ' ILE . 8.0 m-80 -138.41 63.46 34.78 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.602 0.715 . . . . 73.34 110.869 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 73.1 1.36 Allowed 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.719 2.279 . . . . 65.4 112.361 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.907 HG23 HG11 ' A' ' 39' ' ' VAL . 4.8 mp -106.73 136.44 41.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 71.13 111.13 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -133.13 118.05 18.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.169 -0.469 . . . . 63.21 110.891 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.719 ' O ' HG13 ' A' ' 124' ' ' VAL . 19.6 t -119.9 82.8 28.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 73.11 111.146 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.688 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.73 122.06 8.75 Favored 'Trans proline' 0 N--CA 1.465 -0.173 0 C-N-CA 122.718 2.279 . . . . 72.34 112.358 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -69.79 153.03 43.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 43.24 110.914 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.27 -4.62 83.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 64.51 112.484 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.42 156.24 48.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 62.01 111.112 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.726 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.8 mp0 -66.71 140.6 57.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 74.24 110.897 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.726 HD13 ' O ' ' A' ' 60' ' ' GLU . 5.6 mm -130.23 115.01 30.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.134 -0.485 . . . . 72.43 111.116 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.694 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -103.0 90.95 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.17 -0.468 . . . . 71.1 111.161 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.663 ' HB2' HG12 ' A' ' 93' ' ' VAL . 72.2 m-85 -68.13 138.81 56.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 74.13 110.864 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.442 ' HD3' HG21 ' A' ' 90' ' ' VAL . 5.4 mttt -131.83 99.36 4.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 72.44 110.943 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.5 mp -106.76 142.55 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 63.24 111.152 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.429 ' O ' HG23 ' A' ' 66' ' ' THR . 14.2 t -153.81 128.29 9.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 72.22 111.155 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.687 ' CB ' HG23 ' A' ' 70' ' ' VAL . 1.0 OUTLIER -131.33 160.23 68.08 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.677 0.751 . . . . 65.11 110.854 -179.847 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.533 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.72 -53.2 0.28 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.708 2.272 . . . . 62.11 112.343 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . 0.422 ' HA ' ' HG3' ' A' ' 87' ' ' PRO . 3.7 m-20 -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 73.23 110.888 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.687 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.9 133.41 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 65.41 111.16 179.984 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.706 HG22 ' H ' ' A' ' 72' ' ' HIS . 10.1 mm -91.73 172.53 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 62.32 111.105 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.706 ' H ' HG22 ' A' ' 71' ' ' ILE . 0.1 OUTLIER 76.28 148.86 0.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.124 -0.489 . . . . 73.32 110.896 179.915 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -121.12 -94.68 1.37 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.731 -0.747 . . . . 62.23 112.489 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.519 ' CG ' HD11 ' A' ' 122' ' ' ILE . 3.6 p90 -152.02 149.33 28.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.897 0.38 . . . . 73.11 110.871 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -114.73 143.1 45.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 75.33 110.836 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.728 HG12 ' CG2' ' A' ' 81' ' ' ILE . 5.9 p -119.67 145.07 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 65.12 111.141 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.3 172.55 12.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 73.04 110.886 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.51 -52.05 4.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.731 -0.747 . . . . 71.33 112.479 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 16.8 m -123.1 154.13 39.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.333 . . . . 64.31 111.139 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -88.41 65.87 8.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 60.52 110.903 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.728 ' CG2' HG12 ' A' ' 76' ' ' VAL . 0.7 OUTLIER -57.03 134.12 21.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.195 -0.457 . . . . 64.3 111.169 179.922 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.37 81.62 1.61 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 75.3 110.87 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.454 ' O ' HG23 ' A' ' 83' ' ' VAL . 19.6 m -116.63 117.73 56.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 72.22 111.141 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -166.88 117.8 0.92 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 72.43 110.893 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.0 m -140.18 137.4 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 65.33 111.089 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.08 156.44 1.79 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.576 0.703 . . . . 73.34 110.961 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.487 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.1 Cg_endo -69.83 159.21 54.21 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.671 2.247 . . . . 72.22 112.316 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 87.39 3.36 81.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.71 -0.757 . . . . 74.42 112.523 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 -148.59 117.56 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 72.01 110.876 -179.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.45 HG12 ' O ' ' A' ' 9' ' ' GLU . 1.7 p -60.33 137.19 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 74.45 111.138 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.58 163.91 17.17 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 73.52 110.899 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.6 m -146.69 104.83 3.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 54.02 111.135 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.663 HG12 ' HB2' ' A' ' 63' ' ' PHE . 4.4 p -130.07 154.36 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 74.32 111.14 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -122.67 100.4 6.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 73.32 110.912 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.412 ' CD2' HD12 ' A' ' 81' ' ' ILE . 49.9 t80 -134.81 108.31 7.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.19 -0.459 . . . . 70.04 110.885 -179.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.8 t -103.94 135.54 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 75.53 111.184 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.474 ' HD2' HG21 ' A' ' 124' ' ' VAL . 0.1 OUTLIER -93.44 -177.57 4.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 62.54 110.828 -179.942 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.7 mtmt -125.72 -22.03 4.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 62.04 110.897 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.14 158.92 72.75 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.587 0.708 . . . . 71.21 110.868 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 152.89 69.3 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.696 2.264 . . . . 73.24 112.343 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 168.64 143.43 3.83 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 63.1 112.475 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.693 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -110.27 133.09 53.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.832 0.348 . . . . 44.32 110.92 -179.918 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . 0.477 ' CZ ' HG23 ' A' ' 76' ' ' VAL . 1.2 p90 -143.78 136.63 27.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.148 -0.478 . . . . 75.43 110.921 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.912 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.49 -167.82 2.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 63.3 110.894 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.912 HG22 ' O ' ' A' ' 104' ' ' ARG . 8.5 tt 56.64 159.32 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 52.11 111.118 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 63.22 111.112 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.658 ' O ' HD13 ' A' ' 53' ' ' ILE . 52.3 m . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.792 0.33 . . . . 65.11 111.2 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.539 HD12 ' C ' ' A' ' 121' ' ' THR . 4.8 mp -146.82 139.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 61.0 111.098 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.693 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -134.81 135.08 53.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 71.32 111.174 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.719 HG13 ' O ' ' A' ' 55' ' ' VAL . 57.4 t -102.65 123.94 56.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 43.14 111.147 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.1 mmtt -98.29 134.25 41.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 72.34 110.918 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 71.53 110.892 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.882 0.372 . . . . 71.52 110.87 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.3 mpt_? -99.02 121.42 40.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 63.11 110.87 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.436 HG21 ' OG1' ' A' ' 66' ' ' THR . 15.7 m -118.61 -179.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 63.33 111.16 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.99 162.16 39.22 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.688 0.756 . . . . 74.34 110.799 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.85 -2.96 11.12 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.662 2.241 . . . . 73.55 112.349 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -44.86 -62.78 1.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 74.54 111.15 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.8 23.87 0.39 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 72.4 111.166 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.411 HG21 HG21 ' A' ' 11' ' ' VAL . 10.0 p -65.89 -30.98 51.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 72.52 111.098 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.676 ' CB ' HD11 ' A' ' 42' ' ' LEU . 0.2 OUTLIER -106.3 -6.93 18.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 73.33 110.886 -179.978 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -95.24 -36.44 11.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 72.11 110.894 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -140.94 132.28 26.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 75.01 110.85 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.91 -156.95 21.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 73.42 112.487 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.463 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.8 Cg_endo -69.76 -32.91 17.65 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 70.21 112.356 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.786 ' O ' HD12 ' A' ' 42' ' ' LEU . 10.5 m-90 -84.92 -17.87 36.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.445 . . . . 75.44 110.951 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.45 -61.33 2.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 75.51 111.092 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.69 144.36 29.41 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.612 0.72 . . . . 73.42 110.828 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -11.37 30.69 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.692 2.262 . . . . 61.45 112.32 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.69 -27.52 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 63.01 111.119 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.515 HE21 ' N ' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -111.04 31.84 5.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 74.34 110.862 -179.9 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.77 -41.82 29.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 43.11 111.1 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.701 HG21 ' CB ' ' A' ' 54' ' ' GLU . 60.3 t -114.64 130.33 69.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 65.42 111.113 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -146.87 137.87 18.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.096 -0.502 . . . . 61.13 111.064 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -79.68 115.87 19.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 75.33 110.937 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -113.79 -21.06 10.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 73.12 111.142 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.27 -167.48 14.05 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 61.12 112.511 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.94 3.88 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.715 2.277 . . . . 75.32 112.363 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -148.42 29.73 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 71.44 110.876 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -126.95 116.32 20.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 75.32 110.891 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -95.75 140.33 30.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 71.44 110.966 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.716 ' HA ' HG23 ' A' ' 62' ' ' VAL . 88.0 m -92.38 109.9 21.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 72.43 111.176 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 t -89.93 130.07 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 75.34 111.108 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -113.98 105.13 12.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 74.23 110.956 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.554 HG12 HD12 ' A' ' 53' ' ' ILE . 25.0 m -100.15 147.01 8.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.145 -0.48 . . . . 74.42 111.158 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.786 HD12 ' O ' ' A' ' 22' ' ' TRP . 0.3 OUTLIER -133.67 133.16 41.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.245 -0.434 . . . . 65.31 110.948 179.961 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.78 98.72 1.94 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 63.44 111.083 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.507 ' HD1' HD22 ' A' ' 42' ' ' LEU . 52.5 p90 -123.85 143.03 50.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.855 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.86 0.17 53.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 74.41 111.114 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -97.2 66.33 2.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 73.1 110.871 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.28 -137.07 10.47 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.455 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -155.17 150.27 26.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.861 0.363 . . . . 72.2 110.924 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -165.32 163.29 13.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.583 0.706 . . . . 72.44 110.925 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 176.08 7.28 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.618 2.212 . . . . 70.33 112.335 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.441 ' O ' HG12 ' A' ' 53' ' ' ILE . 4.1 m120 -129.86 62.72 65.3 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.623 0.725 . . . . 71.31 110.914 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.662 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.7 Cg_endo -69.73 111.15 2.72 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 53.44 112.342 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.669 HG21 HG13 ' A' ' 122' ' ' ILE . 1.1 mm -130.66 151.58 36.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 71.53 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.701 ' CB ' HG21 ' A' ' 29' ' ' VAL . 6.3 tt0 -156.06 115.77 3.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 60.32 110.866 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.678 ' O ' HG13 ' A' ' 124' ' ' VAL . 6.3 t -135.37 76.44 56.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.699 . . . . 61.33 111.139 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.638 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.2 Cg_endo -69.8 121.55 8.23 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.695 2.263 . . . . 65.42 112.329 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.5 155.29 38.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.239 -0.437 . . . . 74.54 110.949 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.56 -13.32 65.85 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 24.23 112.49 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.43 154.48 50.74 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 63.35 111.077 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.693 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.1 mt-10 -64.69 136.08 56.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 75.25 110.906 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.693 HD13 ' O ' ' A' ' 60' ' ' GLU . 8.1 mm -127.25 96.21 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 75.12 111.11 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.716 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.2 OUTLIER -84.46 102.18 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 71.4 111.143 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -73.49 139.62 45.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 71.41 110.922 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 15.8 mttt -131.83 98.78 4.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.472 . . . . 75.33 110.928 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.747 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.3 mp -97.56 157.29 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 73.02 111.147 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.436 ' OG1' HG21 ' A' ' 11' ' ' VAL . 12.3 t -170.24 126.21 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 42.25 111.164 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.661 ' HB3' HG22 ' A' ' 70' ' ' VAL . 3.6 m -127.44 161.99 51.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.656 0.741 . . . . 63.24 110.879 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -51.8 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.645 2.23 . . . . 74.1 112.334 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -155.52 29.52 0.38 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 63.44 110.809 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.661 HG22 ' HB3' ' A' ' 67' ' ' SER . 25.9 m -128.37 144.35 38.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 71.12 111.109 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.535 HD13 ' HD3' ' A' ' 87' ' ' PRO . 24.1 mm -69.73 157.2 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.479 . . . . 71.23 111.13 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.747 ' HB3' HG21 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -114.7 -164.4 0.94 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.18 -0.464 . . . . 73.5 110.865 179.888 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.71 130.48 3.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.815 -0.707 . . . . 42.31 112.479 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.572 ' CE1' HG21 ' A' ' 83' ' ' VAL . 1.5 p90 -136.76 144.39 43.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.884 0.373 . . . . 74.14 110.91 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 36.8 t-80 -93.66 133.6 36.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.119 -0.492 . . . . 65.2 110.822 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.721 HG13 ' CE2' ' A' ' 103' ' ' TYR . 87.0 t -126.72 143.27 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 73.2 111.117 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -75.52 177.01 7.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 74.43 110.856 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.74 -51.59 4.57 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 61.21 112.489 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.1 m -140.64 154.12 46.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.797 0.332 . . . . 62.51 111.106 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -76.6 64.58 2.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 73.3 110.88 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 11.3 tt -54.9 128.29 14.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.469 . . . . 73.24 111.124 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -115.58 97.06 5.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 64.41 110.869 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.572 HG21 ' CE1' ' A' ' 74' ' ' PHE . 3.5 m -125.48 120.44 57.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 42.4 111.075 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -154.33 115.72 4.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 74.53 110.832 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.661 HG21 ' CB ' ' A' ' 91' ' ' SER . 94.1 t -139.28 146.53 25.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.485 . . . . 73.42 111.16 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.416 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -75.65 157.99 83.54 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.586 0.708 . . . . 73.44 110.923 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.535 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.3 Cg_endo -69.78 153.8 68.43 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.719 2.28 . . . . 74.31 112.321 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.69 7.06 59.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.752 -0.737 . . . . 74.03 112.496 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -156.75 141.94 17.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.873 0.368 . . . . 72.23 110.878 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 3.6 p -95.69 126.3 48.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 71.52 111.122 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.661 ' CB ' HG21 ' A' ' 85' ' ' VAL . 0.8 OUTLIER -87.5 177.36 7.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 71.23 110.798 -179.829 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 98.8 m -144.82 105.48 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 63.44 111.139 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.509 HG11 HG11 ' A' ' 83' ' ' VAL . 9.8 p -134.82 137.8 50.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 74.42 111.109 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -113.27 139.9 48.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 75.25 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -166.06 94.8 0.57 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.245 -0.434 . . . . 75.13 110.955 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -84.33 143.76 29.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 74.43 111.113 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.12 -169.41 2.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.43 110.889 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mttt -124.93 -28.26 3.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 62.53 110.897 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.17 158.87 70.21 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.605 0.717 . . . . 75.43 110.841 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 147.74 63.44 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.722 2.281 . . . . 74.44 112.342 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.27 153.58 8.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 43.35 112.484 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -116.74 132.2 56.75 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.826 0.346 . . . . 75.43 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . 0.721 ' CE2' HG13 ' A' ' 76' ' ' VAL . 2.4 p90 -143.83 141.18 30.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 65.01 110.9 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.85 177.43 8.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.491 . . . . 74.33 110.91 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.3 mm 67.48 146.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.213 -0.449 . . . . 74.13 111.184 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 75.42 111.133 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.665 HG23 HG13 ' A' ' 53' ' ' ILE . 12.5 t . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.793 0.33 . . . . 70.54 111.114 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.669 HG13 HG21 ' A' ' 53' ' ' ILE . 2.9 mp -153.79 137.33 8.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.205 -0.452 . . . . 73.32 111.126 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.5 p -127.55 139.03 53.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 52.34 111.094 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.678 HG13 ' O ' ' A' ' 55' ' ' VAL . 49.1 t -109.27 117.17 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 73.52 111.162 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -86.98 138.76 31.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 74.14 110.888 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.447 . . . . 65.34 110.911 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.821 0.343 . . . . 73.44 110.91 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -96.04 145.18 25.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.494 . . . . 70.13 110.853 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.1 m -136.64 -178.58 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 62.43 111.14 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.13 161.98 42.51 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.641 0.734 . . . . 75.41 110.876 179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 -3.5 12.14 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.692 2.261 . . . . 63.31 112.362 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 25.8 m -44.96 -70.21 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 42.42 111.165 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 25.6 p -149.59 24.1 0.88 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 64.31 111.152 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.6 p -62.85 -26.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 55.12 111.118 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -106.07 -17.21 14.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 70.05 110.865 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -83.91 -35.9 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 64.4 110.923 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 -142.38 140.82 32.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 73.43 110.895 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.24 -158.53 17.86 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.732 -0.747 . . . . 64.24 112.476 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.72 -30.97 21.63 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 72.33 112.398 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 12.2 m-90 -84.6 -13.91 50.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.942 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.88 -59.42 3.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 63.34 111.105 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.01 147.63 34.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.565 0.698 . . . . 64.34 110.876 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -26.67 27.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.667 2.244 . . . . 72.25 112.361 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -80.14 -1.12 38.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 72.41 111.069 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.8 mm-40 -105.27 5.07 31.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 52.34 110.953 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.3 -74.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 73.45 111.099 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 1.066 HG22 HG12 ' A' ' 39' ' ' VAL . 48.0 t -71.91 126.78 33.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.436 . . . . 71.0 111.127 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.45 ' O ' HG23 ' A' ' 30' ' ' VAL . 19.0 m -150.34 127.01 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 73.03 111.13 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -76.28 114.44 14.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.459 . . . . 52.43 110.926 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.2 t -120.05 -13.17 9.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.263 -0.426 . . . . 71.32 111.116 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.36 -173.25 13.78 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.753 -0.737 . . . . 62.11 112.514 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -36.72 10.34 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 73.35 112.336 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -150.86 34.35 0.6 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 72.1 110.863 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -134.55 117.8 16.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 71.54 110.945 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -98.58 134.33 41.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 75.02 110.947 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.783 ' HA ' HG23 ' A' ' 62' ' ' VAL . 56.7 m -95.07 115.04 26.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.482 . . . . 74.34 111.136 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 1.066 HG12 HG22 ' A' ' 29' ' ' VAL . 34.6 m -110.33 126.62 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 75.13 111.131 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 84.8 m-85 -103.13 113.78 27.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.198 -0.455 . . . . 75.12 110.859 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.517 HG12 ' CG1' ' A' ' 53' ' ' ILE . 15.8 m -97.5 131.4 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.11 -0.496 . . . . 71.4 111.126 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.736 HD11 ' CD2' ' A' ' 44' ' ' PHE . 3.2 tm? -120.19 135.66 54.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 71.11 110.89 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.527 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -156.44 113.98 3.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 73.12 111.065 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.736 ' CD2' HD11 ' A' ' 42' ' ' LEU . 7.0 p90 -128.5 151.08 49.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 73.11 110.889 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.47 1.44 48.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 75.23 111.074 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -92.15 75.65 5.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.261 -0.427 . . . . 73.41 110.852 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.46 -127.75 9.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 73.12 112.499 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -141.67 162.34 35.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.824 0.345 . . . . 74.4 110.909 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.405 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 1.8 pm0 -161.07 155.93 20.24 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 73.34 110.93 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.74 -176.23 1.41 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.675 2.25 . . . . 63.23 112.337 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.656 ' O ' HD12 ' A' ' 53' ' ' ILE . 4.1 m120 -130.28 60.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.605 0.717 . . . . 64.24 110.881 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 73.94 1.32 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.675 2.25 . . . . 61.24 112.35 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.656 HD12 ' O ' ' A' ' 51' ' ' ASN . 2.9 mp -125.84 132.39 70.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 73.23 111.146 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -131.62 156.69 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 61.13 110.906 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.836 HG13 HG22 ' A' ' 124' ' ' VAL . 2.9 p -157.47 77.88 3.72 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.619 0.723 . . . . 70.21 111.148 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.769 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.76 121.46 8.15 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.696 2.264 . . . . 73.23 112.356 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -68.26 154.24 42.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 65.24 110.924 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.94 -10.16 69.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.76 -0.733 . . . . 73.11 112.493 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.5 159.9 39.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.773 0.32 . . . . 60.43 111.106 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.63 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.8 mp0 -72.57 141.34 48.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.43 110.895 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.769 HD12 ' HD2' ' A' ' 56' ' ' PRO . 3.8 mm -125.96 119.48 54.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.169 -0.469 . . . . 71.32 111.124 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.783 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -110.19 90.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 55.13 111.087 179.905 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.505 ' CD2' HG21 ' A' ' 39' ' ' VAL . 38.7 m-85 -74.81 144.18 43.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 72.31 110.872 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.402 ' HD3' HG11 ' A' ' 90' ' ' VAL . 0.1 OUTLIER -127.41 100.81 6.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 73.15 110.908 179.956 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.9 mt -94.23 147.3 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 74.32 111.125 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -166.12 136.93 3.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 71.12 111.146 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.457 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -146.34 160.61 41.73 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.698 0.761 . . . . 74.05 110.835 -179.883 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.403 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.6 Cg_endo -69.79 -54.87 0.2 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.674 2.249 . . . . 72.45 112.353 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -156.88 61.43 0.52 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 73.21 110.854 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.457 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.16 135.9 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 53.15 111.112 179.98 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.0 mm -73.61 145.17 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 75.21 111.142 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -126.56 -168.57 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 64.35 110.876 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 133.31 115.21 1.59 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 63.44 112.475 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -111.03 142.71 42.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.842 0.354 . . . . 72.12 110.879 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -115.17 142.63 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 74.55 110.816 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 16.6 t -133.68 147.66 30.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 72.1 111.126 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -70.01 -178.65 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 64.01 110.907 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.53 -51.17 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.721 -0.752 . . . . 71.43 112.5 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.1 m -136.89 153.86 50.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.789 0.328 . . . . 75.02 111.16 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -77.39 60.44 2.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 70.53 110.9 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.467 ' O ' HG23 ' A' ' 81' ' ' ILE . 7.2 tt -69.58 115.26 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 71.34 111.123 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -115.78 104.25 11.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.48 . . . . 74.03 110.883 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.452 HG11 ' CG2' ' A' ' 93' ' ' VAL . 3.6 m -125.79 120.14 56.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 60.44 111.139 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.5 pp20? -157.23 117.23 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 72.24 110.867 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -140.35 146.54 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 62.1 111.113 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.402 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -64.21 158.49 64.06 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.619 0.723 . . . . 73.3 110.922 179.966 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.402 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 54.0 Cg_endo -69.77 152.86 69.37 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.235 . . . . 71.52 112.332 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.62 11.46 63.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.757 -0.735 . . . . 64.02 112.463 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -145.83 118.17 8.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 74.44 110.952 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.402 HG11 ' HD3' ' A' ' 64' ' ' LYS . 39.2 t -63.43 105.59 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 63.25 111.173 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 66.0 p -91.98 114.33 26.84 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 51.11 110.867 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.3 t -81.83 145.99 30.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 61.43 111.17 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.452 ' CG2' HG11 ' A' ' 83' ' ' VAL . 87.2 t -139.94 117.85 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 71.34 111.107 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.0 mmm180 -102.8 107.91 18.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 73.34 110.894 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -155.95 141.38 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 61.25 110.938 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.5 t -135.14 143.63 46.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 74.43 111.102 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -95.56 -175.5 3.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 62.01 110.88 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -123.06 -12.27 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.116 -0.493 . . . . 73.15 110.876 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.83 161.93 28.09 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.646 0.736 . . . . 70.4 110.835 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 156.7 62.68 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 64.55 112.316 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.0 132.51 1.37 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 64.32 112.51 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -101.79 132.84 47.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.889 0.376 . . . . 62.44 110.918 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -143.8 129.61 19.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.49 . . . . 63.3 110.913 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.0 95.3 2.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.501 . . . . 71.52 110.843 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.5 tt -178.19 143.77 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 73.11 111.118 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 64.02 111.106 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.633 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.4 m . . . . . 0 C--O 1.232 0.143 0 CA-C-O 120.768 0.318 . . . . 55.04 111.161 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.579 HG13 HG21 ' A' ' 53' ' ' ILE . 3.7 mp -147.55 140.17 18.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 75.42 111.12 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.478 ' O ' HG12 ' A' ' 55' ' ' VAL . 5.6 m -134.46 138.33 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 71.41 111.099 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.836 HG22 HG13 ' A' ' 55' ' ' VAL . 44.0 t -104.05 125.15 58.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 72.22 111.116 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 31.2 mmtt -107.19 133.83 51.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 65.54 110.91 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 72.43 110.865 179.952 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.871 0.367 . . . . 52.41 110.856 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -84.3 144.33 28.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.492 . . . . 74.21 110.892 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.435 ' HB ' HG21 ' A' ' 16' ' ' VAL . 13.3 m -134.24 -177.37 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 72.1 111.111 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.463 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 21.4 p30 -143.77 157.72 57.75 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.586 0.708 . . . . 74.42 110.855 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.463 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.75 -2.8 10.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.243 . . . . 75.14 112.313 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.606 HG22 HG23 ' A' ' 15' ' ' THR . 9.7 m -48.26 -67.72 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 74.33 111.147 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.606 HG23 HG22 ' A' ' 14' ' ' THR . 38.4 p -151.0 30.24 0.64 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.45 . . . . 72.42 111.131 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.435 HG21 ' HB ' ' A' ' 11' ' ' VAL . 4.9 p -78.83 -24.96 13.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.24 -0.436 . . . . 72.53 111.113 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.505 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.9 OUTLIER -98.65 -18.23 18.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 75.42 110.892 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.9 mm-40 -100.92 -31.42 11.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 63.33 110.896 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -129.28 138.68 51.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 73.41 110.874 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 116.68 -161.78 12.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 41.24 112.494 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -27.77 25.87 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 2.239 . . . . 70.03 112.375 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.449 ' HB3' HD23 ' A' ' 42' ' ' LEU . 13.5 m-90 -84.45 -17.48 39.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 75.54 110.916 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.64 -59.8 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 53.45 111.124 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.45 143.0 25.91 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.605 0.717 . . . . 60.32 110.86 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -14.99 37.04 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 62.51 112.353 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -6.58 48.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 75.2 111.131 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 34.1 mm-40 -108.26 5.8 26.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 64.03 110.965 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.76 -78.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.213 -0.449 . . . . 71.12 111.123 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -81.92 125.88 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 61.04 111.113 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.45 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 25.1 m -141.66 142.62 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 55.25 111.154 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -82.31 110.52 17.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 70.43 110.928 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.7 t -108.89 -41.3 4.78 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 74.3 111.138 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.9 175.61 19.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.47 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 116.53 4.6 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.727 2.285 . . . . 74.11 112.34 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 66.97 35.31 4.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 73.44 110.866 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -147.87 152.6 37.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.218 -0.446 . . . . 74.35 110.941 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -141.72 140.96 33.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.222 -0.445 . . . . 65.3 110.957 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.79 ' HA ' HG23 ' A' ' 62' ' ' VAL . 28.8 m -90.95 117.55 29.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 74.04 111.18 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 t -100.35 107.4 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 71.01 111.14 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.465 ' CZ ' HG21 ' A' ' 38' ' ' THR . 70.7 m-85 -88.45 127.38 35.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.189 -0.46 . . . . 73.52 110.913 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.836 HG22 HD12 ' A' ' 53' ' ' ILE . 77.0 t -119.82 108.04 22.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.109 -0.496 . . . . 75.05 111.119 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.505 HD11 ' HB3' ' A' ' 17' ' ' ARG . 0.7 OUTLIER -101.5 126.57 48.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 65.11 110.904 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -152.87 128.44 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 53.02 111.145 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -145.78 147.01 31.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.44 . . . . 74.31 110.9 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.77 31.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 74.44 111.088 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -104.63 54.84 0.72 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 61.03 110.876 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 131.67 -139.16 10.71 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 53.02 112.445 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -154.98 151.46 28.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.854 0.359 . . . . 73.41 110.926 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -165.68 162.98 12.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.576 0.703 . . . . 60.03 110.901 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 154.04 68.2 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.697 2.264 . . . . 72.42 112.332 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -128.22 66.4 72.67 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.574 0.702 . . . . 73.44 110.921 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.626 ' O ' HD13 ' A' ' 53' ' ' ILE . 54.3 Cg_endo -69.72 115.21 3.98 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.707 2.271 . . . . 52.35 112.374 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.836 HD12 HG22 ' A' ' 41' ' ' VAL . 2.6 mm -125.82 146.47 31.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 73.42 111.1 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -155.1 118.03 4.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 71.22 110.885 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.83 HG23 HG13 ' A' ' 61' ' ' ILE . 2.1 p -132.72 85.32 47.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.669 0.747 . . . . 44.12 111.123 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.4 Cg_endo -69.84 123.13 9.78 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.625 2.217 . . . . 73.21 112.363 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.35 145.98 55.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 74.53 110.865 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.41 -28.31 9.22 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 74.2 112.51 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.6 156.86 17.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.74 0.305 . . . . 72.32 111.103 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.729 ' O ' HD13 ' A' ' 61' ' ' ILE . 2.2 mt-10 -66.4 142.13 57.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 64.25 110.916 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.83 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -131.89 119.95 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 73.31 111.145 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.79 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.3 OUTLIER -114.01 89.44 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 54.43 111.142 179.847 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -66.61 137.18 56.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 65.44 110.92 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . 0.566 ' HD3' HG11 ' A' ' 90' ' ' VAL . 8.6 mttm -133.77 100.65 4.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 64.1 110.898 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.582 HD11 ' CE2' ' A' ' 74' ' ' PHE . 2.6 mp -102.17 157.86 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.444 . . . . 74.53 111.119 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.415 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.7 t -165.48 142.19 5.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 64.41 111.163 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.457 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -151.27 162.18 27.54 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 74.12 110.862 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HD3' ' CZ ' ' A' ' 17' ' ' ARG . 53.8 Cg_endo -69.76 -55.68 0.17 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.729 2.286 . . . . 72.54 112.348 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -155.93 60.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.458 . . . . 74.13 110.832 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.457 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.05 134.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 70.42 111.132 179.986 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.8 mm -64.8 145.06 14.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.142 -0.481 . . . . 70.15 111.118 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.574 ' HB2' HG21 ' A' ' 65' ' ' ILE . 6.8 p80 -140.79 115.49 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.474 . . . . 71.43 110.848 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.26 132.58 3.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 60.43 112.496 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.582 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.9 p90 -117.15 142.64 46.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.829 0.347 . . . . 74.13 110.866 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.6 t-80 -126.05 105.17 8.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 74.32 110.882 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.458 HG12 HG21 ' A' ' 81' ' ' ILE . 4.9 p -97.06 144.95 9.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 43.13 111.102 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -61.16 -175.44 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 71.0 110.92 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 90.36 -51.08 3.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.702 -0.761 . . . . 71.21 112.514 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.425 HG22 ' N ' ' A' ' 80' ' ' ASN . 7.4 m -140.18 158.85 43.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.791 0.329 . . . . 71.12 111.182 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.425 ' N ' HG22 ' A' ' 79' ' ' THR . 3.5 m120 -76.17 60.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 73.03 110.892 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.518 ' O ' HG23 ' A' ' 81' ' ' ILE . 13.4 tt -72.4 110.08 5.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 73.22 111.104 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.12 97.88 6.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 51.4 110.88 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.48 HG11 HG21 ' A' ' 93' ' ' VAL . 2.6 m -118.23 119.9 62.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 74.03 111.11 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -150.71 115.52 5.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 74.51 110.894 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.714 HG11 ' HB2' ' A' ' 91' ' ' SER . 7.3 p -140.67 146.52 24.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 72.01 111.094 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.2 mp -69.71 160.04 81.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.647 0.737 . . . . 51.54 110.915 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 160.29 50.27 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.657 2.238 . . . . 73.31 112.372 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.31 17.71 54.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.775 -0.726 . . . . 54.35 112.474 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -163.38 135.58 5.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.875 0.369 . . . . 73.24 110.909 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.566 HG11 ' HD3' ' A' ' 64' ' ' LYS . 61.9 t -76.37 138.06 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 70.44 111.13 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.714 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -115.2 107.74 15.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 72.34 110.862 -179.836 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.2 m -81.73 120.02 24.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 73.31 111.131 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.48 HG21 HG11 ' A' ' 83' ' ' VAL . 46.7 t -120.61 122.79 68.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.269 -0.423 . . . . 74.14 111.148 179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.4 mmm180 -100.85 102.45 13.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 55.34 110.88 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 52.9 t80 -151.93 120.41 6.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 62.34 110.921 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.3 t -114.93 139.91 49.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.105 -0.498 . . . . 64.41 111.156 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -90.96 -170.1 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 72.44 110.863 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 25.5 mttt -129.44 -25.52 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 70.43 110.896 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.1 mtp180 -135.98 154.64 77.78 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 74.41 110.832 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 156.84 62.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.651 2.234 . . . . 71.04 112.318 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.19 133.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 44.43 112.48 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.57 128.73 38.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.832 0.349 . . . . 72.1 110.871 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.3 p90 -143.87 132.04 21.85 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 72.22 110.911 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 43.5 mtm180 -144.88 -176.59 5.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 64.22 110.892 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.0 mt 66.35 144.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 70.13 111.157 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 74.24 111.15 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.764 HG23 HG13 ' A' ' 53' ' ' ILE . 9.9 t . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.746 0.307 . . . . 73.11 111.135 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.55 HD12 ' C ' ' A' ' 121' ' ' THR . 3.7 mp -150.33 142.01 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.234 -0.439 . . . . 75.2 111.157 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.48 ' O ' HG12 ' A' ' 55' ' ' VAL . 28.0 t -132.97 130.19 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 75.05 111.121 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.824 HG22 HG13 ' A' ' 55' ' ' VAL . 42.5 t -103.07 130.38 53.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 64.44 111.135 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -108.18 134.15 51.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 75.51 110.901 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.34 110.894 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.867 0.365 . . . . 71.33 110.911 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.07 154.09 20.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 70.13 110.895 -179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 16' ' ' VAL . 10.6 m -126.74 -178.05 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 73.13 111.165 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -143.81 161.74 44.6 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.591 0.71 . . . . 62.43 110.867 179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -4.24 13.64 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.695 2.264 . . . . 74.23 112.379 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.721 HG22 HG23 ' A' ' 15' ' ' THR . 42.2 m -48.46 -71.0 0.07 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.198 -0.455 . . . . 75.53 111.157 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.721 HG23 HG22 ' A' ' 14' ' ' THR . 44.8 p -151.59 36.68 0.57 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 62.35 111.159 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 11' ' ' VAL . 10.0 p -78.93 -25.58 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 64.41 111.129 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -97.52 -18.2 19.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 71.51 110.834 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -101.43 -28.4 12.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.445 . . . . 72.45 110.923 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.33 133.17 42.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 73.23 110.914 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.88 -158.67 17.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 74.32 112.473 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.474 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.4 Cg_endo -69.75 -34.65 14.17 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.72 2.28 . . . . 65.53 112.342 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.437 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 14.9 m-90 -84.98 -6.95 59.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 64.52 110.912 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -59.12 4.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 51.21 111.106 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.99 141.7 25.37 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.592 0.71 . . . . 73.3 110.896 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -7.17 20.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 62.31 112.311 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.06 -25.5 60.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 72.22 111.094 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.522 HE21 ' N ' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -110.99 34.21 4.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 72.03 110.919 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.59 -69.03 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 63.04 111.115 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.561 HG11 ' CB ' ' A' ' 54' ' ' GLU . 1.6 p -111.33 125.18 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.448 . . . . 63.53 111.097 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.97 151.46 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 65.35 111.179 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . 0.433 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -72.69 119.29 16.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 74.32 110.879 -179.974 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.2 p -120.94 -42.58 2.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.157 -0.474 . . . . 55.34 111.137 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.39 -168.22 16.83 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.749 -0.739 . . . . 74.2 112.504 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 109.8 2.4 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 73.33 112.354 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.9 t30 49.92 30.58 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 71.43 110.878 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.43 120.98 26.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.177 -0.465 . . . . 72.44 110.891 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . 0.433 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 39.7 m-85 -94.43 141.97 27.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 61.2 110.924 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.419 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 21.9 m -99.66 99.78 10.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 72.21 111.16 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.34 131.57 33.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 61.03 111.087 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -113.63 100.69 8.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.176 -0.465 . . . . 73.22 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.753 HG12 HD12 ' A' ' 53' ' ' ILE . 34.8 m -97.45 129.94 46.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 74.01 111.141 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 18.5 tp -124.24 138.54 54.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 70.34 110.928 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.741 ' HB3' ' CE1' ' A' ' 72' ' ' HIS . . . -155.68 123.41 5.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.467 . . . . 74.34 111.094 179.833 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -143.09 144.1 32.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 72.45 110.876 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.13 4.89 32.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 51.14 111.114 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -103.34 72.9 1.18 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 61.33 110.846 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 115.08 -141.69 17.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 70.13 112.522 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -152.89 148.4 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.807 0.337 . . . . 72.24 110.938 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -165.15 162.97 13.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 73.04 110.913 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 158.58 56.53 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.686 2.257 . . . . 64.12 112.374 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -131.88 67.02 79.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.704 0.764 . . . . 64.51 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.724 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.9 Cg_endo -69.76 119.56 6.49 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 55.31 112.336 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.806 HG13 HG23 ' A' ' 121' ' ' THR . 1.5 mm -131.27 124.13 54.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 74.13 111.106 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.561 ' CB ' HG11 ' A' ' 29' ' ' VAL . 8.6 tt0 -131.24 116.38 17.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 73.01 110.891 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.731 HG13 HG21 ' A' ' 61' ' ' ILE . 5.7 t -130.1 80.6 70.59 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.63 0.729 . . . . 71.25 111.12 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.551 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.7 121.12 7.82 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.746 2.298 . . . . 74.5 112.331 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.12 155.57 39.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 72.22 110.929 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.52 -6.53 76.81 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.754 -0.736 . . . . 74.0 112.481 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.82 155.34 49.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 73.3 111.094 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.763 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.5 mt-10 -64.84 143.42 57.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 71.01 110.897 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.763 HD13 ' O ' ' A' ' 60' ' ' GLU . 8.6 mm -131.65 124.53 54.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 44.21 111.124 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 1.018 HG13 HG23 ' A' ' 92' ' ' THR . 46.8 t -111.22 93.48 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 75.32 111.146 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -71.82 137.06 47.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 65.31 110.858 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -132.28 99.52 4.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 65.44 110.907 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.411 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.6 mp -98.03 153.53 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 70.35 111.147 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.2 t -171.77 137.77 1.03 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 60.15 111.165 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.447 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -142.44 162.21 45.97 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.708 0.766 . . . . 52.43 110.843 -179.836 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.426 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.8 Cg_endo -69.71 -52.01 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 65.13 112.322 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -155.91 36.67 0.35 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 64.5 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.447 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -140.17 -179.24 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 72.12 111.139 -179.961 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . 0.634 HG23 ' O ' ' A' ' 85' ' ' VAL . 33.1 mt -144.91 156.68 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.201 -0.454 . . . . 74.21 111.183 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.741 ' CE1' ' HB3' ' A' ' 43' ' ' ALA . 35.6 p-80 -168.52 98.17 0.41 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 73.33 110.835 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -95.02 135.72 12.56 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 73.13 112.504 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.608 ' CE1' HG21 ' A' ' 83' ' ' VAL . 9.3 p90 -99.05 142.1 30.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.876 0.369 . . . . 72.51 110.872 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.9 p80 -125.24 142.69 51.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 73.32 110.897 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.697 HG11 ' CE1' ' A' ' 97' ' ' PHE . 21.2 t -131.83 147.56 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 75.42 111.134 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -71.49 -175.44 1.3 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 74.43 110.867 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.12 -51.45 4.58 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 73.23 112.49 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.6 m -135.52 151.35 50.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.782 0.325 . . . . 72.55 111.153 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.5 m-80 -74.13 70.13 1.56 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 71.24 110.871 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.547 ' O ' HG23 ' A' ' 81' ' ' ILE . 14.1 tt -87.77 104.37 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 72.44 111.099 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -115.83 103.85 11.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 64.43 110.893 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.765 HG11 HG21 ' A' ' 93' ' ' VAL . 0.9 OUTLIER -114.32 120.62 64.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 62.44 111.113 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.32 121.09 17.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 70.34 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.634 ' O ' HG23 ' A' ' 71' ' ' ILE . 13.7 p -139.36 147.64 24.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 63.42 111.142 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.504 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -90.58 163.92 28.63 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.594 0.712 . . . . 73.05 110.911 179.927 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.504 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.5 Cg_endo -69.77 147.77 63.56 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.682 2.254 . . . . 72.03 112.317 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.01 9.18 58.51 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.754 -0.736 . . . . 73.23 112.492 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -146.34 173.68 12.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.869 0.366 . . . . 72.3 110.876 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 17.5 t -129.37 119.49 48.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 71.31 111.117 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -103.75 133.66 48.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 54.21 110.822 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 1.018 HG23 HG13 ' A' ' 62' ' ' VAL . 60.7 m -103.13 131.87 49.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 71.52 111.12 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.765 HG21 HG11 ' A' ' 83' ' ' VAL . 19.0 t -125.26 127.6 72.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 72.45 111.114 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -107.78 92.6 4.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 52.35 110.858 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -140.77 133.43 28.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.157 -0.474 . . . . 75.04 110.902 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.7 t -123.16 140.19 53.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 71.23 111.159 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . 0.697 ' CE1' HG11 ' A' ' 76' ' ' VAL . 75.2 m-85 -96.3 -174.82 3.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 74.33 110.861 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -125.89 -29.02 3.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 72.2 110.928 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.35 155.59 81.28 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.597 0.713 . . . . 71.11 110.897 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 170.56 16.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.647 2.231 . . . . 64.12 112.351 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 154.99 133.32 1.71 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 70.0 112.479 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.13 125.54 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 65.51 110.903 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.75 146.61 33.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 73.45 110.94 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.23 97.89 1.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.15 110.838 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.4 tt -175.51 151.96 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.151 -0.477 . . . . 74.31 111.118 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 73.34 111.189 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.806 HG23 HG13 ' A' ' 53' ' ' ILE . 4.8 t . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.763 0.316 . . . . 53.14 111.168 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.603 HG13 HG21 ' A' ' 53' ' ' ILE . 2.1 mp -153.9 137.63 8.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 71.53 111.121 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 26.9 t -126.14 122.58 61.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 74.23 111.149 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.652 HG13 ' O ' ' A' ' 55' ' ' VAL . 44.3 t -101.52 112.1 33.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 75.24 111.119 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 17.8 mmmt -84.45 135.26 34.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 54.53 110.897 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 74.43 110.945 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.808 0.337 . . . . 71.21 110.885 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.54 168.46 10.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 75.34 110.851 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.87 ' CG1' HG21 ' A' ' 16' ' ' VAL . 1.4 t -141.54 166.71 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 60.44 111.098 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . 0.427 ' H ' HG12 ' A' ' 11' ' ' VAL . 55.9 p-10 -161.12 153.45 16.97 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.594 0.711 . . . . 73.44 110.843 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -4.34 13.85 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.684 2.256 . . . . 71.1 112.326 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.459 ' O ' HG23 ' A' ' 15' ' ' THR . 40.6 m -44.44 -72.23 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 65.24 111.094 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 14' ' ' THR . 6.7 p -156.62 33.08 0.31 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 52.34 111.144 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.87 HG21 ' CG1' ' A' ' 11' ' ' VAL . 4.9 p -78.58 -19.92 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 74.04 111.105 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -100.68 -9.38 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 60.02 110.896 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -103.53 -32.87 9.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 63.14 110.881 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -140.16 125.98 19.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 73.54 110.861 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 132.26 -155.99 21.78 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.741 . . . . 24.22 112.515 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -37.83 8.65 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.723 2.282 . . . . 71.52 112.349 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . 0.483 ' HE3' HG22 ' A' ' 16' ' ' VAL . 7.8 m-90 -84.51 -12.57 53.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.211 -0.449 . . . . 72.11 110.917 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.79 -59.54 4.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 75.31 111.087 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.21 142.84 25.37 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 51.3 110.88 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 -22.83 31.81 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.644 2.229 . . . . 61.52 112.376 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.51 -17.56 61.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 75.25 111.097 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 3.5 mm100 -89.35 10.13 23.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 75.24 110.929 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.26 -77.53 0.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 50.42 111.083 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.435 HG21 ' HB3' ' A' ' 54' ' ' GLU . 21.1 t -84.38 122.06 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 72.4 111.165 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.8 131.62 53.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.451 . . . . 62.15 111.106 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -71.31 118.28 13.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 72.31 110.899 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.0 t -119.38 -41.49 2.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 71.2 111.175 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.34 171.2 13.72 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.765 -0.731 . . . . 32.34 112.487 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -10.21 28.02 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.685 2.257 . . . . 72.03 112.358 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -157.69 34.81 0.26 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.283 -0.417 . . . . 63.4 110.883 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -151.29 160.04 44.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 63.51 110.896 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.7 m-85 -143.31 146.64 33.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.252 -0.431 . . . . 75.43 110.941 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 99.5 m -97.23 121.99 39.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.119 -0.491 . . . . 74.11 111.165 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 17.9 t -100.37 134.58 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 72.24 111.137 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -120.65 100.51 7.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 73.3 110.932 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.495 HG12 HG13 ' A' ' 53' ' ' ILE . 32.8 m -98.78 128.53 50.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 74.1 111.129 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.706 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.8 tm? -120.74 138.23 54.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 71.24 110.928 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.706 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.22 137.04 14.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 73.12 111.049 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . 0.427 ' HD2' HD11 ' A' ' 42' ' ' LEU . 2.9 p90 -145.29 150.06 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 73.31 110.918 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.41 18.69 4.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 54.42 111.118 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -84.34 -61.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 60.42 110.868 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -127.44 -122.43 2.52 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.786 -0.721 . . . . 75.23 112.488 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -143.91 145.02 31.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.869 0.366 . . . . 74.33 110.904 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . 0.427 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.0 pm0 -154.37 156.09 31.4 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.56 0.695 . . . . 74.53 110.892 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.2 Cg_endo -69.79 177.38 5.65 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.632 2.222 . . . . 75.23 112.343 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.712 ' O ' HD12 ' A' ' 53' ' ' ILE . 8.5 m-20 -131.23 62.3 64.39 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.592 0.71 . . . . 61.15 110.905 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 70.77 1.56 Allowed 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.661 2.241 . . . . 74.25 112.377 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.712 HD12 ' O ' ' A' ' 51' ' ' ASN . 4.3 mp -105.88 128.29 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 75.11 111.151 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.435 ' HB3' HG21 ' A' ' 29' ' ' VAL . 11.2 tt0 -126.3 135.11 51.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.468 . . . . 73.43 110.878 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.741 HG13 HG22 ' A' ' 124' ' ' VAL . 2.5 p -140.12 81.95 17.79 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.657 0.741 . . . . 74.4 111.08 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.59 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.74 123.55 10.22 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.715 2.277 . . . . 61.25 112.328 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -66.87 152.37 45.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 71.44 110.951 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.42 -36.51 3.7 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 61.23 112.49 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -106.22 150.12 26.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.749 0.309 . . . . 61.14 111.129 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.619 ' O ' HD13 ' A' ' 61' ' ' ILE . 18.1 mt-10 -66.42 142.07 57.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 55.32 110.901 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.717 HG13 HG23 ' A' ' 55' ' ' VAL . 5.8 mm -126.25 119.43 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 45.35 111.116 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 1.091 HG13 HG23 ' A' ' 92' ' ' THR . 64.3 t -98.33 92.08 2.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 73.52 111.118 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.506 ' HB2' HG12 ' A' ' 93' ' ' VAL . 66.9 m-85 -70.9 136.59 48.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.906 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 8.7 mttt -132.09 98.64 4.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 64.54 110.908 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.715 HD11 ' CZ ' ' A' ' 74' ' ' PHE . 1.6 mp -103.17 137.5 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 71.23 111.11 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . 0.419 ' OG1' HG11 ' A' ' 11' ' ' VAL . 4.2 t -155.73 135.89 12.99 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 75.43 111.123 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.449 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -135.87 161.19 64.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.633 0.73 . . . . 75.31 110.859 -179.863 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.8 Cg_endo -69.68 -53.95 0.25 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.675 2.25 . . . . 72.11 112.361 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -156.83 56.15 0.54 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 74.54 110.866 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.01 136.23 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 63.2 111.152 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.4 mm -64.33 149.14 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.164 -0.471 . . . . 74.45 111.115 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.582 ' HB2' HG21 ' A' ' 65' ' ' ILE . 2.1 p80 -133.11 -178.5 4.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 65.54 110.886 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 135.37 139.69 4.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 35.45 112.485 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.715 ' CZ ' HD11 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -130.57 144.68 51.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.894 0.378 . . . . 73.2 110.837 -179.845 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 8.0 t-80 -101.06 142.13 32.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.106 -0.497 . . . . 72.3 110.863 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.612 HG22 ' CD2' ' A' ' 103' ' ' TYR . 58.2 t -131.84 138.13 53.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 62.02 111.118 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -75.51 179.45 5.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 73.24 110.862 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.14 -52.03 4.57 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.781 -0.723 . . . . 74.13 112.48 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.62 179.7 4.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.82 0.343 . . . . 75.03 111.123 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -105.77 65.5 0.71 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 61.13 110.893 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.58 HD12 ' CD2' ' A' ' 95' ' ' TYR . 7.5 tt -72.47 121.68 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 73.51 111.159 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.07 90.47 3.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 110.827 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 5.1 m -115.05 118.41 58.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 62.02 111.126 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -166.72 104.73 0.59 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.145 -0.48 . . . . 71.15 110.878 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.576 HG23 ' CE1' ' A' ' 72' ' ' HIS . 2.4 m -140.64 146.61 23.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 72.54 111.109 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.422 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -57.8 159.78 9.36 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.559 0.695 . . . . 72.24 110.915 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 53.9 Cg_endo -69.74 159.67 52.55 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.71 2.274 . . . . 73.32 112.343 179.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 90.82 4.51 69.53 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.695 -0.764 . . . . 21.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -147.19 117.81 7.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.872 0.368 . . . . 73.53 110.928 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 1.8 p -74.49 130.04 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 62.04 111.134 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.54 ' HB2' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -102.17 112.26 24.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 75.25 110.816 -179.812 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . 1.091 HG23 HG13 ' A' ' 62' ' ' VAL . 52.7 m -90.12 115.72 27.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 65.31 111.117 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 63' ' ' PHE . 8.6 p -128.75 152.22 36.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 55.14 111.117 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.82 103.02 11.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 70.52 110.901 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.58 ' CD2' HD12 ' A' ' 81' ' ' ILE . 9.0 t80 -134.28 114.95 13.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 75.14 110.92 -179.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.0 t -129.09 134.85 48.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.117 -0.492 . . . . 65.44 111.109 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -90.85 -176.73 4.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 54.44 110.849 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -121.25 -13.04 8.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 73.21 110.947 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.73 162.74 49.28 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.634 0.731 . . . . 52.23 110.87 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 150.05 67.45 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.686 2.257 . . . . 75.32 112.318 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.73 157.47 10.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.727 -0.749 . . . . 54.44 112.49 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.765 ' HB3' HG23 ' A' ' 123' ' ' VAL . 3.8 pm0 -120.26 125.17 47.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.872 0.368 . . . . 65.23 110.855 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . 0.612 ' CD2' HG22 ' A' ' 76' ' ' VAL . 1.0 OUTLIER -133.01 146.64 51.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.483 . . . . 72.15 110.885 -179.838 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . 0.417 ' O ' ' HB ' ' A' ' 105' ' ' ILE . 0.4 OUTLIER -174.3 -162.11 0.13 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 74.32 110.83 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.417 ' HB ' ' O ' ' A' ' 104' ' ' ARG . 21.2 mm 75.28 117.79 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 71.34 111.161 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 64.24 111.144 179.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.607 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.6 m . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.751 0.31 . . . . 63.5 111.166 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.637 HG13 HG21 ' A' ' 53' ' ' ILE . 5.3 mp -145.35 117.24 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 61.2 111.144 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.765 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -121.65 141.49 41.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 72.14 111.094 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . 0.741 HG22 HG13 ' A' ' 55' ' ' VAL . 87.0 t -101.5 136.59 32.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 74.0 111.163 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -114.49 125.72 54.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 62.21 110.869 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 74.0 110.871 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLU . . . . . 0.427 ' O ' HG12 ' A' ' 90' ' ' VAL . 1.6 mm-40 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.832 0.348 . . . . 74.52 110.896 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 3.7 mpt_? -105.01 121.36 43.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 61.55 110.863 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.462 ' HB ' HG21 ' A' ' 16' ' ' VAL . 5.6 m -113.49 -179.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 75.42 111.17 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 162.63 38.29 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.571 0.7 . . . . 71.22 110.891 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -2.78 10.78 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.656 2.237 . . . . 65.31 112.36 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.751 HG22 HG23 ' A' ' 15' ' ' THR . 29.1 m -44.75 -67.34 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.231 -0.441 . . . . 62.32 111.109 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . 0.751 HG23 HG22 ' A' ' 14' ' ' THR . 43.4 p -150.67 21.29 0.81 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 54.21 111.142 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . 0.462 HG21 ' HB ' ' A' ' 11' ' ' VAL . 1.3 p -77.65 -16.88 14.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 71.11 111.157 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ARG . . . . . 0.431 ' NE ' ' HD3' ' A' ' 68' ' ' PRO . 0.0 OUTLIER -106.66 -25.0 11.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 72.31 110.876 -179.951 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -92.6 -24.24 18.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 74.11 110.92 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLU . . . . . 0.458 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 11.3 tt0 -143.58 147.32 34.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 61.35 110.928 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.01 -158.74 14.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.73 -0.748 . . . . 75.32 112.489 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.42 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.9 Cg_endo -69.81 -33.9 15.48 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.678 2.252 . . . . 71.53 112.332 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 11.8 m-90 -83.2 -12.87 56.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.256 -0.429 . . . . 74.54 110.898 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ALA . . . . . 0.458 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -62.44 -57.13 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.256 -0.429 . . . . 51.01 111.134 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.34 142.22 25.19 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.564 0.697 . . . . 64.23 110.927 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -6.73 19.3 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.708 2.272 . . . . 72.54 112.359 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.79 -12.87 61.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 64.1 111.109 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLN . . . . . 0.42 ' HG3' ' HA ' ' A' ' 21' ' ' PRO . 17.6 mm-40 -99.0 14.4 29.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.443 . . . . 74.51 110.93 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ALA . . . . . 0.458 ' HB2' ' HG2' ' A' ' 52' ' ' PRO . . . -65.0 -14.84 61.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.463 . . . . 71.13 111.089 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.522 HG22 ' HB3' ' A' ' 54' ' ' GLU . 7.0 t -145.21 119.31 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 74.24 111.092 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.766 HG13 ' HB ' ' A' ' 38' ' ' THR . 1.6 p -144.21 140.92 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 60.25 111.153 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.33 100.88 13.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 74.04 110.87 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.4 t -98.07 -34.46 10.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.232 -0.44 . . . . 61.13 111.147 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.71 -168.44 17.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 74.43 112.472 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -37.83 8.56 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.654 2.236 . . . . 54.2 112.334 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -148.27 34.68 0.8 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 73.45 110.864 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -135.41 119.87 18.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 65.32 110.893 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -95.87 140.89 29.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 73.5 110.983 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.766 ' HB ' HG13 ' A' ' 30' ' ' VAL . 22.3 m -94.81 107.82 19.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 70.42 111.141 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.1 t -89.25 130.0 39.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.224 -0.444 . . . . 61.22 111.137 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' TYR . . . . . 0.409 ' CD2' ' HB2' ' A' ' 21' ' ' PRO . 49.0 m-85 -116.03 113.15 22.81 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 74.3 110.909 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 41' ' ' VAL . 31.2 m -111.35 125.1 68.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 71.24 111.117 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.416 HD11 ' CZ ' ' A' ' 17' ' ' ARG . 2.9 tm? -121.92 126.28 48.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.122 -0.49 . . . . 60.23 110.907 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -144.54 144.96 31.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 53.21 111.115 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 12.2 p90 -136.65 152.74 50.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 73.15 110.908 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ALA . . . . . 0.553 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -87.77 12.2 13.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 72.4 111.063 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -120.48 66.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 72.5 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 123.31 -147.88 16.71 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.747 -0.739 . . . . 62.44 112.507 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -150.71 155.88 40.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 64.32 110.929 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -164.48 162.54 15.31 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.624 0.726 . . . . 62.22 110.916 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 140.09 41.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.696 2.264 . . . . 70.2 112.354 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ASN . . . . . 0.621 ' O ' HD12 ' A' ' 53' ' ' ILE . 5.1 m120 -131.61 68.19 80.67 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.624 0.726 . . . . 73.51 110.879 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PRO . . . . . 0.458 ' HG2' ' HB2' ' A' ' 28' ' ' ALA . 53.5 Cg_endo -69.75 72.75 1.42 Allowed 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.707 2.271 . . . . 71.3 112.363 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ILE . . . . . 0.731 HD13 ' O ' ' A' ' 121' ' ' THR . 2.6 mp -77.37 91.34 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 73.4 111.1 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLU . . . . . 0.522 ' HB3' HG22 ' A' ' 29' ' ' VAL . 9.1 tt0 -83.48 138.54 33.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.882 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . 0.586 HG13 HG21 ' A' ' 61' ' ' ILE . 6.5 t -143.93 85.79 8.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.593 0.711 . . . . 70.2 111.101 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . 0.675 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.78 122.95 9.62 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.669 2.246 . . . . 74.2 112.335 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.55 153.09 43.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 72.42 110.901 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.84 -35.83 3.85 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.72 -0.752 . . . . 54.31 112.51 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.86 155.09 19.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.747 0.308 . . . . 73.44 111.112 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.678 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.9 mp0 -65.52 143.8 57.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 73.52 110.886 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ILE . . . . . 0.678 HD13 ' O ' ' A' ' 60' ' ' GLU . 6.6 mm -128.73 118.69 47.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 70.4 111.142 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' VAL . . . . . 0.756 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -107.77 90.06 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 53.53 111.156 179.882 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -65.08 142.03 58.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 70.3 110.884 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -132.63 99.77 4.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 64.52 110.92 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ILE . . . . . 0.697 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.3 mp -102.77 145.65 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 65.24 111.128 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.9 t -161.24 132.57 5.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 75.22 111.154 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' SER . . . . . 0.647 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -145.13 163.97 29.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.674 0.749 . . . . 72.41 110.905 -179.868 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' PRO . . . . . 0.605 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.1 Cg_endo -69.73 -56.36 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.701 2.268 . . . . 62.41 112.385 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -152.87 67.91 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 74.01 110.905 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.647 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.3 134.86 2.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 65.34 111.138 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.02 143.75 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 52.41 111.072 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' HIS . . . . . 0.697 ' HB3' HG21 ' A' ' 65' ' ' ILE . 0.9 OUTLIER -108.75 -166.32 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.128 -0.487 . . . . 75.15 110.864 179.864 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.64 122.45 3.51 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.771 -0.728 . . . . 71.02 112.497 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' PHE . . . . . 0.452 ' CE2' HD11 ' A' ' 65' ' ' ILE . 0.3 OUTLIER -119.87 142.38 48.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.916 0.389 . . . . 62.42 110.898 -179.911 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -93.41 135.63 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.123 -0.489 . . . . 71.53 110.876 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.691 HG13 ' CE2' ' A' ' 103' ' ' TYR . 59.1 t -137.19 142.88 36.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 65.54 111.172 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -75.5 -176.31 3.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 62.03 110.871 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 87.47 -50.91 4.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.777 -0.725 . . . . 61.21 112.474 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.455 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -142.82 173.44 11.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 43.21 111.099 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ASN . . . . . 0.455 ' H ' HG22 ' A' ' 79' ' ' THR . 28.6 m120 -85.41 59.43 5.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 75.54 110.884 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . 0.471 ' O ' HG23 ' A' ' 81' ' ' ILE . 6.4 tp -56.69 116.87 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 51.34 111.101 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.23 100.42 8.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 74.52 110.907 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.486 HG11 HG21 ' A' ' 93' ' ' VAL . 5.7 m -127.29 122.87 60.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 74.15 111.154 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -160.6 114.68 2.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 71.11 110.895 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.721 HG21 ' OG ' ' A' ' 91' ' ' SER . 96.7 t -140.36 145.09 26.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 64.31 111.158 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.22 156.65 89.56 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.609 0.719 . . . . 74.31 110.907 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 160.71 48.7 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.728 2.285 . . . . 64.24 112.347 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 97.84 -0.13 59.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 71.23 112.469 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -146.15 156.7 43.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.889 0.376 . . . . 73.34 110.862 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.43 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 1.6 p -105.7 108.75 25.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 54.52 111.128 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' SER . . . . . 0.721 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -80.22 164.77 22.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.882 -179.865 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 77.7 m -129.24 105.21 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 62.44 111.134 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.486 HG21 HG11 ' A' ' 83' ' ' VAL . 24.6 t -101.79 130.81 50.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.239 -0.437 . . . . 63.31 111.14 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -110.44 92.45 4.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 72.1 110.851 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.2 t80 -143.01 114.08 7.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 74.02 110.927 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.7 t -113.87 142.9 45.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 65.34 111.143 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.08 179.98 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 74.42 110.842 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -121.08 -12.77 8.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.922 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.9 mpp_? -149.05 162.03 30.45 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.564 0.697 . . . . 73.31 110.913 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 153.63 68.67 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.731 2.287 . . . . 75.14 112.313 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 157.18 131.12 1.3 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.725 -0.75 . . . . 71.12 112.435 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.432 ' CG ' HG23 ' A' ' 123' ' ' VAL . 23.0 mt-10 -101.75 138.76 38.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.865 0.364 . . . . 71.21 110.865 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' TYR . . . . . 0.691 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.3 OUTLIER -143.87 140.6 29.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.135 -0.484 . . . . 74.42 110.921 -179.898 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 46.3 mtm180 -144.89 72.79 1.34 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 73.22 110.895 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 55.8 mt -151.05 144.27 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.226 -0.443 . . . . 73.34 111.124 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 73.51 111.145 179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' THR . . . . . 0.731 ' O ' HD13 ' A' ' 53' ' ' ILE . 86.5 m . . . . . 0 C--O 1.232 0.145 0 CA-C-O 120.784 0.326 . . . . 71.11 111.155 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' ILE . . . . . 0.535 HG23 ' CG2' ' A' ' 55' ' ' VAL . 1.4 mp -153.34 136.51 7.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 43.54 111.102 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' VAL . . . . . 0.432 HG23 ' CG ' ' A' ' 102' ' ' GLU . 1.9 p -117.78 126.56 74.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 71.21 111.133 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 61.9 t -101.14 117.68 46.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 74.04 111.109 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.0 mmmt -93.59 137.54 32.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 72.21 110.907 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 64.15 110.924 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.6 ttt . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.812 0.339 . . . . 61.55 110.884 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.571 HG13 ' HB3' ' A' ' 10' ' ' ARG . 90.0 t -72.78 82.65 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 71.05 111.147 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -143.96 78.14 14.18 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.643 0.735 . . . . 65.32 111.133 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -179.34 2.86 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.644 2.229 . . . . 73.31 112.362 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -178.58 -75.29 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.252 -0.431 . . . . 73.12 111.159 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -55.55 -84.27 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.797 -0.716 . . . . 73.1 112.481 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.89 168.37 13.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.822 0.344 . . . . 64.2 110.887 -179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.428 HD12 ' HA ' ' A' ' 8' ' ' LEU . 6.6 tp 66.29 122.82 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.456 . . . . 64.32 110.889 179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.428 ' O ' HG12 ' A' ' 90' ' ' VAL . 0.9 OUTLIER -100.14 132.38 45.53 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.126 -0.488 . . . . 63.33 110.89 179.932 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.571 ' HB3' HG13 ' A' ' 2' ' ' VAL . 0.0 OUTLIER -97.94 131.47 44.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.153 -0.476 . . . . 74.23 110.825 -179.882 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.4 m -120.91 -177.18 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.183 -0.462 . . . . 73.42 111.124 179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.43 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 25.1 p30 -143.42 156.7 60.43 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.591 0.71 . . . . 74.04 110.874 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.43 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.9 Cg_endo -69.79 -3.08 11.3 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.655 2.237 . . . . 73.23 112.358 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.696 HG22 HG23 ' A' ' 15' ' ' THR . 12.4 m -46.76 -68.3 0.2 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.205 -0.452 . . . . 61.41 111.124 -179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.696 HG23 HG22 ' A' ' 14' ' ' THR . 24.4 p -150.02 26.07 0.81 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.209 -0.451 . . . . 75.51 111.133 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 11.4 p -65.39 -29.1 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.26 -0.427 . . . . 75.23 111.102 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 5.9 ptt180 -102.53 -7.91 21.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 74.11 110.884 179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 43.3 mt-30 -96.81 -37.67 10.17 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.197 -0.456 . . . . 63.55 110.914 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.84 133.68 41.87 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.167 -0.47 . . . . 71.32 110.877 -179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.11 -156.91 18.39 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.753 -0.737 . . . . 74.12 112.494 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 -30.79 21.72 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.741 2.294 . . . . 62.34 112.333 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.788 ' HB3' HD13 ' A' ' 42' ' ' LEU . 13.5 m-90 -85.95 -12.53 50.24 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.217 -0.447 . . . . 61.22 110.922 179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.62 -58.98 5.62 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 64.41 111.095 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -109.89 146.5 34.24 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.593 0.711 . . . . 75.12 110.867 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -14.17 35.62 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.664 2.243 . . . . 71.55 112.349 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.13 -24.43 59.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 73.02 111.056 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 46.5 mm-40 -86.34 5.01 36.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.252 -0.431 . . . . 64.44 110.87 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -54.39 -76.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 75.43 111.085 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 12.3 t -89.71 115.6 29.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.188 -0.46 . . . . 71.21 111.144 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.9 t -143.34 119.02 4.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.146 -0.479 . . . . 75.41 111.138 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.427 HE22 ' N ' ' A' ' 36' ' ' GLN . 11.9 tp60 -68.06 123.37 20.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.205 -0.452 . . . . 70.54 110.876 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.4 p -120.18 -11.55 9.2 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.21 -0.45 . . . . 74.55 111.111 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.9 -169.33 12.7 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 75.4 112.517 179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.65 18.05 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.682 2.255 . . . . 75.23 112.395 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.5 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 55.2 t30 -155.69 28.61 0.38 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.178 -0.464 . . . . 74.23 110.884 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.427 ' N ' HE22 ' A' ' 31' ' ' GLN . 1.5 pt20 -126.99 119.42 26.62 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.112 -0.494 . . . . 73.31 110.9 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.7 m-85 -96.32 140.23 31.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.222 -0.444 . . . . 74.21 110.961 -179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.683 ' HA ' HG23 ' A' ' 62' ' ' VAL . 85.9 m -93.76 115.02 27.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 70.33 111.173 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.3 t -102.24 139.06 24.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 63.02 111.124 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -120.49 140.85 50.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 61.54 110.924 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.509 HG22 ' CG1' ' A' ' 53' ' ' ILE . 99.1 t -138.3 136.06 44.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.486 . . . . 73.54 111.106 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.788 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -137.91 140.71 40.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.168 -0.469 . . . . 74.22 110.95 179.92 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.27 102.97 2.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 71.54 111.083 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 3.3 p90 -112.01 156.71 21.73 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.213 -0.449 . . . . 72.24 110.894 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.13 7.79 23.46 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.137 -0.483 . . . . 55.25 111.092 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 24.5 m-85 -103.17 82.9 2.13 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.244 -0.434 . . . . 74.12 110.929 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 100.28 -135.04 11.93 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.739 . . . . 52.23 112.498 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 2.3 m-85 -154.61 150.22 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.799 0.333 . . . . 73.41 110.954 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 2.9 pm0 -154.07 155.02 30.71 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.648 0.737 . . . . 53.32 110.874 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 178.81 4.2 Favored 'Trans proline' 0 C--N 1.342 0.23 0 C-N-CA 122.676 2.25 . . . . 75.3 112.382 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.742 ' O ' HD12 ' A' ' 53' ' ' ILE . 2.1 m120 -134.99 62.88 55.19 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.577 0.703 . . . . 73.34 110.873 -179.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 76.58 1.14 Allowed 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.661 2.241 . . . . 64.34 112.351 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.742 HD12 ' O ' ' A' ' 51' ' ' ASN . 3.9 mp -106.56 143.06 18.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 116.218 -0.446 . . . . 75.31 111.145 179.94 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -138.91 158.51 44.08 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.19 -0.459 . . . . 72.23 110.88 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.8 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -164.09 84.47 1.26 Allowed Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.639 0.733 . . . . 52.21 111.143 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.676 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.72 121.93 8.62 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.675 2.25 . . . . 60.02 112.334 179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -66.76 152.24 45.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.244 -0.434 . . . . 72.0 110.9 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.0 -35.87 3.93 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.708 -0.758 . . . . 52.31 112.478 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.5 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -105.86 157.58 17.37 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.751 0.31 . . . . 74.12 111.114 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.715 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.3 mp0 -66.8 144.78 56.1 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 71.35 110.859 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.763 HG13 HG23 ' A' ' 55' ' ' VAL . 5.7 mm -130.56 124.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.47 . . . . 62.33 111.195 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.683 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -113.73 90.24 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.192 -0.458 . . . . 73.31 111.133 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.59 ' HB2' HG12 ' A' ' 93' ' ' VAL . 64.1 m-85 -67.88 138.8 56.33 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.176 -0.465 . . . . 65.13 110.859 -179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.4 mttt -132.75 100.25 4.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 74.42 110.887 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.57 HD11 ' CE2' ' A' ' 74' ' ' PHE . 2.3 mp -106.87 141.63 21.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.158 -0.474 . . . . 71.25 111.151 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.2 t -154.67 138.02 15.8 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.183 -0.462 . . . . 73.13 111.14 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.411 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -142.8 159.58 56.36 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.671 0.748 . . . . 74.03 110.854 -179.84 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.411 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.7 -51.68 0.38 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.678 2.252 . . . . 74.13 112.361 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 -156.95 49.41 0.46 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 50.54 110.892 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.41 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.13 136.27 5.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.219 -0.446 . . . . 62.43 111.158 -179.948 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 71.4 mt -86.21 142.53 12.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.186 -0.461 . . . . 71.11 111.115 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 55.4 t60 -118.3 -80.99 0.62 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 73.14 110.865 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 57.29 171.46 0.19 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.73 -0.748 . . . . 65.1 112.502 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.57 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.8 p90 -160.45 141.89 12.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.844 0.354 . . . . 63.0 110.927 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 7.1 t-80 -116.18 101.78 9.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 61.24 110.851 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.727 HG12 HG21 ' A' ' 81' ' ' ILE . 5.0 p -96.28 143.78 11.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.188 -0.46 . . . . 61.24 111.104 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 82.8 mt-10 -66.34 -172.25 0.15 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 72.11 110.938 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.89 -46.52 3.3 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.778 -0.725 . . . . 61.2 112.457 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.419 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.8 OUTLIER -146.7 165.68 28.88 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.751 0.31 . . . . 74.42 111.149 -179.82 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.419 ' H ' HG22 ' A' ' 79' ' ' THR . 2.0 m-80 -79.48 58.36 2.65 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 75.12 110.947 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.727 HG21 HG12 ' A' ' 76' ' ' VAL . 12.9 tt -66.35 115.09 3.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 63.41 111.118 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.7 91.05 3.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.174 -0.466 . . . . 73.01 110.863 179.966 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.43 ' CG1' HG21 ' A' ' 93' ' ' VAL . 7.0 m -118.11 120.48 64.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.161 -0.472 . . . . 75.44 111.103 179.933 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.9 pp20? -160.9 117.34 2.28 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.02 110.924 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.498 HG21 ' OG ' ' A' ' 91' ' ' SER . 96.2 t -140.35 127.73 23.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.173 -0.467 . . . . 75.03 111.134 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.419 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -51.07 160.06 0.91 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.601 0.715 . . . . 63.42 110.921 179.972 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.419 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 54.0 Cg_endo -69.73 155.47 65.96 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.724 2.283 . . . . 71.41 112.353 179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.65 10.7 46.33 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.797 -0.716 . . . . 64.35 112.513 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -164.69 119.2 1.37 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.871 0.367 . . . . 74.34 110.867 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.428 HG12 ' O ' ' A' ' 9' ' ' GLU . 2.9 p -68.69 133.73 31.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 63.25 111.141 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.498 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -94.39 168.9 10.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.156 -0.475 . . . . 54.25 110.876 -179.87 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 90.5 m -144.4 105.46 4.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.141 -0.481 . . . . 71.24 111.119 -179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.59 HG12 ' HB2' ' A' ' 63' ' ' PHE . 9.0 p -118.58 141.21 39.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 62.51 111.125 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.5 mmm180 -110.6 101.55 10.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.126 -0.488 . . . . 71.31 110.879 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 50.7 t80 -145.97 119.26 8.94 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.228 -0.442 . . . . 64.42 110.905 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.5 t -117.28 142.97 46.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.125 -0.489 . . . . 71.13 111.181 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.0 -175.93 4.25 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.225 -0.443 . . . . 63.11 110.915 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 20.5 mtpt -126.21 -12.45 6.3 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.16 -0.473 . . . . 74.12 110.917 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.5 mpp_? -148.19 162.22 31.49 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.601 0.715 . . . . 75.5 110.908 179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 156.9 62.23 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.69 2.26 . . . . 73.21 112.344 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.2 133.64 1.51 Allowed Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.743 -0.742 . . . . 60.44 112.523 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -99.4 128.49 45.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.812 0.339 . . . . 74.33 110.897 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.5 p90 -144.13 131.08 20.41 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 74.31 110.889 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 7.1 ptt180 -147.94 83.41 1.51 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.088 -0.506 . . . . 74.15 110.858 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 56.0 mt -151.01 145.03 16.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 73.14 111.155 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.67 140.0 36.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 71.41 111.131 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 179.57 153.44 0.46 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 73.34 110.867 179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 54.2 m-20 51.45 53.29 13.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.221 -0.445 . . . . 54.24 110.902 -179.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.428 HE22 ' N ' ' A' ' 74' ' ' PHE . 39.9 mm-40 -98.6 62.5 1.41 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.225 -0.443 . . . . 73.43 110.96 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 69.43 -75.4 0.07 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.248 -0.433 . . . . 74.01 110.907 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 56.1 m -75.31 -24.81 57.5 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.13 -0.487 . . . . 54.45 110.853 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.02 43.29 9.93 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.74 -0.743 . . . . 63.31 112.529 -179.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -52.82 171.25 0.06 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-O 120.911 0.386 . . . . 72.31 110.875 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 173.88 34.7 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.75 . . . . 71.21 112.444 179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -179.33 37.93 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.754 0.311 . . . . 74.34 110.829 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -162.25 -67.8 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.244 -0.435 . . . . 71.15 110.905 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 27.9 p30 -58.19 -175.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 61.42 110.876 -179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 20.9 mmt -115.28 176.78 4.91 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.182 -0.463 . . . . 75.44 110.898 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 74.2 m-85 -89.27 122.74 32.82 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.277 -0.42 . . . . 70.24 110.885 -179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.93 167.95 0.3 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.753 -0.736 . . . . 65.01 112.475 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.568 ' HB ' HD13 ' A' ' 53' ' ' ILE . 43.1 m -154.03 118.66 4.92 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.814 0.34 . . . . 74.32 111.146 -179.896 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.596 HG13 HG21 ' A' ' 53' ' ' ILE . 4.3 mp -144.92 141.55 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.193 -0.458 . . . . 75.34 111.123 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.493 ' O ' HG12 ' A' ' 55' ' ' VAL . 85.1 t -131.29 133.95 61.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.147 -0.479 . . . . 72.4 111.135 179.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.8 HG22 HG13 ' A' ' 55' ' ' VAL . 97.4 t -103.9 134.93 43.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.168 -0.469 . . . . 54.41 111.093 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 9.1 mmmt -117.87 130.66 56.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 65.33 110.846 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.177 -0.465 . . . . 73.41 110.856 179.973 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.83 0.348 . . . . 73.44 110.876 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 3.2 m 38.06 80.85 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.238 -0.437 . . . . 72.43 111.116 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 8.1 pt -111.81 78.2 2.13 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.602 0.715 . . . . 74.54 111.09 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.73 -170.76 0.41 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.639 2.226 . . . . 71.31 112.349 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.23 35.41 1.21 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 62.34 111.067 179.871 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 171.76 164.77 27.91 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.698 -0.763 . . . . 73.35 112.466 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.46 -166.39 0.23 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.832 0.349 . . . . 62.13 110.9 -179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.616 HD13 ' HB ' ' A' ' 90' ' ' VAL . 3.1 pp -54.82 178.18 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.227 -0.442 . . . . 53.33 110.916 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.425 ' N ' HD12 ' A' ' 8' ' ' LEU . 14.1 pt-20 -103.13 136.27 43.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 73.43 110.883 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.6 mpt_? -89.46 166.76 13.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.167 -0.47 . . . . 70.53 110.885 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.0 m -144.5 -179.31 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.189 -0.459 . . . . 71.3 111.146 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -145.76 161.66 39.42 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.628 0.728 . . . . 65.0 110.904 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 -4.47 14.09 Favored 'Trans proline' 0 C--O 1.232 0.2 0 C-N-CA 122.687 2.258 . . . . 70.51 112.355 -179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.796 HG22 HG23 ' A' ' 15' ' ' THR . 33.9 m -48.47 -70.78 0.08 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.231 -0.44 . . . . 62.33 111.178 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.796 HG23 HG22 ' A' ' 14' ' ' THR . 30.5 p -150.92 35.26 0.6 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.245 -0.434 . . . . 72.03 111.17 179.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 14.0 p -69.56 -31.59 49.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.214 -0.448 . . . . 61.53 111.086 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.407 ' HB3' HD21 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -93.14 -5.09 51.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 75.52 110.889 -179.966 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.4 mm-40 -104.53 -35.7 7.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 73.4 110.9 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -129.0 134.16 48.04 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 63.23 110.861 -179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.73 -160.3 13.77 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.748 -0.739 . . . . 64.21 112.5 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -26.27 27.71 Favored 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.746 2.297 . . . . 73.1 112.342 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 16.1 m-90 -87.17 -9.86 54.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.192 -0.458 . . . . 61.24 110.928 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.77 -59.46 2.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 54.15 111.134 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -102.62 144.38 28.5 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.605 0.717 . . . . 71.43 110.875 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -19.17 36.78 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.695 2.263 . . . . 72.3 112.39 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.75 -20.28 60.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 74.23 111.117 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 35.5 mm-40 -87.28 6.82 31.44 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.184 -0.462 . . . . 73.32 110.868 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -58.43 -76.19 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 70.01 111.112 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.404 HG21 ' HB3' ' A' ' 54' ' ' GLU . 20.1 t -84.53 118.35 31.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.241 -0.436 . . . . 72.02 111.123 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.445 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 11.0 m -132.94 138.75 51.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.142 -0.481 . . . . 75.25 111.151 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -86.14 95.96 9.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.449 . . . . 73.22 110.892 -179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.3 t -95.71 -35.82 11.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.18 -0.464 . . . . 65.31 111.163 -179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.79 -166.54 21.63 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.724 -0.75 . . . . 62.13 112.507 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -44.93 1.77 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.677 2.251 . . . . 65.42 112.315 -179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.7 t30 -143.37 30.24 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.449 . . . . 74.31 110.867 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.2 pt20 -126.95 120.05 28.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 74.42 110.933 179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 28.1 m-85 -96.34 135.73 37.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.205 -0.452 . . . . 72.35 110.924 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.445 ' HB ' ' CG2' ' A' ' 30' ' ' VAL . 49.8 m -96.01 105.0 16.98 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.093 -0.503 . . . . 54.12 111.111 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 22.0 t -84.65 147.23 5.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 73.1 111.141 179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -127.16 121.85 32.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.19 -0.459 . . . . 73.54 110.928 -179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.499 HG22 ' CG1' ' A' ' 53' ' ' ILE . 97.6 t -114.33 124.97 71.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.143 -0.48 . . . . 73.23 111.191 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.667 HD12 ' OE1' ' A' ' 49' ' ' GLN . 3.3 tm? -120.36 136.5 54.69 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.197 -0.456 . . . . 64.53 110.868 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.507 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -155.61 140.55 17.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 52.44 111.122 179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -139.99 159.0 43.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.267 -0.424 . . . . 64.55 110.923 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.71 5.57 35.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 53.55 111.111 179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.6 p90 -122.31 84.88 2.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 72.13 110.853 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.87 179.14 19.16 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.743 -0.742 . . . . 72.02 112.492 -179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -124.65 139.48 53.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.806 0.336 . . . . 63.2 110.922 -179.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.667 ' OE1' HD12 ' A' ' 42' ' ' LEU . 5.4 mt-30 -142.17 162.09 47.24 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.638 0.732 . . . . 73.2 110.875 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 179.9 3.37 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.675 2.25 . . . . 64.43 112.317 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.659 ' O ' HD12 ' A' ' 53' ' ' ILE . 4.6 m-80 -135.98 63.0 49.37 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.629 0.728 . . . . 63.33 110.909 -179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.72 73.77 1.32 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.643 2.229 . . . . 72.13 112.368 179.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.659 HD12 ' O ' ' A' ' 51' ' ' ASN . 4.5 mp -110.57 113.91 45.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.246 -0.434 . . . . 72.44 111.179 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.404 ' HB3' HG21 ' A' ' 29' ' ' VAL . 12.3 tt0 -110.07 135.43 50.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.161 -0.472 . . . . 74.41 110.908 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.857 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -138.9 81.76 21.58 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.665 0.745 . . . . 72.13 111.132 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.626 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.2 Cg_endo -69.71 129.01 16.9 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.731 2.287 . . . . 73.33 112.356 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.44 152.2 40.85 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.436 . . . . 71.12 110.897 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.61 -35.61 3.99 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.758 -0.734 . . . . 52.51 112.474 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.0 155.93 18.5 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.755 0.312 . . . . 71.44 111.127 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.696 ' O ' HD13 ' A' ' 61' ' ' ILE . 40.4 mt-10 -67.18 144.51 55.96 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 75.03 110.896 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.696 HD13 ' O ' ' A' ' 60' ' ' GLU . 6.4 mm -128.83 119.61 50.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.198 -0.455 . . . . 73.35 111.137 179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.822 HG13 HG23 ' A' ' 92' ' ' THR . 55.1 t -107.55 91.22 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 74.42 111.143 179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.571 ' HB2' HG12 ' A' ' 93' ' ' VAL . 65.3 m-85 -70.37 137.25 50.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.141 -0.481 . . . . 61.12 110.864 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 9.5 mttt -129.55 100.88 5.7 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.125 -0.489 . . . . 74.21 110.839 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.732 ' CG2' HG11 ' A' ' 85' ' ' VAL . 1.8 mp -100.31 155.29 4.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 73.53 111.11 179.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.4 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.3 t -169.99 139.21 1.83 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.166 -0.47 . . . . 72.02 111.148 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.4 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -143.46 161.78 45.43 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.688 0.756 . . . . 73.4 110.857 -179.86 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.4 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.72 -54.09 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.69 2.26 . . . . 70.22 112.392 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -159.16 38.3 0.21 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 71.3 110.878 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -138.73 135.16 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.167 -0.47 . . . . 72.42 111.114 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.514 HD13 ' HD3' ' A' ' 87' ' ' PRO . 28.7 mm -88.02 142.89 12.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.116 -0.493 . . . . 73.33 111.133 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 21.5 p-80 -174.85 136.9 0.42 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.465 . . . . 73.01 110.859 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -143.76 -149.62 5.12 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.76 -0.733 . . . . 62.34 112.494 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.468 ' CE2' HD11 ' A' ' 65' ' ' ILE . 7.9 p90 -159.29 138.19 11.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.923 0.392 . . . . 51.12 110.925 -179.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 41.6 t60 -128.34 98.83 5.2 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 71.34 110.858 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.704 HG12 HG21 ' A' ' 81' ' ' ILE . 6.6 p -80.58 144.61 10.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 63.14 111.111 179.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.3 pm0 -67.77 -175.44 0.54 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 62.12 110.894 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.54 -51.1 4.44 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.715 -0.755 . . . . 74.13 112.474 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.7 m -131.46 153.34 49.84 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.321 . . . . 62.41 111.174 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.462 ' H ' ' ND2' ' A' ' 80' ' ' ASN . 2.5 p30 -76.0 66.08 2.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 71.14 110.89 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.704 HG21 HG12 ' A' ' 76' ' ' VAL . 12.5 tt -77.57 113.11 16.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.174 -0.466 . . . . 70.32 111.09 179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.03 98.35 6.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.135 -0.484 . . . . 52.01 110.885 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.9 m -121.25 120.31 61.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.158 -0.474 . . . . 72.22 111.15 179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -125.09 96.02 4.7 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.131 -0.486 . . . . 62.54 110.885 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.732 HG11 ' CG2' ' A' ' 65' ' ' ILE . 5.8 p -86.83 144.37 9.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.171 -0.468 . . . . 63.01 111.072 179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 6.1 mp -111.05 156.62 40.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.6 0.714 . . . . 72.31 110.935 179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.514 ' HD3' HD13 ' A' ' 71' ' ' ILE . 54.1 Cg_endo -69.71 146.96 62.13 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.254 . . . . 74.42 112.365 179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 81.22 8.96 86.65 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.734 -0.746 . . . . 20.31 112.467 179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 18.8 mt-10 -146.69 173.61 12.2 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.918 0.39 . . . . 71.41 110.893 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.616 ' HB ' HD13 ' A' ' 8' ' ' LEU . 18.5 t -120.92 146.21 26.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.175 -0.466 . . . . 70.23 111.155 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.416 ' OG ' HD12 ' A' ' 65' ' ' ILE . 1.5 p -109.84 158.51 18.09 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 72.34 110.87 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.822 HG23 HG13 ' A' ' 62' ' ' VAL . 53.2 m -145.87 105.46 3.96 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.158 -0.474 . . . . 63.33 111.128 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.571 HG12 ' HB2' ' A' ' 63' ' ' PHE . 7.6 p -123.11 136.23 60.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 71.14 111.143 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.2 mtm180 -105.86 92.47 4.18 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 74.12 110.827 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 40.2 t80 -134.66 115.17 13.5 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.207 -0.452 . . . . 73.2 110.939 -179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 9.4 t -116.19 142.93 46.18 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.135 -0.484 . . . . 73.11 111.149 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.95 178.85 6.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 71.35 110.863 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.34 -21.94 7.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.118 -0.492 . . . . 72.55 110.912 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.97 158.3 74.15 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.592 0.71 . . . . 73.12 110.887 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 149.44 66.86 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.678 2.252 . . . . 74.2 112.363 179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.87 156.67 9.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.722 -0.752 . . . . 54.52 112.457 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.616 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -114.54 132.2 56.4 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.847 0.356 . . . . 63.24 110.868 -179.874 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.0 p90 -143.62 146.41 33.24 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.158 -0.473 . . . . 55.41 110.923 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.949 ' O ' HG22 ' A' ' 105' ' ' ILE . 13.9 ptt-85 -164.9 -164.58 0.81 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.141 -0.481 . . . . 74.32 110.863 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.949 HG22 ' O ' ' A' ' 104' ' ' ARG . 7.3 tt 58.2 158.53 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 61.32 111.118 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -119.28 140.05 44.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.185 -0.462 . . . . 61.14 111.16 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.525 ' HA ' HD23 ' A' ' 113' ' ' LEU . 56.7 m -141.67 -42.51 0.36 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.167 -0.47 . . . . 73.43 110.87 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 61.2 m-20 -125.43 76.03 1.52 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.183 -0.462 . . . . 73.43 110.886 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 1.1 mm-40 -122.62 -5.13 8.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.221 -0.445 . . . . 54.52 110.886 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 70.6 t80 63.41 155.39 0.05 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 75.32 110.889 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 7.2 t 65.76 15.34 10.01 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.112 -0.495 . . . . 64.13 110.854 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -159.89 -129.12 1.02 Allowed Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.799 -0.715 . . . . 71.23 112.542 -179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.525 HD23 ' HA ' ' A' ' 107' ' ' CYS . 3.1 tm? 62.54 104.14 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.843 0.354 . . . . 75.25 110.888 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 98.06 -20.56 50.08 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.763 -0.732 . . . . 41.53 112.514 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -152.25 128.93 10.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.723 0.297 . . . . 74.4 110.876 -179.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 14.0 mt-30 63.6 -169.35 0.19 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.179 -0.464 . . . . 75.32 110.909 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 63.76 97.32 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.183 -0.462 . . . . 74.14 110.915 -179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.27 175.32 5.45 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 74.13 110.853 179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 -91.29 161.94 14.82 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.191 -0.459 . . . . 70.21 110.879 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.533 ' O ' HD12 ' A' ' 122' ' ' ILE . . . -130.68 103.88 0.58 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.71 -0.757 . . . . 40.0 112.465 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.644 ' O ' HD13 ' A' ' 53' ' ' ILE . 96.2 m -74.98 116.23 15.48 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.791 0.329 . . . . 75.13 111.166 -179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.533 HD12 ' O ' ' A' ' 120' ' ' GLY . 2.5 mp -140.25 132.92 33.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 65.14 111.069 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.616 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -134.3 141.13 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.126 -0.488 . . . . 73.0 111.093 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.857 HG22 HG13 ' A' ' 55' ' ' VAL . 62.1 t -103.75 130.73 53.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.154 -0.475 . . . . 61.11 111.138 179.945 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -104.1 128.72 51.75 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.197 -0.456 . . . . 70.24 110.917 179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.242 0 CA-C-N 116.23 -0.441 . . . . 75.42 110.853 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.2 mtp . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.799 0.333 . . . . 71.43 110.85 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 98.2 t -108.03 113.15 43.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.436 . . . . 75.55 111.163 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 28.5 pt -151.16 153.75 33.14 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.622 0.725 . . . . 70.22 111.142 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.77 -176.96 1.66 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.651 2.234 . . . . 53.35 112.34 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -94.94 -24.96 16.74 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.255 -0.43 . . . . 50.0 111.085 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -173.62 129.22 1.62 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.749 -0.739 . . . . 74.32 112.526 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.07 163.75 0.11 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.79 0.328 . . . . 63.12 110.894 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.662 HD21 ' NH1' ' A' ' 10' ' ' ARG . 0.2 OUTLIER 61.31 164.38 0.08 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.259 -0.428 . . . . 55.33 110.905 179.934 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.622 ' N ' HD12 ' A' ' 8' ' ' LEU . 3.8 pm0 -132.46 130.36 40.41 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 75.33 110.892 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.662 ' NH1' HD21 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -86.43 142.67 28.24 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 62.45 110.848 -179.919 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.568 HG13 HG23 ' A' ' 90' ' ' VAL . 16.4 m -118.46 -176.64 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.167 -0.469 . . . . 65.52 111.106 179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.444 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 16.5 p30 -142.92 157.39 61.22 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.605 0.717 . . . . 54.52 110.887 179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.444 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 54.0 Cg_endo -69.77 -3.06 11.25 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.646 2.23 . . . . 75.41 112.379 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.82 HG22 HG23 ' A' ' 15' ' ' THR . 25.2 m -46.58 -69.98 0.11 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.452 . . . . 75.51 111.165 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.82 HG23 HG22 ' A' ' 14' ' ' THR . 25.9 p -149.71 24.83 0.86 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.175 -0.466 . . . . 65.43 111.165 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.2 p -63.68 -30.97 51.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.174 -0.467 . . . . 74.31 111.133 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.487 ' NH1' HD21 ' A' ' 42' ' ' LEU . 0.1 OUTLIER -103.28 -5.38 23.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.141 -0.482 . . . . 74.44 110.879 -179.973 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 83.7 mm-40 -92.24 -37.42 12.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.172 -0.467 . . . . 71.11 110.942 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.2 tt0 -141.89 133.42 26.77 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.204 -0.453 . . . . 72.3 110.898 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 126.97 -155.09 19.62 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.7 -0.762 . . . . 72.34 112.502 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 -32.95 17.5 Favored 'Trans proline' 0 C--N 1.341 0.154 0 C-N-CA 122.683 2.256 . . . . 72.45 112.351 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.442 ' HB3' HD23 ' A' ' 42' ' ' LEU . 12.2 m-90 -84.61 -13.98 50.06 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.219 -0.446 . . . . 73.32 110.916 -179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.78 -49.18 75.97 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.203 -0.453 . . . . 72.4 111.082 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -114.07 144.39 31.51 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.608 0.718 . . . . 75.14 110.862 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 -25.7 28.06 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.662 2.242 . . . . 61.43 112.318 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.22 -6.75 49.67 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 74.15 111.098 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 24.0 mm-40 -102.47 9.67 39.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 72.44 110.881 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -56.92 -79.17 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.225 -0.443 . . . . 62.22 111.146 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.572 HG23 ' HB3' ' A' ' 37' ' ' TYR . 1.5 p -84.98 124.34 39.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.188 -0.46 . . . . 53.21 111.12 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 18.5 m -135.29 136.01 51.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.168 -0.469 . . . . 63.25 111.124 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -75.57 107.2 7.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.16 -0.473 . . . . 52.05 110.893 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 9.7 t -111.94 -32.95 6.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.218 -0.446 . . . . 55.02 111.141 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.76 -172.68 19.86 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.756 -0.735 . . . . 34.11 112.504 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.76 -43.8 2.45 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.687 2.258 . . . . 73.23 112.357 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.0 t30 -140.96 35.27 1.75 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.212 -0.449 . . . . 64.31 110.876 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.35 119.09 14.08 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.184 -0.462 . . . . 60.03 110.889 179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.572 ' HB3' HG23 ' A' ' 29' ' ' VAL . 15.2 m-85 -96.79 137.34 36.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 71.42 110.95 -179.905 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.741 ' HA ' HG23 ' A' ' 62' ' ' VAL . 81.2 m -95.74 105.71 17.75 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 73.45 111.147 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.463 ' HA ' ' HA ' ' A' ' 29' ' ' VAL . 9.9 t -92.66 138.52 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.202 -0.453 . . . . 64.13 111.12 179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 74.6 m-85 -120.75 114.82 22.2 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.191 -0.459 . . . . 72.32 110.951 -179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.485 HG22 HG13 ' A' ' 53' ' ' ILE . 64.4 t -104.14 130.79 54.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.14 -0.482 . . . . 73.15 111.102 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.487 HD21 ' NH1' ' A' ' 17' ' ' ARG . 1.7 tm? -125.07 121.52 34.55 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.165 -0.47 . . . . 71.12 110.896 179.982 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -142.89 137.57 29.61 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.218 -0.446 . . . . 62.43 111.088 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -145.52 159.94 42.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.243 -0.435 . . . . 74.04 110.858 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.82 5.55 32.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.165 -0.47 . . . . 54.33 111.108 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 30.0 m-85 -110.26 70.59 0.73 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.225 -0.443 . . . . 74.45 110.831 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.07 -170.09 16.23 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.684 -0.77 . . . . 55.55 112.415 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.23 126.51 23.06 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.795 0.331 . . . . 72.41 110.929 -179.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.46 ' HB3' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -136.42 161.0 64.62 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.567 0.699 . . . . 73.45 110.961 179.974 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.46 ' HD2' ' HB3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.76 178.68 4.32 Favored 'Trans proline' 0 C--N 1.34 0.131 0 C-N-CA 122.707 2.271 . . . . 70.43 112.338 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.708 ' O ' HD12 ' A' ' 53' ' ' ILE . 1.1 m-80 -129.93 62.78 65.72 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.646 0.736 . . . . 64.5 110.905 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.83 75.56 1.23 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.657 2.238 . . . . 71.23 112.314 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.753 HD13 ' O ' ' A' ' 121' ' ' THR . 4.4 mp -106.89 98.18 6.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.204 -0.453 . . . . 64.11 111.133 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 8.1 tt0 -82.14 129.6 34.86 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.216 -0.447 . . . . 61.41 110.889 179.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.69 ' O ' HG13 ' A' ' 124' ' ' VAL . 30.7 t -137.01 81.31 33.35 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.633 0.73 . . . . 75.1 111.118 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.596 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.8 123.05 9.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.702 2.268 . . . . 72.34 112.355 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -69.29 155.18 40.84 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 71.45 110.933 -179.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.36 -4.39 77.59 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.749 -0.739 . . . . 60.13 112.503 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.05 152.46 51.96 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.71 0.29 . . . . 75.1 111.129 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.68 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.0 mp0 -66.66 139.37 57.86 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.265 -0.425 . . . . 64.43 110.887 -179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.68 HD13 ' O ' ' A' ' 60' ' ' GLU . 7.2 mm -127.41 116.33 43.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.198 -0.456 . . . . 64.14 111.123 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.741 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -104.44 90.59 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 71.21 111.108 179.87 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.7 m-85 -68.42 139.7 55.78 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.455 . . . . 75.13 110.883 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 11.7 mttt -131.97 100.57 5.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 64.11 110.913 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.609 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.8 mp -102.05 156.19 4.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.205 -0.452 . . . . 73.32 111.122 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.1 t -168.44 140.49 2.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.135 -0.484 . . . . 72.4 111.137 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.451 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -149.52 161.14 32.69 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.705 0.764 . . . . 75.45 110.861 -179.883 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.424 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.78 -55.46 0.18 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 42.12 112.322 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -156.96 61.97 0.51 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 63.25 110.85 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.451 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.84 135.44 3.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.187 -0.46 . . . . 61.32 111.163 179.955 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 36.4 mm -69.81 130.5 34.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.199 -0.455 . . . . 64.11 111.128 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.66 ' HE2' HG23 ' A' ' 85' ' ' VAL . 9.2 p-80 -119.98 -175.79 3.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.236 -0.438 . . . . 51.22 110.885 179.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 139.92 170.9 12.13 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 33.22 112.502 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.609 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.5 p90 -153.23 141.25 20.3 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.845 0.355 . . . . 75.15 110.918 -179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 76.2 t60 -122.1 104.38 9.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 73.11 110.878 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.686 HG12 HG21 ' A' ' 81' ' ' ILE . 3.5 p -94.3 137.86 21.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.252 -0.431 . . . . 74.44 111.143 -179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -59.96 -175.98 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.153 -0.476 . . . . 61.41 110.904 -179.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.13 -50.97 4.35 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.761 -0.733 . . . . 44.41 112.45 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.464 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -129.26 171.71 12.19 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.773 0.321 . . . . 73.22 111.111 -179.816 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.464 ' H ' HG22 ' A' ' 79' ' ' THR . 3.2 m-80 -93.17 47.61 1.27 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 73.44 110.852 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.686 HG21 HG12 ' A' ' 76' ' ' VAL . 12.5 tt -58.54 112.44 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.182 -0.463 . . . . 60.34 111.172 179.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -115.34 94.16 4.6 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.18 -0.464 . . . . 74.53 110.923 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.421 HG11 ' CG1' ' A' ' 93' ' ' VAL . 3.3 m -117.97 120.35 64.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.153 -0.476 . . . . 54.11 111.096 179.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -150.28 118.46 6.36 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 74.32 110.85 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.851 HG21 ' HB2' ' A' ' 91' ' ' SER . 5.0 m -140.73 146.88 23.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.155 -0.475 . . . . 73.32 111.14 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.27 161.94 75.5 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.554 0.692 . . . . 75.42 110.969 179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 159.65 52.61 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.676 2.25 . . . . 72.11 112.309 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 86.4 13.28 68.36 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.749 -0.739 . . . . 74.42 112.493 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 10.9 mt-10 -146.21 138.43 25.17 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.903 0.383 . . . . 71.23 110.892 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.568 HG23 HG13 ' A' ' 11' ' ' VAL . 99.5 t -90.93 105.89 16.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 53.03 111.153 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.851 ' HB2' HG21 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -89.31 137.67 32.12 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.186 -0.461 . . . . 73.3 110.855 -179.839 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 92.9 m -110.01 105.51 14.67 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.147 -0.479 . . . . 74.23 111.172 -179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.421 ' CG1' HG11 ' A' ' 83' ' ' VAL . 44.7 t -98.19 147.95 6.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.202 -0.454 . . . . 71.54 111.104 179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -123.61 110.93 15.62 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.157 -0.474 . . . . 70.21 110.882 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -156.68 122.64 4.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.222 -0.445 . . . . 72.05 110.887 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 12.8 t -123.39 135.55 54.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.112 -0.494 . . . . 64.43 111.152 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -92.79 -174.22 3.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.238 -0.437 . . . . 65.24 110.871 -179.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -121.9 -26.4 4.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.169 -0.469 . . . . 72.11 110.915 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.1 mpp_? -134.51 161.41 63.89 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.575 0.702 . . . . 70.04 110.88 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 154.22 67.89 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.652 2.235 . . . . 63.32 112.371 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.58 134.4 1.65 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.755 -0.736 . . . . 32.23 112.485 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.743 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -100.69 139.49 36.3 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.837 0.351 . . . . 74.31 110.892 -179.883 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -143.82 132.82 22.83 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.116 -0.493 . . . . 74.24 110.915 -179.82 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.36 94.07 2.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 61.13 110.86 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.8 tt -177.63 131.55 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 75.34 111.17 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.402 HD13 HD23 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -106.2 145.77 13.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.234 -0.439 . . . . 64.33 111.093 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -163.98 -74.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 54.35 110.874 179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 6.4 m120 -81.09 106.67 13.26 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.174 -0.466 . . . . 75.4 110.905 -179.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 3.4 mt-30 -167.8 -77.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 74.32 110.914 179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER 175.91 -168.49 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.262 -0.427 . . . . 72.41 110.915 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 68.66 -76.4 0.06 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.148 -0.478 . . . . 60.22 110.9 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 153.61 95.31 0.11 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.748 -0.739 . . . . 70.2 112.5 -179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.496 ' C ' HD13 ' A' ' 113' ' ' LEU . 3.1 tm? -51.77 131.87 30.86 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.919 0.39 . . . . 73.5 110.88 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.444 ' H ' HD22 ' A' ' 113' ' ' LEU . . . 146.79 -101.77 0.24 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.73 -0.747 . . . . 70.53 112.499 179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 19.0 m170 -94.09 40.3 1.08 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.744 0.307 . . . . 74.12 110.849 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 2.2 mt-30 -172.73 172.54 4.13 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.231 -0.44 . . . . 64.23 110.878 -179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 37.9 t-20 66.08 119.46 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 75.43 110.894 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -71.18 174.88 5.8 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.188 -0.46 . . . . 71.12 110.901 179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 56.9 m-85 -91.28 129.7 37.24 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.21 -0.45 . . . . 71.02 110.886 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.8 82.49 0.4 Allowed Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.713 -0.756 . . . . 53.35 112.476 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.753 ' O ' HD13 ' A' ' 53' ' ' ILE . 6.7 m -80.7 115.02 19.99 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.826 0.346 . . . . 64.42 111.127 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.444 ' CG2' HG21 ' A' ' 55' ' ' VAL . 2.1 mp -149.14 139.12 16.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.181 -0.463 . . . . 74.34 111.177 179.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.743 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.5 p -127.5 135.92 61.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.212 -0.449 . . . . 64.32 111.182 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.69 HG13 ' O ' ' A' ' 55' ' ' VAL . 41.3 t -104.48 127.65 58.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.188 -0.46 . . . . 74.21 111.103 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 12.4 mmmm -102.22 133.6 46.84 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 70.21 110.872 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.228 -0.442 . . . . 75.21 110.919 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.541 ' O ' HG23 ' A' ' 3' ' ' ILE . 2.7 mtt . . . . . 0 C--O 1.23 0.079 0 CA-C-O 120.774 0.321 . . . . 73.24 110.875 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.588 HG22 ' O ' ' A' ' 2' ' ' VAL . 12.3 p 41.43 37.14 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.232 -0.44 . . . . 64.34 111.074 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.541 HG23 ' O ' ' A' ' 1' ' ' MET . 6.4 pt -122.52 77.97 46.28 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.592 0.71 . . . . 61.22 111.099 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -177.65 1.98 Allowed 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.689 2.259 . . . . 74.11 112.369 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -156.26 159.8 39.2 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.257 -0.429 . . . . 71.04 111.101 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 56.95 32.2 62.16 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.742 -0.742 . . . . 71.34 112.515 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -171.48 -168.97 0.66 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.745 0.307 . . . . 72.13 110.931 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.636 HD13 ' O ' ' A' ' 90' ' ' VAL . 0.8 OUTLIER -57.69 -172.98 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.231 -0.44 . . . . 73.54 110.913 179.941 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.48 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.8 OUTLIER -115.8 134.34 55.11 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 64.21 110.891 179.96 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 166.56 10.98 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 75.35 110.884 -179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.8 m -144.41 -179.09 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.158 -0.474 . . . . 71.35 111.074 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -144.68 162.04 40.66 Favored Pre-proline 0 C--N 1.328 -0.333 0 CA-C-O 121.603 0.716 . . . . 62.23 110.902 179.885 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -3.67 12.49 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.676 2.251 . . . . 65.45 112.331 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 28.0 m -46.09 -70.44 0.1 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.239 -0.437 . . . . 63.21 111.17 179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 28.3 p -150.05 27.59 0.77 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.258 -0.428 . . . . 64.4 111.157 179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.2 p -65.22 -30.77 51.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 73.22 111.13 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.428 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.7 OUTLIER -100.74 -15.74 17.57 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.148 -0.478 . . . . 63.33 110.863 -179.95 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -88.45 -33.04 17.98 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.216 -0.447 . . . . 61.04 110.898 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -141.35 135.12 30.17 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.2 -0.454 . . . . 73.03 110.913 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.44 -160.69 19.99 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.753 -0.737 . . . . 72.1 112.492 -179.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 -25.8 28.21 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.698 2.265 . . . . 53.24 112.343 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.733 ' HB3' HD13 ' A' ' 42' ' ' LEU . 14.5 m-90 -87.07 -12.6 46.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 75.32 110.95 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -69.86 -59.43 2.94 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.209 -0.451 . . . . 73.43 111.093 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.42 144.55 28.45 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.556 0.693 . . . . 71.44 110.879 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 -27.75 26.37 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.689 2.26 . . . . 75.41 112.359 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.41 -18.38 60.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 72.32 111.094 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 28.9 mm-40 -87.82 7.64 29.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 70.14 110.939 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -55.14 -78.56 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.156 -0.474 . . . . 64.35 111.112 179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.461 ' HA ' ' HA ' ' A' ' 39' ' ' VAL . 1.8 p -93.1 124.93 45.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.226 -0.443 . . . . 74.23 111.113 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 25.2 m -119.67 149.86 22.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 64.43 111.108 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.65 121.99 27.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.181 -0.463 . . . . 72.21 110.963 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.462 HG21 ' OG1' ' A' ' 38' ' ' THR . 0.6 OUTLIER -121.91 -42.6 2.39 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.233 -0.44 . . . . 73.1 111.122 -179.881 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.47 170.65 13.81 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.759 -0.734 . . . . 61.5 112.488 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 -8.02 22.54 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.695 2.264 . . . . 72.43 112.31 -179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -156.29 34.34 0.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 64.52 110.908 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -154.0 155.64 35.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.128 -0.487 . . . . 74.33 110.898 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.9 m-85 -143.05 147.99 35.98 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.244 -0.435 . . . . 72.34 110.913 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.462 ' OG1' HG21 ' A' ' 32' ' ' THR . 52.0 m -101.37 104.22 15.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.128 -0.487 . . . . 72.53 111.127 -179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.573 HG11 HG23 ' A' ' 53' ' ' ILE . 6.7 t -85.18 135.13 25.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.219 -0.446 . . . . 72.44 111.137 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -117.12 121.66 41.9 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.18 -0.464 . . . . 72.41 110.933 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 27.0 m -122.73 143.9 34.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.151 -0.477 . . . . 55.44 111.131 179.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.733 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -138.69 143.85 39.32 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.479 . . . . 62.23 110.889 179.993 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -149.54 123.52 9.39 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 73.14 111.129 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.3 p90 -121.41 154.47 36.47 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 62.45 110.814 -179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -87.84 6.87 33.28 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.139 -0.482 . . . . 54.42 111.074 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -122.37 86.07 2.52 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 75.43 110.906 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 113.91 -165.92 12.1 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.755 -0.736 . . . . 62.34 112.54 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 m-85 -136.3 143.43 44.18 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.842 0.353 . . . . 74.03 110.893 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.417 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.7 pm0 -145.37 155.59 53.83 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.58 0.705 . . . . 72.13 110.901 -179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.417 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.9 Cg_endo -69.75 174.45 9.48 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.68 2.253 . . . . 63.31 112.35 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.73 ' O ' HD12 ' A' ' 53' ' ' ILE . 2.1 m-20 -127.99 62.37 56.79 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.631 0.729 . . . . 72.23 110.869 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 74.43 1.26 Allowed 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.655 2.237 . . . . 73.1 112.343 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.73 HD12 ' O ' ' A' ' 51' ' ' ASN . 3.9 mp -110.58 113.89 45.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.233 -0.44 . . . . 54.43 111.154 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 24.9 tt0 -108.59 119.47 39.61 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.121 -0.491 . . . . 72.13 110.908 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.848 HG23 HG13 ' A' ' 61' ' ' ILE . 2.1 p -124.77 85.71 56.78 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.61 0.719 . . . . 74.14 111.125 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.619 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.4 Cg_endo -69.76 122.57 9.25 Favored 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 122.673 2.249 . . . . 72.31 112.347 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.57 150.45 48.4 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.22 -0.445 . . . . 64.01 110.881 -179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.81 -30.46 5.78 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.714 -0.755 . . . . 52.23 112.507 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.83 152.12 23.64 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.736 0.303 . . . . 54.21 111.119 180.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.63 ' O ' HD13 ' A' ' 61' ' ' ILE . 0.4 OUTLIER -68.82 142.36 54.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.196 -0.456 . . . . 75.11 110.861 -179.897 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.848 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -126.87 124.16 64.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.11 -0.496 . . . . 62.11 111.106 -179.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 1.042 HG13 HG23 ' A' ' 92' ' ' THR . 55.0 t -107.92 91.25 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 71.11 111.173 179.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -69.48 135.02 49.61 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.171 -0.468 . . . . 65.31 110.887 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 5.2 mttt -131.43 100.44 5.16 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.126 -0.488 . . . . 62.13 110.865 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.775 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.5 mp -97.17 156.07 3.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.264 -0.426 . . . . 73.12 111.098 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.607 HG23 HD12 ' A' ' 42' ' ' LEU . 7.2 t -166.01 137.9 3.86 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.169 -0.469 . . . . 43.44 111.141 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.639 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -152.21 159.76 32.36 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.646 0.736 . . . . 71.14 110.912 -179.876 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.2 Cg_endo -69.76 -53.98 0.24 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.665 2.243 . . . . 71.21 112.403 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -154.88 65.84 0.66 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.196 -0.456 . . . . 73.24 110.864 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.639 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.4 135.55 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.183 -0.462 . . . . 74.32 111.126 -179.998 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.2 mm -66.9 145.54 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.198 -0.455 . . . . 75.31 111.107 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.775 ' HB3' HG21 ' A' ' 65' ' ' ILE . 0.3 OUTLIER -108.75 -167.05 1.17 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.174 -0.466 . . . . 74.45 110.834 179.85 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.84 120.73 3.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.724 -0.75 . . . . 41.12 112.513 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -121.16 142.84 49.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.904 0.383 . . . . 74.54 110.9 -179.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 15.4 t60 -89.14 137.19 32.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.135 -0.484 . . . . 73.11 110.872 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.741 HG13 ' CE2' ' A' ' 103' ' ' TYR . 94.8 t -130.03 141.47 46.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 62.42 111.161 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.6 mt-10 -75.26 175.67 8.11 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.177 -0.465 . . . . 64.11 110.878 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 80.06 -51.65 4.14 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.676 -0.773 . . . . 64.34 112.514 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -133.25 147.24 51.95 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.772 0.32 . . . . 74.11 111.156 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 5.1 m120 -76.71 64.57 2.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.22 -0.445 . . . . 65.55 110.881 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.767 HD12 ' CD2' ' A' ' 95' ' ' TYR . 8.0 tt -58.23 125.94 15.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.193 -0.458 . . . . 73.2 111.176 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.7 89.67 3.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.853 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.575 HG11 HG21 ' A' ' 93' ' ' VAL . 3.7 m -115.87 120.65 65.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 73.42 111.158 179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -155.79 114.51 3.47 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.2 -0.454 . . . . 72.12 110.838 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.652 HG21 ' OG ' ' A' ' 91' ' ' SER . 61.6 t -140.46 146.71 24.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.162 -0.472 . . . . 74.15 111.138 179.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.433 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.6 OUTLIER -69.69 155.68 93.06 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.585 0.707 . . . . 63.03 110.902 179.974 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.433 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 54.1 Cg_endo -69.74 159.8 52.09 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.234 . . . . 71.1 112.379 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.21 17.25 51.31 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.761 -0.733 . . . . 64.11 112.493 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.8 pt-20 -156.26 155.77 32.93 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.88 0.371 . . . . 73.13 110.886 -179.905 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.636 ' O ' HD13 ' A' ' 8' ' ' LEU . 98.2 t -104.85 109.78 28.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 55.31 111.123 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.652 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.4 OUTLIER -83.83 169.46 15.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.172 -0.467 . . . . 73.11 110.879 -179.856 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 1.042 HG23 HG13 ' A' ' 62' ' ' VAL . 98.3 m -137.99 122.22 18.11 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.117 -0.492 . . . . 75.44 111.144 -179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.575 HG21 HG11 ' A' ' 83' ' ' VAL . 21.3 t -124.57 130.6 73.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.208 -0.451 . . . . 71.02 111.155 179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.7 mmm180 -102.57 70.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 70.24 110.9 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.767 ' CD2' HD12 ' A' ' 81' ' ' ILE . 14.8 t80 -110.13 130.73 55.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.153 -0.476 . . . . 72.25 110.931 -179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.1 t -139.64 142.25 37.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.156 -0.475 . . . . 63.02 111.133 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -97.0 -175.49 3.27 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.213 -0.449 . . . . 73.25 110.861 -179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 68.1 mttt -125.34 -12.52 6.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 35.13 110.899 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -145.81 162.14 37.24 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.557 0.694 . . . . 70.22 110.865 -179.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 154.0 68.21 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.679 2.253 . . . . 61.03 112.347 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 163.45 141.17 3.05 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.727 -0.749 . . . . 23.23 112.483 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -106.59 130.14 54.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.808 0.337 . . . . 60.42 110.905 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . 0.741 ' CE2' HG13 ' A' ' 76' ' ' VAL . 4.3 p90 -144.04 146.32 32.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.168 -0.469 . . . . 73.01 110.922 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.494 ' HG2' HD12 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -155.17 -175.76 5.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.117 -0.492 . . . . 74.21 110.848 -179.995 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.494 HD12 ' HG2' ' A' ' 104' ' ' ARG . 1.9 mp 65.62 150.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.192 -0.458 . . . . 72.41 111.195 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.477 HD13 ' N ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -109.68 145.75 15.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.18 -0.464 . . . . 55.31 111.167 179.881 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.477 ' N ' HD13 ' A' ' 106' ' ' ILE . 0.2 OUTLIER -175.07 33.44 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.166 -0.47 . . . . 64.54 110.904 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 22.8 t-20 -174.84 60.43 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.138 -0.483 . . . . 73.14 110.866 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.459 ' HB2' HD11 ' A' ' 106' ' ' ILE . 0.0 OUTLIER -107.46 -175.39 2.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 70.33 110.899 179.997 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 6.4 t80 -121.33 69.76 0.92 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.205 -0.452 . . . . 61.31 110.942 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 35.9 t -176.95 -36.23 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.13 -0.487 . . . . 73.21 110.899 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 156.56 145.77 4.29 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.718 -0.753 . . . . 71.22 112.476 -179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.522 HD23 ' H ' ' A' ' 113' ' ' LEU . 2.1 pt? -127.83 133.49 49.4 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.879 0.371 . . . . 75.25 110.924 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 136.43 -107.49 0.61 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.719 -0.753 . . . . 64.25 112.454 179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -51.91 -73.89 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.743 0.306 . . . . 72.33 110.861 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 8.0 pt20 -71.1 -169.74 0.4 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 71.43 110.899 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.55 95.97 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.208 -0.451 . . . . 73.51 110.904 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.45 174.84 6.06 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.182 -0.463 . . . . 52.12 110.875 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -91.33 120.09 31.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.213 -0.449 . . . . 75.13 110.921 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -87.58 -179.78 47.84 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.747 -0.739 . . . . 72.24 112.531 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.722 ' O ' HD13 ' A' ' 53' ' ' ILE . 67.9 m -154.71 137.02 14.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.74 0.305 . . . . 73.54 111.164 -179.884 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.446 ' CG2' HG11 ' A' ' 55' ' ' VAL . 2.8 mp -147.36 140.72 19.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 72.25 111.123 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.475 ' O ' HG12 ' A' ' 55' ' ' VAL . 50.2 t -128.41 129.28 68.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.186 -0.461 . . . . 35.51 111.116 179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.776 HG22 HG13 ' A' ' 55' ' ' VAL . 87.9 t -103.59 136.86 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.187 -0.46 . . . . 75.35 111.082 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.3 mmmt -113.83 131.78 56.12 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.177 -0.465 . . . . 72.25 110.902 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.283 0 CA-C-N 116.251 -0.431 . . . . 73.34 110.874 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 5.1 ptp . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.807 0.337 . . . . 71.42 110.843 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 63.0 t -116.28 86.07 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.237 -0.438 . . . . 74.22 111.123 -179.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -138.08 77.79 36.12 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.635 0.731 . . . . 72.53 111.143 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -177.59 1.95 Allowed 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.673 2.249 . . . . 62.24 112.356 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -167.56 161.58 13.79 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 73.42 111.111 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 109.31 -34.74 5.33 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.734 -0.746 . . . . 71.33 112.507 -179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -168.4 120.11 0.81 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.813 0.339 . . . . 65.43 110.898 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.638 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 62.07 162.51 0.08 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.218 -0.446 . . . . 53.42 110.885 179.899 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.638 ' N ' HD12 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -123.98 132.93 53.77 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.183 -0.462 . . . . 62.12 110.859 179.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.64 166.78 13.88 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.124 -0.489 . . . . 61.11 110.85 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 16' ' ' VAL . 35.9 m -150.02 140.6 16.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.178 -0.465 . . . . 62.11 111.104 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -100.1 162.84 19.69 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.578 0.704 . . . . 72.03 110.855 179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -1.96 9.33 Favored 'Trans proline' 0 C--O 1.232 0.185 0 C-N-CA 122.651 2.234 . . . . 60.1 112.384 -179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.464 HG22 HG23 ' A' ' 15' ' ' THR . 3.2 m -46.24 -67.43 0.28 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.207 -0.451 . . . . 74.13 111.168 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.464 HG23 HG22 ' A' ' 14' ' ' THR . 26.8 p -146.67 13.86 1.19 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 71.32 111.138 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.566 HG21 HG21 ' A' ' 11' ' ' VAL . 12.6 p -50.64 -31.93 9.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 111.136 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.14 -17.41 14.49 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.173 -0.467 . . . . 74.32 110.883 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 22.1 mm100 -79.62 -31.21 41.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 74.44 110.94 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -149.24 140.48 23.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.231 -0.441 . . . . 72.31 110.884 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.19 -157.16 17.65 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.691 -0.766 . . . . 73.21 112.46 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 -30.6 22.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.672 2.248 . . . . 50.21 112.351 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 14.9 m-90 -87.21 -7.48 57.87 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.226 -0.443 . . . . 62.15 110.921 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -79.29 -60.08 2.51 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.257 -0.429 . . . . 74.53 111.054 179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -89.56 142.59 29.57 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.577 0.703 . . . . 75.32 110.916 179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -28.38 25.07 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.666 2.244 . . . . 65.01 112.347 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.18 -11.69 60.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.218 -0.446 . . . . 73.03 111.115 179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 1.5 mm-40 -95.35 24.71 4.87 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.18 -0.464 . . . . 74.31 110.935 -179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.503 ' HB2' ' HB2' ' A' ' 52' ' ' PRO . . . -56.58 -79.58 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.152 -0.476 . . . . 74.51 111.067 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.507 HG11 ' HB3' ' A' ' 54' ' ' GLU . 1.8 p -106.86 141.01 23.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.232 -0.44 . . . . 72.02 111.153 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 m -128.1 150.16 33.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.184 -0.462 . . . . 74.13 111.164 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.1 118.79 29.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 72.33 110.925 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.9 t -121.06 -21.06 6.6 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.212 -0.449 . . . . 63.33 111.148 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.29 168.38 20.19 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.704 -0.76 . . . . 54.21 112.5 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -7.25 20.57 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.652 2.235 . . . . 65.22 112.33 -179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.507 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 18.0 t30 -159.33 23.25 0.19 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.22 -0.445 . . . . 60.35 110.874 -179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -138.87 153.97 48.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 71.43 110.865 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -141.97 142.15 32.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.206 -0.452 . . . . 72.23 110.966 -179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.2 m -95.74 104.55 16.48 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.115 -0.493 . . . . 75.41 111.144 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 5.9 t -84.5 140.06 16.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.222 -0.445 . . . . 74.5 111.156 179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.29 122.76 39.84 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.475 . . . . 72.14 110.918 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.618 HG12 HD12 ' A' ' 53' ' ' ILE . 16.6 m -118.73 123.26 71.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.11 -0.495 . . . . 71.03 111.113 179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.685 HD11 ' CD2' ' A' ' 44' ' ' PHE . 3.0 tm? -115.88 132.88 56.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.21 -0.45 . . . . 71.15 110.894 179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.507 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -155.44 114.47 3.57 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 52.33 111.087 179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.685 ' CD2' HD11 ' A' ' 42' ' ' LEU . 5.9 p90 -129.36 152.09 49.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.201 -0.454 . . . . 42.02 110.878 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.421 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -85.14 1.77 46.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.09 -0.504 . . . . 53.44 111.145 179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.2 m-85 -95.83 72.0 3.02 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.166 -0.47 . . . . 73.24 110.868 -179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 105.21 -150.88 17.12 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.754 -0.736 . . . . 73.43 112.471 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 p90 -136.37 150.93 49.05 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.857 0.36 . . . . 65.15 110.907 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.1 mt-30 -162.09 162.06 20.49 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.591 0.71 . . . . 73.51 110.904 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 157.36 60.63 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.722 2.281 . . . . 74.44 112.35 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -133.09 66.69 76.32 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.644 0.735 . . . . 62.34 110.877 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.503 ' HB2' ' HB2' ' A' ' 28' ' ' ALA . 53.8 Cg_endo -69.83 114.03 3.58 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.676 2.251 . . . . 73.33 112.367 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.618 HD12 HG12 ' A' ' 41' ' ' VAL . 1.5 mm -117.21 151.53 19.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.23 -0.441 . . . . 61.53 111.136 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.507 ' HB3' HG11 ' A' ' 29' ' ' VAL . 13.2 tt0 -155.25 120.62 4.96 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 71.3 110.929 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.923 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -139.7 82.03 18.75 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.651 0.739 . . . . 74.31 111.131 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.8 Cg_endo -69.81 123.67 10.31 Favored 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.698 2.266 . . . . 74.32 112.349 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.23 155.11 40.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.209 -0.45 . . . . 72.32 110.96 179.989 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.41 -8.73 73.32 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 72.01 112.469 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.507 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -133.02 155.77 48.58 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.745 0.307 . . . . 61.21 111.115 179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.717 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.2 mt-10 -66.75 141.37 57.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 70.51 110.857 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.748 HG13 HG23 ' A' ' 55' ' ' VAL . 5.7 mm -130.14 119.18 46.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.474 . . . . 54.12 111.106 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.553 HG13 ' OG1' ' A' ' 92' ' ' THR . 54.8 t -102.28 98.42 6.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.148 -0.478 . . . . 71.51 111.129 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.5 ' HB2' HG12 ' A' ' 93' ' ' VAL . 72.0 m-85 -76.97 126.34 30.81 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.18 -0.464 . . . . 75.42 110.851 -179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.9 mttt -120.32 100.09 6.96 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.155 -0.475 . . . . 63.32 110.911 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.474 ' HA ' HG23 ' A' ' 41' ' ' VAL . 1.8 mt -98.22 153.21 4.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 72.33 111.111 179.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 13.4 t -171.35 145.97 2.22 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 74.03 111.185 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.448 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -153.29 159.62 31.95 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.678 0.751 . . . . 74.03 110.854 -179.857 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.438 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.76 -54.83 0.2 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.73 2.287 . . . . 63.1 112.325 179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -156.53 60.55 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.238 -0.437 . . . . 72.43 110.884 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.448 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.29 136.35 4.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.189 -0.459 . . . . 64.11 111.136 179.995 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.444 HG22 HD13 ' A' ' 113' ' ' LEU . 41.4 mm -67.08 144.2 14.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.124 -0.489 . . . . 65.53 111.09 179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 6.2 p-80 -136.98 158.11 45.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.128 -0.487 . . . . 74.02 110.827 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 158.71 129.83 1.11 Allowed Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.779 -0.724 . . . . 71.14 112.515 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.0 p90 -117.47 141.93 47.75 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.869 0.366 . . . . 74.23 110.862 -179.806 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -112.1 90.74 3.42 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.158 -0.474 . . . . 75.42 110.846 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.722 ' HB ' HG21 ' A' ' 81' ' ' ILE . 27.6 t -73.36 145.53 11.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.173 -0.467 . . . . 74.22 111.115 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -75.66 -175.56 2.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.166 -0.47 . . . . 71.41 110.858 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.91 -51.38 4.43 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.73 -0.748 . . . . 55.24 112.437 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.45 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -132.41 179.28 6.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.777 0.322 . . . . 71.25 111.161 -179.846 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.45 ' H ' HG22 ' A' ' 79' ' ' THR . 11.2 m-80 -90.19 48.01 1.51 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.203 -0.453 . . . . 63.22 110.868 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.722 HG21 ' HB ' ' A' ' 76' ' ' VAL . 3.3 tp -63.14 111.0 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.138 -0.483 . . . . 64.43 111.139 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.87 122.73 46.23 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 64.43 110.852 179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 3.2 m -143.51 120.1 5.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 34.3 111.126 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.661 ' CB ' HD21 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -159.25 112.59 2.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.463 . . . . 43.21 110.888 179.985 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 23.5 t -140.5 144.28 27.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.14 -0.482 . . . . 73.05 111.142 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 1.4 mp -61.53 161.11 21.16 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.591 0.71 . . . . 54.53 110.919 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 159.53 53.11 Favored 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.667 2.245 . . . . 45.33 112.347 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.23 10.88 60.46 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.718 -0.753 . . . . 75.44 112.492 179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -152.6 159.39 43.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.862 0.363 . . . . 74.35 110.869 -179.88 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 95.7 t -98.43 143.34 13.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.141 -0.481 . . . . 62.44 111.138 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 7.3 p -121.3 97.24 5.42 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.156 -0.475 . . . . 61.22 110.899 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.553 ' OG1' HG13 ' A' ' 62' ' ' VAL . 1.2 t -85.63 141.33 29.87 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.116 -0.493 . . . . 54.51 111.167 -179.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.5 HG12 ' HB2' ' A' ' 63' ' ' PHE . 12.6 p -154.24 150.3 12.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 72.44 111.136 179.908 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.8 mtm180 -109.6 116.4 31.68 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.187 -0.461 . . . . 62.33 110.894 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 29.0 t80 -151.45 114.96 4.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.184 -0.462 . . . . 74.3 110.945 -179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.6 t -116.55 136.24 53.15 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.14 -0.482 . . . . 62.02 111.123 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -87.06 -172.47 3.98 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.451 . . . . 74.33 110.922 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.1 tttt -123.19 -26.14 4.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 61.34 110.909 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -140.71 162.06 50.97 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.588 0.708 . . . . 74.42 110.871 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 150.72 68.57 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 72.12 112.345 179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 164.09 143.85 3.84 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.733 -0.746 . . . . 73.23 112.506 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.743 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -108.82 134.53 51.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.84 0.352 . . . . 73.52 110.906 -179.883 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . 0.604 ' CE2' HG13 ' A' ' 76' ' ' VAL . 2.1 p90 -143.54 131.53 21.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.193 -0.458 . . . . 73.15 110.933 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.39 111.27 5.77 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.08 -0.509 . . . . 74.51 110.867 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.0 tp -178.61 142.95 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.21 -0.45 . . . . 74.23 111.098 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.47 HD13 ' HA2' ' A' ' 114' ' ' GLY . 17.7 tt -130.38 126.39 61.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.131 -0.486 . . . . 42.05 111.11 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 178.98 170.44 0.89 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 73.21 110.913 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 52.5 m-80 51.63 30.41 6.59 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 73.21 110.925 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 5.0 mm-40 -100.58 -25.19 14.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.154 -0.476 . . . . 64.05 110.893 -179.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER 63.14 -173.42 0.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.215 -0.448 . . . . 64.32 110.937 -179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER 57.07 25.77 11.19 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.48 . . . . 64.04 110.882 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 61.88 36.53 92.94 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.772 -0.727 . . . . 73.32 112.501 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.661 HD21 ' CB ' ' A' ' 84' ' ' GLU . 1.3 mm? -70.82 -74.77 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.882 0.372 . . . . 71.1 110.95 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.47 ' HA2' HD13 ' A' ' 106' ' ' ILE . . . -87.0 90.16 1.66 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 61.13 112.482 179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 1.8 m80 -128.11 -74.85 0.57 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.696 0.284 . . . . 74.13 110.884 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -117.03 -23.81 7.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.236 -0.438 . . . . 64.42 110.932 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -59.48 -179.23 0.08 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.217 -0.447 . . . . 45.53 110.927 179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.504 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . 0.0 OUTLIER -71.53 174.47 6.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.143 -0.481 . . . . 65.52 110.879 179.923 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . 0.435 ' CD2' HG22 ' A' ' 106' ' ' ILE . 11.2 m-85 -97.8 149.83 21.92 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.228 -0.442 . . . . 63.54 110.856 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -72.42 79.41 0.67 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.727 -0.749 . . . . 63.13 112.446 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.609 HG23 HG13 ' A' ' 53' ' ' ILE . 15.1 t -85.47 134.28 34.06 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.714 0.293 . . . . 53.13 111.21 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.582 HD12 ' C ' ' A' ' 121' ' ' THR . 3.3 mp -153.1 134.27 4.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.243 -0.435 . . . . 72.2 111.11 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.743 HG23 ' HB3' ' A' ' 102' ' ' GLU . 8.6 p -126.23 137.61 57.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 73.14 111.139 179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.923 HG22 HG13 ' A' ' 55' ' ' VAL . 47.3 t -108.14 141.97 22.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.161 -0.472 . . . . 34.44 111.134 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.8 mmtt -116.33 132.42 56.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.12 -0.491 . . . . 75.43 110.937 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 71.41 110.875 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.1 tpt . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.813 0.34 . . . . 51.22 110.862 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.5 m -116.99 68.85 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.249 -0.432 . . . . 73.12 111.143 179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -124.12 77.97 59.6 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.633 0.73 . . . . 75.0 111.174 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 -177.34 1.82 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.66 2.24 . . . . 74.33 112.354 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -152.4 80.55 1.24 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.2 -0.454 . . . . 44.42 111.132 179.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -179.81 -57.25 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.707 -0.759 . . . . 53.23 112.449 -179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 7.5 tptt -172.32 152.13 2.69 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 63.42 110.878 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.71 HD13 ' O ' ' A' ' 90' ' ' VAL . 0.2 OUTLIER 62.08 162.35 0.08 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.182 -0.463 . . . . 74.25 110.915 179.954 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.635 ' N ' HD12 ' A' ' 8' ' ' LEU . 2.1 pt-20 -118.96 141.79 48.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.151 -0.477 . . . . 72.34 110.892 179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -93.1 135.38 34.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.147 -0.479 . . . . 64.22 110.85 -179.917 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.447 HG21 HG21 ' A' ' 16' ' ' VAL . 7.8 m -115.01 -179.22 1.22 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 60.52 111.133 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -147.04 162.63 32.22 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.608 0.718 . . . . 71.34 110.867 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 -4.33 13.79 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.677 2.251 . . . . 71.41 112.367 -179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.411 ' O ' HG23 ' A' ' 15' ' ' THR . 5.4 m -48.75 -66.61 0.37 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.24 -0.436 . . . . 75.5 111.112 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 14' ' ' THR . 3.2 p -155.59 37.35 0.37 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 71.42 111.149 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.447 HG21 HG21 ' A' ' 11' ' ' VAL . 8.4 p -77.19 -27.52 16.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.214 -0.448 . . . . 73.32 111.137 179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 20.4 ptt85 -104.28 -10.76 17.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.195 -0.457 . . . . 75.24 110.853 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -94.35 -36.96 11.71 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.453 . . . . 72.32 110.927 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -134.87 133.88 40.16 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 55.43 110.883 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 125.02 -157.18 19.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.778 -0.725 . . . . 45.25 112.507 -179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -30.06 22.79 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.654 2.236 . . . . 72.53 112.36 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.777 ' HB3' HD13 ' A' ' 42' ' ' LEU . 14.0 m-90 -86.82 -10.89 52.44 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.221 -0.445 . . . . 74.32 110.926 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -67.66 -59.32 3.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 75.23 111.112 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -101.63 144.85 29.39 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.612 0.72 . . . . 71.44 110.868 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 -17.24 37.75 Favored 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.665 2.243 . . . . 71.03 112.322 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -24.09 59.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 72.02 111.132 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 36.7 mm-40 -90.05 10.54 23.8 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 72.23 110.931 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -78.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.192 -0.458 . . . . 74.12 111.15 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.614 HG11 ' CB ' ' A' ' 54' ' ' GLU . 2.1 p -108.2 128.71 63.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.172 -0.467 . . . . 71.13 111.149 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.7 t -140.01 144.04 28.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.457 . . . . 64.01 111.139 179.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 7.0 tp60 -75.48 121.45 22.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.138 -0.483 . . . . 73.31 110.905 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.5 t -119.95 -12.88 9.09 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.212 -0.449 . . . . 62.12 111.166 -179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.61 -167.66 12.15 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.751 -0.737 . . . . 72.32 112.496 179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.76 -36.12 11.4 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.69 2.26 . . . . 65.3 112.337 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 62.3 t30 -153.58 34.45 0.45 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 73.23 110.884 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.14 118.09 17.3 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 72.21 110.889 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -97.66 138.47 35.01 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.185 -0.461 . . . . 74.44 110.94 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 55.9 m -95.66 102.59 14.4 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.137 -0.483 . . . . 72.34 111.13 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.9 t -84.24 146.33 6.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.177 -0.465 . . . . 75.04 111.156 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 34.7 m-85 -126.8 124.06 38.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.143 -0.48 . . . . 64.4 110.962 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.457 HG22 HD12 ' A' ' 53' ' ' ILE . 92.1 t -125.37 138.67 53.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.119 -0.491 . . . . 70.21 111.121 179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.777 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -138.61 141.84 39.15 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.166 -0.47 . . . . 74.02 110.94 179.951 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.68 109.11 2.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.451 . . . . 45.54 111.065 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 4.5 p90 -122.77 153.43 39.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.215 -0.448 . . . . 74.25 110.852 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.26 4.3 35.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 75.21 111.13 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 14.3 m-85 -95.24 78.11 3.47 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.184 -0.462 . . . . 74.43 110.937 -179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 97.59 -139.92 14.75 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 71.23 112.489 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -148.42 150.06 32.82 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.845 0.355 . . . . 53.03 110.943 -179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 5.7 mt-30 -158.19 162.55 26.69 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.571 0.701 . . . . 73.44 110.963 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 157.03 61.78 Favored 'Trans proline' 0 C--N 1.34 0.124 0 C-N-CA 122.722 2.281 . . . . 73.54 112.317 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.49 66.08 76.11 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.598 0.713 . . . . 45.04 110.847 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.526 ' C ' HD13 ' A' ' 53' ' ' ILE . 53.1 Cg_endo -69.85 118.36 5.64 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.693 2.262 . . . . 63.5 112.302 179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.618 HG21 ' HA ' ' A' ' 122' ' ' ILE . 2.4 mm -124.55 151.51 29.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 73.42 111.123 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.614 ' CB ' HG11 ' A' ' 29' ' ' VAL . 8.3 tt0 -155.22 115.66 3.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.204 -0.453 . . . . 75.4 110.836 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.686 ' O ' HG13 ' A' ' 124' ' ' VAL . 21.2 t -131.34 82.02 63.61 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.647 0.737 . . . . 71.23 111.145 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.729 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.75 121.87 8.56 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.692 2.261 . . . . 71.14 112.368 179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -68.3 152.85 44.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.253 -0.43 . . . . 65.12 110.933 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.95 -36.33 3.7 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.713 -0.756 . . . . 73.11 112.495 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.77 158.06 17.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.8 0.333 . . . . 62.12 111.066 -179.986 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.672 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.5 mt-10 -67.87 144.53 55.25 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.211 -0.45 . . . . 63.24 110.922 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.729 HD12 ' HD2' ' A' ' 56' ' ' PRO . 5.7 mm -128.21 120.01 52.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.135 -0.484 . . . . 72.11 111.114 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.985 HG13 HG23 ' A' ' 92' ' ' THR . 55.2 t -103.9 91.15 1.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.139 -0.482 . . . . 71.34 111.128 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.618 ' HB2' HG12 ' A' ' 93' ' ' VAL . 90.5 m-85 -69.61 134.95 49.36 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.153 -0.476 . . . . 71.31 110.906 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.421 ' HD3' HG21 ' A' ' 90' ' ' VAL . 15.6 mttt -131.53 100.16 5.05 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.153 -0.476 . . . . 64.14 110.877 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.584 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.8 mp -107.11 143.32 17.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 54.02 111.156 179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.5 t -156.38 136.18 12.57 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.236 -0.438 . . . . 74.23 111.166 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.404 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.7 OUTLIER -142.95 161.51 48.3 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.699 0.761 . . . . 73.4 110.853 -179.86 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.404 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.0 Cg_endo -69.77 -50.81 0.43 Allowed 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.671 2.247 . . . . 50.34 112.385 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -155.78 49.9 0.53 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.238 -0.437 . . . . 62.2 110.842 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.21 135.94 3.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.146 -0.479 . . . . 71.51 111.117 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 95.0 mt -86.45 105.64 14.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 72.14 111.147 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.408 ' O ' HG21 ' A' ' 65' ' ' ILE . 44.8 t-80 -99.46 69.65 1.67 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 53.41 110.901 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -96.15 155.5 21.07 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.73 -0.748 . . . . 41.14 112.466 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.584 ' CE2' HD11 ' A' ' 65' ' ' ILE . 3.3 p90 -128.61 142.82 50.92 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.883 0.373 . . . . 72.3 110.886 -179.857 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -118.56 94.1 4.35 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 74.15 110.854 179.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.529 HG13 ' CE2' ' A' ' 103' ' ' TYR . 10.1 t -74.11 140.9 16.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 75.53 111.147 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.5 pm0 -75.3 -176.05 2.96 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.171 -0.468 . . . . 72.43 110.869 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.7 -51.86 4.61 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.723 -0.751 . . . . 61.11 112.491 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.406 HG22 ' N ' ' A' ' 80' ' ' ASN . 10.7 m -124.02 157.16 35.1 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.813 0.34 . . . . 75.53 111.174 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.406 ' N ' HG22 ' A' ' 79' ' ' THR . 1.1 m120 -77.15 60.06 1.84 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.22 -0.445 . . . . 61.04 110.874 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.552 ' O ' HG23 ' A' ' 81' ' ' ILE . 11.5 tt -78.51 116.53 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.183 -0.462 . . . . 53.33 111.137 179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -123.19 96.69 5.1 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.134 -0.485 . . . . 75.41 110.85 179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.6 m -114.39 119.89 62.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.163 -0.471 . . . . 70.14 111.105 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -147.64 117.36 7.11 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.14 -0.482 . . . . 62.22 110.886 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.81 HG11 ' HB2' ' A' ' 91' ' ' SER . 7.6 p -140.62 128.29 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 63.2 111.117 179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -57.52 157.91 12.5 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.59 0.71 . . . . 63.55 110.959 179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 159.16 54.46 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.685 2.256 . . . . 62.22 112.339 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 92.1 11.73 59.68 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.742 -0.742 . . . . 72.01 112.511 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.3 pt-20 -163.86 118.19 1.53 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.897 0.379 . . . . 71.4 110.897 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.71 ' O ' HD13 ' A' ' 8' ' ' LEU . 3.5 p -68.8 143.28 15.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.144 -0.48 . . . . 74.45 111.129 179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.81 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.3 OUTLIER -107.09 169.29 8.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 70.42 110.814 -179.854 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.985 HG23 HG13 ' A' ' 62' ' ' VAL . 87.8 m -145.45 111.28 5.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.121 -0.491 . . . . 73.14 111.112 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.618 HG12 ' HB2' ' A' ' 63' ' ' PHE . 8.0 p -124.45 150.7 29.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.236 -0.438 . . . . 71.13 111.131 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.7 mtm-85 -114.93 97.49 6.27 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.176 -0.466 . . . . 73.22 110.831 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.544 ' CD2' HD12 ' A' ' 81' ' ' ILE . 40.5 t80 -139.9 110.08 6.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 73.33 110.947 -179.907 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.1 t -110.68 143.5 41.05 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.122 -0.49 . . . . 71.4 111.177 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.6 -178.89 5.66 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.258 -0.428 . . . . 74.21 110.853 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 31.7 mttt -119.85 -12.9 9.13 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 73.13 110.927 179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -149.16 161.66 31.5 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.62 0.724 . . . . 75.01 110.831 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.67 152.43 69.75 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.691 2.26 . . . . 64.42 112.384 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 159.4 130.43 1.14 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.785 -0.722 . . . . 52.22 112.494 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.6 pm0 -99.22 130.46 45.52 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.836 0.35 . . . . 72.35 110.866 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . 0.529 ' CE2' HG13 ' A' ' 76' ' ' VAL . 1.0 OUTLIER -135.42 146.39 48.23 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.197 -0.456 . . . . 74.2 110.93 -179.872 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.942 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.7 OUTLIER -148.22 -163.88 1.88 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.126 -0.488 . . . . 71.32 110.907 179.99 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.942 HG22 ' O ' ' A' ' 104' ' ' ARG . 1.2 tt 58.94 158.63 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.236 -0.438 . . . . 73.34 111.129 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.56 138.41 43.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.204 -0.453 . . . . 72.14 111.157 179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 6.9 t -171.61 71.44 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.225 -0.443 . . . . 73.53 110.864 179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -179.68 -37.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 75.0 110.886 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 2.6 mt-30 -57.25 179.73 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.169 -0.469 . . . . 71.21 110.92 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 1.6 p90 -104.56 -20.06 13.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.194 -0.457 . . . . 73.31 110.94 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -52.1 -63.41 1.15 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.142 -0.481 . . . . 72.24 110.88 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -178.04 -156.73 17.26 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.735 -0.745 . . . . 34.05 112.47 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.515 ' O ' HD12 ' A' ' 113' ' ' LEU . 3.4 pp -162.7 26.49 0.1 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.853 0.359 . . . . 73.44 110.935 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -168.42 -89.46 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.774 -0.727 . . . . 41.15 112.505 179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 15.8 p80 -64.64 -14.74 59.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.739 0.304 . . . . 65.24 110.869 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 4.0 tp60 -61.9 -164.36 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.157 -0.474 . . . . 75.21 110.871 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -56.33 -175.35 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.169 -0.469 . . . . 74.5 110.92 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 1.2 mtt -69.47 175.29 4.16 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.199 -0.455 . . . . 72.43 110.876 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . 0.401 ' HB3' ' HA ' ' A' ' 105' ' ' ILE . 19.0 m-85 -91.19 167.62 12.2 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.243 -0.435 . . . . 63.31 110.878 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -101.48 166.1 18.33 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.695 -0.764 . . . . 72.14 112.49 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.586 ' C ' HD12 ' A' ' 122' ' ' ILE . 68.7 m -154.93 127.6 8.02 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.771 0.32 . . . . 65.32 111.118 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.618 ' HA ' HG21 ' A' ' 53' ' ' ILE . 4.3 mp -150.01 143.66 17.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.229 -0.441 . . . . 72.34 111.136 179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 3.6 m -134.47 140.74 45.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 73.33 111.133 179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.686 HG13 ' O ' ' A' ' 55' ' ' VAL . 58.5 t -113.68 126.03 71.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.182 -0.463 . . . . 73.5 111.17 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 11.3 mmmm -108.92 141.51 40.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 61.24 110.909 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 32.8 mt-10 . . . . . 0 C--N 1.33 -0.259 0 CA-C-N 116.209 -0.451 . . . . 72.55 110.928 179.963 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 18.8 mmt . . . . . 0 C--O 1.23 0.071 0 CA-C-O 120.866 0.365 . . . . 62.35 110.914 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 6.3 p -154.07 128.02 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.217 -0.447 . . . . 74.54 111.121 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.9 pt -129.43 153.71 80.63 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.642 0.734 . . . . 74.34 111.155 179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 -177.3 1.81 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.699 2.266 . . . . 71.5 112.328 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -162.09 74.32 0.43 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.212 -0.449 . . . . 72.23 111.062 179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.26 -17.74 54.58 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.791 -0.719 . . . . 45.34 112.463 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.515 ' HE2' HD23 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -104.04 -172.22 2.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.758 0.313 . . . . 71.43 110.905 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.596 HD13 ' O ' ' A' ' 90' ' ' VAL . 2.3 pp -58.74 -174.78 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.266 -0.425 . . . . 62.21 110.922 179.931 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.532 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.3 OUTLIER -86.39 131.02 34.3 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.227 -0.442 . . . . 75.12 110.867 179.971 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 1.3 mpt_? -104.52 143.98 32.31 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 72.01 110.904 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.514 HG21 ' OG1' ' A' ' 66' ' ' THR . 17.0 m -110.64 -177.55 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.21 -0.45 . . . . 73.44 111.138 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.416 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 4.9 p30 -143.79 156.18 59.31 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.626 0.727 . . . . 70.15 110.87 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.81 -3.58 12.34 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.652 2.235 . . . . 41.12 112.338 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 3.7 m -47.56 -63.74 0.97 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.237 -0.438 . . . . 63.51 111.14 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -155.67 29.04 0.38 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.244 -0.435 . . . . 61.44 111.133 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.4 p -64.57 -30.23 49.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.435 . . . . 65.25 111.12 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.453 ' HB3' HD21 ' A' ' 42' ' ' LEU . 4.0 ptt-85 -101.17 -6.63 24.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.204 -0.453 . . . . 74.35 110.874 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 11.3 mm-40 -97.43 -37.46 9.99 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.179 -0.464 . . . . 75.5 110.924 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -135.11 133.93 39.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.228 -0.442 . . . . 71.1 110.852 -179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 124.05 -158.76 18.67 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.717 -0.754 . . . . 72.23 112.466 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -29.02 24.71 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.657 2.238 . . . . 72.32 112.364 -179.975 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.783 ' HB3' HD13 ' A' ' 42' ' ' LEU . 15.0 m-90 -87.12 -11.42 50.13 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.26 -0.427 . . . . 64.43 110.893 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -63.36 -59.16 5.07 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.267 -0.424 . . . . 74.13 111.074 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.91 143.63 26.99 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.598 0.713 . . . . 75.12 110.885 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 -22.69 31.51 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.735 2.29 . . . . 72.43 112.288 -179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.8 -7.27 51.52 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.271 -0.422 . . . . 23.02 111.104 179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 31.7 mm-40 -104.73 5.27 33.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.184 -0.462 . . . . 71.44 110.887 -179.921 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.85 -77.37 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.205 -0.452 . . . . 62.23 111.1 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.445 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.3 p -103.39 108.4 24.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 74.43 111.109 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.1 t -114.91 149.86 17.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.215 -0.448 . . . . 74.14 111.138 179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -67.96 122.32 17.94 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 60.23 110.895 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.572 HG23 ' HG3' ' A' ' 36' ' ' GLN . 1.7 t -119.73 -33.55 3.98 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.234 -0.439 . . . . 51.32 111.132 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.06 175.85 17.94 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.754 -0.736 . . . . 60.52 112.493 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 -8.67 24.21 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.721 2.281 . . . . 74.12 112.336 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -161.03 34.79 0.15 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.227 -0.442 . . . . 74.14 110.895 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.572 ' HG3' HG23 ' A' ' 32' ' ' THR . 0.2 OUTLIER -150.91 160.29 44.0 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.205 -0.452 . . . . 64.31 110.94 -179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 7.1 m-85 -143.12 144.32 32.18 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.244 -0.435 . . . . 73.4 110.906 -179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 57.2 m -97.62 103.14 15.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 64.3 111.142 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 8.9 t -85.05 137.67 20.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 62.35 111.18 179.864 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 58.7 m-85 -120.26 113.12 19.94 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.186 -0.461 . . . . 73.35 110.966 -179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.494 HG22 HG13 ' A' ' 53' ' ' ILE . 59.1 t -110.42 133.82 54.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.137 -0.483 . . . . 74.13 111.122 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.783 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.6 OUTLIER -139.31 139.36 37.29 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.209 -0.451 . . . . 53.51 110.868 -179.982 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.648 ' HB3' ' CE1' ' A' ' 72' ' ' HIS . . . -155.16 122.66 5.63 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.174 -0.466 . . . . 74.22 111.107 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -121.56 145.57 47.83 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.252 -0.431 . . . . 75.31 110.874 -179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -86.32 48.12 1.57 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.474 . . . . 72.51 111.117 179.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -120.9 -50.7 2.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 64.02 110.879 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -133.71 -119.01 1.95 Allowed Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.773 -0.727 . . . . 75.32 112.54 -180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 5.7 t80 -150.17 136.68 19.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.882 0.372 . . . . 74.34 110.894 -179.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -130.39 159.41 70.76 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-O 121.578 0.704 . . . . 61.23 110.939 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.77 -176.97 1.66 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.672 2.248 . . . . 62.3 112.367 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.514 ' C ' HD12 ' A' ' 53' ' ' ILE . 1.0 OUTLIER -137.57 62.5 36.23 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.672 0.748 . . . . 52.42 110.926 179.976 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 6.45 1.3 Allowed 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.67 2.247 . . . . 74.54 112.313 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.935 HD13 HG22 ' A' ' 121' ' ' THR . 4.7 mp -48.39 131.28 5.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 75.13 111.136 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.445 ' HB3' HG11 ' A' ' 29' ' ' VAL . 10.6 tt0 -140.18 149.6 43.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.165 -0.47 . . . . 52.34 110.883 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.737 HG13 HG13 ' A' ' 61' ' ' ILE . 86.9 t -151.0 81.96 6.09 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.618 0.723 . . . . 60.23 111.132 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.69 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.5 Cg_endo -69.79 123.08 9.74 Favored 'Trans proline' 0 C--O 1.231 0.147 0 C-N-CA 122.647 2.232 . . . . 71.33 112.332 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.1 155.3 40.81 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.187 -0.46 . . . . 65.24 110.923 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.54 -9.67 70.04 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.729 -0.748 . . . . 70.23 112.469 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.36 154.35 50.81 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.759 0.314 . . . . 71.02 111.125 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.681 ' O ' HD13 ' A' ' 61' ' ' ILE . 20.9 mt-10 -64.88 144.55 57.2 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.237 -0.438 . . . . 75.44 110.944 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.737 HG13 HG13 ' A' ' 55' ' ' VAL . 7.6 mm -129.44 115.16 33.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.164 -0.471 . . . . 65.13 111.127 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.593 HG13 ' OG1' ' A' ' 92' ' ' THR . 77.2 t -99.06 97.72 6.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.141 -0.481 . . . . 44.33 111.122 179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.514 ' HB2' HG12 ' A' ' 93' ' ' VAL . 87.9 m-85 -75.85 132.06 40.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 70.41 110.872 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -130.82 100.06 5.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.1 -0.5 . . . . 75.24 110.931 179.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.8 mp -100.38 153.24 4.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.21 -0.45 . . . . 75.51 111.11 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.771 HG23 HD12 ' A' ' 42' ' ' LEU . 9.5 t -167.1 128.66 1.62 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.205 -0.452 . . . . 72.23 111.134 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.473 ' HB2' HG23 ' A' ' 70' ' ' VAL . 0.1 OUTLIER -140.25 166.16 25.39 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.637 0.732 . . . . 74.33 110.84 -179.875 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' CB ' ' A' ' 67' ' ' SER . 54.4 Cg_endo -69.72 -54.8 0.2 Allowed 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.668 2.245 . . . . 72.1 112.389 179.922 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -158.7 57.22 0.44 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.25 -0.432 . . . . 74.32 110.917 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.473 HG23 ' HB2' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.62 140.23 9.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.142 -0.481 . . . . 71.44 111.108 -179.989 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.463 HD13 ' HD3' ' A' ' 87' ' ' PRO . 35.0 mm -85.3 150.82 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.16 -0.473 . . . . 74.1 111.101 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.648 ' CE1' ' HB3' ' A' ' 43' ' ' ALA . 11.9 m170 -115.69 -84.34 0.62 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.472 . . . . 74.43 110.903 179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.88 98.85 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.743 -0.741 . . . . 73.05 112.492 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 4.2 p90 -106.31 142.47 35.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.868 0.366 . . . . 74.35 110.89 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -110.8 142.39 42.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.147 -0.479 . . . . 75.55 110.885 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 21.4 t -135.89 136.19 50.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.25 -0.432 . . . . 62.02 111.142 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 78.3 mt-10 -64.21 -177.2 0.26 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.181 -0.463 . . . . 74.34 110.925 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 84.32 -51.22 4.53 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.747 -0.74 . . . . 60.14 112.479 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 3.1 m -135.12 160.94 36.76 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.774 0.321 . . . . 74.02 111.202 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 24.1 m120 -86.01 76.58 9.8 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 64.03 110.893 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.451 ' O ' HG23 ' A' ' 81' ' ' ILE . 4.8 tt -85.01 121.81 37.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.156 -0.474 . . . . 72.45 111.11 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -116.5 95.42 5.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.203 -0.453 . . . . 73.42 110.878 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 2.8 m -115.63 120.37 64.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.452 . . . . 63.03 111.147 179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -156.59 110.02 2.65 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.2 -0.454 . . . . 71.31 110.874 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.759 HG11 ' HB2' ' A' ' 91' ' ' SER . 13.8 p -140.74 147.11 23.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.164 -0.471 . . . . 62.54 111.12 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.28 161.1 80.26 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.567 0.699 . . . . 62.32 110.905 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.463 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.6 Cg_endo -69.75 159.64 52.67 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.654 2.236 . . . . 74.14 112.333 179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 80.76 10.39 85.19 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.722 -0.751 . . . . 75.11 112.469 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 7.2 mt-10 -139.37 145.25 38.74 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.932 0.396 . . . . 74.53 110.889 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.596 ' O ' HD13 ' A' ' 8' ' ' LEU . 21.2 t -99.3 110.66 27.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.165 -0.47 . . . . 72.25 111.157 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.759 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -91.37 165.97 13.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 51.33 110.846 -179.851 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.593 ' OG1' HG13 ' A' ' 62' ' ' VAL . 1.4 t -144.19 140.15 29.16 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.087 -0.506 . . . . 43.21 111.168 -179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.514 HG12 ' HB2' ' A' ' 63' ' ' PHE . 9.9 p -153.79 127.55 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.217 -0.447 . . . . 73.11 111.126 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.0 mtm180 -93.95 111.11 22.77 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 73.14 110.885 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 7.9 t80 -145.75 118.45 8.63 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.429 . . . . 73.12 110.872 -179.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.3 t -114.39 132.03 56.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 71.44 111.161 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -83.15 -177.59 6.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.227 -0.442 . . . . 73.42 110.854 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.3 ttpt -121.52 -24.28 5.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.148 -0.478 . . . . 61.42 110.901 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.49 160.21 57.69 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.613 0.721 . . . . 65.35 110.899 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 127.85 15.16 Favored 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.689 2.26 . . . . 72.21 112.313 -179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.12 146.33 14.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.772 -0.728 . . . . 63.44 112.521 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.2 pp20? -105.57 135.71 46.49 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.84 0.352 . . . . 74.34 110.881 -179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -143.97 148.87 35.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.169 -0.469 . . . . 73.13 110.947 -179.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.421 ' C ' HD12 ' A' ' 105' ' ' ILE . 30.6 ttp85 -168.78 157.9 8.65 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.161 -0.472 . . . . 65.52 110.882 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.421 HD12 ' C ' ' A' ' 104' ' ' ARG . 2.0 mp 66.79 147.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.176 -0.466 . . . . 74.44 111.096 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -101.86 136.85 31.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.13 -0.487 . . . . 74.12 111.11 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -179.89 36.75 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.171 -0.468 . . . . 74.34 110.9 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.3 t-20 -175.72 63.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.185 -0.461 . . . . 71.31 110.902 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 6.9 pt20 -174.03 -170.14 0.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 62.33 110.924 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 5.3 t80 -67.2 89.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.205 -0.452 . . . . 60.43 110.971 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -179.24 -60.15 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.127 -0.488 . . . . 52.51 110.847 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.73 19.08 58.77 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.81 -0.71 . . . . 74.0 112.485 -179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.531 ' O ' HD23 ' A' ' 113' ' ' LEU . 1.6 tt 52.14 86.56 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.81 0.338 . . . . 74.43 110.899 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -110.25 -135.91 7.18 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.756 -0.735 . . . . 73.45 112.541 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 36.0 p-80 -126.68 26.46 6.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.686 0.279 . . . . 74.12 110.827 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -145.83 46.19 1.27 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.263 -0.426 . . . . 72.43 110.924 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.1 t30 -145.62 173.55 11.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 73.4 110.904 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 10.1 mmt -134.22 174.44 10.51 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.192 -0.458 . . . . 45.04 110.91 179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -100.62 159.85 14.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.203 -0.453 . . . . 74.33 110.904 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -151.69 110.65 0.47 Allowed Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.756 -0.735 . . . . 41.42 112.465 -179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.935 HG22 HD13 ' A' ' 53' ' ' ILE . 0.8 OUTLIER -86.77 152.92 22.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.73 0.3 . . . . 64.41 111.197 -179.907 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.658 HG13 HG21 ' A' ' 53' ' ' ILE . 4.4 mp -149.06 120.53 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.236 -0.438 . . . . 55.21 111.13 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.494 HG12 ' O ' ' A' ' 53' ' ' ILE . 3.0 p -114.83 127.14 72.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.175 -0.466 . . . . 74.41 111.089 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.711 HG13 ' O ' ' A' ' 55' ' ' VAL . 42.7 t -97.88 131.2 45.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.491 . . . . 74.32 111.149 179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 15.2 mmmt -104.97 128.53 53.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.237 -0.438 . . . . 64.1 110.86 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.243 -0.435 . . . . 60.22 110.884 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.521 ' HG3' HG13 ' A' ' 2' ' ' VAL . 5.5 ptm . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.761 0.315 . . . . 74.3 110.877 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.521 HG13 ' HG3' ' A' ' 1' ' ' MET . 25.0 m -114.12 139.37 40.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.261 -0.427 . . . . 75.22 111.111 179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.4 pt -150.96 77.88 7.51 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.594 0.712 . . . . 74.12 111.133 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 -178.14 2.2 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.73 2.287 . . . . 65.53 112.346 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -152.74 91.82 1.6 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.224 -0.444 . . . . 65.32 111.098 179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 169.86 -119.69 0.83 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.761 -0.733 . . . . 72.23 112.521 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -106.07 157.03 17.83 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.814 0.34 . . . . 75.24 110.879 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.699 HD13 ' O ' ' A' ' 90' ' ' VAL . 0.2 OUTLIER 61.49 163.75 0.08 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.23 -0.441 . . . . 73.12 110.909 179.93 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.631 ' N ' HD12 ' A' ' 8' ' ' LEU . 1.0 OUTLIER -119.22 141.38 48.95 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.208 -0.451 . . . . 71.54 110.869 179.934 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -86.02 137.97 32.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.113 -0.494 . . . . 71.21 110.867 -179.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.453 HG21 ' OG1' ' A' ' 66' ' ' THR . 17.1 m -120.72 -177.86 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 74.52 111.131 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.447 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 33.8 p30 -144.16 156.75 57.88 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.596 0.712 . . . . 72.03 110.882 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.6 Cg_endo -69.76 -2.28 9.9 Favored 'Trans proline' 0 C--O 1.232 0.195 0 C-N-CA 122.674 2.249 . . . . 73.31 112.356 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.75 HG22 HG23 ' A' ' 15' ' ' THR . 26.6 m -45.24 -65.24 0.56 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.223 -0.444 . . . . 72.44 111.124 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.75 HG23 HG22 ' A' ' 14' ' ' THR . 38.2 p -150.26 17.84 0.84 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 71.12 111.121 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 13.4 p -57.17 -25.8 23.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.201 -0.454 . . . . 64.3 111.145 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.442 HH12 ' NE2' ' A' ' 18' ' ' GLN . 3.5 ptt85 -106.71 -8.05 17.03 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 73.12 110.851 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.442 ' NE2' HH12 ' A' ' 17' ' ' ARG . 0.8 OUTLIER -94.03 -32.22 13.91 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 73.4 110.92 -179.955 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.471 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 7.8 pt-20 -142.56 144.19 32.78 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.174 -0.466 . . . . 74.35 110.902 -179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.96 -156.56 15.58 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.765 -0.731 . . . . 33.41 112.482 -179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.454 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.3 Cg_endo -69.77 -35.94 11.69 Favored 'Trans proline' 0 C--O 1.231 0.148 0 C-N-CA 122.661 2.24 . . . . 65.34 112.328 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.403 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 13.5 m-90 -84.66 -7.25 59.3 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.213 -0.449 . . . . 70.34 110.92 179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.471 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -62.02 -54.19 45.01 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.24 -0.437 . . . . 52.13 111.105 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -118.68 141.99 30.89 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.653 0.74 . . . . 75.04 110.855 179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -7.3 20.69 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.673 2.248 . . . . 72.31 112.372 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.59 -36.99 65.61 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.21 -0.45 . . . . 64.21 111.06 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.471 HE21 ' N ' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -95.31 33.06 1.62 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.226 -0.443 . . . . 74.4 110.929 -179.962 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.478 ' HB2' ' HG2' ' A' ' 52' ' ' PRO . . . -55.73 -76.67 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.224 -0.444 . . . . 73.22 111.101 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.734 HG11 ' CB ' ' A' ' 54' ' ' GLU . 2.3 p -101.88 129.79 52.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 62.34 111.103 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -142.33 139.99 29.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 73.32 111.151 179.897 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.425 HE22 ' N ' ' A' ' 36' ' ' GLN . 13.0 tp60 -72.4 123.34 22.86 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.17 -0.468 . . . . 75.33 110.903 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 7.3 p -120.28 -10.45 9.34 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.209 -0.45 . . . . 75.24 111.165 -179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.98 -168.83 12.46 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.755 -0.736 . . . . 51.5 112.479 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 -33.8 16.03 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.654 2.236 . . . . 50.34 112.368 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 48.1 t30 -154.31 28.7 0.45 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.236 -0.438 . . . . 73.04 110.896 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.425 ' N ' HE22 ' A' ' 31' ' ' GLN . 1.4 pt20 -126.83 119.43 26.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.179 -0.464 . . . . 42.02 110.912 179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 63.0 m-85 -96.37 134.7 39.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.223 -0.444 . . . . 74.25 110.906 -179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.689 ' HA ' HG23 ' A' ' 62' ' ' VAL . 92.5 m -93.84 104.23 16.31 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 64.13 111.119 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.1 t -86.85 132.27 32.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.203 -0.453 . . . . 71.31 111.096 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 48.9 m-85 -118.07 115.66 25.3 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.19 -0.459 . . . . 75.1 110.917 -179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.473 HG12 HD12 ' A' ' 53' ' ' ILE . 15.8 m -114.05 119.71 61.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.133 -0.485 . . . . 72.04 111.131 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.49 ' C ' HD13 ' A' ' 42' ' ' LEU . 3.2 tm? -114.97 132.86 56.44 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.154 -0.475 . . . . 73.13 110.927 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.46 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -154.59 131.28 10.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.171 -0.468 . . . . 75.3 111.066 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.404 ' CD2' HD11 ' A' ' 42' ' ' LEU . 2.9 p90 -127.1 163.03 24.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 75.13 110.868 -179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.799 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -87.03 2.9 48.11 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.098 -0.501 . . . . 71.21 111.124 179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 3.5 p90 -122.3 84.43 2.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.178 -0.464 . . . . 73.12 110.865 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 114.01 158.72 12.73 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.734 -0.746 . . . . 75.31 112.464 -179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -111.77 120.8 43.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.798 0.332 . . . . 73.4 110.976 -179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -127.08 162.36 48.39 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.619 0.723 . . . . 60.24 110.883 -179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.78 162.49 41.87 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.659 2.239 . . . . 62.43 112.34 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 17.7 m-20 -137.95 67.19 48.8 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.614 0.721 . . . . 72.45 110.851 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.478 ' HG2' ' HB2' ' A' ' 28' ' ' ALA . 53.9 Cg_endo -69.81 98.99 0.72 Allowed 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.643 2.228 . . . . 73.22 112.35 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.545 HG13 HG23 ' A' ' 121' ' ' THR . 1.5 mm -100.57 157.44 4.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 75.34 111.131 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.734 ' CB ' HG11 ' A' ' 29' ' ' VAL . 16.4 tt0 -155.42 122.08 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.909 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.957 HG12 HG21 ' A' ' 61' ' ' ILE . 6.0 m -142.68 86.6 9.53 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.612 0.72 . . . . 72.15 111.137 179.988 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.549 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.8 Cg_endo -69.76 122.74 9.41 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.689 2.259 . . . . 73.31 112.344 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -62.06 155.75 23.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 64.51 110.904 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 78.98 -0.97 76.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.694 -0.765 . . . . 72.44 112.484 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.95 150.4 52.16 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.787 0.327 . . . . 74.23 111.086 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.676 ' O ' HD13 ' A' ' 61' ' ' ILE . 2.6 mp0 -68.14 138.23 55.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.202 -0.454 . . . . 65.24 110.883 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.957 HG21 HG12 ' A' ' 55' ' ' VAL . 5.0 mm -128.28 117.78 46.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.186 -0.461 . . . . 53.14 111.139 179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.689 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -104.23 94.2 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 71.52 111.145 179.841 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.663 ' CZ ' HG11 ' A' ' 55' ' ' VAL . 40.2 m-85 -64.52 142.86 58.27 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.2 -0.455 . . . . 74.23 110.899 -179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -133.36 98.36 4.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.173 -0.467 . . . . 74.24 110.917 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.676 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.3 mp -106.8 137.01 39.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.26 -0.427 . . . . 73.31 111.15 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.453 ' OG1' HG21 ' A' ' 11' ' ' VAL . 6.5 t -154.96 134.62 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.171 -0.468 . . . . 70.04 111.121 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.415 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -146.2 161.38 39.42 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.688 0.756 . . . . 64.31 110.852 -179.893 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.415 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.5 Cg_endo -69.72 -52.98 0.3 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.699 2.266 . . . . 73.4 112.308 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -158.31 53.61 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.249 -0.432 . . . . 62.51 110.856 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.799 HG11 ' HB2' ' A' ' 45' ' ' ALA . 0.0 OUTLIER -155.12 140.95 11.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.213 -0.449 . . . . 71.41 111.121 179.977 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.572 HD13 ' HD3' ' A' ' 87' ' ' PRO . 30.5 mm -85.83 151.23 3.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.15 -0.477 . . . . 52.02 111.132 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.564 ' HB3' HG21 ' A' ' 65' ' ' ILE . 78.2 t60 -125.47 -83.93 0.63 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.17 -0.468 . . . . 61.35 110.872 179.852 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 61.13 158.57 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.724 -0.751 . . . . 71.34 112.504 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.676 ' CE2' HD11 ' A' ' 65' ' ' ILE . 0.8 OUTLIER -145.76 141.9 28.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.928 0.394 . . . . 65.32 110.859 -179.864 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.651 ' HB3' HG23 ' A' ' 105' ' ' ILE . 31.0 t-80 -104.35 140.29 38.1 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.153 -0.476 . . . . 70.51 110.844 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.62 HG22 ' CE2' ' A' ' 103' ' ' TYR . 94.1 t -126.31 134.66 65.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.23 -0.441 . . . . 71.02 111.154 179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 12.5 mt-10 -75.14 169.69 17.52 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.212 -0.449 . . . . 75.42 110.887 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 81.33 -51.28 4.36 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 51.33 112.504 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 20.3 m -116.29 151.47 35.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.795 0.331 . . . . 74.3 111.109 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 19.5 m120 -86.04 58.79 5.25 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.208 -0.451 . . . . 75.24 110.909 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.504 HD12 ' CD2' ' A' ' 95' ' ' TYR . 7.7 tt -62.87 126.11 20.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 70.11 111.121 179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -116.53 90.9 3.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 74.44 110.896 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.581 HG11 HG11 ' A' ' 93' ' ' VAL . 3.6 m -115.74 120.06 63.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 74.3 111.1 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -155.71 114.66 3.52 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.143 -0.48 . . . . 74.14 110.834 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.581 HG21 ' HB3' ' A' ' 91' ' ' SER . 94.3 t -140.2 145.04 26.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.138 -0.483 . . . . 65.42 111.104 179.958 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.1 mp -79.79 159.91 70.35 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.644 0.735 . . . . 60.33 110.904 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.572 ' HD3' HD13 ' A' ' 71' ' ' ILE . 54.0 Cg_endo -69.74 159.7 52.43 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.687 2.258 . . . . 73.4 112.354 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.58 10.02 48.49 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.75 -0.738 . . . . 74.24 112.519 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.5 pt-20 -169.36 126.24 0.91 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.891 0.376 . . . . 71.24 110.888 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.699 ' O ' HD13 ' A' ' 8' ' ' LEU . 2.4 p -65.17 118.73 8.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 70.33 111.158 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.581 ' HB3' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -81.57 166.7 20.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 64.14 110.894 -179.852 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 97.8 m -136.27 134.86 38.47 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.162 -0.472 . . . . 73.43 111.174 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.581 HG11 HG11 ' A' ' 83' ' ' VAL . 16.2 t -144.48 131.5 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.21 -0.45 . . . . 72.33 111.116 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.6 mmm180 -109.58 95.1 5.39 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.216 -0.447 . . . . 75.02 110.904 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.504 ' CD2' HD12 ' A' ' 81' ' ' ILE . 41.5 t80 -136.13 127.25 27.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.196 -0.456 . . . . 71.23 110.874 -179.856 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.8 t -128.2 143.27 51.03 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.05 -0.523 . . . . 70.3 111.145 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -100.75 -173.26 2.35 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 72.02 110.907 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.03 -24.43 4.75 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.141 -0.482 . . . . 70.34 110.855 -179.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -132.39 162.16 58.72 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.613 0.72 . . . . 74.43 110.895 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 155.45 65.84 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.711 2.274 . . . . 64.03 112.358 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 147.46 133.15 2.34 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.74 -0.743 . . . . 74.43 112.433 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -97.24 144.09 27.39 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.863 0.363 . . . . 75.35 110.866 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . 0.62 ' CE2' HG22 ' A' ' 76' ' ' VAL . 0.1 OUTLIER -137.74 132.63 33.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.19 -0.459 . . . . 72.31 110.949 -179.885 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -146.82 120.98 9.48 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 73.24 110.853 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.651 HG23 ' HB3' ' A' ' 75' ' ' HIS . 5.6 tt -178.22 137.32 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.195 -0.457 . . . . 75.25 111.136 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.442 HD13 ' N ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -141.08 142.93 28.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 44.01 111.106 179.881 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.699 ' HA ' HD13 ' A' ' 113' ' ' LEU . 6.3 p -179.96 -42.32 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.456 . . . . 51.42 110.848 179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -153.7 127.52 8.85 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.218 -0.446 . . . . 51.34 110.853 -179.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.407 HE22 ' N ' ' A' ' 74' ' ' PHE . 3.3 mt-30 -131.39 -40.14 1.13 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 64.42 110.912 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 41.7 t80 -175.48 -40.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.144 -0.48 . . . . 75.11 110.874 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.8 t -94.46 -39.86 10.2 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.143 -0.48 . . . . 75.24 110.896 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 139.49 -129.42 4.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.712 -0.756 . . . . 52.44 112.482 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.699 HD13 ' HA ' ' A' ' 107' ' ' CYS . 2.6 pt? -173.12 -169.88 0.59 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.861 0.362 . . . . 74.25 110.886 -179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 162.76 -171.22 38.52 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.761 -0.733 . . . . 62.23 112.464 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 40.6 p-80 -57.16 -24.25 53.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.773 0.32 . . . . 75.31 110.867 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 21.7 mt-30 -103.69 70.1 1.0 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.233 -0.44 . . . . 73.05 110.892 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -155.67 100.96 2.12 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.227 -0.442 . . . . 72.55 110.922 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -71.57 173.88 7.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 72.41 110.873 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -92.17 120.1 32.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 62.33 110.888 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.42 ' HA3' ' HB3' ' A' ' 74' ' ' PHE . . . -81.87 92.26 1.53 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.742 -0.742 . . . . 72.23 112.485 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.602 ' O ' HD13 ' A' ' 122' ' ' ILE . 13.4 t -86.48 154.14 21.34 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.794 0.331 . . . . 74.1 111.107 -179.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 121' ' ' THR . 5.9 mm -141.52 148.24 21.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.221 -0.445 . . . . 73.51 111.121 179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.405 ' O ' HG22 ' A' ' 55' ' ' VAL . 71.3 t -135.07 115.46 18.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.143 -0.481 . . . . 55.33 111.146 179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.847 HG22 HG23 ' A' ' 55' ' ' VAL . 95.9 t -102.25 121.69 53.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 74.42 111.112 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.1 mmmt -106.22 138.73 41.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.145 -0.48 . . . . 64.04 110.878 179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 23.5 mt-10 . . . . . 0 C--N 1.33 -0.275 0 CA-C-N 116.222 -0.445 . . . . 73.22 110.868 179.996 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.9 ptt? . . . . . 0 C--O 1.23 0.063 0 CA-C-O 120.797 0.332 . . . . 63.42 110.819 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 22.0 t -79.33 78.29 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.225 -0.443 . . . . 72.34 111.14 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.9 pt -145.23 78.58 12.2 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.604 0.716 . . . . 72.44 111.144 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -177.59 1.93 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.726 2.284 . . . . 70.4 112.356 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -170.49 -37.72 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.218 -0.446 . . . . 71.34 111.148 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -52.53 -50.96 46.14 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.754 -0.736 . . . . 71.33 112.464 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 41.5 tptt -171.13 154.23 3.98 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.792 0.33 . . . . 73.24 110.901 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.624 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.81 163.29 0.08 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.231 -0.441 . . . . 63.41 110.939 179.942 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.624 ' N ' HD12 ' A' ' 8' ' ' LEU . 15.8 mp0 -119.41 136.54 54.24 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.156 -0.474 . . . . 74.24 110.921 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.616 ' HD2' HD11 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -99.71 149.46 23.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.176 -0.466 . . . . 75.32 110.866 -179.884 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.601 HG21 HG21 ' A' ' 16' ' ' VAL . 13.8 m -147.39 -178.29 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 51.44 111.125 179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -144.3 162.31 40.47 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.618 0.723 . . . . 73.31 110.858 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 -4.59 14.34 Favored 'Trans proline' 0 C--N 1.342 0.184 0 C-N-CA 122.633 2.222 . . . . 74.13 112.317 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.408 ' O ' HG23 ' A' ' 15' ' ' THR . 4.6 m -48.83 -67.14 0.29 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.251 -0.431 . . . . 72.31 111.105 -179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.408 HG23 ' O ' ' A' ' 14' ' ' THR . 3.1 p -155.46 38.27 0.38 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.246 -0.434 . . . . 61.21 111.179 -179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.601 HG21 HG21 ' A' ' 11' ' ' VAL . 11.8 p -76.22 -31.97 21.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 75.44 111.139 179.941 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.476 ' HB3' HD11 ' A' ' 42' ' ' LEU . 7.4 ptt-85 -97.25 -11.61 23.94 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 74.41 110.894 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.6 mm-40 -95.53 -37.32 10.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.175 -0.466 . . . . 74.43 110.893 -179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -132.65 134.17 44.51 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 73.22 110.869 -179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.57 -158.95 18.23 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.764 -0.731 . . . . 74.33 112.506 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -26.86 26.93 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.623 2.215 . . . . 62.54 112.373 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.732 ' HB3' HD13 ' A' ' 42' ' ' LEU . 13.3 m-90 -87.39 -13.34 43.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.184 -0.462 . . . . 64.43 110.91 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -70.18 -59.67 2.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.267 -0.424 . . . . 73.33 111.054 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -91.18 144.07 29.34 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.623 0.725 . . . . 75.52 110.833 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -28.97 24.7 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.62 2.213 . . . . 60.2 112.369 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.4 -16.98 60.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 70.15 111.089 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 32.2 mm-40 -88.36 8.3 28.3 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.2 -0.455 . . . . 74.4 110.947 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -61.39 -78.4 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.167 -0.469 . . . . 71.21 111.08 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 2.1 p -103.02 126.51 57.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 64.43 111.114 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 2.6 t -134.97 150.13 29.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 44.53 111.083 179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -71.02 121.03 17.46 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.178 -0.464 . . . . 63.21 110.892 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.552 HG23 ' HG3' ' A' ' 36' ' ' GLN . 1.7 t -120.13 -33.05 4.02 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.223 -0.444 . . . . 75.34 111.153 -179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.79 178.49 16.49 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.706 -0.759 . . . . 74.22 112.476 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -18.14 37.33 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.727 2.284 . . . . 71.52 112.368 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 -153.3 30.08 0.49 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.196 -0.456 . . . . 71.21 110.872 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.552 ' HG3' HG23 ' A' ' 32' ' ' THR . 0.1 OUTLIER -140.96 157.46 45.32 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.203 -0.453 . . . . 62.44 110.919 179.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 17.3 m-85 -140.56 138.39 34.45 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.196 -0.456 . . . . 75.34 110.95 -179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.753 ' HA ' HG23 ' A' ' 62' ' ' VAL . 75.4 m -92.98 103.86 16.14 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.499 . . . . 75.51 111.143 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 t -90.25 140.39 16.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 64.45 111.158 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 56.9 m-85 -124.14 120.44 32.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.185 -0.461 . . . . 74.01 110.893 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.658 HG23 HG23 ' A' ' 65' ' ' ILE . 4.5 m -121.61 146.52 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.088 -0.505 . . . . 74.43 111.129 179.909 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.732 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.5 OUTLIER -139.1 143.94 38.5 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.166 -0.47 . . . . 72.41 110.935 179.967 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -150.84 106.2 3.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.441 . . . . 72.23 111.102 179.795 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 9.6 p90 -129.07 144.99 51.38 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.249 -0.432 . . . . 65.22 110.855 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.62 0.36 52.82 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.125 -0.489 . . . . 52.42 111.132 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -94.55 33.97 1.37 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.456 . . . . 74.21 110.848 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 154.75 -141.73 8.41 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.743 -0.741 . . . . 51.25 112.494 -179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -155.48 155.17 33.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.848 0.356 . . . . 71.21 110.899 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.412 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 0.0 OUTLIER -156.66 156.2 29.62 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.607 0.718 . . . . 75.3 110.883 179.981 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.412 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.4 Cg_endo -69.82 -179.78 3.18 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.669 2.246 . . . . 65.14 112.334 179.96 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.438 ' HB3' ' HB ' ' A' ' 121' ' ' THR . 0.4 OUTLIER -131.94 61.36 57.59 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.609 0.719 . . . . 73.44 110.881 -179.971 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 7.16 1.05 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.659 2.24 . . . . 75.32 112.359 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.646 HG21 HG13 ' A' ' 122' ' ' ILE . 3.7 mp -46.86 143.34 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.214 -0.448 . . . . 61.13 111.121 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -144.18 164.69 29.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.178 -0.465 . . . . 64.53 110.891 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.879 HG13 HG22 ' A' ' 124' ' ' VAL . 2.4 p -165.4 82.87 1.11 Allowed Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.597 0.713 . . . . 72.22 111.15 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.589 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.72 122.49 9.18 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.699 2.266 . . . . 75.13 112.354 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.25 154.9 40.82 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.219 -0.446 . . . . 72.43 110.89 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.59 -7.87 77.52 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.771 -0.728 . . . . 62.21 112.451 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.03 159.03 41.24 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.768 0.318 . . . . 65.12 111.064 -179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.754 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.4 mp0 -71.76 140.71 49.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.199 -0.455 . . . . 73.31 110.917 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.778 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -129.56 115.48 34.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.181 -0.463 . . . . 53.31 111.169 179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.753 HG23 ' HA ' ' A' ' 38' ' ' THR . 1.1 m -103.76 90.24 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.207 -0.452 . . . . 73.12 111.107 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.522 ' HB2' HG12 ' A' ' 93' ' ' VAL . 71.4 m-85 -66.45 140.87 58.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 71.21 110.913 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 10.7 mttt -132.42 98.61 4.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.184 -0.462 . . . . 71.13 110.931 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.658 HG23 HG23 ' A' ' 41' ' ' VAL . 1.4 mp -97.72 158.41 3.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.214 -0.448 . . . . 71.24 111.157 179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.433 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.2 t -168.73 135.59 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.2 -0.455 . . . . 72.35 111.144 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.63 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -139.72 159.93 63.11 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.669 0.747 . . . . 50.41 110.858 -179.847 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.416 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.1 Cg_endo -69.71 -52.77 0.31 Allowed 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.697 2.265 . . . . 70.11 112.398 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -153.02 41.11 0.56 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 53.54 110.847 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.63 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -142.3 135.07 27.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.229 -0.441 . . . . 73.15 111.125 179.991 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.9 mt -72.95 146.39 10.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 72.01 111.134 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.588 ' CB ' HG21 ' A' ' 65' ' ' ILE . 30.6 p80 -113.65 -168.16 1.3 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.175 -0.466 . . . . 71.32 110.848 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 128.87 118.16 2.06 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.743 -0.742 . . . . 35.4 112.51 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 1.3 p90 -117.63 144.38 45.23 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.924 0.392 . . . . 63.22 110.842 -179.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 32.9 t-80 -106.03 130.19 53.99 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 75.21 110.839 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.676 HG12 HG21 ' A' ' 81' ' ' ILE . 2.4 p -131.71 128.82 60.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.163 -0.472 . . . . 63.51 111.089 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 68.7 mt-10 -58.08 -177.53 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 63.21 110.874 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.3 -47.6 1.95 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.738 -0.744 . . . . 74.11 112.444 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.409 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -147.28 179.49 7.61 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.857 0.36 . . . . 73.12 111.086 -179.803 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.409 ' H ' HG22 ' A' ' 79' ' ' THR . 4.2 m120 -92.31 78.88 5.06 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 74.13 110.896 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.676 HG21 HG12 ' A' ' 76' ' ' VAL . 6.8 tt -88.56 123.43 40.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.152 -0.476 . . . . 71.21 111.102 179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -122.67 92.56 3.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 72.2 110.919 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 7.6 m -116.48 119.92 63.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.221 -0.445 . . . . 51.0 111.174 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -165.44 111.15 0.91 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.186 -0.461 . . . . 61.32 110.906 -179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.414 HG21 ' OG ' ' A' ' 91' ' ' SER . 86.2 t -140.63 140.81 33.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 70.44 111.133 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.0 mp -56.88 160.77 5.46 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-O 121.567 0.699 . . . . 72.34 110.928 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 160.68 48.83 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.672 2.248 . . . . 60.1 112.375 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.2 17.24 56.14 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.742 -0.742 . . . . 43.41 112.504 179.989 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.4 pt-20 -159.79 157.47 29.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.881 0.372 . . . . 74.31 110.886 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 86.1 t -102.92 133.5 46.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.169 -0.469 . . . . 54.11 111.107 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.414 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.6 OUTLIER -109.53 115.29 29.64 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 73.1 110.845 -179.871 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.5 m -94.46 124.43 38.48 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.062 -0.517 . . . . 74.21 111.158 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.522 HG12 ' HB2' ' A' ' 63' ' ' PHE . 10.7 p -134.67 137.66 50.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.22 -0.446 . . . . 74.32 111.197 179.904 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 4.5 mtm180 -103.24 108.56 19.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.154 -0.476 . . . . 70.42 110.902 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -141.35 112.26 7.22 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.158 -0.474 . . . . 74.11 110.909 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 10.7 t -112.86 137.31 51.4 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.165 -0.47 . . . . 61.42 111.109 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -93.32 -175.28 3.77 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.182 -0.463 . . . . 71.24 110.919 179.967 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 10.5 mtmm -123.63 -12.78 7.63 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.173 -0.467 . . . . 74.31 110.871 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.6 mpp_? -150.87 161.79 28.94 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.603 0.716 . . . . 75.3 110.904 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 155.83 64.95 Favored 'Trans proline' 0 N--CA 1.465 -0.171 0 C-N-CA 122.763 2.309 . . . . 71.44 112.331 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.92 141.58 3.18 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.733 -0.746 . . . . 62.53 112.493 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -106.18 128.84 54.21 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.852 0.358 . . . . 62.22 110.898 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 5.9 p90 -143.98 146.19 32.75 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.155 -0.475 . . . . 72.01 110.947 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -153.92 -176.52 5.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 73.11 110.846 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.406 HG22 ' N ' ' A' ' 106' ' ' ILE . 18.9 mm 66.37 155.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.188 -0.46 . . . . 73.11 111.103 179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.654 HG22 ' HD2' ' A' ' 119' ' ' PHE . 0.0 OUTLIER -110.81 145.73 16.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.14 -0.482 . . . . 74.43 111.096 179.866 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.479 ' N ' HD13 ' A' ' 106' ' ' ILE . 1.8 t -170.95 137.31 1.19 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.169 -0.469 . . . . 72.31 110.861 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 69.53 -75.27 0.07 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.179 -0.464 . . . . 63.35 110.921 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 8.0 mm-40 59.22 172.03 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 71.42 110.922 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 8.1 t80 -77.06 64.31 2.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.237 -0.438 . . . . 75.22 110.91 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 75.38 46.28 0.12 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.137 -0.483 . . . . 55.02 110.852 179.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -132.09 -133.16 3.41 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.774 -0.727 . . . . 63.35 112.484 -179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.613 HD13 ' CD1' ' A' ' 106' ' ' ILE . 52.2 tp 61.99 -85.31 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.899 0.38 . . . . 71.31 110.887 -179.93 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 47.48 53.19 12.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 61.21 112.458 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 20.0 m170 50.92 32.67 7.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.786 0.327 . . . . 72.43 110.889 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -154.02 -165.02 2.0 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.201 -0.454 . . . . 72.21 110.912 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.6 t30 67.45 120.61 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.201 -0.454 . . . . 71.13 110.91 -179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 5.8 mmm -71.52 174.55 6.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 71.21 110.817 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . 0.654 ' HD2' HG22 ' A' ' 106' ' ' ILE . 0.1 OUTLIER -130.64 167.7 18.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.145 -0.48 . . . . 75.45 110.885 -179.911 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -150.14 156.07 26.55 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 63.42 112.5 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.535 ' O ' HD13 ' A' ' 53' ' ' ILE . 4.2 m -85.16 145.23 27.72 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.777 0.322 . . . . 73.31 111.152 -179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.646 HG13 HG21 ' A' ' 53' ' ' ILE . 4.6 mp -146.77 120.4 2.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.212 -0.449 . . . . 75.25 111.174 179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 55' ' ' VAL . 2.6 p -116.41 142.2 31.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.161 -0.472 . . . . 73.32 111.103 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.879 HG22 HG13 ' A' ' 55' ' ' VAL . 60.5 t -106.05 122.17 59.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.162 -0.472 . . . . 74.2 111.161 179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 26.9 mmmt -90.39 134.94 34.0 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 75.31 110.936 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 71.53 110.897 179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.554 ' HG3' HG12 ' A' ' 2' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.817 0.342 . . . . 74.53 110.849 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.554 HG12 ' HG3' ' A' ' 1' ' ' MET . 2.5 p -162.2 95.05 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.266 -0.425 . . . . 52.24 111.134 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -153.15 78.08 5.97 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.551 0.691 . . . . 74.01 111.121 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 -177.4 1.84 Allowed 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.721 2.28 . . . . 75.41 112.319 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -168.21 126.48 1.16 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.205 -0.452 . . . . 52.52 111.101 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 132.81 -57.47 0.71 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.772 -0.728 . . . . 33.42 112.507 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -152.53 133.03 13.79 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.82 0.343 . . . . 72.44 110.898 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.608 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.23 164.37 0.08 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.196 -0.456 . . . . 64.15 110.913 179.952 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.608 ' N ' HD12 ' A' ' 8' ' ' LEU . 25.2 mp0 -129.64 135.99 49.19 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.199 -0.455 . . . . 73.51 110.888 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.485 ' HD2' HD11 ' A' ' 8' ' ' LEU . 0.4 OUTLIER -92.59 137.71 32.13 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.16 -0.473 . . . . 73.24 110.863 -179.885 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.47 HG21 HG21 ' A' ' 16' ' ' VAL . 12.5 m -136.32 -177.94 2.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 65.32 111.127 179.972 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -143.93 162.52 40.47 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.589 0.709 . . . . 70.14 110.897 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.74 -4.12 13.38 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.697 2.265 . . . . 73.45 112.355 -179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.425 ' O ' HG23 ' A' ' 15' ' ' THR . 23.3 m -47.64 -70.04 0.11 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.202 -0.454 . . . . 70.43 111.126 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.425 HG23 ' O ' ' A' ' 14' ' ' THR . 3.7 p -155.96 38.74 0.36 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.206 -0.452 . . . . 73.42 111.147 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.581 HG22 ' CE3' ' A' ' 22' ' ' TRP . 13.4 p -75.52 -42.25 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.253 -0.431 . . . . 73.5 111.13 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.548 ' HB2' HD22 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -108.97 11.25 26.02 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 74.32 110.868 -179.97 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 16.7 mm-40 -105.55 -33.26 8.15 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 71.34 110.879 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.47 ' CG ' ' O ' ' A' ' 19' ' ' GLU . 28.5 tt0 -142.55 13.15 1.94 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.217 -0.447 . . . . 74.31 110.859 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . -103.35 -154.85 24.4 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.741 -0.742 . . . . 75.23 112.487 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.462 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.2 Cg_endo -69.75 -23.06 31.26 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.684 2.256 . . . . 62.21 112.351 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.581 ' CE3' HG22 ' A' ' 16' ' ' VAL . 18.2 m-90 -91.03 -7.27 52.35 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.197 -0.456 . . . . 73.44 110.939 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.18 -44.02 55.03 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 51.41 111.132 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -110.43 137.71 20.74 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.61 0.719 . . . . 73.4 110.892 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 -17.83 37.14 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.692 2.261 . . . . 61.23 112.314 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.19 -37.8 69.21 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.233 -0.44 . . . . 31.43 111.134 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 57.3 mm-40 -84.79 4.9 30.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.461 . . . . 72.32 110.911 -179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.65 -73.29 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.176 -0.466 . . . . 50.03 111.107 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.475 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.0 p -105.93 123.01 60.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.235 -0.439 . . . . 60.35 111.105 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.6 t -137.76 150.35 25.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.196 -0.457 . . . . 72.24 111.126 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -75.67 121.29 22.26 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.176 -0.465 . . . . 70.41 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 10.4 p -121.31 -41.6 2.5 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.246 -0.433 . . . . 75.53 111.163 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -95.73 -166.74 34.8 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.734 -0.746 . . . . 60.52 112.515 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -36.76 10.21 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.673 2.248 . . . . 64.23 112.378 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . 0.502 ' O ' ' HB1' ' A' ' 59' ' ' ALA . 63.8 t30 -152.7 28.95 0.53 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.249 -0.432 . . . . 73.03 110.861 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.04 127.53 44.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 74.23 110.893 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 18.0 m-85 -96.66 135.62 38.33 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.182 -0.463 . . . . 73.32 110.899 -179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.78 ' HA ' HG23 ' A' ' 62' ' ' VAL . 51.7 m -92.01 102.36 14.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.114 -0.493 . . . . 52.01 111.162 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.424 HG11 HG23 ' A' ' 53' ' ' ILE . 12.5 t -85.75 139.01 18.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.204 -0.453 . . . . 64.23 111.099 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -120.2 100.61 7.29 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.151 -0.477 . . . . 75.03 110.927 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.497 HG12 HG12 ' A' ' 53' ' ' ILE . 15.4 m -96.33 142.43 13.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.104 -0.498 . . . . 70.42 111.108 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.568 HD21 ' CE2' ' A' ' 44' ' ' PHE . 15.1 tp -130.31 144.21 51.24 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.194 -0.457 . . . . 65.54 110.925 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.58 ' HB1' ' HG2' ' A' ' 118' ' ' MET . . . -154.52 98.57 2.1 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.215 -0.448 . . . . 63.33 111.132 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.568 ' CE2' HD21 ' A' ' 42' ' ' LEU . 3.1 p90 -113.88 155.96 24.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.186 -0.461 . . . . 71.24 110.854 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.76 31.52 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 62.21 111.103 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -105.73 75.36 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.19 -0.459 . . . . 54.33 110.866 -179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.43 -162.37 17.88 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.713 -0.756 . . . . 53.11 112.491 -179.973 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 34.1 p90 -126.67 151.88 47.49 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.834 0.349 . . . . 73.21 110.926 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.438 ' H ' ' NE2' ' A' ' 49' ' ' GLN . 0.0 OUTLIER -136.08 159.97 68.95 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.64 0.733 . . . . 63.25 110.889 179.991 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.81 -176.38 1.48 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.701 2.267 . . . . 74.3 112.316 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.478 ' CB ' HG21 ' A' ' 121' ' ' THR . 1.6 m120 -138.11 62.16 30.91 Favored Pre-proline 0 C--N 1.33 -0.269 0 CA-C-O 121.615 0.721 . . . . 72.25 110.856 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 6.27 1.37 Allowed 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.719 2.28 . . . . 65.12 112.334 179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.645 HG21 HG13 ' A' ' 122' ' ' ILE . 3.6 mp -48.4 107.84 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 74.23 111.094 179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.475 ' HB3' HG11 ' A' ' 29' ' ' VAL . 39.7 tt0 -110.75 140.19 45.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.186 -0.461 . . . . 74.14 110.9 179.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 1.0 HG12 HG21 ' A' ' 61' ' ' ILE . 3.0 m -140.59 86.36 12.32 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.655 0.74 . . . . 73.52 111.152 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.658 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.0 Cg_endo -69.74 121.92 8.61 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.686 2.258 . . . . 64.11 112.374 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.95 153.33 42.38 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 71.02 110.906 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.8 -9.59 75.78 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.761 -0.733 . . . . 71.14 112.52 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.502 ' HB1' ' O ' ' A' ' 35' ' ' ASN . . . -133.58 154.72 50.64 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.741 0.305 . . . . 74.03 111.12 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.713 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.6 mm-40 -67.09 144.4 56.12 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 70.03 110.899 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 1.0 HG21 HG12 ' A' ' 55' ' ' VAL . 6.7 mm -129.12 101.03 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 64.4 111.142 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.78 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.4 OUTLIER -89.19 100.1 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.223 -0.444 . . . . 63.52 111.104 179.919 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.476 ' HZ ' HG11 ' A' ' 55' ' ' VAL . 70.0 m-85 -72.89 141.6 47.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 62.51 110.911 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.5 mttt -132.62 99.21 4.56 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.16 -0.473 . . . . 75.03 110.901 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.598 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.4 mp -98.37 153.92 3.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 72.52 111.081 179.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -169.18 136.62 1.83 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.173 -0.467 . . . . 62.43 111.127 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.491 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.8 OUTLIER -148.22 159.44 39.54 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.67 0.748 . . . . 63.53 110.857 -179.823 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.403 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.4 Cg_endo -69.81 -55.14 0.19 Allowed 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.659 2.239 . . . . 73.35 112.352 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -156.3 62.89 0.55 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.22 -0.445 . . . . 72.32 110.866 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.491 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.28 136.15 4.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 63.21 111.162 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 30.2 mm -71.12 143.7 14.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.208 -0.451 . . . . 73.3 111.124 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.598 ' CG ' HG21 ' A' ' 65' ' ' ILE . 9.5 p-80 -125.55 -168.89 1.91 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 74.24 110.852 179.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 130.18 132.89 3.49 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.722 -0.751 . . . . 65.2 112.439 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -126.35 142.04 51.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 65.23 110.903 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -103.93 89.28 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.184 -0.462 . . . . 75.24 110.902 179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.787 HG13 ' CE2' ' A' ' 103' ' ' TYR . 15.6 t -74.63 131.81 34.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 63.43 111.138 -180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -68.14 178.36 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.115 -0.493 . . . . 71.31 110.908 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 95.96 -51.05 1.71 Allowed Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.729 -0.748 . . . . 65.32 112.495 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.435 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -140.0 179.51 6.57 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.822 0.344 . . . . 52.23 111.142 -179.831 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.435 ' H ' HG22 ' A' ' 79' ' ' THR . 22.5 m120 -87.94 67.42 9.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.235 -0.439 . . . . 70.11 110.871 179.964 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.467 ' O ' HG23 ' A' ' 81' ' ' ILE . 13.2 tt -76.86 119.71 25.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.212 -0.449 . . . . 74.24 111.134 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -116.35 103.32 10.36 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 74.31 110.933 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.519 HG11 HG21 ' A' ' 93' ' ' VAL . 2.8 m -125.59 120.52 57.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 74.44 111.195 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 71.4 tt0 -155.33 113.45 3.43 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.195 -0.457 . . . . 73.32 110.878 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.668 HG21 ' OG ' ' A' ' 91' ' ' SER . 60.9 t -140.85 147.31 22.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 71.13 111.099 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.492 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -73.48 158.68 86.17 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.632 0.73 . . . . 73.21 110.954 179.928 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.6 Cg_endo -69.82 159.79 52.05 Favored 'Trans proline' 0 C--N 1.342 0.209 0 C-N-CA 122.686 2.258 . . . . 63.34 112.333 179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 91.41 17.35 50.17 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.767 -0.73 . . . . 32.4 112.479 -179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -165.24 138.48 4.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.947 0.403 . . . . 71.52 110.858 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 48.5 t -79.38 137.69 21.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.137 -0.483 . . . . 70.22 111.081 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.668 ' OG ' HG21 ' A' ' 85' ' ' VAL . 3.5 t -119.98 131.7 55.25 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.113 -0.494 . . . . 62.43 110.847 -179.864 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.4 t -96.92 145.76 25.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.169 -0.469 . . . . 54.41 111.119 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.519 HG21 HG11 ' A' ' 83' ' ' VAL . 40.1 t -145.99 125.6 5.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 73.23 111.139 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.7 mmm180 -102.99 115.43 30.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.449 . . . . 71.21 110.89 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 33.9 t80 -162.27 109.62 1.33 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.238 -0.437 . . . . 62.55 110.908 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -107.72 143.04 36.81 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.13 -0.487 . . . . 74.43 111.115 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -97.41 174.91 6.45 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 64.34 110.858 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -119.72 -20.36 7.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.125 -0.489 . . . . 65.54 110.858 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -139.35 158.48 68.79 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.653 0.74 . . . . 75.51 110.814 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.424 ' HA ' ' HB ' ' A' ' 124' ' ' VAL . 53.7 Cg_endo -69.76 158.07 58.22 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.656 2.237 . . . . 74.35 112.355 179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 156.27 136.53 2.17 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.738 -0.744 . . . . 54.24 112.497 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.507 ' HB3' HG23 ' A' ' 123' ' ' VAL . 1.5 pm0 -101.67 134.75 44.33 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.876 0.37 . . . . 74.42 110.892 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . 0.787 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.7 OUTLIER -143.9 127.24 16.77 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.157 -0.474 . . . . 73.44 110.951 -179.82 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -148.8 105.96 3.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 75.13 110.901 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 6.3 tt 179.8 142.92 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 62.41 111.103 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.448 HD11 ' SG ' ' A' ' 111' ' ' CYS . 0.0 OUTLIER -122.84 141.51 42.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.183 -0.462 . . . . 72.44 111.125 179.839 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.433 ' N ' HD13 ' A' ' 106' ' ' ILE . 5.4 p 179.4 -42.93 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 51.33 110.848 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.4 t30 -89.57 62.37 5.88 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.188 -0.46 . . . . 54.23 110.881 -179.892 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 7.3 pt20 -178.69 136.82 0.15 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.155 -0.475 . . . . 73.11 110.909 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -72.06 121.1 18.62 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.185 -0.461 . . . . 74.4 110.91 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.448 ' SG ' HD11 ' A' ' 106' ' ' ILE . 6.3 p -179.85 34.47 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.122 -0.49 . . . . 75.02 110.906 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 53.98 66.12 2.99 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.733 -0.746 . . . . 71.11 112.471 -179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.434 ' O ' HD23 ' A' ' 113' ' ' LEU . 1.2 tt -51.8 108.97 0.31 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.839 0.352 . . . . 41.33 110.897 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 149.99 -89.73 0.14 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.794 -0.717 . . . . 74.53 112.5 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -113.58 -28.6 7.44 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.719 0.295 . . . . 74.52 110.859 -179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -54.5 -27.02 35.07 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.194 -0.457 . . . . 62.43 110.925 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 2.6 p-10 -144.75 -169.41 3.16 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.171 -0.468 . . . . 71.15 110.856 -179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.58 ' HG2' ' HB1' ' A' ' 43' ' ' ALA . 0.5 OUTLIER -134.99 177.99 7.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 64.14 110.907 179.865 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 -88.07 119.3 28.31 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.228 -0.442 . . . . 75.2 110.928 -179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.9 173.15 23.36 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.728 -0.749 . . . . 42.21 112.53 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.557 ' O ' HD13 ' A' ' 53' ' ' ILE . 46.3 m -154.41 119.98 5.15 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.779 0.323 . . . . 62.02 111.201 -179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.645 HG13 HG21 ' A' ' 53' ' ' ILE . 4.6 mp -141.73 119.46 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 64.34 111.158 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.507 HG23 ' HB3' ' A' ' 102' ' ' GLU . 9.0 p -116.44 136.88 52.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 71.11 111.125 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.535 HG22 HG23 ' A' ' 55' ' ' VAL . 35.5 t -100.67 128.1 53.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.205 -0.452 . . . . 30.31 111.169 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 19.6 mmtt -111.99 132.55 54.72 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 71.23 110.896 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 . . . . . 0 C--N 1.33 -0.262 0 CA-C-N 116.207 -0.451 . . . . 64.0 110.926 179.961 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.114 0 CA-C-O 120.839 0.352 . . . . 71.42 110.88 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 20.6 t -127.31 66.41 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.249 -0.432 . . . . 75.31 111.106 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.6 pt -112.18 78.38 2.43 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.603 0.715 . . . . 73.32 111.109 179.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -176.47 1.5 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.695 2.263 . . . . 75.33 112.31 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -86.72 -169.46 2.64 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.229 -0.441 . . . . 62.21 111.068 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 69.61 26.8 74.09 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.735 -0.745 . . . . 72.55 112.471 -179.97 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.43 170.04 0.15 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.851 0.358 . . . . 73.34 110.877 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.627 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.56 163.79 0.08 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 73.03 110.922 179.929 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.627 ' N ' HD12 ' A' ' 8' ' ' LEU . 0.4 OUTLIER -120.28 138.17 53.83 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 72.31 110.908 179.919 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.44 ' HD2' HD11 ' A' ' 8' ' ' LEU . 2.9 mpt_? -93.77 127.91 39.73 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.145 -0.479 . . . . 73.22 110.892 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.437 HG21 HG21 ' A' ' 16' ' ' VAL . 7.1 m -110.8 -178.79 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.189 -0.46 . . . . 63.22 111.153 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -144.41 162.17 40.81 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.593 0.711 . . . . 74.04 110.909 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.81 -3.32 11.81 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.705 2.27 . . . . 43.31 112.306 -179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 26.9 m -44.92 -70.14 0.11 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 63.35 111.09 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 27.6 p -149.62 22.97 0.9 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 74.42 111.148 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.437 HG21 HG21 ' A' ' 11' ' ' VAL . 10.6 p -61.42 -23.75 31.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 74.35 111.106 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.518 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.6 OUTLIER -105.91 -19.88 13.6 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.153 -0.476 . . . . 72.31 110.844 -179.939 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 32.5 mm-40 -85.29 -28.29 25.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.451 . . . . 61.1 110.912 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.402 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 4.9 pt-20 -145.06 146.66 31.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.467 . . . . 74.11 110.864 -179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.64 -158.91 14.02 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.794 -0.717 . . . . 31.34 112.453 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.46 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 54.0 Cg_endo -69.73 -30.26 22.71 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.665 2.243 . . . . 72.3 112.373 -179.986 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.729 ' HB3' HD13 ' A' ' 42' ' ' LEU . 17.2 m-90 -85.86 -8.36 58.11 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.196 -0.457 . . . . 74.12 110.887 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.402 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -72.63 -59.63 2.63 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 33.22 111.103 179.881 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -113.54 145.8 34.09 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.588 0.709 . . . . 74.44 110.891 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -7.29 20.67 Favored 'Trans proline' 0 C--N 1.342 0.218 0 C-N-CA 122.644 2.229 . . . . 64.33 112.36 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.0 -22.62 60.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 74.12 111.089 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -116.42 30.86 7.08 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 54.13 110.916 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -79.35 -57.01 3.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 74.43 111.097 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.78 HG21 ' HB3' ' A' ' 54' ' ' GLU . 21.9 t -113.18 101.89 13.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.25 -0.432 . . . . 74.02 111.124 179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.9 t -117.14 148.87 19.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 75.32 111.119 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.452 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -80.39 117.4 21.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 64.24 110.915 179.976 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . 0.449 HG21 ' OG1' ' A' ' 38' ' ' THR . 15.9 p -105.79 -43.6 4.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.212 -0.449 . . . . 65.03 111.131 -179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.13 -173.24 22.55 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.79 -0.719 . . . . 73.31 112.501 179.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 -5.61 16.63 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.7 2.267 . . . . 74.23 112.307 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 55.9 t30 -175.41 30.15 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.232 -0.44 . . . . 74.31 110.845 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . 0.412 ' HG3' ' HB2' ' A' ' 60' ' ' GLU . 4.6 mp0 -126.62 118.42 24.77 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.188 -0.46 . . . . 74.33 110.91 179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.452 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 54.2 m-85 -98.93 130.4 45.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.2 -0.454 . . . . 74.31 110.94 -179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.449 ' OG1' HG21 ' A' ' 32' ' ' THR . 24.7 m -95.62 105.65 17.66 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.11 -0.496 . . . . 71.01 111.157 -179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.437 HG13 HG22 ' A' ' 29' ' ' VAL . 18.3 t -88.02 146.3 6.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.22 -0.446 . . . . 75.04 111.128 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -127.27 106.65 9.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.203 -0.453 . . . . 74.54 110.947 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.532 HG12 ' CG1' ' A' ' 53' ' ' ILE . 16.2 m -107.08 142.76 19.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.144 -0.48 . . . . 60.43 111.096 179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.729 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.6 OUTLIER -139.41 143.27 37.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 74.45 110.858 179.973 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.35 114.76 3.64 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.14 -0.482 . . . . 71.3 111.083 179.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.507 ' CD2' HD21 ' A' ' 42' ' ' LEU . 4.1 p90 -127.67 155.06 44.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 75.42 110.905 -179.918 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.9 4.21 38.47 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.176 -0.465 . . . . 53.14 111.103 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.0 m-85 -104.25 74.76 1.21 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 72.41 110.861 -179.914 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 109.37 -160.11 13.68 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.726 -0.749 . . . . 75.55 112.544 -179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 11.4 p90 -135.25 144.94 47.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.793 0.33 . . . . 73.14 110.948 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.2 mt-30 -143.69 162.3 42.21 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.609 0.718 . . . . 45.23 110.883 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 -176.09 1.38 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.63 2.22 . . . . 72.12 112.338 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.678 ' O ' HD12 ' A' ' 53' ' ' ILE . 62.9 m-20 -130.79 59.93 49.46 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.622 0.725 . . . . 73.13 110.884 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 73.84 1.31 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.7 2.267 . . . . 64.11 112.353 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.7 HG21 HG13 ' A' ' 122' ' ' ILE . 4.1 mp -117.14 122.71 70.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.23 -0.441 . . . . 75.15 111.086 179.962 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.78 ' HB3' HG21 ' A' ' 29' ' ' VAL . 10.5 tt0 -125.75 129.3 49.21 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.879 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.679 ' O ' HG13 ' A' ' 124' ' ' VAL . 2.6 p -136.51 80.47 38.69 Favored Pre-proline 0 C--N 1.33 -0.263 0 CA-C-O 121.635 0.731 . . . . 54.41 111.098 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.446 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.74 122.92 9.59 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.701 2.268 . . . . 75.35 112.321 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . 0.481 ' NE2' HG12 ' A' ' 124' ' ' VAL . 0.0 OUTLIER -67.49 154.71 40.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.237 -0.438 . . . . 74.23 110.932 179.954 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.33 -10.34 71.74 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.748 -0.739 . . . . 54.51 112.49 -179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.28 143.11 48.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 73.04 111.087 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.559 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.9 mp0 -61.15 135.19 57.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.216 -0.447 . . . . 71.21 110.867 -179.899 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.651 HG13 HG23 ' A' ' 55' ' ' VAL . 12.4 mm -122.62 123.5 68.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.118 -0.492 . . . . 73.43 111.135 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.963 HG13 HG23 ' A' ' 92' ' ' THR . 41.9 t -101.9 92.23 2.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.194 -0.457 . . . . 74.42 111.134 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -68.79 138.33 54.72 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.459 . . . . 73.43 110.873 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.3 mttt -131.15 102.01 5.82 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.122 -0.49 . . . . 74.55 110.91 179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.504 HD11 ' CZ ' ' A' ' 74' ' ' PHE . 1.6 mp -102.92 139.84 22.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.248 -0.433 . . . . 71.52 111.146 179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 10.1 t -158.62 137.74 11.45 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.111 -0.495 . . . . 53.54 111.163 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.457 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.8 OUTLIER -141.59 160.93 54.78 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.674 0.75 . . . . 64.31 110.865 -179.875 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.457 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.86 -54.39 0.22 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.655 2.237 . . . . 52.14 112.349 -179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -157.32 59.03 0.51 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.211 -0.449 . . . . 44.44 110.882 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.407 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -155.93 135.97 4.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.216 -0.447 . . . . 73.42 111.17 179.983 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 42.1 mm -67.4 144.97 14.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.215 -0.448 . . . . 73.11 111.126 179.942 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.4 ' HB2' HG21 ' A' ' 65' ' ' ILE . 9.1 p80 -132.96 -176.58 4.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 72.43 110.848 179.875 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 134.62 132.66 3.21 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.741 -0.742 . . . . 60.2 112.455 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.504 ' CZ ' HD11 ' A' ' 65' ' ' ILE . 1.8 p90 -121.03 144.3 48.6 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.845 0.355 . . . . 64.32 110.891 -179.879 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.42 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 9.7 p80 -103.82 88.17 2.98 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 72.45 110.881 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.784 HG13 ' CE2' ' A' ' 103' ' ' TYR . 10.9 t -74.94 115.67 16.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.199 -0.455 . . . . 62.01 111.125 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -54.89 177.45 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.165 -0.47 . . . . 74.11 110.91 179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 94.41 -49.07 2.12 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.788 -0.72 . . . . 62.22 112.489 -179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.437 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -134.46 179.38 6.32 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.751 0.31 . . . . 70.02 111.163 -179.905 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.437 ' H ' HG22 ' A' ' 79' ' ' THR . 24.4 m120 -88.35 50.36 1.96 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.245 -0.434 . . . . 70.41 110.882 179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.494 ' O ' HG23 ' A' ' 81' ' ' ILE . 6.2 tp -60.94 116.04 1.77 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.207 -0.452 . . . . 71.34 111.1 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.2 p30 -116.9 100.82 8.03 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.208 -0.451 . . . . 42.54 110.876 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.605 HG11 HG21 ' A' ' 93' ' ' VAL . 3.4 m -121.86 124.13 70.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 73.04 111.13 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -164.61 108.62 0.92 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.171 -0.468 . . . . 71.03 110.856 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.591 HG21 ' OG ' ' A' ' 91' ' ' SER . 45.1 t -140.4 146.49 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.182 -0.463 . . . . 44.13 111.189 179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -66.74 161.23 62.68 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.58 0.705 . . . . 72.01 110.948 179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 159.94 51.54 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.73 2.287 . . . . 71.43 112.305 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.37 5.48 75.67 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.75 -0.738 . . . . 50.01 112.515 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 22.5 mt-10 -147.9 117.95 7.24 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.899 0.38 . . . . 73.24 110.872 -179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.497 HG12 ' O ' ' A' ' 9' ' ' GLU . 3.8 p -77.94 118.98 25.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.19 -0.459 . . . . 70.42 111.104 -179.998 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.591 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -94.85 134.05 37.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.11 -0.495 . . . . 74.02 110.835 -179.835 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.963 HG23 HG13 ' A' ' 62' ' ' VAL . 74.2 m -98.84 109.39 22.15 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.16 -0.473 . . . . 70.42 111.15 -179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.605 HG21 HG11 ' A' ' 83' ' ' VAL . 39.7 t -106.86 148.33 11.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 61.3 111.138 179.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -121.05 107.52 12.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.154 -0.476 . . . . 74.54 110.831 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -153.18 130.39 11.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.189 -0.459 . . . . 52.34 110.949 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 29.7 m -139.95 141.57 36.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 75.34 111.143 -179.977 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -96.57 -176.42 3.61 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.253 -0.431 . . . . 74.2 110.907 179.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -123.15 -12.55 7.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 61.11 110.905 179.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.95 162.85 51.84 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.647 0.737 . . . . 74.35 110.863 179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 149.54 66.92 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 122.686 2.257 . . . . 64.34 112.328 -179.978 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.4 136.92 2.15 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.727 -0.749 . . . . 61.52 112.459 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.711 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.5 OUTLIER -109.41 132.82 53.77 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.847 0.356 . . . . 70.23 110.875 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . 0.784 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.9 OUTLIER -143.27 137.17 28.69 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.181 -0.463 . . . . 52.21 110.895 -179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.93 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.17 -164.77 1.97 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.129 -0.487 . . . . 73.23 110.877 -179.977 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.93 HG22 ' O ' ' A' ' 104' ' ' ARG . 7.7 tt 57.55 158.99 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.17 -0.468 . . . . 75.43 111.097 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.441 HD13 ' N ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -119.91 145.32 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.176 -0.466 . . . . 60.31 111.118 179.88 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.441 ' N ' HD13 ' A' ' 106' ' ' ILE . 0.1 OUTLIER -179.29 35.19 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.172 -0.467 . . . . 73.12 110.923 179.979 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 2.8 t-20 -159.95 80.75 0.71 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.162 -0.472 . . . . 73.21 110.858 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 4.1 mp0 -160.37 -44.05 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 73.42 110.901 179.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.7 OUTLIER 63.35 94.38 0.05 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.239 -0.437 . . . . 71.41 110.932 -179.876 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -179.58 34.53 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.087 -0.506 . . . . 74.55 110.894 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 103.02 26.06 7.22 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.746 -0.74 . . . . 70.33 112.495 -179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.513 HD12 ' N ' ' A' ' 114' ' ' GLY . 2.9 pp -60.71 -170.78 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.878 0.37 . . . . 61.25 110.861 -179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.513 ' N ' HD12 ' A' ' 113' ' ' LEU . . . 80.52 -85.64 1.34 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.752 -0.737 . . . . 43.03 112.475 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 6.1 t-80 -75.14 -25.02 58.08 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.776 0.322 . . . . 74.13 110.851 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -117.32 -169.68 1.71 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.212 -0.449 . . . . 73.01 110.975 -179.973 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 5.6 t-20 63.61 106.58 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.213 -0.448 . . . . 62.51 110.899 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 1.1 ptp -71.49 173.12 8.37 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.158 -0.474 . . . . 65.23 110.913 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -92.16 125.9 37.02 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.203 -0.453 . . . . 63.23 110.886 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -81.8 179.5 53.33 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.727 -0.749 . . . . 53.12 112.437 -179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.567 ' O ' HD13 ' A' ' 53' ' ' ILE . 55.1 m -155.24 117.24 4.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.775 0.321 . . . . 73.43 111.169 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.7 HG13 HG21 ' A' ' 53' ' ' ILE . 5.1 mp -146.48 129.66 9.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.215 -0.448 . . . . 64.42 111.115 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.711 HG23 ' HB3' ' A' ' 102' ' ' GLU . 9.9 p -132.27 137.06 55.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.178 -0.464 . . . . 71.42 111.119 179.816 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.679 HG13 ' O ' ' A' ' 55' ' ' VAL . 15.7 t -99.73 125.18 53.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.155 -0.475 . . . . 72.03 111.115 179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.6 mmmt -99.26 130.68 45.57 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 71.34 110.879 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 61.5 110.863 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.457 -0.087 0 CA-C-O 120.833 0.349 . . . . 72.45 110.912 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 21.3 t 60.89 84.62 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 75.41 111.148 179.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.8 pt -120.32 153.47 55.9 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-O 121.619 0.723 . . . . 72.31 111.12 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.7 -176.73 1.56 Allowed 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.664 2.243 . . . . 54.32 112.374 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -95.1 -62.97 1.22 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 74.4 111.107 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -154.44 19.32 0.61 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.752 -0.737 . . . . 61.0 112.512 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -170.16 146.04 2.91 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.786 0.327 . . . . 73.21 110.932 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.697 HD13 ' O ' ' A' ' 90' ' ' VAL . 0.2 OUTLIER 61.16 164.66 0.08 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.247 -0.433 . . . . 64.45 110.925 179.934 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.617 ' N ' HD12 ' A' ' 8' ' ' LEU . 2.1 mt-10 -120.45 143.56 48.43 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.186 -0.461 . . . . 75.41 110.919 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.12 136.74 38.65 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.148 -0.478 . . . . 73.41 110.85 -179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.518 HG21 HG21 ' A' ' 16' ' ' VAL . 15.2 m -128.46 -178.66 2.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.205 -0.452 . . . . 64.34 111.103 179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 161.94 41.54 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.647 0.737 . . . . 64.14 110.854 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -4.71 14.58 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.735 2.29 . . . . 62.01 112.359 -179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.407 ' O ' HG23 ' A' ' 15' ' ' THR . 4.2 m -48.44 -66.92 0.32 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.185 -0.461 . . . . 74.35 111.138 -179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 14' ' ' THR . 2.8 p -155.62 37.59 0.37 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.218 -0.446 . . . . 63.15 111.163 179.975 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.518 HG21 HG21 ' A' ' 11' ' ' VAL . 14.7 p -74.29 -34.5 37.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.236 -0.438 . . . . 75.11 111.119 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.427 ' HB3' HD11 ' A' ' 42' ' ' LEU . 11.5 ptt85 -95.17 -10.73 29.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 73.45 110.865 -179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 53.4 mt-30 -97.69 -35.08 10.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 62.41 110.892 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 -131.86 136.95 47.84 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.194 -0.457 . . . . 63.24 110.906 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 118.21 -159.5 14.25 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.719 -0.753 . . . . 11.21 112.495 -179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -26.89 26.94 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.63 2.22 . . . . 62.15 112.325 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.748 ' HB3' HD13 ' A' ' 42' ' ' LEU . 15.7 m-90 -86.37 -10.94 53.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.235 -0.439 . . . . 71.54 110.929 179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -68.9 -59.0 3.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.207 -0.451 . . . . 61.14 111.079 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.85 144.61 29.7 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.573 0.702 . . . . 73.31 110.898 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -15.32 37.02 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.686 2.257 . . . . 62.21 112.349 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.29 -6.46 48.12 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 31.04 111.117 179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 29.8 mm-40 -106.39 6.49 30.44 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.209 -0.45 . . . . 72.54 110.883 -179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -51.95 -76.55 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.184 -0.462 . . . . 70.54 111.07 179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.451 HG13 ' HB3' ' A' ' 37' ' ' TYR . 14.2 t -83.13 130.75 35.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.177 -0.465 . . . . 74.34 111.131 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 32.3 t -144.67 114.35 1.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.128 -0.487 . . . . 73.43 111.109 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -60.03 116.51 4.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.185 -0.461 . . . . 74.34 110.904 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.4 t -119.9 -38.74 2.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.189 -0.46 . . . . 63.43 111.136 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.91 173.61 18.82 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.764 -0.732 . . . . 24.35 112.539 179.946 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 114.04 3.57 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.726 2.284 . . . . 64.21 112.339 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 53.2 t30 67.78 34.96 4.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 74.33 110.898 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 4.4 pt20 -145.48 156.96 44.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.177 -0.465 . . . . 62.14 110.901 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.451 ' HB3' HG13 ' A' ' 29' ' ' VAL . 43.1 m-85 -143.16 141.27 31.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 74.55 110.955 -179.909 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.528 HG23 ' HE3' ' A' ' 64' ' ' LYS . 54.4 m -94.86 104.87 16.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.117 -0.492 . . . . 74.21 111.152 -179.979 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.466 HG11 HG23 ' A' ' 53' ' ' ILE . 15.7 t -87.35 152.62 3.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 51.24 111.097 179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 -127.2 140.25 52.37 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 64.11 110.913 -179.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.593 HG22 ' CG1' ' A' ' 53' ' ' ILE . 60.0 t -139.1 137.98 41.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.169 -0.469 . . . . 63.54 111.106 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.748 HD13 ' HB3' ' A' ' 22' ' ' TRP . 0.4 OUTLIER -138.42 141.49 39.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.163 -0.471 . . . . 73.3 110.873 179.92 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.58 101.18 2.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 73.1 111.104 179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 30.5 p90 -116.57 147.35 41.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 74.44 110.857 -179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.23 0.26 52.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.164 -0.471 . . . . 73.44 111.115 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -94.19 39.28 1.08 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.186 -0.461 . . . . 75.44 110.908 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 142.63 -137.93 8.08 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.74 -0.743 . . . . 64.51 112.526 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 31.1 t80 -155.24 160.6 40.96 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 120.802 0.334 . . . . 74.23 110.959 -179.828 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.8 mt-30 -165.23 162.18 14.07 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.581 0.705 . . . . 73.04 110.912 -179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 176.74 6.37 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.703 2.269 . . . . 72.14 112.348 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.639 ' C ' HD12 ' A' ' 53' ' ' ILE . 6.6 m120 -133.89 63.25 62.08 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.616 0.722 . . . . 53.51 110.85 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 72.1 1.48 Allowed 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.701 2.268 . . . . 74.4 112.372 179.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.722 HG21 HG13 ' A' ' 122' ' ' ILE . 4.9 mp -106.41 121.55 59.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.203 -0.453 . . . . 70.14 111.152 179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 13.1 tt0 -120.0 115.4 23.67 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 75.31 110.893 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.862 HG13 HG22 ' A' ' 124' ' ' VAL . 2.6 p -123.35 78.47 53.56 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.621 0.724 . . . . 54.42 111.15 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.721 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.73 123.02 9.7 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.704 2.27 . . . . 64.14 112.342 179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -68.61 154.72 41.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.267 -0.424 . . . . 61.14 110.875 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.1 -6.28 76.13 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.702 -0.761 . . . . 73.41 112.517 -179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.31 156.44 47.59 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.76 0.314 . . . . 72.03 111.072 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.742 ' O ' HD13 ' A' ' 61' ' ' ILE . 6.3 mt-10 -67.42 138.53 56.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 75.35 110.915 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.742 HD13 ' O ' ' A' ' 60' ' ' GLU . 4.4 mm -130.87 114.8 28.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.139 -0.482 . . . . 41.31 111.118 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.58 HG13 HG23 ' A' ' 92' ' ' THR . 39.5 t -101.23 94.29 3.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.217 -0.447 . . . . 75.35 111.123 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 79.6 m-85 -70.47 132.61 45.83 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.202 -0.453 . . . . 74.44 110.884 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.528 ' HE3' HG23 ' A' ' 38' ' ' THR . 36.2 mttt -128.74 99.74 5.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.122 -0.49 . . . . 75.23 110.914 179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.502 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.8 mp -104.22 158.63 5.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.182 -0.463 . . . . 72.22 111.159 179.863 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.414 ' N ' HG22 ' A' ' 65' ' ' ILE . 7.9 t -167.01 141.91 4.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.179 -0.464 . . . . 62.13 111.144 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.586 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -148.48 158.46 40.5 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.686 0.755 . . . . 62.51 110.852 -179.88 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.45 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.6 Cg_endo -69.8 -55.48 0.17 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.725 2.283 . . . . 74.12 112.31 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -154.91 68.39 0.7 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 70.12 110.852 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.586 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.2 -171.15 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.215 -0.448 . . . . 74.22 111.143 -179.992 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.509 HD13 ' O ' ' A' ' 70' ' ' VAL . 30.9 mm -138.11 140.49 40.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.17 -0.468 . . . . 71.14 111.126 179.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.502 ' CG ' HG21 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -115.23 -85.46 0.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.211 -0.45 . . . . 73.3 110.848 179.917 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 53.85 94.44 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.71 -0.757 . . . . 31.34 112.48 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 5.1 p90 -100.14 143.09 30.75 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.902 0.382 . . . . 70.13 110.868 -179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.1 t-80 -120.22 142.84 48.65 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.141 -0.481 . . . . 73.04 110.846 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.806 HG11 ' CZ ' ' A' ' 95' ' ' TYR . 4.9 p -127.78 122.83 59.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.151 -0.477 . . . . 71.34 111.112 179.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -52.16 160.85 0.7 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.168 -0.469 . . . . 74.04 110.897 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.15 -51.93 4.55 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.786 -0.721 . . . . 41.14 112.467 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -93.85 160.91 14.53 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.827 0.346 . . . . 73.24 111.132 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -101.03 35.49 2.2 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.176 -0.466 . . . . 71.24 110.924 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.635 HG21 HG12 ' A' ' 76' ' ' VAL . 20.0 tt -54.73 124.91 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 75.03 111.117 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -123.76 82.75 2.05 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 74.24 110.897 179.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.447 HG11 HG11 ' A' ' 93' ' ' VAL . 5.1 m -110.33 119.33 59.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.188 -0.46 . . . . 62.51 111.106 179.945 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -165.39 103.32 0.73 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.155 -0.475 . . . . 62.42 110.896 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 18.1 m -140.36 139.37 35.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.148 -0.478 . . . . 75.1 111.13 179.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 2.7 mp -59.88 163.39 7.63 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.583 0.706 . . . . 72.45 110.936 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 159.93 51.6 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.669 2.246 . . . . 50.43 112.343 179.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 88.5 17.38 57.1 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 71.31 112.469 179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -158.42 143.45 16.35 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 74.34 110.881 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.697 ' O ' HD13 ' A' ' 8' ' ' LEU . 52.3 t -81.42 146.12 7.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.136 -0.484 . . . . 74.13 111.115 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -103.82 158.08 16.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.227 -0.442 . . . . 73.44 110.891 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.58 HG23 HG13 ' A' ' 62' ' ' VAL . 26.6 m -147.28 123.23 10.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.147 -0.479 . . . . 75.33 111.164 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.447 HG11 HG11 ' A' ' 83' ' ' VAL . 9.4 p -153.15 136.17 7.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 116.23 -0.441 . . . . 51.33 111.126 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 2.0 mtm180 -96.33 81.46 3.29 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.173 -0.467 . . . . 75.02 110.84 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.806 ' CZ ' HG11 ' A' ' 76' ' ' VAL . 2.9 t80 -106.11 121.89 45.06 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.209 -0.451 . . . . 72.5 110.935 -179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 6.9 t -133.74 138.46 45.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.153 -0.476 . . . . 70.13 111.135 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.3 OUTLIER -99.43 -168.9 1.68 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.216 -0.447 . . . . 75.12 110.899 -179.99 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 5.5 mtpt -123.12 -27.12 4.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.191 -0.459 . . . . 70.42 110.917 179.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . 0.437 ' HB3' ' HD2' ' A' ' 100' ' ' PRO . 13.3 mmt180 -129.18 156.07 78.87 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.618 0.723 . . . . 73.04 110.916 179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . 0.437 ' HD2' ' HB3' ' A' ' 99' ' ' ARG . 54.0 Cg_endo -69.72 152.08 69.43 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.672 2.248 . . . . 52.33 112.329 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.7 150.49 6.84 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.758 -0.734 . . . . 70.34 112.485 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.691 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -112.63 127.74 56.19 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.885 0.374 . . . . 63.31 110.867 -179.879 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 7.7 p90 -143.93 136.46 26.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.139 -0.482 . . . . 72.51 110.911 -179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.914 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.1 OUTLIER -144.38 -167.29 2.59 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.119 -0.492 . . . . 74.23 110.885 -179.996 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.914 HG22 ' O ' ' A' ' 104' ' ' ARG . 0.6 OUTLIER 56.93 159.25 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 55.12 111.074 179.936 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.408 HG22 ' CD1' ' A' ' 119' ' ' PHE . 7.0 tt -104.66 134.81 45.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.13 -0.486 . . . . 75.22 111.121 179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 26.4 m -141.45 -42.3 0.37 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.184 -0.462 . . . . 64.34 110.858 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -106.64 126.03 51.76 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.166 -0.47 . . . . 63.14 110.914 -179.879 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -175.46 -51.74 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.171 -0.468 . . . . 73.52 110.916 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 2.4 t80 63.33 83.83 0.16 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 65.12 110.93 -179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -179.49 -34.97 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.143 -0.48 . . . . 61.24 110.869 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 178.2 33.01 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.728 -0.748 . . . . 35.2 112.49 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -70.27 -179.5 2.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.849 0.357 . . . . 63.31 110.935 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 91.7 -114.85 4.62 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.748 -0.739 . . . . 63.3 112.481 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 59.1 t-80 -68.11 -29.3 68.19 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.767 0.317 . . . . 73.25 110.881 -179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 2.1 mt-30 -106.7 -175.62 2.84 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 75.33 110.877 -179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER 63.88 104.63 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.167 -0.469 . . . . 71.2 110.883 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -70.96 174.59 5.99 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.183 -0.462 . . . . 42.45 110.865 179.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . 0.408 ' CD1' HG22 ' A' ' 106' ' ' ILE . 1.2 p90 -141.63 167.66 21.62 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 73.53 110.907 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -143.6 162.21 27.69 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.734 -0.746 . . . . 74.23 112.513 -179.96 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.568 ' O ' HD13 ' A' ' 53' ' ' ILE . 28.6 m -85.81 141.19 29.82 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.775 0.321 . . . . 73.34 111.161 -179.855 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.722 HG13 HG21 ' A' ' 53' ' ' ILE . 4.8 mp -147.88 109.19 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.229 -0.441 . . . . 73.35 111.112 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.691 HG23 ' HB3' ' A' ' 102' ' ' GLU . 8.6 p -114.97 140.65 35.07 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 75.24 111.091 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.862 HG22 HG13 ' A' ' 55' ' ' VAL . 68.9 t -104.16 118.49 51.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.149 -0.478 . . . . 74.51 111.125 179.906 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 5.1 mmmt -89.98 131.21 35.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 70.24 110.912 179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.222 -0.445 . . . . 72.23 110.906 179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.2 mtt . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.848 0.356 . . . . 73.3 110.91 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 40.0 t -85.85 73.16 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.222 -0.445 . . . . 51.54 111.119 179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.3 pt -140.62 78.0 21.9 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.588 0.708 . . . . 72.43 111.082 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.76 -178.14 2.21 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.679 2.253 . . . . 71.55 112.357 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.99 175.06 10.5 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.219 -0.446 . . . . 62.24 111.137 179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 93.13 -61.18 2.23 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.757 -0.735 . . . . 53.21 112.491 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -174.41 156.16 2.45 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.789 0.328 . . . . 72.12 110.922 -179.951 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.617 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.65 163.68 0.08 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.249 -0.432 . . . . 71.23 110.871 179.927 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.617 ' N ' HD12 ' A' ' 8' ' ' LEU . 0.5 OUTLIER -127.58 143.7 51.15 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.12 -0.491 . . . . 62.15 110.9 179.916 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.95 124.14 34.99 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.116 -0.493 . . . . 74.34 110.92 -179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 16' ' ' VAL . 13.9 m -111.4 -178.99 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.198 -0.456 . . . . 74.4 111.146 180.0 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -145.59 162.27 37.21 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.594 0.711 . . . . 72.02 110.887 179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 -4.03 13.19 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.688 2.258 . . . . 71.53 112.339 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.411 ' O ' HG23 ' A' ' 15' ' ' THR . 1.9 m -46.93 -65.2 0.6 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 71.43 111.166 -179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.411 HG23 ' O ' ' A' ' 14' ' ' THR . 2.0 p -155.63 32.54 0.36 Allowed 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.237 -0.438 . . . . 72.44 111.127 179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.44 HG21 HG21 ' A' ' 11' ' ' VAL . 13.9 p -70.96 -29.14 35.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.232 -0.44 . . . . 63.13 111.125 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 3.8 ptt-85 -97.55 -9.03 27.77 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.149 -0.478 . . . . 72.23 110.879 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 28.6 mm-40 -101.41 -31.9 10.7 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.479 . . . . 73.33 110.918 -179.963 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 15.0 tt0 -132.8 134.82 45.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 74.12 110.908 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 117.98 -158.56 14.62 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.782 -0.723 . . . . 73.2 112.542 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.446 ' HG2' ' CE3' ' A' ' 22' ' ' TRP . 53.8 Cg_endo -69.78 -28.81 24.68 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.693 2.262 . . . . 64.34 112.377 -179.943 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.446 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 18.5 m-90 -87.01 -5.67 59.0 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.208 -0.451 . . . . 75.31 110.921 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.5 -59.34 2.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.246 -0.434 . . . . 55.44 111.062 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -113.93 144.68 32.0 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.554 0.692 . . . . 65.2 110.891 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -5.02 15.23 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.683 2.256 . . . . 70.12 112.384 -179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.77 -19.0 61.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.183 -0.462 . . . . 74.33 111.128 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.24 31.16 6.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.155 -0.475 . . . . 74.21 110.929 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -65.2 -73.1 0.13 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.186 -0.461 . . . . 75.13 111.05 179.943 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.655 HG11 ' HB3' ' A' ' 54' ' ' GLU . 2.0 p -111.63 106.54 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.231 -0.441 . . . . 65.02 111.157 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.5 t -117.45 149.92 19.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 64.35 111.157 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 8.5 tp60 -79.64 124.21 28.34 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 73.24 110.94 179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 4.7 t -119.19 -14.83 9.25 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.156 -0.474 . . . . 52.11 111.136 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.42 -170.93 12.81 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.744 -0.741 . . . . 73.22 112.484 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 -36.02 11.42 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.679 2.252 . . . . 72.14 112.33 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 20.2 t30 -149.76 34.61 0.69 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.225 -0.443 . . . . 61.24 110.861 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 2.2 pt20 -137.33 117.44 13.44 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.177 -0.465 . . . . 73.4 110.91 179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 57.6 m-85 -98.24 143.13 29.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 74.23 110.918 -179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.408 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 51.9 m -99.05 102.21 13.84 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.143 -0.48 . . . . 73.33 111.158 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 16.4 t -83.53 143.15 12.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.23 -0.441 . . . . 75.52 111.117 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 30.1 m-85 -125.0 112.7 16.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.196 -0.456 . . . . 73.01 110.937 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.5 HG22 HD12 ' A' ' 53' ' ' ILE . 85.4 t -109.53 125.9 66.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.12 -0.491 . . . . 63.01 111.107 179.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.692 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.5 tm? -115.64 137.18 52.33 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 74.21 110.928 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.692 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.05 117.56 4.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.204 -0.453 . . . . 72.11 111.082 179.793 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 1.9 p90 -145.38 140.54 27.73 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 53.33 110.885 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.4 27.03 1.31 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.141 -0.481 . . . . 74.31 111.124 179.921 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 1.9 m-85 -120.92 25.26 9.77 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 73.43 110.886 -179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 169.32 -146.9 10.53 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.816 -0.707 . . . . 52.22 112.523 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -155.57 116.4 3.86 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.798 0.332 . . . . 74.32 110.914 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.457 ' HG3' ' HD2' ' A' ' 50' ' ' PRO . 2.1 mp0 -134.65 163.32 52.02 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.591 0.71 . . . . 75.14 110.919 179.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.457 ' HD2' ' HG3' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.79 162.15 43.19 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.64 2.226 . . . . 74.34 112.362 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 -124.29 64.34 36.81 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.586 0.708 . . . . 73.32 110.917 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.601 ' C ' HD13 ' A' ' 53' ' ' ILE . 54.3 Cg_endo -69.72 113.18 3.28 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.669 2.246 . . . . 74.54 112.375 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.601 HD13 ' C ' ' A' ' 52' ' ' PRO . 1.5 mm -126.13 144.99 34.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.239 -0.437 . . . . 71.22 111.161 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.655 ' HB3' HG11 ' A' ' 29' ' ' VAL . 24.0 tt0 -155.23 115.6 3.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 74.14 110.918 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 1.002 HG12 HG21 ' A' ' 61' ' ' ILE . 2.7 m -130.75 84.29 59.08 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.63 0.729 . . . . 73.34 111.127 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.703 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.77 122.62 9.3 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.66 2.24 . . . . 73.02 112.369 179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -65.7 154.56 38.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.248 -0.433 . . . . 53.45 110.9 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.62 -8.39 72.34 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.725 -0.75 . . . . 72.43 112.476 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.16 157.32 45.64 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.714 0.292 . . . . 51.1 111.142 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.728 ' O ' HD13 ' A' ' 61' ' ' ILE . 3.0 mt-10 -70.19 144.7 51.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.246 -0.434 . . . . 71.4 110.915 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 1.002 HG21 HG12 ' A' ' 55' ' ' VAL . 5.4 mm -128.79 105.35 12.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.153 -0.476 . . . . 52.54 111.112 -179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.622 HG13 HG23 ' A' ' 92' ' ' THR . 25.4 t -84.74 100.68 8.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.141 -0.481 . . . . 73.24 111.074 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.478 ' CZ ' HG11 ' A' ' 55' ' ' VAL . 96.0 m-85 -76.89 135.15 38.81 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 72.1 110.876 -179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.47 ' HD3' HG21 ' A' ' 90' ' ' VAL . 8.7 mttt -132.28 100.19 4.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.2 -0.454 . . . . 62.32 110.93 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.508 HG21 ' CG ' ' A' ' 72' ' ' HIS . 1.6 mp -109.08 141.11 25.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 55.42 111.115 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 7.8 t -155.92 135.3 12.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.198 -0.456 . . . . 72.13 111.135 179.951 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.44 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -141.96 161.1 53.02 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.7 0.762 . . . . 54.03 110.826 -179.867 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.419 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.0 Cg_endo -69.74 -53.34 0.28 Allowed 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.674 2.249 . . . . 51.4 112.365 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -156.67 57.82 0.55 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.207 -0.451 . . . . 71.14 110.823 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.44 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.49 141.43 8.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.254 -0.43 . . . . 75.13 111.126 179.972 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.426 HG22 ' N ' ' A' ' 72' ' ' HIS . 25.1 mm -85.35 155.18 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.199 -0.455 . . . . 71.53 111.093 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.508 ' CG ' HG21 ' A' ' 65' ' ' ILE . 0.2 OUTLIER -123.75 -86.28 0.64 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.121 -0.49 . . . . 71.12 110.857 179.872 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 54.04 101.6 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.259 0 C-N-CA 120.721 -0.752 . . . . 62.14 112.469 -179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.479 ' CE2' HD11 ' A' ' 65' ' ' ILE . 2.5 p90 -103.5 144.94 30.75 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.917 0.389 . . . . 74.34 110.854 -179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 2.3 p80 -106.0 142.25 36.02 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 71.33 110.884 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.747 ' HB ' HG21 ' A' ' 81' ' ' ILE . 44.3 t -137.53 143.6 33.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.219 -0.446 . . . . 52.23 111.131 179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -73.2 -175.7 1.94 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.147 -0.478 . . . . 64.11 110.912 -179.953 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 88.09 -51.09 3.98 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.75 -0.738 . . . . 52.12 112.493 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.442 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -142.14 179.5 6.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.828 0.347 . . . . 62.0 111.127 -179.862 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.442 ' H ' HG22 ' A' ' 79' ' ' THR . 6.8 t-20 -88.17 61.05 6.07 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 65.21 110.891 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.747 HG21 ' HB ' ' A' ' 76' ' ' VAL . 4.8 tp -71.16 99.72 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 73.11 111.13 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -110.4 112.11 23.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 72.24 110.919 179.903 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.808 HG11 HG21 ' A' ' 93' ' ' VAL . 1.5 m -130.82 122.93 53.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.196 -0.457 . . . . 72.52 111.161 179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -152.64 112.79 4.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.214 -0.448 . . . . 71.44 110.874 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.631 HG21 ' OG ' ' A' ' 91' ' ' SER . 57.3 t -140.55 144.28 27.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 60.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.7 mp -69.27 160.06 80.54 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.631 0.729 . . . . 71.33 110.899 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.424 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.4 Cg_endo -69.76 159.82 51.97 Favored 'Trans proline' 0 C--N 1.34 0.126 0 C-N-CA 122.708 2.272 . . . . 53.31 112.28 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 99.61 -1.27 56.92 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.736 -0.745 . . . . 74.34 112.465 179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -147.0 156.75 43.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.884 0.374 . . . . 74.45 110.891 -179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.546 HG12 ' O ' ' A' ' 9' ' ' GLU . 2.1 p -105.55 113.9 43.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 71.03 111.119 179.984 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.631 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -80.54 168.2 19.2 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.151 -0.477 . . . . 34.43 110.876 -179.87 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 0.622 HG23 HG13 ' A' ' 62' ' ' VAL . 96.5 m -134.5 139.35 45.4 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.166 -0.47 . . . . 65.34 111.129 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.808 HG21 HG11 ' A' ' 83' ' ' VAL . 9.9 t -143.45 137.63 25.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.236 -0.438 . . . . 71.01 111.128 179.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.04 72.63 0.79 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.469 . . . . 71.51 110.886 -179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -108.41 141.17 40.65 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.164 -0.471 . . . . 74.51 110.924 -179.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.1 t -140.06 143.19 36.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.137 -0.483 . . . . 63.21 111.162 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -101.1 177.18 5.01 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.25 -0.432 . . . . 70.35 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -121.34 -12.79 8.56 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.462 . . . . 71.54 110.877 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -144.57 162.03 41.01 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.653 0.74 . . . . 74.3 110.914 179.991 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 155.58 65.62 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.73 2.287 . . . . 62.25 112.314 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 162.27 135.37 1.8 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.773 -0.727 . . . . 74.32 112.53 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.841 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.6 OUTLIER -108.92 124.89 51.38 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.866 0.365 . . . . 74.14 110.901 -179.896 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -136.04 135.27 39.29 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.198 -0.456 . . . . 71.21 110.954 -179.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.95 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.5 OUTLIER -144.24 -177.56 5.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.128 -0.487 . . . . 60.11 110.858 -179.95 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.95 HG22 ' O ' ' A' ' 104' ' ' ARG . 6.6 tt 59.79 158.94 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.209 -0.451 . . . . 73.13 111.122 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -113.33 140.26 34.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.205 -0.452 . . . . 72.04 111.164 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -177.96 47.55 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.195 -0.457 . . . . 72.51 110.894 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -177.36 50.7 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.162 -0.472 . . . . 74.53 110.904 -179.914 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -174.12 177.57 2.29 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.191 -0.458 . . . . 65.33 110.882 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -114.43 121.18 42.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.455 . . . . 74.42 110.901 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -169.37 -40.99 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.117 -0.492 . . . . 50.12 110.88 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 166.39 -43.13 0.27 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.731 -0.747 . . . . 74.25 112.53 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.401 HD23 ' N ' ' A' ' 114' ' ' GLY . 0.4 OUTLIER 62.56 164.38 0.1 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.849 0.357 . . . . 64.53 110.905 -179.939 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.401 ' N ' HD23 ' A' ' 113' ' ' LEU . . . 52.59 -112.54 2.16 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.748 -0.739 . . . . 70.03 112.498 179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 52.8 p-80 -79.96 175.84 10.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.738 0.304 . . . . 75.41 110.893 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 69.14 -75.57 0.07 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.25 -0.432 . . . . 73.12 110.953 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 35.5 t30 -71.83 124.59 25.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.182 -0.463 . . . . 51.51 110.896 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.553 ' SD ' ' HB1' ' A' ' 43' ' ' ALA . 21.8 mmt -71.35 174.75 6.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.174 -0.466 . . . . 64.22 110.847 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 43.3 m-85 -90.89 152.77 20.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.237 -0.438 . . . . 71.12 110.899 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -101.08 73.42 0.38 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.698 -0.763 . . . . 74.15 112.484 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.557 ' C ' HD12 ' A' ' 122' ' ' ILE . 99.4 m -74.38 124.84 27.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.741 0.305 . . . . 63.42 111.138 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.576 HG13 HG21 ' A' ' 53' ' ' ILE . 3.1 mp -153.41 138.08 9.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.202 -0.454 . . . . 73.12 111.131 179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.841 HG23 ' HB3' ' A' ' 102' ' ' GLU . 11.5 p -134.22 134.69 55.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.156 -0.475 . . . . 71.12 111.151 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.742 HG22 HG23 ' A' ' 55' ' ' VAL . 48.1 t -103.61 129.13 56.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.207 -0.451 . . . . 73.41 111.152 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmt -107.19 129.1 54.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.134 -0.484 . . . . 63.31 110.885 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.187 -0.461 . . . . 64.51 110.878 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.863 0.363 . . . . 74.22 110.85 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.404 HG21 ' HB3' ' A' ' 12' ' ' ASP . 90.4 t -81.15 99.91 4.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.235 -0.439 . . . . 75.24 111.136 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 31.3 pt -95.78 153.81 39.24 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.665 0.745 . . . . 74.51 111.081 179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -178.73 2.48 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.624 2.216 . . . . 70.53 112.395 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -173.35 76.54 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.25 -0.432 . . . . 60.21 111.103 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 95.78 -18.7 56.93 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.693 -0.765 . . . . 63.25 112.477 -179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.15 -177.51 3.22 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.809 0.338 . . . . 74.1 110.913 -179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.591 HD13 ' O ' ' A' ' 90' ' ' VAL . 3.2 pp -60.76 -175.44 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.21 -0.45 . . . . 71.12 110.927 179.893 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.54 ' O ' HD12 ' A' ' 8' ' ' LEU . 4.0 mm-40 -64.89 123.16 18.69 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 73.1 110.877 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -105.67 139.26 40.53 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.168 -0.469 . . . . 74.04 110.874 -179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.8 m -130.1 -177.55 2.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.232 -0.44 . . . . 73.35 111.124 179.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.411 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 55.9 p-10 -144.07 155.47 58.6 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.563 0.697 . . . . 73.01 110.893 179.923 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.411 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.4 Cg_endo -69.84 -3.94 13.07 Favored 'Trans proline' 0 C--O 1.232 0.197 0 C-N-CA 122.656 2.237 . . . . 73.53 112.351 -179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.43 ' O ' HG23 ' A' ' 15' ' ' THR . 23.2 m -49.07 -64.7 0.73 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 44.23 111.092 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.43 HG23 ' O ' ' A' ' 14' ' ' THR . 2.7 p -156.04 34.91 0.34 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 62.21 111.15 -179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.6 p -70.59 -29.19 37.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.182 -0.463 . . . . 61.33 111.069 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.552 ' HB3' HD21 ' A' ' 42' ' ' LEU . 7.2 ptt-85 -98.74 -7.91 26.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.204 -0.453 . . . . 71.43 110.879 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 27.0 mm-40 -101.62 -34.79 9.36 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 73.15 110.927 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.51 133.2 46.07 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.188 -0.46 . . . . 73.53 110.891 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 120.25 -158.15 15.51 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.747 -0.74 . . . . 62.11 112.507 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 -30.11 22.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.73 2.287 . . . . 74.0 112.321 -179.966 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.416 ' HB3' HD23 ' A' ' 42' ' ' LEU . 13.5 m-90 -84.89 -10.21 57.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.279 -0.418 . . . . 74.1 110.921 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -71.85 -59.46 2.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 74.41 111.072 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -96.76 144.64 28.21 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.64 0.733 . . . . 72.33 110.815 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 -26.35 27.8 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.686 2.257 . . . . 75.32 112.335 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.02 -18.31 60.87 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.262 -0.426 . . . . 52.32 111.093 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 19.0 mm-40 -87.35 6.85 31.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.245 -0.434 . . . . 75.22 110.887 -179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -68.87 -77.04 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.266 -0.424 . . . . 62.55 111.084 179.929 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 21.5 t -78.54 116.95 23.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.207 -0.451 . . . . 71.34 111.131 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 12.0 t -145.77 131.06 12.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 71.5 111.167 179.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -69.59 125.47 26.8 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 72.23 110.877 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 3.2 t -117.46 -41.39 2.96 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.14 -0.482 . . . . 72.24 111.148 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.73 -164.11 18.68 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.758 -0.734 . . . . 73.35 112.482 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 -43.99 2.37 Favored 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.7 2.266 . . . . 41.51 112.372 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 66.9 t30 -141.27 34.45 1.69 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.225 -0.443 . . . . 73.31 110.908 179.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -131.4 119.71 22.03 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 71.31 110.847 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 38.5 m-85 -97.0 140.93 30.8 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.216 -0.447 . . . . 62.4 110.919 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.694 ' HA ' HG23 ' A' ' 62' ' ' VAL . 96.7 m -93.79 122.45 36.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 61.22 111.137 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.907 HG11 HG23 ' A' ' 53' ' ' ILE . 18.5 t -109.05 108.3 24.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.195 -0.457 . . . . 60.44 111.107 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.408 ' CZ ' HG21 ' A' ' 38' ' ' THR . 66.6 m-85 -94.18 105.45 17.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.208 -0.451 . . . . 73.21 110.924 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.602 HG22 ' CG1' ' A' ' 53' ' ' ILE . 59.8 t -98.73 132.65 43.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.082 -0.508 . . . . 71.44 111.167 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.643 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.6 tm? -123.85 133.82 53.71 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.226 -0.443 . . . . 74.13 110.91 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.643 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.06 132.01 10.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.186 -0.461 . . . . 74.41 111.083 179.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 13.6 p90 -145.26 147.54 32.49 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 72.41 110.912 -179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.17 0.74 50.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.179 -0.464 . . . . 71.51 111.133 179.903 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 6.3 m-85 -95.72 34.05 1.56 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.203 -0.453 . . . . 73.31 110.86 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 151.49 -138.56 6.61 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.75 -0.738 . . . . 65.05 112.505 -179.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -155.17 157.02 36.75 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.801 0.334 . . . . 65.41 110.957 -179.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.6 mt-30 -165.33 162.05 13.93 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.582 0.706 . . . . 73.31 110.938 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 178.64 4.34 Favored 'Trans proline' 0 C--N 1.341 0.167 0 C-N-CA 122.677 2.251 . . . . 75.11 112.37 179.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.63 ' C ' HD12 ' A' ' 53' ' ' ILE . 8.0 m-80 -138.41 63.46 34.78 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.602 0.715 . . . . 73.34 110.869 -179.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.69 73.1 1.36 Allowed 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.719 2.279 . . . . 65.4 112.361 179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.907 HG23 HG11 ' A' ' 39' ' ' VAL . 4.8 mp -106.73 136.44 41.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 71.13 111.13 179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 18.8 tt0 -133.13 118.05 18.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.169 -0.469 . . . . 63.21 110.891 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.719 ' O ' HG13 ' A' ' 124' ' ' VAL . 19.6 t -119.9 82.8 28.68 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.591 0.71 . . . . 73.11 111.146 179.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.688 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.73 122.06 8.75 Favored 'Trans proline' 0 N--CA 1.465 -0.173 0 C-N-CA 122.718 2.279 . . . . 72.34 112.358 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -69.79 153.03 43.9 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.218 -0.446 . . . . 43.24 110.914 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.27 -4.62 83.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.729 -0.748 . . . . 64.51 112.484 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.42 156.24 48.06 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.772 0.32 . . . . 62.01 111.112 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.726 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.8 mp0 -66.71 140.6 57.89 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.248 -0.433 . . . . 74.24 110.897 -179.937 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.726 HD13 ' O ' ' A' ' 60' ' ' GLU . 5.6 mm -130.23 115.01 30.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.134 -0.485 . . . . 72.43 111.116 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.694 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -103.0 90.95 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.17 -0.468 . . . . 71.1 111.161 179.84 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.663 ' HB2' HG12 ' A' ' 93' ' ' VAL . 72.2 m-85 -68.13 138.81 56.0 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.143 -0.481 . . . . 74.13 110.864 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.442 ' HD3' HG21 ' A' ' 90' ' ' VAL . 5.4 mttt -131.83 99.36 4.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.13 -0.486 . . . . 72.44 110.943 179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.5 mp -106.76 142.55 19.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.206 -0.452 . . . . 63.24 111.152 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.429 ' O ' HG23 ' A' ' 66' ' ' THR . 14.2 t -153.81 128.29 9.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.225 -0.443 . . . . 72.22 111.155 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.687 ' CB ' HG23 ' A' ' 70' ' ' VAL . 1.0 OUTLIER -131.33 160.23 68.08 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.677 0.751 . . . . 65.11 110.854 -179.847 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.533 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.7 Cg_endo -69.72 -53.2 0.28 Allowed 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.708 2.272 . . . . 62.11 112.343 179.963 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . 0.422 ' HA ' ' HG3' ' A' ' 87' ' ' PRO . 3.7 m-20 -155.94 72.08 0.76 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.198 -0.456 . . . . 73.23 110.888 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.687 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -158.9 133.41 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.172 -0.467 . . . . 65.41 111.16 179.984 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.706 HG22 ' H ' ' A' ' 72' ' ' HIS . 10.1 mm -91.73 172.53 0.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.19 -0.459 . . . . 62.32 111.105 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.706 ' H ' HG22 ' A' ' 71' ' ' ILE . 0.1 OUTLIER 76.28 148.86 0.1 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.124 -0.489 . . . . 73.32 110.896 179.915 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -121.12 -94.68 1.37 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.731 -0.747 . . . . 62.23 112.489 -179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.519 ' CG ' HD11 ' A' ' 122' ' ' ILE . 3.6 p90 -152.02 149.33 28.74 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.897 0.38 . . . . 73.11 110.871 -179.889 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -114.73 143.1 45.59 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 75.33 110.836 -179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.728 HG12 ' CG2' ' A' ' 81' ' ' ILE . 5.9 p -119.67 145.07 26.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.193 -0.458 . . . . 65.12 111.141 179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 33.1 mt-10 -75.3 172.55 12.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.176 -0.465 . . . . 73.04 110.886 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 79.51 -52.05 4.06 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.731 -0.747 . . . . 71.33 112.479 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 16.8 m -123.1 154.13 39.01 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.333 . . . . 64.31 111.139 -179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -88.41 65.87 8.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.22 -0.446 . . . . 60.52 110.903 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.728 ' CG2' HG12 ' A' ' 76' ' ' VAL . 0.7 OUTLIER -57.03 134.12 21.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.195 -0.457 . . . . 64.3 111.169 179.922 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.37 81.62 1.61 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.452 . . . . 75.3 110.87 179.965 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.454 ' O ' HG23 ' A' ' 83' ' ' VAL . 19.6 m -116.63 117.73 56.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.179 -0.464 . . . . 72.22 111.141 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -166.88 117.8 0.92 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 72.43 110.893 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 13.0 m -140.18 137.4 37.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 65.33 111.089 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -51.08 156.44 1.79 Allowed Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.576 0.703 . . . . 73.34 110.961 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.487 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.1 Cg_endo -69.83 159.21 54.21 Favored 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.671 2.247 . . . . 72.22 112.316 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 87.39 3.36 81.74 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.71 -0.757 . . . . 74.42 112.523 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . 0.419 ' HB3' HD11 ' A' ' 8' ' ' LEU . 26.6 mt-10 -148.59 117.56 6.75 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 72.01 110.876 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.591 ' O ' HD13 ' A' ' 8' ' ' LEU . 1.7 p -60.33 137.19 23.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 74.45 111.138 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -86.58 163.91 17.17 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.215 -0.448 . . . . 73.52 110.899 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 82.6 m -146.69 104.83 3.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.164 -0.471 . . . . 54.02 111.135 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.663 HG12 ' HB2' ' A' ' 63' ' ' PHE . 4.4 p -130.07 154.36 40.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.224 -0.444 . . . . 74.32 111.14 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -122.67 100.4 6.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.177 -0.465 . . . . 73.32 110.912 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.412 ' CD2' HD12 ' A' ' 81' ' ' ILE . 49.9 t80 -134.81 108.31 7.88 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.19 -0.459 . . . . 70.04 110.885 -179.789 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.8 t -103.94 135.54 45.27 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.128 -0.487 . . . . 75.53 111.184 179.973 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.474 ' HD2' HG21 ' A' ' 124' ' ' VAL . 0.1 OUTLIER -93.44 -177.57 4.46 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.435 . . . . 62.54 110.828 -179.942 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.7 mtmt -125.72 -22.03 4.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.146 -0.479 . . . . 62.04 110.897 179.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.14 158.92 72.75 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.587 0.708 . . . . 71.21 110.868 179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.78 152.89 69.3 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.696 2.264 . . . . 73.24 112.343 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 168.64 143.43 3.83 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.723 -0.751 . . . . 63.1 112.475 179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.693 ' HB3' HG23 ' A' ' 123' ' ' VAL . 0.3 OUTLIER -110.27 133.09 53.59 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.832 0.348 . . . . 44.32 110.92 -179.918 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . 0.477 ' CZ ' HG23 ' A' ' 76' ' ' VAL . 1.2 p90 -143.78 136.63 27.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.148 -0.478 . . . . 75.43 110.921 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.912 ' O ' HG22 ' A' ' 105' ' ' ILE . 0.0 OUTLIER -144.49 -167.82 2.74 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.117 -0.492 . . . . 63.3 110.894 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.912 HG22 ' O ' ' A' ' 104' ' ' ARG . 8.5 tt 56.64 159.32 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 52.11 111.118 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -116.47 142.64 29.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 63.22 111.112 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 5.8 p 179.53 -42.64 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.186 -0.461 . . . . 74.53 110.937 179.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -100.82 81.25 2.26 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.16 -0.473 . . . . 73.33 110.854 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 9.1 mm-40 -129.42 -76.11 0.55 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.213 -0.449 . . . . 72.43 110.927 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 9.4 t80 179.69 -47.34 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.216 -0.447 . . . . 74.3 110.893 -179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -92.58 97.71 10.99 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.136 -0.484 . . . . 75.14 110.881 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -45.98 105.22 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.728 -0.749 . . . . 72.32 112.514 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.685 HD23 ' ND2' ' A' ' 117' ' ' ASN . 13.6 tp -142.77 137.82 30.02 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.891 0.376 . . . . 74.52 110.917 -179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -122.59 -11.5 5.48 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.769 -0.729 . . . . 61.3 112.461 179.945 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 20.9 m80 -130.82 -169.4 2.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.705 0.288 . . . . 72.13 110.883 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER 67.85 -77.88 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 71.43 110.892 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . 0.685 ' ND2' HD23 ' A' ' 113' ' ' LEU . 28.1 p30 -57.32 -176.88 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 63.43 110.904 -179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -123.25 175.57 6.6 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.165 -0.47 . . . . 74.0 110.879 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -90.89 120.26 31.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.218 -0.446 . . . . 74.24 110.868 -179.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -77.18 170.35 55.08 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.731 -0.747 . . . . 60.54 112.537 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.658 ' O ' HD13 ' A' ' 53' ' ' ILE . 52.3 m -154.7 121.36 5.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.792 0.33 . . . . 65.11 111.2 -179.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.539 HD12 ' C ' ' A' ' 121' ' ' THR . 4.8 mp -146.82 139.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 61.0 111.098 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.693 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -134.81 135.08 53.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.126 -0.488 . . . . 71.32 111.174 179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.719 HG13 ' O ' ' A' ' 55' ' ' VAL . 57.4 t -102.65 123.94 56.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 43.14 111.147 179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 20.1 mmtt -98.29 134.25 41.57 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.134 -0.485 . . . . 72.34 110.918 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.285 -0.416 . . . . 71.53 110.892 179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.545 ' O ' HG23 ' A' ' 3' ' ' ILE . 14.0 mmt . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.788 0.328 . . . . 64.32 110.902 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.592 HG22 ' O ' ' A' ' 2' ' ' VAL . 12.1 p 41.51 37.01 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 70.4 111.15 179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.545 HG23 ' O ' ' A' ' 1' ' ' MET . 6.9 pt -112.53 78.6 2.75 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.622 0.725 . . . . 73.21 111.133 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.71 -178.81 2.5 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.71 2.273 . . . . 61.03 112.361 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -150.48 92.03 1.81 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.189 -0.459 . . . . 34.35 111.086 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 166.56 62.0 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.719 -0.753 . . . . 43.44 112.5 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 66.0 146.73 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.814 0.34 . . . . 63.24 110.877 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.596 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.1 164.56 0.08 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.201 -0.454 . . . . 73.13 110.895 179.917 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.596 ' N ' HD12 ' A' ' 8' ' ' LEU . 2.0 mt-10 -126.97 148.23 50.09 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.187 -0.46 . . . . 71.52 110.87 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.549 ' NH1' HD21 ' A' ' 8' ' ' LEU . 3.3 mpt_? -99.02 121.42 40.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.486 . . . . 63.11 110.87 -179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.436 HG21 ' OG1' ' A' ' 66' ' ' THR . 15.7 m -118.61 -179.33 1.54 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 63.33 111.16 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.99 162.16 39.22 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.688 0.756 . . . . 74.34 110.799 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.85 -2.96 11.12 Favored 'Trans proline' 0 C--N 1.342 0.223 0 C-N-CA 122.662 2.241 . . . . 73.55 112.349 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -44.86 -62.78 1.09 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.218 -0.446 . . . . 74.54 111.15 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -155.8 23.87 0.39 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.194 -0.457 . . . . 72.4 111.166 179.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.411 HG21 HG21 ' A' ' 11' ' ' VAL . 10.0 p -65.89 -30.98 51.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.199 -0.455 . . . . 72.52 111.098 179.922 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.676 ' CB ' HD11 ' A' ' 42' ' ' LEU . 0.2 OUTLIER -106.3 -6.93 18.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.207 -0.451 . . . . 73.33 110.886 -179.978 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 49.0 mt-30 -95.24 -36.44 11.44 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.19 -0.459 . . . . 72.11 110.894 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -140.94 132.28 26.7 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 75.01 110.85 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 128.91 -156.95 21.39 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 73.42 112.487 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.463 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.8 Cg_endo -69.76 -32.91 17.65 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.669 2.246 . . . . 70.21 112.356 -179.974 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.786 ' O ' HD12 ' A' ' 42' ' ' LEU . 10.5 m-90 -84.92 -17.87 36.43 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.22 -0.445 . . . . 75.44 110.951 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.45 -61.33 2.52 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.205 -0.452 . . . . 75.51 111.092 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.69 144.36 29.41 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.612 0.72 . . . . 73.42 110.828 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -11.37 30.69 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.692 2.262 . . . . 61.45 112.32 -179.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.69 -27.52 62.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.223 -0.444 . . . . 63.01 111.119 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.515 HE21 ' N ' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -111.04 31.84 5.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.184 -0.462 . . . . 74.34 110.862 -179.9 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -78.77 -41.82 29.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.241 -0.436 . . . . 43.11 111.1 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.701 HG21 ' CB ' ' A' ' 54' ' ' GLU . 60.3 t -114.64 130.33 69.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.185 -0.462 . . . . 65.42 111.113 179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -146.87 137.87 18.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.096 -0.502 . . . . 61.13 111.064 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -79.68 115.87 19.54 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.154 -0.476 . . . . 75.33 110.937 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -113.79 -21.06 10.88 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.216 -0.447 . . . . 73.12 111.142 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.27 -167.48 14.05 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 61.12 112.511 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -41.94 3.88 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.715 2.277 . . . . 75.32 112.363 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 60.7 t30 -148.42 29.73 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.21 -0.45 . . . . 71.44 110.876 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -126.95 116.32 20.61 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.2 -0.454 . . . . 75.32 110.891 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -95.75 140.33 30.7 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.189 -0.46 . . . . 71.44 110.966 -179.892 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.716 ' HA ' HG23 ' A' ' 62' ' ' VAL . 88.0 m -92.38 109.9 21.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.146 -0.479 . . . . 72.43 111.176 -179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.1 t -89.93 130.07 39.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.292 -0.413 . . . . 75.34 111.108 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 55.1 m-85 -113.98 105.13 12.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.185 -0.461 . . . . 74.23 110.956 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.554 HG12 HD12 ' A' ' 53' ' ' ILE . 25.0 m -100.15 147.01 8.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.145 -0.48 . . . . 74.42 111.158 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.786 HD12 ' O ' ' A' ' 22' ' ' TRP . 0.3 OUTLIER -133.67 133.16 41.56 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.245 -0.434 . . . . 65.31 110.948 179.961 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -155.78 98.72 1.94 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 63.44 111.083 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.507 ' HD1' HD22 ' A' ' 42' ' ' LEU . 52.5 p90 -123.85 143.03 50.59 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 74.32 110.855 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.86 0.17 53.75 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.123 -0.489 . . . . 74.41 111.114 179.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -97.2 66.33 2.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.193 -0.458 . . . . 73.1 110.871 -179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 124.28 -137.07 10.47 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.455 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.6 t80 -155.17 150.27 26.9 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.861 0.363 . . . . 72.2 110.924 -179.788 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -165.32 163.29 13.38 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.583 0.706 . . . . 72.44 110.925 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.81 176.08 7.28 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.618 2.212 . . . . 70.33 112.335 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.441 ' O ' HG12 ' A' ' 53' ' ' ILE . 4.1 m120 -129.86 62.72 65.3 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.623 0.725 . . . . 71.31 110.914 -179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.662 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.7 Cg_endo -69.73 111.15 2.72 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.678 2.252 . . . . 53.44 112.342 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.669 HG21 HG13 ' A' ' 122' ' ' ILE . 1.1 mm -130.66 151.58 36.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.228 -0.442 . . . . 71.53 111.095 179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.701 ' CB ' HG21 ' A' ' 29' ' ' VAL . 6.3 tt0 -156.06 115.77 3.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.159 -0.473 . . . . 60.32 110.866 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.678 ' O ' HG13 ' A' ' 124' ' ' VAL . 6.3 t -135.37 76.44 56.2 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.567 0.699 . . . . 61.33 111.139 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.638 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.2 Cg_endo -69.8 121.55 8.23 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.695 2.263 . . . . 65.42 112.329 179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -66.5 155.29 38.04 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.239 -0.437 . . . . 74.54 110.949 -179.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 90.56 -13.32 65.85 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.744 -0.741 . . . . 24.23 112.49 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.43 154.48 50.74 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.774 0.321 . . . . 63.35 111.077 179.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.693 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.1 mt-10 -64.69 136.08 56.57 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 75.25 110.906 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.693 HD13 ' O ' ' A' ' 60' ' ' GLU . 8.1 mm -127.25 96.21 3.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.168 -0.469 . . . . 75.12 111.11 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.716 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.2 OUTLIER -84.46 102.18 10.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 71.4 111.143 179.822 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -73.49 139.62 45.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 71.41 110.922 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 15.8 mttt -131.83 98.78 4.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.163 -0.472 . . . . 75.33 110.928 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.747 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.3 mp -97.56 157.29 3.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.203 -0.453 . . . . 73.02 111.147 179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.436 ' OG1' HG21 ' A' ' 11' ' ' VAL . 12.3 t -170.24 126.21 0.79 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.465 . . . . 42.25 111.164 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.661 ' HB3' HG22 ' A' ' 70' ' ' VAL . 3.6 m -127.44 161.99 51.4 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.656 0.741 . . . . 63.24 110.879 -179.851 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.82 -51.8 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.645 2.23 . . . . 74.1 112.334 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -155.52 29.52 0.38 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.248 -0.433 . . . . 63.44 110.809 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.661 HG22 ' HB3' ' A' ' 67' ' ' SER . 25.9 m -128.37 144.35 38.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 71.12 111.109 179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.535 HD13 ' HD3' ' A' ' 87' ' ' PRO . 24.1 mm -69.73 157.2 6.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.145 -0.479 . . . . 71.23 111.13 179.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.747 ' HB3' HG21 ' A' ' 65' ' ' ILE . 0.1 OUTLIER -114.7 -164.4 0.94 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.18 -0.464 . . . . 73.5 110.865 179.888 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 121.71 130.48 3.79 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.815 -0.707 . . . . 42.31 112.479 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.572 ' CE1' HG21 ' A' ' 83' ' ' VAL . 1.5 p90 -136.76 144.39 43.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.884 0.373 . . . . 74.14 110.91 -179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 36.8 t-80 -93.66 133.6 36.84 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.119 -0.492 . . . . 65.2 110.822 -179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.721 HG13 ' CE2' ' A' ' 103' ' ' TYR . 87.0 t -126.72 143.27 40.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.218 -0.446 . . . . 73.2 111.117 -179.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 32.0 mt-10 -75.52 177.01 7.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.448 . . . . 74.43 110.856 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.74 -51.59 4.57 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.716 -0.754 . . . . 61.21 112.489 -179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 12.1 m -140.64 154.12 46.3 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.797 0.332 . . . . 62.51 111.106 -179.869 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 7.4 t30 -76.6 64.58 2.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.19 -0.459 . . . . 73.3 110.88 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 11.3 tt -54.9 128.29 14.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.167 -0.469 . . . . 73.24 111.124 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -115.58 97.06 5.93 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 64.41 110.869 179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.572 HG21 ' CE1' ' A' ' 74' ' ' PHE . 3.5 m -125.48 120.44 57.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.158 -0.474 . . . . 42.4 111.075 179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 13.9 tt0 -154.33 115.72 4.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.149 -0.478 . . . . 74.53 110.832 -179.968 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.661 HG21 ' CB ' ' A' ' 91' ' ' SER . 94.1 t -139.28 146.53 25.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.132 -0.485 . . . . 73.42 111.16 179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.416 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -75.65 157.99 83.54 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.586 0.708 . . . . 73.44 110.923 -179.998 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.535 ' HD3' HD13 ' A' ' 71' ' ' ILE . 53.3 Cg_endo -69.78 153.8 68.43 Favored 'Trans proline' 0 C--N 1.341 0.142 0 C-N-CA 122.719 2.28 . . . . 74.31 112.321 179.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.69 7.06 59.19 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.752 -0.737 . . . . 74.03 112.496 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -156.75 141.94 17.3 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.873 0.368 . . . . 72.23 110.878 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 3.6 p -95.69 126.3 48.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 71.52 111.122 179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.661 ' CB ' HG21 ' A' ' 85' ' ' VAL . 0.8 OUTLIER -87.5 177.36 7.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.184 -0.462 . . . . 71.23 110.798 -179.829 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 98.8 m -144.82 105.48 4.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.1 -0.5 . . . . 63.44 111.139 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.509 HG11 HG11 ' A' ' 83' ' ' VAL . 9.8 p -134.82 137.8 50.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.209 -0.45 . . . . 74.42 111.109 179.869 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.3 ptt180 -113.27 139.9 48.43 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 75.25 110.887 -179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -166.06 94.8 0.57 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.245 -0.434 . . . . 75.13 110.955 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.0 t -84.33 143.76 29.29 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 74.43 111.113 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.12 -169.41 2.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.216 -0.447 . . . . 75.43 110.889 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 75.7 mttt -124.93 -28.26 3.5 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 62.53 110.897 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.17 158.87 70.21 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.605 0.717 . . . . 75.43 110.841 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 147.74 63.44 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.722 2.281 . . . . 74.44 112.342 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 169.27 153.58 8.53 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.752 -0.737 . . . . 43.35 112.484 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -116.74 132.2 56.75 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.826 0.346 . . . . 75.43 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . 0.721 ' CE2' HG13 ' A' ' 76' ' ' VAL . 2.4 p90 -143.83 141.18 30.22 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.128 -0.487 . . . . 65.01 110.9 -179.777 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -143.85 177.43 8.54 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.121 -0.491 . . . . 74.33 110.91 -179.972 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.468 HD13 ' HB3' ' A' ' 119' ' ' PHE . 20.3 mm 67.48 146.84 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.213 -0.449 . . . . 74.13 111.184 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.467 HD12 HD23 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -108.17 143.56 18.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 75.42 111.133 179.866 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 4.9 p -127.08 84.19 2.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.156 -0.475 . . . . 55.1 110.865 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 3.4 m120 72.3 -69.31 0.19 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.193 -0.458 . . . . 74.32 110.892 -179.9 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 59.91 20.33 9.31 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.184 -0.462 . . . . 72.41 110.909 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 1.2 m-30 62.67 82.3 0.18 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.17 -0.468 . . . . 73.35 110.91 -179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 179.63 -70.16 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.095 -0.502 . . . . 72.11 110.901 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 161.96 74.33 0.02 OUTLIER Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.741 -0.742 . . . . 55.45 112.507 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.478 ' C ' HD13 ' A' ' 113' ' ' LEU . 3.1 tm? -51.75 120.62 5.44 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.81 0.338 . . . . 72.55 110.97 -179.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 152.12 -117.33 0.81 Allowed Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.71 -0.757 . . . . 53.34 112.495 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 19.4 p80 -91.16 48.43 1.5 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.762 0.315 . . . . 73.23 110.878 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.8 tt0 -151.17 19.74 0.76 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.2 -0.455 . . . . 64.15 110.916 -179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 4.6 p30 -179.9 -176.36 0.34 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.205 -0.452 . . . . 71.31 110.935 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -142.8 175.06 10.11 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.197 -0.456 . . . . 75.42 110.876 179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . 0.468 ' HB3' HD13 ' A' ' 105' ' ' ILE . 11.4 m-85 -91.06 123.37 34.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 74.2 110.873 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -123.22 124.11 5.52 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.716 -0.754 . . . . 32.24 112.494 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.665 HG23 HG13 ' A' ' 53' ' ' ILE . 12.5 t -86.47 154.24 21.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.793 0.33 . . . . 70.54 111.114 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.669 HG13 HG21 ' A' ' 53' ' ' ILE . 2.9 mp -153.79 137.33 8.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.205 -0.452 . . . . 73.32 111.126 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 6.5 p -127.55 139.03 53.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 52.34 111.094 179.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.678 HG13 ' O ' ' A' ' 55' ' ' VAL . 49.1 t -109.27 117.17 53.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.2 -0.454 . . . . 73.52 111.162 179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -86.98 138.76 31.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.462 . . . . 74.14 110.888 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.447 . . . . 65.34 110.911 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 14.7 ptm . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.851 0.358 . . . . 70.04 110.899 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 32.8 m -88.93 137.21 21.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.212 -0.449 . . . . 44.22 111.136 179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 7.9 pt -153.03 78.45 5.94 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.615 0.721 . . . . 53.42 111.131 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -177.49 1.89 Allowed 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.688 2.259 . . . . 61.24 112.396 179.851 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -147.94 60.11 1.12 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.234 -0.439 . . . . 72.41 111.085 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -146.47 -78.83 0.03 OUTLIER Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.756 -0.735 . . . . 74.1 112.465 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.06 127.92 55.92 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.86 0.362 . . . . 62.41 110.887 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 48.29 -168.76 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.236 -0.438 . . . . 75.42 110.894 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -123.02 131.91 53.91 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.158 -0.474 . . . . 73.44 110.91 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 6.2 mpt_? -96.04 145.18 25.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.112 -0.494 . . . . 70.13 110.853 -179.903 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.1 m -136.64 -178.58 2.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.175 -0.466 . . . . 62.43 111.14 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -144.13 161.98 42.51 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.641 0.734 . . . . 75.41 110.876 179.883 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 -3.5 12.14 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.692 2.261 . . . . 63.31 112.362 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.821 HG22 HG23 ' A' ' 15' ' ' THR . 25.8 m -44.96 -70.21 0.11 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.219 -0.446 . . . . 42.42 111.165 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.821 HG23 HG22 ' A' ' 14' ' ' THR . 25.6 p -149.59 24.1 0.88 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 64.31 111.152 -179.976 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 10.6 p -62.85 -26.08 39.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.225 -0.443 . . . . 55.12 111.118 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -106.07 -17.21 14.4 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 70.05 110.865 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 20.0 mm-40 -83.91 -35.9 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.18 -0.464 . . . . 64.4 110.923 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 -142.38 140.82 32.18 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.204 -0.453 . . . . 73.43 110.895 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 123.24 -158.53 17.86 Favored Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.732 -0.747 . . . . 64.24 112.476 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -69.72 -30.97 21.63 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.72 2.28 . . . . 72.33 112.398 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 12.2 m-90 -84.6 -13.91 50.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.186 -0.461 . . . . 75.43 110.942 179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.88 -59.42 3.88 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.208 -0.451 . . . . 63.34 111.105 179.845 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -102.01 147.63 34.2 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.565 0.698 . . . . 64.34 110.876 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 -26.67 27.39 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.667 2.244 . . . . 72.25 112.361 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -80.14 -1.12 38.85 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.196 -0.456 . . . . 72.41 111.069 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 42.8 mm-40 -105.27 5.07 31.71 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.235 -0.438 . . . . 52.34 110.953 -179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -73.3 -74.32 0.18 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.181 -0.463 . . . . 73.45 111.099 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 1.066 HG22 HG12 ' A' ' 39' ' ' VAL . 48.0 t -71.91 126.78 33.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.242 -0.436 . . . . 71.0 111.127 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.45 ' O ' HG23 ' A' ' 30' ' ' VAL . 19.0 m -150.34 127.01 2.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 73.03 111.13 179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 1.2 tp60 -76.28 114.44 14.97 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.459 . . . . 52.43 110.926 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.2 t -120.05 -13.17 9.01 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.263 -0.426 . . . . 71.32 111.116 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.36 -173.25 13.78 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.753 -0.737 . . . . 62.11 112.514 179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -36.72 10.34 Favored 'Trans proline' 0 C--N 1.341 0.169 0 C-N-CA 122.682 2.255 . . . . 73.35 112.336 -179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -150.86 34.35 0.6 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 72.1 110.863 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -134.55 117.8 16.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.186 -0.461 . . . . 71.54 110.945 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 22.0 m-85 -98.58 134.33 41.68 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 75.02 110.947 -179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.783 ' HA ' HG23 ' A' ' 62' ' ' VAL . 56.7 m -95.07 115.04 26.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.482 . . . . 74.34 111.136 -179.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 1.066 HG12 HG22 ' A' ' 29' ' ' VAL . 34.6 m -110.33 126.62 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.454 . . . . 75.13 111.131 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 84.8 m-85 -103.13 113.78 27.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.198 -0.455 . . . . 75.12 110.859 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.517 HG12 ' CG1' ' A' ' 53' ' ' ILE . 15.8 m -97.5 131.4 44.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.11 -0.496 . . . . 71.4 111.126 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.736 HD11 ' CD2' ' A' ' 44' ' ' PHE . 3.2 tm? -120.19 135.66 54.9 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.212 -0.449 . . . . 71.11 110.89 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.527 ' H ' HD22 ' A' ' 42' ' ' LEU . . . -156.44 113.98 3.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.14 -0.482 . . . . 73.12 111.065 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.736 ' CD2' HD11 ' A' ' 42' ' ' LEU . 7.0 p90 -128.5 151.08 49.83 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 73.11 110.889 -179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.47 1.44 48.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.203 -0.453 . . . . 75.23 111.074 179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -92.15 75.65 5.4 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.261 -0.427 . . . . 73.41 110.852 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 101.46 -127.75 9.34 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.756 -0.735 . . . . 73.12 112.499 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.0 m-85 -141.67 162.34 35.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.824 0.345 . . . . 74.4 110.909 -179.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.405 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 1.8 pm0 -161.07 155.93 20.24 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.591 0.71 . . . . 73.34 110.93 179.993 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.405 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.7 Cg_endo -69.74 -176.23 1.41 Allowed 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.675 2.25 . . . . 63.23 112.337 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.656 ' O ' HD12 ' A' ' 53' ' ' ILE . 4.1 m120 -130.28 60.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.605 0.717 . . . . 64.24 110.881 179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 73.94 1.32 Allowed 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.675 2.25 . . . . 61.24 112.35 179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.656 HD12 ' O ' ' A' ' 51' ' ' ASN . 2.9 mp -125.84 132.39 70.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.221 -0.445 . . . . 73.23 111.146 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -131.62 156.69 45.37 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.198 -0.455 . . . . 61.13 110.906 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.836 HG13 HG22 ' A' ' 124' ' ' VAL . 2.9 p -157.47 77.88 3.72 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.619 0.723 . . . . 70.21 111.148 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.769 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.76 121.46 8.15 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.696 2.264 . . . . 73.23 112.356 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -68.26 154.24 42.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.23 -0.441 . . . . 65.24 110.924 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.94 -10.16 69.34 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.76 -0.733 . . . . 73.11 112.493 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -133.5 159.9 39.01 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.773 0.32 . . . . 60.43 111.106 179.96 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.63 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.8 mp0 -72.57 141.34 48.42 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.211 -0.45 . . . . 73.43 110.895 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.769 HD12 ' HD2' ' A' ' 56' ' ' PRO . 3.8 mm -125.96 119.48 54.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.169 -0.469 . . . . 71.32 111.124 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.783 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.0 OUTLIER -110.19 90.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.149 -0.478 . . . . 55.13 111.087 179.905 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.505 ' CD2' HG21 ' A' ' 39' ' ' VAL . 38.7 m-85 -74.81 144.18 43.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.173 -0.467 . . . . 72.31 110.872 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.402 ' HD3' HG11 ' A' ' 90' ' ' VAL . 0.1 OUTLIER -127.41 100.81 6.19 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 73.15 110.908 179.956 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . . . . . . . . . 1.9 mt -94.23 147.3 5.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.214 -0.448 . . . . 74.32 111.125 179.866 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.8 t -166.12 136.93 3.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.194 -0.457 . . . . 71.12 111.146 179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.457 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -146.34 160.61 41.73 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 121.698 0.761 . . . . 74.05 110.835 -179.883 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.403 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.6 Cg_endo -69.79 -54.87 0.2 Allowed 'Trans proline' 0 C--N 1.342 0.2 0 C-N-CA 122.674 2.249 . . . . 72.45 112.353 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -156.88 61.43 0.52 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 73.21 110.854 179.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.457 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.16 135.9 3.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.183 -0.462 . . . . 53.15 111.112 179.98 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 43.0 mm -73.61 145.17 11.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.136 -0.484 . . . . 75.21 111.142 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -126.56 -168.57 1.88 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 64.35 110.876 179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 133.31 115.21 1.59 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.703 -0.761 . . . . 63.44 112.475 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . . . . . . . . . 3.9 p90 -111.03 142.71 42.81 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.842 0.354 . . . . 72.12 110.879 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.602 ' N ' HE22 ' A' ' 109' ' ' GLN . 6.9 p80 -115.17 142.63 46.41 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.146 -0.479 . . . . 74.55 110.816 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 16.6 t -133.68 147.66 30.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.15 -0.477 . . . . 72.1 111.126 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 31.7 mt-10 -70.01 -178.65 1.65 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.148 -0.478 . . . . 64.01 110.907 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 85.53 -51.17 4.45 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.721 -0.752 . . . . 71.43 112.5 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 18.1 m -136.89 153.86 50.64 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.789 0.328 . . . . 75.02 111.16 -179.888 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.4 p-10 -77.39 60.44 2.03 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.194 -0.457 . . . . 70.53 110.9 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.467 ' O ' HG23 ' A' ' 81' ' ' ILE . 7.2 tt -69.58 115.26 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.166 -0.47 . . . . 71.34 111.123 179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -115.78 104.25 11.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.143 -0.48 . . . . 74.03 110.883 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.452 HG11 ' CG2' ' A' ' 93' ' ' VAL . 3.6 m -125.79 120.14 56.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.141 -0.481 . . . . 60.44 111.139 179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 1.5 pp20? -157.23 117.23 3.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.137 -0.483 . . . . 72.24 110.867 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -140.35 146.54 24.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.47 . . . . 62.1 111.113 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.402 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -64.21 158.49 64.06 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.619 0.723 . . . . 73.3 110.922 179.966 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.402 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 54.0 Cg_endo -69.77 152.86 69.37 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.652 2.235 . . . . 71.52 112.332 179.877 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.62 11.46 63.97 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.757 -0.735 . . . . 64.02 112.463 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -145.83 118.17 8.44 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.893 0.378 . . . . 74.44 110.952 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.402 HG11 ' HD3' ' A' ' 64' ' ' LYS . 39.2 t -63.43 105.59 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.192 -0.458 . . . . 63.25 111.173 179.979 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 66.0 p -91.98 114.33 26.84 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.196 -0.456 . . . . 51.11 110.867 -179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 1.3 t -81.83 145.99 30.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.181 -0.463 . . . . 61.43 111.17 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.452 ' CG2' HG11 ' A' ' 83' ' ' VAL . 87.2 t -139.94 117.85 10.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.241 -0.436 . . . . 71.34 111.107 179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 5.0 mmm180 -102.8 107.91 18.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.207 -0.451 . . . . 73.34 110.894 -179.982 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -155.95 141.38 17.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.189 -0.46 . . . . 61.25 110.938 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 13.5 t -135.14 143.63 46.64 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.16 -0.473 . . . . 74.43 111.102 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -95.56 -175.5 3.48 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.213 -0.448 . . . . 62.01 110.88 179.981 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -123.06 -12.27 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.116 -0.493 . . . . 73.15 110.876 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -151.83 161.93 28.09 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-O 121.646 0.736 . . . . 70.4 110.835 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 156.7 62.68 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 64.55 112.316 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.0 132.51 1.37 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.771 -0.728 . . . . 64.32 112.51 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -101.79 132.84 47.31 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.889 0.376 . . . . 62.44 110.918 -179.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 2.0 p90 -143.8 129.61 19.35 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.123 -0.49 . . . . 63.3 110.913 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.0 95.3 2.67 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.097 -0.501 . . . . 71.52 110.843 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 3.5 tt -178.19 143.77 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.219 -0.446 . . . . 73.11 111.118 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -118.1 144.59 25.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.159 -0.473 . . . . 64.02 111.106 179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . . . . . . . . . 55.3 m -114.42 -75.81 0.59 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.169 -0.468 . . . . 62.43 110.889 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 4.5 m-20 -134.38 -39.46 0.82 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.209 -0.45 . . . . 74.43 110.929 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . 0.602 HE22 ' N ' ' A' ' 75' ' ' HIS . 5.8 mm100 71.32 -70.02 0.17 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.141 -0.481 . . . . 73.44 110.923 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 73.6 t80 -152.68 -74.38 0.14 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.177 -0.465 . . . . 52.23 110.958 -179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.8 t -52.51 -35.35 52.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.056 -0.52 . . . . 55.21 110.879 -179.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 109.91 59.63 0.51 Allowed Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.763 -0.732 . . . . 71.34 112.487 -179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.611 HD12 ' HB2' ' A' ' 117' ' ' ASN . 11.2 tp 57.5 95.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.889 0.376 . . . . 62.42 110.917 -179.911 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -60.15 -169.61 0.44 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.714 -0.755 . . . . 73.44 112.479 179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 73.6 t60 -55.95 -25.65 44.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.725 0.298 . . . . 73.12 110.858 -179.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -133.4 -68.9 0.56 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.204 -0.453 . . . . 75.42 110.938 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . 0.611 ' HB2' HD12 ' A' ' 113' ' ' LEU . 0.1 OUTLIER 61.99 102.54 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.178 -0.464 . . . . 74.55 110.86 -179.986 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -71.44 174.33 6.72 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.204 -0.453 . . . . 52.24 110.868 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 46.3 m-85 -91.78 121.97 33.9 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.198 -0.455 . . . . 73.32 110.9 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.416 ' C ' HD12 ' A' ' 122' ' ' ILE . . . -69.3 84.86 0.24 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.725 -0.75 . . . . 72.32 112.495 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.633 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.4 m -75.21 117.73 17.35 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.768 0.318 . . . . 55.04 111.161 -179.875 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.579 HG13 HG21 ' A' ' 53' ' ' ILE . 3.7 mp -147.55 140.17 18.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.196 -0.456 . . . . 75.42 111.12 179.936 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.478 ' O ' HG12 ' A' ' 55' ' ' VAL . 5.6 m -134.46 138.33 49.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.177 -0.465 . . . . 71.41 111.099 179.831 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.836 HG22 HG13 ' A' ' 55' ' ' VAL . 44.0 t -104.05 125.15 58.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.185 -0.461 . . . . 72.22 111.116 179.923 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 31.2 mmtt -107.19 133.83 51.19 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 65.54 110.91 179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 . . . . . 0 C--N 1.329 -0.304 0 CA-C-N 116.242 -0.435 . . . . 72.43 110.865 179.952 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.454 ' O ' HG23 ' A' ' 3' ' ' ILE . 4.2 mmt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.832 0.349 . . . . 41.44 110.876 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 35.5 m 40.14 44.51 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.224 -0.444 . . . . 61.01 111.115 179.953 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.454 HG23 ' O ' ' A' ' 1' ' ' MET . 8.0 pt -109.92 81.33 2.02 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.596 0.713 . . . . 75.42 111.108 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -173.22 0.68 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.645 2.23 . . . . 74.05 112.391 179.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.56 144.47 31.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.237 -0.438 . . . . 54.52 111.093 179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 63.53 95.83 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.702 -0.761 . . . . 72.12 112.521 -179.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 63.29 164.29 0.11 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.838 0.352 . . . . 73.35 110.915 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.3 tp 65.86 121.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.214 -0.448 . . . . 70.54 110.938 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -121.16 117.1 26.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.201 -0.454 . . . . 52.41 110.856 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -84.3 144.33 28.94 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.119 -0.492 . . . . 74.21 110.892 -179.916 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.435 ' HB ' HG21 ' A' ' 16' ' ' VAL . 13.3 m -134.24 -177.37 2.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.227 -0.442 . . . . 72.1 111.111 179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.463 ' HB2' ' HD2' ' A' ' 13' ' ' PRO . 21.4 p30 -143.77 157.72 57.75 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.586 0.708 . . . . 74.42 110.855 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.463 ' HD2' ' HB2' ' A' ' 12' ' ' ASP . 53.7 Cg_endo -69.75 -2.8 10.79 Favored 'Trans proline' 0 C--O 1.232 0.188 0 C-N-CA 122.665 2.243 . . . . 75.14 112.313 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.606 HG22 HG23 ' A' ' 15' ' ' THR . 9.7 m -48.26 -67.72 0.25 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 74.33 111.147 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.606 HG23 HG22 ' A' ' 14' ' ' THR . 38.4 p -151.0 30.24 0.64 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.209 -0.45 . . . . 72.42 111.131 -179.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.435 HG21 ' HB ' ' A' ' 11' ' ' VAL . 4.9 p -78.83 -24.96 13.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.24 -0.436 . . . . 72.53 111.113 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.505 ' HB3' HD11 ' A' ' 42' ' ' LEU . 0.9 OUTLIER -98.65 -18.23 18.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.189 -0.46 . . . . 75.42 110.892 -179.978 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 62.9 mm-40 -100.92 -31.42 11.14 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.144 -0.48 . . . . 63.33 110.896 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 7.6 tt0 -129.28 138.68 51.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.203 -0.453 . . . . 73.41 110.874 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 116.68 -161.78 12.91 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.722 -0.751 . . . . 41.24 112.494 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.8 -27.77 25.87 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.659 2.239 . . . . 70.03 112.375 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.449 ' HB3' HD23 ' A' ' 42' ' ' LEU . 13.5 m-90 -84.45 -17.48 39.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.228 -0.442 . . . . 75.54 110.916 179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -62.64 -59.8 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 53.45 111.124 179.864 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -105.45 143.0 25.91 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.605 0.717 . . . . 60.32 110.86 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 -14.99 37.04 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.697 2.265 . . . . 62.51 112.353 -179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.91 -6.58 48.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 75.2 111.131 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 34.1 mm-40 -108.26 5.8 26.01 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 64.03 110.965 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -50.76 -78.93 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.213 -0.449 . . . . 71.12 111.123 179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 9.0 t -81.92 125.88 39.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.216 -0.447 . . . . 61.04 111.113 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.45 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 25.1 m -141.66 142.62 28.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.154 -0.476 . . . . 55.25 111.154 179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -82.31 110.52 17.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.194 -0.457 . . . . 70.43 110.928 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 1.7 t -108.89 -41.3 4.78 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.191 -0.459 . . . . 74.3 111.138 -179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.9 175.61 19.04 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.731 -0.747 . . . . 62.12 112.47 179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 116.53 4.6 Favored 'Trans proline' 0 N--CA 1.465 -0.17 0 C-N-CA 122.727 2.285 . . . . 74.11 112.34 -179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 8.3 t-20 66.97 35.31 4.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.215 -0.448 . . . . 73.44 110.866 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -147.87 152.6 37.88 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.218 -0.446 . . . . 74.35 110.941 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -141.72 140.96 33.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.222 -0.445 . . . . 65.3 110.957 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.79 ' HA ' HG23 ' A' ' 62' ' ' VAL . 28.8 m -90.95 117.55 29.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.472 . . . . 74.04 111.18 179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 t -100.35 107.4 20.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 71.01 111.14 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.465 ' CZ ' HG21 ' A' ' 38' ' ' THR . 70.7 m-85 -88.45 127.38 35.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.189 -0.46 . . . . 73.52 110.913 -179.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.836 HG22 HD12 ' A' ' 53' ' ' ILE . 77.0 t -119.82 108.04 22.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.109 -0.496 . . . . 75.05 111.119 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.505 HD11 ' HB3' ' A' ' 17' ' ' ARG . 0.7 OUTLIER -101.5 126.57 48.31 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 65.11 110.904 -179.991 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -152.87 128.44 10.04 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.234 -0.439 . . . . 53.02 111.145 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -145.78 147.01 31.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.233 -0.44 . . . . 74.31 110.9 -179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.92 5.77 31.47 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 74.44 111.088 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.3 m-85 -104.63 54.84 0.72 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.184 -0.462 . . . . 61.03 110.876 -179.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 131.67 -139.16 10.71 Favored Glycine 0 N--CA 1.452 -0.258 0 C-N-CA 120.697 -0.763 . . . . 53.02 112.445 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -154.98 151.46 28.52 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.854 0.359 . . . . 73.41 110.926 -179.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -165.68 162.98 12.99 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.576 0.703 . . . . 60.03 110.901 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 154.04 68.2 Favored 'Trans proline' 0 C--N 1.341 0.133 0 C-N-CA 122.697 2.264 . . . . 72.42 112.332 -179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 7.2 m120 -128.22 66.4 72.67 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.574 0.702 . . . . 73.44 110.921 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.626 ' O ' HD13 ' A' ' 53' ' ' ILE . 54.3 Cg_endo -69.72 115.21 3.98 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.707 2.271 . . . . 52.35 112.374 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.836 HD12 HG22 ' A' ' 41' ' ' VAL . 2.6 mm -125.82 146.47 31.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.231 -0.44 . . . . 73.42 111.1 179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . . . . . . . . . 15.2 tt0 -155.1 118.03 4.36 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 71.22 110.885 179.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.83 HG23 HG13 ' A' ' 61' ' ' ILE . 2.1 p -132.72 85.32 47.52 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.669 0.747 . . . . 44.12 111.123 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.66 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.4 Cg_endo -69.84 123.13 9.78 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.625 2.217 . . . . 73.21 112.363 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.35 145.98 55.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 74.53 110.865 -179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 92.41 -28.31 9.22 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.758 -0.734 . . . . 74.2 112.51 -179.965 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.6 156.86 17.84 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.74 0.305 . . . . 72.32 111.103 179.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.729 ' O ' HD13 ' A' ' 61' ' ' ILE . 2.2 mt-10 -66.4 142.13 57.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 64.25 110.916 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.83 HG13 HG23 ' A' ' 55' ' ' VAL . 4.7 mm -131.89 119.95 42.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.163 -0.471 . . . . 73.31 111.145 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.79 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.3 OUTLIER -114.01 89.44 1.31 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 54.43 111.142 179.847 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 48.2 m-85 -66.61 137.18 56.55 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.127 -0.488 . . . . 65.44 110.92 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . 0.566 ' HD3' HG11 ' A' ' 90' ' ' VAL . 8.6 mttm -133.77 100.65 4.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.185 -0.461 . . . . 64.1 110.898 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.582 HD11 ' CE2' ' A' ' 74' ' ' PHE . 2.6 mp -102.17 157.86 4.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.222 -0.444 . . . . 74.53 111.119 179.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.415 ' N ' HG22 ' A' ' 65' ' ' ILE . 6.7 t -165.48 142.19 5.54 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.16 -0.473 . . . . 64.41 111.163 179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.457 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -151.27 162.18 27.54 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.657 0.741 . . . . 74.12 110.862 -179.87 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HD3' ' CZ ' ' A' ' 17' ' ' ARG . 53.8 Cg_endo -69.76 -55.68 0.17 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.729 2.286 . . . . 72.54 112.348 179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -155.93 60.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.191 -0.458 . . . . 74.13 110.832 179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.457 HG23 ' CB ' ' A' ' 67' ' ' SER . 0.0 OUTLIER -156.05 134.99 3.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.172 -0.467 . . . . 70.42 111.132 179.986 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 39.8 mm -64.8 145.06 14.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.142 -0.481 . . . . 70.15 111.118 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.574 ' HB2' HG21 ' A' ' 65' ' ' ILE . 6.8 p80 -140.79 115.49 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.156 -0.474 . . . . 71.43 110.848 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -156.26 132.58 3.37 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.775 -0.726 . . . . 60.43 112.496 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.582 ' CE2' HD11 ' A' ' 65' ' ' ILE . 1.9 p90 -117.15 142.64 46.76 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.829 0.347 . . . . 74.13 110.866 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.6 t-80 -126.05 105.17 8.69 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.13 -0.487 . . . . 74.32 110.882 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.458 HG12 HG21 ' A' ' 81' ' ' ILE . 4.9 p -97.06 144.95 9.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 43.13 111.102 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.8 pm0 -61.16 -175.44 0.05 OUTLIER 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.179 -0.464 . . . . 71.0 110.92 179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 90.36 -51.08 3.35 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.702 -0.761 . . . . 71.21 112.514 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.425 HG22 ' N ' ' A' ' 80' ' ' ASN . 7.4 m -140.18 158.85 43.39 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.791 0.329 . . . . 71.12 111.182 -179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.425 ' N ' HG22 ' A' ' 79' ' ' THR . 3.5 m120 -76.17 60.67 1.5 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.245 -0.434 . . . . 73.03 110.892 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.518 ' O ' HG23 ' A' ' 81' ' ' ILE . 13.4 tt -72.4 110.08 5.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 73.22 111.104 179.956 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -115.12 97.88 6.46 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.167 -0.47 . . . . 51.4 110.88 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.48 HG11 HG21 ' A' ' 93' ' ' VAL . 2.6 m -118.23 119.9 62.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.176 -0.466 . . . . 74.03 111.11 179.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 4.4 mm-40 -150.71 115.52 5.25 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 74.51 110.894 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.714 HG11 ' HB2' ' A' ' 91' ' ' SER . 7.3 p -140.67 146.52 24.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.149 -0.478 . . . . 72.01 111.094 179.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 4.2 mp -69.71 160.04 81.44 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.647 0.737 . . . . 51.54 110.915 179.945 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 160.29 50.27 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.657 2.238 . . . . 73.31 112.372 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 89.31 17.71 54.77 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.775 -0.726 . . . . 54.35 112.474 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 4.0 pt-20 -163.38 135.58 5.17 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.875 0.369 . . . . 73.24 110.909 -179.853 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.566 HG11 ' HD3' ' A' ' 64' ' ' LYS . 61.9 t -76.37 138.06 21.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.179 -0.464 . . . . 70.44 111.13 179.953 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.714 ' HB2' HG11 ' A' ' 85' ' ' VAL . 0.1 OUTLIER -115.2 107.74 15.69 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.47 . . . . 72.34 110.862 -179.836 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 52.2 m -81.73 120.02 24.6 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 73.31 111.131 -179.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.48 HG21 HG11 ' A' ' 83' ' ' VAL . 46.7 t -120.61 122.79 68.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.269 -0.423 . . . . 74.14 111.148 179.887 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 1.4 mmm180 -100.85 102.45 13.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.201 -0.454 . . . . 55.34 110.88 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 52.9 t80 -151.93 120.41 6.43 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 62.34 110.921 -179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.3 t -114.93 139.91 49.43 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.105 -0.498 . . . . 64.41 111.156 -179.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -90.96 -170.1 2.57 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.232 -0.44 . . . . 72.44 110.863 -179.96 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 25.5 mttt -129.44 -25.52 2.65 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.149 -0.478 . . . . 70.43 110.896 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.1 mtp180 -135.98 154.64 77.78 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.633 0.73 . . . . 74.41 110.832 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.82 156.84 62.16 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.651 2.234 . . . . 71.04 112.318 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.19 133.3 1.47 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.733 -0.746 . . . . 44.43 112.48 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -92.57 128.73 38.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.832 0.349 . . . . 72.1 110.871 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 4.3 p90 -143.87 132.04 21.85 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.173 -0.467 . . . . 72.22 110.911 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 43.5 mtm180 -144.88 -176.59 5.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.133 -0.485 . . . . 64.22 110.892 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 20.0 mt 66.35 144.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.192 -0.458 . . . . 70.13 111.157 -179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.456 HD13 ' N ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -103.68 145.05 13.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.188 -0.46 . . . . 74.24 111.15 179.819 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.456 ' N ' HD13 ' A' ' 106' ' ' ILE . 9.0 t -104.46 -67.24 0.91 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.212 -0.449 . . . . 62.31 110.894 179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -146.81 102.29 3.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 63.15 110.866 -179.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -97.72 25.83 5.55 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.185 -0.461 . . . . 74.51 110.864 -179.986 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 1.5 m-85 59.11 175.67 0.07 Allowed 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.236 -0.438 . . . . 71.14 110.903 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER 63.18 25.64 14.92 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.12 -0.491 . . . . 70.22 110.89 -179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.6 95.92 0.39 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.721 -0.752 . . . . 72.13 112.499 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.53 HD12 ' N ' ' A' ' 114' ' ' GLY . 0.8 OUTLIER -66.06 -178.4 0.61 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.889 0.376 . . . . 71.32 110.899 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.53 ' N ' HD12 ' A' ' 113' ' ' LEU . . . 88.53 -117.31 4.81 Favored Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.772 -0.727 . . . . 65.33 112.481 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 31.3 m170 -52.51 148.17 7.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.748 0.308 . . . . 63.4 110.88 -179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER 61.83 55.35 2.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.224 -0.444 . . . . 75.12 110.902 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -179.25 93.98 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.206 -0.452 . . . . 74.23 110.869 -179.969 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -71.66 174.45 6.75 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 72.44 110.904 179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 26.1 m-85 -91.84 121.1 33.14 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.228 -0.442 . . . . 71.22 110.909 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -83.8 176.57 52.21 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.752 -0.737 . . . . 71.35 112.503 -179.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.764 HG23 HG13 ' A' ' 53' ' ' ILE . 9.9 t -154.56 136.8 14.84 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.746 0.307 . . . . 73.11 111.135 -179.874 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.55 HD12 ' C ' ' A' ' 121' ' ' THR . 3.7 mp -150.33 142.01 16.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.234 -0.439 . . . . 75.2 111.157 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.48 ' O ' HG12 ' A' ' 55' ' ' VAL . 28.0 t -132.97 130.19 58.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 75.05 111.121 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.824 HG22 HG13 ' A' ' 55' ' ' VAL . 42.5 t -103.07 130.38 53.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.125 -0.489 . . . . 64.44 111.135 179.889 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 10.1 mmmt -108.18 134.15 51.43 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.167 -0.47 . . . . 75.51 110.901 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.205 -0.452 . . . . 74.34 110.894 179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.815 0.341 . . . . 73.11 110.844 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . 0.507 HG22 ' O ' ' A' ' 2' ' ' VAL . 2.4 p 38.15 82.94 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.234 -0.439 . . . . 63.14 111.098 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.473 HD13 ' H ' ' A' ' 3' ' ' ILE . 0.2 OUTLIER -117.31 153.29 49.99 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.642 0.734 . . . . 53.53 111.125 179.889 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.73 -176.94 1.64 Allowed 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.663 2.242 . . . . 74.21 112.392 179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -144.99 68.3 1.24 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.202 -0.453 . . . . 44.31 111.089 179.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 127.62 -93.21 0.37 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.787 -0.72 . . . . 50.25 112.514 -179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -108.96 161.65 14.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.818 0.342 . . . . 63.23 110.914 179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.798 HD11 ' HD2' ' A' ' 10' ' ' ARG . 0.2 OUTLIER 61.41 164.29 0.08 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.225 -0.443 . . . . 63.32 110.891 179.937 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.615 ' N ' HD12 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -128.35 131.53 48.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 71.33 110.911 179.933 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.798 ' HD2' HD11 ' A' ' 8' ' ' LEU . 0.0 OUTLIER -90.07 154.09 20.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.136 -0.483 . . . . 70.13 110.895 -179.913 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 16' ' ' VAL . 10.6 m -126.74 -178.05 2.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.206 -0.452 . . . . 73.13 111.165 179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.464 ' OD1' HG21 ' A' ' 2' ' ' VAL . 0.4 OUTLIER -143.81 161.74 44.6 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 121.591 0.71 . . . . 62.43 110.867 179.914 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -4.24 13.64 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.695 2.264 . . . . 74.23 112.379 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.721 HG22 HG23 ' A' ' 15' ' ' THR . 42.2 m -48.46 -71.0 0.07 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.198 -0.455 . . . . 75.53 111.157 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.721 HG23 HG22 ' A' ' 14' ' ' THR . 44.8 p -151.59 36.68 0.57 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.27 -0.423 . . . . 62.35 111.159 -179.976 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.464 HG21 HG21 ' A' ' 11' ' ' VAL . 10.0 p -78.93 -25.58 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 64.41 111.129 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -97.52 -18.2 19.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.172 -0.467 . . . . 71.51 110.834 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 70.4 mm-40 -101.43 -28.4 12.6 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.222 -0.445 . . . . 72.45 110.923 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -133.33 133.17 42.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.183 -0.462 . . . . 73.23 110.914 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 122.88 -158.67 17.54 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.686 -0.768 . . . . 74.32 112.473 -179.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.474 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.4 Cg_endo -69.75 -34.65 14.17 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.72 2.28 . . . . 65.53 112.342 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.437 ' CE3' ' HG2' ' A' ' 21' ' ' PRO . 14.9 m-90 -84.98 -6.95 59.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.219 -0.446 . . . . 64.52 110.912 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -65.91 -59.12 4.16 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.246 -0.434 . . . . 51.21 111.106 179.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -111.99 141.7 25.37 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.592 0.71 . . . . 73.3 110.896 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -7.17 20.38 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.706 2.271 . . . . 62.31 112.311 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.06 -25.5 60.93 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.232 -0.44 . . . . 72.22 111.094 179.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.522 HE21 ' N ' ' A' ' 27' ' ' GLN . 0.0 OUTLIER -110.99 34.21 4.16 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 72.03 110.919 -179.934 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -67.59 -69.03 0.34 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.194 -0.457 . . . . 63.04 111.115 179.905 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.561 HG11 ' CB ' ' A' ' 54' ' ' GLU . 1.6 p -111.33 125.18 68.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.213 -0.448 . . . . 63.53 111.097 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 1.3 t -145.97 151.46 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.15 -0.477 . . . . 65.35 111.179 179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . 0.433 ' HG2' ' CD1' ' A' ' 37' ' ' TYR . 0.1 OUTLIER -72.69 119.29 16.71 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.185 -0.461 . . . . 74.32 110.879 -179.974 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 5.2 p -120.94 -42.58 2.49 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.157 -0.474 . . . . 55.34 111.137 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.39 -168.22 16.83 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.749 -0.739 . . . . 74.2 112.504 179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 109.8 2.4 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.654 2.236 . . . . 73.33 112.354 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 59.9 t30 49.92 30.58 4.05 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.205 -0.452 . . . . 71.43 110.878 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -129.43 120.98 26.4 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.177 -0.465 . . . . 72.44 110.891 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . 0.433 ' CD1' ' HG2' ' A' ' 31' ' ' GLN . 39.7 m-85 -94.43 141.97 27.96 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 61.2 110.924 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.419 ' O ' ' HA ' ' A' ' 29' ' ' VAL . 21.9 m -99.66 99.78 10.67 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.14 -0.482 . . . . 72.21 111.16 -179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 12.0 t -84.34 131.57 33.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.212 -0.449 . . . . 61.03 111.087 179.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 52.1 m-85 -113.63 100.69 8.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.176 -0.465 . . . . 73.22 110.918 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.753 HG12 HD12 ' A' ' 53' ' ' ILE . 34.8 m -97.45 129.94 46.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.131 -0.486 . . . . 74.01 111.141 179.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 18.5 tp -124.24 138.54 54.39 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.186 -0.461 . . . . 70.34 110.928 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.741 ' HB3' ' CE1' ' A' ' 72' ' ' HIS . . . -155.68 123.41 5.63 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.174 -0.467 . . . . 74.34 111.094 179.833 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -143.09 144.1 32.11 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.175 -0.466 . . . . 72.45 110.876 -179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -85.13 4.89 32.2 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.167 -0.469 . . . . 51.14 111.114 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -103.34 72.9 1.18 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.218 -0.446 . . . . 61.33 110.846 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 115.08 -141.69 17.18 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.759 -0.734 . . . . 70.13 112.522 -179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -152.89 148.4 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.807 0.337 . . . . 72.24 110.938 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -165.15 162.97 13.92 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.601 0.715 . . . . 73.04 110.913 179.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 158.58 56.53 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.686 2.257 . . . . 64.12 112.374 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . . . . . . . . . 9.4 m-80 -131.88 67.02 79.06 Favored Pre-proline 0 C--N 1.329 -0.297 0 CA-C-O 121.704 0.764 . . . . 64.51 110.919 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.724 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.9 Cg_endo -69.76 119.56 6.49 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.696 2.264 . . . . 55.31 112.336 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.806 HG13 HG23 ' A' ' 121' ' ' THR . 1.5 mm -131.27 124.13 54.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.2 -0.455 . . . . 74.13 111.106 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.561 ' CB ' HG11 ' A' ' 29' ' ' VAL . 8.6 tt0 -131.24 116.38 17.56 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.147 -0.479 . . . . 73.01 110.891 179.935 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.731 HG13 HG21 ' A' ' 61' ' ' ILE . 5.7 t -130.1 80.6 70.59 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.63 0.729 . . . . 71.25 111.12 179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.551 ' HD2' HD12 ' A' ' 61' ' ' ILE . 54.1 Cg_endo -69.7 121.12 7.82 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.746 2.298 . . . . 74.5 112.331 179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -68.12 155.57 39.31 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.249 -0.432 . . . . 72.22 110.929 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 84.52 -6.53 76.81 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.754 -0.736 . . . . 74.0 112.481 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -132.82 155.34 49.13 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.739 0.304 . . . . 73.3 111.094 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.763 ' O ' HD13 ' A' ' 61' ' ' ILE . 4.5 mt-10 -64.84 143.42 57.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.17 -0.468 . . . . 71.01 110.897 -179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.763 HD13 ' O ' ' A' ' 60' ' ' GLU . 8.6 mm -131.65 124.53 54.29 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.188 -0.46 . . . . 44.21 111.124 179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 1.018 HG13 HG23 ' A' ' 92' ' ' THR . 46.8 t -111.22 93.48 2.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.182 -0.463 . . . . 75.32 111.146 179.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -71.82 137.06 47.29 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 65.31 110.858 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 6.8 mttt -132.28 99.52 4.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.132 -0.485 . . . . 65.44 110.907 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.411 HD11 ' CE2' ' A' ' 74' ' ' PHE . 1.6 mp -98.03 153.53 3.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.199 -0.455 . . . . 70.35 111.147 179.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 5.2 t -171.77 137.77 1.03 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 60.15 111.165 179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.447 ' HB3' HG23 ' A' ' 70' ' ' VAL . 0.7 OUTLIER -142.44 162.21 45.97 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-O 121.708 0.766 . . . . 52.43 110.843 -179.836 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.426 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.8 Cg_endo -69.71 -52.01 0.36 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.708 2.272 . . . . 65.13 112.322 179.986 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -155.91 36.67 0.35 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.225 -0.443 . . . . 64.5 110.905 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.447 HG23 ' HB3' ' A' ' 67' ' ' SER . 0.0 OUTLIER -140.17 -179.24 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.201 -0.454 . . . . 72.12 111.139 -179.961 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . 0.634 HG23 ' O ' ' A' ' 85' ' ' VAL . 33.1 mt -144.91 156.68 14.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.201 -0.454 . . . . 74.21 111.183 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.741 ' CE1' ' HB3' ' A' ' 43' ' ' ALA . 35.6 p-80 -168.52 98.17 0.41 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.212 -0.449 . . . . 73.33 110.835 179.857 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -95.02 135.72 12.56 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.731 -0.747 . . . . 73.13 112.504 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.608 ' CE1' HG21 ' A' ' 83' ' ' VAL . 9.3 p90 -99.05 142.1 30.97 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.876 0.369 . . . . 72.51 110.872 -179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 12.9 p80 -125.24 142.69 51.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 73.32 110.897 179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.697 HG11 ' CE1' ' A' ' 97' ' ' PHE . 21.2 t -131.83 147.56 32.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.242 -0.435 . . . . 75.42 111.134 179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 4.2 pm0 -71.49 -175.44 1.3 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 74.43 110.867 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 83.12 -51.45 4.58 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.77 -0.728 . . . . 73.23 112.49 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 32.6 m -135.52 151.35 50.26 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.782 0.325 . . . . 72.55 111.153 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 8.5 m-80 -74.13 70.13 1.56 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.233 -0.44 . . . . 71.24 110.871 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.547 ' O ' HG23 ' A' ' 81' ' ' ILE . 14.1 tt -87.77 104.37 14.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 72.44 111.099 179.928 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -115.83 103.85 11.05 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.164 -0.471 . . . . 64.43 110.893 179.9 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.765 HG11 HG21 ' A' ' 93' ' ' VAL . 0.9 OUTLIER -114.32 120.62 64.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.169 -0.469 . . . . 62.44 111.113 179.908 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.32 121.09 17.46 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.144 -0.48 . . . . 70.34 110.896 179.984 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.634 ' O ' HG23 ' A' ' 71' ' ' ILE . 13.7 p -139.36 147.64 24.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.16 -0.473 . . . . 63.42 111.142 179.981 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.504 ' HB3' ' HD2' ' A' ' 87' ' ' PRO . 0.3 OUTLIER -90.58 163.92 28.63 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.594 0.712 . . . . 73.05 110.911 179.927 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.504 ' HD2' ' HB3' ' A' ' 86' ' ' LEU . 53.5 Cg_endo -69.77 147.77 63.56 Favored 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.682 2.254 . . . . 72.03 112.317 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 95.01 9.18 58.51 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.754 -0.736 . . . . 73.23 112.492 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 12.3 mt-10 -146.34 173.68 12.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.869 0.366 . . . . 72.3 110.876 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.53 ' O ' HD13 ' A' ' 8' ' ' LEU . 17.5 t -129.37 119.49 48.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.143 -0.48 . . . . 71.31 111.117 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -103.75 133.66 48.37 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.138 -0.483 . . . . 54.21 110.822 -179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 1.018 HG23 HG13 ' A' ' 62' ' ' VAL . 60.7 m -103.13 131.87 49.81 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.131 -0.486 . . . . 71.52 111.12 -179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.765 HG21 HG11 ' A' ' 83' ' ' VAL . 19.0 t -125.26 127.6 72.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.209 -0.45 . . . . 72.45 111.114 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 3.1 mmm180 -107.78 92.6 4.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.161 -0.472 . . . . 52.35 110.858 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -140.77 133.43 28.76 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.157 -0.474 . . . . 75.04 110.902 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 11.7 t -123.16 140.19 53.28 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.133 -0.485 . . . . 71.23 111.159 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . 0.697 ' CE1' HG11 ' A' ' 76' ' ' VAL . 75.2 m-85 -96.3 -174.82 3.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.217 -0.447 . . . . 74.33 110.861 -179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -125.89 -29.02 3.14 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.121 -0.49 . . . . 72.2 110.928 179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.35 155.59 81.28 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.597 0.713 . . . . 71.11 110.897 179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 170.56 16.34 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.647 2.231 . . . . 64.12 112.351 -179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 154.99 133.32 1.71 Allowed Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.755 -0.736 . . . . 70.0 112.479 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -101.13 125.54 47.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.833 0.349 . . . . 65.51 110.903 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -143.75 146.61 33.27 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 73.45 110.94 -179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -156.23 97.89 1.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.138 -0.483 . . . . 72.15 110.838 -179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 19.4 tt -175.51 151.96 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.151 -0.477 . . . . 74.31 111.118 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.567 ' O ' HD13 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -114.43 141.47 30.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.152 -0.476 . . . . 73.34 111.189 179.822 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.404 ' N ' HD13 ' A' ' 106' ' ' ILE . 24.9 t -179.07 -74.36 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.2 -0.455 . . . . 74.31 110.907 179.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 45.2 m-20 -62.52 94.7 0.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.185 -0.461 . . . . 74.21 110.886 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -170.2 -173.58 1.53 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.193 -0.458 . . . . 74.52 110.914 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 6.2 t80 -119.56 68.88 0.82 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.2 -0.454 . . . . 72.32 110.918 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -151.98 -49.19 0.11 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 72.54 110.897 -179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 127.57 104.03 1.25 Allowed Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.746 -0.74 . . . . 71.33 112.467 -179.908 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.567 HD13 ' O ' ' A' ' 106' ' ' ILE . 21.1 tp -51.36 149.09 4.33 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.835 0.35 . . . . 74.23 110.885 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.537 ' H ' HD12 ' A' ' 113' ' ' LEU . . . 90.5 -157.8 25.9 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.696 -0.764 . . . . 73.14 112.489 179.883 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 58.36 -165.71 0.17 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.773 0.321 . . . . 75.13 110.859 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 39.8 mt-30 -51.44 -26.95 8.96 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 63.14 110.943 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 21.8 t-20 -53.63 101.64 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.47 . . . . 61.43 110.883 -179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . 0.465 ' SD ' ' HB1' ' A' ' 43' ' ' ALA . 0.3 OUTLIER -76.16 177.03 7.49 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 52.31 110.884 179.903 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 39.8 m-85 -89.71 120.21 30.78 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.245 -0.434 . . . . 71.42 110.872 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -72.28 -175.93 26.98 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.735 -0.745 . . . . 53.1 112.472 -179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.806 HG23 HG13 ' A' ' 53' ' ' ILE . 4.8 t -154.88 146.82 23.52 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.763 0.316 . . . . 53.14 111.168 -179.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.603 HG13 HG21 ' A' ' 53' ' ' ILE . 2.1 mp -153.9 137.63 8.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.434 . . . . 71.53 111.121 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . . . . . . . . . 26.9 t -126.14 122.58 61.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.2 -0.454 . . . . 74.23 111.149 179.892 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.652 HG13 ' O ' ' A' ' 55' ' ' VAL . 44.3 t -101.52 112.1 33.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.258 -0.428 . . . . 75.24 111.119 179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 17.8 mmmt -84.45 135.26 34.33 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.199 -0.455 . . . . 54.53 110.897 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.232 -0.44 . . . . 74.43 110.945 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.804 0.335 . . . . 45.45 110.859 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 14.1 m -111.28 139.01 37.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.237 -0.438 . . . . 44.23 111.163 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 6.5 pt -150.46 77.93 7.89 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.639 0.733 . . . . 63.43 111.124 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -177.51 1.91 Allowed 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.692 2.262 . . . . 61.31 112.33 179.904 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -145.0 -70.77 0.28 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.156 -0.475 . . . . 61.41 111.108 179.887 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -101.14 17.55 55.78 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.766 -0.731 . . . . 32.43 112.446 -179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . 0.429 ' HE3' HD23 ' A' ' 8' ' ' LEU . 13.1 mmmt -115.08 178.93 4.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.831 0.348 . . . . 63.52 110.88 -179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.429 HD23 ' HE3' ' A' ' 7' ' ' LYS . 0.5 OUTLIER -63.77 -174.06 0.09 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.22 -0.446 . . . . 63.54 110.948 179.905 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.406 ' O ' HD12 ' A' ' 8' ' ' LEU . 0.8 OUTLIER -78.53 129.37 34.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.235 -0.438 . . . . 71.21 110.885 179.96 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.54 168.46 10.35 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.165 -0.471 . . . . 75.34 110.851 -179.899 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.87 ' CG1' HG21 ' A' ' 16' ' ' VAL . 1.4 t -141.54 166.71 17.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.177 -0.465 . . . . 60.44 111.098 179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . 0.427 ' H ' HG12 ' A' ' 11' ' ' VAL . 55.9 p-10 -161.12 153.45 16.97 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.594 0.711 . . . . 73.44 110.843 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -4.34 13.85 Favored 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.684 2.256 . . . . 71.1 112.326 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.459 ' O ' HG23 ' A' ' 15' ' ' THR . 40.6 m -44.44 -72.23 0.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 65.24 111.094 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.459 HG23 ' O ' ' A' ' 14' ' ' THR . 6.7 p -156.62 33.08 0.31 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.209 -0.45 . . . . 52.34 111.144 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.87 HG21 ' CG1' ' A' ' 11' ' ' VAL . 4.9 p -78.58 -19.92 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 74.04 111.105 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -100.68 -9.38 21.91 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.192 -0.458 . . . . 60.02 110.896 -179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 31.4 mm-40 -103.53 -32.87 9.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.171 -0.468 . . . . 63.14 110.881 -179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -140.16 125.98 19.45 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.187 -0.46 . . . . 73.54 110.861 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 132.26 -155.99 21.78 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.745 -0.741 . . . . 24.22 112.515 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.75 -37.83 8.65 Favored 'Trans proline' 0 C--O 1.231 0.163 0 C-N-CA 122.723 2.282 . . . . 71.52 112.349 -179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . 0.483 ' HE3' HG22 ' A' ' 16' ' ' VAL . 7.8 m-90 -84.51 -12.57 53.97 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.211 -0.449 . . . . 72.11 110.917 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -64.79 -59.54 4.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.231 -0.44 . . . . 75.31 111.087 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -100.21 142.84 25.37 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.622 0.725 . . . . 51.3 110.88 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 -22.83 31.81 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.644 2.229 . . . . 61.52 112.376 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.51 -17.56 61.2 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.199 -0.455 . . . . 75.25 111.097 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . . . . . . . . . 3.5 mm100 -89.35 10.13 23.56 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.216 -0.447 . . . . 75.24 110.929 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . . . . . . . . . . . -63.26 -77.53 0.05 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.206 -0.452 . . . . 50.42 111.083 179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.435 HG21 ' HB3' ' A' ' 54' ' ' GLU . 21.1 t -84.38 122.06 37.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.205 -0.452 . . . . 72.4 111.165 179.962 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.7 t -134.8 131.62 53.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.209 -0.451 . . . . 62.15 111.106 179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -71.31 118.28 13.92 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 72.31 110.899 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 2.0 t -119.38 -41.49 2.72 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.181 -0.463 . . . . 71.2 111.175 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.34 171.2 13.72 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.765 -0.731 . . . . 32.34 112.487 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.73 -10.21 28.02 Favored 'Trans proline' 0 C--N 1.341 0.156 0 C-N-CA 122.685 2.257 . . . . 72.03 112.358 -179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 39.3 t30 -157.69 34.81 0.26 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.283 -0.417 . . . . 63.4 110.883 179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -151.29 160.04 44.01 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.149 -0.478 . . . . 63.51 110.896 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 8.7 m-85 -143.31 146.64 33.75 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.252 -0.431 . . . . 75.43 110.941 -179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 99.5 m -97.23 121.99 39.75 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.119 -0.491 . . . . 74.11 111.165 -179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 17.9 t -100.37 134.58 39.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.219 -0.446 . . . . 72.24 111.137 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . . . . . . . . . 72.1 m-85 -120.65 100.51 7.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.173 -0.467 . . . . 73.3 110.932 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.495 HG12 HG13 ' A' ' 53' ' ' ILE . 32.8 m -98.78 128.53 50.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 74.1 111.129 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.706 HD13 ' N ' ' A' ' 43' ' ' ALA . 2.8 tm? -120.74 138.23 54.1 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.191 -0.459 . . . . 71.24 110.928 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.706 ' N ' HD13 ' A' ' 42' ' ' LEU . . . -155.22 137.04 14.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.189 -0.459 . . . . 73.12 111.049 179.831 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . 0.427 ' HD2' HD11 ' A' ' 42' ' ' LEU . 2.9 p90 -145.29 150.06 35.97 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.18 -0.464 . . . . 73.31 110.918 -179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . . . . . . . . . . . -88.41 18.69 4.29 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.147 -0.479 . . . . 54.42 111.118 179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 12.2 m-85 -84.34 -61.87 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.165 -0.47 . . . . 60.42 110.868 -179.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -127.44 -122.43 2.52 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.786 -0.721 . . . . 75.23 112.488 -179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 3.3 t80 -143.91 145.02 31.99 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.869 0.366 . . . . 74.33 110.904 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . 0.427 ' HB2' ' HD2' ' A' ' 50' ' ' PRO . 2.0 pm0 -154.37 156.09 31.4 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.56 0.695 . . . . 74.53 110.892 -179.985 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . 0.427 ' HD2' ' HB2' ' A' ' 49' ' ' GLN . 53.2 Cg_endo -69.79 177.38 5.65 Favored 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.632 2.222 . . . . 75.23 112.343 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.712 ' O ' HD12 ' A' ' 53' ' ' ILE . 8.5 m-20 -131.23 62.3 64.39 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-O 121.592 0.71 . . . . 61.15 110.905 179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.75 70.77 1.56 Allowed 'Trans proline' 0 C--O 1.231 0.143 0 C-N-CA 122.661 2.241 . . . . 74.25 112.377 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.712 HD12 ' O ' ' A' ' 51' ' ' ASN . 4.3 mp -105.88 128.29 60.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.213 -0.449 . . . . 75.11 111.151 179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.435 ' HB3' HG21 ' A' ' 29' ' ' VAL . 11.2 tt0 -126.3 135.11 51.12 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.468 . . . . 73.43 110.878 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.741 HG13 HG22 ' A' ' 124' ' ' VAL . 2.5 p -140.12 81.95 17.79 Favored Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.657 0.741 . . . . 74.4 111.08 179.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.59 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.9 Cg_endo -69.74 123.55 10.22 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.715 2.277 . . . . 61.25 112.328 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -66.87 152.37 45.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 71.44 110.951 179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 93.42 -36.51 3.7 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 61.23 112.49 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -106.22 150.12 26.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.749 0.309 . . . . 61.14 111.129 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.619 ' O ' HD13 ' A' ' 61' ' ' ILE . 18.1 mt-10 -66.42 142.07 57.71 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.212 -0.449 . . . . 55.32 110.901 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.717 HG13 HG23 ' A' ' 55' ' ' VAL . 5.8 mm -126.25 119.43 54.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.129 -0.487 . . . . 45.35 111.116 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 1.091 HG13 HG23 ' A' ' 92' ' ' THR . 64.3 t -98.33 92.08 2.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 73.52 111.118 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.506 ' HB2' HG12 ' A' ' 93' ' ' VAL . 66.9 m-85 -70.9 136.59 48.67 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 75.33 110.906 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 8.7 mttt -132.09 98.64 4.48 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.175 -0.466 . . . . 64.54 110.908 179.939 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.715 HD11 ' CZ ' ' A' ' 74' ' ' PHE . 1.6 mp -103.17 137.5 31.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.465 . . . . 71.23 111.11 179.904 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . 0.419 ' OG1' HG11 ' A' ' 11' ' ' VAL . 4.2 t -155.73 135.89 12.99 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 75.43 111.123 179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.449 ' HB3' ' HD2' ' A' ' 68' ' ' PRO . 0.9 OUTLIER -135.87 161.19 64.17 Favored Pre-proline 0 C--N 1.329 -0.294 0 CA-C-O 121.633 0.73 . . . . 75.31 110.859 -179.863 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.449 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 53.8 Cg_endo -69.68 -53.95 0.25 Allowed 'Trans proline' 0 C--O 1.231 0.156 0 C-N-CA 122.675 2.25 . . . . 72.11 112.361 179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -156.83 56.15 0.54 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.198 -0.455 . . . . 74.54 110.866 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -156.01 136.23 4.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.182 -0.463 . . . . 63.2 111.152 -179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 35.4 mm -64.33 149.14 11.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.164 -0.471 . . . . 74.45 111.115 179.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.582 ' HB2' HG21 ' A' ' 65' ' ' ILE . 2.1 p80 -133.11 -178.5 4.99 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.189 -0.46 . . . . 65.54 110.886 179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 135.37 139.69 4.07 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.724 -0.75 . . . . 35.45 112.485 -179.955 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.715 ' CZ ' HD11 ' A' ' 65' ' ' ILE . 1.0 OUTLIER -130.57 144.68 51.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.894 0.378 . . . . 73.2 110.837 -179.845 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 8.0 t-80 -101.06 142.13 32.96 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.106 -0.497 . . . . 72.3 110.863 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.612 HG22 ' CD2' ' A' ' 103' ' ' TYR . 58.2 t -131.84 138.13 53.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.457 . . . . 62.02 111.118 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -75.51 179.45 5.28 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 73.24 110.862 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 82.14 -52.03 4.57 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.781 -0.723 . . . . 74.13 112.48 -179.979 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -122.62 179.7 4.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.82 0.343 . . . . 75.03 111.123 -179.86 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . . . . . . . . . 3.0 m-80 -105.77 65.5 0.71 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 61.13 110.893 179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.58 HD12 ' CD2' ' A' ' 95' ' ' TYR . 7.5 tt -72.47 121.68 23.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 73.51 111.159 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -117.07 90.47 3.34 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 73.41 110.827 -179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . . . . . . . . . 5.1 m -115.05 118.41 58.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.17 -0.468 . . . . 62.02 111.126 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -166.72 104.73 0.59 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.145 -0.48 . . . . 71.15 110.878 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.576 HG23 ' CE1' ' A' ' 72' ' ' HIS . 2.4 m -140.64 146.61 23.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.182 -0.463 . . . . 72.54 111.109 179.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.422 ' HB2' ' HD2' ' A' ' 87' ' ' PRO . 0.2 OUTLIER -57.8 159.78 9.36 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.559 0.695 . . . . 72.24 110.915 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . 0.422 ' HD2' ' HB2' ' A' ' 86' ' ' LEU . 53.9 Cg_endo -69.74 159.67 52.55 Favored 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.71 2.274 . . . . 73.32 112.343 179.864 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 90.82 4.51 69.53 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.695 -0.764 . . . . 21.0 112.463 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 13.0 mt-10 -147.19 117.81 7.52 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.872 0.368 . . . . 73.53 110.928 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . . . . . . . . . 1.8 p -74.49 130.04 36.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 62.04 111.134 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.54 ' HB2' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -102.17 112.26 24.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.151 -0.477 . . . . 75.25 110.816 -179.812 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . 1.091 HG23 HG13 ' A' ' 62' ' ' VAL . 52.7 m -90.12 115.72 27.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.149 -0.478 . . . . 65.31 111.117 -179.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.506 HG12 ' HB2' ' A' ' 63' ' ' PHE . 8.6 p -128.75 152.22 36.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.164 -0.471 . . . . 55.14 111.117 179.895 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.82 103.02 11.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.155 -0.475 . . . . 70.52 110.901 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.58 ' CD2' HD12 ' A' ' 81' ' ' ILE . 9.0 t80 -134.28 114.95 13.55 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.192 -0.458 . . . . 75.14 110.92 -179.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 15.0 t -129.09 134.85 48.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.117 -0.492 . . . . 65.44 111.109 -179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -90.85 -176.73 4.76 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.231 -0.44 . . . . 54.44 110.849 -179.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -121.25 -13.04 8.56 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.115 -0.493 . . . . 73.21 110.947 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -139.73 162.74 49.28 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.634 0.731 . . . . 52.23 110.87 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 150.05 67.45 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.686 2.257 . . . . 75.32 112.318 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 165.73 157.47 10.01 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.727 -0.749 . . . . 54.44 112.49 179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.765 ' HB3' HG23 ' A' ' 123' ' ' VAL . 3.8 pm0 -120.26 125.17 47.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.872 0.368 . . . . 65.23 110.855 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . 0.612 ' CD2' HG22 ' A' ' 76' ' ' VAL . 1.0 OUTLIER -133.01 146.64 51.94 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.136 -0.483 . . . . 72.15 110.885 -179.838 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . 0.417 ' O ' ' HB ' ' A' ' 105' ' ' ILE . 0.4 OUTLIER -174.3 -162.11 0.13 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.107 -0.497 . . . . 74.32 110.83 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.417 ' HB ' ' O ' ' A' ' 104' ' ' ARG . 21.2 mm 75.28 117.79 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 71.34 111.161 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.477 HG23 ' N ' ' A' ' 107' ' ' CYS . 0.0 OUTLIER -85.2 -175.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.185 -0.461 . . . . 64.24 111.144 179.849 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.477 ' N ' HG23 ' A' ' 106' ' ' ILE . 2.9 t 79.8 42.97 0.06 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.185 -0.462 . . . . 71.12 110.871 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . 0.48 ' O ' ' N ' ' A' ' 110' ' ' TYR . 8.2 m-20 -154.16 -81.38 0.09 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 70.13 110.928 -179.943 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 17.9 mp0 50.49 -87.76 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.181 -0.463 . . . . 72.31 110.912 179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . 0.48 ' N ' ' O ' ' A' ' 108' ' ' ASN . 87.2 t80 -134.96 -39.1 0.78 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.183 -0.462 . . . . 74.53 110.938 -179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.2 m -114.83 -33.8 5.34 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.105 -0.498 . . . . 44.53 110.843 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 103.88 122.8 5.15 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.746 -0.74 . . . . 23.44 112.519 -179.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -131.54 -78.76 0.52 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.852 0.358 . . . . 71.5 110.932 -179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 44.88 -153.17 0.55 Allowed Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.722 -0.751 . . . . 65.44 112.47 179.854 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 15.1 t-160 53.66 67.57 0.98 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.745 0.307 . . . . 74.11 110.9 -179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . . . . . . . . . 1.7 tt0 -179.47 -79.04 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.456 . . . . 75.13 110.887 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 10.4 p-10 -95.78 179.77 4.99 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.231 -0.44 . . . . 74.14 110.912 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.88 175.41 7.34 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.192 -0.458 . . . . 73.33 110.86 179.96 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 16.4 m-85 -90.56 133.48 35.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.245 -0.434 . . . . 73.4 110.868 -179.924 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -73.15 -173.78 26.09 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 61.12 112.457 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.607 ' O ' HD13 ' A' ' 53' ' ' ILE . 53.6 m -156.41 126.04 6.29 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.751 0.31 . . . . 63.5 111.166 -179.819 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.637 HG13 HG21 ' A' ' 53' ' ' ILE . 5.3 mp -145.35 117.24 2.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.219 -0.446 . . . . 61.2 111.144 179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.765 HG23 ' HB3' ' A' ' 102' ' ' GLU . 10.6 p -121.65 141.49 41.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 72.14 111.094 179.874 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . 0.741 HG22 HG13 ' A' ' 55' ' ' VAL . 87.0 t -101.5 136.59 32.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 74.0 111.163 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 24.8 mmtt -114.49 125.72 54.13 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.2 -0.455 . . . . 62.21 110.869 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.193 -0.458 . . . . 74.0 110.871 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.5 mmm . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.857 0.361 . . . . 63.12 110.884 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' VAL . . . . . . . . . . . . . 17.3 m -68.62 136.63 26.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.21 -0.45 . . . . 73.13 111.095 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . . . . . . . . . 29.8 pt -108.14 153.59 41.74 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.603 0.716 . . . . 63.13 111.149 179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 -176.26 1.43 Allowed 'Trans proline' 0 C--O 1.231 0.146 0 C-N-CA 122.731 2.288 . . . . 71.44 112.323 179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -150.49 84.75 1.37 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.24 -0.436 . . . . 73.32 111.097 179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 79.21 -101.31 1.84 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.695 -0.764 . . . . 73.32 112.51 -179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.35 158.41 19.04 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.787 0.327 . . . . 71.32 110.886 -179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.61 HD12 ' N ' ' A' ' 9' ' ' GLU . 0.2 OUTLIER 61.33 164.34 0.08 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.222 -0.445 . . . . 73.55 110.956 179.945 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . 0.61 ' N ' HD12 ' A' ' 8' ' ' LEU . 1.6 mm-40 -123.44 148.26 46.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.197 -0.456 . . . . 74.52 110.896 179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ARG . . . . . 0.589 ' HD2' HD11 ' A' ' 8' ' ' LEU . 3.7 mpt_? -105.01 121.36 43.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 61.55 110.863 -179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.462 ' HB ' HG21 ' A' ' 16' ' ' VAL . 5.6 m -113.49 -179.15 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.181 -0.463 . . . . 75.42 111.17 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -144.54 162.63 38.29 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.571 0.7 . . . . 71.22 110.891 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 -2.78 10.78 Favored 'Trans proline' 0 C--O 1.231 0.157 0 C-N-CA 122.656 2.237 . . . . 65.31 112.36 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.751 HG22 HG23 ' A' ' 15' ' ' THR . 29.1 m -44.75 -67.34 0.29 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.231 -0.441 . . . . 62.32 111.109 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . 0.751 HG23 HG22 ' A' ' 14' ' ' THR . 43.4 p -150.67 21.29 0.81 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.176 -0.465 . . . . 54.21 111.142 -179.95 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.462 HG21 ' HB ' ' A' ' 11' ' ' VAL . 1.3 p -77.65 -16.88 14.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.22 -0.445 . . . . 71.11 111.157 179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ARG . . . . . 0.431 ' NE ' ' HD3' ' A' ' 68' ' ' PRO . 0.0 OUTLIER -106.66 -25.0 11.96 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.124 -0.489 . . . . 72.31 110.876 -179.951 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 63.1 mm-40 -92.6 -24.24 18.76 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.19 -0.459 . . . . 74.11 110.92 -179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.458 ' CA ' ' HB2' ' A' ' 23' ' ' ALA . 11.3 tt0 -143.58 147.32 34.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.178 -0.464 . . . . 61.35 110.928 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . . . . . . . . . . . 114.01 -158.74 14.11 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.73 -0.748 . . . . 75.32 112.489 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.42 ' HA ' ' HG3' ' A' ' 27' ' ' GLN . 53.9 Cg_endo -69.81 -33.9 15.48 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.678 2.252 . . . . 71.53 112.332 -179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' TRP . . . . . . . . . . . . . 11.8 m-90 -83.2 -12.87 56.44 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.256 -0.429 . . . . 74.54 110.898 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.458 ' HB2' ' CA ' ' A' ' 19' ' ' GLU . . . -62.44 -57.13 12.35 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.256 -0.429 . . . . 51.01 111.134 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -109.34 142.22 25.19 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.564 0.697 . . . . 64.23 110.927 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -6.73 19.3 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.708 2.272 . . . . 72.54 112.359 -179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.79 -12.87 61.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.465 . . . . 64.1 111.109 179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLN . . . . . 0.42 ' HG3' ' HA ' ' A' ' 21' ' ' PRO . 17.6 mm-40 -99.0 14.4 29.3 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.224 -0.443 . . . . 74.51 110.93 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ALA . . . . . 0.458 ' HB2' ' HG2' ' A' ' 52' ' ' PRO . . . -65.0 -14.84 61.41 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.463 . . . . 71.13 111.089 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.522 HG22 ' HB3' ' A' ' 54' ' ' GLU . 7.0 t -145.21 119.31 2.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.247 -0.433 . . . . 74.24 111.092 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.766 HG13 ' HB ' ' A' ' 38' ' ' THR . 1.6 p -144.21 140.92 24.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.136 -0.484 . . . . 60.25 111.153 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -88.33 100.88 13.35 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.167 -0.469 . . . . 74.04 110.87 -179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 8.4 t -98.07 -34.46 10.77 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.232 -0.44 . . . . 61.13 111.147 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.71 -168.44 17.44 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.716 -0.755 . . . . 74.43 112.472 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -37.83 8.56 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.654 2.236 . . . . 54.2 112.334 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ASN . . . . . . . . . . . . . 3.3 t30 -148.27 34.68 0.8 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 73.45 110.864 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLN . . . . . . . . . . . . . 1.7 pt20 -135.41 119.87 18.04 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 65.32 110.893 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' TYR . . . . . . . . . . . . . 19.6 m-85 -95.87 140.89 29.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.212 -0.449 . . . . 73.5 110.983 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.766 ' HB ' HG13 ' A' ' 30' ' ' VAL . 22.3 m -94.81 107.82 19.84 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.151 -0.477 . . . . 70.42 111.141 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 39.1 t -89.25 130.0 39.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.224 -0.444 . . . . 61.22 111.137 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' TYR . . . . . 0.409 ' CD2' ' HB2' ' A' ' 21' ' ' PRO . 49.0 m-85 -116.03 113.15 22.81 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.197 -0.456 . . . . 74.3 110.909 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 41' ' ' VAL . 31.2 m -111.35 125.1 68.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.129 -0.487 . . . . 71.24 111.117 179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.416 HD11 ' CZ ' ' A' ' 17' ' ' ARG . 2.9 tm? -121.92 126.28 48.3 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.122 -0.49 . . . . 60.23 110.907 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -144.54 144.96 31.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.163 -0.471 . . . . 53.21 111.115 179.821 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PHE . . . . . . . . . . . . . 12.2 p90 -136.65 152.74 50.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.223 -0.444 . . . . 73.15 110.908 -179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ALA . . . . . 0.553 ' HB2' HG11 ' A' ' 70' ' ' VAL . . . -87.77 12.2 13.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.113 -0.494 . . . . 72.4 111.063 179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -120.48 66.65 0.84 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.25 -0.432 . . . . 72.5 110.928 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 123.31 -147.88 16.71 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.747 -0.739 . . . . 62.44 112.507 -179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -150.71 155.88 40.2 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.833 0.349 . . . . 64.32 110.929 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -164.48 162.54 15.31 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.624 0.726 . . . . 62.22 110.916 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 140.09 41.91 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.696 2.264 . . . . 70.2 112.354 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASN . . . . . 0.621 ' O ' HD12 ' A' ' 53' ' ' ILE . 5.1 m120 -131.61 68.19 80.67 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.624 0.726 . . . . 73.51 110.879 179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PRO . . . . . 0.458 ' HG2' ' HB2' ' A' ' 28' ' ' ALA . 53.5 Cg_endo -69.75 72.75 1.42 Allowed 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.707 2.271 . . . . 71.3 112.363 179.927 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ILE . . . . . 0.731 HD13 ' O ' ' A' ' 121' ' ' THR . 2.6 mp -77.37 91.34 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.19 -0.459 . . . . 73.4 111.1 179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLU . . . . . 0.522 ' HB3' HG22 ' A' ' 29' ' ' VAL . 9.1 tt0 -83.48 138.54 33.4 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 73.41 110.882 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . 0.586 HG13 HG21 ' A' ' 61' ' ' ILE . 6.5 t -143.93 85.79 8.89 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.593 0.711 . . . . 70.2 111.101 -179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . 0.675 ' HD2' HD12 ' A' ' 61' ' ' ILE . 53.6 Cg_endo -69.78 122.95 9.62 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.669 2.246 . . . . 74.2 112.335 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.55 153.09 43.26 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.224 -0.444 . . . . 72.42 110.901 179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 91.84 -35.83 3.85 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.72 -0.752 . . . . 54.31 112.51 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -105.86 155.09 19.66 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.747 0.308 . . . . 73.44 111.112 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.678 ' O ' HD13 ' A' ' 61' ' ' ILE . 1.9 mp0 -65.52 143.8 57.41 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.246 -0.434 . . . . 73.52 110.886 -179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ILE . . . . . 0.678 HD13 ' O ' ' A' ' 60' ' ' GLU . 6.6 mm -128.73 118.69 47.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 70.4 111.142 179.945 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . 0.756 HG23 ' HA ' ' A' ' 38' ' ' THR . 0.1 OUTLIER -107.77 90.06 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.144 -0.48 . . . . 53.53 111.156 179.882 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 70.8 m-85 -65.08 142.03 58.53 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.223 -0.444 . . . . 70.3 110.884 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' LYS . . . . . . . . . . . . . 1.8 mttt -132.63 99.77 4.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.179 -0.464 . . . . 64.52 110.92 179.942 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ILE . . . . . 0.697 HG21 ' HB3' ' A' ' 72' ' ' HIS . 1.3 mp -102.77 145.65 11.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.214 -0.448 . . . . 65.24 111.128 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.9 t -161.24 132.57 5.48 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.177 -0.465 . . . . 75.22 111.154 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' SER . . . . . 0.647 ' CB ' HG23 ' A' ' 70' ' ' VAL . 0.9 OUTLIER -145.13 163.97 29.61 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.674 0.749 . . . . 72.41 110.905 -179.868 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' PRO . . . . . 0.605 ' HD2' ' HB3' ' A' ' 67' ' ' SER . 54.1 Cg_endo -69.73 -56.36 0.15 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.701 2.268 . . . . 62.41 112.385 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -152.87 67.91 0.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.157 -0.474 . . . . 74.01 110.905 179.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.784 HG12 ' HB3' ' A' ' 116' ' ' GLN . 0.0 OUTLIER -158.3 134.86 2.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 65.34 111.138 -179.998 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ILE . . . . . . . . . . . . . 33.4 mm -68.02 143.75 15.01 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 52.41 111.072 179.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' HIS . . . . . 0.697 ' HB3' HG21 ' A' ' 65' ' ' ILE . 0.9 OUTLIER -108.75 -166.32 1.11 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.128 -0.487 . . . . 75.15 110.864 179.864 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . 115.64 122.45 3.51 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.771 -0.728 . . . . 71.02 112.497 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' PHE . . . . . 0.452 ' CE2' HD11 ' A' ' 65' ' ' ILE . 0.3 OUTLIER -119.87 142.38 48.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.916 0.389 . . . . 62.42 110.898 -179.911 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 3.1 t60 -93.41 135.63 34.46 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.123 -0.489 . . . . 71.53 110.876 179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.691 HG13 ' CE2' ' A' ' 103' ' ' TYR . 59.1 t -137.19 142.88 36.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.197 -0.456 . . . . 65.54 111.172 179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -75.5 -176.31 3.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 62.03 110.871 -179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 87.47 -50.91 4.11 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.777 -0.725 . . . . 61.21 112.474 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.455 HG22 ' H ' ' A' ' 80' ' ' ASN . 0.2 OUTLIER -142.82 173.44 11.55 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.852 0.358 . . . . 43.21 111.099 -179.842 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ASN . . . . . 0.455 ' H ' HG22 ' A' ' 79' ' ' THR . 28.6 m120 -85.41 59.43 5.63 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.211 -0.45 . . . . 75.54 110.884 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . 0.471 ' O ' HG23 ' A' ' 81' ' ' ILE . 6.4 tp -56.69 116.87 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.197 -0.456 . . . . 51.34 111.101 179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -115.23 100.42 8.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.171 -0.468 . . . . 74.52 110.907 179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.486 HG11 HG21 ' A' ' 93' ' ' VAL . 5.7 m -127.29 122.87 60.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 74.15 111.154 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 6.0 tt0 -160.6 114.68 2.13 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.242 -0.436 . . . . 71.11 110.895 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.721 HG21 ' OG ' ' A' ' 91' ' ' SER . 96.7 t -140.36 145.09 26.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 64.31 111.158 179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.22 156.65 89.56 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.609 0.719 . . . . 74.31 110.907 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.71 160.71 48.7 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.728 2.285 . . . . 64.24 112.347 179.865 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' GLY . . . . . . . . . . . . . . . 97.84 -0.13 59.14 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.725 -0.75 . . . . 71.23 112.469 179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -146.15 156.7 43.6 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.889 0.376 . . . . 73.34 110.862 -179.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.43 ' HA ' ' O ' ' A' ' 65' ' ' ILE . 1.6 p -105.7 108.75 25.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 54.52 111.128 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.721 ' OG ' HG21 ' A' ' 85' ' ' VAL . 0.2 OUTLIER -80.22 164.77 22.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.164 -0.471 . . . . 73.21 110.882 -179.865 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' THR . . . . . . . . . . . . . 77.7 m -129.24 105.21 7.99 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 62.44 111.134 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.486 HG21 HG11 ' A' ' 83' ' ' VAL . 24.6 t -101.79 130.81 50.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.239 -0.437 . . . . 63.31 111.14 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -110.44 92.45 4.05 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 72.1 110.851 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 46.2 t80 -143.01 114.08 7.73 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.227 -0.442 . . . . 74.02 110.927 -179.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' THR . . . . . . . . . . . . . 14.7 t -113.87 142.9 45.53 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.176 -0.466 . . . . 65.34 111.143 -179.968 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -89.08 179.98 6.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.221 -0.445 . . . . 74.42 110.842 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LYS . . . . . . . . . . . . . 1.5 ttmm -121.08 -12.77 8.66 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.13 -0.486 . . . . 74.24 110.922 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' ARG . . . . . . . . . . . . . 1.9 mpp_? -149.05 162.03 30.45 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.564 0.697 . . . . 73.31 110.913 179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.77 153.63 68.67 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.731 2.287 . . . . 75.14 112.313 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 157.18 131.12 1.3 Allowed Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.725 -0.75 . . . . 71.12 112.435 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.432 ' CG ' HG23 ' A' ' 123' ' ' VAL . 23.0 mt-10 -101.75 138.76 38.31 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.865 0.364 . . . . 71.21 110.865 -179.875 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' TYR . . . . . 0.691 ' CE2' HG13 ' A' ' 76' ' ' VAL . 0.3 OUTLIER -143.87 140.6 29.87 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.135 -0.484 . . . . 74.42 110.921 -179.898 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ARG . . . . . . . . . . . . . 46.3 mtm180 -144.89 72.79 1.34 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 73.22 110.895 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 55.8 mt -151.05 144.27 16.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.226 -0.443 . . . . 73.34 111.124 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.682 ' CD1' HD12 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -133.87 142.17 42.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 73.51 111.145 179.861 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' CYS . . . . . 0.465 ' N ' HD13 ' A' ' 106' ' ' ILE . 34.7 t -177.78 113.89 0.08 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.146 -0.479 . . . . 74.14 110.89 179.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ASN . . . . . . . . . . . . . 49.6 t-20 56.96 94.73 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.48 . . . . 73.25 110.922 -179.892 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -92.81 42.92 1.11 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 73.32 110.945 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' TYR . . . . . . . . . . . . . 41.3 t80 70.05 -71.83 0.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.185 -0.461 . . . . 65.4 110.918 -179.863 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 8.5 p -52.92 -39.49 62.83 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.118 -0.492 . . . . 73.43 110.889 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 138.73 103.11 0.58 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.724 -0.75 . . . . 43.23 112.474 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.682 HD12 ' CD1' ' A' ' 106' ' ' ILE . 1.4 tt -51.7 140.69 18.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.872 0.368 . . . . 71.35 110.962 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -131.72 -162.55 10.51 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.753 . . . . 51.34 112.447 179.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' HIS . . . . . . . . . . . . . 62.0 m170 -96.25 164.59 12.6 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.735 0.303 . . . . 74.35 110.883 -179.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLN . . . . . 0.784 ' HB3' HG12 ' A' ' 70' ' ' VAL . 60.5 mm-40 63.67 16.24 9.56 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 74.21 110.936 -179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -94.9 130.99 41.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.187 -0.46 . . . . 72.51 110.891 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -71.32 175.4 5.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.177 -0.465 . . . . 74.14 110.911 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' PHE . . . . . . . . . . . . . 30.9 m-85 -90.5 167.39 12.62 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.251 -0.432 . . . . 74.31 110.886 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -79.45 53.6 4.25 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.768 -0.73 . . . . 71.03 112.494 -179.943 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.731 ' O ' HD13 ' A' ' 53' ' ' ILE . 86.5 m -75.0 112.45 11.25 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.784 0.326 . . . . 71.11 111.155 -179.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ILE . . . . . 0.535 HG23 ' CG2' ' A' ' 55' ' ' VAL . 1.4 mp -153.34 136.51 7.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.212 -0.449 . . . . 43.54 111.102 179.911 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' VAL . . . . . 0.432 HG23 ' CG ' ' A' ' 102' ' ' GLU . 1.9 p -117.78 126.56 74.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 71.21 111.133 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 61.9 t -101.14 117.68 46.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.139 -0.482 . . . . 74.04 111.109 179.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' LYS . . . . . . . . . . . . . 4.0 mmmt -93.59 137.54 32.75 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 72.21 110.907 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 64.15 110.924 179.94 . . . . . . . . 1 1 . 1 stop_ save_